0001802768-22-000011.txt : 20220215 0001802768-22-000011.hdr.sgml : 20220215 20220215090334 ACCESSION NUMBER: 0001802768-22-000011 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220215 DATE AS OF CHANGE: 20220215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Royalty Pharma plc CENTRAL INDEX KEY: 0001802768 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39329 FILM NUMBER: 22637203 BUSINESS ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 883-0200 MAIL ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 10-K 1 rprx-20211231.htm 10-K rprx-20211231
00018027682021FYFALSE129.6http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member20020020018018018020018022000018027682021-01-012021-12-3100018027682021-06-30iso4217:USD0001802768us-gaap:CommonClassAMember2022-02-11xbrli:shares0001802768us-gaap:CommonClassBMember2022-02-110001802768rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember2021-12-3100018027682021-12-3100018027682020-12-310001802768us-gaap:CommonClassAMember2020-12-31iso4217:USDxbrli:shares0001802768us-gaap:CommonClassAMember2021-12-310001802768us-gaap:CommonClassBMember2020-12-310001802768us-gaap:CommonClassBMember2021-12-310001802768rprx:ClassRRedeemableStockMember2020-12-31iso4217:GBPxbrli:shares0001802768rprx:ClassRRedeemableStockMember2021-12-310001802768rprx:FinancialRoyaltyAssetsMember2021-01-012021-12-310001802768rprx:FinancialRoyaltyAssetsMember2020-01-012020-12-310001802768rprx:FinancialRoyaltyAssetsMember2019-01-012019-12-310001802768rprx:IntangibleRoyaltyAssetsMember2021-01-012021-12-310001802768rprx:IntangibleRoyaltyAssetsMember2020-01-012020-12-310001802768rprx:IntangibleRoyaltyAssetsMember2019-01-012019-12-310001802768rprx:RoyaltyIncomeOtherMember2021-01-012021-12-310001802768rprx:RoyaltyIncomeOtherMember2020-01-012020-12-310001802768rprx:RoyaltyIncomeOtherMember2019-01-012019-12-3100018027682020-01-012020-12-3100018027682019-01-012019-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2018-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2018-12-310001802768us-gaap:CommonStockMemberrprx:ClassRRedeemableStockMember2018-12-310001802768rprx:DeferredSharesMember2018-12-310001802768us-gaap:AdditionalPaidInCapitalMember2018-12-310001802768rprx:UnitHoldersAndShareholdersContributionsMember2018-12-310001802768us-gaap:RetainedEarningsMember2018-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2018-12-310001802768us-gaap:NoncontrollingInterestMember2018-12-310001802768us-gaap:TreasuryStockMember2018-12-3100018027682018-12-310001802768us-gaap:RetainedEarningsMember2019-01-012019-12-310001802768us-gaap:NoncontrollingInterestMember2019-01-012019-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2019-01-012019-12-310001802768us-gaap:TreasuryStockMember2019-01-012019-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2019-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2019-12-310001802768us-gaap:CommonStockMemberrprx:ClassRRedeemableStockMember2019-12-310001802768rprx:DeferredSharesMember2019-12-310001802768us-gaap:AdditionalPaidInCapitalMember2019-12-310001802768rprx:UnitHoldersAndShareholdersContributionsMember2019-12-310001802768us-gaap:RetainedEarningsMember2019-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2019-12-310001802768us-gaap:NoncontrollingInterestMember2019-12-310001802768us-gaap:TreasuryStockMember2019-12-3100018027682019-12-310001802768rprx:UnitHoldersAndShareholdersContributionsMember2020-01-012020-12-310001802768us-gaap:NoncontrollingInterestMember2020-01-012020-12-310001802768us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310001802768srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310001802768us-gaap:RetainedEarningsMember2020-01-012020-12-310001802768us-gaap:CommonStockMemberrprx:ClassRRedeemableStockMember2020-01-012020-12-310001802768us-gaap:RetainedEarningsMember2020-01-012020-06-170001802768us-gaap:NoncontrollingInterestMember2020-01-012020-06-1700018027682020-01-012020-06-170001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2020-01-012020-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-01-012020-12-310001802768rprx:DeferredSharesMember2020-01-012020-12-310001802768us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2020-01-012020-12-310001802768us-gaap:TreasuryStockMember2020-01-012020-12-310001802768us-gaap:RetainedEarningsMember2020-06-182020-12-310001802768us-gaap:NoncontrollingInterestMember2020-06-182020-12-3100018027682020-06-182020-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2020-12-310001802768us-gaap:CommonStockMemberrprx:ClassRRedeemableStockMember2020-12-310001802768rprx:DeferredSharesMember2020-12-310001802768us-gaap:AdditionalPaidInCapitalMember2020-12-310001802768rprx:UnitHoldersAndShareholdersContributionsMember2020-12-310001802768us-gaap:RetainedEarningsMember2020-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001802768us-gaap:NoncontrollingInterestMember2020-12-310001802768us-gaap:TreasuryStockMember2020-12-310001802768us-gaap:NoncontrollingInterestMember2021-01-012021-12-310001802768us-gaap:RetainedEarningsMember2021-01-012021-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-01-012021-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2021-01-012021-12-310001802768rprx:DeferredSharesMember2021-01-012021-12-310001802768us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-12-310001802768us-gaap:TreasuryStockMember2021-01-012021-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-12-310001802768us-gaap:CommonStockMemberus-gaap:CommonClassBMember2021-12-310001802768us-gaap:CommonStockMemberrprx:ClassRRedeemableStockMember2021-12-310001802768rprx:DeferredSharesMember2021-12-310001802768us-gaap:AdditionalPaidInCapitalMember2021-12-310001802768rprx:UnitHoldersAndShareholdersContributionsMember2021-12-310001802768us-gaap:RetainedEarningsMember2021-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001802768us-gaap:NoncontrollingInterestMember2021-12-310001802768us-gaap:TreasuryStockMember2021-12-310001802768rprx:LegacyInvestorsPartnershipsMemberrprx:ExchangeOfferTransactionMember2020-02-112020-02-11xbrli:pure0001802768rprx:RoyaltyPharmaInvestmentsOldRPIMemberrprx:ExchangeOfferTransactionMember2020-02-110001802768rprx:RoyaltyPharmaCollectionTrustMember2020-02-110001802768rprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMemberrprx:RoyaltyPharmaCollectionTrustMember2020-02-110001802768rprx:LegacyInvestorsPartnershipsMemberrprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Memberus-gaap:SecuredDebtMember2020-02-110001802768rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Memberus-gaap:SecuredDebtMemberrprx:RPI2019IntermediateFinanceMember2020-02-110001802768us-gaap:SecuredDebtMemberrprx:OldCreditFacilityMember2020-02-112020-02-110001802768us-gaap:SecuredDebtMemberrprx:RPIFTSeniorSecuredCreditFacilitiesMemberrprx:RPI2019IntermediateFinanceMember2020-02-112020-02-110001802768us-gaap:IPOMemberus-gaap:CommonClassAMember2020-06-182020-06-180001802768us-gaap:IPOMemberus-gaap:CommonClassAMember2020-06-180001802768us-gaap:CommonClassAMemberrprx:IPOSharesFromCompanyMember2020-06-182020-06-180001802768us-gaap:CommonClassAMemberrprx:IPOSharesFromSellingShareholdersMember2020-06-182020-06-180001802768us-gaap:CommonClassAMember2020-06-182020-06-180001802768rprx:IPOContinuingInvestorsPartnershipsMemberus-gaap:CommonClassBMember2020-06-012020-06-300001802768rprx:LegacyInvestorsPartnershipsMemberrprx:RoyaltyPharmaInvestmentsOldRPIMember2020-02-2900018027682020-06-30rprx:partnership0001802768rprx:ContinuingInvestorsPartnershipMemberrprx:RPHoldingsMemberus-gaap:NoncontrollingInterestMember2021-12-310001802768srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2019-12-310001802768srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2019-01-012019-12-310001802768us-gaap:FinanceReceivablesMemberus-gaap:CustomerConcentrationRiskMemberrprx:VertexMember2021-01-012021-12-310001802768us-gaap:FinanceReceivablesMemberus-gaap:CustomerConcentrationRiskMemberrprx:VertexMember2020-01-012020-12-31rprx:segment0001802768us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2019-04-052019-04-050001802768us-gaap:SeriesAPreferredStockMember2019-04-052019-04-050001802768us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2020-08-072020-08-070001802768us-gaap:SeriesBPreferredStockMember2020-08-072020-08-070001802768us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2021-01-012021-12-310001802768rprx:MorphoSysMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-06-022021-06-020001802768us-gaap:SeriesAPreferredStockMember2021-12-310001802768us-gaap:SeriesBPreferredStockMember2021-12-310001802768us-gaap:ForwardContractsMember2021-12-310001802768rprx:DevelopmentFundingBondForwardMember2021-12-310001802768us-gaap:SeriesAPreferredStockMember2020-12-310001802768us-gaap:ForwardContractsMember2020-12-310001802768us-gaap:PreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMemberus-gaap:SeriesAPreferredStockMembersrt:MaximumMember2019-04-052019-04-050001802768us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember2019-04-052019-04-050001802768us-gaap:PreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMemberus-gaap:SeriesBPreferredStockMember2020-08-072020-08-070001802768us-gaap:PreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMemberus-gaap:SeriesBPreferredStockMember2020-08-072020-08-070001802768rprx:TreasuryRateLockContractsMember2021-07-012021-07-310001802768us-gaap:InterestRateSwapMember2020-01-012020-12-310001802768us-gaap:InterestRateSwapMember2019-01-012019-12-310001802768rprx:EpizymeIncMember2019-11-300001802768rprx:EpizymeIncMember2019-11-012019-11-300001802768rprx:EpizymeCommonStockWarrantMember2019-11-300001802768rprx:EpizymeIncMemberrprx:EpizymeCommonStockWarrantMember2019-11-300001802768rprx:EpizymeIncMemberus-gaap:PutOptionMember2019-11-012019-11-300001802768rprx:EpizymeIncMemberus-gaap:PutOptionMember2019-11-300001802768rprx:EpizymeIncMemberus-gaap:ForwardContractsMember2019-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:WarrantMember2021-01-012021-12-310001802768us-gaap:WarrantMember2020-01-012020-12-310001802768us-gaap:WarrantMember2019-01-012019-12-310001802768us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:GainLossOnDerivativeInstrumentsMember2021-01-012021-12-310001802768us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:GainLossOnDerivativeInstrumentsMember2020-01-012020-12-310001802768us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:GainLossOnDerivativeInstrumentsMember2019-01-012019-12-310001802768us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2021-01-012021-12-310001802768us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2020-01-012020-12-310001802768us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2019-01-012019-12-310001802768us-gaap:NondesignatedMemberus-gaap:InterestRateSwapMemberus-gaap:GainLossOnDerivativeInstrumentsMember2021-01-012021-12-310001802768us-gaap:NondesignatedMemberus-gaap:InterestRateSwapMemberus-gaap:GainLossOnDerivativeInstrumentsMember2020-01-012020-12-310001802768us-gaap:NondesignatedMemberus-gaap:InterestRateSwapMemberus-gaap:GainLossOnDerivativeInstrumentsMember2019-01-012019-12-310001802768us-gaap:InterestExpenseMemberus-gaap:NondesignatedMemberus-gaap:InterestRateSwapMember2021-01-012021-12-310001802768us-gaap:InterestExpenseMemberus-gaap:NondesignatedMemberus-gaap:InterestRateSwapMember2020-01-012020-12-310001802768us-gaap:InterestExpenseMemberus-gaap:NondesignatedMemberus-gaap:InterestRateSwapMember2019-01-012019-12-310001802768us-gaap:NondesignatedMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:WarrantMember2021-01-012021-12-310001802768us-gaap:NondesignatedMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:WarrantMember2020-01-012020-12-310001802768us-gaap:NondesignatedMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:WarrantMember2019-01-012019-12-310001802768us-gaap:NondesignatedMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:ForwardContractsMember2021-01-012021-12-310001802768us-gaap:NondesignatedMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:ForwardContractsMember2020-01-012020-12-310001802768us-gaap:NondesignatedMemberus-gaap:GainLossOnDerivativeInstrumentsMemberus-gaap:ForwardContractsMember2019-01-012019-12-310001802768rprx:TreasuryRateLockContractsMemberus-gaap:GainLossOnDerivativeInstrumentsMember2021-01-012021-12-310001802768rprx:TreasuryRateLockContractsMemberus-gaap:GainLossOnDerivativeInstrumentsMember2020-01-012020-12-310001802768rprx:TreasuryRateLockContractsMemberus-gaap:GainLossOnDerivativeInstrumentsMember2019-01-012019-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:WarrantMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:WarrantMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768us-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001802768rprx:MorphoSysMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-01-012021-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2020-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2019-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2021-01-012021-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2020-01-012020-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2021-12-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2020-12-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2019-12-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-12-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-12-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2020-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2019-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:AvailableforsaleSecuritiesMemberus-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-12-310001802768us-gaap:AvailableforsaleSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:SeriesBPreferredStockMember2021-01-012021-12-310001802768us-gaap:AvailableforsaleSecuritiesMemberus-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-12-310001802768us-gaap:AvailableforsaleSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:SeriesBPreferredStockMember2020-01-012020-12-310001802768us-gaap:AvailableforsaleSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-01-012021-12-310001802768us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2021-01-012021-12-310001802768us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2020-01-012020-12-310001802768rprx:BioCrystPharmaceuticalsIncMemberus-gaap:FairValueInputsLevel3Member2021-11-012021-11-300001802768us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2020-12-310001802768us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2020-12-310001802768us-gaap:PreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMembersrt:MaximumMember2019-04-052019-04-050001802768us-gaap:PreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMemberus-gaap:SeriesBPreferredStockMember2021-01-012021-12-310001802768rprx:CysticFibrosisFranchiseMember2021-12-310001802768rprx:TysabriMember2021-12-310001802768rprx:ImbruvicaMember2021-12-310001802768rprx:XtandiMember2021-12-310001802768rprx:TremfyaMember2021-12-310001802768rprx:EvrysdiMember2021-12-310001802768rprx:OtherFinancialRoyaltyAssetMember2021-12-310001802768rprx:CysticFibrosisFranchiseMember2020-12-310001802768rprx:TysabriMember2020-12-310001802768rprx:ImbruvicaMember2020-12-310001802768rprx:XtandiMember2020-12-310001802768rprx:PromactaMember2020-12-310001802768rprx:EvrysdiMember2020-12-310001802768rprx:OtherFinancialRoyaltyAssetMember2020-12-310001802768rprx:DPPIVPatentsMember2021-12-310001802768rprx:DPPIVPatentsMember2020-12-310001802768rprx:DPPIVPatentsMember2021-01-012021-12-310001802768rprx:IndividualLicenseesConcentrationRiskMemberrprx:IntangibleRoyaltyAssetsMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310001802768rprx:IndividualLicenseesConcentrationRiskMemberrprx:IntangibleRoyaltyAssetsMemberus-gaap:SalesRevenueNetMember2020-01-012020-12-310001802768rprx:IndividualLicenseesConcentrationRiskMemberrprx:IntangibleRoyaltyAssetsMemberus-gaap:SalesRevenueNetMember2019-01-012019-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-02-110001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2021-01-012021-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-01-012020-12-310001802768rprx:AvillionEntitiesMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2021-01-012021-12-310001802768rprx:AvillionEntitiesMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-01-012020-12-310001802768rprx:AvillionEntitiesMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2019-01-012019-12-310001802768us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMemberrprx:AvillionIMember2020-01-012020-12-310001802768us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMemberrprx:AvillionIMember2021-01-012021-12-310001802768us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMemberrprx:AvillionIMember2019-01-012019-12-310001802768rprx:MerckAssetPhaseIIClinicalTrialMemberrprx:AvillionIIMember2017-03-310001802768us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMemberrprx:AvillionIIMember2020-01-012020-12-310001802768rprx:MerckAssetPhaseIIClinicalTrialMemberrprx:AvillionIIMember2021-07-310001802768rprx:MerckAssetPhaseIIClinicalTrialMemberrprx:AvillionIIMember2018-05-310001802768rprx:AZAssetPhaseIIAndPhaseIIIClinicalTrialMemberrprx:AvillionIIMember2018-05-310001802768rprx:AvillionEntitiesMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2021-12-310001802768rprx:AvillionEntitiesMemberus-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2020-12-310001802768rprx:FundingAgreementsWithSanofiMember2021-01-012021-12-310001802768rprx:MorphoSysMember2021-01-012021-12-310001802768rprx:MorphoSysMemberrprx:BioCrystPharmaceuticalsIncMember2021-11-012021-11-300001802768rprx:FundingAgreementsWithSanofiMember2020-01-012020-12-310001802768rprx:FundingAgreementWithBioCrystMember2020-01-012020-12-310001802768rprx:FundingAgreementsWithSanofiMember2019-01-012019-12-310001802768rprx:FundingAgreementsWithPfizerMember2019-01-012019-12-310001802768rprx:FundingAgreementsWithSanofiMember2021-12-310001802768rprx:PointSevenFivePercentSeniorNotesDue2023Memberus-gaap:UnsecuredDebtMember2021-12-310001802768rprx:PointSevenFivePercentSeniorNotesDue2023Memberus-gaap:UnsecuredDebtMember2021-01-012021-12-310001802768rprx:PointSevenFivePercentSeniorNotesDue2023Memberus-gaap:UnsecuredDebtMember2020-12-310001802768rprx:OnePointTwoZeroPercentSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2021-12-310001802768rprx:OnePointTwoZeroPercentSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2021-01-012021-12-310001802768rprx:OnePointTwoZeroPercentSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:OnePointSevenFivePercentSeniorNotesDue2027Member2021-12-310001802768us-gaap:UnsecuredDebtMemberrprx:OnePointSevenFivePercentSeniorNotesDue2027Member2021-01-012021-12-310001802768us-gaap:UnsecuredDebtMemberrprx:OnePointSevenFivePercentSeniorNotesDue2027Member2020-12-310001802768rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Memberus-gaap:UnsecuredDebtMember2021-12-310001802768rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Memberus-gaap:UnsecuredDebtMember2021-01-012021-12-310001802768rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Memberus-gaap:UnsecuredDebtMember2020-12-310001802768rprx:TwoPointOneFivePercentSeniorNotesDue2031Memberus-gaap:UnsecuredDebtMember2021-12-310001802768rprx:TwoPointOneFivePercentSeniorNotesDue2031Memberus-gaap:UnsecuredDebtMember2021-01-012021-12-310001802768rprx:TwoPointOneFivePercentSeniorNotesDue2031Memberus-gaap:UnsecuredDebtMember2020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member2021-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member2021-01-012021-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member2020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointFiveFivePercentSeniorNotesDue2050Member2021-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointFiveFivePercentSeniorNotesDue2050Member2021-01-012021-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointFiveFivePercentSeniorNotesDue2050Member2020-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointThreeFivePercentSeniorNotesDue2051Member2021-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointThreeFivePercentSeniorNotesDue2051Member2021-01-012021-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointThreeFivePercentSeniorNotesDue2051Member2020-12-310001802768us-gaap:SeniorNotesMember2021-07-260001802768us-gaap:SeniorNotesMemberrprx:SeniorNotesDue2031Member2021-07-260001802768us-gaap:SeniorNotesMemberrprx:SeniorNotesDue2051Member2021-07-260001802768us-gaap:SeniorNotesMemberrprx:SeniorNotesDue2051Member2021-12-310001802768rprx:TheNotesMemberus-gaap:UnsecuredDebtMember2020-09-020001802768rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Memberus-gaap:SecuredDebtMemberrprx:RPI2019IntermediateFinanceMember2020-09-020001802768rprx:TheNotesMemberus-gaap:UnsecuredDebtMember2021-12-310001802768rprx:TheNotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:UnsecuredDebtMember2020-09-022020-09-020001802768us-gaap:DebtInstrumentRedemptionPeriodThreeMemberrprx:TheNotesMemberus-gaap:UnsecuredDebtMember2020-09-022020-09-020001802768rprx:TheNotesMemberus-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel2Member2021-12-310001802768rprx:TheNotesMemberus-gaap:UnsecuredDebtMemberus-gaap:FairValueInputsLevel2Member2020-12-310001802768us-gaap:RevolvingCreditFacilityMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMember2020-09-182020-09-180001802768us-gaap:RevolvingCreditFacilityMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMember2020-09-180001802768rprx:OvernightBankFundingRateMemberus-gaap:RevolvingCreditFacilityMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMember2020-09-182020-09-180001802768us-gaap:FederalFundsPurchasedMemberus-gaap:RevolvingCreditFacilityMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMember2020-09-182020-09-180001802768us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMember2020-09-182020-09-180001802768rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Memberus-gaap:SecuredDebtMember2020-02-110001802768rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Memberus-gaap:SecuredDebtMember2020-02-110001802768rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Memberus-gaap:SecuredDebtMember2020-01-012020-12-310001802768rprx:TheNotesMemberus-gaap:UnsecuredDebtMember2020-01-012020-12-31rprx:class0001802768rprx:ClassRRedeemableStockMember2021-01-012021-12-31rprx:noncontrolling_interest0001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2019-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2019-12-310001802768rprx:ContinuingInvestorsPartnershipMemberus-gaap:NoncontrollingInterestMember2019-12-310001802768rprx:EPAHoldingsMemberus-gaap:NoncontrollingInterestMember2019-12-310001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2020-01-012020-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2020-01-012020-12-310001802768rprx:ContinuingInvestorsPartnershipMemberus-gaap:NoncontrollingInterestMember2020-01-012020-12-310001802768rprx:EPAHoldingsMemberus-gaap:NoncontrollingInterestMember2020-01-012020-12-310001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2020-01-012020-06-170001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2020-01-012020-06-170001802768rprx:ContinuingInvestorsPartnershipMemberus-gaap:NoncontrollingInterestMember2020-01-012020-06-170001802768rprx:EPAHoldingsMemberus-gaap:NoncontrollingInterestMember2020-01-012020-06-170001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2020-06-182020-09-300001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2020-06-182020-09-300001802768rprx:ContinuingInvestorsPartnershipMemberus-gaap:NoncontrollingInterestMember2020-06-182020-09-300001802768rprx:EPAHoldingsMemberus-gaap:NoncontrollingInterestMember2020-06-182020-09-300001802768us-gaap:NoncontrollingInterestMember2020-06-182020-09-300001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2020-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2020-12-310001802768rprx:ContinuingInvestorsPartnershipMemberus-gaap:NoncontrollingInterestMember2020-12-310001802768rprx:EPAHoldingsMemberus-gaap:NoncontrollingInterestMember2020-12-310001802768rprx:ContinuingInvestorsPartnershipMemberrprx:RPHoldingsMemberus-gaap:NoncontrollingInterestMember2020-12-310001802768rprx:RPHoldingsMemberus-gaap:NoncontrollingInterestMember2020-12-310001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2021-01-012021-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2021-01-012021-12-310001802768rprx:ContinuingInvestorsPartnershipMemberus-gaap:NoncontrollingInterestMember2021-01-012021-12-310001802768rprx:EPAHoldingsMemberus-gaap:NoncontrollingInterestMember2021-01-012021-12-310001802768rprx:RoyalPharmacySelectFinanceTrustMemberus-gaap:NoncontrollingInterestMember2021-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2021-12-310001802768rprx:ContinuingInvestorsPartnershipMemberus-gaap:NoncontrollingInterestMember2021-12-310001802768rprx:EPAHoldingsMemberus-gaap:NoncontrollingInterestMember2021-12-310001802768rprx:RPHoldingsMemberus-gaap:NoncontrollingInterestMember2021-12-3100018027682021-01-012021-03-3100018027682021-04-012021-06-3000018027682021-10-012021-12-3100018027682021-07-012021-09-300001802768rprx:A2020EquityIncentivePlanMemberus-gaap:CommonClassAMember2020-06-150001802768rprx:A2020EquityIncentivePlanMemberus-gaap:CommonClassAMember2021-12-310001802768us-gaap:RestrictedStockUnitsRSUMember2021-12-310001802768us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001802768us-gaap:CommonClassAMember2021-01-012021-12-310001802768us-gaap:CommonClassAMember2020-01-012020-12-310001802768rprx:ClassBHoldersMember2021-01-012021-12-310001802768rprx:LegacyInvestorsPartnershipsAndRPSFTMember2021-01-012021-12-310001802768rprx:ClassBHoldersMember2020-01-012020-12-310001802768rprx:LegacyInvestorsPartnershipsAndRPSFTMember2020-01-012020-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310001802768us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2019-12-310001802768us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-12-310001802768us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-01-012020-12-310001802768us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310001802768us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-12-310001802768us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-12-310001802768us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-12-310001802768us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310001802768us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-12-310001802768us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001802768us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001802768us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001802768us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001802768us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001802768us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001802768srt:ManagementMemberrprx:OperatingAndPersonnelPaymentsMember2021-12-310001802768srt:ManagementMemberrprx:OperatingAndPersonnelPaymentsMember2021-01-012021-12-310001802768srt:ManagementMemberrprx:FormerOperatingAndPersonnelPaymentsMember2021-01-012021-12-310001802768srt:ManagementMemberrprx:FormerOperatingAndPersonnelPaymentsMember2020-01-012020-12-310001802768srt:ManagementMemberrprx:FormerOperatingAndPersonnelPaymentsMember2019-01-012019-12-310001802768srt:AffiliatedEntityMemberrprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember2021-12-310001802768srt:AffiliatedEntityMemberrprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember2020-12-310001802768srt:AffiliatedEntityMemberrprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember2021-12-310001802768srt:AffiliatedEntityMemberrprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember2020-12-310001802768rprx:AssignmentAgreementBenefitOfPaymentStreamMembersrt:AffiliatedEntityMemberrprx:BristolMyersSquibbMember2017-12-082017-12-080001802768rprx:AssignmentAgreementFundingObligationsMembersrt:AffiliatedEntityMemberrprx:BristolMyersSquibbMember2017-12-082017-12-080001802768rprx:AssignmentAgreementFundingObligationsMembersrt:AffiliatedEntityMemberrprx:BristolMyersSquibbMember2020-03-310001802768rprx:AssignmentAgreementFundingObligationsMembersrt:AffiliatedEntityMemberrprx:BristolMyersSquibbMember2021-12-310001802768rprx:AssignmentAgreementFundingObligationsMembersrt:AffiliatedEntityMemberrprx:BristolMyersSquibbMember2020-12-310001802768rprx:AgreementWithMSCIMember2021-04-162021-04-160001802768rprx:AgreementWithMSCIMember2021-12-310001802768rprx:PabloLegorretaMemberrprx:PurchasingAndDonatingVentilatorsMember2020-01-012020-12-310001802768rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMembersrt:AffiliatedEntityMember2021-01-012021-12-310001802768rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMembersrt:AffiliatedEntityMemberus-gaap:TreasuryStockMember2021-01-012021-12-310001802768rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMembersrt:AffiliatedEntityMemberus-gaap:NoncontrollingInterestMember2021-01-012021-12-310001802768rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMembersrt:AffiliatedEntityMemberus-gaap:NoncontrollingInterestMember2020-01-012020-12-310001802768rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember2020-08-072020-08-070001802768rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember2019-11-012019-11-300001802768rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember2020-01-012020-01-310001802768rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember2020-11-012020-11-300001802768rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember2021-11-042021-11-040001802768rprx:MorphoSysMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-06-020001802768us-gaap:SubsequentEventMember2022-01-012022-01-31rprx:paymentrprx:tranche

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2021
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 001-39329
Royalty Pharma plc
(Exact name of registrant as specified in its charter)
England and Wales
98-1535773
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
110 East 59th Street
New York, New York 10022
(Address of principal executive offices and Zip Code)
(212) 883-0200
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A ordinary shares, par value $0.0001
RPRXThe Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes  ☒    No  ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐     No ☒ 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐ 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes  ☒   No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer  
☐
Smaller reporting company
☐
Emerging growth company
☐
                
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes  ☐     No  ☒

The aggregate market value of the voting and non-voting ordinary shares held by non-affiliates of the registrant as of June 30, 2021, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $16.6 billion based upon the closing price reported for such date on the Nasdaq Stock Market LLC. This determination of affiliate status is not necessarily a conclusive determination for any other purposes.

As of February 11, 2022, Royalty Pharma plc had 432,963,472 Class A ordinary shares outstanding and 174,212,681 Class B ordinary shares outstanding.

DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement for the 2022 Annual General Meeting of Shareholders, or Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2021. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof.





ROYALTY PHARMA PLC
PART I
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
PART II
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
PART III
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
PART IV
Item 15.
Item 16.













Special Note Regarding Forward-Looking Statements

This Annual Report on Form 10-K contains statements reflecting our views about our future performance that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about us, our current and prospective assets, our industry, our beliefs and our assumptions. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. You should evaluate all forward-looking statements made in this Annual Report on Form 10-K in the context of the numerous risks outlined in Part I under Item 1A. under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

These risks and uncertainties include factors related to:
•sales risks of biopharmaceutical products on which we receive royalties;
•the ability of RP Management, LLC (the “Manager”) to locate suitable assets for us to acquire;
•uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add development-stage product candidates to our product portfolio;
•the assumptions underlying our business model;
•our ability to successfully execute our royalty acquisition strategy;
•our ability to leverage our competitive strengths;
•actual and potential conflicts of interest with the Manager and its affiliates;
•the ability of the Manager or its affiliates to attract and retain highly talented professionals;
•the effect of changes to tax legislation and our tax position; and
•the risks, uncertainties and other factors we identify elsewhere in this Annual Report on Form 10-K and in our other filings with the U.S. Securities and Exchange Commission.

Although we believe the expectations reflected in the forward-looking statements are reasonable, any of those expectations could prove to be inaccurate, and as a result, the forward-looking statements based on those expectations also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this Annual Report on Form 10-K should not be regarded as a representation by us that our plans and business objectives will be achieved. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. We are under no duty to update any of these forward-looking statements after the date of this Annual Report on Form 10-K to conform our prior statements to actual results or revised expectations.





PART I     
Item 1.         BUSINESS

Overview

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

Our capital-efficient business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, including long product life cycles, significant barriers to entry and noncyclical revenues, but with substantially reduced exposure to many common industry challenges such as early stage development risk, therapeutic area constraints, high research and development costs, and high fixed manufacturing and marketing costs. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies across the biopharmaceutical industry.

The success of our business has been the result of a focused strategy of actively identifying and tracking the development and commercialization of key new therapies, allowing us to move quickly to make acquisitions when opportunities arise. We acquire royalties on approved products, often in the early stages of their commercial launches, and development-stage product candidates with strong proof of concept data, mitigating development risk and expanding our opportunity set. From 1996 through 2021, we have deployed more than $22 billion of cash to acquire biopharmaceutical royalties, representing more than 50% of all royalty transactions during this period. From 2012, when we began acquiring royalties on development-stage product candidates, through 2021, we have deployed more than $17 billion of cash to acquire biopharmaceutical royalties, representing approximately 60% of all royalty transactions during this period.

In 2021, we generated cash from operating activities of $2.0 billion, Adjusted Cash Receipts (as defined in “—Non-GAAP Financial Results”) of $2.1 billion and Adjusted Cash Flow (as defined in “—Non-GAAP Financial Results”) of $1.8 billion. We deployed $2.7 billion of cash in 2021 for royalties and related securities.

Portfolio Overview

Our portfolio consists of royalties on more than 35 commercial products and ten development-stage product candidates. We believe that end market sales of the therapies in our portfolio are important drivers of our financial performance as a substantial portion of our royalties are based on end market sales. In addition, end market sales are a strong indicator of the importance of the therapies to both patients and the marketers. The following table provides an overview of our current portfolio of royalties:

1

Product(s)Marketer(s)Product Detail 2021 Royalty Receipts
(in millions)		2021 End Market Sales (in millions) (1)
Approved Products
Cystic fibrosis franchise (2)VertexCystic fibrosis$702$7,573
TysabriBiogenRelapsing forms of multiple sclerosis3692,063
ImbruvicaAbbVie, Johnson & JohnsonHematological malignancies and chronic graft versus host disease3536,943
PromactaNovartisChronic immune thrombocytopenic purpura and aplastic anemia 1742,016
XtandiPfizer, AstellasProstate cancer1584,582
Januvia, Janumet, Other DPP-IVsMerck & Co., othersDiabetes1515,288
HIV franchise (3)Gilead, othersHuman immunodeficiency virus (HIV)7816,315
Nurtec ODT/Biohaven payment (4)Biohaven, PfizerMigraine70455
PrevymisMerck & Co.Prophylaxis of CMV in adult recipients of stem cell transplant38370
Farxiga/OnglyzaAstraZenecaDiabetes363,365
TremfyaJohnson & JohnsonPlaque psoriasis and psoriatic arthritis362,127
Cabometyx/CometriqExelixis, Ipsen, TakedaKidney, liver and thyroid cancers341,590
CrysvitaUltragenyx, Kyowa KirinX-linked hypophoshatemia17179
EvrysdiRocheSpinal muscular atrophy16659
EmgalityLillyMigraine prevention & episodic cluster headache15577
ErleadaJohnson & JohnsonProstate cancer141,291
TrodelvyGileadMetastatic triple-negative breast cancer13380
IDHIFABristol Myers SquibbRelapsed/refractory AML with an IDH2 mutation12Not disclosed
OrladeyoBioCrystHereditary angioedema prophylaxis7117
TazverikEpizymeEpithelioid sarcoma and follicular lymphoma332
OxlumoAlnylamPrimary hyperoxaluria type 1160
Other products (5)(6)311—
Total royalty receipts$2,609
Development Stage Product Candidates
Aficamten (7)CytokineticsObstructive hypertrophic cardiomyopathy (Phase 3)——
BCX9930BioCrystParoxysmal nocturnal hemoglobinuria (Phase 3) ——
CPI-0209MorphoSysHematological malignancies and solid tumors (Phase 2)——
GantenerumabRocheAlzheimer’s disease (Phase 3)——
Omecamtiv mecarbil (8)CytokineticsHeart failure (Phase 3)——
OtilimabGlaxoSmithKlineRheumatoid arthritis (Phase 3)——
PelabresibMorphoSysMyelofibrosis (Phase 3)——
PT027AstraZenecaAsthma (Phase 3) ——
SeltorexantJohnson & JohnsonMDD with insomnia symptoms (Phase 3) ——
ZavegepantBiohavenMigraine (Phase 3) ——
CMV is Cytomegalovirus, AML is Acute Myelogenous Leukemia, IDH2 is isocitrate dehydrogenase-2 and MDD is Major Depressive Disorder.
Amounts shown in the table may not add due to rounding.
Notes:
(1)     Represents end market sales for the year ended December 31, 2021 as reported by respective product marketers or based on Visible Alpha projections as of February 9, 2022 where marketers have not reported end market sales. Sales shown for Crysvita represent Europe, the Middle East and Africa only. For the majority of our royalties, royalty receipts lag product performance by one quarter and can generally be estimated by applying our publicly disclosed royalty rate to the preceding quarter’s marketer-announced net revenues on a product-by-product basis.
(2)     The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio.
(3)     The HIV franchise includes the following approved products: Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza and Biktarvy. Royalties are received on the emtricitabine portion of sales only.
(4)     Includes royalty receipts for Nurtec ODT of $7.7 million and quarterly redemptions of $15.6 million of the Series A Biohaven Preferred Shares (presented as Proceeds from available for sale debt securities on the Statement of Cash Flows).
(5)     Excludes duplicate end-market sales where we have multiple royalties on the same product: Kombiglyze, Nesina, Onglyza and Soliqua.
(6)     Other products primarily include royalties on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion, for which receipts are presented as Distributions from non-consolidated affiliates on the Statement of Cash Flows), Lexiscan, Soliqua, Nesina, Cimzia, Letairis, Entyvio, Myozyme and Mircera. Other products includes a one-time $45.0 million milestone payment that we received on Soliqua and contributions from the Legacy SLP Interest (defined below).
(7)     Royalty was acquired in January 2022.
(8)     The financial royalty asset associated with omecamtiv mecarbil was written off in the year ended December 31, 2020 given the uncertainty around the future of omecamtiv mecarbil at the time.
2



Biopharmaceutical Industry and the Role of Royalties

Our business is supported by significant growth and unprecedented innovation within the biopharmaceutical industry. Global prescription pharmaceutical sales are projected to grow from approximately $0.9 trillion in 2021 to approximately $1.3 trillion in 2026, representing a CAGR of 7% according to EvaluatePharma despite more than $130 billion in cumulative sales being lost to expected patent expiries during the same period. The growth of the biopharmaceutical industry is driven by global secular trends, including population growth, increasing life expectancy and growth of the middle classes in emerging markets. In addition, a dramatic acceleration of medical research in recent years has led to a better understanding of the molecular origins of disease and identification of potential targets for therapeutic intervention. This has created research and development opportunities for new drugs. The significant pace of biopharmaceutical innovation coupled with the proliferation of new biotechnology companies and the increasing cost of drug development has created a significant capital need over recent years that we believe will provide a sustainable tailwind for our business.

Royalties play a fundamental and growing role in the biopharmaceutical industry. As a result of the increasing cost and complexity of drug development, the creation of a new drug today typically involves a number of industry participants. Academia and other research institutions conduct basic research and license new technologies to industry for further development. Biotechnology companies typically in-license these new technologies, add value through applied research and early-stage clinical development, and then either out-license the resulting development-stage product candidates to large biopharmaceutical companies for late-stage clinical development and commercialization, or commercialize the products themselves. As new drugs are transferred along this value chain, royalties are created as compensation for the licensing or selling institutions. Biotechnology companies are also increasingly creating royalties on existing products within their portfolios, known as synthetic royalties, in order to provide a source of non-dilutive capital to fund their businesses. As a result of this industry paradigm, the development of a single new drug can lead to the creation of multiple royalties. Given our leadership position within the biopharmaceutical royalty sector, we are able to capitalize on the growing volumes of royalties that are created as new therapies are developed to address unmet medical needs.

Our Business Model

We believe that the following elements of our business and product portfolio provide a unique and compelling proposition to investors seeking exposure to the biopharmaceutical sector.

Our portfolio provides direct exposure to a broad array of blockbuster therapies. As of December 31, 2021, our portfolio included royalties on 14 therapies that each generated end-market sales of more than $1 billion, including five therapies that each generated end-market sales of more than $3 billion. The therapies within our royalty portfolio are marketed by leading global biopharmaceutical companies for whom these products are important sources of revenue. Given the marketers’ significant focus on and investment in these products, they are motivated to invest substantial resources in driving continued sales growth.

Our portfolio is highly diversified across products, therapeutic areas and marketers. Our portfolio consists of royalties on more than 35 marketed biopharmaceutical therapies which address a wide range of therapeutic areas, including rare diseases, cancer, neurology, immunology, hematology and diabetes. In the year ended December 31, 2021, no individual therapy accounted for more than 19% of our royalty receipts, no therapeutic area accounted for more than 29% of our royalty receipts and no marketer represented more than 27% of our royalty receipts. The royalties in our portfolio entitle us to payments based directly on the top-line sales of the associated therapies, rather than the profits of these therapies. As such, the diversification of our profits directly reflects the diversification of our royalty receipts, rather than varying levels of product-level profitability, as would typically be expected within a biopharmaceutical company. The graphic below shows the diversification within our 2021 royalty receipts by product, therapeutic area and marketer.

3

rprx-20211231_g1.jpg


Note: Only categories of at least 5% are separately presented in the charts.
(1)    Comprised of royalty receipts from Januvia, Janumet and other DPP-IVs

The key growth-driving royalties in our portfolio are protected by long patent lives. The estimated weighted average royalty duration of our portfolio is approximately 13 years based on projected cumulative cash royalty receipts. Our largest marketed royalty in 2021 was on Vertex’s cystic fibrosis franchise, and existing patent applications covering Trikafta, the most significant product in that franchise, are expected to provide exclusivity through 2037. Our right to receive royalties is perpetual, but we expect that the 2037 patent expiration for Trikafta may result in potential sales declines based on potential generic entry. Several of our marketed royalties have unlimited durations and could provide cash flows for many years after key patents have expired.

Simple and efficient operating model generates substantial cash flow for reinvestment in new biopharmaceutical royalties. Our capital-efficient operating model requires limited operating expenses and no material capital investment in fixed assets or infrastructure in order to support the ongoing growth of our business. As a result, we generate high Adjusted Cash Flow relative to our Adjusted Cash Receipts and we convert the vast majority of our Adjusted Cash Flow into operating cash flow. In 2021, we generated cash from operating activities of $2.0 billion, Adjusted Cash Receipts of $2.1 billion and Adjusted Cash Flow of $1.8 billion. We deployed $2.7 billion of cash in 2021 for royalties and related securities. Our high cash flow conversion provides us with significant capital that we can deploy for new royalty acquisitions and also use to grow our dividend to shareholders.

Our business model captures many of the most attractive aspects of the biopharmaceutical industry, but with reduced exposure to many common industry challenges. The biopharmaceutical industry benefits from a number of highly attractive characteristics, including long product life cycles, significant barriers to entry and non-cyclical revenues. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies from across the biopharmaceutical industry. We focus on the acquisition of royalties on approved products or development-stage product candidates that have generated strong proof of concept data, avoiding the risks associated with early stage research and development. By acquiring royalties, we are able to realize payments based directly on the top-line sales of leading biopharmaceutical therapies, without the costs associated with fixed research and development, manufacturing and commercial infrastructure.

Our unique role in the biopharmaceutical ecosystem positions us to benefit from multiple compounding growth drivers. As a result of our significant scale and highly flexible business model, we believe that we are uniquely positioned to capitalize on multiple compounding growth drivers: an accelerating understanding of the molecular origins of disease, technological innovation leading to the creation of new treatment modalities, an increasing number of biopharmaceutical industry participants with significant capital needs, competitive industry dynamics which reward companies that can rapidly execute broad clinical development programs, increasing U.S. Food and Drug Administration (“FDA”) drug approvals which reached an all-time high in 2018 and the potential for multiple royalties to be created from each new drug that reaches the market.

4

We have the ability to access innovation from across the biopharmaceutical ecosystem. Our approach is to first assess innovative science in areas of significant unmet medical need and then evaluate how to acquire royalties on therapies that we believe are attractive. We closely follow a broad range of therapeutic areas and treatment modalities and are therefore able to move quickly when we identify compelling opportunities to acquire new royalties.

We have deep access to attractively priced investment grade debt that provides a significant cost of capital advantage. We believe that we have an attractive cost of capital that enables us to acquire high-quality biopharmaceutical royalties at competitive prices while still creating value for our shareholders. As of December 31, 2021, we had an aggregate principal amount of $7.3 billion of senior unsecured notes outstanding with a weighted average coupon of 2.24% and a weighted-average maturity of approximately 13 years. In addition, we have an undrawn $1.5 billion senior unsecured revolving credit facility.

We have a talented, long-tenured team with extensive experience and deep industry relationships. Our team has significant experience identifying, evaluating and acquiring royalties on biopharmaceutical therapies. Together they have been responsible for more than $22 billion of acquisitions of biopharmaceutical royalties and related assets. Our acquisitions have included many of the industry’s leading therapies across the past three decades, such as Humira, Imbruvica, Trikafta, Lyrica, Tecfidera, Truvada, Xtandi, Neupogen, Remicade and Rituxan, among others. Our long history of collaboration has resulted in deep relationships with a broad range of participants across the biopharmaceutical industry.

We are the leader in acquiring biopharmaceutical royalties. We are the leader within the space, having executed transactions with an aggregate announced transaction value of more than $17 billion from 2012 through December 31, 2021. We estimate this to represent an estimated market share of approximately 60% by value. This compares to our next nearest competitor, which we believe has executed $2.8 billion of transactions, which we estimate to represent market share of 9%. Given the scale of our business relative to our competitors, we have a particularly strong leadership position within large royalty transactions. Since 2012, there have been 11 transactions with an aggregate value of more than $500 million each. We executed 9 of these 11 royalty transactions, for a total aggregate transaction value of $11.6 billion of cash and estimated market share of more than 80%, in this transaction size range. The charts below show our market share since 2012 across all transaction sizes and in royalty transactions with an aggregate value of more than $500 million.

rprx-20211231_g2.jpg
Note: Graphs above include transactions through December 31, 2021 and exclude royalty debt transactions from market share calculations.

5

Our Strategic Plan to Grow the Portfolio

We intend to grow our business by continuing to partner with constituents across the biopharmaceutical value chain to fund innovation. The three key pillars of our growth strategy are summarized below.

• Acquisition of royalties on approved products which provide dependable cash flows. We intend to continue capturing a leading share of royalties on approved products, particularly those that are early in their life cycles, so that we can participate in the growth that is generated as they penetrate their markets, and enter new indications or geographies.

• Acquisition of royalties on attractive development-stage product candidates. We intend to supplement our diverse portfolio of royalties on approved products with acquisitions of royalties on development-stage product candidates that have generated strong clinical proof of concept data to minimize risk and provide attractive upside potential.

• Acquisition of royalties in connection with merger and acquisition (“M&A”) transactions. We acquire royalties in connection with M&A transactions in a number of ways: by purchasing non-strategic assets following the closing of acquisitions, by partnering with biopharmaceutical companies to acquire other biopharmaceutical companies that own significant royalties, or in select circumstances, by seeking to acquire biopharmaceutical companies on our own that have significant royalties or products that could be out-licensed to create royalties.

We acquire royalties in a number of ways including by acquiring existing royalties, acquiring new synthetic royalties and by funding R&D in exchange for future royalties and/or milestones. During the early years of our business, we focused our acquisitions on royalties on approved biopharmaceutical products. However, as we grew and diversified our business, we began acquiring royalties on development-stage product candidates that had demonstrated strong clinical proof of concept. These development-stage transactions have broadened our landscape of potential opportunities where we are able to leverage our scientific expertise and financial strength.

From 2012 through 2021, we deployed $7.8 billion of cash to acquire royalties and milestones on development-stage product candidates. Products underlying $6.3 billion of these acquisitions have already been approved, representing a success rate to date of 81%, while products underlying $0.3 billion were not approved and products underlying $1.1 billion are still in development.

rprx-20211231_g3.jpg

Notes:
(1)     Reflects cash deployed for royalty acquisitions from 2012 through 2021.
(2)     Not approved includes investments in vosaroxin, palbociclib, and Merck KgaA’s anti-IL17 nanobody M1095.


6

In recent years, we have increased the scope of our investments beyond royalties to include additional assets such as equity investments and the acquisition of businesses with significant royalty assets. Our broad scope maximizes our total addressable market and has allowed us to provide a broad range of solutions to our partners across the biopharmaceutical ecosystem.

Our approach is to first assess innovative science in areas of significant unmet medical need and then evaluate how to acquire royalties on therapies that we believe are attractive. We have a strong base of institutional knowledge of important therapeutic areas and key industry trends. Our team of scientific experts actively monitors the evolving treatment landscape across many therapeutic areas and treatment modalities in order to identify new opportunities. We analyze a wide range of scientific data and stay in constant communication with leading physicians, scientists, biopharmaceutical executives and venture capital firms. This allows us to quickly assess and gain conviction in the value of assets when acquisition opportunities arise.

We take a disciplined approach in assessing opportunities and seek to acquire exposure to therapies based on the following key product characteristics:

• Clinically validated: therapies that have received regulatory approval or have strong clinical proof-of-concept data that gives us confidence in the clinical and commercial profile.

• High unmet need: therapies that address areas of significant unmet medical need that also represent large commercial opportunities.

• Significant benefits to patients: therapies that have potential to disrupt or significantly enhance the treatment paradigm for patients and physicians based on compelling clinical data.

• Unique competitive positioning: therapies that are well-positioned to be leaders in their respective categories and are expected to maintain a competitive advantage in the long-term.

• Growth potential: therapies where we see strong long-term potential, based on our in-depth evaluation and in-house expertise.

• Strong marketer: therapies marketed by biopharmaceutical companies that have the resources, capabilities and commitment to successfully develop them and maximize their commercial potential.

• Intellectual Property: therapies that have strong patent portfolios and offer durable, long-term cash flows.

• Attractive value proposition: therapies that we believe provide value-add to the healthcare system.

Our focus is to create significant long-term value for our shareholders by acquiring both approved and development-stage product candidates through a variety of structures. In evaluating these acquisition opportunities, we focus on the following financial characteristics:

• Long duration cash flows: we prioritize long-duration assets over short-duration assets that may boost near-term financial performance. The durability of our cash flows also allows us to add leverage to our portfolio, enhancing returns and providing capital that we can use to acquire additional assets.

• Attractive risk-adjusted returns: we focus on generating attractive returns on our investments on a risk-adjusted basis. We do not target the same return for all assets and evaluate opportunities across the risk spectrum.

• Growth and scale: we seek assets that are accretive to our long-term growth profile and additive to our overall scale.

7

We conduct extensive due diligence when evaluating potential new opportunities. We have end-to-end capabilities that span clinical and commercial analysis, valuation and transaction structuring. We have a highly focused and experienced team that conducts proprietary primary market research, forms its own views on the clinical and commercial outlook for the product, and builds its own financial models, allowing us to generate direct insights and allowing us to take significant accountability and ownership for our investments. We invest significant time and resources across all levels of the organization, including senior leadership, in the evaluation of potential opportunities.

Our Portfolio

Commercial Products

The key royalties in our marketed portfolio related to approved products include the ones listed below. Descriptions of estimated royalty expiration dates are based on our estimates of patent expiry dates (which may include estimated patent term extensions) or estimates of the dates on which the royalties otherwise expire and are based on each product’s key geographies; duration may differ in other geographies. Royalty expiration dates can change due to patent, regulatory, commercial or other developments. In addition, the royalties in our portfolio are subject to the underlying contractual agreements from which they arise and may be subject to reductions or other adjustments in accordance with the terms of such agreements.

Cystic fibrosis franchise

Our cystic fibrosis franchise consists of our right to receive royalty payments on the sale of various products marketed by Vertex for use in the treatment of cystic fibrosis, including Kalydeco (ivacaftor), Orkambi (lumacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor and ivacaftor) and Trikafta/Kaftrio (elexacaftor, tezacaftor and ivacaftor). Vertex’s cystic fibrosis franchise represents the leading treatments for cystic fibrosis, providing treatment options for approximately 90% of cystic fibrosis patients.

We added the cystic fibrosis franchise to our portfolio in November 2014 and purchased an additional residual royalty interest in November 2020. Our right to receive royalties is perpetual, but we expect that the 2037 patent expiration for Trikafta may result in potential sales declines based on potential generic entry. Total global end market sales for the cystic fibrosis franchise during 2021 were approximately $7.6 billion and we collected $702 million in related royalty receipts over the same period. Global end market sales of the cystic fibrosis franchise are projected to grow to approximately $10.4 billion in 2026, according to Visible Alpha.

Tysabri

Tysabri (natalizumab) is a monoclonal antibody marketed by Biogen for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Tysabri competes in the high efficacy segment of the multiple sclerosis market, often reserved for patients with aggressive disease at onset and patients who have failed front-line therapies.

We added Tysabri to our portfolio in February 2017. Our right to receive royalties is perpetual. Total global end market sales for Tysabri during 2021 were approximately $2.1 billion and we collected $369 million in related royalty receipts over the same period. Global end market sales of Tysabri are projected to be approximately $1.7 billion in 2026, according to Visible Alpha.

Imbruvica

Imbruvica (ibrutinib) is a first-in-class small molecule Bruton’s tyrosine kinase inhibitor that is the leading therapy in chronic lymphocytic leukemia, relapsed/refractory mantle cell lymphoma and other blood cancers. Imbruvica is marketed by AbbVie and Janssen, a subsidiary of Johnson & Johnson. A robust clinical program supports Imbruvica’s use across a wide range of patient populations and cancer types, including 11 FDA approvals in six distinct indications.

We added Imbruvica to our portfolio in July 2013. We estimate that our royalties will substantially end between 2027 and 2032. Total global end market sales for Imbruvica during 2021 were approximately $6.9 billion and we collected $353 million in related royalty receipts over the same period. Global end market sales of Imbruvica are projected to grow to approximately $7.9 billion in 2026, according to Visible Alpha.
8


Promacta

Promacta (eltrombopag) is an oral, small molecule activator of the thrombopoietin receptor used to increase the number of platelets in the blood, marketed by Novartis for the treatment of chronic immune thrombocytopenia and aplastic anemia.

We added Promacta to our portfolio in March 2019. We estimate that our royalties will substantially end between 2025 and 2028. Total global end market sales for Promacta during 2021 were approximately $2.0 billion and we collected $174 million in related royalty receipts over the same period. Global end market sales of Promacta are projected to be approximately $600 million in 2026, according to Visible Alpha.

Xtandi

Xtandi (enzalutamide) is an oral, small molecule androgen receptor inhibitor marketed by Pfizer and Astellas for the treatment of non-metastatic and metastatic castration-resistant prostate cancer as well as metastatic castration sensitive prostate cancer.

We added Xtandi to our portfolio in March 2016. We estimate that our royalties will substantially end between 2027 and 2028. Total global end market sales for Xtandi during 2021 were approximately $4.6 billion and we collected $158 million in related royalty receipts over the same period. Global end market sales of Xtandi are projected to grow to approximately $6.3 billion in 2026, according to Visible Alpha.

Januvia, Janumet, other DPP-IVs

We hold patents covering the DPP-IV inhibitors which entitle us to royalty payments on the sale of various products, including Januvia (sitagliptin)/Janumet (sitagliptin and metformin) marketed by Merck & Co.; Tradjenta (linagliptin)/Jentadueto (linagliptin and metformin) marketed by Boehringer Ingelheim and Lilly; and Nesina (alogliptin) marketed by Takeda and Teijin Pharma, which have been approved for the treatment of type 2 diabetics in substitution of, or in addition to, insulin therapy.

We added the DPP-IV inhibitors to our portfolio in June 2011. Our royalties on Januvia and Janumet will expire in 2022 and royalties on the other DPP-IVs have substantially ended. Total global end market sales for the DPP-IV inhibitors during 2021 were approximately $5.3 billion and we collected $151 million in related royalty receipts over the same period.

HIV franchise

Our HIV franchise consists of our right to receive royalty payments on the sale of various products, including Atripla, Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Symtuza and Truvada, which have been approved for the treatment and prevention of HIV and acquired immune deficiency syndrome. Gilead is the primary marketer for the products in our HIV franchise.

We added the HIV franchise to our portfolio starting in July 2005. Our royalties substantially ended in 2021. Total global end market sales for the products in the HIV franchise during 2021 were approximately $16.3 billion and we collected $78 million in related royalty receipts over the same period.

9

Nurtec ODT/Biohaven fixed payments

Nurtec ODT (rimegepant) is an oral, small molecule calcitonin gene-related peptide receptor antagonist marketed by Biohaven and Pfizer for the acute treatment and prevention of migraine.

We added Nurtec ODT to our portfolio in June 2018 and purchased an additional interest in Nurtec ODT as part of our expanded funding agreement with Biohaven in August 2020. We estimate that our royalties will substantially end between 2034 and 2036. Total global end market sales for Nurtec ODT during 2021 were estimated to be approximately $455 million and we collected $8 million in related royalty receipts over the same period. In addition, as a result of the approval of Nurtec ODT in February 2020, we received $63 million in fixed payments from Biohaven during the year ended December 31, 2021, which represent the first four of 16 consecutive quarterly payments to be received from Biohaven relating to the Series A Biohaven Preferred Shares. Global end market sales of Nurtec ODT are projected to grow to approximately $2.4 billion in 2026, according to Visible Alpha.

Prevymis

Prevymis (letermovir) is a first-in-class prophylactic marketed by Merck & Co. for the prophylaxis of cytomegalovirus infection and disease in adults who have received an allogeneic hematopoietic stem cell transplant.

We added Prevymis to our portfolio in June 2020. We estimate that our royalties will substantially end in 2029. Total global end market sales for Prevymis during 2021 were approximately $370 million and we collected $38 million in related royalty receipts over the same period. Global end market sales of Prevymis are projected to grow to approximately $450 million in 2026, according to Visible Alpha.

Farxiga/Onglyza

Farxiga (dapagliflozin) is a first-in-class selective inhibitor of human sodium-glucose co-transporter 2 indicated as both monotherapy and as part of combination therapy with Onglyza, a dipeptidyl peptidase-4 inhibitor, to improve glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes. Farxiga received FDA approval in May 2020 for the treatment of patients with heart failure with reduced ejection fraction in both patients with and without type 2 diabetes. Farxiga and Onglyza are both marketed by AstraZeneca.

We added Farxiga/Onglyza to our portfolio in November 2017. We estimate that our royalties will substantially end in 2025. Total global end market sales for Farxiga/Onglyza during 2021 were approximately $3.4 billion and we collected $36 million in related royalty receipts over the same period. Global end market sales of Farxiga/Onglyza are projected to grow to approximately $4.2 billion in 2026, according to Visible Alpha.

Tremfya

Tremfya (guselkumab) is an anti-interleukin 23 marketed by Johnson & Johnson for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis. Tremfya is also in clinical development for ulcerative colitis and Crohn’s disease.

We added Tremfya to our portfolio in July 2021. We estimate that our royalties will substantially end between 2031 and 2032. Total global end market sales for Tremfya during 2021 were approximately $2.1 billion and we collected $36 million in related royalty receipts for the partial period subsequent to acquisition in July 2021. Global end market sales of Tremfya are projected to grow to approximately $5.4 billion in 2026, according to Visible Alpha.

10

Cabometyx/Cometriq

Cabometyx (cabozantinib) is a multi-tyrosine kinase inhibitor approved for the treatment of patients with advanced renal cell carcinoma (RCC) both as monotherapy and in combination with Bristol Myers Squibb’s Opdivo (nivolumab) as a first line treatment. Cabometyx is also approved for hepatocellular carcinoma in patients previously treated with sorafenib. Cometriq is approved for progressive, metastatic medullary thyroid cancer. Cabometyx and Cometriq are marketed by Exelixis in the United States and by Ipsen in regions outside the United States and Japan. Cabometyx is marketed in Japan by Takeda.

We added Cabometyx/Cometriq to our portfolio in March 2021. We estimate that our royalties will substantially end between 2026 and 2029. Total global end market sales for Cabometyx/Cometriq during 2021 were estimated to be approximately $1.6 billion and we collected $34 million in related royalty receipts for the partial period subsequent to acquisition in March 2021. Global end market sales of Cabometyx/Cometriq are projected to grow to approximately $3.4 billion in 2026, according to Visible Alpha.

Crysvita

Crysvita (burosumab) is a monoclonal antibody against fibroblast growth factor 23 marketed by Ultragenyx and Kyowa Kirin that has received European Commission (“EC”) conditional marketing authorization for the treatment of X-linked hypophosphatemia with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons. In October 2020, this authorization was expanded to include older adolescents and adults.

We added a royalty on Crysvita sales in Europe to our portfolio in December 2019. Our royalties expire when we receive aggregate royalties equal to $608 million if that happens prior to December 31, 2030, and otherwise when we receive aggregate royalties of $800 million. We estimate that our royalties will substantially end between 2033 and 2038. End market sales for Crysvita in Europe during 2021 were $179 million and we collected approximately $17 million in related royalty receipts over the same period. End market sales of Crysvita in Europe are projected to grow to approximately $400 million in 2026, according to Visible Alpha.

Evrysdi

Evrysdi (risdiplam) is a survival motor neuron 2 splicing modifier marketed by Roche, and is the first oral treatment approved for infants, children and adults with all types of spinal muscular atrophy.

We added Evrysdi to our portfolio in July 2020. Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion. Total global end market sales for Evrysdi during 2021 were approximately $659 million and we collected $16 million in related royalty receipts over the same period. Global end market sales of Evrysdi are projected to grow to approximately $2.9 billion in 2026, according to Visible Alpha.

Emgality

Emgality (galcanezumab-gnlm) is a monoclonal antibody calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine and for the treatment of episodic cluster headache marketed by Lilly.

We added Emgality to our portfolio in March 2019. We estimate that our royalties will substantially end in 2033. Total global end market sales for Emgality during 2021 were approximately $577 million and we collected $15 million in related royalty receipts over the same period. Global end market sales of Emgality are projected to grow to approximately $1.4 billion in 2026, according to Visible Alpha.

11

Erleada

Erleada (apalutamide) is an oral, small molecule androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer and for the treatment of patients with metastatic castration sensitive prostate cancer. It is marketed by Johnson & Johnson.

We added Erleada to our portfolio in February 2019. We estimate that our royalties will substantially end in 2032. Total global end market sales for Erleada during 2021 were approximately $1.3 billion and we collected $14 million in related royalty receipts over the same period. Global end market sales of Erleada are projected to grow to approximately $4.0 billion in 2026, according to Visible Alpha.

Trodelvy

Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate for the treatment of adult patients with metastatic triple-negative breast cancer. Trodelvy was initially developed by Immunomedics and is now marketed by Gilead following the acquisition of Immunomedics in 2020. Gilead is exploring monotherapy and combinations of Trodelvy across numerous cancer indications and lines of therapy.

We added Trodelvy to our portfolio in January 2018. Our right to receive royalties is perpetual. Total global end market sales for Trodelvy during 2021 were approximately $380 million and we collected $13 million in related royalty receipts over the same period. Global end market sales of Trodelvy are projected to grow to approximately $2.3 billion in 2026, according to Visible Alpha.

IDHIFA

IDHIFA (enasidenib) is an oral, targeted therapy approved by the FDA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. It is marketed by Bristol Myers Squibb.

We added IDHIFA to our portfolio in June 2020. We estimate that our royalties will substantially end in the U.S. in 2033. End market sales for IDHIFA are not disclosed by Bristol Myers Squibb. We collected $12 million in related royalty receipts in 2021. We also hold rights to receive up to $55 million in outstanding regulatory milestone payments from Bristol Myers Squibb. Visible Alpha does not currently have estimates available for global end market sales of IDHIFA in 2026.

Orladeyo

Orladeyo (berotralstat) is a first-in-class oral inhibitor of plasma kallikrein marketed by BioCryst for the prevention of hereditary angioedema attacks.

We added Orladeyo to our portfolio in December 2020 and purchased an additional interest as part of our expanded funding agreement with BioCryst in November 2021. Our right to receive royalties is perpetual, but we expect that the 2036-2039 patent expirations for Orladeyo may result in potential sales declines based on potential generic entry. Total global end market sales for Orladeyo during 2021 were estimated to be approximately $117 million and we collected $7 million in related royalty receipts over the same period. Global end market sales of Orladeyo are projected to grow to approximately $600 million in 2026, according to Visible Alpha.

Tazverik

Tazverik (tazemetostat) is a first-in-class, oral EZH2 inhibitor marketed by Epizyme that was granted accelerated approval for the treatment of epithelioid sarcoma and follicular lymphoma.

We added Tazverik to our portfolio in November 2019. We estimate that our royalties will substantially end in 2034. Total global end market sales for Tazverik during 2021 were estimated to be approximately $32 million and we collected $3 million in related royalty receipts over the same period. Global end market sales of Tazverik are projected to grow to approximately $400 million in 2026, according to Visible Alpha.

12

Oxlumo

Oxlumo (lumasiran) is a small interfering ribonucleic acid therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1 marketed by Alnylam. Oxlumo was approved by the FDA in November 2020.

We added Oxlumo to our portfolio in April 2021. We estimate that our royalties will substantially end between 2034 and 2035. Total global end market sales for Oxlumo during 2021 were approximately $60 million and we collected $1 million in related royalty receipts over the same period. Global end market sales of Oxlumo are projected to grow to approximately $350 million in 2026, according to Visible Alpha.

Development-Stage Product Candidates

Our current portfolio includes ten development-stage product candidates. These development-stage product candidates have not yet been approved, and therefore have not generated any royalties (and we have not collected any related royalty receipts) to date.

Aficamten

Aficamten is a small molecule cardiac myosin inhibitor, in Phase 3 development by Cytokinetics for obstructive hypertrophic cardiomyopathy (oHCM). We added aficamten to our portfolio in January 2022. If approved, global end market sales of aficamten are projected to grow to approximately $400 million in 2026, according to Visible Alpha.

BCX9930

BCX9930 is an oral Factor D inhibitor in Phase 3 clinical development by BioCryst as monotherapy for paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases. We added BCX9930 to our portfolio in December 2020 and purchased an additional interest as part of our expanded funding agreement with BioCryst in November 2021. If approved, global end market sales of BCX9930 are projected to grow to approximately $200 million in 2026, according to Visible Alpha.

CPI-0209

CPI-0209 is a second-generation enhancer of zeste homolog 2 inhibitor, in Phase 2 development by MorphoSys for hematological malignancies and solid tumors. We added CPI-0209 to our portfolio in July 2021. Visible Alpha does not currently have estimates available for global end market sales of CPI-0209 in 2026.

Gantenerumab

Gantenerumab is an anti-amyloid-beta monoclonal antibody, in Phase 3 development by Roche for Alzheimer’s disease. We added gantenerumab to our portfolio in July 2021. If approved, global end market sales of gantenerumab are projected to grow to approximately $1.9 billion in 2026, according to Visible Alpha.

Omecamtiv mecarbil

Omecamtiv mecarbil is an oral, small molecule cardiac myosin activator in Phase 3 clinical development by Cytokinetics for the treatment of heart failure with reduced ejection fraction.

We added omecamtiv mecarbil to our portfolio in 2017. In November 2020, results from the Phase 3 GALACTIC-HF trial of omecamtiv mecarbil in patients with heart failure were presented at the American Hearth Association Scientific Sessions which showed that the trial met the primary composite endpoint of reduction in cardiovascular death or heart failure events, but did not meet the secondary endpoint of reduction in cardiovascular death. Cytokinetics subsequently regained global rights to develop and commercialize omecamtiv mecarbil when Amgen and Servier elected to terminate their collaboration agreement. Following the Phase 3 results and termination of the collaboration announced in 2020, given the uncertainty around the future of omecamtiv mecarbil at the time, we recognized an impairment charge of $65 million related to the write-off of the associated financial royalty asset of $90 million and its associated provision of $25 million in the year ended December 31, 2020. If approved, global end market sales of omecamtiv mecarbil are projected to grow to approximately $200 million in 2026, according to Visible Alpha.

13

Otilimab

Otilimab is a fully human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor, in Phase 3 development by GlaxoSmithKline for rheumatoid arthritis. We added otilimab to our portfolio in July 2021. We are also entitled to 100% of future regulatory and success-based milestone payments on otilimab. If approved, global end market sales of otilimab are projected to grow to approximately $250 million in 2026, according to Visible Alpha.

Pelabresib

Pelabresib is a bromodomain and extra-terminal inhibitor, in Phase 3 development by MorphoSys for myelofibrosis. We added pelabresib to our portfolio in July 2021. If approved, global end market sales of pelabresib are projected to grow to approximately $200 million in 2026, according to Visible Alpha.

PT027

PT027 is an investigational fixed dose combination of the inhaled corticosteroid, budesonide and albuterol, a short-acting beta-2 agonist for the treatment of asthma in Phase 3 development.

In 2018, we entered into an agreement with Avillion II, which was amended in July 2021, to fund up to approximately $122.5 million over multiple years to fund a portion of the costs for Phase 2 and 3 clinical trials of Avillion II, which is a party to a co-development agreement with AstraZeneca to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones, and other potential payments. We estimate that our royalties will substantially end in 2030, but AstraZeneca is entitled to certain buyout rights which, if exercised, would result in earlier expiration. If approved, global end market sales of PT027 are projected to grow to approximately $500 million in 2026, according to Visible Alpha.

Seltorexant

Seltorexant is a selective orexin 2 receptor antagonist currently in Phase 3 development for the treatment of major depressive disorder with insomnia symptoms by Johnson & Johnson. We added seltorexant to our portfolio in January 2021. Visible Alpha does not currently have estimates available for global end market sales of seltorexant in 2026.

Zavegepant

Zavegepant is a small molecule calcitonin gene-related peptide receptor antagonist in clinical development by Biohaven for the acute treatment and prevention of migraines in Phase 3 development. In November 2021, Biohaven and Pfizer announced a strategic commercialization arrangement for Pfizer to commercialize zavegepant in markets outside of the United States upon approval.

We added zavegepant to our portfolio in June 2018 and purchased an additional interest as part of our expanded funding agreement with Biohaven in August 2020. We estimate that our royalties will substantially end between 2034 and 2036. As a result of an additional transaction in 2020, we are also entitled to success-based milestone payments. If approved, global end market sales of zavegepant are projected to grow to approximately $650 million in 2026, according to Visible Alpha.


Royalty Portfolio Summary

The table below provides a summary of the estimated royalty expiration and the royalty rates for our portfolio:


14

ProductTherapeutic Area
Estimated Royalty 
Expiration(1)
Royalty Rate(2)
Approved Products
Cystic fibrosis franchiseRare disease
2037(3)
For combination therapies, sales are allocated equally to each of the active pharmaceutical ingredients; tiered royalties ranging from single digit to subteen percentages on annual worldwide net sales of ivacaftor, lumacaftor and tezacaftor, and mid-single digit percentages on annual worldwide net sales of elexacaftor
TysabriNeurologyPerpetualContingent payments of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales above $2.0 billion
ImbruvicaCancer2027-2032Tiered royalty in the mid-single digits on annual worldwide net sales
PromactaHematology2025-2028Tiered royalty ranging from 4.7% to 9.4% on annual worldwide net sales
XtandiCancer2027-2028Royalty slightly less than 4% on annual worldwide net sales
Januvia and JanumetDiabetes2022Low-single digit royalty on annual worldwide net sales
Nurtec ODTNeurology2034-20362.1% royalty on annual combined worldwide net sales of Nurtec ODT and zavegepant up to $1.5 billion and 1.5% on annual combined worldwide net sales above $1.5 billion. 0.4% incremental royalty on all Nurtec ODT worldwide net sales.
PrevymisInfectious disease2029Low-double digit royalty on annual worldwide net sales up to $300 million
Farxiga/OnglyzaDiabetes2025Payments to Royalty Pharma equivalent to low-single digit downward tiered royalty on annual worldwide net sales
TremfyaImmunology2031-2032Mid-single digit, tiered royalty on annual worldwide net sales
Cabometyx/CometriqCancer
2026-2029(4)
3% royalty on annual worldwide net sales
CrysvitaRare disease
2033-2038(5)
10% royalty on annual EU, U.K. and Switzerland net sales
EvrysdiRare disease
2030-2035(6)
Total royalties are tiered at 8% on worldwide annual net sales up to $500 million, 11% on net sales between $500 million and $1 billion, 14% on net sales between $1 billion and $2 billion, 16% on net sales over $2 billion; Royalty Pharma is entitled to approximately 43% of total royalties
EmgalityNeurology2033Low-single digit royalties on annual worldwide net sales
ErleadaCancer2032Low-single digit royalties on annual worldwide net sales
TrodelvyCancerPerpetual4.15% royalty on annual worldwide net sales up to $2 billion, declining stepwise based on sales tiers to 1.75% on annual worldwide net sales above $6 billion
IDHIFA Cancer2033Tiered royalty in the low-double digits to mid-teens based on annual worldwide net sales
OrladeyoRare disease
2036-2039(7)
9.50% royalty on direct annual net sales of up to $350 million, 4.50% on sales between $350 million and $550 million, no royalty on sales over $550 million; tiered percentage of sublicense revenue in certain territories
TazverikCancer
2034(8)
Royalties in the mid-teens percentages on annual worldwide net sales, stepping down on annual worldwide net sales above certain sales thresholds
OxlumoRare disease2034-2035Royalties in the mid- to high-single digits based on annual worldwide net sales
Development Stage Product Candidates
Aficamten(9)
Cardiology—4.5% royalty on annual worldwide net sales up to $1 billion and 3.5% on net sales above $1 billion, subject to certain potential step-downs
BCX9930Rare disease—4.0% royalty on annual worldwide net sales up to $1.5 billion, 3.0% royalty on annual worldwide net sales between $1.5 billion and $3.0 billion, and 1.0% royalty on annual worldwide net sales above $3.0 billion
CPI-0209Cancer—3.0% royalty on annual worldwide net sales
GantenerumabNeurology—Total royalties tiered between 5.5% and 7.0% on annual worldwide net sales; Royalty Pharma is entitled to 60% of total royalties
Omecamtiv mecarbilCardiology2032-2033Mid-single digit royalty on worldwide net sales
OtilimabImmunology—Tiered double-digit total royalties on annual worldwide net sales; Royalty Pharma is entitled to 80% of total royalties
PelabresibCancer—3.0% royalty on annual worldwide net sales
PT027Respiratory
2030(10)
Tiered royalties in the low-single digits on annual worldwide net sales(11)
Seltorexant Neurology—Mid-single digit royalty on worldwide net sales
 ZavegepantNeurology2034-20362.1% royalty on annual combined worldwide net sales of Nurtec ODT and zavegepant up to $1.5 billion and 1.5% on annual combined worldwide net sales above $1.5 billion. Up to a 3.0% incremental royalty on zavegepant worldwide net sales up to $1.5 billion and up to 2.0% incremental royalty on zavegepant worldwide net sales above $1.5 billion.
Notes:
(1)     Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
15

(2)     The royalties in our portfolio are subject to the underlying contractual agreements from which they arise and may be subject to reductions or other adjustments in accordance with the terms of such agreements.
(3)     Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(4)     Royalties on net sales of cabozantinib products in the United States through September 2026 and non-U.S. markets through the full term of the royalty.
(5)     Royalties expire when we receive aggregate royalties equal to $608 million if that happens prior to December 31, 2030, and otherwise when we receive aggregate royalties of $800 million.
(6)     Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
(7)     Royalty is perpetual; years shown represent estimated United States patent expiration for Orladeyo and potential sales decline based on timing of potential generic entry.
(8)     Represents the estimated patent expiration date in the United States.
(9)     Royalty was acquired in January 2022.
(10)     AstraZeneca is entitled to certain buyout rights which, if exercised, would result in earlier expiration.
(11)     Represents the portion of the royalties owed to Avillion II attributable to our minority ownership stake in Avillion II.


There can be no assurance that our royalties will expire when expected. Any reductions in the durations of royalties relative to our estimates may adversely affect our financial condition and results of operations. See “Risk Factors” in Item 1A, Risk Factors for further information.

Fixed Payment Arrangements

The table below provides a summary of our fixed payment arrangements:

Funding ArrangementTherapeutic Area
Key Terms(1)
Biohaven Series A
Preferred Shares		Neurology
16 consecutive quarterly payments of $15.6 million to Royalty Pharma from the three months ended March 31, 2021 through the three months ended December 31, 2024 totaling $250.0 million (2.0 times the $125.0 million total purchase price of Series A Biohaven Preferred Shares that Royalty Pharma acquired in 2019).
Biohaven Series B
Preferred Shares		Neurology
24 consecutive quarterly payments of $14.8 million to Royalty Pharma from the three months ended March 31, 2025 through the three months ended December 31, 2030 totaling $354.5 million (approximately 1.8 times the $200.0 million total purchase price of Series B Biohaven Preferred Shares that Royalty Pharma has agreed to acquire between the three months ended March 31, 2021 and the three months ended December 31, 2024).
Zavegepant Success-Based Milestones
Neurology
Success-based milestone payments to Royalty Pharma ranging from 1.9 to 2.95 times the funded amount of $250.0 million, depending on achievement of specific regulatory approvals for zavegepant. 40 consecutive quarterly payments commencing on the first day of the second calendar quarter following a milestone event. If zavegepant’s first regulatory approval in migraine is achieved, Royalty Pharma will receive total success-based milestone payments of $475.0 million, or 1.9 times the funded amount, related to this specific approval. Incremental payments of up to 1.05 times the funded amount could be triggered by certain additional regulatory approvals.
MorphoSys Development Funding Bonds
Not applicable
Payments to Royalty Pharma totaling approximately 2.2 times the amount drawn by MorphoSys. Up to $350.0 million in potential funding is available to be drawn through July 15, 2022, with a minimum draw of $150.0 million. 36 consecutive quarterly payments to Royalty Pharma commencing in the ninth quarter following the quarter of the applicable funding date. As of February 15, 2022, the Development Funding Bonds remain undrawn.
Cytokinetics Commercial Launch Funding
Cardiology
Payments to Royalty Pharma totaling 1.9 times the amount drawn for up to five tranches totaling $300.0 million in potential funding to Cytokinetics, including an initial $50.0 million tranche that was funded in the three months ended March 31, 2022. Each subsequent tranche has a 12-month draw period following achievement of certain clinical and regulatory milestones. 34 consecutive quarterly payments to Royalty Pharma commencing on the last business day of the seventh quarter following the quarter of the applicable funding date for each tranche.
(1)     Our fixed payment arrangements are subject to the underlying contractual agreements and legal instruments from which they arise and may be subject to reduction, accelerations, and other adjustments in accordance with the respective terms of such agreements and instruments.

16


Competition

We face competition from other entities that acquire biopharmaceutical royalties, including competitors to the Manager that are in the similar business of acquiring biopharmaceutical royalties. There are a limited number of suitable and attractive acquisition opportunities available in the market. Therefore, competition to acquire such assets is intense. The Manager is subject to competition from other potential royalty buyers, including from the companies that market the products on which royalties are paid, financial institutions and other entities. These potential royalty buyers may be larger and better capitalized than us. The Manager may not be able to identify and obtain a sufficient number of asset acquisition opportunities to invest the full amount of capital that may be available to us. There can be no assurance that we will continue to acquire biopharmaceutical products and companies that hold biopharmaceutical royalties that are acceptable to us.

The products that provide the basis for the cash flows of the biopharmaceutical products in which we invest are also subject to intense competition. The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product’s commercial life cannot be predicted. There can be no assurance that one or more products will not be rendered obsolete or non-competitive by new products or improvements made to existing products, either by the current marketer of such products or by another marketer. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which serve as the security or other support for the payments due under the biopharmaceutical products that we hold.

Competitive factors affecting the market position and success of each product include:
• effectiveness;
• safety and side effect profile;
• price, including third-party insurance reimbursement policies;
• timing and introduction of the product;
• efficacy of marketing strategy;
• governmental regulation;
• availability of lower-cost generics and/or biosimilars;
• treatment innovations that eliminate or minimize the need for a product; and
• product liability claims.

If a product for which we have a royalty receivable or other interest is rendered obsolete or non-competitive by new products, including generics and/or biosimilars, or improvements on existing therapies or governmental or regulatory action, such developments could have a material adverse effect on the ability of the payor with respect to a biopharmaceutical asset to make payments to us, and consequently could materially adversely affect our business, financial condition and results of operations. If additional side effects or complications are discovered with respect to a product, and such product’s market acceptance is impaired or it is withdrawn from the market, continuing payments with respect to biopharmaceutical products, including royalty payments and payments of interest on and repayment of the principal, relating to such product may not be made on time or at all.

Corporate Responsibility

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharma industry. We play an important role in providing capital to the biopharma ecosystem and thereby positively impact human health. Our responsibility to stakeholders is based around three key areas: integrity (maintaining the highest ethical standards), culture (promoting an inclusive and diverse workforce) and taking responsibility (being a responsible citizen). We do not directly conduct biopharmaceutical research and development or manufacture or market the biopharmaceutical assets in which we participate. We strive to invest in novel therapies that address unmet patient needs and to support ethical business practices that drive innovation, competition and patient choice.

17

Integrity

We maintain the highest standards of integrity and trust in our role as investors and partners to the biopharma industry. This is recognized in our market-leading position and the high esteem with which we believe we are held in the industry. We conduct thorough diligence and monitoring with all of our investment positions. The biopharmaceutical companies and academic and non-profit institutions with which we work typically have well-developed and transparent environmental, social and governance (ESG) policies, which seek to benefit wider society through sustainable and ethical business practices.

Culture

A diverse, talented and motivated workforce is essential to maintain our competitive advantages and to successfully execute our business strategy. We consider it highly important to strive for an appropriate gender balance: currently approximately 50% of the workforce of our Manager are women.

Responsibility

We are committed to good corporate citizenship and actively support the work of a number of patient advocacy groups and medical research foundations, including the American Heart Association, the Alliance for Lupus Research, Children of Bellevue, the Melanoma Research Alliance, the National Multiple Sclerosis Society and the Prostate Cancer Foundation. Over one-third (by value) of the transactions we have completed since our founding have been with leading academic and non-profit institutions. By partnering with these institutions, we have provided capital which has been used to further scientific research (for example, the Cystic Fibrosis Foundation) or to help fund capital projects. These diverse organizations are united in their quest to advance science, the careers of scientists and human health around the globe.

Employees

Our directors and executive officers manage our operations and activities. However, we do not currently have any employees or any officers other than our executive officers. Pursuant to the management agreement entered into in connection with our initial public offering (the “Management Agreement”) with the Manager, the Manager performs corporate and administration services for us.

As of December 31, 2021, the Manager had 66 employees. None of these employees are represented by labor unions or covered by any collective bargaining agreement. We believe that the Manager’s relations with its employees are satisfactory.

Human Capital Resources

Because we are “externally managed,” we do not employ our own personnel, but instead depend upon the Manager and its executive officers and employees for all of the services we require. Under the Management Agreement, the Manager manages the assets of our business and sources and evaluates royalty acquisitions. Accordingly, our success is dependent upon the expertise and services of the executive officers and other personnel provided to us through the Manager. The Manager is responsible for the selection of these executive officers and other personnel, and our Board of Directors reviews personnel with the Manager with the objective of evaluating the Manager’s internal capabilities. The Management Agreement requires the Manager’s executives to devote substantially all of their time to managing us, Royalty Pharma Investments 2019 ICAV (“RPI” or “RPI 2019 ICAV”) and any legacy vehicles related to Royalty Pharma Investments, an Irish unit trust (“Old RPI”) unless otherwise approved by our Board of Directors. The Management Agreement also provides for the development of succession plans for the senior management of the Manager by the Management Development and Compensation Committee of our Board of Directors in consultation with the Manager.

18

Governmental Regulation and Environmental Matters

Our business has been and will continue to be subject to numerous laws and regulations. Failure to comply with these laws and regulations could subject us to administrative and legal proceedings and actions by various governmental bodies. See “Risk Factors” in Item 1A, Risk Factors for further information. Our compliance with these laws and regulations has not had a material impact on our capital expenditures, earnings, financial condition or competitive position in excess of those affecting
others in our industry.

We believe that there are no compliance issues with laws and regulations that have been enacted or adopted regulating the discharge of materials into the environment, or otherwise relating to the protection of the environment, that have adversely affected, or are reasonably expected to adversely affect, our business, financial condition and results of operations, and we do not currently anticipate material capital expenditures arising from environmental regulation. We believe that climate change could present risks to our business. Some of the potential impacts of climate change to our business include increased operating costs due to additional regulatory requirements and the risk of disruptions to our business. We do not believe these risks are material to our business at this time.

U.S. Investment Company Act Status

We intend to conduct our business so as not to become regulated as an investment company under the U.S. Investment Company Act. An entity generally will be determined to be an investment company for purposes of the U.S. Investment Company Act if, absent an applicable exemption, (i) it is or holds itself out as being engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (ii) it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis, which we refer to as the ICA 40% Test.

We do not hold ourselves out as being engaged primarily, or propose to engage primarily, in the business of investing, reinvesting or trading in securities, and believe that we are not engaged primarily in the business of investing, reinvesting or trading in securities. We believe that, for U.S. Investment Company Act purposes, we are engaged primarily, through one or more of our subsidiaries, in the business of purchasing or otherwise acquiring certain obligations that represent part or all of the sales price of merchandise. Our subsidiaries that are so engaged rely on Section 3(c)(5)(A) of the U.S. Investment Company Act, which, according to certain SEC staff interpretations, generally may be available to an issuer that invests at least 55% of its assets in “notes, drafts, acceptances, open accounts receivable, and other obligations representing part or all of the sales price of merchandise, insurance, and services,” which we refer to as ICA Exception Qualifying Assets and that does not issue any redeemable securities, face-amount certificates of the installment type or periodic payment plan certificates.
In a no-action letter, dated August 13, 2010, to our predecessor, the SEC staff promulgated an interpretation that royalties that entitle an issuer to collect royalty receivables that are directly based on the sales price of specific biopharmaceutical assets that use intellectual property covered by specific license agreements are ICA Exception Qualifying Assets under Section 3(c)(5)(A). We rely on this no-action letter for the position that royalty receivables relating to biopharmaceutical assets that we hold are ICA Exception Qualifying Assets under Section 3(c)(5)(A) and Section 3(c)(6), which is described below.

As the parent of one or more subsidiaries that rely on Section 3(c)(5)(A), we currently are excepted from registration as an investment company based on Section 3(a)(1)(C) and/or Section 3(c)(6) of the U.S. Investment Company Act. To ensure that we are not obligated to register as an investment company, we must not exceed the thresholds provided by the ICA 40% Test. For purposes of the ICA 40% Test, the term “investment securities” does not include U.S. government securities or securities issued by majority-owned subsidiaries that are not themselves investment companies and are not relying on Section 3(c)(1) or Section 3(c)(7) of the U.S. Investment Company Act, such as majority-owned subsidiaries that rely on Section 3(c)(5)(A). We also may rely on Section 3(c)(6), which, based on SEC staff interpretations, requires us to invest, either directly or through majority-owned subsidiaries, at least 55% of our assets in, as relevant here, businesses relying on Section 3(c)(5)(A). For a subsidiary to be “majority-owned,” a parent entity must own a majority of the voting securities of the applicable security. Therefore, the assets that we and our subsidiaries hold and acquire are limited by the provisions of the U.S. Investment Company Act and the rules and regulations promulgated thereunder.

19

If the SEC or its staff in the future adopts a contrary interpretation to that provided in the no-action letter to Royalty Pharma or otherwise restricts the conclusions in the SEC staff’s no-action letter such that royalties are no longer treated as ICA Exception Qualifying Assets for purposes of Section 3(c)(5)(A) and Section 3(c)(6), or the SEC or its staff in the future determines that the no-action letter does not apply to some or all types of royalty receivables relating to biopharmaceutical assets, our business will be materially and adversely affected. In particular, we would be required either to convert to a corporation formed under the laws of the United States or a state thereof (which would likely result in our being subject to U.S. federal corporate income taxation) and to register as an investment company, or to stop all business activities in the United States until such time as the SEC grants an application to register us as an investment company formed under non-U.S. law. It is unlikely that such an application would be granted and, even if it were, requirements imposed by the Investment Company Act, including limitations on our capital structure, our ability to transact business with affiliates and our ability to compensate key employees, could make it impractical for us to continue our business as currently conducted. Our no longer qualifying for an exemption from registration as an investment company would materially and adversely affect the value of your Class A ordinary shares and our ability to pay dividends in respect of our Class A ordinary shares.

Corporate Information

Our predecessor was founded in 1996 and we were incorporated under the laws of England and Wales on February 6, 2020. We are a holding company, and our principal asset is a controlling equity interest in Royalty Pharma Holdings Ltd. (“RP Holdings”). Our principal executive offices are located at 110 East 59th Street, New York, NY 10022, and our telephone number is (212) 883-0200. Our Internet site is www.royaltypharma.com. Our website and the information contained therein or connected thereto is not incorporated into this Annual Report on Form 10-K. Our agent for service in the United States is CSC North America located at 251 Little Falls Drive, Wilmington, Delaware, 19808.

Available Information

Our reports filed with or furnished to the SEC pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available, free of charge, on the Investors section of our website at https://royaltypharma.com as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a website at http://www.sec.gov that contains reports, and other information regarding us and other companies that file materials with the SEC electronically. We use the Investor section of our website as a means of disclosing material information. Accordingly, investors should monitor our website, in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Item 1A.    RISK FACTORS

Described below are certain risks that we believe apply to our business. You should carefully consider the following information about these risks, together with the other information contained in this Annual Report on Form 10-K, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business.

Summary of Risk Factors

Our business is subject to a number of risks, including risks that may adversely affect our business, financial condition and results of operations. These risks are discussed more fully below and include, but are not limited to, risks related to:

Risks Relating to Our Business

•sales risks of biopharmaceutical products on which we receive royalties;
•the growth of the royalty market;
•the ability of the Manager to identify suitable assets for us to acquire;
•uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add development-stage product candidates to our product portfolio;
•potential strategic acquisitions of biopharmaceutical companies;
20

•our use of leverage in connection with our capital deployment;
•our reliance on the Manager for all services we require;
•our reliance on key members of the Manager’s senior advisory team;
•our ability to successfully execute our royalty acquisition strategy;
•our ability to leverage our competitive strengths;
•actual and potential conflicts of interest with the Manager and its affiliates;
•interest rate and foreign exchange fluctuations;
•the assumptions underlying our business model;
•our reliance on a limited number of products;
•the ability of the Manager or its affiliates to attract and retain highly talented professionals;
•the competitive nature of the biopharmaceutical industry;
Risks Relating to Our Organization and Structure

•our organizational structure, including our status as a holding company;
Risks Relating to Our Class A Ordinary Shares

•volatility of the market price of our Class A ordinary shares;
•our incorporation under English law;
Risks Relating to Taxation

•the effect of changes to tax legislation and our tax position; and
General Risk Factors

•the impact of COVID-19, or the future outbreak of any other infectious or contagious diseases, on our operations.
Risks Relating to Our Business

Biopharmaceutical products are subject to sales risks.

Biopharmaceutical product sales may be lower than expected due to a number of reasons, including pricing pressures, insufficient demand, product competition, failure of clinical trials, lack of market acceptance, obsolescence, lack of acceptance by government healthcare programs and private insurance plans, loss of patent protection, the impact of the COVID-19 global pandemic or other factors and development-stage product candidates may fail to reach the market. Unexpected side effects, safety or efficacy concerns can arise with respect to a product, leading to product recalls, withdrawals or declining sales. As a result, payments of our royalties may be reduced or cease. In addition, these payments may be delayed, causing our near-term financial performance to be weaker than expected.

21

The royalty market may not grow at the same rate as it has in the past, or at all, and we may not be able to acquire sufficient royalties to sustain the growth of our business.

We have been able to grow our business over time by primarily acquiring royalties. However, we may not be able to identify and acquire a sufficient number of royalties, or royalties of sufficient scale, to invest the full amount of capital that may be available to us in the future, or at our targeted amount and rate of deployment, which could prevent us from executing our growth strategy and negatively impact our results of operations. Changes in the royalty market, including its structure and participants, or a reduction in the growth of the biopharmaceutical industry, could lead to diminished opportunities for us to acquire royalties, fewer royalties (or royalties of significant scale) being available, or increased competition for royalties. Even if we continue to acquire royalties, they may not generate a meaningful return for a period of several years, if at all, due to the price we pay for such royalties or other factors relating to the underlying products. As a result, we may not be able to continue to grow as we have in the past, or at all.

Acquisitions of royalties from development-stage biopharmaceutical product candidates are subject to a number of uncertainties.

We may acquire more royalties on development-stage product candidates that have not yet received marketing approval by any regulatory authority. There can be no assurance that the FDA, the European Medicines Agency (“EMA”) or other regulatory authorities will approve such products or that such products will be brought to market timely or at all, or that the market will be receptive to such products. For example, in January 2016, we partnered with Pfizer to provide up to $300 million in funding for Pfizer’s ongoing Phase 3 clinical trials, the PALLAS and PENELOPE-B trials, of Ibrance (palbociclib) for the adjuvant treatment of breast cancer. On May 29, 2020, Pfizer reported that the independent data monitoring committee for the PALLAS trial had concluded after the recent interim analysis that the PALLAS trial is “unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival.” Subsequently on October 9, 2020, Pfizer announced that the Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival in women with hormone receptor-positive (HR+), human epidermal growth factor-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy. If the FDA, the EMA or other regulatory authority approves a development-stage product candidate that generates our royalties, the labeling, packaging, manufacturing, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The subsequent discovery of previously unknown problems with the product, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the product, and could include withdrawal of the product from the market.

In addition, the developers of these development-stage product candidates may not be able to raise additional capital to continue their discovery, development and commercialization activities, which may cause them to delay, reduce the scope of, or eliminate one or more of their clinical trials or research and development programs. If other product developers introduce and market products that are more effective, safer or less expensive than the relevant products that generate our royalties, or if such developers introduce their products prior to the competing products underlying our royalties, such products may not achieve commercial success and thereby result in a loss for us.

Further, the developers of such products may not have sales, marketing or distribution capabilities. If no sales, marketing or distribution arrangements can be made on acceptable terms or at all, the affected product may not be able to be successfully commercialized, which will result in a loss for us. Losses from such assets could adversely affect our business, financial condition and results of operations.

While we believe that we can evaluate the likelihood of a development-stage product candidate’s approval and achieving significant sales, there can be no assurance that our assumptions will prove correct, that regulatory authorities will approve such development-stage product candidates, that such development-stage product candidates will be brought to market timely or at all, or that such products will achieve commercial success.

22

Our strategy of acquiring royalty interests in development-stage product candidates, including by co-funding clinical development and acquiring securities of biopharmaceutical companies, is subject to risks and uncertainties.

We intend to continue to provide capital to innovators to co-fund clinical development of a product candidate in exchange for a share of the future revenues of that asset and when we do so, we do not control its clinical development. In these situations, the innovators may not complete activities on schedule or in accordance with our expectations or in compliance with applicable laws and regulations. Failure by one or more of these third parties to meet their obligations, comply with applicable laws or regulations or any disruption in the relationships between us and these third parties, could delay or prevent the development, approval, manufacturing or commercialization of the development-stage product candidate for which we have provided funding.
We seek to further expand our market opportunity by acquiring securities issued by biopharmaceutical companies. Where we may acquire equity securities as all or part of the consideration for business development activities, the value of those securities will fluctuate, and may depreciate in value. We will likely not control the company in which we acquire securities, and as a result, we may have limited ability to determine its management, operational decisions and policies. Further, while we may seek to mitigate the risks and liabilities of such transactions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. In addition, as a result of our activities we receive material non-public information about other companies from time to time. Where such information relates to a company whose equity securities we hold, we may be delayed or prevented from selling such securities when we would otherwise choose to do so, and such delay or prohibition may result in a loss or reduced gain on such securities.
We may undertake strategic acquisitions of biopharmaceutical companies with significant royalty assets. Our failure to realize expected benefits of such acquisitions or our incurrence of unanticipated liabilities, could adversely affect our business, financial condition and results of operations.
We may acquire companies with significant royalty assets or where we believe we could create significant synthetic royalties. These acquired or created royalty assets may not perform as we project. Moreover, the acquisition of operating biopharmaceutical companies will result in the assumption of, or exposure to, liabilities of the acquired business that are not inherent in our other royalty acquisitions, such as direct exposure to product liability claims, high fixed costs and an expansion of our operations and expense structure, thereby potentially decreasing our profitability. The diversion of our management’s attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our on-going business operations. Despite our business, financial and legal due diligence efforts, we have limited experience in assessing acquisition opportunities, and we ultimately may be unsuccessful in ascertaining or evaluating all risks associated with such acquisitions. Moreover, we may need to raise additional funds through public or private debt or equity financing to acquire any businesses or products, which may result in dilution for shareholders or the incurrence of indebtedness. As a result, our acquisition of biopharmaceutical companies could adversely affect our business, financial condition and results of operations.
We use leverage in connection with our capital deployment, which magnifies the potential for loss if the royalties acquired do not generate sufficient income to us.
We use borrowed funds to finance a significant portion of our deployed capital. The use of leverage creates an opportunity for an increased return but also increases the risk of loss if our assets do not generate sufficient income to us. The interest expense and other costs incurred in connection with such borrowings may not be covered by our cash flow. In addition, leverage may inhibit our operating flexibility and reduce cash flow available for dividends to our shareholders. The level of our indebtedness could limit our ability to respond to changing business conditions. The various agreements relating to our borrowings may impose operating and financial restrictions on us which could affect the number and size of the royalties that we may pursue. Therefore, no assurance can be given that we will be able to take advantage of favorable conditions or opportunities as a result of any restrictive covenants under our indebtedness. There can also be no assurance that additional debt financing, either to replace or increase existing debt financing, will be available when needed or, if available, will be obtainable on terms that are commercially reasonable. Additional risks related to our leverage include:
• our royalties may be used as collateral for our borrowings;
• in the event of a default under secured borrowings, if any, one or more of our creditors or their assignees could obtain control of our royalties and, in the event of a distressed sale, these creditors could dispose of these royalties for significantly less value than we could realize for them;
23

• we have to comply with various financial covenants in the agreements that govern our debt, including requirements to maintain certain leverage ratios and coverage ratios, which may affect our ability to achieve our business objectives;
• our ability to pay dividends to our shareholders may be restricted; and
• to the extent that interest rates at which we borrow increase, our borrowing costs will increase and our leveraging strategy will become more costly, which could lead to diminished net profits.
We do not employ our own personnel and are entirely dependent upon the Manager for all the services we require.
Because we are “externally managed,” we do not employ our own personnel but instead depend upon the Manager, its executive officers and its employees for all of the services we require. The Manager selects and manages the acquisition of royalties and similar payment streams that meet our investment criteria and provides all of our other administrative services. Accordingly, our success is dependent upon the expertise and services of the executive officers and other personnel provided to us through the Manager. The Management Agreement has an initial term of ten years, after which it can be renewed for an additional term of three years, unless either we or the Manager provide notice of non-renewal 180 days prior the expiration of the initial term or renewal term. The Manager may not be removed during the initial or any renewal term without cause. While our agreement with the Manager requires its executives to devote substantially all of their time to managing us and any legacy vehicles related to Old RPI or RPI unless otherwise approved by the board of directors, such resources may prove to be inadequate to meet our needs.
The success of our business depends upon key members of the Manager’s senior advisory team who may not continue to work for the Manager.
We depend on the expertise, skill and network of business contacts of the advisory professionals of the Manager, who evaluate, negotiate, structure, execute, monitor and service our assets in accordance with the terms of the Management Agreement between us and the Manager. Our future success depends to a significant extent on the continued service and coordination of the senior advisory professionals of the Manager, particularly Mr. Legorreta. Pursuant to the Management Agreement, executives of the Manager must devote substantially all of their business time to managing us, unless otherwise approved by the board of directors. Despite this, Mr. Legorreta and other key advisory professionals may have other demands on their time now and in the future, and we cannot assure you that they will continue to be actively involved in our business. Each of these individuals is an employee of the Manager and is not subject to an employment contract with us. The departure of any of these individuals or competing demands on their time in the future could impact our ability to achieve our business objectives. This could adversely affect our financial condition and results of operations.
The senior advisory professionals of the Manager have relationships with participants in the biopharmaceutical industry, financial institutions and other advisory professionals, which we rely upon to source potential asset acquisition opportunities. If the senior advisory professionals of the Manager fail to maintain such relationships, or to develop new relationships with other sources, we will not be able to grow our current asset portfolio. In addition, we can offer no assurance that these relationships, even if maintained, will generate asset acquisition opportunities for us in the future.
There can be no assurance that the policies and procedures we have established to mitigate conflicts of interest will be effective in doing so.
Pursuant to the Management Agreement, the Manager cannot manage another entity that invests in or acquires royalties other than any legacy vehicle related to Old RPI or RPI. Every executive of our Manager is subject to a non-compete agreement that is effective for 18 months following termination of their employment with the Manager for any reason. We are a beneficiary of this agreement. In addition, executives of the Manager must devote substantially all of their business time to managing us and any legacy vehicle related to Old RPI or RPI, unless otherwise approved by the board of directors. Despite this, the ability of our Manager and its officers and employees to engage in other business activities, subject to the terms of our Management Agreement, may reduce the amount of time our Manager, its officers or other employees spend managing us.
24

Furthermore, there could be conflicts of interest between us and our senior advisory personnel. For instance, Mr. Legorreta, our Chief Executive Officer, is also a co-founder of and has significant influence over Pharmakon Advisors, which shares physical premises with the Manager. Pharmakon manages BioPharma Credit PLC (LSE: BPCR) and other investment vehicles that collectively are leading providers of debt capital to the biopharmaceutical industry. Mr. Legorreta has a substantial investment in BioPharma Credit. Even though he has the involvement with Pharmakon and BioPharma Credit PLC described above, Mr. Legorreta does not have any material constraints on the time he has available to devote to us and the Manager. From time to time, the Manager and Pharmakon may pursue similar investment opportunities for their respective clients, although we believe that actual conflicts of interest are rare due to the differing investment strategies of Pharmakon and us, and the fact that royalty holders, rather than Pharmakon and us, determine the type of transaction they seek. Under arrangements with Pharmakon, the Manager subleases office space to Pharmakon, and the parties may provide research, business development, legal, compliance, financial and administrative services to one another. The Manager and Pharmakon reimburse each other to the extent that one of them provides materially more services to the other than they receive in return. In consideration of the support provided to Pharmakon by the Manager, certain employees of the Manager receive compensation from Pharmakon. In addition, Mr. Legorreta has founded and participates in two foundations that provide medical research funding.
In addition, the structure of our Manager’s compensation arrangements may have unintended consequences for us. We have agreed to pay our Manager or its affiliates quarterly operating and personnel expenses (the “Operating and Personnel Payments”), a portion of which is based on the mark-to-market value of security investments, including equity securities and derivative financial instruments, at the end of each quarter and is payable to the Manager regardless of whether we realize any gain on the security investments when sold. Consequently, the Manager may be incentivized to have us make security investments regardless of our expected gain on such investments, which may not align with our or our shareholders’ long-term interests.
To service our indebtedness and meet our other ongoing liquidity needs, we will require a significant amount of cash. Our ability to generate cash depends on many factors beyond our control. If we cannot generate the required cash, we may not be able to make the required payments under our indebtedness.
As of December 31, 2021, our total principal amount of Notes outstanding was $7.3 billion. In addition, we have up to $1.5 billion of available revolving commitments under our unsecured revolving credit facility (the “Revolving Credit Facility”). Except for RP Holdings, our subsidiaries that do not guarantee the Notes will have no obligation, contingent or otherwise, to pay amounts due under the Notes or to make any funds available to pay those amounts, whether by dividend, distribution, loan or other payment. We cannot assure you that our business will generate sufficient cash flow from operations to enable us to pay our indebtedness or to fund our other liquidity needs.
Absent sufficient cash flow and the ability to refinance, we could also be forced to sell assets to make up for any shortfall in our payment obligations. However, the terms of the agreements that govern our existing outstanding debt limit, our and our subsidiaries’ ability to sell assets and also restrict the use of proceeds from such a sale. Accordingly, we may not be able to sell assets quickly enough or for sufficient amounts to enable us to meet our obligations on our indebtedness.

Our business is subject to interest rate and foreign exchange risk.
We are subject to interest rate fluctuation exposure through any borrowings under our Revolving Credit Facility and our investments in money market accounts and marketable securities, the majority of which bear a variable interest rate. To the extent that interest rates generally increase, our borrowing costs will increase and our leveraging strategy will become more costly, leading to diminished net profits.
Certain products pay royalties in currencies other than U.S. dollars, which creates foreign currency risk primarily with respect to the Euro, Canadian Dollar, Swiss Franc and Japanese Yen, as our functional and reporting currency is the U.S. dollar. In addition, our results of operations are subject to foreign currency exchange risk through transactional exposure resulting from movements in exchange rates between the time we recognize royalty income or royalty revenue and the time at which the transaction settles, or we receive the royalty payment. Because we are entitled to royalties on worldwide sales for various products, there is an underlying exposure to foreign currency as the marketer converts payment amounts from local currencies to U.S. dollars using a quarterly average exchange rate. Therefore, cash received may differ from the estimated receivable based on fluctuations in currency. As a result, significant changes in foreign exchange rates can impact our results.
25

Information about the biopharmaceutical products underlying the royalties we buy available to us may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited.
We may have limited information concerning the products generating the royalties we are evaluating for acquisition. Often, the information we have regarding products following our acquisition of a royalty may be limited to the information that is available in the public domain. Therefore, there may be material information that relates to such products that we would like to know but do not have and may not be able to obtain. For example, we do not always know the results of studies conducted by marketers of the products or others or the nature or amount of any complaints from doctors or users of such products. In addition, the market data that we obtain independently may also prove to be incomplete or incorrect. Due to these and other factors, the actual cash flow from a royalty may be significantly lower than our estimates.
Our future income is dependent upon numerous royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns.
Our business model is based on multiple-year internal and external forecasts regarding product sales and numerous product-specific assumptions in connection with each royalty acquisition, including where we have limited information regarding the product. There can be no assurance that the assumptions underlying our financial models, including those regarding product sales or competition, patent expirations or license terminations for the products underlying our portfolio, are accurate. These assumptions involve a significant element of subjective judgment and may be and in the past have been adversely affected by post-acquisition changes in market conditions and other factors affecting the underlying product. Our assumptions regarding the financial stability or operational or marketing capabilities of the partner obligated to pay us royalties may also prove and in the past have proven to be incorrect. Due to these and other factors, the assets in our current portfolio or future assets may not generate expected returns or returns in line with our historical financial performance or in the time periods we expect. This could negatively impact our results of operation for a given period.
We make assumptions regarding the royalty duration for terms that are not contractually fixed, and a shortened royalty term could result in a reduction in the effective interest rate, a decline in income from royalties, significant reductions in royalty payments compared to expectations, or a permanent impairment.
In accordance with generally accepted accounting principles in the United States GAAP, we classify most royalty assets that we acquire as financial assets that are measured at amortized cost using the prospective effective interest method described in ASC 835-30. The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount, net of any purchased receivables. A critical component of such forecast is our assumptions regarding duration of the royalty.
The royalty duration is important for purposes of accurately measuring interest income over the life of a royalty. In making assumptions around the royalty duration for terms that are not contractually fixed, we consider the strength of existing patent protection, expected entry of generics, geographical exclusivity periods and potential patent term extensions tied to the underlying product.
The duration of a royalty usually varies on a country-by-country basis and can be based on a number of factors, such as patent expiration dates, regulatory exclusivity, years from first commercial sale of the patent-protected product, the entry of competing generic or biosimilar products, or other terms set out in the contracts governing the royalty. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen positive or negative developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing for the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles, and industry consolidations.
If an unexpected shortening of a royalty term were to occur, it could result in a reduction in the effective interest rate, a decline in income from royalties, a significant reduction in royalty payments compared to expectations, or a permanent impairment.
26

Our reliance on a limited number of products may adversely affect our business, financial condition and results of operation.
While our current asset portfolio includes royalties relating to over 35 marketed products and ten development-stage product candidates, the top five product franchises accounted for 67% of our royalty receipts in the year ended December 31,
2021. In addition, our asset portfolio may not be fully diversified by geographic region or other criteria. Any significant deterioration in the cash flows from the top products in our asset portfolio could adversely affect our business, financial condition and results of operations.
We face competition in acquiring assets and locating suitable assets to acquire.
There are a limited number of suitable and attractive opportunities to acquire high-quality royalties available in the market. Therefore, competition to acquire such royalties is intense and may increase. We compete with other potential acquirers for these opportunities, including companies that market the products on which royalties are paid, financial institutions and others. These competitors may be able to access lower cost capital, may be larger than us, may have relationships that provide them access to opportunities before us, or may be willing to acquire royalties for lower projected returns than we are.
Biopharmaceutical products are subject to substantial competition.
The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product’s commercial life cannot be predicted with certainty. There can be no assurance that one or more products on which we are entitled to a royalty will not be rendered obsolete or non-competitive by new products or improvements on which we are not entitled to a royalty made to existing products, either by the current marketer of such products or by another marketer. Current marketers of products may undertake these development efforts in order to improve their products or to avoid paying our royalty. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which generate our royalties.
Competitive factors affecting the market position and success of each product include:
• effectiveness;
• safety and side effect profile;
• price, including third-party insurance reimbursement policies;
• timing and introduction of the product;
• effectiveness of marketing strategy and execution;
• governmental regulation;
• availability of lower-cost generics and/or biosimilars;
• treatment innovations that eliminate or minimize the need for a product; and
• product liability claims.
Products on which we have a royalty may be rendered obsolete or non-competitive by new products, including generics and/or biosimilars, improvements on existing products or governmental or regulatory action. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies using gene editing and new curative modalities, such as cell and gene therapy, products on which we have a royalty may become obsolete. These developments could adversely affect the sales of the biopharmaceutical products that generate our royalties, and consequently could adversely affect our business, financial condition and results of operations.
27

Marketers of products that generate our royalties are outside of our control.
In the case of our royalty receivables, our cash flow consists primarily of payments supported by royalties paid by marketers. These marketers may have interests that are different from our interests. For example, these marketers may be motivated to maximize income by allocating resources to other products and, in the future, may decide to focus less attention on the products generating our royalties or by allocating resources to develop products that do not generate royalties to us. There can be no assurance that any marketer or person with whom the marketer has a working relationship has adequate resources and motivation to continue to produce, market and sell the products generating our royalties. Aside from any limited audit rights relating to the activities of the marketers that we may have in certain circumstances pursuant to the terms of our arrangements with the licensor, we do not have oversight rights with respect to the marketers’ operations and do not have rights allowing us to direct their operations or strategy nor do our agreements contain performance standards for their operations. We also have limited information on the marketers’ operations.
In these circumstances, while we may be able to receive certain information relating to sales of products through the exercise of audit rights and review of royalty reports we receive from the licensor, we will not have the right to review or receive certain information relating to products that the marketers may have, including the results of any studies conducted by the marketers or others, or complaints from doctors or users of products. The market performance of the products generating our royalties may therefore be diminished by any number of factors relating to the marketers that are outside of our control.
The marketers of biopharmaceutical products are, generally, entirely responsible for the ongoing regulatory approval, commercialization, manufacturing and marketing of products.
Generally, the holders of royalties on products have granted exclusive regulatory approval, commercialization, manufacturing and marketing rights to the marketers of such products. The marketers have full control over those efforts and sole discretion to determine the extent and priority of the resources they will commit to their program for a product. Accordingly, the successful commercialization of a product depends on the marketer’s efforts and is beyond our control. If a marketer does not devote adequate resources to the ongoing regulatory approval, commercialization and manufacture of a product, or if a marketer engages in illegal or otherwise unauthorized practices, the product’s sales may not generate sufficient royalties, or the product’s sales may be suspended, and consequently, could adversely affect our business.
License agreements relating to products may, in some instances, be unilaterally terminated or disputes may arise which may affect our royalties.
License agreements relating to the products generating our royalties may be terminated, which may adversely affect sales of such products and therefore the payments we receive. For example, under certain license agreements, marketers retain the right to unilaterally terminate the agreements with the licensors. When the last patent covering a product expires or is otherwise invalidated in a country, a marketer may be economically motivated to terminate its license agreement, either in whole or with respect to such country, in order to terminate its payment and other obligations. In the event of such a termination, a licensor may no longer receive all of the payments it expected to receive from the licensee and may also be unable to find another company to continue developing and commercializing the product on the same or similar terms as those under the license agreement that has been terminated.
In addition, license agreements may fail to provide significant protection for the licensor in case of the licensee’s failure to perform or in the event of disputes. License agreements which relate to the products underlying our royalties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what the licensor believes to be the scope of its rights to the relevant intellectual property or technology, or decrease the licensee’s financial or other obligations under the relevant agreement, any of which could in turn impact the value of our royalties and adversely affect our business, financial condition and results of operations. If a marketer were to default on its obligations under a license agreement, the licensor’s remedy may be limited either to terminating certain licenses related to certain countries or to generally terminate the license agreement with respect to such country. In such cases, we may not have the right to seek to enforce the rights of the licensor and we may be required to rely on the resources and willingness of the licensor to enforce its rights against the licensee.
In any of these situations, if the expected payments under the license agreements do not materialize, this could result in a significant loss to us and adversely affect our business, financial condition and results of operations.
28

The insolvency of a marketer could adversely affect our receipt of cash flows on the related royalties that we hold.
If a marketer were to become insolvent and seek to reorganize under Chapter 11 of Title 11 of the U.S. Code, as amended, or the Bankruptcy Code, or liquidate under Chapter 7 of the Bankruptcy Code (or foreign equivalent), such event could delay or impede the payment of the amounts due under a license agreement, pending a resolution of the insolvency proceeding. Any unpaid royalty payments due for the period prior to the filing of the bankruptcy proceeding would be unsecured claims against the marketer, which might not be paid in full or at all. While royalty payments due for periods after the filing may qualify as administrative expenses entitled to a higher priority, the actual payment of such post-filing royalty payments could be delayed for a substantial period of time and might not be in the full amount due under the license agreement. The licensor would be prevented by the automatic stay from taking any action to enforce its rights without the permission of the bankruptcy court. In addition, the marketer could elect to reject the license agreement, which would require the licensor to undertake a new effort to market the applicable product with another distributor. Such proceedings could adversely affect the ability of a payor to make payments with respect to a royalty, and could consequently adversely affect our business, financial condition and results of operations.
Unsuccessful attempts to acquire new royalties could result in significant costs and negatively impact subsequent attempts to locate and acquire other assets.
The investigation of each specific target royalty and the negotiation, drafting and execution of relevant agreements, disclosure and other documents requires substantial management time and attention and results in substantial costs for accountants, attorneys and others. If a decision is made not to complete a specific acquisition, the costs incurred for the proposed transaction would not be recoverable from a third party. Furthermore, even if an agreement is reached relating to a specific target asset, we may fail to consummate the acquisition for any number of reasons, including, in the case of an acquisition of a royalty through a business combination with a public company, approval by the target company’s public shareholders. Multiple unsuccessful attempts to acquire new royalties could hurt our reputation, result in significant costs and waste the Manager’s time. The opportunity cost of diverting management and financial resources could negatively impact our ability to locate and acquire other assets.
Most of our royalties are classified as financial assets that are measured at amortized cost using the effective interest method as a result of which our GAAP results of operations can be volatile and unpredictable.
In accordance with GAAP, most of the royalty assets we acquire are treated as investments in cash flow streams and are thus classified as financial assets. Under this classification, our financial royalty assets are treated as having a yield component that resembles loans measured at amortized cost under the effective interest accounting methodology. Under this accounting methodology, we calculate the effective interest rate on each financial royalty asset using a forecast of the expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. The yield, which is calculated at the end of each reporting period and applied prospectively, is then recognized via accretion into our income at the effective rate of return over the expected life of the financial royalty asset.
As a result of the non-cash charges associated with the application of the effective interest method accounting methodology, our income statement activity in respect of many of our royalties can be volatile and unpredictable. Small declines in sell-side equity research analysts’ consensus sales forecasts over a long time horizon can result in an immediate non-cash income statement expense recognition, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014 we acquired the cystic fibrosis franchise royalty, which is classified as a financial royalty asset. Beginning in the second quarter of 2015, declines in near-term sales forecasts of sell-side equity research analysts caused us to recognize non-cash provision expenses to the income statement and build up a corresponding cumulative allowance which reduced the gross balance for this financial royalty asset. Over the course of 10 quarters, we recognized non-cash provision expenses as a result of these changes in forecasts, including a non-cash expense of $743.2 million in 2016, ultimately reaching a peak cumulative allowance of $1.30 billion by September 30, 2017 related to this financial royalty asset. With the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts’ consensus sales forecasts increased to reflect the larger addressable market and the extension of the expected duration of the Trikafta royalty. While small reductions in the cumulative allowance for the cystic fibrosis franchise were recognized as provision income in 2017 and 2018, there remained a $1.10 billion cumulative allowance that was fully reduced by $1.10 billion in 2019 as a result of an increase in sell-side equity research analysts’ consensus sales forecasts associated with the Trikafta approval. The financial statement impact caused by the application of the effective interest accounting methodology could result in a negative perception of our results in a given period.
29

Sales of the products that generate our royalties are subject to uncertainty related to healthcare reimbursement policies, managed care considerations and pricing pressures.
In both the U.S. and non-U.S. markets, sales of biopharmaceutical products, and the success of such products, depends in part on the availability and extent of coverage and reimbursement from third-party payors, including government healthcare programs and private insurance plans.
In the United States, pharmaceutical product pricing is subject to enhanced government regulation, public scrutiny and calls for reforms. Some states have implemented, and other states are considering, pharmaceutical price controls or patient access constraints under their Medicaid program. There have also been recent state legislative efforts that have generally focused on increasing transparency around drug costs or limiting drug prices. In addition, the growth of large managed care organizations and prescription benefit managers, as well as the prevalence of generic substitution, has hindered price increases for prescription drugs. Continued intense public scrutiny of the price of drugs, together with government and payor dynamics, may limit the ability of producers and marketers to set or adjust the price of products based on their value. There can be no assurance that new or proposed products will be considered cost-effective or that adequate third-party reimbursement will be available to enable the producer or marketer of such product to maintain price levels sufficient to realize an appropriate return. Outside the United States, numerous major markets, including the EU, Japan and China, have pervasive government involvement in funding healthcare, and, in that regard, fix the pricing and reimbursement of pharmaceutical products. Consequently, in those markets, the products generating our royalties are subject to government decision-making and budgetary actions.
These pricing pressures may adversely affect our current royalties and the attractiveness of future acquisitions of royalties.
The products that generate our royalties are subject to uncertainty related to the regulation of the healthcare industry.
The U.S. healthcare industry is highly regulated and subject to frequent and substantial changes. For example, the U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (the “ACA”) was enacted by Congress in March 2010 and established a major expansion of healthcare coverage, financed in part by a number of new rebates, discounts, and taxes that had a significant effect on the expenses and profitability on the companies that manufacture the products that generate our royalties. These companies and their products face uncertainty due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA.
Other U.S. federal or state legislative or regulatory action and/or policy efforts could adversely affect the healthcare industry, including, among others, general budget control actions, changes in patent laws, the importation of prescription drugs from outside the United States at prices that are regulated by governments of various foreign countries, revisions to reimbursement of biopharmaceutical products under government programs, restrictions on U.S. direct-to-consumer advertising or limitations on interactions with healthcare professionals. No assurances can be provided that these laws and regulations will not adversely affect our business, financial condition and results of operations.
In addition, many of the products in our portfolio benefit from regulatory exclusivity. If, in an effort to regulate pricing, regulatory exclusivity is not maintained, our business, financial condition and results of operations may be adversely impacted.
The biopharmaceutical industry may be negatively affected by federal government deficit reduction policies, which could reduce the value of the royalties that we hold.
In an effort to contain the U.S. federal deficit, the pharmaceutical industry could be considered a potential source of savings via legislative proposals. Government action to reduce federal spending on entitlement programs, including Medicare, Medicaid or other publicly funded or subsidized health programs, or to lower drug spending, may affect payment for the products that generate our royalties. These and any other cost controls and/or any significant additional taxes or fees that may be imposed on the biopharmaceutical industry as part of deficit reduction efforts could reduce cash flows from our royalties and therefore adversely affect our business, financial condition and results of operations.
30

Sales of products that generate our royalties are subject to regulatory approvals and actions in the United States and foreign jurisdictions that could harm our business.
The procedures to approve biopharmaceutical products for commercialization vary among countries and can involve additional testing and time. Such procedures may include on-site inspections by regulatory authorities at clinical trial sites or manufacturing facilities, which inspections may be delayed by travel restrictions imposed in response to the COVID-19 pandemic or other pandemics. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval and many include additional risks, such as pricing approval.
There can be no assurance that any of these regulatory approvals will be granted or not be revoked or restricted in a manner that would adversely affect the sales of such products and on the ability of payors to make payments with respect to such royalties to us.
The manufacture and distribution of a biopharmaceutical product may be interrupted by regulatory agencies or supplier deficiencies.
The manufacture of products generating our royalties is typically complex and is highly regulated. In particular, biopharmaceutical products are manufactured in specialized facilities that require the approval of, and ongoing regulation by, the FDA in the United States and, if manufactured outside of the United States, both the FDA and non-U.S. regulatory agencies, such as the EMA. With respect to a product, to the extent that operational standards set by such agencies are not adhered to, manufacturing facilities may be closed or production interrupted until such time as any deficiencies noted by such agencies are remedied. Any such closure or interruption may interrupt, for an indefinite period of time, the manufacture and distribution of a product and therefore the cash flows from the related biopharmaceutical asset may be significantly less than expected.
In addition, manufacturers of a product may rely on third parties for selected aspects of product development, such as packaging or to supply bulk raw material used in the manufacture of such product. In the United States, the FDA requires that all suppliers of pharmaceutical bulk materials and all manufacturers of pharmaceuticals for sale in or from the United States adhere to the FDA’s current “Good Manufacturing Practice” regulations and guidelines and similar requirements that exist in jurisdictions outside the United States. Licensees generally rely on a small number of key, highly specialized suppliers, manufacturers and packagers. Any interruptions, however minimal, in the operation of these manufacturing and packaging facilities could adversely affect production and product sales and therefore adversely affect our business, financial condition and results of operations.
Product liability claims may diminish the returns on biopharmaceutical products.
The developer, manufacturer or marketer of a product could become subject to product liability claims. A product liability claim, regardless of its merits, could adversely affect the sales of the product and the amount of any related royalty payments, and consequently, could adversely affect the ability of a payor to make payments with respect to a royalty.
Although we believe that we will not bear responsibility in the event of a product liability claim against the developer, manufacturer, marketer or other seller of the product that generates our royalty, such claims could adversely affect our business, financial condition and results of operations due to the lower than expected cash flows from the royalty.
We are typically not involved in maintaining, enforcing and defending patent rights on products that generate our royalties.
Our right to receive royalties generally depends on the existence of valid and enforceable claims of registered and/or issued patents in the United States and elsewhere in the world. The products on which we receive payments are dependent on patent protection and on the fact that the manufacturing, marketing and selling of such products do not infringe, misappropriate or otherwise violate intellectual property rights of third parties. Typically, we have no ability to control the prosecution, maintenance, enforcement or defense of patent rights, but must rely on the willingness and ability of our partners or their marketers to do so. There can be no assurance that these third parties will vigorously prosecute, maintain, enforce or defend such rights. Even if such third parties seek to prosecute, maintain, enforce or defend such rights, they may not be successful.
31

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation. Furthermore, changes in patent laws or interpretation of patent laws in the United States and in other jurisdictions could increase the uncertainties surrounding the successful prosecution of patent applications and the successful enforcement or defense of issued patents by our partners, all of which could diminish the value of patent protection relating to the biopharmaceutical assets. As a result, the issuance, scope, validity, enforceability and commercial value of the patent rights of our partners and their marketers are highly uncertain. In addition, such third parties’ pending and future patent applications may not result in patents being issued which protect their products, development-stage product candidates and technologies or which effectively prevent others from commercializing competitive products, development-stage product candidates and technologies. Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance.
Even if the patent applications our partners and their marketers license or own do issue as patents, they may not issue in a form that will provide them with any meaningful protection, prevent competitors or other third parties from competing with them or otherwise provide them with any competitive advantage. Competitors or other third parties may be able to circumvent patents of our partners and their marketers by developing similar or alternative products in a non-infringing manner. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit the ability of our partners and their marketers from preventing others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of their products, development-stage product candidates and technologies.
Any loss or reduction in the scope or duration of patent protection for any product that generates our royalties, or any failure to successfully prosecute, maintain, enforce or defend any patents that protect any such product may result in a decrease in the sales of such product and any associated royalties payable to us. Any such event would adversely affect the ability of the payor to make payments of royalties to us or may otherwise reduce the value of our royalty interest, and could consequently adversely affect our business, financial condition and results of operations. In cases where our contractual arrangements with our partner permit us to do so, we could participate in patent suits brought by third parties but this could result in substantial litigation costs, divert management’s attention from our core business and there can be no assurance that such suits would be successful.
The existence of third-party patents in relation to products may result in additional costs for the marketer and reduce the amount of royalties paid to us.
The commercial success of a product depends, in part, on avoiding infringement, misappropriation or other violations of the intellectual property rights and proprietary technologies of others. Third-party issued patents or patent applications claiming subject matter necessary to manufacture and market a product could exist or issue in the future. Such third-party patents or patent applications may include claims directed to the mechanism of action of a product. There can be no assurance that a license would be available to marketers for such subject matter if such infringement were to exist or, if offered, would be offered on reasonable and/or commercially feasible terms. Without such a license, it may be possible for third parties to assert infringement or other intellectual property claims against the marketer of such product based on such patents or other intellectual property rights.
Even if the marketer was able to obtain a license, it could be non-exclusive, thereby giving its competitors and other third parties access to the same technologies. In addition, if a marketer of a product that generates our royalties is required to obtain a license from a third party, the marketer may, in some instances, have the right to offset the licensing and royalty payments to such third party against royalties that would be owed to our partner, which may ultimately reduce the value of our royalty interest. An adverse outcome in infringement or other intellectual property-related proceedings could subject a marketer to significant liabilities to third parties, require disputed rights to be licensed from third parties or require the marketer to cease or modify its manufacturing, marketing and distribution of any affected product, any of which could reduce the amount of cash flow generated by the affected products and any associated royalties payable to us and therefore adversely affect our business, financial condition and results of operations.
32

Disclosure of trade secrets of marketers of products could negatively affect the competitive position of the products underlying our biopharmaceutical assets.
The marketers of the products that generate our royalties depend, in part, on trade secrets, know-how and technology, which are not protected by patents, to maintain the products’ competitive position. This information is typically protected through confidentiality agreements with parties that have access to such information, such as collaborative partners, licensors, employees and consultants. Any of these parties may breach the agreements and disclose the confidential information or competitors might independently develop or learn of the information in some other way, which could harm the competitive position of the products and therefore reduce the amount of cash flow generated by our royalty interest.
The internal computer systems of our counterparties may fail or suffer security breaches, which could result in a significant disruption of their ability to operate their business effectively, adversely affect the cash flow generated by the related biopharmaceutical products, and adversely affect our business, financial condition and results of operations.
The internal computer systems and cloud-based computing services of our counterparties and those of their current and any future collaborators and other contractors or consultants are vulnerable to damage or interruption from computer viruses, data corruption, cyber-based attacks, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. We have been subject to cyber-based attacks and unauthorized access in the past. If such an event were to occur in the future and cause interruptions in their operations, it could result in a disruption of their development and commercialization programs and business operations, whether due to a loss of trade secrets or other proprietary information or other similar disruptions. To the extent that any disruption or security breach were to result in a loss of, or damage to, a counterparties’ data or applications, or inappropriate disclosure of confidential or proprietary information, our partners’ operations may be harmed and the development and commercialization of their products, development-stage product candidates and technologies could be delayed. Such an event may reduce the amount of cash flow generated by the related biopharmaceutical products and therefore adversely affect our business, financial condition and results of operations.
Our ability to pay periodic dividends to our shareholders or make share repurchases may be limited by applicable provisions of English law and contractual restrictions and obligations.
Under English law, we will only be able to declare dividends, make distributions or repurchase shares (other than out of the proceeds of a new issuance of shares for that purpose) out of profits available for distribution. Profits available for distribution are accumulated, realized profits, to the extent that they have not been previously utilized by distribution or capitalization, less its accumulated, realized losses, to the extent that they have not been previously written off in a reduction or reorganization of capital duly made. The amount of our distributable reserves is a cumulative calculation. We may be profitable in a single financial year but unable to pay a dividend or make share repurchases if our accumulated, realized profits do not offset all previous years’ accumulated, realized losses. Additionally, we may only make a distribution if our net assets are not less than the amount of our aggregate called-up share capital and distributable reserves, and if, and to the extent that, the distribution does not reduce the amount of those assets to less than that aggregate.
Subject to the terms of our indebtedness or other contractual obligations, the approval and payment of any interim dividends are at the sole discretion of our board of directors, which may change our dividend policy at any time and the payment of any final dividends will be subject to majority approval by holders of Class A ordinary and Class B ordinary shares and in each case will be paid out of profits available for that purpose under English law. Our Articles of Association authorize the board of directors to approve interim dividends without shareholder approval to the extent that such dividends appear justified by profits available for such purpose. The board of directors may also recommend final dividends be approved and declared by shareholders at an annual general meeting. No such dividend may exceed the amount recommended by the board of directors.
There can be no assurance that any dividends, whether quarterly or otherwise, will or can be paid or that any shares will or can be repurchased. Our ability to pay dividends to our shareholders or make share repurchases depends on a number of factors, including among other things, general economic and business conditions, our strategic plans and prospects, our business and acquisition opportunities, our financial condition and results of operations, working capital requirements and anticipated cash needs, contractual restrictions and obligations, including fulfilling our current and future capital commitments, legal, tax and regulatory restrictions, restrictions and other implications on the payment of dividends by us to our shareholders or make any share repurchases and such other factors as our board of directors may deem relevant.
A shareholder who receives a distribution under circumstances where he or she knows or has reasonable grounds for believing that the distribution is unlawful in the circumstances is obliged to repay such distribution (or that part of it, as the case may be) to us.
33

If we were determined to be an investment company under the U.S. Investment Company Act of 1940, applicable restrictions could make it impractical for us to continue our business as contemplated and could adversely affect our business, financial condition and results of operations.
We intend to conduct our business so as not to become regulated as an investment company under the U.S. Investment Company Act. An entity generally will be determined to be an investment company for purposes of the U.S. Investment Company Act if, absent an applicable exemption, (i) it is or holds itself out as being engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities; or (ii) it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis, which we refer to as the ICA 40% Test.
We do not hold ourselves out as being engaged primarily, or propose to engage primarily, in the business of investing, reinvesting or trading in securities, and believe that we are not engaged primarily in the business of investing, reinvesting or trading in securities. We believe that, for U.S. Investment Company Act purposes, we are engaged primarily, through one or more of our subsidiaries, in the business of purchasing or otherwise acquiring certain obligations that represent part or all of the sales price of merchandise. Our subsidiaries that are so engaged rely on Section 3(c)(5)(A) of the U.S. Investment Company Act, which, as interpreted by the SEC staff, requires each such subsidiary to invest at least 55% of its assets in “notes, drafts, acceptances, open accounts receivable, and other obligations representing part or all of the sales price of merchandise, insurance, and services,” which we refer to as the ICA Exception Qualifying Assets.
In a no-action letter, dated August 13, 2010, to our predecessor, the SEC staff promulgated an interpretation that royalty interests that entitle an issuer to collect royalty receivables that are directly based on the sales price of specific biopharmaceutical assets that use intellectual property covered by specific license agreements are ICA Exception Qualifying Assets under Section 3(c)(5)(A). We rely on this no-action letter for the position that royalty receivables relating to biopharmaceutical assets that we hold are ICA Exception Qualifying Assets under Section 3(c)(5)(A) and Section 3(c)(6), which is described below.
To ensure that we are not obligated to register as an investment company, we must not exceed the thresholds provided by the ICA 40% Test. For purposes of the ICA 40% Test, the term investment securities does not include U.S. government securities or securities issued by majority-owned subsidiaries that are not themselves investment companies and are not relying on Section 3(c)(1) or Section 3(c)(7) of the U.S. Investment Company Act, such as majority-owned subsidiaries that rely on Section 3(c)(5)(A). We also may rely on Section 3(c)(6), which, based on SEC staff interpretations, requires us to invest, either directly or through majority-owned subsidiaries, at least 55% of our assets in, as relevant here, businesses relying on Section 3(c)(5)(A). Therefore, the assets that we and our subsidiaries hold and acquire are limited by the provisions of the U.S. Investment Company Act and the rules and regulations promulgated thereunder.
If the SEC or its staff in the future adopts a contrary interpretation to that provided in the no-action letter to Royalty Pharma or otherwise restricts the conclusions in the SEC staff’s no-action letter such that royalty interests are no longer treated as ICA Exception Qualifying Assets for purposes of Section 3(c)(5)(A) and Section 3(c)(6), or the SEC or its staff in the future determines that the no-action letter does not apply to some or all types of royalty receivables relating to biopharmaceutical assets, our business will be materially and adversely affected. In particular, we would be required either to convert to a corporation formed under the laws of the United States or a state thereof (which would likely result in our being subject to U.S. federal corporate income taxation) and to register as an investment company, or to stop all business activities in the United States until such time as the SEC grants an application to register us as an investment company formed under non-U.S. law. It is unlikely that such an application would be granted and, even if it were, requirements imposed by the Investment Company Act, including limitations on our capital structure, our ability to transact business with affiliates and our ability to compensate key employees, could make it impractical for us to continue our business as currently conducted. Our ceasing to qualify for an exemption from registration as an investment company could materially and adversely affect the value of our Class A ordinary shares and our ability to pay dividends in respect of our Class A ordinary shares.
34

The equity performance awards payable to an affiliate of the Manager may create incentives that are not fully aligned with the interests of our shareholders.
Subject to certain conditions, at the end of each fiscal quarter, an affiliate of the Manager is entitled to a distribution in the form of equity from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The right to Equity Performance Awards may create an incentive for the Manager to make riskier or more speculative asset acquisitions than would be the case absent such Equity Performance Awards. In addition, the Manager may cause us to incur more debt or otherwise use more leverage in connection with asset acquisitions, as generally the use of leverage can increase the rate of return on an investment and therefore our profits. This Equity Performance Awards structure may encourage the Manager to cause us to borrow money to finance additional asset acquisitions or to maintain leverage which poses higher risks for our business when it would otherwise be appropriate to not use such leverage. Under certain circumstances, the use of borrowed money may increase the likelihood of default, which would disfavor our shareholders. In addition, there is no correlation between our profits and the obligation of our board of directors to pay dividends to shareholders. Consequently, you may receive limited or no dividends while an affiliate of the Manager remains entitled to Equity Performance Awards based on our Net Economic Profit. In addition, even though Equity Performance Awards are payable on a portfolio-by-portfolio basis (with portfolios comprised of investments made during sequential two-year periods) in order to reduce the risks that affiliates of the Manager will be paid Equity Performance Awards on individual investments even though our overall portfolio of investments is not performing well, Equity Performance Awards may nevertheless be payable to affiliates of the Manager when our overall portfolio of investments is not performing as well as the individual portfolios that are used as the basis for measuring the Equity Performance Awards.
Our board of directors may make decisions with respect to the cash generated from our operations that may result in no dividends paid to our shareholders or no repurchases made of our ordinary shares.
Our board of directors is under no obligation to pay dividends, make distributions or repurchase our ordinary shares and it may decide to use cash to fund asset acquisitions or operations in lieu of paying dividends, making distributions or repurchasing our ordinary shares. We will pay Equity Performance Awards to an affiliate of the Manager based on our Net Economic Profit regardless of whether any dividends are paid to our shareholders or any ordinary shares are repurchased. Our board of directors’ decisions with respect to our cash may result in no dividends to our shareholders and no ordinary shares repurchased. Furthermore, our board of directors’ decisions with respect to dividends or repurchases of ordinary shares may adversely affect the market price of our Class A ordinary shares. In the event that we generate positive income, but pay limited or no dividends, holders of Class A ordinary shares may, if they have made certain elections for U.S. federal income tax purposes with respect to their Class A ordinary shares, have a tax liability on our income in excess of the actual cash dividends received by such holders. If our board of directors decides to approve limited or no dividends or repurchases of ordinary shares, the primary remedy for holders of Class A ordinary shares will be to sell their shares at prevailing market prices, including at a loss, which prices may be low due to unfavorable or inconsistent dividends or repurchases of our ordinary shares.
The royalties that we acquire may fall outside the biopharmaceutical industry, and any such assets, and the cash flows therefrom, may not resemble the assets in our current portfolio.
We have discretion as to the types of healthcare assets that we may acquire. While we expect the Manager to acquire assets that primarily fall within the biopharmaceutical industry, we are not obligated to do so and may acquire other types of healthcare assets that are peripheral to or outside of the biopharmaceutical industry. Consequently, our asset acquisitions in the future, and the cash flows from such assets, may not resemble those of the assets in our current portfolio. There can be no assurance that assets acquired in the future will have returns similar to the returns expected of the assets in our current portfolio or be profitable at all.
The Manager may be the subject of a change of control resulting in a disruption in our operations that could adversely affect our business, financial condition and results of operations.
There could be a change of control of the Manager and, in such a case, the new controlling party may have a different philosophy, employ advisory professionals who are less experienced, be unsuccessful in identifying asset acquisition opportunities or have a track record that is not as successful as that of the Manager prior to such a change of control. If the foregoing were to occur, we could experience difficulty in making new asset acquisitions, and the value of our existing assets, our business, financial condition and results of operations could materially suffer.
35

The Manager’s liability is limited under the Management Agreement, and we have agreed to indemnify the Manager against certain liabilities. As a result, we could experience unfavorable operating results or incur losses for which the Manager would not be liable.
Pursuant to the Management Agreement, the Manager does not assume any responsibility other than to render the services called for thereunder. Under the terms of the Management Agreement, the Manager and its affiliates (including RPI EPA Holdings, LP (“EPA Holdings”)) and their respective officers, directors, stockholders, members, employees, agents and partners, and any other person who is entitled to indemnification (each, an “Indemnitee”) is not liable to us, any subsidiary of ours, our directors, our stockholders or any subsidiary’s stockholders or partners for acts or omissions performed in accordance with and pursuant to the Management Agreement, except those resulting from acts constituting fraud, bad faith, willful misconduct, gross negligence (as such concept is interpreted under the laws of the State of New York) and a material breach of the Management Agreement that is not cured in accordance with its terms or a violation of applicable securities laws.
In addition, to the fullest extent permitted by law, we have agreed to indemnify the Indemnitees from and against any and all claims, liabilities, damages, losses, penalties, actions, judgments, costs and expenses (including amounts paid in satisfaction of judgments, in compromises and settlements, as fines and penalties and legal or other costs and reasonable expenses of investigating or defending against any claim or alleged claim) of any nature whatsoever, known or unknown, liquidated or unliquidated that are incurred by any Indemnitee or to which such Indemnitee may be subject by reason of its activities on behalf of us or any of our subsidiaries to the extent that such Indemnitee’s conduct did not constitute fraud, bad faith, willful misconduct, gross negligence (as such concept is interpreted under the laws of the State of New York), material breach of the Management Agreement that is not cured in accordance with the terms of the Management Agreement or a violation of applicable securities laws. As a result, we could experience unfavorable operating results or incur losses for which the Manager would not be liable.
Operational risks may disrupt our businesses, result in losses or limit our growth.
We and the Manager rely heavily on our respective financial, accounting, information and other data processing systems and cloud computing services, as well as those of our current and future collaborators, contractors or consultants. Such systems are vulnerable to damage or interruption from computer viruses, data corruption, cyber-based attacks, unauthorized access, natural disasters, pandemics, such as the current COVID-19 pandemic, terrorism, war and telecommunication and electrical failures. If any of these events occur and such systems do not operate properly or are disabled or if there is any unauthorized disclosure of data, whether as a result of tampering, a breach of network security systems, a cyber-incident or attack or otherwise, we could suffer substantial financial loss, increased costs, a disruption of our business, loss of trade secrets or other proprietary information, liability to us, regulatory intervention or reputational damage.
Furthermore, federal, state and international laws and regulations relating to data privacy and protection, such as the European Union’s General Data Protection Regulation, which took effect in May 2018, and the California Consumer Privacy Act, which took effect in January 2020, can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties and significant legal liability, if our information technology security efforts or data privacy and protection compliance efforts fail. In addition, we operate a business that is highly dependent on information systems and technology. Our information systems and technology and that of the Manager may not continue to be able to accommodate our growth, and the cost of maintaining such systems may increase from its current level. Such a failure to accommodate growth, or an increase in costs related to such information systems, could adversely affect our business, financial condition and results of operations.
A disaster or a disruption in the public infrastructure that supports our business, including a disruption involving electronic communications or other services used by us or third parties with whom we conduct business, could adversely affect our ability to continue to operate our business without interruption. Our disaster recovery programs and those of the Manager may not be sufficient to mitigate the harm that may result from such a disaster or disruption. In addition, insurance and other safeguards might only partially reimburse us for our losses, if at all.
In addition, sustaining our growth may require us or the Manager to commit additional management, operational and financial resources to identify new professionals to join the team and to maintain appropriate operational and financial systems to adequately support expansion. Due to the fact that the market for hiring talented professionals is competitive, we may not be able to grow at the pace we desire.
36

We are subject to the U.K. Bribery Act, the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations.
Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010 (“Bribery Act”), the U.S. Foreign Corrupt Practices Act of 1977, as amended the (“FCPA”), the U.S. domestic bribery statute contained in 18 U.S.C. §201, the U.S. Travel Act, and other anti-corruption laws that apply in countries where we do business. The Bribery Act, the FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We and the marketers of products that generate our royalties operate in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.
We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws.
There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by the United Kingdom, United States or other authorities could also have an adverse impact on our reputation, our business, financial condition and results of operations.
Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities or our business arrangements with third parties could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices or the business practices of the marketers of products that generate our royalties may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations or the operations of the marketers of products that generate are royalties are found to be in violation of any of these laws or any other governmental regulations, we or marketers of products that generate our royalties may be subject to significant criminal, civil and administrative sanctions, including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we or marketers of products that generate our royalties become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we or marketers of products that generate our royalties may be required to curtail or restructure operations, any of which could adversely affect our ability to operate our business and our results of operations.
The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.
37

The EU directive on alternative investment fund managers (the “AIFM Directive”) may significantly increase our compliance costs.
The AIFM Directive has been implemented into the national law of the majority of member states of the European Economic Area and the United Kingdom (each an “AIFM state”). The AIFM Directive sets out minimum conditions related to the marketing of interests in alternative investment funds (such as our Class A ordinary shares) in the AIFM states and may impact our ability to attract investors in the AIFM states and may significantly increase our and the Manager’s compliance costs. Such conditions include requirements for us to register with the competent authority in the relevant AIFM in order to market the Class A ordinary shares to investors, state requirements to file periodic reports with the competent authority in the relevant AIFM state and requirements to comply with disclosure and reporting obligations in respect of investors in the relevant AIFM state. Such reports and disclosures may become publicly available. While such conditions are met in relation to the AIFM states where our Class A ordinary shares will be marketed, there can be no guarantee that this will continue to be the case. The AIFM Directive does not, however, prohibit an investor in such AIFM state from subscribing for our Class A ordinary shares at their own initiative in circumstances where such Class A ordinary shares have not been marketed in such AIFM state and we may issue our Class A ordinary shares to such investors, as long as they have provided us and the Manager with representations that they have done so at their own initiative.
In each AIFM state, our Class A ordinary shares may only be offered to investors in accordance with local measures implementing the AIFM Directive. Investors, together with any person making or assisting in the decision to invest in us, who are situated, domiciled or who have a registered office, in an AIFM state where our Class A ordinary shares are not being offered pursuant to private placement rules implementing the AIFM Directive may invest, or effect an investment in our Class A ordinary shares, but only in circumstances where they do so at their own initiative. Any investor acquiring our Class A ordinary shares at their own initiative in such AIFM state should note that as we have not been registered for marketing in that AIFM state, no reports will be filed with the competent authority in the relevant AIFM state by or in respect of us and no investor shall be entitled to receive any disclosure or report that is mandated in respect of an alternative investment fund being marketed pursuant to the AIFM Directive.
Risks Relating to Our Organization and Structure
We are a holding company with no operations and rely on our subsidiaries to provide us with funds necessary to meet our financial obligations and to pay dividends.
We are a holding company with no material direct operations. Our principal asset is our controlling equity interest in RP Holdings. As a result, we are dependent on loans, dividends and other payments from our subsidiaries to generate the funds necessary to meet our financial obligations and to pay dividends on our Class A ordinary shares. Our subsidiaries are legally distinct from us and may be prohibited or restricted from paying dividends or otherwise making funds available to us under certain conditions. If the cash we receive from our subsidiaries pursuant to dividend payments is insufficient for us to fund our obligations, or if a subsidiary is unable to pay dividends to us, provided that we have sufficient distributable profits, our net assets exceed the total of our called-up share capital and distributable reserves and any dividend would not reduce our net assets to less than such total, we may be required to raise cash through the incurrence of debt, the issuance of equity or the sale of assets to fund the payment of the dividends. However, there is no assurance that we would be able to raise cash by these means. If the ability of any of our subsidiaries to pay dividends or make other distributions or payments to us is materially restricted by regulatory or legal requirements, bankruptcy or insolvency, or our need to maintain our financial strength ratings, or is limited due to operating results or other factors, it could adversely affect our ability to pay our operating costs and other corporate expenses and we may be unable to, or our board may exercise its discretion not to, pay dividends.
Our structure will result in tax distributions to the owner of the RP Holdings Class C Special Interest.
RP Holdings is treated as a partnership for U.S. federal income tax purposes and has owners that are subject to U.S. federal income taxation. To the extent permitted by applicable law, RP Holdings is required to make cash distributions, or tax distributions, to the owner of the RP Holdings Class C Special Interest, calculated using an assumed tax rate that is generally uniform for all recipients regardless of their tax status. Funds used by RP Holdings to satisfy its tax distribution obligations will not be available for reinvestment in our business.
38

Risks Relating to Our Class A Ordinary Shares
The market price of our Class A ordinary shares may be volatile, which could cause the value of your investment to decline.
The market price of our Class A ordinary shares may be highly volatile and could be subject to wide fluctuations. Securities markets worldwide experience significant price and volume fluctuations. This market volatility, as well as general economic, market or political conditions, could reduce the market price of Class A ordinary shares in spite of our operating performance. In addition to the factors discussed in this Annual Report on Form 10-K, our operating results could be below the expectations of public market analysts and investors due to a number of potential factors, including:
• market conditions in the broader stock market in general, or in our industry in particular;
• variations in our quarterly operating results or dividends to shareholders;
• additions or departures of key management personnel at the Manager;
• timing and rate of capital deployment, including relative to estimates;
• changes in our portfolio mix or acquisition strategy;
• failure to meet analysts’ earnings estimates;
• publication of research reports about our industry;
• third-party healthcare reimbursement policies and practices;
• litigation and government investigations;
• changes or proposed changes in laws or regulations or differing interpretations or enforcement thereof affecting our business;
• no results, or projected results, from marketers of products that generate our royalties;
• results from, and any delays to, the clinical trial programs of development-stage product candidates underlying our biopharmaceutical assets or other issues relating to such products, including regulatory approval or commercialization;
• adverse market reaction to any indebtedness that we may incur or securities we may issue in the future;
• changes in market valuations of similar companies or speculation in the press or investment community;
• announcements by our competitors of significant contracts, acquisitions, dispositions, strategic partnerships, joint ventures or capital commitments;
• litigation;
• economic and political conditions or events; and
• adverse publicity about us or the industries in which we participate or individual scandals.
These and other factors may cause the market price of and demand for our Class A ordinary shares to fluctuate significantly, which may limit or prevent our existing shareholders from reselling their Class A ordinary shares at or above the purchase price.
The stock market in general has from time to time experienced extreme price and volume fluctuations, including in recent months. In addition, in the past, following periods of volatility in the overall market and the market price of a company’s securities, securities class action litigation has often been instituted against public companies. This type of litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources.
39

Our Articles of Association provide that the courts of England and Wales will be the exclusive forum for the resolution of all shareholder complaints other than complaints asserting a cause of action arising under the Securities Act and the Exchange Act, and that the U.S. federal district courts will be the exclusive forum for the resolution of any shareholder complaint asserting a cause of action arising under the Securities Act and the Exchange Act.
Our Articles of Association provide that the courts of England and Wales will be the exclusive forum for resolving all shareholder complaints other than shareholder complaints asserting a cause of action arising under the Securities Act and the Exchange Act, and that the U.S. federal district courts will be the exclusive forum for resolving any shareholder complaint asserting a cause of action arising under the Securities Act and the Exchange Act. This choice of forum provision may limit a shareholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits. If a court were to find either choice of forum provision contained in our Articles of Association to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition.
U.S. investors may have difficulty enforcing civil liabilities against our company, our directors or members of senior management and the experts named herein.
We are a public limited company with our registered office in England and our subsidiaries are incorporated in various jurisdictions, including jurisdictions outside the United States. One of our directors is not a resident of the United States, and a substantial portion of our assets and the assets of this director are located outside the United States. As a result, it may be difficult for investors to effect service of process on this director in the United States or to enforce in the United States judgments obtained in U.S. courts against us or this director based on the civil liability provisions of the U.S. securities laws or otherwise. Even if you are successful in bringing an action of this kind, the laws of England may render you unable to enforce a judgment against our assets or the assets of our directors and executive officers. In addition, it is doubtful whether English courts would enforce certain civil liabilities under U.S. securities laws in original actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in the United Kingdom. An award for monetary damages under the U.S. securities laws would likely be considered punitive if it does not seek to compensate the claimant for loss or damage suffered and is intended to punish the defendant. The enforceability of any judgment in the United Kingdom will depend on the particular facts of the case as well as the laws and treaties in effect at the time. The United States and the United Kingdom do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. As a result of the above, public holders of our Class A ordinary shares may have more difficulty in protecting their interest through actions against our management, directors or major shareholders than they would as shareholders of a U.S. public company.
The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation and these differences may make our Class A ordinary shares less attractive to investors.
We are incorporated under English law. The rights of holders of our Class A ordinary shares are governed by English law, including the provisions of the Companies Act 2006 (the “U.K. Companies Act”), and by our Articles of Association. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations and these differences may make our Class A ordinary shares less attractive to investors.
The City Code on Takeovers and Mergers (the “Takeover Code”) applies, among other things, to an offer for a public company whose registered office is in the United Kingdom (or the Channel Islands or the Isle of Man) and whose securities are not admitted to trading on a regulated market in the United Kingdom (or the Channel Islands or the Isle of Man) if the company is considered by the Panel on Takeovers and Mergers (the “Takeover Panel”) to have its place of central management and control in the United Kingdom (or the Channel Islands or the Isle of Man). This is known as the “residency test.” The test for central management and control under the Takeover Code is different from that used by the U.K. tax authorities. Under the Takeover Code, the Takeover Panel will determine whether we have our place of central management and control in the United Kingdom by looking at various factors, including the structure of our board of directors, the functions of the directors and where they are resident.
If at the time of a takeover offer the Takeover Panel determines that we have our place of central management and control in the United Kingdom, we would be subject to a number of rules and restrictions, including but not limited to the following: (i) our ability to enter into deal protection arrangements with a bidder would be extremely limited; (ii) we might not, without the approval of our shareholders, be able to perform certain actions that could have the effect of frustrating an offer, such as issuing shares or carrying out acquisitions or disposals; and (iii) we would be obliged to provide equality of information to all bona fide competing bidders.
40

Given that our central management and control is currently not situated within, and our current intention is not to have it in the future situated within the United Kingdom (or the Channel Islands or the Isle of Man), but to have such management and control situated within the United States, we do not currently envisage that the Takeover Code will apply to an offer for us.
Under English law, and whether or not we are subject to the Takeover Code, an offeror for us that has acquired (i) 90% in value of; and (ii) 90% of the voting rights carried by the shares to which the offer relates may exercise statutory squeeze-out rights to compulsorily acquire the shares of the non-assenting minority. However, if an offer for us is conducted by way of a scheme of arrangement the threshold for the offeror obtaining 100% of Company shares comprises two components (i) approval by a majority in number of each class of Company shareholders present and voting at the shareholder meeting; and (ii) approval of Company shareholders representing 75% or more in value of each class of Company shareholders present and voting at that meeting.
As an English public limited company, certain capital structure decisions will require shareholder approval, which may limit our flexibility to manage our capital structure.
We are a public limited company incorporated under the laws of England and Wales. English law provides that a board of directors may only allot shares (or rights to subscribe for or convert into shares) with the prior authorization of shareholders, such authorization stating the aggregate nominal amount of shares that it covers and valid for a maximum period of five years, each as specified in the articles of association or relevant shareholder resolution. We have obtained authority from our shareholders to allot additional shares for a period expiring on May 31, 2025, which authorization will need to be renewed upon expiration (i.e., at least every five years) but may be sought more frequently for additional five-year terms (or any shorter period).
English law also generally provides shareholders with preemptive rights when new shares are issued for cash. However, it is possible for the articles of association, or for shareholders to pass a special resolution at a general meeting, being a resolution passed by at least 75% of the votes cast, to disapply preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the disapplication is contained in the articles of association, or from the date of the shareholder special resolution, if the disapplication is by shareholder special resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every five years). We have obtained authority from our shareholders to disapply preemptive rights for a period expiring on May 31, 2025, which disapplication will need to be renewed upon expiration (i.e., at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).
English law also generally prohibits a public company from repurchasing its own shares by way of “off market purchases” without the prior approval of shareholders by ordinary resolution, being a resolution passed by a simple majority of votes cast, and other formalities. Such approval may be for a maximum period of up to five years but may be sought more frequently. English law prohibits us from conducting “on market purchases” as our shares are listed on the NASDAQ and will not be traded on a recognized investment exchange in the United Kingdom.
The United Kingdom’s vote in favor of withdrawing from the European Union may have a negative effect on global economic conditions, financial markets and our business, which could reduce the market price of our Class A ordinary shares.
The withdrawal of the United Kingdom from the European Union (commonly referred to as “Brexit”) took effect on January 31, 2020. On December 30, 2020, the United Kingdom passed legislation giving effect to a trade and cooperation agreement, with the EU, which became effective on May 1, 2021. The trade and cooperation agreement covers the general objectives and framework of the relationship between the United Kingdom and the European Union, including as it related to trade, transport, visas, judicial, law enforcement and security matters, and provides for continued participation in community programs and mechanisms for dispute resolution. Notably, under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire EU single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the United Kingdom and the European Union. Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, the impact on the regulatory regime with respect to obtaining marketing approval of our development-stage product candidates in the United Kingdom remains unclear. The United Kingdom will no longer be covered by the centralized procedures for obtaining European Union-wide marketing authorization from the EMA and, unless a specific agreement is entered into, a separate process for authorization of drug products will be required in the United Kingdom. Depending on the outcome of these developments, we could face new regulatory costs and challenges that could adversely affect our operations and the market price of our Class A ordinary shares.
41

If our Class A ordinary shares are not eligible for deposit and clearing within the facilities of DTC, then transactions in our securities may be disrupted.
The facilities of The Depository Trust Company (“DTC”) are a widely-used mechanism that allow for rapid electronic transfers of securities between the participants in the DTC system, which include many large banks and brokerage firms. While our Class A ordinary shares are eligible for deposit and clearing within the DTC system and DTC has agreed to accept our Class A ordinary shares for deposit and clearing within its facilities in certain specified circumstances, DTC will generally have discretion to cease to act as a depository and clearing agency for the Class A ordinary shares, including to the extent that any changes in U.K. law change the stamp duty or stamp duty reserve tax (“SDRT”) position in relation to the Class A ordinary shares. If DTC determined at any time that the shares were not eligible for continued deposit and clearance within its facilities, then we believe the shares would not be eligible for continued listing on a U.S. securities exchange and trading in the shares would be disrupted. While we would pursue alternative arrangements to preserve our listing and maintain trading, any such disruption could adversely affect the market price of our Class A ordinary shares.
The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain qualified board members.
As a public company, we are subject to the reporting requirements of the Exchange Act, the requirements of the U.S. Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley Act”), and the requirements of the U.K. Companies Act and, if applicable, the Takeover Code. The requirements of these rules and regulations increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources.
We are obligated to file with the SEC annual and quarterly information and other reports that are specified in the Exchange Act, and therefore will need to have the ability to prepare financial statements that are compliant with all SEC reporting requirements on a timely basis. In addition, we are subject to other reporting and corporate governance requirements, including certain requirements of Nasdaq and certain provisions of the Sarbanes-Oxley Act and the regulations promulgated thereunder, which will impose significant compliance obligations upon us.
We are required to comply with Section 404 of the Sarbanes-Oxley Act, which requires management assessments of the effectiveness of internal control over financial reporting and disclosure controls and procedures. If we are unable to maintain effective internal control over financial reporting or disclosure controls and procedures, our ability to record, process and report financial information accurately and to prepare financial statements within required time periods could be adversely affected, which could subject us to regulatory consequences, including sanctions by the SEC, negatively affect investor confidence in our financial statements, restrict access to capital markets and adversely impact the market price of our Class A ordinary shares.
Our compliance with the requirements under the Exchange Act, the Sarbanes-Oxley Act, the U.K. Companies Act and, if applicable, the Takeover Code and the rules and regulations thereunder increases our legal and financial compliance costs and makes some activities more time consuming and costly. These rules and regulations have made it more difficult and more expensive for us to obtain directors’ and officers’ liability insurance, and we may in the future be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers. We may not be able to predict or estimate accurately the amount of additional costs we may incur or the timing of such costs.
Risks Relating to Taxation
Our structure involves complex provisions of tax law for which no clear precedent or authority may be available. Our structure also is subject to potential legislative, judicial or administrative change and differing interpretations, possibly on a retroactive basis.
Our tax treatment, including Irish, U.K. and U.S. federal income tax treatment, depends in some instances on determinations of fact and interpretations of complex provisions of applicable tax law for which no clear precedent or authority may be available. You should be aware that our tax position is not free from doubt, and that applicable tax rules are generally subject to ongoing review by legislative and administrative bodies and relevant tax authorities, as well as by the Organization for Economic Co-operation and Development (“OECD”), which is continuously considering recommendations for changes to existing tax rules. These review processes could result in revised interpretations of established concepts, statutory changes, revisions to regulations and other modifications and interpretations. No ruling will be sought from the relevant tax authority regarding any of the tax issues discussed herein, and no assurance can be given that the relevant tax authorities will not challenge any of our tax positions and that such challenge would not succeed. If any such position is successfully challenged, our tax liabilities could materially increase, which would have an adverse effect on our profitability and cash flows.
42

There have been significant changes both made and proposed to international tax laws that increase the complexity, burden and cost of tax compliance for all multinational groups. We expect to continue to monitor these and other developments in international tax law.
We could be liable for significant taxes due to changes in our eligibility for certain income tax treaty benefits or challenges to our tax positions with respect to the application of income tax treaties.
Our subsidiaries expect to receive revenue from both U.S. and non-U.S. sources. We expect that our subsidiaries generally will be eligible for benefits under the applicable income tax treaties between Ireland and the jurisdictions where income is sourced. However, no assurances can be provided in this regard, and it is possible that a taxing authority could successfully assert that any of our subsidiaries does not qualify for treaty benefits as a result of its failure to satisfy the applicable requirements to be eligible to claim treaty benefits. If a taxing authority were to challenge our position regarding the application of an applicable income tax treaty, we could become subject to increased withholding taxes, and such taxes could be significant.
Specifically, with respect to certain U.S.-source income, we expect that our subsidiaries will be eligible for benefits under the U.S.-Ireland income tax treaty (the “Treaty”), and, under that Treaty, will not be subject to any U.S. withholding taxes on such U.S.-source payments. Our current treaty position with respect to U.S.-source payments relies in part on U.S. citizens or tax residents (as defined for purposes of the Treaty) owning, directly or indirectly, at least 50% of the beneficial interest in, or at least 50% of the aggregate vote and value of, each of our subsidiaries that earns U.S.-source income. Our treaty position is based on the current U.S. status of the majority of the existing indirect investors in RP Holdings and Old RPI. Subject to certain exceptions, the existing indirect U.S. investors in RP Holdings have the right to exchange their interests for our publicly traded Class A ordinary shares. Such publicly traded Class A ordinary shares could be further transferred on the public market to other persons. Therefore, it is possible that over time U.S. persons will own indirectly in the aggregate less than 50% of the interests in our subsidiaries. We currently expect that our Class A ordinary shares and other existing indirect interests in RP Holdings and Old RPI in the aggregate will continue to be owned in sufficient amount by U.S. citizens or tax residents, and that we will be able to establish such ownership, for purposes of satisfying the 50% ownership requirement under the Treaty. However, there is no assurance that RP Holdings and Old RPI will continue to be owned directly or indirectly by sufficient U.S. citizens or residents or that we will be able to establish to the IRS’ satisfaction such ownership for purposes of satisfying the 50% U.S. ownership requirement under the Treaty. It is possible that if the indirect U.S. ownership in our subsidiaries becomes lower than 50% (or we cannot establish such ownership) we may in the future be able to qualify for another applicable exemption from U.S. withholding under the Treaty, but there can be no assurance in this regard. A substantial portion of our revenue is, and is expected to continue to be, derived from U.S.-source royalties. Therefore, if our subsidiaries failed to qualify for an exemption from U.S. withholding tax under the Treaty (by satisfying either the 50% U.S. ownership requirement or an alternative Treaty exemption) and such royalties were subject to a 30% U.S. withholding tax, our financial position, profitability and cash flows could be adversely affected.
Furthermore, on August 25, 2016, the Irish Department of Finance announced that, in the context of the publication by the United States Treasury Department of a revised U.S. Model Income Tax Convention in February 2016, discussions have begun with the United States Treasury on updating certain elements of the Treaty. It is at this time not clear what elements of the Treaty may be updated, or when any such updates would go into effect. However, certain elements of the revised U.S. Model Income Tax Convention could, if included in an update to the Treaty, result in our subsidiaries being unable to qualify for the benefits of the Treaty or eliminate or reduce the benefits of the Treaty that otherwise would have been available to us. If our subsidiaries are unable to qualify for the benefits of the Treaty, or if any benefits of the Treaty that otherwise would have been available to us are eliminated or reduced, then all or a portion of our income may become subject to increased withholding taxes, and such taxes could be very significant and materially and adversely affect our financial position, profitability and cash flows.
If our subsidiaries are considered to be engaged in a U.S. trade or business, we could be liable for significant U.S. taxation.
In general, if a foreign corporation, such as Royalty Pharma plc, is considered to be engaged in a U.S. trade or business, such corporation’s share of any income that is effectively connected with such U.S. trade or business will be subject to regular U.S. federal income taxation (currently imposed at a maximum rate of 21%) on a net basis and, potentially, an additional 30% U.S. “branch profits” tax on distributions attributable to income that is effectively connected with such U.S. trade or business. In addition, it is possible that such corporation could be subject to taxation on a net basis by state or local jurisdictions within the United States. We intend to conduct our activities, through our subsidiaries, such that no income realized by us will be effectively connected with the conduct of a U.S. trade or business or otherwise subject to regular U.S. federal income taxation on a net basis. If we are able to conduct our activities in this way, income or gains realized by us will not be subject to U.S. net
43

federal income taxation. However, no assurance can be provided in this regard. The proper characterization of our income and gains for U.S. tax purposes is not certain, and it is possible that all or a portion of our income and gains could be characterized as income that is “effectively connected” with the conduct of a U.S. trade or business. If our income and gains were characterized as effectively connected with a U.S. trade or business, we would be subject to significant U.S. taxes plus interest and possible penalties, and our financial position, cash flows and profitability could be materially and adversely affected.
We expect to operate, and expect that RP Holdings will operate, so as to be treated solely as a resident of the U.K. for tax purposes, but changes to our management and organizational structure and/or to the tax residency laws of other jurisdictions where we operate may cause the relevant tax authorities to treat us or RP Holdings as also being a resident of another jurisdiction for tax purposes.
Under current U.K. tax law, a company that is incorporated in the U.K. is regarded as resident for tax purposes in the U.K. unless (i) it is concurrently treated as resident for tax purposes in another jurisdiction (applying the rules of that other jurisdiction for determining tax residency) that has a double tax treaty with the U.K. and (ii) there is a residency tie-breaker provision in that tax treaty which allocates tax residence to that other jurisdiction.
Based upon our anticipated management and organizational structure, we believe that we and RP Holdings should be regarded as tax resident solely in the U.K. However, because this analysis is highly factual and may depend on future changes in our management and organizational structure, as well as future changes in the tax residency laws of other jurisdictions where we operate, there can be no assurance regarding the determination of our tax residence in the future.
As U.K. tax resident companies, we and RP Holdings will be subject to U.K. corporation tax on our worldwide taxable profits and gains. Should we (or RP Holdings) be treated as resident in a jurisdiction other than the U.K., we (or RP Holdings, as applicable) could be subject to taxation in that jurisdiction and may be required to comply with a number of material and formal tax obligations, including withholding tax and/or reporting obligations provided under the relevant tax law, which could result in additional costs and expenses.
We believe that we should not be subject to material U.K. corporation tax in respect of certain profits of our non-U.K. tax resident subsidiaries as a result of the U.K.’s “controlled foreign companies” rules but it cannot be guaranteed that this will continue to be the case.
As U.K. tax resident companies, we and RP Holdings will be subject to the U.K.’s “controlled foreign companies” rules (the “U.K. CFC Rules”). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the “Controlled Foreign Company”) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. The types of profits of a Controlled Foreign Company that can potentially be subject to a U.K. corporation tax charge under the U.K. CFC Rules include business profits of the Controlled Foreign Company that are attributable to assets or risks that are managed by activities in the U.K., or certain finance profits of the Controlled Foreign Company that arise from capital or other assets contributed, directly or indirectly, to the Controlled Foreign Company from a connected U.K. tax resident company.
Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings), will be Controlled Foreign Companies for U.K. tax purposes. We and RP Holdings will therefore be required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets or our financing arrangements, however no assurances can be given that this will continue to be the case. The U.K. CFC Rules are highly complex and fact-dependent, and changes to, or adverse interpretations of, these rules, or changes in the future activities of RPI or other non-U.K. companies in which we hold an interest, directly or indirectly, may alter this position and could impact our group’s effective tax rate.
We believe that dividends received by us and RP Holdings should be exempt from U.K. corporation tax, but it cannot be guaranteed that this will continue to be the case.
U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. However, a number of conditions must be met in order for such dividends to qualify for this tax exemption, including (in respect of dividends paid by RPI, which are tax resident in Ireland) conditions relating to the application of Irish tax law. As such, it cannot be guaranteed that these conditions for the
44

U.K. tax exemption in respect of distributions will continue at all times to be satisfied. If distributions received by us or by RP Holdings were not to fall within an exempt class, such distributions would likely be subject to U.K. corporation tax at the then prevailing corporation tax rate.
Even where distributions fall within an exempt class, certain anti-avoidance and recharacterization rules may also apply. For instance, if RPI were to constitute an “offshore fund” for U.K. tax purposes that has at any time in an accounting period more than 60% by market value of its investments in debt securities, money placed at interest (other than cash awaiting investment), certain contracts for differences, or in holdings in other offshore funds with, broadly, more than 60% of their investments similarly invested, RP Holdings’ shareholding in RPI may be subject to U.K. corporation tax as a deemed “loan relationship”, with the result that dividends received by RP Holdings from RPI could be subject to U.K. tax as deemed interest and RP Holdings may be subject to U.K. corporation tax on increases in the fair market value of its shareholding in RPI. The term “offshore fund” is defined for U.K. tax purposes through a characteristics-based approach and, broadly, can include arrangements constituted by a non-U.K. resident body corporate in which a reasonable investor would expect to be able to realize their investment entirely, or almost entirely, by reference to net asset value. We believe and have been advised that RP Holdings’ shareholding in RPI should not fall within these rules, however no guarantee can be offered that this will continue to be the case. Changes to, or adverse interpretations of, the offshore funds rules, or changes in the nature of our investments, may alter this position and could impact our group’s effective rate.

Distributions that we pay to individual and other non-corporate U.S. Holders will not be eligible for taxation at reduced rates, which could potentially adversely affect the value of our Class A ordinary shares.
Distributions made to non-corporate U.S. Holders will not be eligible for taxation at reduced tax rates generally applicable to dividends paid by certain U.S. corporations and “qualified foreign corporations” because of our status as a passive foreign investment company (“PFIC”). The more favorable rates applicable to qualifying corporate dividends could cause individuals to perceive investment in our Class A ordinary shares to be less attractive than investment in the shares of other corporations because of our PFIC status, and this perception could adversely affect the value of our Class A ordinary shares.

General Risk Factors

Cyber-attacks or other failures in telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations.
We utilize information technology systems and networks to process, transmit and store electronic information in connection with our business activities. As use of digital technologies has increased, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our systems and networks and the confidentiality, availability and integrity of our data. We have been subject to these attacks in the past and expect to be subject to them in the future. There can be no assurance that we will be successful in preventing cyber-attacks or mitigating their effects. Any cyber-attack or destruction or loss of data could adversely affect our business. In addition, we may suffer reputational harm or face litigation as a result of cyber-attacks or other data security breaches and may incur significant additional expense to implement further data protection measures.
Changes in the application of accounting standards issued by the U.S. Financial Accounting Standards Board or other standard-setting bodies may adversely affect our financial statements.
Our financial statements are prepared in accordance with GAAP, which are periodically revised, interpreted and/or expanded. From time to time, we are required to adopt new or revised accounting standards issued by recognized authoritative bodies. It is possible that future accounting standards we are required to adopt may require changes to the current accounting treatment that we apply to our consolidated financial statements and may require us to make significant changes to our systems. Such changes could adversely affect our financial condition and results of operations.
45

The current outbreak of the novel coronavirus, or COVID-19, or the future outbreak of any other infectious or contagious diseases, could materially and adversely affect our results of operations, financial condition and cash flows. Further, the spread of the COVID-19 outbreak has caused severe disruptions in the U.S. and global economy and financial markets and could potentially create widespread business continuity issues of an as yet unknown magnitude and duration.
In December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in Wuhan, China. COVID-19 has since spread to over 100 countries, including every state in the United States. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020 the United States declared a national emergency with respect to COVID-19.
The outbreak of COVID-19 has severely impacted global economic activity and caused significant volatility and negative pressure in financial markets. The global impact of the outbreak has been rapidly evolving and many countries, including the United States, have reacted by instituting quarantines, mandating business and school closures and restricting travel. Many experts predict that the outbreak will trigger a period of global economic slowdown or a global recession. COVID-19 or another pandemic could have material and adverse effects on us due to, among other factors:
• a general decline in business activity;
• the destabilization of the markets could negatively impact our partners in the biopharmaceutical industry and the sales of products generating our royalties;
• difficulty accessing the capital and credit markets on favorable terms, or at all, and a severe disruption and instability in the global financial markets, or deteriorations in credit and financing conditions which could affect our access to capital necessary to fund business operations or address maturing liabilities on a timely basis;
• the potential negative impact on the health of our Manager’s highly qualified personnel, especially if a significant number of them are impacted;
• a deterioration in our ability to ensure business continuity during a disruption;
• interruptions, shortages, delivery delays and potential discontinuation of supply to our partners, which could (i) delay the clinical trials of the development-stage product candidates underlying our assets and result in a loss of our market share for products generating our royalties or development-stage product candidates underlying our assets, if approved, and (ii) hinder our partners’ ability to timely distribute products generating our royalties and satisfy customer demand;
• travel restrictions, shelter-in-place policies or restrictions and other disruptions, which could cause or continue to cause delays and other direct impacts at our partners’ manufacturing sites, which could impact the ability of our partners to manufacture development-stage product candidates underlying our biopharmaceutical assets and products generating our royalties; and
• potential interruptions to our partners’ clinical trial programs of development-stage product candidates underlying our biopharmaceutical assets, including: (i) the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns; (ii) changes in hospital or research institution policies or government regulations, which could delay or adversely impact our partners’ ability to conduct their clinical trials; and (iii) pauses to or delays of trial procedures (particularly any procedures that may be deemed non-essential), patient dosing, shipment of our partners’ development-stage product candidates, distribution of clinical trial materials, study monitoring, site inspections and data analysis due to reasons related to the pandemic, each of which could cause or continue to cause a disruption or delay to the development or the approval of development-stage product candidates underlying our biopharmaceutical assets.
To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Nevertheless, COVID-19 presents material uncertainty which could adversely affect our results of operations, financial condition and cash flows.
46

Legal claims and proceedings could adversely affect our business.
We may be subject to a wide variety of legal claims and proceedings. Regardless of their merit, these claims can require significant time and expense to investigate and defend. Since litigation is inherently uncertain, there is no guarantee that we will be successful in defending ourselves against such claims or proceedings, or that our assessment of the materiality of these matters, including any reserves taken in connection therewith, will be consistent with the ultimate outcome of such matters. The resolution of, or increase in the reserves taken in connection with, one or more of these matters could adversely affect our business, financial condition and results of operations.

Item 1B.    UNRESOLVED STAFF COMMENTS

None.

Item 2.        PROPERTIES

Our executive offices are located at 110 East 59th Street, New York, NY 10022, and are provided by the Manager. We believe that our office facilities are suitable and adequate for our business as it is contemplated to be conducted.

Item 3.         LEGAL PROCEEDINGS

From time to time, we may be a party to various claims, charges and litigation matters arising in the ordinary course of business. Management and legal counsel regularly review the probable outcome of such proceedings. While we cannot feasibly predict the outcome of these matters with certainty, we believe, based on examination of these matters, experience to date and discussions with counsel, that the ultimate liability, individually or in the aggregate, will not adversely affect our business, financial condition or results of operations.

Item 4.        MINE SAFETY DISCLOSURES

Not applicable.

PART II.     

Item 5.        MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our Class A ordinary shares are traded in the Nasdaq Global Select Market under the symbol “RPRX”. Our Class B ordinary shares are not listed on any stock exchange nor traded on any public market. As of February 11, 2022, there were 2 shareholders of record of our Class A ordinary shares and 2 shareholders of record of our Class B ordinary shares. The number of record holders does not include persons who held our Class A ordinary shares in nominee or “street name” accounts through brokers or other institutions on behalf of shareholders.

Use of Proceeds

None.

Dividends

In the year ended December 31, 2021, we declared and paid four quarterly cash dividends of $0.17 per Class A ordinary share for an aggregate amount of $285.2 million to holders of our Class A ordinary shares. Future dividends are subject to declaration by the board of directors. To the extent approved and payable, we intend to pay dividends on or about March 15, June 15, September 15 and December 15 to holders of record on or about the twentieth day of each such prior month.

47

Securities Authorized for Issuance Under Equity Compensation Plans

See Item 12, “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” for information regarding securities authorized for issuance.

Stock Performance Graph

The graph below compares the cumulative total stockholder return, calculated on a dividend-reinvested basis, on our Class A ordinary shares, the Standard & Poor’s 500 Index (“S&P 500”) and the Nasdaq Composite Index (“Nasdaq Composite”). The graph assumes an initial investment of $100 in our Class A ordinary shares at the market close on June 16, 2020, which was our initial trading day and its relative performance is tracked through December 31, 2021. The comparisons in the graph below are based upon historical data and are not indicative of, nor intended to forecast, future performance of our Class A ordinary shares.
rprx-20211231_g4.jpg

The above performance graph shall not be deemed soliciting material or to be filed with the SEC for purposes of Section 18 of the Exchange Act, nor shall such information be incorporated by reference into any of our other filings under the Exchange Act or the Securities Act.

Recent Sales of Unregistered Securities

There were no unregistered sales of equity securities in the year ended December 31, 2021.

Issuer Purchases of Equity Securities

None.
48

Item 6.         Reserved


Item 7.         MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand our results of operations and financial condition, cash flows and other changes in financial condition. MD&A is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements and the accompanying notes to our consolidated financial statements included in our Annual Report on Form 10-K. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Special Note Regarding Forward-Looking Statements and the section titled “Risk Factors” in Part I, Item 1A.

Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (“IPO”) of our Class A ordinary shares that was completed in June 2020. “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Exchange Offer Transactions (as defined below) and execution of the Management Agreement (collectively, the “Reorganization Transactions”) in February 2020 and before the consummation of the IPO, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma Investments 2019 ICAV (“RPI 2019 ICAV”). Prior to the Reorganization Transactions, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma Investments, an Irish unit trust (“Old RPI”).

Business Overview

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

Our capital-efficient business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, including long product life cycles, significant barriers to entry and noncyclical revenues, but with substantially reduced exposure to many common industry challenges such as early stage development risk, therapeutic area constraints, high research and development costs, and high fixed manufacturing and marketing costs. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies across the biopharmaceutical industry.

We classify our royalty acquisitions by the approval status of the therapy at the time of acquisition:

•Approved Products – We acquire royalties in approved products that generate predictable cash flows and may offer upside potential from unapproved indications. Since inception in 1996 through 2021, we have deployed $15.0 billion of cash to acquire royalties on approved products. From 2012 through 2021, we have acquired $10.2 billion of royalties on approved products.

•Development-Stage Product Candidates – We acquire royalties on development-stage product candidates that have demonstrated strong clinical proof of concept. From 2012, when we began acquiring royalties on development-stage product candidates, through 2021, we have deployed $7.8 billion to acquire royalties on development-stage product candidates.

49

While we classify our acquisitions in these two broad categories, several of our acquisitions of royalties on approved products were driven by the long-term potential of these products in other, unapproved indications. Similarly, some of our royalty acquisitions in development-stage product candidates are for products that are approved in other indications.

We acquire product royalties in a variety of ways that can be tailored to the needs of our partners. We classify our product royalty acquisitions according to the following structures:

•Third-party Royalties – A royalty is the contractual right to a percentage of top-line sales from a licensee’s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties.

•Synthetic/Hybrid Royalties – A synthetic royalty is the contractual right to a percentage of top-line sales created by the developer and/or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone payments, or be structured as a long-term stream of fixed-payments with a predetermined schedule. In many of our synthetic royalties, we may also make investments in the public equity of the company, where the main value driver of the company is the product on which we concurrently acquired a royalty.

•Research & Development (“R&D”) Funding – We have historically funded ongoing R&D, typically for large biopharmaceutical companies, in exchange for future royalties and/or milestones if the product or indication we are funding is approved. We have also made upfront R&D payments to biotechnology companies to acquire royalties and/or milestones on development-stage product candidates.

•M&A – We acquire royalties in connection with M&A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.

Background and Format of Presentation

In connection with our IPO, we consummated an exchange offer on February 11, 2020 (the “Exchange Date”). Through the exchange offer, investors representing 82% of the aggregate limited partnership in the various partnerships owned by Old RPI (the “Legacy Investors Partnerships”), exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in RPI US Partners 2019, LP, a Delaware limited partnership or RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”). The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under a new credit facility and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”

Following our IPO, we operate and control the business affairs of Royalty Pharma Holdings Ltd, (“RP Holdings”) through our controlling ownership of RP Holdings’ Class A ordinary shares (the “RP Holdings Class A Interests”) and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). We include RP Holdings and its subsidiaries in our consolidated financial statements. RP Holdings is the sole owner of RPI 2019 ICAV, which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions.

As a result of the Exchange Offer Transactions, we own, through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”), an 82% economic interest in Old RPI. Through our 82% indirect ownership of Old RPI, we are legally entitled to 82% of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”).

The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish unit trust. From the Exchange Date until the expiration of the Legacy Investors Partnerships’ investment period on June 30, 2020 (the “Legacy Date”), the Legacy Investors Partnerships had the option to participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Following the Legacy Date, we have made and plan to make new investments solely through our subsidiaries.

50

Following management’s determination that a high degree of common ownership exists in Royalty Pharma both before and after the Exchange Date, Royalty Pharma recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date. Old RPI is our predecessor for financial reporting purposes. The results of operations in the following discussion is comprised of the financial results of Old RPI prior to the Reorganization Transactions, RPI 2019 ICAV subsequent to the Reorganization Transactions and before the consummation of the IPO, and Royalty Pharma plc subsequent to the consummation of the IPO.

Understanding Our Financial Reporting

In accordance with U.S. GAAP, most of the royalties we acquire are treated as investments in cash flow streams and are thus classified as financial assets. These investments have yield components that most closely resemble loans measured at amortized cost under the effective interest accounting methodology. Under this accounting methodology, we calculate the effective interest rate on each financial royalty asset using a forecast of the expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. The yield, which is calculated at the end of each reporting period and applied prospectively, is then recognized via accretion into our income at the effective rate of return over the expected life of the financial royalty asset.

The preparation of our financial statements in this manner requires the use of estimates, judgments and assumptions that affect both our reported assets and liabilities and our income and revenue and expenses. The most significant judgments and estimates applied by management are associated with the measurement of income derived from our financial royalty assets, including management’s judgment in forecasting the expected future cash flows of the underlying royalties and the expected duration of the financial royalty asset. Our cash flow forecasts are generated and updated each reporting period by manually compiling sell-side equity research analysts’ consensus sales estimates for each of the products in which we own royalties. We then calculate our expected royalty cash flows using these consensus sales forecasts. In any given reporting period, any decline or increase in the expected future cash flows associated with a financial royalty asset is recognized in our income statement as non-cash provision expense or provision income, respectively.

As a result of the non-cash charges associated with applying the effective interest method accounting methodology, our income statement activity in respect of many of our royalties can be volatile and unpredictable. Small declines in sell-side equity research analysts’ consensus sales forecasts over a long time horizon can result in an immediate non-cash income statement expense recognition, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014 we acquired the cystic fibrosis franchise royalty, which is classified as a financial royalty asset. Beginning in the second quarter of 2015, declines in near-term sales forecasts of sell-side equity research analysts caused us to recognize non-cash provision expenses to the income statement and build up a corresponding cumulative allowance which reduced the gross balance for this financial royalty asset. Over the course of 10 quarters, we recognized non-cash provision expenses as a result of these changes in forecasts including non-cash provision expense of $743.2 million in 2016, ultimately reaching a peak cumulative allowance of $1.30 billion by September 30, 2017 related to this financial royalty asset. With the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts’ consensus sales forecasts increased to reflect the larger addressable market and the extension of the expected duration of the Trikafta royalty. While small reductions in the cumulative allowance for the cystic fibrosis franchise were recognized as provision income in 2017 and 2018, there remained a $1.10 billion cumulative allowance that was fully reduced by $1.10 billion recognized in 2019 as a result of an increase in sell-side equity research analysts’ consensus sales forecasts associated with the Trikafta approval. This example illustrates the volatility caused by our accounting model. Therefore, management believes investors should not look to income from royalties and the associated provision for changes in future cash flows as a measure of our near-term financial performance or as a source for predicting future income or growth trends.

Our operations have historically been financed primarily with cash flows generated by our royalties. Due to the nature of our accounting methodology for our financial royalty assets, there is no direct correlation between our income from royalties and our royalty receipts. As noted above, income from such royalties is measured at amortized cost under the effective interest method accounting methodology. Given the importance of cash flows and their predictability to management’s operation of the business, management uses royalty receipts as the primary measure of our operating performance. Royalty receipts refer to the summation of the following line items from our GAAP Statement of Cash Flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from non-consolidated affiliates.

51

In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. The closest comparable GAAP measure to each of the non-GAAP measures that management review is Net cash provided by operating activities. The key non-GAAP metrics we focus on are Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow, each of which is further discussed in the section titled “Non-GAAP Financial Results.”

Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of the strength of the Company and the performance of the business. Management uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income used by companies in the biopharmaceutical industry. Adjusted EBITDA, which is derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants.

Refer to the section titled “Non-GAAP Reconciliations” for additional discussion of management’s use of non-GAAP measures as supplemental financial measures.

Portfolio Overview

Our portfolio consists of royalties on more than 35 marketed therapies and ten development-stage product candidates. The therapies in our portfolio address therapeutic areas such as rare disease, cancer, neurology, infectious disease, hematology and diabetes, and are delivered to patients across both primary and specialty care settings. The     table below includes royalty receipts for the years ended December 31, 2021 and 2020 in order of contributions to royalty receipts for the year ended December 31, 2021.

Royalty Receipts
(in thousands)Years Ended December 31,
Marketer(s)Therapeutic Area20212020
Products
Cystic fibrosis franchise (1)VertexRare disease$702,140 $551,338 
TysabriBiogenNeurology369,149 345,845 
ImbruvicaAbbVie, Johnson & JohnsonCancer352,911 322,071 
PromactaNovartisHematology173,621 143,741 
XtandiPfizer, AstellasCancer158,103 146,374 
Januvia, Janumet, Other DPP-IVs (2)Merck & Co., othersDiabetes151,158 143,753 
HIV franchise (3)Gilead, othersInfectious disease78,038 293,808 
Nurtec ODT/Biohaven payment (4)Biohaven, PfizerNeurology70,188 3,667 
PrevymisMerck & Co.Infectious disease37,505 21,492 
Farxiga/Onglyza AstraZenecaDiabetes36,378 25,004 
TremfyaJohnson & JohnsonImmunology35,718 — 
Cabometyx/CometriqExelixis, Ipsen, TakedaCancer33,722 — 
CrysvitaUltragenyx, Kyowa KirinRare disease16,741 9,454 
EvrysdiRocheRare disease16,098 273 
EmgalityLillyNeurology15,481 9,529 
ErleadaJohnson & JohnsonCancer14,227 7,876 
TrodelvyGileadCancer13,395 3,031 
IDHIFABristol Myers SquibbCancer12,404 6,111 
OrladeyoBioCrystRare disease6,740 — 
TazverikEpizymeCancer2,794 522 
OxlumoAlnylamRare disease1,248 — 
Other products (5)310,783 310,510 
Total royalty receipts$2,608,542 $2,344,399 
(1) The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio.
(2) Januvia, Janumet, Other DPP-IVs include the following approved products: Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas and Nesina. The Other DPP-IVs are marketed by Boehringer Ingelheim, AstraZeneca, Novartis and Takeda.
(3) The HIV franchise includes the following approved products: Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza and Biktarvy. Royalties are received on the emtricitabine portion of sales only.
52

(4) Includes royalty receipts for Nurtec ODT of $7.7 million for the year ended December 31, 2021 and quarterly redemptions of $15.6 million of the Series A Biohaven Preferred Shares (presented as Proceeds from available for sale debt securities on the Statement of Cash Flows) in 2021. For the year ended December 31, 2020, the amount also includes a payment from Biohaven in respect of an expired option to exercise additional funding of the Biohaven Series A Preferred Shares which is presented as Proceeds from available for sale debt securities on the Statement of Cash Flows in 2020.
(5) Other products primarily include royalties on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion, for which receipts are presented as Distributions from non-consolidated affiliates on the Statement of Cash Flows), Lexiscan, Soliqua, Nesina, Cimzia, Letairis, Entyvio, Myozyme, Mircera and Lyrica. Other products for the year ended December 31, 2021 includes a one-time milestone payment of $45.0 million that we received on Soliqua. Other products for the year ended December 31, 2020 includes a one-time $21.3 million distribution from Avillion in respect of the Merck KGaA Asset (defined below) for which the receipt is presented as Distributions from non-consolidated affiliates in both the operating and investing section of the Statement of Cash Flows. Subsequent to the Exchange Offer Transactions, other products also includes contributions from the Legacy SLP Interest (defined below).

Financial Overview

Financial highlights

•Net cash provided by operating activities totaled $2.0 billion, $2.0 billion and $1.7 billion for the years ended December 31, 2021, 2020 and 2019, respectively. Net cash provided by operating activities is the closest comparable GAAP financial measure to the supplemental non-GAAP liquidity measures that follow.
•Adjusted Cash Receipts (a non-GAAP metric) totaled $2.1 billion, $1.8 billion and $2.1 billion for the years ended December 31, 2021, 2020 and 2019, respectively.
•Adjusted EBITDA (a non-GAAP metric) totaled $1.9 billion, $1.6 billion and $2.0 billion for the years ended December 31, 2021, 2020 and 2019, respectively.
•Adjusted Cash Flow (a non-GAAP metric) totaled $1.8 billion, $1.5 billion and $1.6 billion for the years ended December 31, 2021, 2020 and 2019, respectively.

Understanding Our Results of Operations

In connection with our IPO, Royalty Pharma plc became a holding company whose principal asset is a controlling equity interest in RP Holdings, which is the sole equity owner of RPI 2019 ICAV, an entity that is included in our consolidated financial statements. We report non-controlling interest related to four minority interests in our subsidiaries held by third parties.

1.     The first minority interest is attributable to the Legacy Investors Partnerships’ 18% ownership interest in Old RPI. The value of this non-controlling interest will decline over time as the assets in Old RPI expire.

2.     The second minority interest is attributable to the RP Holdings Class C ordinary share (the “RP Holdings Class C Special Interest”) held by RPI EPA Holdings, LP (“EPA Holdings”), an affiliate of the Manager. Income will not be allocated to this non-controlling interest until certain conditions are met.

3.     The third minority interest is attributable to the RP Holdings Class B Interests held indirectly by the Continuing Investors Partnerships, which represent an approximate 29% ownership interest in RP Holdings as of December 31, 2021 and are exchangeable for our Class A ordinary shares. The value of this non-controlling interest will decline over time if the investors who indirectly own the RP Holdings Class B Interests conduct exchanges for our Class A ordinary shares. During the year ended December 31, 2021, 44,763 thousand RP Holdings Class B Interests were exchanged for our Class A ordinary shares.

4.     The fourth minority interest is attributable to a de minimis interest in RPCT held by RPSFT as a result of a 2011 reorganization transaction. The value of this non-controlling interest will decline over time as the royalty assets owned by RPCT expire and is expected to be substantially eliminated by the end of 2022.

53

The fourth non-controlling interest related to ownership in RPCT held by RPSFT, is the only non-controlling interest that existed prior to the Exchange Offer Transactions and is reflected in our financial statements through December 31, 2019. The non-controlling interest related to the Legacy Investors Partnerships’ 18% ownership interest in Old RPI is reflected in our financial statements from and after the Exchange Date. The other two non-controlling interests are reflected in our financial statements from and after the date of our IPO. All of the results of operations of RP Holdings, Old RPI and RPCT are consolidated into our financial statements.

Following the IPO, EPA Holdings is entitled to receive Equity Performance Awards through its RP Holdings Class C Special Interest. Equity Performance Awards owed to EPA Holdings will be recognized as an equity transaction when the obligation becomes due and will impact the income allocated to non-controlling interest related to the RP Holdings Class C Special Interest at that time. We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions are met, which we do not expect to occur until the mid-2020s.

Total income and other revenues

Total income and other revenues is primarily comprised of income from our financial royalty assets, royalty revenue from our intangible royalty assets, and royalty income arising from successful commercialization of products developed through joint R&D funding arrangements. Most of our royalties on both approved products and development-stage product candidates that are not accounted for as R&D funding expense are classified as financial assets as our ownership rights are generally passive in nature. In instances in which we acquire a royalty that does include more substantial rights or ownership of the underlying intellectual property, we classify such royalties as intangible assets.

We recognize interest income related to our financial royalty assets. Royalty revenue relates solely to revenue from our DPP-IV patent estate for which the patent rights have been licensed to various counterparties. For the years ended December 31, 2021 and 2020, the royalty payors accounting for greater than 10% of our total income and other revenues in any one year are shown in the table below:

Years Ended December 31,
Royalty PayorProduct(s)20212020
VertexCystic fibrosis franchise33 %29 %
AbbVieImbruvica17 %19 %
GileadHIV franchise, Letairis, Lexiscan, Trodelvy (1)*14 %
BiogenTysabri*10 %
(1) We began recognizing income related to Trodelvy in the three months ended June 30, 2020.
*Represents less than 10%.

Income from financial royalty assets

Our financial royalty assets represent investments in cash flow streams with yield components that most closely resemble loans measured at amortized cost under the effective interest method. We calculate the effective interest rate using forecasted expected cash flows to be received over the life of the royalty asset relative to the initial acquisition price. Interest income is recognized at the effective rate of return over the expected life of the asset, which is calculated at the end of each reporting period and applied prospectively. As changes in sell-side equity research analysts’ consensus sales estimates are updated on a quarterly basis, the effective rate of return changes. For example, if sell-side equity research analysts’ consensus sales forecasts increase, the yield to derive income on a financial royalty asset will increase and result in higher income for subsequent periods.

Variables affecting the recognition of interest income from financial royalty assets on individual products under the prospective effective interest method include any one of the following: (1) additional acquisitions, (2) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts’ consensus sales forecasts, (3) regulatory approval of additional indications which leads to new cash flow streams, (4) changes to the estimated duration of the royalty (i.e., patent expiration date) and (5) changes in amounts and timing of projected royalty receipts and milestone payments. Our financial royalty assets are directly linked to sales of underlying pharmaceutical products whose life cycle typically peaks at a point in time, followed frequently by declining sales trends due to the entry of generic competition, resulting in natural declines in the asset balance and periodic interest income over the life of our royalties. The recognition of interest income from royalties requires management to make estimates and assumptions around many factors, including those impacting the variables noted above.

54

Revenue from intangible royalty assets

Revenue from intangible royalty assets is derived from sales of Januvia, Janumet and other DPP-IV products by our licensees.

Other royalty income

Other royalty income includes primarily income from financial royalty assets that have been fully amortized by the expected expiry date and royalty income from synthetic royalties arising out of R&D funding arrangements. Occasionally, a royalty asset may be amortized on an accelerated basis due to collectability concerns, which, if resolved, may result in future cash collections when no financial royalty asset remains. Similarly, we may continue to collect royalties on a financial royalty asset beyond the estimated patent expiration date by which the financial asset was amortized in full. In each scenario where a financial royalty asset has been fully amortized, income from such royalty is recognized as Other royalty income.

Provision for changes in expected cash flows from financial royalty assets

The provision for changes in expected future cash flows from financial royalty assets includes the following:

•the movement in the cumulative allowance for changes in expected future cash flows; and
•expense or income related to the provision for current expected credit losses subsequent to adoption of ASU 2016-13 on January 1, 2020.

The provision for changes in expected cash flows is the current period activity resulting from adjustments to the cumulative allowance for changes in expected cash flows, which is netted against the non-current portion of Financial royalty assets, net balance on the consolidated balance sheets. As discussed above, income is accreted on our financial royalty assets using the effective interest method. As we update our forecasted cash flows on a periodic basis and recalculate the present value of the remaining future cash flows, any shortfall when compared to the carrying value of the financial royalty asset is recorded directly to the income statement through the line item Provision for changes in expected cash flows from financial royalty assets. If, in a subsequent period, there is an increase in expected cash flows or if actual cash flows are greater than cash flows previously expected, we reduce the cumulative allowance previously established for a financial royalty asset for the incremental increase in the present value of cash flows expected to be collected. This results in provision income (i.e., a credit to the provision).

Most of the same variables and management’s estimates affecting the recognition of interest income on our financial royalty assets also impact the provision. In any period, we will recognize provision income or expense as a result of the following factors: (1) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts’ consensus sales forecasts, (2) regulatory approval of additional indications which leads to new cash flow streams, (3) changes to the estimated duration of the royalty (i.e., patent expiration date) and (4) changes in amounts and timing of projected royalty receipts and milestone payments.

Upon the adoption on January 1, 2020 of ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), we recorded a cumulative adjustment to Retained earnings of $192.7 million to recognize an allowance for current expected credit losses on our portfolio of financial royalty assets. The Provision for changes in expected cash flows from financial royalty assets reflects the activity for the period, primarily new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts used in the effective interest model to measure income from our financial royalty assets.

R&D funding expense

R&D funding expense consists of upfront and ongoing R&D payments we have made to counterparties to acquire royalties and/or milestones on development-stage product candidates. Ongoing R&D payments are made as the related development-stage product candidates undergo clinical trials with our counterparties. These expenditures relate to the activities performed by our counterparties to develop and test new products, to test existing products for treatment in new indications, and to ensure product efficacy and regulatory compliance prior to launch.

55

General and administrative expenses

General and administrative (“G&A”) expenses include primarily Operating and Personnel Payments, legal expenses, other expenses for professional services and share-based compensation. The expenses incurred in respect of Operating and Personnel Payments are expected to comprise the most significant component of G&A expenses on an ongoing basis.

Under the Management Agreement, we pay Operating and Personnel Payments equal to 6.5% of the Adjusted Cash Receipts for each quarter and 0.25% of the value of our security investments under GAAP as of the end of each quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in our consolidated net income, are payable in equal quarterly installments and calculated as the greater of $1 million per quarter and 0.3125% of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investors Partnerships) during the previous twelve calendar months.

Prior to the Exchange Date, operating and personnel payments were fixed and grew at 5% annually and were not linked to any financial line item.

Equity in losses/(earnings) of non-consolidated affiliates

Legacy SLP Interest

In connection with the Exchange Offer Transactions, we acquired an equity method investment from the Continuing Investors Partnerships in the form of a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) in exchange for issuing shares in our subsidiary. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and a performance income allocation on a similar basis. The performance income allocation attributable to us is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships.

As the Legacy Investors Partnerships no longer participate in investment opportunities, the value of the Legacy SLP Interest is expected to decline over time. Our equity method investee, the Legacy Investors Partnerships, also owns a non-controlling interest in Old RPI.

The Avillion Entities

The Avillion entities (as defined below) partner with global biopharmaceutical companies to perform R&D in exchange for success-based milestones and/or royalties once products are commercialized.

In December 2017, our equity method investee Avillion Financing I, LP (“Avillion I”) received U.S. Food and Drug Administration (“FDA”) approval of a supplemental New Drug Application for Pfizer’s Bosulif to expand its label into front-line chronic myeloid leukemia, which triggered a series of contractual fixed payments from Pfizer to Avillion I over a 10-year period, which we recognize through receipt of Distributions from non-consolidated affiliates on the Statement of Cash Flows.

In 2019, we entered into an amended agreement with BAv Financing II, LP (“Avillion II”, or, together with Avillion I, the “Avillion Entities”), to invest $19.0 million to fund approximately 50% of the costs of a Phase 2 clinical trial for the use of Merck KGaA’s anti-IL 17 nanobody M1095 (the “Merck KGaA Asset”) for the treatment of psoriasis in exchange for certain milestone and royalty payments. During 2020, our involvement in the development for the Merck KGaA Asset ceased. We do not expect to record significant earnings or losses in the future related to this investment.

In July 2021, we entered into an amended agreement with Avillion II to increase our investment from $105.0 million to $122.5 million over multiple years to fund a portion of the costs for Phase 2 and 3 clinical trials of Avillion II, which is a party to a co-development agreement with AstraZeneca to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones, and other potential payments.

Other expense/(income), net

Other expense/(income), net primarily includes the change in fair market value of our equity securities and the unrealized (gains)/losses on our available for sale debt securities, including related forwards and derivatives. Other expense/(income), net also includes losses on extinguishment of debt and interest income.

56

Net income attributable to non-controlling interest

Subsequent to our IPO, net income attributable to non-controlling interest includes the RP Holdings Class B Interests held by the Continuing Investors Partnerships and will include net income attributable to the Class C Special Interest held by EPA Holdings once certain conditions have been met. Future net income attributable to the non-controlling interest related to the RP Holdings Class B Interests held by the Continuing Investors Partnerships will decline over time if the investors who indirectly own the RP Holdings Class B Interests conduct exchanges for our Class A ordinary shares.

As of and following the Exchange Date, the net income attributable to non-controlling interest also includes the Legacy Investors Partnerships’ approximately 18% share of earnings in Old RPI. As the Legacy Investors Partnerships no longer participate in investment opportunities, the related net income attributable to this non-controlling interest is expected to decline over time.

Net income attributable to non-controlling interest also includes RPSFT’s 20% share of earnings in RPCT, which is a consolidated subsidiary of Old RPI. We expect net income attributable to this non-controlling interest to decline over time as the royalty assets owned by RPCT expire and to be substantially eliminated by the end of 2022.

Results of Operations

In this section, we discuss the results of our operations for the year ended December 31, 2021 compared to the year ended December 31, 2020. For a discussion of the year ended December 31, 2020 compared to the year ended December 31, 2019, please refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

The comparison of our historical results of operations for the years ended December 31, 2021 and 2020 is as follows:

(in thousands)Years Ended December 31,2021 vs. 2020 Change
20212020$ %
Income and other revenues:
Income from financial royalty assets $2,065,083 $1,959,975 $105,108 5.4 %
Revenue from intangible royalty assets 171,248 143,382 27,866 19.4 %
Other royalty income 53,132 18,996 34,136 179.7 %
Total income and other revenues 2,289,463 2,122,353 167,110 7.9 %
Operating expenses:
Provision for changes in expected cash flows from financial royalty assets 452,842 230,839 222,003 96.2 %
Research and development funding expense 200,084 26,289 173,795 661.1 %
Amortization of intangible assets 22,996 23,058 (62)(0.3)%
General and administrative expenses 182,826 181,715 1,111 0.6 %
Other operating expenses— 65,053 (65,053)(100.0)%
Total operating expense, net858,748 526,954 331,794 63.0 %
Operating income 1,430,715 1,595,399 (164,684)(10.3)%
Other expense/(income)
Equity in losses/(earnings) of non-consolidated affiliates 19,490 (44,459)63,949 (143.8)%
Interest expense 166,142 157,059 9,083 5.8 %
Other expense/(income), net3,882 (219,155)223,037 (101.8)%
Total other expense/(income), net 189,514 (106,555)296,069 (277.9)%
Consolidated net income 1,241,201 1,701,954 (460,753)(27.1)%
Net income attributable to non-controlling interest 621,473 726,914 (105,441)(14.5)%
Net income attributable to controlling interest $619,728 $975,040 $(355,312)(36.4)%

57

Total income and revenues

Income from financial royalty assets

Income from financial royalty assets by product for our top products for the years ended December 31, 2021 and 2020 is as follows, in order of contribution to income for the year ended December 31, 2021.

(in thousands)Years Ended December 31,2021 vs. 2020 Change
20212020$ %
Cystic fibrosis franchise$762,885 $611,948 $150,937 24.7 %
Imbruvica385,350 396,285 (10,935)(2.8)%
Tysabri211,422 218,370 (6,948)(3.2)%
Xtandi107,833 102,791 5,042 4.9 %
Promacta73,372 53,314 20,058 37.6 %
Tazverik70,326 56,464 13,862 24.6 %
Other453,895 520,803 (66,908)(12.8)%
Total income from financial royalty assets$2,065,083 $1,959,975 $105,108 5.4 %

Income from financial royalty assets increased by $105.1 million, or 5.4%, in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by the performance of the cystic fibrosis franchise, including additional interest income attributable to the residual royalty interest that we acquired in the three months ended December 31, 2020. We also recorded $57.0 million in income in the year ended December 31, 2021 related to newly acquired assets in 2021, primarily Cabometyx/Cometriq, Tremfya and Oxlumo. The increase in income was partially offset by declines from the maturity of our royalties from the HIV franchise.

Revenue from intangible royalty assets

Revenue from intangible royalty interests increased by $27.9 million, or 19.4%, in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily related to the expected recovery of underpaid royalties on Tradjenta of approximately $16.5 million based on a legal judgment received in a litigation with Boehringer Ingelheim.

Other royalty income

Other royalty income increased by $34.1 million, or 179.7%, in the year ended December 31, 2021 compared to the year ended December 31, 2020, driven primarily by increased income from Nurtec ODT and Trodelvy that arose from our R&D funding agreements with Biohaven and Immunomedics, respectively. Other royalty income in the year ended December 31, 2021 also includes income from the HIV franchise, a fully amortized financial royalty asset, and Letairis, which was also fully amortized, but for which we expect minimal residual royalty income.

Provision for changes in expected cash flows from financial royalty assets

The breakdown of our provision for changes in expected future cash flows includes the following:

•movement in the cumulative allowance for changes in expected future cash flows; and
•expense or income related to the provision for current expected credit losses subsequent to adoption of ASU 2016-13 on January 1, 2020.

As the former activity is a combination of income and expense items, the provision breakdown by product, exclusive of the provision for current expected credit losses, is as follows, based on the largest contributors to each year’s provision income or expense:

58

(in thousands)
Product2021Product2020
Tazverik$210,567 IDHIFA$87,835 
Imbruvica189,999 Imbruvica46,872 
Emgality68,716 Tysabri40,931 
Cystic fibrosis franchise48,636 Soliqua32,735 
Tysabri(96,103)Xtandi(187,059)
Other43,940 Other53,339 
Total provision, exclusive of provision for credit losses465,755 Total provision, exclusive of provision for credit losses74,653 
Provision for current expected credit losses(12,913)Provision for current expected credit losses156,186 
Total provision expense$452,842 Total provision expense$230,839 

In the year ended December 31, 2021, we recorded total provision expense of $452.8 million, of which $465.8 million and $12.9 million related to provision expense for changes in expected cash flows and provision income for current expected credit losses, respectively. We recorded provision expense for Tazverik, Imbruvica, Emgality and the cystic fibrosis franchise, primarily due to significant declines in sell-side research analysts’ consensus sales forecasts. The provision expense was partially offset by provision income from a significant increase in sell-side equity research analysts’ consensus sales forecasts for Tysabri. The current expected credit loss activity in the year ended December 31, 2021 resulted in provision income that was primarily driven by a significant decrease in current expected credit losses related to Tazverik as a result of the corresponding significant decline in the financial asset value. This was partially offset by provision expense for credit losses recognized as a result of the increases to our portfolio of financial royalty assets with limited protective rights, primarily related to zavegepant from a $100.0 million funding payment we made to Biohaven upon the start of the oral zavegepant Phase 3 program and a new royalty interest in Cabometyx/Cometriq.

In the year ended December 31, 2020, we recorded total provision expense of $230.8 million, of which $74.7 million and $156.2 million related to provision expense for changes in expected cash flows and provision expense for current expected credit losses, respectively. We recorded provision expense for IDHIFA, which was acquired in the year ended December 31, 2020, and for Imbruvica and Tysabri due to declines in sell-side research analysts’ consensus sales forecasts. The provision expense was partially offset by provision income from a significant increase in sell-side equity research analysts’ consensus sales forecasts for Xtandi. We recognized provision expense for current expected credit losses as a result of our adoption of the new accounting standard in the year ended December 31, 2020. The provision expense for current expected credit losses in the year ended December 31, 2020 was driven primarily by certain additions to our portfolio of financial royalty assets, including the additional tranche of Tazverik and our acquisition of the zavegepant royalty.

R&D funding expense

R&D funding expense incurred in the year ended December 31, 2021 was comprised of $193.2 million in upfront R&D funding and $6.9 million in ongoing R&D expenses, primarily under our co-funding agreement with Sanofi. The increase of R&D funding expense of $173.8 million, or 661.1%, in the year ended December 31, 2021 as compared to the year ended December 31, 2020 was primarily driven by upfront R&D funding of $103.2 million related to an additional royalty on a development-stage product that we acquired from BioCryst in November 2021 and $90.0 million related to royalties on two development-stage products acquired from MorphoSys in July 2021.

R&D funding expense incurred in the year ended December 31, 2020 was comprised of $20.5 million in ongoing development-stage funding payments, primarily under our co-funding agreement with Sanofi, and $5.8 million in upfront funding related to a royalty on a development-stage product that we acquired from BioCryst.

G&A expenses

G&A expenses were relatively flat in the year ended December 31, 2021 compared to the year ended December 31, 2020.

59

Other operating expenses

Other operating expenses were $65.1 million in the year ended December 31, 2020 due to the recognition of a non-cash impairment charge related to the write-off of our omecamtiv mecarbil financial royalty asset balance of $90.2 million, net of cumulative allowance of $25.2 million. During the three months ended December 31, 2020, it was announced that omecamtiv mecarbil, a development stage product, did not meet the clinical trial objectives. There was no comparable activity in the year ended December 31, 2021.

Equity in losses/(earnings) of non-consolidated affiliates

We recorded equity in losses of non-consolidated affiliates of $19.5 million for the year ended December 31, 2021 compared to equity in earnings of non-consolidated affiliates of 44.5 million for the year ended December 31, 2020.

Equity in earnings of the Legacy SLP Interest was $8.9 million and $62.0 million during the years ended December 31, 2021 and 2020, respectively. Equity in losses of the Avillion Entities was $28.4 million and $17.6 million during the years ended December 31, 2021 and 2020, respectively.

Interest expense

Interest expense increased by $9.1 million, or 5.8%, in the year ended December 31, 2021 as compared to the year ended December 31, 2020, primarily driven by interest expense related to the $1.3 billion senior unsecured notes issued in July 2021 (“2021 Notes”) offset by the lower interest expense related to the $6.0 billion senior unsecured notes issued in September 2020 (the “2020 Notes”), which had a lower weighted average interest rate compared to the senior secured credit facilities that were in place during the year ended December 31, 2020. We refer to the 2020 Notes and 2021 Notes, collectively, as the “Notes”.
Refer to the “Liquidity and Capital Resources” section for additional discussion of the Notes and our debt refinancings in 2020.

Other expense/(income), net

Other expense, net of $3.9 million in the year ended December 31, 2021 was primarily comprised of net losses on equity securities of $48.1 million, including losses on MorphoSys ordinary shares and Epizyme common stock, partially offset by a gain on Biohaven common shares; and losses of $21.5 million on our derivative financial instruments related to our treasury rate lock contracts that were unwound and settled in connection with the issuance of the 2021 Notes. The losses were partially offset by interest income of $50.9 million related to our Series A Biohaven Preferred Shares and a gain of $17.9 million on the unrealized change in fair value of our available for sale debt securities.

Other income, net of $219.2 million in the year ended December 31, 2020 was primarily comprised of net gains on equity securities of $247.1 million, of which $292.3 million was driven by the redemption of our investment in Immunomedics common stock upon Gilead’s acquisition of Immunomedics in October 2020 and $66.0 million was related to an increase in share price of our investment in Biohaven common shares. These gains were partially offset by a loss of $120.1 million related to a decrease in share price of our investment in Epizyme common stock. In the year ended December 31, 2020, we also recognized $42.1 million in losses on our derivative financial instruments, primarily related to Epizyme warrants as a result of the decrease in Epizyme common stock price. Additionally, we recognized a loss on debt extinguishment of $30.5 million related to the debt refinancings completed in the year ended December 31, 2020.

60

Net income attributable to non-controlling interest

Net income attributable to the Continuing Investors Partnerships was $297.3 million and $317.0 million in the years ended December 31, 2021 and 2020, respectively. The net income attributable to the Continuing Investors Partnerships reflects a partial period of net income subsequent to the IPO in the year ended December 31, 2020 compared to the full period of net income in the year ended December 31, 2021. The decrease in net income attributable to Continuing Investors Partnerships was primarily driven by lower net income attributable to RP Holdings in the year ended December 31, 2021. The decrease was further driven by the ongoing exchanges in 2021 by investors in the Continuing Investors Partnerships who indirectly own the RP Holdings Class B Interests for our Class A ordinary shares, resulting in a decline in the Continuing Investors Partnerships’ ownership of RP Holdings.

Net income attributable to the Legacy Investors Partnerships, which arose in February 2020 in connection with the Exchange Offer Transactions, was $266.6 million and $321.0 million in the years ended December 31, 2021 and 2020, respectively. The net income attributable to the Legacy Investors Partnerships reflects a partial period of net income subsequent to the Exchange Date in the year ended December 31, 2020. The decrease in net income attributable to the Legacy Investors Partnerships was primarily driven by lower net income attributable to Old RPI in 2021.

Net income attributable to RPSFT was $57.6 million and $88.9 million in the years ended December 31, 2021 and 2020, respectively. We expect net income attributable to RPSFT to continue to decline as the royalty assets owned by RPCT mature.

Key developments and upcoming events relating to our portfolio

The key developments impacting our cash receipts and income and revenue from our royalty interests are discussed below:

Commercial Products

•Cystic fibrosis franchise. In October 2019, Vertex received approval from the FDA for Trikafta for the treatment of patients with cystic fibrosis ages 12 years and older who have at least one copy of the F508del mutation.

In August 2020, Vertex announced that the EC had granted marketing authorization of Kaftrio in combination with ivacaftor for the treatment of patients with cystic fibrosis ages 12 years and older with one F508del mutation and one minimal function mutation, or two F508del mutations in the cystic fibrosis transmembrane conductance regulator gene.

In December 2020, the FDA expanded the eligibility for Trikafta to include people with cystic fibrosis ages 12 and older with certain mutations that are responsive to Trikafta based on in vitro data.

In April 2021, Vertex announced EC approval for Kaftrio in combination with ivacaftor for the treatment of patients with cystic fibrosis ages 12 and older who have at least one F508del mutation.

In June 2021, Vertex announced that FDA approved Trikafta for the treatment of children with cystic fibrosis ages 6 through 11 who have at least one F508del mutation or have certain mutations that are responsive to Trikafta based on in vitro data.

In January 2022, Vertex announced that the EC granted approval for the label expansion of Kaftrio in combination with ivacaftor for the treatment of cystic fibrosis in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

•Tysabri. In April 2021, Biogen announced that the EC granted marketing authorization for a subcutaneous injection of Tysabri to treat relapsing-remitting multiple sclerosis. Biogen also announced that it had received a Complete Response Letter from the FDA for its sBLA for subcutaneous Tysabri. The Complete Response Letter indicates that the FDA is unable to approve Biogen’s filing as submitted. Biogen announced that it is evaluating the Complete Response Letter and will determine next steps in the United States.

61

In August 2021, Biogen announced results from Phase 3b NOVA study evaluation every six-week dosing with Tysabri intravenous administration in relapsing-remitting multiple sclerosis. Results show that every six-week Tysabri intravenous administration provides a high level of efficacy in controlling multiple sclerosis disease activity in patients who switched from the approved every four-week dosing regimen.

•Imbruvica. In April 2020, Imbruvica received FDA approval for use in combination with rituximab for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

In August 2020, the EC granted marketing authorization for Imbruvica in combination with rituximab for the treatment of adult patients with previously untreated CLL. This milestone marked the 11th FDA approval for Imbruvica since it was first approved in 2013 and sixth in CLL.

In June 2021, Phase 3 GLOW study results for Imbruvica in combination with Venetoclax for the treatment of first-line CLL and SLL demonstrated superior progression-free survival versus chlorambucil plus obinutuzumab as a first-line treatment of CLL. The study also showed improved duration of remission and significantly improved depth of remission. AbbVie has indicated that approval could occur in 2022.

In August 2021, AbbVie announced that the U.S. District Court for the District of Delaware had issued a decision holding patent rights relating to Imbruvica were valid and infringed by a generic product from Alvogen and Natco. The decision, which is subject to appeal, prohibits regulatory approval of that generic product until the last AbbVie patent expires. Previously, AbbVie entered into several settlement and license agreements with other generic companies. Consequently, AbbVie does not expect any generic product entry prior to March 30, 2032, assuming pediatric exclusivity is granted.

•Xtandi. In December 2019, Astellas and Pfizer announced that the FDA approved Xtandi for the treatment of patients with metastatic castration sensitive prostate cancer.

In May 2021, Astellas and Pfizer announced that the EC approved Xtandi for the treatment of patients with metastatic hormone-sensitive prostate cancer.

In September 2021, Astellas Pharma and Pfizer announced that Xtandi plus androgen deprivation therapy (ADT) reduced the risk of death by 34% compared to placebo plus ADT in the Phase 3 ARCHES study in men with metastatic hormone-sensitive prostate cancer. The primary results from the ARCHES trial were published in 2019.

Astellas and Pfizer have indicated that there could be a potential readout of the Phase 3 EMBARK trial for high-risk non-metastatic prostate cancer in the second half of 2022.

•Nurtec ODT. In February 2020, Biohaven announced that the FDA approved Nurtec ODT for the acute treatment of migraine in adults. The FDA approval of Nurtec ODT triggered a redemption provision related to our investment in the Series A Biohaven Preferred Shares, which entitles us to receive a fixed payment amount of $250.0 million payable in equal quarterly payments from March 31, 2021 through December 31, 2024.

In May 2021, Biohaven announced that the FDA approved Nurtec ODT for the preventative treatment of migraine, indicated for adult patients with episodic migraine who experience less than 15 headache days per month.

In November 2021, Biohaven announced a strategic collaboration with Pfizer for the commercialization of rimegepant outside the United States. Pfizer also gains rights outside the U.S. to zavegepant, which is being studied in an intranasal delivery and an oral formulation in Phase 3 clinical trials for migraine indications.

Biohaven has indicated it expects an EMA decision on Vydura (rimegepant) in the first half of 2022.

•Trodelvy. In April 2020, Immunomedics announced that the FDA granted accelerated approval of Trodelvy for the treatment of patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease.

62

In September 2020, Gilead and Immunomedics announced that Gilead would acquire Immunomedics for approximately $21 billion in cash. In 2018, we entered into a partnership with Immunomedics whereby we acquired a tiered sales-based royalty on Trodelvy for $175.0 million and acquired 4,373,178 shares of Immunomedics common stock for $75.0 million. Gilead’s acquisition of Immunomedics closed in October 2020, resulting in gross cash proceeds upon redemption of our Immunomedics common stock of approximately $385 million.

In April 2021, Gilead announced the FDA granted full approval to Trodelvy for adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. The approval is supported by data from the Phase 3 ASCENT study.

In April 2021, Gilead announced that the FDA granted an accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 or a programmed death-ligand 1 inhibitor. The accelerated approval was based on data from the international Phase 2, single-arm TROPHY study.

In June 2021, Gilead announced superior outcomes to standard of care in second-line treatment of metastatic TNBC in the Phase 3 ASCENT study. Trodelvy more than doubled overall survival as a second-line treatment in the new ASCENT subgroup analysis.

In October 2021, Gilead announced a collaboration with Merck & Co. to investigate Trodelvy in combination with Keytruda as a first-line treatment for people with locally advanced or metastatic TNBC.

In November 2021, Gilead announced that the EC granted marketing authorization for Trodelvy as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for advanced disease. The EC’s decision is supported by results from the Phase 3 ASCENT study, where Trodelvy reduced the risk of death by 49% and improved median overall survival to 11.8 months versus 6.9 months with physician’s choice of chemotherapy.

In January 2022, Gilead announced it has entered into two clinical trial collaboration and supply agreements with Merck & Co. to evaluate the combination of Trodelvy and Merck’s anti-PD-1 therapy Keytruda in first-line metastatic non-small cell lung cancer (NSCLC). As part of the collaboration, Merck will sponsor a global Phase 3 clinical trial of Trodelvy in combination with Keytruda as a first-line treatment of patients with metastatic NSCLC. Additionally, the companies recently established an agreement whereby Gilead will sponsor a Phase 2 signal-seeking study evaluating combinations that include pembrolizumab in first-line NSCLC.

Gilead has indicated that it expects progression-free survival data as well as the first planned interim analysis of overall survival data from the Phase 3 TROPiCS-02 trial in hormone receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer in March 2022.

•Cabometyx. In January 2021, Exelixis announced that the FDA approved Cabometyx for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in combination with Bristol Myers Squibb’s Opdivo. The approval was based on the Phase 3 CheckMate -9ER trial, in which the combination of Cabometyx and Opdivo significantly improved overall survival while doubling progression-free survival and objective response rate versus sunitinib as a first-line treatment for patients with advanced RCC.

In March 2021, Ipsen announced that the EC approved the combination of Cabometyx and Opdivo for the first-line treatment of advanced RCC.

In May 2021, Exelixis announced results from cohort six of COSMIC-021, a Phase 1b trial evaluating Cabometyx in combination with atezolizumab in patients with locally advanced or metastatic solid tumors, including patients with metastatic castration-resistant prostate cancer (CRPC). In high-risk patients, the combination of Cabometyx and atezolizumab resulted in objective response rates of 27% and 18% per investigator assessment and Blinded Independent Radiology Committee, respectively.

63

In June 2021, Exelixis and Ipsen announced that COSMIC-312, a Phase 3 trial evaluating Cabometyx in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. The trial met one of its primary endpoints by demonstrating significant improvement in progression-free survival at the planned primary analysis. However, a prespecified interim analysis was not statistically significant for the second primary endpoint of overall survival. Based on the preliminary overall survival data, Exelixis anticipates that the probability of reaching statistical significance at the time of the final analysis is low.

In August 2021, Exelixis announced that their partners Takeda and Ono received approval in Japan for Cabometyx in combination with Opdivo for the treatment of unresectable or metastatic RCC. Approval is based on the CheckMate -9ER trial of Cabometyx in combination with Opdivo, which demonstrated superior overall survival and doubled mean progression-free survival and objective response rate versus sunitinib, with a favorable safety profile.

In September 2021, Exelixis announced detailed results from the expanded Cohort 6 of the Phase 1b COSMIC-021 trial of Cabometyx in combination with atezolizumab in patients with metastatic CRPC, which included patients with metastatic CRPC who had been previously treated with novel hormone therapies enzalutamide and/or abiraterone acetate used along with prednisone. Following discussions with FDA, Exelixis will not pursue a regulatory submission for the combination regimen based on cohort 6 of COSMIC-021. CONTACT-02, a global Phase 3 pivotal trial that initiated enrollment in June 2020 may serve as a basis for future regulatory applications.

In September 2021, Exelixis announced FDA approved Cabometyx for patients with previously treated radioactive iodine-refractory differentiated thyroid cancer. The approval was based on the Phase 3 COSMIC-311 pivotal trial.

Exelixis has indicated it expects Phase 3 data from the COSMIC-313 trial in 1L RCC in the first half of 2022 and initial Phase 3 data in the second half of 2022 from CONTACT-01 in metastatic NSCLC and CONTACT-03 in advanced or metastatic RCC.

•Evrysdi. In August 2020, the FDA approved Evrysdi, the first at-home, orally administered treatment for spinal muscular atrophy (SMA) in adults and children ages 2 months and older.

In March 2021, Roche announced that the EC approved Evrysdi for the treatment of SMA in patients two months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four splicing modifier of motor neuron 2 copies.

In June 2021, Evrysdi was approved in Japan for the treatment of SMA.

•Orladeyo. In December 2020, BioCryst announced that Orladeyo was approved by the FDA for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ages 12 years and older.

In January 2021, Orladeyo was approved in Japan, becoming the first and only prophylactic HAE medication approved in the region.

In April 2021, BioCryst announced that the EC approved Orladeyo for the prevention of recurrent HAE attacks in patients 12 years and older.

In April 2021, BioCryst announced approval of Japanese National Health Insurance System price listing of Orladeyo for prophylactic treatment of HAE.

•Oxlumo. In July 2021, Alnylam announced results from ILLUMINATE-C, a Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 associated with progressive decline in renal function. Results from the primary analysis at six months demonstrated a substantial reduction in plasma oxalate from baseline in patients with advanced disease, including those on hemodialysis. The safety and tolerability profile of lumasiran following six months of treatment was encouraging across all ages, with no drug related serious adverse events and injection site reactions as the most common adverse event.

64

In December 2021, Alnylam submitted a supplemental New Drug Application for lumasiran to the FDA and a Type II Variation with the EMA for the reduction of plasma oxalate in the treatment of patients with advanced primary hyperoxaluria type 1.

Development-Stage Product Candidates

•Aficamten. In February 2022, Cytokinetics announced positive topline results from Cohort 3 of the REDWOOD-HCM Phase 2 trial. Results from Cohort 3 showed that substantial reductions in the average resting LVOT-G as well as the post-Valsalva LVOT-G were achieved for patients with oHCM and a resting or post-Valsalva LVOT-G of ≥50 mmHg whose background therapy included disopyramide and in the majority a beta-adrenergic blocker. The safety and tolerability of aficamten were consistent with prior experience in REDWOOD-HCM with no treatment interruptions and no serious adverse events attributed to treatment reported by the investigators.

In December 2021, Cytokinetics announced the FDA granted Breakthrough Therapy Designation for aficamten for the treatment of symptomatic oHCM based on results from REDWOOD-HCM. Cytokinetics has indicated it plans to initiate a pivotal study of aficamten in oHCM in the first quarter of 2022.

•Gantenerumab. In October 2021, Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the FDA for the treatment of people living with Alzheimer’s disease. This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of Alzheimer’s disease, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies. Roche has indicated it expects Phase 3 data from the GRADUATE 1/2 trial in Alzheimer’s disease in the fourth quarter of 2022.

•Omecamtiv mecarbil. In November 2020, Amgen, Cytokinetics and Servier presented the results of GALACTIC-HF study, a Phase 3 trial of omecamtiv mecarbil in patients with heart failure, at the American Heart Association Scientific Sessions. The trial met the primary composite endpoint of reduction in cardiovascular death or heart failure events, but did not meet the secondary endpoint of reduction in cardiovascular death. Cytokinetics subsequently regained global rights to develop and commercialize omecamtiv mecarbil when Amgen and Servier elected to terminate their collaboration agreement effective, May 2021. Following the Phase 3 results and termination of the collaboration, we wrote off the full value of our financial royalty asset given the uncertainty around the future of omecamtiv mecarbil.

In February 2022, Cytokinetics announced that FDA has accepted and filed the company’s New Drug Application (NDA) for omecamtiv mecarbil. The FDA assigned the NDA a standard review with a PDUFA target action date of November 30, 2022. The FDA also indicated that it is currently not planning to hold an advisory committee meeting to discuss the application. The submission is supported by GALACTIC-HF, which demonstrated a positive effect on the primary composite endpoint of cardiovascular death or heart failure events in patients with heart failure and reduced ejection fraction who were receiving standard of care plus omecamtiv mecarbil.

•Otilimab. GlaxoSmithKline has indicated it expects Phase 3 data from the contRast trials in rheumatoid arthritis in the second half of 2022.

•Pelabresib: In December 2021, MorphoSys presented the latest data from the Phase 2 MANIFEST study evaluating pelabresib in the treatment of myelofibrosis. As of September 10, 2021, the data cut-off, a total of 84 JAK inhibtor-naive patients were enrolled and received the first-line combination of pelabresib and ruxolitinib. The data showed 68% (n=57) of patients treated with the combination achieved a greater than or equal to 35% reduction in spleen volume (SVR35) from baseline at week 24 and 60% (n=47) maintained SVR35 at week 48. Most patients also saw their symptoms reduced, with 56% (n=46) achieving greater than or equal to 50% reduction in total symptom score from baseline at week 24.

65

•PT027. In September 2021, AstraZeneca and Avillion announced positive results from MANDALA and DENALI, two Phase 3 trials evaluating PT027 (albuterol/budesonide) in patients with asthma. PT027 is a potential first-in-class inhaled, fixed-dose combination of albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. In MANDALA, PT027 demonstrated a statistically significant and clinically meaningful reduction in the risk of severe exacerbations compared to albuterol, when used as a rescue medicine in response to symptoms. In DENALI, PT027 showed a statistically significant improvement in lung function measured by forced expiratory volume in one second, compared to the individual components albuterol and budesonide, and compared to placebo. The safety and tolerability of PT027 in both trials was consistent with the known profiles of the components. AstraZeneca has indicated PT027 regulatory submissions will occur in the first half of 2022.

•Zavegepant. In December 2019, Biohaven announced positive topline results from the Phase 2/3 trial of intranasal zavegepant for the acute treatment of migraine.

In March 2021, Biohaven announced that it enrolled the first patient in a Phase 2/3 clinical trial of oral zavegepant for the preventive treatment of migraine. Accordingly, per the agreement with Biohaven announced in August 2020, Royalty Pharma paid $100 million to Biohaven for the achievement of this milestone, bringing the total zavegepant funding to $250 million.

In December 2021, Biohaven announced positive topline results from the second pivotal clinical trial evaluating the safety and efficacy of intranasal zavegepant for the acute treatment of migraine in adults. The Phase 3 study achieved its co-primary regulatory endpoints of pain freedom and freedom of most bothersome symptom at 2 hours and showed broad efficacy by demonstrating statistically significant superiority to placebo across a total of 15 prespecified primary and secondary outcome measures. Biohaven plans to file an NDA for zavegepant with the FDA in the first quarter of 2022 and other countries thereafter.


Non-GAAP Financial Results

In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. There is no direct correlation between income from financial royalty assets and royalty receipts due to the nature of the accounting methodology applied for financial royalty assets. Further, income from financial royalty assets and the provision for changes in expected cash flows related to these financial royalty assets can be volatile and unpredictable. As a result, management places importance on royalty receipts as they are predictable and we use them as a measure of our operating performance. Refer to section titled “Non-GAAP Reconciliations” for additional discussion of management’s use of non-GAAP measures as supplemental financial measures and reconciliations from the most directly GAAP comparable measures of Net cash provided by operating activities.

Adjusted Cash Receipts is a measure calculated with inputs directly from the Statement of Cash Flows and includes (1) royalty receipts by product: (i) Cash collections from royalty assets (financial assets and intangible assets), (ii) Other royalty cash collections, (iii) Distributions from non-consolidated affiliates, plus (2) Proceeds from available for sale debt securities; less (3) Distributions to non-controlling interest, which represents contractual distributions of royalty receipts and proceeds from available for sale debt securities to our historical non-controlling interest attributable to a de minimis interest in RPCT held by certain legacy investors and to the non-controlling interest that was created as a result of the Exchange Offer Transactions in February 2020 related to the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI. Adjusted Cash Receipts is most directly comparable to the GAAP measure of Net cash provided by operating activities.

Adjusted EBITDA and Adjusted Cash Flow are similar non-GAAP liquidity measures that are both most closely comparable to the GAAP measure, Net cash provided by operating activities. Adjusted EBITDA is important to our lenders and is defined under the Credit Agreement as Adjusted Cash Receipts less Payments for operating and professional costs. Payments for operating and professional costs are comprised of Payments for operating and professional costs and Payments for rebates from the Statement of Cash Flows.

Adjusted Cash Flow is defined as Adjusted EBITDA less (1) Ongoing development-stage funding payments, (2) Interest paid, net of Interest received, (3) Other (including Derivative collateral posted, net of Derivative collateral received, and Termination payments on derivative instruments) and (4) Investments in non-consolidated affiliates, plus (1) Contributions from non-controlling interest- R&D, all directly reconcilable to the Statement of Cash Flows.

66

Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of the strength of the Company and the performance of the business. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income used by companies in the biopharmaceutical industry. Adjusted EBITDA, as derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants.

The following is a discussion of our results on a non-GAAP basis for the years ended December 31, 2021 and 2020. For a discussion comparing our results on a non-GAAP basis for the years ended December 31, 2020 and 2019, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

The table below includes the royalty receipts and non-GAAP financial results for the years ended December 31, 2021 and 2020 by product in order of contribution to royalty receipts for the year ended December 31, 2021.

(in thousands)Years Ended December 31,2021 vs. 2020 Change
20212020$ %
Products
Cystic fibrosis franchise (1)$702,140 $551,338 $150,802 27.4 %
Tysabri369,149 345,845 23,304 6.7 %
Imbruvica352,911 322,071 30,840 9.6 %
Promacta173,621 143,741 29,880 20.8 %
Xtandi158,103 146,374 11,729 8.0 %
Januvia, Janumet, Other DPP-IVs (2)151,158 143,753 7,405 5.2 %
HIV franchise (3)78,038 293,808 (215,770)(73.4)%
Nurtec ODT/Biohaven payment (4)70,188 3,667 66,521 *
Prevymis37,505 21,492 16,013 74.5 %
Farxiga/Onglyza 36,378 25,004 11,374 45.5 %
Tremfya35,718 — 35,718 — %
Cabometyx/Cometriq33,722 — 33,722 — %
Crysvita16,741 9,454 7,287 77.1 %
Evrysdi16,098 273 15,825 *
Emgality15,481 9,529 5,952 62.5 %
Erleada14,227 7,876 6,351 80.6 %
Trodelvy13,395 3,031 10,364 *
IDHIFA12,404 6,111 6,293 103.0 %
Orladeyo6,740 — 6,740 — %
Tazverik2,794 522 2,272 *
Oxlumo1,248 — 1,248 — %
Other products (5)310,783 310,510 273 0.1 %
Total royalty receipts$2,608,542 $2,344,399 $264,143 11.3 %
Distributions to non-controlling interest(479,604)(543,952)64,348 (11.8)%
Adjusted Cash Receipts (non-GAAP)$2,128,938 $1,800,447 $328,491 18.2 %
Payments for operating and professional costs(184,511)(179,709)(4,802)2.7 %
Adjusted EBITDA (non-GAAP)$1,944,427 $1,620,738 $323,689 20.0 %
Interest paid, net(127,295)(95,492)(31,803)33.3 %
Investments in non-consolidated affiliates(34,855)(40,155)5,300 (13.2)%
Ongoing development-stage funding payments(6,876)(20,479)13,603 (66.4)%
Other(16,093)9,804 (25,897)(264.1)%
Contributions from non-controlling interest- R&D7,339 8,482 (1,143)(13.5)%
Adjusted Cash Flow (non-GAAP)$1,766,647 $1,482,898 $283,749 19.1 %
Fully diluted Class A ordinary shares outstanding607,176 607,111 
*Percentage change is not meaningful.
67


(1) The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio.
(2) Januvia, Janumet, Other DPP-IVs include the following approved products: Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas and Nesina. The Other DPP-IVs are marketed by Boehringer Ingelheim, AstraZeneca, Novartis and Takeda.
(3) The HIV franchise includes the following approved products: Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza and Biktarvy. Royalties are received on the emtricitabine portion of sales only.
(4) Includes royalty receipts for Nurtec ODT of $7.7 million and quarterly redemptions of $15.6 million of the Series A Biohaven Preferred Shares (presented as Proceeds from available for sale debt securities on the Statement of Cash Flows) for the year ended December 31, 2021. For the year ended December 31, 2020, the amount also includes a payment from Biohaven in respect of an expired option to exercise additional funding of the Biohaven Series A Preferred Shares which is presented as Proceeds from available for sale debt securities on the Statement of Cash Flows.
(5) Other products primarily include royalties on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion, for which receipts are presented as Distributions from non-consolidated affiliates on the Statement of Cash Flows), Lexiscan, Soliqua, Nesina, Cimzia, Letairis, Entyvio, Myozyme, Mircera and Lyrica. Other products for the year ended December 31, 2021 includes a one-time milestone payment of $45.0 million that we received on Soliqua. Other products for the year ended December 31, 2020 includes a one-time $21.3 million distribution from Avillion in respect of the Merck KGaA Asset for which the receipt is presented as Distributions from non-consolidated affiliates in both the operating and investing section of the Statement of Cash Flows. Subsequent to the Exchange Offer Date, other products also includes contributions from the Legacy SLP Interest.

Adjusted Cash Receipts (non-GAAP)

Adjusted Cash Receipts increased by $328.5 million to $2.1 billion in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by an increase in royalty receipts from the cystic fibrosis franchise, including royalty receipts related to the residual interest in the cystic fibrosis franchise that we acquired in October 2020, fixed payments from Biohaven on the Series A Biohaven Preferred Shares and new assets acquired subsequent to the year ended December 31, 2020. Offsetting the increase in royalty receipts was a decline in royalty receipts from maturing assets, primarily the HIV franchise, Lyrica and Letairis. Additionally, we received one-time payments of $45.0 million related to a commercial milestone for Soliqua and $21.3 million from Avillion II in connection with the cessation of our involvement in the Merck KGaA Asset development in the years ended December 31, 2021 and 2020, respectively. The increase in Adjusted Cash Receipts was further driven by a decrease in distributions to non-controlling interest, primarily due to a decline in royalty receipts from maturing assets in the year ended December 31, 2021 and a non-recurring distribution to the Legacy Investors Partnerships made in connection with the Exchange Offer Transactions that occurred in the three months ended March 31, 2020.

Below we discuss the key drivers of royalty receipts.

Royalty Receipts

•Cystic fibrosis franchise – Royalty receipts from the cystic fibrosis franchise, which includes Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio, which are marketed by Vertex for patients with certain mutations causing cystic fibrosis, increased by $150.8 million in the year ended December 31, 2021 compared to the year ended December 31, 2020. The increase was primarily driven by the performance of Trikafta in the United States, including its rapid uptake in children 6 through 11 years old and the launch of Kaftrio in Europe. The year ended December 31, 2021 also benefited from a clawback adjustment related to Vertex’s agreement with French authorities around reimbursement for Orkambi, which had reduced royalty receipts in the three months ended March 31, 2020 by approximately $41 million (to reflect a true-up in prior periods where we collected royalties on sales in France at a higher selling price). Following our acquisition of the residual interest in the cystic fibrosis franchise from the Cystic Fibrosis Foundation in the three months ended December 31, 2020, we are entitled to all royalty receipts on annual worldwide net sales above $5.8 billion. We received royalty receipts related to the residual interest in the cystic fibrosis franchise in the year ended December 31, 2021.

•Tysabri – Royalty receipts from Tysabri, which is marketed by Biogen for the treatment of multiple sclerosis, increased by $23.3 million in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by continued patient growth.

68

•Imbruvica – Royalty receipts from Imbruvica, which is marketed by AbbVie and Johnson & Johnson for the treatment of blood cancers and chronic graft versus host disease, increased by $30.8 million in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by continued global penetration in patients with chronic lymphocytic leukemia and favorable pricing. This increase was partially offset by modest market share losses in the United States, lower new patient starts due to the COVID-19 pandemic as well as the impact of COVID-19 inventory stocking.

•Promacta – Royalty receipts from Promacta, which is marketed by Novartis for the treatment of chronic immune thrombocytopenia and aplastic anemia, increased by $29.9 million in the year ended December 31, 2021 compared to the year ended December 31, 2020. This growth was primarily driven by increased use in chronic immune thrombocytopenia and as first-line treatment for severe aplastic anemia in the United States.

•Xtandi – Royalty receipts from Xtandi, which is marketed by Pfizer and Astellas for the treatment of prostate cancer, increased by $11.7 million in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by demand across various prostate cancer indications.

•Januvia, Janumet, Other DPP-IVs – Royalty receipts from the DPP-IVs for type 2 diabetes, which includes Januvia and Janumet, both marketed by Merck & Co., increased $7.4 million in the year ended December 31, 2021 compared to the year ended December 31, 2020.

•Nurtec ODT – Royalty receipts from Nurtec ODT, marketed by Biohaven and Pfizer for the acute treatment of migraine, were $7.7 million in the year ended December 31, 2021. In addition, as a result of the approval of Nurtec ODT in February 2020, we received $62.5 million in fixed payments from Biohaven in the year ended December 31, 2021, which represent the first four of 16 consecutive quarterly payments to be received from Biohaven relating to the Series A Biohaven Preferred Shares.

•Tremfya – Royalty receipts from Tremfya, which is marketed by Johnson & Johnson, were $35.7 million in the year ended December 31, 2021. We acquired the Tremfya royalty in July 2021.

•Cabometyx/Cometriq – Royalty receipts from Cabometyx/Cometriq, which is marketed by Exelixis, Ipsen and Takeda, were $33.7 million in the year ended December 31, 2021. We acquired the Cabometyx/Cometriq royalty in March 2021.

•HIV franchise – Royalty receipts from the HIV franchise, which is based on products marketed by Gilead that contain emtricitabine, including Biktarvy, Genvoya and Truvada, among others, decreased by $215.8 million in the year ended December 31, 2021 compared to the year ended December 31, 2020. This decrease was driven by the maturity of our royalties from the HIV franchise in 2021.

Distributions to Non-Controlling Interest

Distributions to non-controlling interest decreased by $64.3 million to $479.6 million in the year ended December 31, 2021 compared to the year ended December 31, 2020, which positively impacted Adjusted Cash Receipts. The decrease in distributions to non-controlling interest is primarily due to a decline in royalty receipts from maturing assets, primarily the HIV franchise, and a non-recurring distribution to the Legacy Investors Partnerships made in connection with the Exchange Offer Transactions that occurred in the three months ended March 31, 2020. Partially offsetting these decreases was a distribution to non-controlling interest related to the one-time milestone payment we received on Soliqua in the year ended December 31, 2021.

Adjusted EBITDA (non-GAAP)

Adjusted EBITDA increased by $323.7 million to $1.9 billion in the year ended December 31, 2021 compared to the year ended December 31, 2020 as a result of the factors noted above in “Adjusted Cash Receipts (Non-GAAP).” Payments for operating and professional costs, the only adjustment between Adjusted Cash Receipts and Adjusted EBITDA, increased slightly in the year ended December 31, 2021 as a result of higher Operating and Personnel Payments under the terms of our Management Agreement offset by a decrease in non-recurring professional services fees, restructuring fees and refinancing fees incurred in the year ended December 31, 2020 in connection with the Exchange Offer Transactions and the IPO.
69


Adjusted Cash Flow (non-GAAP)

Years ended December 31, 2021 and 2020

Adjusted Cash Flow increased by $283.7 million to $1.8 billion in the year ended December 31, 2021 compared to the year ended December 31, 2020 primarily for the same reasons noted above in “Adjusted Cash Receipts (Non-GAAP)” and “Adjusted EBITDA (non-GAAP).” The adjustments between “Adjusted EBITDA (non-GAAP)” and “Adjusted Cash Flow (non-GAAP)” increased by $39.9 million in the year ended December 31, 2021 compared to the year ended December 30, 2020. The increase was driven by a $31.8 million increase in net interest paid in the year ended December 31, 2021 due to a shift to semi-annual interest payments on the 2020 Notes and a $16.1 million one-time payment related to the settlement of treasury rate lock contracts in connection with the 2021 Notes issuance. This increase was partially offset by lower ongoing development-stage funding requirements under our co-funding agreement with Sanofi and lower funding requirements by the Avillion entities in 2021 following the cessation of our involvement in the Merck KGaA Asset development in 2020.

Non-GAAP Reconciliations

Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow are non-GAAP measures presented as supplemental measures to our GAAP financial performance. These non-GAAP financial measures exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. In each case, because our operating performance is a function of our liquidity, the non-GAAP measures used by management are presented and defined as supplemental liquidity measures. We caution readers that amounts presented in accordance with our definitions of Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow may not be the same as similar measures used by other companies. Not all companies and analysts calculate the non-GAAP measures we use in the same manner. We compensate for these limitations by using non-GAAP financial measures as supplements to GAAP financial measures and by presenting the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures, in each case being Net cash provided by operating activities.

We believe that Adjusted Cash Receipts and Adjusted Cash Flow provide meaningful information about our operating performance because the business is heavily reliant on its ability to generate consistent cash flows and these measures reflect the core cash collections and cash charges comprising our operating results. Management strongly believes that our significant operating cash flow is one of the attributes that attracts potential investors to our business.

In addition, we believe that Adjusted Cash Receipts and Adjusted Cash Flow help identify underlying trends in the business and permit investors to more fully understand how management assesses the performance of the Company, including planning and forecasting for future periods. Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of the Company’s ability to generate cash from operations. Both measures are an indication of the strength of the Company and the performance of the business. Management uses Adjusted Cash Receipts and Adjusted Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, voluntary debt repayments, dividends and other discretionary investments. Further, these non-GAAP financial measures help management, the audit committee and investors evaluate our ability to generate liquidity from operating activities.

Management believes that Adjusted EBITDA is an important non-GAAP measure in analyzing our liquidity and is a key component of certain material covenants contained within the Company’s credit agreement. Noncompliance with the interest coverage ratio and leverage ratio covenants under the credit agreement could result in our lenders requiring the Company to immediately repay all amounts borrowed. If we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the assessment of our liquidity.

Management uses Adjusted Cash Flow to evaluate its ability to generate cash and performance of the business and to evaluate the Company’s performance as compared to its peer group. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income measures used by many companies in the biopharmaceutical industry, even though each company may customize its own calculation and therefore one company’s metric may not be directly comparable to another’s. We believe that non-GAAP financial measures, including Adjusted Cash Flow, are frequently used by securities analysts, investors and other interested parties to evaluate companies in our industry.

70

The non-GAAP financial measures used in this Annual Report on Form 10-K have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of our results as reported under GAAP. We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, in each case being Net cash provided by operating activities below.

To arrive at Adjusted Cash Receipts, we start with the GAAP line item, Net cash provided by operating activities, and adjust for the following items from the Statement of Cash Flows: to add back (1) Proceeds from available for sale debt securities (primarily the redemption of Biohaven Preferred Shares), which are cash inflows that management believes are derived from royalties and form part of our core business strategy, (2) Distributions from non-consolidated affiliates which are cash inflows from investing activities, (3) Interest paid, net of Interest received, (4) Development-stage funding payments, (5) Payments for operating and professional costs, (6) Payments for rebates and (7) Termination payments on derivative instruments, and to deduct (1) Distributions to non-controlling interest, which represents distributions to our historical non-controlling interest attributable to a de minimis interest in RPCT held by certain legacy investors and to a new non-controlling interest that was created as a result of the Exchange Offer Transactions in February 2020 related to the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI and (2) Derivative collateral posted or (received), net, both of which are excluded when management assesses its operating performance through cash collections, or, Adjusted Cash Receipts.

To arrive at Adjusted EBITDA, we start with Net cash provided by operating activities and adjust for the following items from the Statement of Cash Flows: to add back (1) Proceeds from available for sale debt securities (primarily redemption of Biohaven Preferred Shares), (2) Distributions from non-consolidated affiliates which are cash inflows from investing activities, (3) Interest paid, net of Interest received, (4) Development-stage funding payments and (5) Termination payments on derivative instruments, and to deduct (1) Distributions to non-controlling interest and (2) Derivative collateral posted or (received), net.

To arrive at Adjusted Cash Flow, we start with Net cash provided by operating activities and adjust for the following items from the Statement of Cash Flows: to add back (1) Proceeds from available for sale debt securities (primarily redemption of Biohaven Preferred Shares), (2) Distributions from non-consolidated affiliates classified as Cash used in investing activities, (3) Upfront development-stage funding payments and (4) Contributions from non-controlling interest- R&D, and to deduct (1) Distributions to non-controlling interest and (2) Investments in non-consolidated affiliates. This is intended to present an Adjusted Cash Flow measure that is representative of cash generated from the broader business strategy of acquiring royalty-generating assets that are available for reinvestment and for discretionary purposes.

71

(in thousands)Years Ended December 31,
20212020
Net cash provided by operating activities (GAAP)$2,017,536 $2,034,629 
Adjustments:
Proceeds from available for sale debt securities (1), (2)62,500 3,000 
Distributions from non-consolidated affiliates – investing (2)523 15,084 
Interest paid, net (2)127,295 95,492 
Ongoing development-stage funding payments (3)6,876 20,479 
Upfront development-stage funding payments (3)193,208 5,810 
Payments for operating and professional costs184,511 179,709 
Termination payments on derivative instruments16,093 35,448 
Distributions to non-controlling interest (2)(479,604)(543,952)
Derivative collateral received, net (2)— (45,252)
Adjusted Cash Receipts (non-GAAP)$2,128,938 $1,800,447 
Net cash provided by operating activities (GAAP)$2,017,536 $2,034,629 
Adjustments:
Proceeds from available for sale debt securities (1), (2)62,500 3,000 
Distributions from non-consolidated affiliates – investing (2)523 15,084 
Interest paid, net (2)127,295 95,492 
Ongoing development-stage funding payments (3)6,876 20,479 
Upfront development-stage funding payments (3)193,208 5,810 
Termination payments on derivative instruments16,093 35,448 
Distributions to non-controlling interest (2)(479,604)(543,952)
Derivative collateral received, net (2)— (45,252)
Adjusted EBITDA (non-GAAP)$1,944,427 $1,620,738 
Net cash provided by operating activities (GAAP)$2,017,536 $2,034,629 
Adjustments:
Proceeds from available for sale debt securities (1), (2)62,500 3,000 
Distributions from non-consolidated affiliates – investing (2)523 15,084 
Upfront development-stage funding payments (3)193,208 5,810 
Distributions to non-controlling interest (2)(479,604)(543,952)
Investments in non-consolidated affiliates (2), (4)(34,855)(40,155)
Contributions from non-controlling interests-R&D (2)7,339 8,482 
Adjusted Cash Flow (non-GAAP)$1,766,647 $1,482,898 

72

(1) Receipts from the quarterly redemption of the Series A Biohaven Preferred Shares are presented as Proceeds from available for sale debt securities on the Statement of Cash Flows for the year ended December 31, 2021. A payment from Biohaven in respect of an expired option to exercise additional funding of the Biohaven Series A Preferred Shares is presented as Proceeds from available for sale debt securities on the Statement of Cash Flows for the year ended December 31, 2020.
(2) The table below shows the line item for each adjustment and the direct location for such line item on the Statement of Cash Flows.
Reconciling AdjustmentStatement of Cash Flows Classification
Proceeds from available for sale debt securitiesInvesting activities
Investments in non-consolidated affiliatesInvesting activities
Distributions to non-controlling interestFinancing activities
Interest paid, net
Operating activities (Interest paid less Interest received)
Derivative collateral (received)/posted, net
Operating activities (Derivative collateral received less Derivative collateral posted)
Contributions from non-controlling interest- R&DFinancing activities
Distributions from non-consolidated affiliates - investingInvesting activities
(3) Our lenders consider all payments made to support R&D activities for products undergoing late-stage development similar to asset acquisitions as these funds are expected to generate operational returns in the future. All ongoing and upfront development-stage funding payments are reported in R&D funding expense in net income and are added back in aggregate to Net cash provided by operating activities to arrive at Adjusted EBITDA. As a result, Adjusted EBITDA captures the full add-back for R&D funding payments while Adjusted Cash Flow only reflects the add-back for the upfront portion of development-stage funding payments due to the fact that ongoing development-stage funding payments are considered an ongoing business expense.
(4) We consider all payments to fund our operating joint ventures that are performing R&D activities for products undergoing late stage development similar to asset acquisitions as these funds are expected to generate operational returns in the future. As a result, amounts funded through capital calls by our equity method investees, the Avillion Entities, are deducted to arrive at Adjusted Cash Flow, but are not deducted in Adjusted EBITDA.

Investments Overview

Ongoing investment in new royalties is fundamental to the long-term prospects of our business. New investments provide a source of growth for our royalty receipts, supplementing growth within our existing portfolio and offsetting declines for products in our portfolio that have lost market exclusivity. We evaluate an array of royalty acquisition opportunities on a continuous basis and expect to continue to make acquisitions in the ordinary course of our business. Our team has established a strong track record of identifying, evaluating and investing in royalties tied to leading products across therapeutic areas and treatment modalities. We invest in approved products and development-stage product candidates that have generated robust proof of concept data. We invest in these therapies through the purchase of royalties, by making hybrid investments and by acquiring businesses with significant existing royalty assets or the potential for the creation of such assets.

For the year ended December 31, 2021, we invested $2.7 billion in royalties and related assets across five separate transactions. While volatility exists in the quantum of our new acquisitions on a year-to-year basis due to the unpredictable timing of new investment opportunities, we have consistently deployed significant amounts of cash when measured over multi-year periods. Our approach is rooted in a highly disciplined evaluation process that is not dictated by a minimum annual investment threshold.

Included below is a table of investment activity over each of the last ten years based on the type of investment at the acquisition date. Amounts presented in the table below reflect cash paid at the acquisition date; any associated contractual payments are reflected in the period in which cash was paid.

(in thousands)Average2021202020192018201720162015201420132012
Approved / marketed royalties$1,018,039 $1,819,903 $1,404,221 $1,848,711 $269,554 $2,200,480 $1,197,210 $337,882 $468,427 $510,000 $124,000 
Development-stage royalties (1) (2)778,633830,713894,469445,699569,592220,09399,242120,2853,428,530391,287786,417
Totals$1,796,672 $2,650,616 $2,298,690 $2,294,410 $839,146 $2,420,573 $1,296,452 $458,167 $3,896,957 $901,287 $910,417 
(1) Development stage royalties include: direct R&D funding arrangements and funding arrangements executed through our joint venture partnership with the Avillion Entities, investments in development-stage product candidates, and investments in securities primarily made in connection with acquisitions of royalties on development stage products from the seller.
(2) In 2014, acquisitions of development-stage royalties included $3.3 billion for the acquisition of royalties on the cystic fibrosis franchise. At the time of the investment, Kalydeco was the only approved product in the franchise, while the vast majority of the value of our investment was tied to development-stage product candidates.

73

Summary of royalty acquisition activity

•In January 2022, we acquired a royalty interest in aficamten from Cytokinetics, Incorporated (“Cytokinetics”) for $150.0 million comprised of an upfront payment of $50 million and two additional $50 million payments, conditional upon the initiation of potential pivotal clinical trials for oHCM and nonobstructive hypertrophic cardiomyopathy, respectively. Additionally, we will provide Cytokinetics long-term capital of up to $300 million (“Cytokinetics Commercial Launch Funding”) to support potential commercialization of omecamtiv mecarbil and further development of aficamten. The Cytokinetics Commercial Launch Funding is available in five tranches, including an initial tranche of $50 million funded upon closing and four additional tranches in the aggregate amount of $250 million to be funded upon the occurrence of certain regulatory and clinical development milestones.

•In November 2021, we acquired incremental royalty interests in BCX9930 and Orladeyo (berotralstat) from BioCryst for an upfront cash payment of $150 million. Additionally, we paid $50 million to purchase 3,846 thousand shares of common stock in BioCryst, which was calculated based on the volume-weighted average price of BioCryst common stock over a period preceding the closing of the transaction. The funds from this transaction will enable further advancement of BCX9930 and support additional investment in the global launch of Orladeyo (berotralstat).

•In June 2021, we announced a long-term strategic funding partnership with MorphoSys AG (“MorphoSys”) to support MorphoSys’ acquisition of Constellation Pharmaceuticals, Inc. (“Constellation”), which closed on July 15, 2021. We agreed to provide up to $2.025 billion of funding to MorphoSys, comprised of an upfront payment of $1.425 billion, additional milestone payments of up to $150 million, up to $350 million of capital (“Development Funding Bonds”), which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150 million of Development Funding Bonds. In connection with the closing of MorphoSys’ acquisition of Constellation, we purchased 1,337,552 ordinary shares of MorphoSys for $100 million at a price of €63.35 per ordinary share, based on the average trading price of the ordinary shares over a period preceding the closing of the acquisition.

•In April 2021, we acquired a royalty interest in Oxlumo from Dicerna Pharmaceuticals, Inc. for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. Oxlumo, which has been approved by the FDA and EMA for the treatment of primary hyperoxaluria (PH) type 1, is marketed by Alnylam.

•In March 2021, we acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GSK for an upfront payment of $342 million and up to $50 million in additional payments contingent on the achievement of regulatory approvals of cabozantinib for prostate cancer and lung cancer in the United States and Europe.

•In January 2021, we acquired a royalty interest in seltorexant from Minerva Neurosciences, Inc. for an upfront payment of $60 million and up to $95 million in additional milestone payments, contingent on the achievement of certain clinical, regulatory and commercialization milestones. Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder (MDD) with insomnia symptoms by Johnson & Johnson.

•In December 2020, we acquired royalty interests from BioCryst on (1) Orladeyo (berotralstat) to support the launch of the product in hereditary angioedema (HAE) and (2) its development stage Factor D inhibitor BCX9930 in exchange for an upfront cash payment of $125 million.

•In October 2020, we acquired the residual royalty interest in Vertex’s cystic fibrosis franchise owned by the Cystic Fibrosis Foundation. The agreement includes an upfront payment of $575 million and a potential milestone payment of $75 million.

74

•In August 2020, we entered into an expanded agreement with Biohaven for up to $450 million to fund the development of zavegepant and the commercialization of Nurtec ODT. Biohaven received an upfront payment of $150 million at closing and received an additional $100 million payment in March 2021 upon the start of the oral zavegepant Phase 3 program. We will receive a royalty on Nurtec ODT and zavegepant and success-based milestone payments based on zavegepant regulatory approvals. We are also committed to provide further support for the ongoing launch of Nurtec ODT through the purchase of committed, non-contingent Commercial Launch Preferred Equity (defined below) for a total of $200 million payable on a quarterly basis from the three months ended March 31, 2021 through the three months ended December 31, 2024. In return, Biohaven will pay a series of equal fixed payments from the three months ended March 31, 2025 through the three months ended December 31, 2030.

•In July 2020, we acquired a royalty on risdiplam, a development-stage product for the treatment of Types 1, 2 and 3 spinal muscular atrophy (SMA) from PTC Therapeutics, Inc. in exchange for an upfront payment of $650 million. Evrysdi (risdiplam) was subsequently approved by the FDA in August 2020, representing the first, oral treatment approved for infants, children and adults with all SMA types.

•In June 2020, we acquired a royalty on (1) Prevymis, an approved product to prevent cytomegalovirus infection in stem cell transplants, from AiCuris Anti-infective Cures GmbH in exchange for an upfront payment of $220 million and (2) IDHIFA, an approved product for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 mutation, from Agios Pharmaceuticals, Inc. in exchange for an upfront payment of $255 million.

•In March 2020, we acquired a royalty on Entyvio, an approved product for the treatment of ulcerative colitis and Crohn’s disease, from The General Hospital Corporation in exchange for an upfront payment of $86.6 million.

•In the fourth quarter of 2019, we agreed to pay $320 million to acquire from Ultragenyx Pharmaceutical, Inc. a royalty on the European sales of Crysvita, an approved product for the treatment of x-linked hypophosphatemia, a rare genetic orphan disease that has a profound impact on bone development in adults and children, subject to certain caps.

•In the fourth quarter of 2019, we agreed to pay up to $330 million to purchase a royalty owned by Eisai, on future worldwide sales outside Japan of Tazverik (tazemetostat), a novel targeted therapy in late-stage clinical development with the potential to be approved in several cancer indications. We acquired a portion Eisai’s future worldwide royalties on net sales by Epizyme of Tazverik outside Japan, for an upfront payment of $110 million plus up to an additional $220 million for the remainder of the royalty upon FDA approval of Tazverik for certain indications. The FDA approved Tazverik in January 2020 for epithelioid sarcoma which triggered our obligation to fund the second $110 million tranche in November 2020. In June 2020, the FDA approval of additional indications triggered our recognition of a liability for the final tranche of $110.0 million, which was paid in November 2021.

•In the fourth quarter of 2019, we made a $100 million investment in Epizyme. In exchange for an upfront payment of $100 million, we received (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5 million shares of Epizyme common stock at $20 per share over a three-year term and (3) Epizyme’s royalty on sales of Tazverik in Japan payable by Eisai. We also lowered Epizyme’s royalty on Tazverik above certain sales thresholds and granted Epizyme an 18-month put option to sell an additional $50 million of its common stock to RPIFT at then-prevailing prices, not to exceed $20 per share. Epizyme exercised its put option on December 30, 2019, which resulted in Epizyme issuing RPIFT 2.5 million shares on settlement in February 2020.

•In the first quarter of 2019, we entered into a preferred share purchase agreement with Biohaven through which we purchased $125 million in Series A Preferred Shares, providing us with a fixed return on redemption of two times our investment on FDA approval of Biohaven’s pipeline product, Nurtec ODT, for migraine treatment. The FDA approved Nurtec ODT for the acute treatment of migraine in adults in February 2020.

75

•In the first quarter of 2019, we acquired the following: (1) a royalty on Promacta, an approved product for the treatment of chronic immune thrombocytopenia and aplastic anemia, from Ligand Pharmaceuticals in exchange for an upfront payment of $827 million, (2) a royalty on Lilly’s Emgality, an approved product for the treatment of migraine, from Atlas Ventures and Orbimed for $260 million and (3) a royalty on Johnson & Johnson’s Erleada, an approved product for the treatment of prostate cancer, from the Regents of the University of California for $105.4 million and potential future milestones.

Additionally, in April 2021, we entered into an agreement with MSCI Inc. (“MSCI”), a leading provider of critical decision support tools and services where we will assist MSCI to design a classification framework and index methodologies which will expand MSCI’s thematic index suite with the launch of new indexes. In return, we will receive a portion of MSCI’s revenues from those indexes. The financial statement impact associated with this transaction was not material for the year ended December 31, 2021.

Liquidity and Capital Resources

Overview

Our primary source of liquidity is cash provided by operations. For the years ended December 31, 2021, 2020 and 2019, we generated $2.0 billion, $2.0 billion and $1.7 billion, respectively, in Net cash provided by operating activities. We believe that our existing capital resources, cash provided by operating activities and our Revolving Credit Facility will continue to allow us to meet our operating and working capital requirements, to fund planned strategic acquisitions and R&D funding arrangements, and to meet our debt service obligations for the foreseeable future. We have historically operated at a low level of fixed operating costs. Our primary cash operating expenses, other than R&D funding commitments, include interest expense, our Operating and Personnel Payments, and legal and professional fees.

We have access to substantial sources of funds in the capital markets and we may, from time to time, seek additional capital through a combination of additional debt or equity financings. In June 2020, we completed our IPO and received net proceeds of approximately $1.9 billion from the IPO after deducting underwriting discounts and commissions of approximately $86.3 million. In February 2020, in connection with the Exchange Offer Transactions, we repaid outstanding debt held by RPIFT in full and issued new long-term debt at RPI Intermediate FT. In September 2020, we repaid in full our senior secured credit facilities entered into in February 2020 using the proceeds of the 2020 Notes in addition to cash on hand. In July 2021, we issued an additional $1.3 billion of senior unsecured notes. Additionally, we have a Revolving Credit Facility which provides for borrowing capacity of up to $1.5 billion that remains undrawn and available to us as of December 31, 2021. As of December 31, 2021 and 2020, we had total long-term debt outstanding of $7.1 billion and $5.8 billion, respectively.
We have historically funded our acquisition program through free cash flow, equity contributions and debt. Our low operating costs coupled with a lack of capital expenditures and low taxes have contributed to our strong financial profile, resulting in high operating leverage and high conversion of our Adjusted Cash Receipts to Adjusted Cash Flow. We expect to continue funding our current and planned operating costs (excluding acquisitions) principally through our cash flow from operations and our acquisition program through cash flow and issuances of equity and debt. In the past, we have supplemented our available cash and cash equivalents on hand with attractive debt capital to fund certain strategic acquisitions.

Our ability to satisfy our working capital needs, debt service and other obligations, and to comply with the financial covenants under our financing agreements depends on our future operating performance and cash flow, which are in turn subject to prevailing economic conditions and other factors, many of which are beyond our control.

Cash flows

The following table and analysis of cash flow changes presents a summary of our cash flow activity for the year ended December 31, 2021 compared to the year ended December 31, 2020. For a discussion of the year ended December 31, 2020 compared to the year ended December 31, 2019, please refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

76

(in thousands)Years Ended December 31,2021 vs 2020
20212020Change
Cash provided by (used in):
     Operating activities$2,017,536 $2,034,629 $(17,093)
     Investing activities$(1,870,280)$(2,759,320)$889,040 
     Financing activities$385,112 $1,487,172 $(1,102,060)

Analysis of Cash Flow Changes

Operating activities

Years ended December 31, 2021 and 2020

Cash provided by operating activities decreased by $17.1 million in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by an increase of $187.4 million in upfront R&D funding and an increase of $27.2 million in interest paid. The increase was driven by upfront R&D funding payments of $103.2 million related to an additional royalty on a development-stage product acquired in connection with our expanded funding agreement with BioCryst and $90.0 million related royalties on two development-stage products acquired from MorphoSys. The increase in interest paid was primarily due to the shift from quarterly to semi-annual interest payments with the issuance of the 2020 Notes, for which we did not make any interest payments on the 2020 Notes in the year ended December 31, 2020. The higher uses of cash were partially offset by an increase in cash collections from financial royalty assets of $193.9 million.

Investing activities

Years ended December 31, 2021 and 2020

Cash used in investing activities decreased by $889.0 million in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by a $1.3 billion increase in the overall net cash provided by marketable securities which was partially offset by a decrease of $268.9 million in proceeds from equity securities. We received $116.0 million related to the sale of our Cytokinetics common stock and a portion of our Biohaven common shares in the year ended December 31, 2021, as compared to $384.8 million received from the full redemption of our investment in Immunomedics common stock upon its acquisition by Gilead in the fourth quarter of 2020. The decrease in cash used in investing activities was further offset by an increase of $85.1 million in purchases of equity securities. We purchased $135.1 million of equity securities in Morphosys and BioCryst in the year ended December 31, 2021, compared to purchases of equity securities of $50.0 million related to the exercise of the Epizyme put option in the year ended December 31, 2020.

Financing activities

Years ended December 31, 2021 and 2020

Cash provided by financing activities decreased by $1.1 billion in the year ended December 31, 2021 compared to the year ended December 31, 2020, primarily driven by the $1.9 billion net proceeds received from our IPO in June 2020. Offsetting the decreases in cash provided by financing activities were net proceeds of $1.3 billion from issuance of 2021 Notes in the year ended December 31, 2021 compared to the net proceeds of $727.9 million related to the debt refinancings in the year ended December 31, 2020.
77


Sources of Capital

As of December 31, 2021, our cash and cash equivalents and marketable securities totaled $1.5 billion and $581.9 million, respectively. As of December 31, 2020, our cash and cash equivalents and marketable securities totaled $1.0 billion and $983.3 million, respectively. We intend to fund short-term and long-term financial obligations as they mature through cash and cash equivalents, sales of marketable securities, future cash flows from operations or the issuance of additional debt. Our ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the sales of the underlying pharmaceutical products in which we hold royalties, deterioration in our key financial ratios or credit ratings, or other material unfavorable changes in business conditions. Currently, we believe that we have sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support our growth objectives.

Borrowings

Our borrowings at December 31, 2021 and 2020 consisted of the following (in thousands):

Date of IssuanceMaturityDecember 31, 2021December 31, 2020
Senior Unsecured Notes:
$1,000,000, 0.75% (issued at 99.322% of par)9/20209/2023$1,000,000 $1,000,000 
$1,000,000, 1.20% (issued at 98.875% of par)9/20209/20251,000,000 1,000,000 
$1,000,000, 1.75% (issued at 98.284% of par)9/20209/20271,000,000 1,000,000 
$1,000,000, 2.20% (issued at 97.760% of par)9/20209/20301,000,000 1,000,000 
$600,000, 2.15% (issued at 98.263% of par)7/20219/2031600,000 — 
$1,000,000, 3.30% (issued at 95.556% of par)9/20209/20401,000,000 1,000,000 
$1,000,000, 3.55% (issued at 95.306% of par)9/20209/20501,000,000 1,000,000 
$700,000, 3.35% (issued at 97.565% of par)7/20219/2051700,000 — 
Total senior unsecured debt7,300,000 6,000,000 
Unamortized debt discount and issuance costs(203,930)(183,416)
Total long-term debt$7,096,070 $5,816,584 

Senior Unsecured Notes

On July 26, 2021, we issued $1.3 billion of the 2021 Notes with a weighted average coupon rate of 2.80% and requiring annual interest payments of approximately $36.4 million, paid semi-annually. On September 2, 2020, we issued $6.0 billion of the 2020 Notes with a weighted average coupon rate of 2.125% and requiring annual interest payments of approximately $127.5 million, paid semi-annually. We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the senior secured credit facilities. Indentures governing the Notes contain certain covenants, which we were in compliance with as of December 31, 2021.

Senior Unsecured Revolving Credit Facility

On September 15, 2021, we entered into an amended and restated revolving credit agreement (the “Credit Agreement”). The Credit Agreement amends and restates the credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured Revolving Credit Facility with borrowing capacity of up to $1.5 billion for general corporate purposes. The Credit Agreement extends the maturity of the Revolving Credit Facility to September 15, 2026. The Credit Agreement contains certain customary covenants, which we were in compliance as of December 31, 2021. The Revolving Credit Facility remains undrawn and available to us as of December 31, 2021.

78

Senior Secured Credit Facilities

On February 11, 2020, in connection with the Exchange Offer Transactions and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. In September 2020, we repaid in full the outstanding principal amounts of term loans under the senior secured credit facilities with the net proceeds from the 2020 Notes and available cash on hand.

RPIFT Senior Secured Credit Facilities

The RPIFT Senior Secured Credit Facilities were repaid in full in February 2020 and new senior secured credit facilities were issued by RPI Intermediate FT in connection with the Exchange Offer Transactions.

Uses of Capital

Acquisitions of royalties

We acquire product royalties in a variety of ways that can be tailored to the needs of our partners. We classify our product royalty acquisitions by the following structures:

•Third-party Royalties – A royalty is the contractual right to a percentage of top-line sales from a licensee’s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties.

•Synthetic / Hybrid Royalties – A synthetic royalty is the contractual right to a percentage of top-line sales created by the developer and/or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone payments, or be structured as a long-term stream of fixed-payments with a predetermined schedule. In many of our synthetic royalties, we also make investments in the public equity of the company, where the main value driver of the company is the product for which we concurrently acquired a royalty.

•R&D Funding – We have historically funded ongoing R&D, typically for large biopharmaceutical companies, in exchange for future royalties and/or milestones if the product or indication we are funding is approved. We have also made upfront R&D payments to biotechnology companies to acquire royalties and/or milestones on development-stage product candidates.

•M&A – We acquire royalties in connection with M&A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.

Distributions to Shareholders/Unitholders

We paid dividends to holders of our Class A ordinary shares of $285.2 million in the year ended December 31, 2021. We do not have a legal obligation to pay a quarterly dividend or dividends at any specified rate or at all.

We made distributions of $285.4 million to shareholders/unitholders prior to the IPO in June 2020. We paid dividends to holders of our Class A ordinary shares of $112.5 million in the year ended December 31, 2020 subsequent to the IPO.

We made distributions of $739.3 million to unitholders in the year ended December 31, 2019.

79

Other Funding Arrangements

In June 2021, we announced a long-term strategic funding partnership with MorphoSys to support MorphoSys’ acquisition of Constellation, which closed on July 15, 2021. As part of the partnership, we agreed to provide MorphoSys up to $350 million of Development Funding Bonds, which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150 million of Development Funding Bonds. In return, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds.

On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”), for a total of $200.0 million payable on a quarterly basis from the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began purchasing the Series B Biohaven Preferred Shares and have a remaining commitment of $129.6 million under our Commercial Launch Preferred Equity as of December 31, 2021.

We have other funding arrangements where we are contractually obligated to fund R&D activities performed by our development partners and to provide additional capital related to our equity method investment in the Avillion entities. As our committed capital requirements are based on phases of development, the completion of which is highly uncertain, only the capital required to fund the current stage of development under such funding arrangements is considered committed capital requirements which approximate $41.0 million as of December 31, 2021.

We also have certain milestone payments that are contingent on the successful achievement of certain development, regulatory approval or commercial milestones. As such, these contingent milestone payments are not considered contractual obligations. In the year ended December 31, 2021, we made a $100.0 million payment to Biohaven related to a development milestone that was achieved upon the start of the oral zavegepant Phase 3 program.

Debt service

As of December 31, 2021, the future principal and interest payments under our Notes over the next five years and thereafter are as follows:

(in thousands)Principal PaymentsInterest Payments
Year
2022$— $167,384 
20231,000,000 163,850 
2024— 156,350 
20251,000,000 156,350 
2026— 144,350 
Thereafter5,300,000 2,070,250 
Total (1)$7,300,000 $2,858,534 
(1) Excludes unamortized debt discount and issuance costs of $203.9 million as of December 31, 2021, which are amortized through interest expense over the remaining life of the underlying debt obligations.

80

Operating and Personnel Payments

Under the Management Agreement, we pay quarterly Operating and Personnel Payments equal to 6.5% of the Adjusted Cash Receipts for such quarter and 0.25% of our security investments under GAAP as of the end of each quarter. Because the Operating and Personnel Payments is determined based on Adjusted Cash Receipts, the amounts are fixed. The expenses incurred in respect of Operating and Personnel Payments are expected to comprise the most significant component of G&A expenses on an ongoing basis.

Guarantor Financial Information

Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary (the “Guarantor Subsidiary”). Our remaining subsidiaries (the “Non-Guarantor Subsidiaries”) do not guarantee the Notes. Under the terms of the indenture governing the Notes, Royalty Pharma plc and the Guarantor Subsidiary each fully and unconditionally, jointly and severally, guarantee the payment of interest, principal and premium, if any, on the Notes. As of December 31, 2021, the par value and carrying value of the total outstanding and guaranteed Notes was $7.3 billion and $7.1 billion, respectively.

The following financial information presents summarized combined balance sheet financial information as of December 31, 2021, and summarized combined statement of operations information for the year ended December 31, 2021 for Royalty Pharma plc and RP Holdings. All intercompany balances and transactions between Royalty Pharma plc and RP Holdings are eliminated in the presentation of the combined financial statements. RP Holdings’ most significant asset is its investment in operating subsidiaries, which has been eliminated in the table below to exclude investments in Non-Guarantor Subsidiaries. Our operating subsidiaries hold the majority of our cash and cash equivalents, marketable securities and financial royalty assets. As a result, our ability to make required payments on the Notes depends on the performance of our operating subsidiaries and their ability to distribute funds to us. There are no material restrictions on distributions from the operating subsidiaries. Amounts presented below do not represent our total consolidated amounts as of December 31, 2021 or for the year ended December 31, 2021.

Summarized Combined Balance Sheet
(in thousands)As of December 31, 2021
Current assets$95,946 
Current interest receivable on intercompany notes due from Non-Guarantor Subsidiaries16,974 
Non-current assets 4,145 
Non-current intercompany notes receivable due from Non-Guarantor Subsidiaries2,039,576 
Current liabilities59,030 
Current interest payable on intercompany notes due to Non-Guarantor Subsidiaries16,974 
Non-current liabilities7,095,450 
Non-current intercompany notes payable due to Non-Guarantor Subsidiaries2,039,576 

Summarized Combined Statement of Operations
(in thousands)Year Ended December 31, 2021
Interest income on intercompany notes receivable from Non-Guarantor Subsidiaries$50,423 
Operating expenses187,863 
Interest expense on intercompany notes payable with Non-Guarantor Subsidiaries50,423 
Other expenses11,320 
Net loss 199,183 


81

Critical Accounting Policies and Use of Estimates

The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses. Certain of these policies are considered critical as they have the most significant impact on our financial condition and results of operations and require the most difficult, subjective, or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain. On an ongoing basis, we evaluate our estimates that are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The result of these evaluations forms the basis for making judgments about the carrying values of assets and liabilities and the reported amount of income and expenses that are not readily apparent from other sources. Because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

Our most critical accounting policies relate to our financial royalty assets and the full descriptions can be found in Note 2–Summary of Significant Accounting Policies to our consolidated financial statements. Similarly, the most significant judgments and estimates applied by management are associated with the measurement of our financial royalty assets at amortized cost using the prospective effective interest method. The application of the prospective approach to calculate interest income from our financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties. These estimates and judgments arise because of the inherent uncertainty in predicting future events.

We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate for the current period is lower than the prior period, and if the gross cash flows have declined (expected and collected), management records a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset’s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period’s effective interest rate. The amount recognized as provision expense increases the financial royalty asset’s cumulative allowance, which reduces the net carrying value of the financial royalty asset.

Factors Impacting Expected Future Cash Flows

The amounts and timing of forecasted expected future cash flows are largely influenced by sell-side equity research analyst coverage, commercial performance of the product and the royalty duration.

•Analyst coverage. Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts’ consensus sales forecasts for a product to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst estimates are not available for the full term of the royalty, particularly for the later years in a product’s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management’s own expertise.

•Commercial performance. The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts’ forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product’s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.

82

•Royalty duration. The duration of a financial royalty asset can be based on a number of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, strength of patent protection, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product’s life cycle at which we acquire the financial royalty asset. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term.

Significant Assumptions Applied in Developing Forecasted Expected Future Cash Flows

The most significant assumptions used in forecasting the expected future cash flows for our royalties and requiring management’s judgement include (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, and (2) sales trends and product growth rates in outer years of the royalty term, which are primarily based on statistical models.

The royalty duration is important for purposes of accurately measuring interest income over the life of a financial royalty asset. In making assumptions around the royalty duration for terms that are not contractually fixed, management considers the strength of existing patent protection, expected entry of generics, geographical exclusivity periods and potential patent term extensions tied to the underlying product. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing for the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles, and industry consolidations.

When royalty-bearing pharmaceutical products have limited or no coverage by sell-side equity research analysts, or where sell-side equity research analyst estimates are not available for the full term of our royalty, particularly for the later years in a product’s life, we generally incorporate a statistical curve developed using historical sales data and available consensus sales projections to forecast product sales over the remaining life of the product. In cases where the statistical curve is not used, we use reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, publicly available information for the marketer, industry data and market trends and our own expertise.

Even though we believe interest income from financial royalty assets and the associated non-cash provision for changes in future cash flows are not indicative of our near-term financial performance and should not be used as a source for predicting future income or growth trends, changes in the aforementioned assumptions could result in a material impact to our financial statements. A shortened royalty term can result in a reduction in interest income, significant reductions in total royalty payments over time compared to expectations or a permanent impairment. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected) this would result in the immediate recognition of non-cash provision expense even though the applicable cash inflows will not be realized for many years into the future. Changes in sell-side equity research analyst consensus sales forecasts directly impact future interest income and recognition of any provision income or expense in a similar manner.

Below is a summary of the sensitivity of our current year results in relation to the royalty duration for our top three financial royalty assets based on net carrying value as of December 31, 2021. Because these are long-dated financial royalty assets, we have assumed a change of two years in the estimated duration to sensitize the financial statement impact. The effect of a change in estimated duration is the factor that would have the most significant impact on our consolidated statement of operations. There have not been any significant changes to the estimated duration of expected future cash flows for our top three financial royalty assets during the years ended December 31, 2021, 2020 and 2019, with the exception of the cystic fibrosis franchise due to the FDA approval of Trikafta in 2019, which extended the expected duration at that time.

83

If the duration of these financial royalty assets were extended by two years by assuming the statistically projected growth trends continue and all other royalty terms and assumptions remain unchanged, any impact to interest income would not be reflected until the subsequent period and is therefore not disclosed below. However, an extended duration for a financial royalty asset could result in the reduction of any cumulative allowance for changes in expected future cash flows, which would be recognized in the current period as provision income and is reflected in the table below for these top three financial royalty assets. If the duration for these financial royalty assets were shortened by two years by eliminating the estimated expected future cash flows for the final two years while keeping all other royalty terms and assumptions unchanged, we would recognize immediate incremental provision expense in the current period as a result of applying the prospective method of the effective interest rate methodology. The disclosure of the duration sensitivity below does not include any consideration of the related allowance for current expected credit losses. The impact of these sensitivity assumptions is summarized as follows (in thousands):
Year Ended December 31, 2021
Estimated Royalty Duration (a)Change in Duration Assumption Applied Provision (Income)/Expense for Changes in Expected Cash Flows
Cystic fibrosis franchise2037 (b) +/- 2 years$(48,636)$261,265 
Tysabri(c) +/- 2 years $(16,617)$173,098 
Imbruvica2027-2032 +/- 2 years $(99,398)$173,129 
(a)Dates shown represent our estimates as of the date of this Annual Report on Form 10-K of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, our estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(b)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of generic entry.
(c)Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.

Recent Accounting Pronouncements

See Note 2–Summary of Significant Accounting Policies to our consolidated financial statements for additional information on recently issued accounting standards.

Item 7A.     QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market Risk

We are subject to certain risks which may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates and interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the nature of the marketable securities we hold. In order to manage our exposures, we follow established risk management policies and procedures, including the use of derivative financial instruments, such as swaps, rate locks and forwards. We do not enter into derivative instruments for trading or speculative purposes. The counterparties to these contracts are all major financial institutions.

Foreign Currency Exchange Risk

Our results of operations are subject to foreign currency exchange risk through transactional exposure resulting from movements in exchange rates between the time we recognize royalty income or royalty revenue and the time at which the transaction settles, or we receive the royalty payment. The current portion of Financial royalty assets, net and Accrued royalty receivable account for the most common types of transactional exposure. Because we are entitled to royalties on worldwide sales for various products, there is an underlying exposure to foreign currency as the marketer converts payment amounts from local currencies to U.S. dollars using a quarterly average exchange rate. Therefore, cash received may differ from the estimated receivable based on fluctuations in currency. In addition, certain products pay royalties in currencies other than U.S. dollars, which also creates foreign currency risk primarily with respect to the Euro, Canadian Dollar, Swiss Franc and Japanese Yen, as our functional and reporting currency is the U.S. dollar. To manage foreign currency exchange risk, we may periodically utilize non-deliverable forward exchange contracts. We do not currently have any foreign exchange contracts in place.

84

Interest Rate Risk

We are subject to interest rate fluctuation exposure through our investments in money market accounts and marketable securities, the majority of which bear a variable interest rate. As of December 31, 2021, we held cash and cash equivalents of $1.5 billion, of which $887.8 million was cash, $598.3 million was invested in interest-bearing money market funds and $55.0 million was invested in commercial paper and certificates of deposit. We also held $581.9 million in marketable securities at December 31, 2021 which was invested in commercial paper and certificates of deposit.

As of December 31, 2020, we had cash and cash equivalents of $1.0 billion, of which $832.7 million was cash, $151.7 million was invested in commercial paper and certificates of deposit and $24.3 million was invested in interest-bearing money market funds. In addition, as of December 31, 2020, we had $983.3 million in marketable securities which was invested in corporate debt securities, commercial paper and certificates of deposit.
The objectives of our investment policy are the preservation of capital and fulfillment of liquidity needs. In order to maximize income without assuming significant market risk, we maintain our excess cash and cash equivalents in money market funds and marketable securities, largely composed of investment grade, short to intermediate term fixed income and debt securities. Because of the short term maturities of our cash equivalents and the short term nature of our marketable securities, we do not believe that a decrease in interest rates would have any material negative impact on the fair value of our cash equivalents or marketable securities.

Our debt portfolio is managed on a consolidated basis and management makes financing decisions to achieve the lowest cost of debt capital and to maximize portfolio objectives. As of December 31, 2021, 100% of our outstanding debt has fixed interest rates. We have a $1.5 billion Revolving Credit Facility with a variable interest rate that remained undrawn as of December 31, 2021. We are subject to interest rate fluctuation exposure related to the Revolving Credit Facility, if drawn.

We may manage our exposure to interest rate volatility on future debt issuances by entering into treasury rate lock contracts to lock in the rate on the interest payments related to anticipated debt issuances. In June 2021, we executed treasury rate lock contracts with notional amounts totaling $600.0 million to fix the interest rate on a portion of the principal related to our 2021 Notes issued in July 2021. The treasury lock contracts were terminated in July 2021.

Credit and Counterparty Risk

We are exposed to credit risk related to the counterparties with which we do business. We are subject to credit risk from our royalty assets, our receivables and our derivative financial instruments. The majority of our royalty assets and receivables arise from contractual royalty agreements that pay royalties on the sales of underlying pharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading biopharmaceutical industry participants, including, among others, AbbVie, Amgen, Bristol Myers Squibb, Gilead, Johnson & Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche/Genentech and Vertex. For the years ended December 31, 2021 and 2020, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32% and 27% of our current portion of Financial royalty assets, net, respectively, representing the largest individual marketer and payor of our royalties. Refer to “—Understanding Our Results of Operations” within this MD&A for a discussion of the marketers or royalty payors accounting for 10% or more of our total income and other revenues for the years ended December 31, 2021 and 2020.

We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements and to our derivative financial instruments so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets or on the settlement of our derivative financial instruments. If a counterparty becomes bankrupt, or otherwise fails to perform its obligations under a derivative financial instruments due to financial difficulties, we may experience significant delays in obtaining any recovery under the derivative financial instruments in a bankruptcy or other reorganization proceeding.

85

Item 8.         Financial Statements and Supplementary Data

ROYALTY PHARMA PLC
Index to Audited Consolidated Financial Statements



86

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Royalty Pharma plc

Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Royalty Pharma plc (the “Company”) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income, shareholders' equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 15, 2022 expressed an unqualified opinion thereon.

Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.


87

Valuation of Financial Royalty Assets and related Interest Income
Description of the Matter
As disclosed in Note 6 to the consolidated financial statements, the Company’s total financial royalty assets, net, were carried at $14,332,596 thousand as of December 31, 2021. For the year ended December 31, 2021, the Company recognized income from financial royalty assets of $2,065,083 thousand. As explained in Note 2 to the consolidated financial statements, the Company’s financial royalty assets are measured at amortized cost using the prospective effective interest rate method.
Auditing the valuation of the financial royalty assets and related interest income involved complex auditor judgment, because the assumptions used by management to forecast the expected cash flows from the underlying royalties are forward-looking and are therefore affected by future economic and market conditions, such as the impact of the entry of competing or generic products to the market, among other uncertainties. The key assumptions used in the valuation of the financial royalty assets and related interest income are product growth rates applied to forecasted sales in the later years in the royalty life and the royalty duration.
How We Addressed the Matter in Our Audit
To test the valuation of the financial royalty assets and related interest income, our audit procedures included, among others, evaluating the methodology and completeness and accuracy of the data used to develop the key assumptions identified above. For example, with the support of statistical modelling specialists, we evaluated management’s statistical methodology for sales growth forecasts and performed sensitivity analysis over the resulting forecasted product sales. We also tested the inputs to the model, principally comprising historic product sales and third-party analyst estimates of nearer-term sales amounts, by comparing to analyst reports or published sales information. For royalty duration, among other procedures, we compared management’s assessment of the likely date of expiry of the Company’s cash flows against original purchase agreements, as well as independently assessing the royalty duration against available published information sources, such as those from regulatory bodies, counterparties, and product marketers.
We assessed the historical accuracy of management’s estimates by comparing expected cash flows to actual cash receipts. We also evaluated the related disclosures in the consolidated financial statements.

/s/ Ernst & Young

We have served as the Company’s auditor since 2003.

Dublin, Ireland
February 15, 2022




















88

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Royalty Pharma plc

Opinion on Internal Control Over Financial Reporting
We have audited Royalty Pharma plc’s (the Company) internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income, shareholders' equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated February 15, 2022 expressed an unqualified opinion thereon.

Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young

Dublin, Ireland
February 15, 2022
89



ROYALTY PHARMA PLC
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
As of December 31,
20212020
Assets
Current assets
Cash and cash equivalents$1,541,048 $1,008,680 
Marketable securities581,872 983,279 
Financial royalty assets614,351 587,193 
Accrued royalty receivable53,286 33,155 
Available for sale debt securities66,000 69,984 
Other royalty income receivable15,023 6,011 
Other current assets6,631 8,596 
Total current assets2,878,211 2,696,898 
Financial royalty assets, net13,718,245 12,368,084 
Intangible royalty assets, net5,670 28,666 
Equity securities269,800 298,689 
Available for sale debt securities204,400 163,016 
Investments in non-consolidated affiliates435,394 454,936 
Other assets4,145 9,997 
Total assets$17,515,865 $16,020,286 
Liabilities and equity
Current liabilities
Distribution payable to non-controlling interest$107,934 $126,366 
Accounts payable and accrued expenses5,620 10,775 
Interest payable57,696 42,146 
Accrued purchase obligation— 110,000 
Other current liabilities— 18,600 
Total current liabilities171,250 307,887 
Long-term debt7,096,070 5,816,584 
Total liabilities7,267,320 6,124,471 
Commitments and contingencies
Shareholders’ equity
Class A ordinary shares, $0.0001 par value; 432,963 and 388,135 issued and outstanding, respectively
43 39 
Class B ordinary shares, $0.000001 par value; 174,213 and 218,976 issued and outstanding, respectively
— — 
Class R redeemable shares, £1 par value; 50 and 50 issued and outstanding, respectively
63 63 
Deferred shares, $0.000001 par value, 361,170 and 316,407 issued and outstanding, respectively
— — 
Additional paid-in capital3,507,533 2,865,964 
Retained earnings2,255,179 1,920,635 
Non-controlling interest4,471,951 5,077,036 
Accumulated other comprehensive income16,491 34,395 
Treasury interests(2,715)(2,317)
Total shareholders’ equity10,248,545 9,895,815 
Total liabilities and shareholders’ equity$17,515,865 $16,020,286 
See accompanying notes to these consolidated financial statements.
90



ROYALTY PHARMA PLC
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
Years Ended December 31,
202120202019
Total income and revenues
Income from financial royalty assets$2,065,083 $1,959,975 $1,648,837 
Revenue from intangible royalty assets171,248 143,382 145,775 
Other royalty income53,132 18,996 19,642 
Total income and other revenues2,289,463 2,122,353 1,814,254 
Operating expenses
Provision for changes in expected cash flows from financial royalty assets452,842 230,839 (1,019,321)
Research and development funding expense200,084 26,289 83,036 
Amortization of intangible assets22,996 23,058 23,924 
General and administrative expenses182,826 181,715 103,439 
Other operating expenses— 65,053 — 
Total operating expenses/(income), net858,748 526,954 (808,922)
Operating income1,430,715 1,595,399 2,623,176 
Other expense/(income)
Equity in losses/(earnings) of non-consolidated affiliates19,490 (44,459)32,517 
Interest expense166,142 157,059 268,573 
Losses on derivative financial instruments21,532 42,076 39,138 
Losses/(gains) on equity securities48,066 (247,073)(155,749)
Unrealized gains on available for sale debt securities(17,859)(18,600)— 
Interest income(53,535)(28,379)(22,329)
Other non-operating expense/(income), net5,678 32,821 (393)
Total other expense/(income), net189,514 (106,555)161,757 
Consolidated net income before tax1,241,201 1,701,954 2,461,419 
Income tax expense— — — 
Consolidated net income1,241,201 1,701,954 2,461,419 
Net income attributable to non-controlling interest621,473 726,914 112,884 
Net income attributable to controlling interest$619,728 $975,040 $2,348,535 
Earnings per Class A ordinary share (1):
     Basic$1.49 $1.32 N/A
     Diluted$1.49 $1.32 N/A
Weighted average Class A ordinary shares outstanding (1):
     Basic414,794 375,444 N/A
     Diluted414,802 375,455 N/A
(1) Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (“IPO”) in the year ended December 31, 2020. See Note 13–Earnings per Share.

See accompanying notes to these consolidated financial statements.
91



ROYALTY PHARMA PLC
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)

Years Ended December 31,
202120202019
Consolidated net income$1,241,201 $1,701,954 $2,461,419 
Changes in other comprehensive income/(loss):
Reclassification of loss on interest rate swaps— 4,066 6,189 
Unrealized gains on available for sale debt securities11,600 83,120 6,159 
Reclassification of unrealized gains on available for sale debt securities(50,896)(20,551)— 
Total other comprehensive (loss)/income$(39,296)$66,635 $12,348 
Comprehensive income$1,201,905 $1,768,589 $2,473,767 
Comprehensive income attributable to non-controlling interest604,323 739,787 112,884 
Comprehensive income attributable to controlling interest$597,582 $1,028,802 $2,360,883 

See accompanying notes to these consolidated financial statements.
92

ROYALTY PHARMA PLC
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(In thousands)
Class A
Ordinary Shares		Class B
Ordinary Shares		Class R
Redeemable Shares		Deferred SharesAdditional Paid-In CapitalUnitholders’/ Shareholders’ ContributionsRetained EarningsAccumulated Other Comprehensive Income/(Loss)Non-Controlling InterestTreasury InterestsTotal Equity
SharesAmountSharesAmountSharesAmountSharesAmount
Balance at December 31, 2018— $— — $— — $— — $— $— $3,282,516 $1,215,953 $(10,255)$63,865 $— $4,552,079 
Distributions— — — — — — — — — — (739,276)— (140,866)— (880,142)
Net income— — — — — — — — — — 2,348,535 — 112,884 — 2,461,419 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— — — — — — — — — — — 6,159 — — 6,159 
Reclassification of loss on interest rate swaps— — — — — — — — — — — 6,189 — — 6,189 
Purchase of treasury interests— — — — — — — — — — — — — (4,266)(4,266)
Balance at December 31, 2019— $— — $— — $— — $— $— $3,282,516 $2,825,212 $2,093 $35,883 $(4,266)$6,141,438 
Contributions— — — — — — — — — 307,646 — — 1,174,676 — 1,482,322 
Transfer of interests— — — — — — — — — (1,037,161)— — 1,037,161 — — 
Cumulative adjustment for adoption of ASU 2016-13— — — — — — — — — — (192,705)— — — (192,705)
Distributions— — — — — — — — — — (313,408)— (792,357)— (1,105,765)
Initial share issuance upon registration of Royalty Pharma plc— — — — 50 63 — — — — — — — — 63 
Net income prior to IPO— — — — — — — — — — 479,842 — 145,043 — 624,885 
Issuance of Class B ordinary shares to Continuing Investors Partnerships— — 535,383 1 — — — — — — — — — — 1 
Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity294,176 30 (294,176)(1)— — 294,176 — 1,402,762 (2,553,001)(1,261,014)(24,022)2,433,098 2,147 (1)
Issuance of Class A ordinary shares sold in IPO, net of offering costs71,652 7 — — — — — — 1,150,383 — — — 758,354 — 1,908,744 
Share-based compensation and related issuances of Class A ordinary shares76 — — — — — — — 5,428 — — — — — 5,428 
Other exchanges22,231 2 (22,231)— — — 22,231 — 307,391 — — 2,562 (309,566)(198)191 
Dividends ($0.30 per Class A ordinary share)
— — — — — — — — — — (112,490)— — — (112,490)
Net income subsequent to IPO— — — — — — — — — — 495,198— 581,871 — 1,077,069
Other comprehensive income/(loss):
Reclassification of loss on interest rate swaps— — — — — — — — — — — 4,066 — — 4,066
Unrealized gains on available for sale debt securities— — — — — — — — — — — 60,617 22,503 — 83,120
Reclassification of unrealized gains on available for sale debt securities— — — — — — — — — — — (10,921)(9,630)— (20,551)
Balance at December 31, 2020388,135 $39 218,976 $— 50 $63 316,407 $— $2,865,964 $— $1,920,635 $34,395 $5,077,036 $(2,317)$9,895,815 

See accompanying notes to these consolidated financial statements.
93


ROYALTY PHARMA PLC
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(In thousands)
Class A
Ordinary Shares		Class B
Ordinary Shares		Class R
Redeemable Shares		Deferred SharesAdditional Paid-In CapitalShareholders’ ContributionsRetained EarningsAccumulated Other Comprehensive Income/(Loss)Non-Controlling InterestTreasury InterestsTotal Equity
SharesAmountSharesAmountSharesAmountSharesAmount
Balance at December 31, 2020388,135 $39 218,976 $— 50 $63 316,407 $— $2,865,964 $— $1,920,635 $34,395 $5,077,036 $(2,317)$9,895,815 
Contributions— — — — — — — — — — — — 48,539 — 48,539 
Distributions— — — — — — — — — — — — (614,973)— (614,973)
Dividends ($0.68 per Class A ordinary share)
— — — — — — — — — — (285,184)— — — (285,184)
Other exchanges44,763 4 (44,763)— — — 44,763 — 639,126 — — 4,242 (642,974)(398)— 
Share-based compensation and related issuances of Class A ordinary shares65 — — — — — — — 2,443 — — — — — 2,443 
Net income— — — — — — — — — — 619,728 — 621,473 — 1,241,201 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— — — — — — — — — — — 6,335 5,265 — 11,600 
Reclassification of unrealized gains on available for sale debt securities— — — — — — — — — — — (28,481)(22,415)— (50,896)
Balance at December 31, 2021432,963 $43 174,213 $— 50 $63 361,170 $— $3,507,533 $— $2,255,179 $16,491 $4,471,951 $(2,715)$10,248,545 
See accompanying notes to these consolidated financial statements.
94

ROYALTY PHARMA PLC
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Years Ended December 31,
202120202019
Cash flows from operating activities:
Cash collections from financial royalty assets$2,315,854 $2,121,923 $1,934,092 
Cash collections from intangible royalty assets151,158 143,753 143,298 
Other royalty cash collections44,123 18,305 27,448 
Distributions from non-consolidated affiliates34,384 42,334 14,059 
Interest received3,135 7,704 20,136 
Derivative collateral received34,660 45,252 360 
Derivative collateral posted(34,660)— (45,630)
Termination payments on derivative instruments(16,093)(35,448)— 
Ongoing development-stage funding payments(6,876)(20,479)(83,036)
Upfront development-stage funding payments(193,208)(5,810)— 
Payments for operating and professional costs(184,511)(179,709)(88,524)
Interest paid(130,430)(103,196)(254,964)
Net cash provided by operating activities2,017,536 2,034,629 1,667,239 
Cash flows from investing activities:
Distributions from non-consolidated affiliates523 15,084 — 
Investments in non-consolidated affiliates(34,855)(40,155)(27,042)
Purchases of equity securities(135,134)(50,000)(78,999)
Proceeds from equity securities115,957 384,840 — 
Purchases of available for sale debt securities(70,441)— (125,121)
Proceeds from available for sale debt securities62,500 3,000 150,000 
Purchases of marketable securities(1,196,579)(1,705,283)(817,402)
Proceeds from sales and maturities of marketable securities1,597,851 815,440 725,070 
Purchase of warrants— — (8,840)
Acquisitions of financial royalty assets(2,191,502)(2,182,246)(1,721,291)
Milestone payments(18,600)— (250,000)
Net cash used in investing activities(1,870,280)(2,759,320)(2,153,625)
Cash flows from financing activities:
Distributions to shareholders/unitholders— (285,353)(739,276)
Distributions to non-controlling interest(479,604)(543,952)(154,084)
Distributions to non-controlling interest- other(153,800)(181,135)— 
Dividends to shareholders(285,184)(112,490)— 
Contributions from non-controlling interest- R&D7,339 8,482 — 
Contributions from non-controlling interest- other36,874 58,957 — 
Scheduled repayments of long-term debt— (94,200)(294,000)
Repayments of long-term debt— (11,116,196)— 
Proceeds from issuance of long-term debt, net of discount1,272,533 11,891,030 — 
Debt issuance costs and other(13,046)(46,715)— 
Purchase of treasury interests— — (4,266)
Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs— 1,908,744 — 
Net cash provided by/(used in) financing activities385,112 1,487,172 (1,191,626)
Net change in cash and cash equivalents532,368 762,481 (1,678,012)
Cash and cash equivalents, beginning of year1,008,680 246,199 1,924,211 
Cash and cash equivalents, end of year$1,541,048 $1,008,680 $246,199 
See accompanying notes to these consolidated financial statements.
95
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS


1. Organization and Purpose

Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the IPO of our Class A ordinary shares that was completed in June 2020.

Following our IPO, we control Royalty Pharma Holdings Ltd. (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K. tax resident through our ownership of RP Holdings’ Class A ordinary shares (the “RP Holdings Class A Interests”) and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our consolidated financial statements.

RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (“RPI 2019 ICAV”), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (“Old RPI”), for accounting and financial reporting purposes. RP Holdings is owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”), and Royalty Pharma plc. Old RPI is a unit trust established in August 2011 under the laws of Ireland and authorized by the Central Bank of Ireland pursuant to the Unit Trusts Act, 1990. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”).

RP Management, LLC (the “Manager”), a Delaware limited liability company, is an external adviser which is responsible for our management. RP Management (Ireland) Ltd. (“RP Ireland”), is the manager of Old RPI and equivalent to the board of directors of a company or general partner of a partnership and is responsible for the day to day operations of Old RPI. Its functions can be delegated to third parties. RP Ireland delegated responsibility for investment management of Old RPI to its parent company, the Manager, in accordance with the investment objectives and policies of Old RPI.

“Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Reorganization Transactions (defined below) and before the consummation of the IPO, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to RPI 2019 ICAV. Prior to the Reorganization Transactions, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Old RPI.
We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

Reorganization Transactions

In connection with our IPO, we consummated an exchange offer on February 11, 2020 (the “Exchange Date”). Through the exchange offer, investors representing 82% of the aggregate limited partnership in the Legacy Investors Partnerships, exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under our new credit facility and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”

96
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



As a result of the Exchange Offer Transactions, we own, through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”), an 82% economic interest in Old RPI. Through our 82% indirect ownership of Old RPI, we are legally entitled to 82% of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish unit trust. From the Exchange Date until the expiration of the Legacy Investors Partnerships’ investment period on June 30, 2020 (the “Legacy Date”), the Legacy Investors Partnerships were offered to participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Since the Legacy Date, we have made and plan to make new investments through our subsidiaries, including RPI Intermediate FT.

As part of the Exchange Offer Transactions, the Legacy Investors Partnerships and RPI Intermediate FT entered into new credit facilities in the amount of $1.3 billion and $6.0 billion, respectively, the proceeds of which were used to repay the $6.3 billion outstanding debt of RPIFT and, in the case of RPI Intermediate FT, were also available to be used to fund investments. As part of the new credit facilities, RPI Intermediate FT repaid $5.2 billion, its pro rata portion of RPIFT’s outstanding debt and accrued interest. RPIFT also terminated all outstanding interest rate swaps in connection with the debt refinancing.
Prior to, and as a condition precedent to the closing of the IPO, various reorganization transactions became effective, including the following:

•the Exchange Offer Transactions (as described above); and
•the execution of a new management agreement with the Manager (the “Management Agreement”).

We refer to these transactions collectively as the “Reorganization Transactions.”

As Old RPI is our predecessor for financial reporting purposes, we have recorded Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date. The references in the following notes for the periods prior to the Exchange Date refer to the financial results of Old RPI for the same periods.

IPO

On June 18, 2020, we completed our IPO on the Nasdaq Global Select Market under the ticker symbol “RPRX”, in which we issued 89,334 thousand Class A ordinary shares at a price to the public of $28.00 per Class A ordinary share, of which 71,652 thousand Class A ordinary shares and 17,682 thousand Class A ordinary shares were offered by the Company and selling shareholders, respectively. We used the net proceeds from the IPO to acquire RP Holdings Class A Interests and, as a result, we own 100% of RP Holdings Class A Interests.

Upon consummation of the IPO, certain of the Continuing Investors agreed to exchange, pursuant to the Exchange Offer Transactions, interests in the Continuing Investors Partnerships represented by their ownership of 294,176 thousand RP Holdings Class B Interests into an aggregate of 294,176 thousand Class A ordinary shares of Royalty Pharma plc. Upon completion of the exchange, Royalty Pharma plc indirectly owned 294,176 thousand RP Holdings Class B Interests. The remaining investors in the Continuing Investors Partnerships who did not elect to exchange into Class A ordinary shares held 241,207 thousand newly issued Class B ordinary shares of Royalty Pharma plc. As a result, the Continuing Investors Partnerships held a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests indirectly held by them at such time which are exchangeable on a one-for-one basis for Class A ordinary shares of Royalty Pharma plc.

2. Summary of Significant Accounting Policies

Basis of preparation and use of estimates

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

97
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.

The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.

Basis of consolidation

The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record Net income attributable to non-controlling interest in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

Following management’s determination that a high degree of common ownership existed in Royalty Pharma both before and after the Exchange Date, Royalty Pharma recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date.

Prior to the Exchange Offer Transactions, our only historical non-controlling interest was attributable to a de minimis interest in RPCT held by RPSFT. As a result of the Exchange Offer Transactions in February 2020, a new non-controlling interest was created related to the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI.

Following the consummation of our IPO in June 2020, two new non-controlling interests were created: (1) a non-controlling interest related to the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, which amounted to approximately 29% as of December 31, 2021, and (2) a non-controlling interest related to RPI EPA Holdings, LP (“EPA Holdings”), an affiliate of the Manager through its ownership of the RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to the latter non-controlling interest until certain conditions are met.

All intercompany transactions and balances have been eliminated in consolidation.

Adjustment to prior period presentation

In connection with the preparation of our condensed consolidated interim financial statements for the three months ended September 30, 2020, we identified an adjustment to the classification of our short-term investments on our consolidated balance sheets, as of December 31, 2019, based on the original maturity dates of the investments. The adjustment resulted in an increase of $37.5 million to Marketable securities and a corresponding decrease to Cash and cash equivalents on the consolidated balance sheet as of December 31, 2019. In addition, the adjustment resulted in an increase of $388.0 million and $350.5 million in cash activity related to Purchases of marketable securities and Proceeds from sales and maturities of marketable securities, respectively, within Net cash used in investing activities for the year ended December 31, 2019, with a net impact on net cash flow from investing of $37.5 million. The adjustment had no effect on our reported total income and revenues, consolidated net income, total assets, or shareholders’ equity for any period. In addition, the adjustment does not impact net cash provided by operating activities in any period. We evaluated the adjustment and determined that, based on quantitative and qualitative analysis, it was not material to the consolidated financial statements as of and for the year ended December 31, 2019.

Reclassification

Certain prior period amounts have been reclassified to conform to the current period presentation.

98
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Concentrations of credit risk

Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2021 and 2020 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.

The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, AbbVie, Bristol Myers Squibb, Gilead, Johnson & Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche and Vertex. For the years ended December 31, 2021 and 2020, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32% and 27% of our current portion of Financial royalty assets, net, respectively, representing the largest individual receivable balance in both years.

We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.

Segment information

Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.

Royalty assets

An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.

In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.

Financial royalty assets, net

Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (“ASC”), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 Imputation of Interest.

99
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as Provision for changes in expected cash flows from financial royalty assets and the carrying value of Financial royalty assets, net is presented net of the cumulative allowance for changes in expected future cash flows.

The application of the prospective approach to measure financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below.

•Analyst coverage. Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts’ consensus sales forecasts for a product to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst consensus sales estimates are not available for the full term of the royalty, particularly for the later years in a product’s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management’s own expertise. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves based on historical trends to project future sales when sell-side equity research analyst consensus sales estimates end or are not available for the full term of the royalty. In other cases, management may develop and apply growth rate estimates from existing sell-side equity research analysts’ consensus sales forecasts to project future sales for products that cannot be modeled through the statistical curves, such as those where the entrance of a biosimilar is expected to impact future sales. Based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset’s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.

•Commercial performance. The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts’ consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product’s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.

100
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



•Royalty duration. The duration of a royalty can be based on a number of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product’s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.

As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts’ models. The most sensitive of these assumptions relates to management’s estimate of the royalty duration in the final years of an asset’s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows.

A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.

The current portion of Financial royalty assets, net represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears.

Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets

We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset’s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period’s effective interest rate. The amount recognized as provision expense increases the financial royalty asset’s cumulative allowance, which reduces the net carrying value of the financial royalty asset.

101
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.

Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the Financial royalty assets, net line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset’s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either Provision for changes in expected cash flows from financial royalty assets or as Income from financial royalty assets on the consolidated statements of operations.

Income from financial royalty assets

We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition of a financial royalty asset, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.

When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as Other royalty income.

Allowance for current expected credit losses

On January 1, 2020, we adopted ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of Financial royalty assets, net on the consolidated balance sheets. Any subsequent movement in the allowance for credit losses is recorded as part of the Provision for changes in expected future cash flows from financial royalty assets on the consolidated statements of operations.

Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for further information.

Intangible royalty assets, net

Currently, our only intangible royalty assets are the Januvia and Janumet (“DPP-IV”) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, the majority of which terminate at various dates through 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.

102
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10, Property, Plant, and Equipment - Overall. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product’s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty’s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.

Revenue from intangible royalty assets and Accrued royalty receivable

We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts’ projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.

Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.

Milestone payments

Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts’ consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved.

Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.

Financial instruments

Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than Financial royalty assets, net are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 5–Fair Value Measurements and Financial Instruments.

Cash and cash equivalents and Marketable securities

Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value.

103
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Equity securities and Available for sale debt securities

Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities are measured at fair value. The unrealized change in fair value of available for sale debt securities for which we elected the fair value option is recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations. The unrealized change in fair value for the Biohaven Series A Preferred Share is included in Accumulated other comprehensive income (“AOCI”) and are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows.

A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management’s assessment.

We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.

Derivatives

All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements.

Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of operations as part of Losses on derivative financial instruments.

Investment in non-consolidated affiliates

Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee’s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within Equity in losses/(earnings) of non-consolidated affiliates in the consolidated statements of operations. The investment is reflected as Investments in non-consolidated affiliates on the consolidated balance sheet.

We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the “Avillion entities”). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.

104
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets.

Research and development funding expense

We enter into transactions where we agree to fund a portion of the research and development (“R&D”) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, Research and Development, we account for the funded amounts as R&D expense when we have the ability to obtain the results of the R&D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. We may pay funded amounts upfront or over time as the underlying products undergo clinical trials.

Royalty payments owed to the Company on successfully commercialized products generated from R&D arrangements are recognized as Other royalty income in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria for products arising out of our R&D arrangements are also recognized as Other royalty income in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed.

Income taxes

We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (“the Code”) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.

While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments.

Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes.

While we do not currently record a provision for income taxes, we are party to certain arrangements that will give rise to a tax provision in the future. We currently have funding arrangements in place that allow our counterparties to draw on capital over a prescribed period of time. When such funding arrangements are drawn and we begin to recognize income from these funding arrangements, such activities will be subject to U.S. taxation and we will record a provision for income taxes in accordance with ASC 740, Income Taxes. We also entered into an arrangement with MSCI during 2021 as discussed in Note 16–Related Party Transactions that will become subject to U.S. taxation when we begin to recognize revenue from this transaction.

We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI.

105
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



We are also subject to the U.K.’s “controlled foreign companies” rules (the “U.K. CFC Rules”). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the “Controlled Foreign Company”) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings), will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes.

Earnings per share

Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to RPI EPA Holdings, LP (“EPA Holdings”) related to Equity Performance Awards and unvested restricted share units (“RSUs”) issued under our 2020 Independent Director Equity Incentive Plan (“Equity Incentive Plan”). We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable. We use the “if-converted” method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.

There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information has been presented for any period prior to that date.

Recently adopted accounting standards

In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to Retained earnings of $192.7 million to recognize an allowance for current expected credit losses on our financial royalty assets.

In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.

106
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



3. Available for Sale Debt Securities

Series A Biohaven Preferred Shares

On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”) at a price of $50,100.00 per preferred share, for a total of $125.0 million (the “First Tranche”). The approval of Nurtec ODT by the U.S. Food and Drug Administration (“FDA”) in February 2020 results in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price. In the event that Biohaven defaults on any obligation to redeem Series A Biohaven Preferred Shares when required, the redemption amount shall accrue interest at the rate of 18% annually until the redemption price for such unredeemed Series A Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert all unredeemed Series A Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date.

The Series A Biohaven Preferred Shares are classified as Available for sale debt securities in our consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within Unrealized gains on available for sale debt securities on the consolidated statements of comprehensive income.

Series B Biohaven Preferred Shares

On August 7, 2020 we entered into a Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”), for a total of $200.0 million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the Series B original issue price per share. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares. In the event that Biohaven defaults on any obligation to redeem Series B Biohaven Preferred Shares, the redemption amount shall accrue interest on the applicable original issue price at the rate of 18% annually until the redemption price for such unredeemed Series B Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert any or all unredeemed Series B Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date.

In the three months ended March 31, 2021, we began purchasing the Series B Biohaven Preferred Shares. As of December 31, 2021, we have acquired 1,406 shares of Series B Biohaven Preferred Shares. We have elected the fair value option to account for the Series B Forwards and the Series B Biohaven Preferred Shares, which are recorded in aggregate on the consolidated balance sheets as Available for sale debt securities. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations.

107
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



MorphoSys Development Funding Bonds

On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (“MorphoSys”) to support MorphoSys’ acquisition of Constellation Pharmaceuticals, Inc. (“Constellation”), which closed on July 15, 2021. As part of the funding agreement, we agreed to provide MorphoSys up to $350 million of capital (the “Development Funding Bonds”), which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150 million. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds. Our commitment to fund at least $150 million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding.

We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within Available for sale debt securities in our consolidated balance sheet. The unrealized change in fair value of the Development Funding Bond Forward is recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations.

The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2021 and 2020 (in thousands):
Cost (1)Unrealized GainsFair Value Current AssetsNon-Current AssetsTotal
As of December 31, 2021
Series A Biohaven Preferred Shares$134,068 $29,432 $163,500 $66,000 $97,500 $163,500 
Series B Biohaven Preferred Shares70,441 19,759 90,200 — 90,200 90,200 
Series B Forwards— 12,300 12,300 — 12,300 12,300 
Development Funding Bond Forward— 4,400 4,400 — 4,400 4,400 
Total available for sale debt securities$204,509 $65,891 $270,400 $66,000 $204,400 $270,400 
As of December 31, 2020
Series A Biohaven Preferred Shares$145,647 $68,753 $214,400 $69,984 $144,416 $214,400 
Series B Forwards— 18,600 18,600 — 18,600 18,600 
Total available for sale debt securities$145,647 $87,353 $233,000 $69,984 $163,016 $233,000 
(1)Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. There were no costs associated with the Series B Forwards and Development Funding Bond Forward.

4. Derivative Instruments

We have historically managed the impact of foreign currency exchange rate and interest rate risk through various financial instruments, including derivative instruments such as treasury rate lock contracts, interest rate swap contracts and foreign currency forward contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash flow arising from our exposure to interest rate risk and foreign currency risk. We may also acquire other financial instruments that are classified as derivatives. We do not enter into derivative instruments for trading or speculative purposes.

Treasury rate lock contracts

In June 2021, we entered into treasury rate lock contracts with notional amounts totaling $600.0 million to manage the impact of fluctuations in the underlying benchmark interest rate associated with the 2021 Notes (as further discussed and defined in Note 11–Borrowings). The treasury rate lock contracts were not designated as hedge instruments. All of the treasury rate lock contracts had collateral requirements. The treasury rate lock contracts were unwound and settled in connection with the issuance of the 2021 Notes and the resulting net loss was recognized in earnings in the year ended December 31, 2021. We paid $16.1 million in July 2021 to terminate our treasury rate lock contracts.
108
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS




Interest rate swaps

In February 2020, RPIFT terminated all outstanding interest rate swaps in connection with the Exchange Offer Transactions. We paid $35.4 million to terminate these swaps and reclaimed $45.3 million of collateral that was held by the respective counterparties. During the years ended December 31, 2020 and 2019, we recorded unrealized losses of $10.9 million and $72.6 million, respectively, on interest rate swaps in the consolidated statements of operations. We did not enter into any interest rate swaps subsequent to the February 2020 termination discussed above and as of December 31, 2021, we do not hold any interest rate swap contracts.

Epizyme put option and warrant

In November 2019, RPIFT made an equity investment in Epizyme, Inc. (“Epizyme”) of $100.0 million. Under the terms of the agreement with Epizyme, we made an upfront payment of $100.0 million for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5 million shares of Epizyme common stock at $20 per share over a three-year term and (3) Epizyme’s royalty on sales of Tazverik in Japan payable by Eisai Co., Ltd (“Eisai”). In addition, Epizyme had an 18 month put option to sell an additional $50.0 million of its common stock to RPIFT at then prevailing prices, not to exceed $20 per share. On December 31, 2019, Epizyme notified RPIFT of its intention to exercise the put option. As a result, we recorded a forward purchase contract equal to the difference between the market value and exercise price of $11.5 million within Other assets on the consolidated balance sheets at December 31, 2019. The exercise of the put option was settled in February 2020.

The warrant was recognized at fair value of $5.4 million within Other assets on the consolidated balance sheets at December 31, 2020. The fair value of the warrant was not material as of December 31, 2021. We recorded an unrealized loss of $5.4 million, an unrealized loss of $25.4 million and an unrealized gain of $22.0 million on derivative contracts related to the change in fair value of the warrant on the consolidated statements of operations for the years ended December 31, 2021, 2020 and 2019, respectively.

Summary of derivatives and reclassifications

The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2021, 2020 and 2019 and the line items within the consolidated statements of operations where the gains or losses on these derivatives are recorded (in thousands).
Years Ended December 31,Location on Consolidated Statements of Operations
202120202019
Derivatives in hedging relationships (1)
Interest Rate Swaps:
Amount of loss reclassified from accumulated other comprehensive income into income$— $4,066 $6,189 Losses on derivative financial instruments
Change in fair value of interest rate swaps— (73)16,954 Losses on derivative financial instruments
Interest expense/(income)— 114 (9,565)Interest expense
Derivatives not designated as hedging instruments
Interest Rate Swaps:
Change in fair value of interest rate swaps— 6,908 49,472 Losses on derivative financial instruments
Interest expense/(income)— 408 (2,681)Interest expense
Warrant:
Change in fair value of warrant5,439 25,375 (21,977)Losses on derivative financial instruments
Forward purchase contract:
Change in fair value of forward purchase contract— 5,800 (11,500)Losses on derivative financial instruments
Treasury rate lock contracts:
Change in fair value of treasury rate lock contracts16,093 — — Losses on derivative financial instruments
(1)     Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in Accumulated other comprehensive income were released into earnings.

109
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



5. Fair Value Measurements and Financial Instruments

Fair value hierarchy

We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
•Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.
•Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.
Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives and available for sale debt securities are reported at their respective fair values in our consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs in our consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported in our consolidated balance sheets at amounts that approximate current fair values.

Assets and liabilities measured at fair value on a recurring basis

The following table summarizes financial assets and financial liabilities that we measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):

As of December 31, 2021As of December 31, 2020
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Cash equivalents
Money market funds$598,253 $— $— $598,253 $24,302 $— $— $24,302 
Commercial paper— 13,997 — 13,997 — 77,176 — 77,176 
Certificates of deposit— 40,954 — 40,954 — 74,502 — 74,502 
Marketable securities
Corporate debt securities— — — — — 32,754 — 32,754 
Commercial paper— 207,457 — 207,457 — 444,554 — 444,554 
Certificates of deposit— 374,415 — 374,415 — 505,971 — 505,971 
Available for sale debt securities— — 66,000 66,000 — — 69,984 69,984 
Total current assets$598,253 $636,823 $66,000 $1,301,076 $24,302 $1,134,957 $69,984 $1,229,243 
Equity securities226,787 — 43,013 269,800 298,689 — — 298,689 
Available for sale debt securities— — 187,700 187,700 — — 144,416 144,416 
Forwards (1)— — 16,700 16,700 — — 18,600 18,600 
Warrant (2)— — — — — 5,439 — 5,439 
Total non-current assets$226,787 $— $247,413 $474,200 $298,689 $5,439 $163,016 $467,144 
(1)The balance as of December 31, 2021 includes Series B Forwards and the Development Funding Bond Forward, recorded within Available for sale debt securities in the consolidated balance sheet, related to our obligations to fund acquisitions of the Series B Biohaven Preferred Shares and $150 million of the Development Funding Bonds, respectively. The balance as of December 31, 2020 relates to Series B Forwards, recorded within Available for sale debt securities in the consolidated balance sheet. See Note 3–Available for Sale Debt Securities for additional discussion.
(2)Related to the Epizyme transaction as described in Note 4–Derivative Instruments and recorded in Other assets in the consolidated balance sheets as of December 31, 2021 and 2020. The fair value of the warrant was not material as of December 31, 2021.

110
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



For the years ended December 31, 2021, 2020 and 2019, we recognized a loss of $60.1 million, a loss of $85.4 million and a gain of $104.4 million, on equity securities still held as of December 31, 2021, respectively.

The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities and available for sale debt securities, including the underlying debt securities and related forwards (in thousands).

Years Ended December 31,
20212020
Equity Securities
Balance at the beginning of the year$— $— 
Purchases35,120 — 
Gains on equity securities7,893 — 
Balance at the end of the year$43,013 $— 
Years Ended December 31,
20212020
Debt Securities
Balance at the beginning of the year$214,400 $131,280 
Purchases70,441 — 
Unrealized gains on available for sale debt securities (1)12,900 52,725 
Settlement of forwards (2)18,459 — 
Transfer to Level 2— (184,005)
Transfer from Level 2 (3)— 198,526 
Unrealized gains on available for sale debt securities (1)— 15,874 
Redemption(62,500)— 
Balance at the end of the year$253,700 $214,400 
Years Ended December 31,
20212020
Forwards
Balance at the beginning of the year$18,600 $— 
Unrealized gains (4)16,559 18,600 
Settlement of forwards (2)(18,459)— 
Balance at the end of the year$16,700 $18,600 
(1)For the year ended December 31, 2021, the unrealized gains on available for sale debt securities is comprised of $11.6 million related to Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income and $1.3 million related to the Series B Biohaven Preferred Shares as recorded on the consolidated statements of operations. For the year ended December 31, 2020, the unrealized gains on available for sale debt securities related to the Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income, including $52.7 million prior to transferring out of Level 3 and then $15.9 million after transferring back to Level 3.     
(2)Reflects the fair value attributed to the Series B Forwards that were settled in the period as the Series B Biohaven Preferred Shares were acquired, which is included in the fair value of the Series B Biohaven Preferred Shares. See Note 3–Available for Sale Debt Securities.
(3)Includes $14.5 million of unrealized gains on available for sale debt securities included in other comprehensive income while the Series A Biohaven Preferred Shares was classified as a Level 2 asset.
(4)Recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations.

Valuation inputs

Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.

111
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Investment in Series A Biohaven Preferred Shares

The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was based on the cash flows due to us from Biohaven of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6 million following the FDA approval and starting one-year after FDA approval, through December 31, 2024. The FDA approved Nurtec ODT in February 2020, at which point we became entitled to receive a fixed payment amount of $250.0 million payable in equal quarterly payments from March 31, 2021 through December 31, 2024.

The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate of 9.5% and 8.3% as of December 31, 2021 and 2020, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower.

Prior to February 2020, we measured our investment in the Series A Biohaven Preferred Shares using a Black-Derman- Toy lattice model, which included the use of Level 3 fair value measurements and inputs. In February 2020, when Nurtec ODT received FDA approval, we began measuring the fair value of the Series A Biohaven Preferred Shares using a discounted cash flow analysis that relied on observable inputs, and therefore, we transferred the Series A Biohaven Preferred Shares from a Level 3 to a Level 2 asset. During the three months ended December 31, 2020, information pertaining to Biohaven’s issuance of debt and its effective interest rate became available and we refined our valuation of the Series A Biohaven Preferred shares as of December 31, 2020 to incorporate this significant unobservable input. As a result, we reclassified the investment from a Level 2 to a Level 3 asset during the three months ended December 31, 2020.

112
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Investment in Series B Biohaven Preferred Shares

The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of December 31, 2021 and the fair value of the Series B Forwards as of December 31, 2020 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower.

MorphoSys Development Funding Bonds

The fair value of the Development Funding Bond Forward as of December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument.

BioCryst Equity Securities

In November 2021, we purchased 3,846 thousand shares of common stock in BioCryst Pharmaceuticals, Inc.(“BioCryst”), which was calculated based on the volume-weighted average price of BioCryst common stock over a period preceding the closing of the transaction. As part of the transaction, we are restricted from selling the common stock for six months following the close of the transaction. The fair value of the BioCryst common stock as of December 31, 2021 was based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the common stock to match the duration of the transfer restriction. This methodology includes the use of Level 3 inputs, including the estimated volatility of the BioCryst common stock, which requires the use of significant judgement. Our estimated volatility could be reasonably different than the actual volatility for the common stock which would mean that the estimated fair value for the common stock could be significantly higher or lower than the fair value determined by management at any particular date.

Other financial instruments

We use third party pricing services for Level 2 inputs used to value cash equivalents, marketable securities, derivative instruments and borrowings, which provide documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. Warrants are valued using a Black-Scholes option pricing model which considers observable and unobservable inputs.

Financial assets not measured at fair value

Financial royalty assets are measured and carried on the consolidated balance sheets at amortized cost using the effective interest method. The fair value of financial royalty assets is calculated by management using the forecasted royalty payments we expect to receive based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts’ consensus sales forecasts or, where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments are then discounted to a present value using appropriate individual discount rates. The fair value of our financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for our financial royalty assets as of December 31, 2021 and 2020 are presented below (in thousands).

113
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



December 31, 2021December 31, 2020
Fair ValueCarrying Value, netFair ValueCarrying Value, net
Financial royalty assets, net$19,047,183 $14,332,596 $18,718,179 $12,955,277 

6. Financial Royalty Assets, Net

Financial royalty assets, net consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.

The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2021 and 2020 are as follows (in thousands):
As of December 31, 2021
Estimated Royalty Duration (a)Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 7)Net Carrying Value (e)
Cystic fibrosis franchise2037 (b)$5,335,641 $(48,636)$5,287,005 
Tysabri(c)1,846,069 (16,617)1,829,452 
Imbruvica2027-20321,438,730 (236,871)1,201,859 
Xtandi2027-20281,100,065 (172,101)927,964 
Tremfya2031-2032881,671 — 881,671 
Evrysdi2030-2035 (d)727,774 — 727,774 
Other2020-20394,697,591 (909,916)3,787,675 
Total$16,027,541 $(1,384,141)$14,643,400 
Less: Cumulative allowance for credit losses (Note 7)(310,804)
Total financial royalty assets, net$14,332,596 
(a)Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(b)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(c)Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(d)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
(e)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

As of December 31, 2020
Estimated Royalty Duration (a)Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 7)Net Carrying Value (e)
Cystic fibrosis franchise2037 (b)$5,274,896 $— $5,274,896 
Tysabri(c)2,003,797 (112,720)1,891,077 
Imbruvica2027-20321,406,291 (46,872)1,359,419 
Xtandi2027-20281,150,335 (145,565)1,004,770 
Promacta2025-2028686,129 — 686,129 
Evrysdi2030-2035 (d)675,440 — 675,440 
Other2020-20393,022,213 (634,950)2,387,263 
Total$14,219,101 $(940,107)$13,278,994 
Less: Cumulative allowance for credit losses (Note 7)(323,717)
Total financial royalty assets, net$12,955,277 
(a)Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
114
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



(b)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(c)Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(d)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
(e)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

7. Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets

The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of Financial royalty assets, net on the consolidated balance sheets and includes the following activities:

•the movement in the cumulative allowance related to changes in forecasted royalty payments we expect to receive based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts’ consensus sales forecasts, and
•the movement in the cumulative allowance for current expected credit losses.

The periodic movement in the cumulative allowance is presented on the consolidated statements of operations as the Provision for changes in expected cash flows from financial royalty assets.

Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to Retained earnings of $192.7 million to recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The current period provision for changes in expected cash flows from financial royalty assets reflects the activity for the period primarily new financial royalty assets and changes in the underlying cash flow forecasts used in the effective interest model to measure income from our financial royalty assets. Refer to Note 2–Summary of Significant Accounting Policies for further information.
The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):
Activity for the Year
Balance at December 31, 2018$(1,982,897)
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(322,717)
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets1,342,038 
Write-off of cumulative allowance (a)95,158 
Balance at December 31, 2019$(868,418)
Cumulative adjustment for adoption of ASU 2016-13(192,705)
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(645,612)
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets570,959 
Write-off of cumulative allowance (a)2,964 
Write-off of credit loss allowance (b)25,174 
Current period provision expense for credit losses, net (c)(156,186)
Balance at December 31, 2020$(1,263,824)
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(912,710)
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets446,955 
Write-off of cumulative allowance (a)21,721 
Current period provision income for credit losses, net (c)12,913 
Balance at December 31, 2021$(1,694,945)
(a)     Relates to amounts removed from the allowance at the end of a royalty asset’s life to bring the account balance to zero. Write-offs solely impact the asset account and allowance account; there is no impact on the consolidated statements of operations.
(b)     Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the write-off of the related financial royalty asset balance of $90.2 million.
(c)     In the year ended December 31, 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights in 2020, mainly the final tranche of Tazverik. In the year ended December 31, 2021,the provision income for credit losses was primarily related to a significant decline in the financial asset value for Tazverik, which was offset by increases in our portfolio of financial royalty assets with limited protective rights in 2021, primarily related to zavegepant.

115
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



8. Intangible Royalty Assets, Net

The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2021 and 2020 (in thousands).
As of December 31, 2021CostAccumulated AmortizationNet Carrying Value
DPP-IV patents$606,216 $600,546 $5,670 
Total intangible royalty assets$606,216 $600,546 $5,670 
As of December 31, 2020CostAccumulated AmortizationNet Carrying Value
DPP-IV patents$606,216 $577,550 $28,666 
Total intangible royalty assets$606,216 $577,550 $28,666 

The majority of our DPP-IV patents associated with the intangible royalty assets terminate at various dates through 2022. The weighted average remaining life of the intangible royalty assets is less than one year. We project amortization expense will be $5.7 million in 2022.

Our revenue is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue from royalty assets is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate our royalty revenue from licensees based on the geography of the underlying sales, as this level of information is not always included in royalty reports provided to us. The marketers paying us royalties on these products do not always provide, and are not necessarily required to provide, the breakdown of product sales by geography. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 86%, 97% and 91% of our revenues from intangible royalty assets in the years ended December 31, 2021, 2020 and 2019, respectively.

9. Non-Consolidated Affiliates

The Legacy SLP Interest

In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) from the Continuing Investors Partnerships for $303.7 million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also own a non-controlling interest in Old RPI.

The income allocation from the Legacy SLP Interest is based on an estimate, as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this annual report. Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the years ended December 31, 2021 and 2020, we recorded an income allocation of $8.9 million and $62.0 million, respectively, within Equity in losses/(earnings) of non-consolidated affiliates. We received cash distributions from the Legacy SLP Interest of $21.0 million and $22.7 million during the years ended December 31, 2021 and 2020, respectively.

116
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



The Avillion Entities

We account for our partnership interests in Avillion Financing I, LP (“Avillion I”) and BAv Financing II, LP (“Avillion II”, or, together, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the entities. We recorded a loss allocation from the Avillion Entities of $28.4 million, $17.6 million and $32.5 million within Equity in losses/(earnings) of non-consolidated affiliates during the years ended December 31, 2021, 2020 and 2019, respectively.

On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval. Subsequent to the asset sale, the only operations of Avillion I are the collection of cash and unwinding of discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.4 million during each of the years ended December 31, 2021 and 2020, and $14.1 million in the year ended December 31, 2019 in connection with Avillion I’s receipt of the fixed annual payments due under its co-development agreement with Pfizer.

In March 2017, RPIFT entered into an agreement with Avillion II, which was amended in 2019, to invest approximately $19.0 million to fund approximately 50% of the costs of a Phase 2 clinical trial for the use of Merck KGaA’s anti-IL 17 nanobody M1095 (the “Merck KGaA Asset”) for the treatment of psoriasis in exchange for certain milestone and royalty payments. Our involvement in the development for the Merck KGaA Asset ceased in the year ended December 31, 2020, for which we received a distribution of $21.3 million from Avillion II.

In May 2018, RPIFT entered into an additional agreement, which was amended in July 2021, to increase our investment up to $122.5 million from $105.0 million in Avillion II over multiple years to fund approximately 44% of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.

As of December 31, 2021 and 2020, RPIFT had $11.2 million and $28.6 million respectively, of unfunded commitments related to the Avillion Entities. Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments.

10. Research & Development (“R&D”) Funding Expense

R&D funding expense consists of upfront and ongoing R&D payments we have made to counterparties to acquire royalties and/or milestones on development-stage product candidates. Ongoing R&D payments are made as the related development-stage product candidates undergo clinical trials with our counterparties. During the year ended December 31, 2021, 2020, and 2019 we did not enter into any new ongoing R&D funding arrangements.

We recognized R&D funding expense of $200.1 million during the year ended December 31, 2021, comprised of $6.9 million in ongoing R&D expenses, primarily under our co-funding agreement with Sanofi, and $193.2 million in upfront R&D funding. As part of a long-term strategic funding partnership with MorphoSys, which closed on July 15, 2021 (as further discussed in Note 17–Commitments and Contingencies), we allocated $90.0 million of the upfront payment to R&D funding expense, representing two development-stage products acquired in exchange for future royalties. Additionally, we made an upfront payment of $103.2 million to BioCryst to acquire a royalty on a development-stage product in November 2021.

We recognized R&D funding expense of $26.3 million during the year ended December 31, 2020, of which $20.5 million related to ongoing development-stage funding payments, primarily under our co-funding agreement with Sanofi and $5.8 million related to upfront funding for a royalty on a development-stage product that we acquired from BioCryst.

We recognized $83.0 million of R&D funding expense during the year ended December 31, 2019, of which $18.2 million and $62.8 million related to our funding agreements with both Sanofi and Pfizer, respectively. We completed our funding commitments in the fourth quarter of 2019 under our agreement with Pfizer. We did not have upfront development-stage R&D funding expense in 2019.

As of December 31, 2021, we have a remaining commitment of $10.7 million related to our R&D funding agreement with Sanofi.
117
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS




11. Borrowings

Our borrowings at December 31, 2021 and 2020 consisted of the following (in thousands):

Type of BorrowingDate of IssuanceMaturityDecember 31, 2021December 31, 2020
Senior Unsecured Notes:
$1,000,000, 0.75% (issued at 99.322% of par)
9/20209/2023$1,000,000 $1,000,000 
$1,000,000, 1.20% (issued at 98.875% of par)
9/20209/20251,000,000 1,000,000 
$1,000,000, 1.75% (issued at 98.284% of par)
9/20209/20271,000,000 1,000,000 
$1,000,000, 2.20% (issued at 97.760% of par)
9/20209/20301,000,000 1,000,000 
$600,000, 2.15% (issued at 98.263% of par)
7/20219/2031600,000 — 
$1,000,000, 3.30% (issued at 95.556% of par)
9/20209/20401,000,000 1,000,000 
$1,000,000, 3.55% (issued at 95.306% of par)
9/20209/20501,000,000 1,000,000 
$700,000, 3.35% (issued at 97.565% of par)
7/20219/2051700,000 — 
Unamortized debt discount and issuance costs(203,930)(183,416)
Total debt carrying value7,096,070 5,816,584
Less: Current portion of long-term debt— —
Total long-term debt$7,096,070 $5,816,584 

Senior Unsecured Notes

On July 26, 2021, we issued $1.3 billion of senior unsecured notes (the “2021 Notes”) comprised of $600.0 million principal amount of notes due September 2031 and $700.0 million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, beginning on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5 million and we capitalized approximately $12.3 million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively.

On September 2, 2020, we issued $6.0 billion of senior unsecured notes (the “2020 Notes” and, together with the 2021 Notes, the “Notes”). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0 million and we capitalized approximately $40.4 million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50%, respectively.    

On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933.

The Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.

Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.
118
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and, as of December 31, 2021, we were in compliance with all applicable covenants.

As of December 31, 2021 and 2020, the estimated fair value of our outstanding Notes using Level 2 inputs was approximately $7.2 billion and $6.2 billion, respectively.

Senior Unsecured Revolving Credit Facility

On September 15, 2021, we entered into an amended and restated revolving credit agreement (the “Credit Agreement”). The Credit Agreement amends and restates the existing credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) with borrowing capacity of up to $1.5 billion for general corporate purposes. The Credit Agreement extends the maturity of the Revolving Credit Facility to September 15, 2026. As of December 31, 2021 and 2020, there were no outstanding borrowings under the Revolving Credit Facility.

The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.

The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. As of December 31, 2021, RP Holdings was in compliance with these covenants.

Senior Secured Credit Facilities

On February 11, 2020, in connection with the Exchange Offer Transactions (as discussed in Note 1–Organization and Purpose) and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. The senior secured credit facilities consisted of a term loan A and term loan B in the amounts of $3.20 billion and $2.84 billion, respectively. In September 2020, we repaid in full the outstanding principal amounts of term loans under the senior secured credit facilities with net proceeds from the 2020 Notes and available cash on hand. Upon refinancing our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $25.1 million as part of Other non-operating expense/(income), net, which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.

RPIFT Senior Secured Credit Facilities

The RPIFT Senior Secured Credit Facilities were repaid in full in February 2020 in connection with the Exchange Offer Transactions. We recorded a loss on debt extinguishment of $5.4 million as part of Other non-operating expense/(income), net during the year ended December 31, 2020.

Principal Payments on the Notes

The future principal payments for our borrowings as of December 31, 2021 over the next five years and thereafter are as follows (in thousands):

119
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



YearPrincipal Payments
2022$— 
20231,000,000
2024—
20251,000,000
2026—
Thereafter5,300,000
Total (1)$7,300,000 
(1)     Excludes unamortized debt discount and issuance costs of $203.9 million as of December 31, 2021, which are amortized through interest expense over the remaining life of the underlying debt obligations.

12. Shareholders’ Equity

Capital structure

Following the completion of our IPO as discussed in Note 1–Organization and Purpose, we have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company.

An exchange agreement entered into by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the “Exchange Agreement”) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. As of December 31, 2021, we have outstanding 432,963 thousand Class A ordinary shares and 174,213 thousand Class B ordinary shares. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of December 31, 2021, we have outstanding deferred shares of 361,170 thousand.

In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The purpose of the Class R redeemable shares was to ensure Royalty Pharma Limited had sufficient sterling denominated share capital at the time it was re-registered as a public limited company to Royalty Pharma plc, as required by the U.K. Companies Act. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of £1 each.
120
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Non-controlling interests

The only non-controlling interest in the year ended December 31, 2019 related to RPSFT, for which the net change in the related balance is as presented in the statements of shareholders’ equity. The net change in the balance of our four non-controlling interests for the years ended December 31, 2021 and 2020 is as follows (in thousands):

RPSFTLegacy Investors PartnershipsContinuing Investors Partnerships (1)EPA HoldingsTotal
December 31, 2019$35,883 $— $— $— $35,883 
Contributions— 1,165,258 9,418 — 1,174,676 
Transfer of interests— 1,037,161 — — 1,037,161 
Distributions(112,339)(594,592)(85,426)— (792,357)
Net Income prior to IPO42,151 102,892 — — 145,043 
Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity— (750)2,433,848 — 2,433,098 
Issuance of Class A ordinary shares sold in IPO, net of offering costs— — 758,354 — 758,354 
Other exchanges— — (309,566)— (309,566)
Net income subsequent to IPO46,741 218,137 316,993 — 581,871 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 15,015 7,488 — 22,503 
Reclassification of unrealized losses on available for sale debt securities— (3,612)(6,018)— (9,630)
December 31, 2020$12,436 $1,939,509 $3,125,091 $— $5,077,036 
(1)     Related to the Continuing Investors Partnerships’ ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2020.

RPSFTLegacy Investors PartnershipsContinuing Investors Partnerships (1)EPA HoldingsTotal
December 31, 2020$12,436 $1,939,509 $3,125,091 $— $5,077,036 
Contributions— 35,148 13,391 — 48,539 
Distributions(56,490)(425,050)(133,433)— (614,973)
Other exchanges— — (642,974)— (642,974)
Net Income57,582 266,570 297,321 — 621,473 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 2,038 3,227 — 5,265 
Reclassification of unrealized losses on available for sale debt securities— (8,946)(13,469)— (22,415)
December 31, 2021$13,528 $1,809,269 $2,649,154 $— $4,471,951 
(1)     Related to the Continuing Investors Partnerships’ ownership of approximately 29% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2021. Royalty Pharma plc owns the remaining 71% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2021.

121
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



RP Holdings Class C Special Interest held by EPA Holdings

EPA Holdings is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period will be grouped together as separate portfolios (each, a “Portfolio”). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests for which we will issue the same number of Class B ordinary shares, which may be subsequently exchanged for our Class A ordinary shares. We do not currently expect any material Equity Performance Awards to be payable until the performance conditions discussed above are met.

Dividends

The holders of Class A ordinary shares are entitled to receive dividends subject to approval by the board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings, our consolidated subsidiary. In the year ended December 31, 2021, we declared and paid four quarterly cash dividends of $0.17 per Class A ordinary share for an aggregate amount of $285.2 million to holders of our Class A ordinary shares.

2020 Independent Directors Equity Incentive Plan

On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors. As of December 31, 2021, approximately 620 thousand shares remain reserved for future issuance under the Equity Incentive Plan.

RSU activity and share-based compensation

We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year as part of General and administrative expenses in the consolidated statement of comprehensive income. The estimated fair value of RSUs is based on the closing price of our Class A ordinary shares on the grant date.

We recognized share-based compensation of approximately $3.1 million and $5.7 million for the years ended December 31, 2021 and 2020, which is recorded as part of General and administrative expenses in the consolidated statement of operations. There were no share-based awards or related expenses in periods prior to the IPO. As of December 31, 2021, the total unrecognized share-based compensation expense related to total outstanding RSUs was less than $1.0 million, which we expect to recognize in the next six months.

13. Earnings per Share

Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards, and unvested RSUs issued under our Equity Incentive Plan. We use the “if-converted” method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.

122
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Our Class B ordinary shares, Class R redeemable shares, and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares, and deferred shares under the two-class method has not been presented. Our Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because shares of Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. For the years ended December 31, 2021 and 2020, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. Additionally, Class B ordinary shares in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive for the years ended December 31, 2021 and 2020, and therefore were excluded from the computation of diluted earnings per shares of Class A ordinary share. As of December 31, 2021 and 2020, we had 607,176 thousand and 607,111 thousand fully diluted Class A ordinary shares outstanding, respectively.

The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2021 (in thousands, except per share amounts).
Year Ended December 31, 2021
Numerator
Consolidated net income$1,241,201 
Less: Net income attributable to Continuing Investors Partnerships297,321 
Less: Net income attributable to Legacy Investors Partnerships and RPSFT324,152 
Net income attributable to Royalty Pharma plc - basic and diluted$619,728 
Denominator
Weighted average Class A ordinary shares outstanding - basic414,794 
Add: Dilutive effect of unvested RSUs8 
Weighted average Class A ordinary shares outstanding - diluted414,802 
Earnings per Class A ordinary share - basic$1.49 
Earnings per Class A ordinary share - diluted$1.49 

Prior to the IPO, our capital structure mainly included unitholder interests. We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements. Therefore, the basic and diluted earnings per share for the year ended December 31, 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares. The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2020 (in thousands, except per share amounts).
Year Ended
December 31, 2020
Numerator
Consolidated net income $1,701,954 
Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)479,842 
Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO316,993 
Less: Net income attributable to Legacy Investors Partnerships and RPSFT409,921 
Net income attributable to Royalty Pharma plc - basic and diluted$495,198 
Denominator
Weighted average Class A ordinary shares outstanding - basic375,444 
Add: Dilutive effect of unvested RSUs11 
Weighted average Class A ordinary shares outstanding - diluted375,455 
Earnings per Class A ordinary share - basic$1.32 
Earnings per Class A ordinary share - diluted$1.32 
(1)     Reflected as Net income attributable to controlling interest on the consolidated statements of operations.
123
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



14. Indirect Cash Flow

Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).
Years Ended December 31,
202120202019
Cash flow from operating activities:
Consolidated net income$1,241,201 $1,701,954 $2,461,419 
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Income from financial royalty assets(2,065,083)(1,959,975)(1,648,837)
Provision for changes in expected cash flows from financial royalty assets452,842 230,839 (1,019,321)
Amortization of intangible assets22,996 23,058 23,924 
Amortization of debt discount and issuance costs20,162 11,715 12,790 
Losses on derivative financial instruments21,532 42,076 39,138 
Losses/(gains) on equity securities48,066 (247,073)(155,749)
Equity in losses/(earnings) of non-consolidated affiliates19,490 (44,459)32,517 
Distributions from non-consolidated affiliates34,384 42,334 14,059 
Loss on extinguishment of debt358 30,272 — 
Share-based compensation2,443 5,428 — 
Interest income accretion(50,896)(20,551)— 
Unrealized gains on available for sale debt securities(17,859)(18,600)— 
Impairment charge— 65,053 — 
Termination of derivative financial instruments(16,093)(34,952)— 
Other4,461 9,621 (2,122)
Decrease/(increase) in operating assets:
Cash collected on financial royalty assets2,315,854 2,121,923 1,934,092 
Available for sale debt securities— — (150,000)
Accrued royalty receivable(20,131)370 2,471 
Other receivables— — 150,000 
Other royalty income receivable(9,012)(770)7,390 
Other current assets and other assets1,857 34,986 (41,028)
(Decrease)/increase in operating liabilities:
Accounts payable and accrued expenses(4,586)(766)6,496 
Interest payable15,550 42,146 — 
Net cash provided by operating activities$2,017,536 $2,034,629 $1,667,239 

Non-cash investing and financing activities are summarized below (in thousands).
Years Ended December 31,
Supplemental Schedule of Non-cash Investing/Financing Activities:202120202019
Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)$— $303,679 $— 
Settlement of Epizyme forward purchase contract— 5,700 — 
Accrued purchase obligation - Tazverik (Note 17)— 110,000 — 
Repayments of long-term debt by contributions from non-controlling interest (1)— 1,103,774 — 
Milestone payable - Erleada (2)— 18,600 — 
(1) Related to the pro rata portion of RPIFT’s outstanding debt repaid by the Legacy Investors Partnerships.
(2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020 as recorded within Other current liabilities on the consolidated balance sheet.

124
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



15. Accumulated Other Comprehensive Income

As of December 31, 2021 and 2020, the only component of accumulated other comprehensive income related to the Unrealized gains on available for sale debt securities on the Series A Biohaven Preferred Shares. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in Accumulated other comprehensive income were released into earnings.

The components of accumulated other comprehensive income as of December 31, 2021 and 2020 are as follows (in thousands):
Unrealized Gains on Available for Sale Debt SecuritiesUnrealized Losses on Interest Rate SwapsTotal Accumulated Other Comprehensive Income
Balance at December 31, 20196,159 (4,066)2,093 
Reclassification to net income(10,921)4,066 (6,855)
Activity for the year60,617 — 60,617 
Reclassification to non-controlling interest(24,022)— (24,022)
Reclassification from non-controlling interest2,562 — 2,562 
Balance at December 31, 202034,395 — 34,395 
Reclassification to net income(28,481)— (28,481)
Activity for the year6,335 — 6,335 
Reclassification from non-controlling interest4,242 — 4,242 
Balance at December 31, 2021$16,491 $— $16,491 

The total reclassification of unrealized gains on available for sale debt securities of $50.9 million in the year ended December 31, 2021 is presented within Interest income on the consolidated statements of operations, including $28.5 million attributable to controlling interest noted in the table above and $22.4 million attributable to the non-controlling interest. The total reclassification of unrealized gains on available for sale debt securities of $20.6 million in the year ended December 31, 2020 is presented within Interest income on the consolidated statements of operations, including $10.9 million attributable to controlling interest noted in the table above and $9.6 million attributable to the non-controlling interest.

16. Related Party Transactions

The Manager

The Manager is the investment manager of Royalty Pharma and its subsidiaries. The Manager is an affiliate of RP Ireland, the administrator of RPIFT, RPI Intermediate FT and RPSFT. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of the board of directors, and as a director on the board of directors of RP Holdings.

In connection with the Exchange Offer Transactions (discussed in Note 1–Organization and Purpose), the Manager entered into Management Agreements with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the Management Agreements, we pay quarterly operating and personnel expenses to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5% of the Adjusted Cash Receipts (both, as defined in the Management Agreement) for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in our consolidated net income, is calculated as the greater of $1 million per quarter and 0.3125% of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months.

125
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Prior to the Exchange Date, the Manager received operating and personnel payments payable in equal quarterly installments that increased by 5% annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships. RP Ireland receives an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the limited partnership agreements of the Legacy Investors Partnerships. After the Exchange Date, operating and personnel payments were calculated in accordance with the methodology discussed in the paragraph above.

During the years ended December 31, 2021, 2020 and 2019, total operating and personnel payments incurred were $145.2 million, $112.5 million and $60.0 million, respectively, including the amounts attributable to Old RPI, and were recognized within General and administrative expenses on the consolidated statements of operations.

Distribution Payable to Non-Controlling Interest

The distribution payable to non-controlling interest represents the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPSFT’s non-controlling interest in RPCT. The distribution payable to non-controlling interest as of December 31, 2021 and 2020 included the following (in thousands).

December 31, 2021December 31, 2020
Due to Legacy Investors Partnerships$92,608 $100,047 
Due to RPSFT15,326 26,319 
Total distribution payable to non-controlling interest$107,934 $126,366 

Acquisition from Epizyme

In November 2019, in connection with a royalty acquisition and an equity investment in Epizyme made by RPIFT, Pablo Legorreta, our Chief Executive Officer, was appointed as a director of Epizyme, for which he received, and continues to receive, compensation in cash and shares of Epizyme, all of which are and will continue to be contributed to the Manager and used to reduce costs and expenses which would otherwise be billed to us or our affiliates. We continue to hold Epizyme common stock as of December 31, 2021.

Acquisition from Bristol Myers Squibb

In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”). We agreed to make payments to BMS based on sales of the products over eight quarters beginning with the first quarter of 2018 in exchange for a high single-digit royalty on worldwide sales of the products from 2020 through 2025.

On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly owned subsidiary of BioPharma Credit PLC (“BPCR”), an affiliate of us. We considered BPCR as a related party due to the sole member of the Manager having significant influence over BPCR’s investment manager. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement.

We began making installment payments to BMS in 2018 and completed our funding requirement, net of the assigned funding obligations, totaling $162.4 million in the three months ended March 31, 2020. We began to measure this financial royalty asset using the effective interest method once our installment funding obligation was completed and we received our first royalty payment in the three months ended June 30, 2020. As of December 31, 2021 and 2020, the financial royalty asset of $130.9 million and $150.6 million, respectively, included in Financial royalty assets, net on the consolidated balance sheets represents only our right to the future payment streams acquired from BMS.

126
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



Other transactions

Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI, Inc (“MSCI”). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI’s thematic index suite with the launch of new indexes. In return, we will receive a percentage of MSCI’s revenues from those indexes. No amounts were due from MSCI as of December 31, 2021. The financial statement impact associated with this transaction was not material for the year ended December 31, 2021.

In the year ended December 31, 2020, we reimbursed Pablo Legorreta approximately $1.0 million for the cost of purchasing and donating ventilators to hospitals on behalf of Royalty Pharma.

In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 9–Non-Consolidated Affiliates for additional discussion.

RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnership whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3 million is recorded as treasury interests, of which $1.6 million and $1.9 million are held by non-controlling interest as of December 31, 2021 and 2020, respectively.

Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.

17. Commitments and Contingencies

In the ordinary course of its business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.

On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys to support MorphoSys’ acquisition of Constellation, which closed on July 15, 2021. As part of the funding agreement, we agreed to make additional milestone payments of up to $150.0 million and provide up to $350.0 million of Development Funding Bonds, which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150.0 million, for which we have recognized the Development Funding Bond Forward within Available for sale debt securities on the consolidated balance sheet as of December 31, 2021 (See Note 3–Available for Sale Debt Securities for additional discussion). Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds.

On August 7, 2020, we entered into a funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones. Pursuant to the Series B Biohaven Preferred Share Agreement, we agreed to provide further support for the ongoing launch of Nurtec ODT with the purchase of committed, non-contingent Commercial Launch Preferred Equity for a total of $200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030. During the three months ended March 30, 2021, we began purchasing the Series B Biohaven Preferred Shares. We have a remaining commitment of $129.6 million under the Commercial Launch Preferred Equity, for which we have recognized the Series B Forwards within Available for sale debt securities on the consolidated balance sheet as of December 31, 2021. See Note 3–Available for Sale Debt Securities for additional discussion.

127
ROYALTY PHARMA PLC
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS



In November 2019, RPIFT agreed to pay $330.0 million to purchase Eisai’s royalties on future worldwide sales of Tazverik, a novel targeted therapy in late-stage clinical development that was approved by the FDA in January 2020 for epithelioid sarcoma, and with the potential to be approved in several cancer indications. Under the terms of our agreement with Eisai, we acquired Eisai’s future worldwide royalties on net sales by Epizyme of Tazverik outside of Japan, for an upfront payment of $110.0 million plus up to an additional $220.0 million for the remainder of the royalty upon FDA approval of Tazverik for certain indications. The FDA approval of Tazverik in January 2020 triggered our obligation to fund the second $110.0 million tranche in November 2020. On November 4, 2021, we funded the final $110.0 million tranche.

We have commitments to advance funds to counterparties through our investment in the Avillion Entities and R&D arrangements. Please refer to Note 9–Non-Consolidated Affiliates and Note 10–Research & Development (“R&D”) Funding Expense, respectively, for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the management agreement as described in Note 16–Related Party Transactions, which are variable and primarily based on cash receipts.

Legal Proceedings

We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings in our consolidated balance sheets as of December 31, 2021 and 2020. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.

18. Subsequent Events

In January 2022, we acquired a royalty interest in aficamten from Cytokinetics, Incorporated (“Cytokinetics”) for $150.0 million, comprised of an upfront payment of $50 million and two additional $50 million payments which are conditional upon the initiation of potential pivotal clinical trials for obstructive hypertrophic cardiomyopathy and nonobstructive hypertrophic cardiomyopathy, respectively. Additionally, we will provide Cytokinetics long-term capital of up to $300 million (“Cytokinetics Commercial Launch Funding”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. The Cytokinetics Commercial Launch Funding is available in five tranches, including an initial tranche of $50 million funded upon closing and four additional tranches in the aggregate amount of $250 million upon the occurrence of certain regulatory and clinical development milestones.


128


Item 9.         CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES

None.

Item 9A.     CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this Annual Report on Form 10-K. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were, in design and operation, effective to the reasonable assurance level.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act of 1934, as amended). Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission in its 2013 Internal Control-Integrated Framework. Based on this assessment, our management has concluded that our internal control over financial reporting was effective as of December 31, 2021 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. Our independent registered public accounting firm, Ernst & Young, has issued an audit report on our internal control over financial reporting as of December 31, 2021. Their report is included in Item 8 of this Annual Report on Form 10-K.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal controls over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the three months ended December 31, 2021 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.

Item 9B.     OTHER INFORMATION

Not applicable.

PART III

Item 10.     DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this Item will be presented in our Proxy Statement to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.


129

Item 11.     EXECUTIVE COMPENSATION

The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.

Item 12.     SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.

Item 13.     CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTORS INDEPENDENCE

The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.

Item 14.     PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this Item will be presented in our Proxy Statement, to be filed not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and is incorporated herein by reference.

130

PART IV

Item 15.     EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

The following exhibits are filed as a part of this Annual Report on Form 10-K:

Incorporated by Reference
Exhibit Number
Exhibit Description
FormExhibitFiling Date/
Period End Date		Filed or Furnished Herewith
3.18-K3.16/19/2020
3.28-K3.26/19/2020
4.1S-1/A4.16/11/2020
4.2x
10.18-K10.26/19/2020
10.28-K10.16/19/2020
10.38-K10.46/19/2020
10.4†S-1/A10.56/2/2020
10.5†S-1/A10.66/11/2020
10.6#S-1/A10.76/2/2020
10.7#S-1/A10.86/2/2020
10.8#S-110.95/22/2020
10.9#S-110.105/22/2020
10.10S-110.115/22/2020
10.11#S-110.125/22/2020
10.12#S-110.135/22/2020
131

10.138-K10.36/19/2020
10.14†S-1/A10.156/11/2020
10.158-K4.19/2/2020
10.168-K4.29/2/2020
10.178-K4.99/2/2020
10.18#8-K10.111/5/2020
10.198-K4.27/26/2021
21.1S-121.15/22/2020
23.1x
24.1Power of Attorney (reference is made to the signature page hereto)x
31.1x
31.2x
32*x
101.INS
XBRL Taxonomy Extension Instance Document
x
101.SCH
XBRL Taxonomy Extension Schema Document
x
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
x
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
x
101.LAB
XBRL Taxonomy Extension Label Linkbase Document
x
101.PRE
XBRL Taxonomy Extension Presentation Linkbase
x
104Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101)x

†     Management contract or compensatory plan or arrangement.
#     Certain information has been excluded from the exhibit because it both (i) is not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
*     The certifications furnished in Exhibit 32 hereto are deemed to accompany this Annual Report on Form 10-K and are not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of the Exchange Act.
Item 16.     FORM 10-K SUMMARY
None.
132

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

ROYALTY PHARMA PLC
(Registrant)

Date: February 15, 2022/s/ Pablo Legorreta
Pablo Legorreta
Chief Executive Officer
Date: February 15, 2022/s/ Terrance Coyne
Terrance Coyne
Chief Financial Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Terrance Coyne and George Lloyd, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.























133

SignatureTitleDate
/s/ Pablo Legorreta
 Chairman of the Board, Director & Chief Executive Officer
(Principal Executive Officer and Royalty Pharma plc’s authorized representative in the United States)
February 15, 2022
Pablo Legorreta
/s/ Terrance Coyne
Executive Vice President & Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
February 15, 2022
Terrance Coyne
/s/ Bonnie BasslerDirectorFebruary 15, 2022
Bonnie Bassler
/s/ Errol De SouzaDirectorFebruary 15, 2022
Errol De Souza
/s/ Catherine EngelbertDirectorFebruary 15, 2022
Catherine Engelbert
/s/ Henry FernandezDirectorFebruary 15, 2022
Henry Fernandez
/s/ William FordDirectorFebruary 15, 2022
William Ford
/s/ M. Germano GiulianiDirectorFebruary 15, 2022
M. Germano Giuliani
/s/ Ted LoveDirectorFebruary 15, 2022
Ted Love
/s/ Gregory NordenDirectorFebruary 15, 2022
Gregory Norden
/s/ Rory RiggsDirectorFebruary 15, 2022
Rory Riggs
134
 EX-4.2 2 rprx-20211231ex42.htm EX-4.2 Document
Exhibit 4.2

DESCRIPTION OF SECURITIES
REGISTERED UNDER SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934
As of December 31, 2021, Royalty Pharma plc (“Royalty Pharma” or the “Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934: our Class A ordinary shares, par value $0.0001 per share, which are listed on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “RPRX.”
The following description is a summary of our share capital as specified in our Articles of Association. This summary does not purport to be complete and the statements in this summary are qualified in their entirety by reference to, and are subject to, the detailed provisions of our Articles of Association and the U.K. Companies Act.
Capital Structure
Issued Share Capital
We have two classes of voting shares: Class A and Class B, each of which has one vote per share. The Class A ordinary shares and Class B shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. We also have in issue 50,000 Class R redeemable shares, which do not entitle the holder to voting or dividend rights, and deferred shares, which do not entitle the holder to voting or dividend rights. The purpose of the Class R redeemable shares was to ensure we had sufficient sterling denominated share capital at the time we re-registered as a public limited company, as required by the U.K. Companies Act. The Class R redeemable shares may be redeemed at some future point in order to leave the Company with only U.S. dollar denominated share capital. Any such redemption would be at nominal value.
The board of directors has been granted authority from our shareholders to allot and issue new Class A ordinary shares and other shares, and to grant rights to subscribe for or to convert any security into new Class A ordinary shares or other shares, up to a maximum aggregate nominal amount (i.e., par value) of $300,000, for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) on May 31, 2025. Renewal of such authorization is expected to be sought at least once every five years, and possibly more frequently. This authority is in addition to authorities to allot and issue new Class A ordinary shares in exchange for Royalty Pharma Holdings Ltd Class B ordinary shares or the depositary receipts that represent them. The rights and restrictions to which the Class A ordinary shares are subject are prescribed by our Articles of Association.
Class A Ordinary Shares
Voting rights. The holders of Class A ordinary shares are entitled to one vote per share on all matters to be voted upon by the shareholders other than with respect to matters that require a separate class vote in accordance with applicable law.
Dividend rights. Subject to preferences that may be applicable, the holders of Class A ordinary shares are entitled to receive ratably such dividends, if any, as may be approved from time to time by the board of directors out of funds legally available therefor.
Rights upon liquidation. In the event of liquidation, dissolution or winding up of Royalty Pharma the holders of Class A ordinary shares are entitled to share ratably in all assets remaining after payment of liabilities.
Class B Shares
Voting rights. The holders of Class B shares are entitled to one vote per share on all matters to be voted upon by the shareholders other than with respect to matters that require a separate class vote in accordance with applicable law.
 
Dividend rights. The holders of Class B shares do not have any rights to receive dividends.


Rights upon liquidation. The holders of Class B shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of Royalty Pharma, following the prior payment of the nominal capital paid up or credited as paid up on each Class A ordinary share as well as an amount of $10,000,000 on each Class A ordinary share upon such liquidation, dissolution or winding up.
Dividends
Under English law, the Company may only pay dividends out of profits available for that purpose. The Company’s profits available for distribution are its accumulated, realized profits, to the extent that they have not been previously utilized by distribution or capitalization, less its accumulated, realized losses, to the extent that they have not been previously written off in a reduction or reorganization of capital duly made. The amount of the Company’s distributable reserves is a cumulative calculation. The Company may be profitable in a single financial year but unable to pay a dividend if our accumulated, realized profits of that year do not offset all previous years’ accumulated, realized losses.
Additionally, the Company may only make a distribution if the amount of its net assets is not less than the aggregate of its called-up share capital and undistributable reserves, and if, and to the extent that, the distribution does not reduce the amount of those assets to less than that aggregate.
Our Articles of Association authorize our board of directors to approve interim dividends without shareholder approval to the extent that the approval of such dividends appears justified by profits. Our board of directors may also recommend a final dividend to be approved and declared by the shareholders at an annual general meeting and may direct that the payment be made by distribution of assets, shares or cash. No dividend may exceed the amount recommended by the board of directors.
Our Articles of Association also permit a scrip dividend scheme under which the board of directors may offer any holders of Class A ordinary shares the right to elect to receive Class A ordinary shares, credited as fully paid, instead of cash in respect of the whole (or some part determined by the board of directors) of all or any dividend subject to certain terms and conditions set out in our Articles of Association.
The entitlement to a dividend lapses if unclaimed for 12 years.
Voting Rights
Under the Articles of Association, each holder of Class A ordinary shares or Class B shares is entitled to one vote for each share that he or she holds as of the record date for the meeting. Neither English law nor any of our constituent documents places limitations on the right of nonresident or foreign owners to vote or hold ordinary shares. The voting at a general meeting must be taken by poll. Subject to any relevant special rights or restrictions attached to any shares, on a poll taken at a general meeting, each qualifying shareholder present in person or by proxy (or, in the case of a corporation, a corporate representative) and entitled to vote on the resolution has one vote for every Class A ordinary share or Class B share held by such shareholder.
An ordinary resolution must be approved by a simple majority, and a special resolution approved by at least 75%, of shareholders attending and voting, whether in person or by proxy.
Amendment to our Articles of Association
Under English law, shareholders may amend the articles of association of a company by special resolution. However, certain provisions of our Articles of Association require a higher threshold of shareholder approval or satisfaction of other procedures before such provision or provisions can be varied.
The article in our Articles of Association which requires voting at a general meeting to be taken on a poll may only be removed, amended or varied by resolution of the shareholders passed unanimously.


Winding Up
In the event of a voluntary winding up of the Company, the liquidator may, with the sanction of a special resolution of the Company and any other sanction required by law, subject to the U.K. Insolvency Act of 1986, after effectively applying the Company’s property to satisfy the Company’s liabilities, divide among the holders of Class A ordinary shares of the Company the whole or any part of the assets of the Company, whether they consist of property of the same kind or not, and vest the whole or any part of the assets in trustees upon such trusts for the benefit of the holders of Class A ordinary shares of the Company as the liquidator, with such sanction, may determine. No shareholder of the Company shall be compelled to accept any assets upon which there is a liability.
On a return of capital on a liquidation, reduction of capital or otherwise, the surplus assets of the Company available for distribution among the holders of Class A ordinary shares shall be applied pro rata (rounded to the nearest whole number).
Rights of Pre-Emption on New Issues of Shares
Under the U.K. Companies Act, the allotment of “equity securities” (except pursuant to an employees’ share scheme and as bonus shares) that are to be paid for wholly in cash must be offered first to the existing holders of ordinary shares in proportion to the respective nominal amounts (i.e., par values) of their holdings on the same or more favorable terms, unless a special resolution to the contrary has been passed or the articles of association otherwise provide disapplication from this requirement (which disapplication can be for a maximum of five years after which shareholders’ approval would be required to renew the disapplication). “Equity securities” means ordinary shares or rights to subscribe for, or convert securities into, ordinary shares where ordinary shares means shares other than shares that, with respect to dividends and capital, carry a right to participate only up to a specified amount in a distribution. In relation to the Company, “equity securities” will therefore include the Class A ordinary shares, and all rights to subscribe for or convert securities into such shares.
The board of directors has been granted authority from our shareholders to allot and issue new Class A ordinary shares and other shares and to grant rights to subscribe for or to convert any security into new Class A ordinary shares or other shares, up to a maximum aggregate nominal amount (i.e., par value) of $300,000 for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) on May 31, 2025. Renewal of such authorization is expected to be sought at least once every five years, and possibly more frequently.
Disclosure of Ownership Interests in Shares
Section 793 of the U.K. Companies Act gives us the power to require persons whom we know have, or whom we have reasonable cause to believe have, or within the previous three years have had, an interest in any shares of the Company to disclose specified information regarding those shares. Failure to provide the information requested within the prescribed period (or knowingly or recklessly providing false information after the date the notice is sent) can result in criminal or civil sanctions being imposed against the person in default.
Under our Articles of Association, if any of our shareholders, or any other person appearing to be interested in the shares of the Company held by such shareholder, has been duly served with a notice under section 793 and fails to give us the information required by such notice or has made a statement which is false or inadequate in a material particular, then our board of directors may, in its absolute discretion at any time by notice, withdraw voting rights and place restrictions on the rights to receive dividends and refuse to register a transfer of such shares.
 
Alteration of Share Capital/Share Repurchases
Subject to the provisions of the U.K. Companies Act, and without prejudice to any relevant special rights attached to any class of shares, we may, from time to time, among other things:
•    increase our share capital by allotting and issuing new shares in accordance with our Articles of Association and any relevant shareholder resolution;


•    consolidate all or any of our share capital into shares of a larger nominal amount (i.e., par value) than the existing shares;
•    subdivide any of our shares into shares of a smaller nominal amount (i.e., par value) than the existing shares; or
•    redenominate our share capital or any class of share capital
The Company may not consolidate, divide, subdivide or redenominate any class of voting shares without consolidating, dividing, subdividing or redenominating (as the case may be) the other classes of voting shares.
English law prohibits us from purchasing our own shares unless such purchase has been approved by our shareholders. Shareholders may approve two different types of such share purchases: “on-market” share purchases or “off-market” share purchases. “On-market” purchases may only be made on a “recognised investment exchange,” which does not include Nasdaq, which is the only exchange on which the Company’s shares are traded. In order to purchase our own shares, as a Company listed on Nasdaq, we must therefore obtain the approval of our shareholders for an “off-market purchase” (on the basis of a specific purchase agreement with a financial intermediary) to acquire shares that are traded on Nasdaq. This requires our shareholders to pass an ordinary resolution approving an “off-market purchase,” where such approval may be for a maximum period of five years. In relation to an “off-market purchase,” we may not acquire our own shares until the terms of the contract pursuant to which the purchase(s) are to be made have been authorized by our shareholders.
Transfer and Registration of Shares
Our Articles of Association allow shareholders to transfer all or any of their shares by instrument of transfer in writing in any usual form or in any other form which our board of directors may approve.
The instrument of transfer must be executed by or on behalf of the transferor and (in the case of a transfer of a share that is not fully paid) by or on behalf of the transferee. Our Articles of Association also permit transfer of shares in uncertificated form by means of a relevant electronic system.
We may not charge a fee for registering the transfer of a share.
Our board of directors may, in its absolute discretion, refuse to register a transfer of shares in certificated form if it is not fully paid (provided that the refusal does not prevent dealings in the shares from taking place on an open and proper basis) or is with respect to a share on which we have a lien and sums in respect of which the lien exists are payable and are not paid within 14 clear days after due notice has been sent. If our board of directors refuses to register a transfer of a share, it shall notify the transferor of the refusal and the reasons for it as soon as practicable and in any event within two months after the date on which the instrument of transfer was lodged with us (in the case of a transfer of a share in certificated form) or the instructions to the relevant system received. Any instrument of transfer which our board of directors refuses to register shall (except in the case of fraud) be returned to the person lodging it when notice of the refusal is sent.
Computershare Trust Company, N.A. acts as our transfer agent and registrar. The share register reflects only registered owners of our Class A ordinary shares, Class B shares, Class R redeemable shares and deferred shares. Registration in the Company’s share register is determinative of ownership of shares of the Company. A shareholder who holds shares beneficially is not the holder of record of such shares. Instead, the clearance service or depositary (for example, Cede & Co, as nominee for the Depository Trust Company, or DTC, or GTU Ops, Inc., as nominee for Computershare Trust Company, N.A.) or other nominee is the holder of record of those shares. Accordingly, a transfer of shares from a person who holds such shares beneficially to a person who holds such shares beneficially through a clearance service or depositary or other nominee will not be registered in the Company’s official share register, as the depositary or other nominee will remain the record holder of any such shares.
In the event that the Company notifies one or both of the parties to a share transfer that it believes stamp duty or stamp duty reserve tax is required to be paid in connection with a transfer of shares of the Company, if the parties


to the transfer have an instrument of transfer duly stamped to the extent required and then provide such instrument of transfer to the Company’s share registrar, the buyer will be registered as the legal owner of the relevant shares on the official share register, subject to our rights with respect to the disclosure of interests in our shares.

Takeover Provisions
Regulation of Takeover Bids
Given that our central management and control is currently not situated within, and our current intention is not to have it in the future situated within the United Kingdom (or the Channel Islands or the Isle of Man), we do not currently envisage that the City Code on Takeovers and Mergers (the “Takeover Code”) will apply to an offer for the Company. It is possible that in the future circumstances could change that may cause the Takeover Code to apply to us. The Takeover Code provides a framework within which takeovers of companies subject to it are conducted. In particular, the Takeover Code contains certain rules in respect of mandatory offers. Under Rule 9 of the Takeover Code, if a person:
•    acquires an interest in shares that, when taken together with shares in which such person is already interested and in which persons acting in concert with such person are interested, carries 30% or more of the voting rights of shares; or
•    who, together with persons acting in concert with such person, is interested in shares that in the aggregate carry not less than 30% of the voting rights but is not interested in shares carrying more than 50% of such voting rights and such person, or any person acting in concert with such person, acquires an additional interest in shares that increases the percentage of shares carrying voting rights in which that person is interested,
the acquirer, and, depending on the circumstances, its concert parties, would be required (except with the consent of the Takeover Panel) to make a cash offer for the outstanding shares at a price not less than the highest price paid for any interests in the shares by the acquirer or its concert parties during the previous 12 months.
Under English law, an offeror for the Company that has acquired (i) not less than 90% in value of; and (ii) not less than 90% of the voting rights carried by the shares to which the offer relates may exercise statutory squeeze-out rights to compulsorily acquire the shares of the non-assenting minority. However, if an offer for the Company is conducted by way of a scheme of arrangement the threshold for the offeror obtaining 100% of Company shares comprises two components (i) approval by a majority in number of each class of Company shareholders present and voting at the shareholder meeting; and (ii) approval of Company shareholders representing 75% or more in value of each class of Company shareholders present and voting at that meeting.
Share Issues in the Context of an Acquisition
Our Articles of Association provide the board of directors with the power to establish a rights plan and to grant rights to subscribe for our shares pursuant to a rights plan where, in the opinion of the board of directors, acting in good faith, in the context of an acquisition or potential acquisition of 15% or more of our issued voting shares, to do so would improve the likelihood that:
•    an acquisition process is conducted in an orderly manner;
•    all our shareholders are treated equally and fairly and in a similar manner;
•    an optimum price is achieved for our Class A ordinary shares;
•    the board of directors would have time to gather relevant information and pursue appropriate strategies;
•    the success of Royalty Pharma would be promoted for the benefit of our shareholders as a whole;
•    the long term interests of Royalty Pharma, our shareholders and business would be safeguarded; and/or
•    Royalty Pharma would not suffer serious economic harm.


Our Articles of Association further provide that the board of directors may, in accordance with the terms of a rights plan, determine to (i) allot shares pursuant to the exercise of rights or (ii) exchange rights for our shares, where in the opinion of the board of directors acting in good faith, in the context of an acquisition or potential acquisition of 15% or more of our issued voting shares, to do so is necessary in order to prevent:
•    the use of abusive tactics by any person in connection with such acquisition;
•    unequal treatment of shareholders;
•    an acquisition which would undervalue Royalty Pharma;
•    harm to the prospects of the success of Royalty Pharma for the benefit of its shareholder as a whole; and/or
•    serious economic harm to the prospects of Royalty Pharma,
or where to do so is otherwise necessary to safeguard the long term interests of Royalty Pharma, our shareholders and our business.
Under the Takeover Code, the board of a public company incorporated under the laws of England and Wales is constrained from implementing such defensive measures. However, as discussed above, these measures are included in our Articles of Association as the Takeover Code is not expected to apply to us and these measures are included commonly in the constitution of U.S. companies.
These provisions will apply for so long as we are not subject to the Takeover Code.
 


 EX-23.1 3 rprx-20211231ex231.htm EX-23.1 Document



Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
1.Registration Statement (Form S-8 No. 333-239193) pertaining to the Royalty Pharma plc 2020 Independent Director Equity Incentive Plan; and
2.Registration Statement (Form S-4 No. 333-257188) of Royalty Pharma plc; and
3.Registration Statement (Form S-3ASR No. 333-257883) of Royalty Pharma plc;
of our report dated February 15, 2022, with respect to the consolidated financial statements of Royalty Pharma plc and the effectiveness of internal control over financial reporting of Royalty Pharma plc, included in this Annual Report (Form 10-K) of Royalty Pharma plc for the year ended December 31, 2021.

/s/ Ernst & Young

Dublin, Ireland

February 15, 2022



 EX-31.1 4 rprx-20211231ex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Pablo Legorreta, certify that:
1.    I have reviewed this Annual Report on Form 10-K of Royalty Pharma plc;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 15, 2022
/s/ Pablo Legorreta
Pablo Legorreta
Chief Executive Officer

2
    
 EX-31.2 5 rprx-20211231ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Terrance Coyne, certify that:
1.    I have reviewed this Annual Report on Form 10-K of Royalty Pharma plc;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 15, 2022

/s/ Terrance Coyne
Terrance Coyne
Chief Financial Officer

2
    
 EX-32 6 rprx-20211231ex32.htm EX-32 Document

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report on Form 10-K of Royalty Pharma plc (the “Company”) for the fiscal year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company certifies pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and;
2.    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 15, 2022
/s/ Pablo Legorreta
Name: Pablo Legorreta
Chief Executive Officer
/s/ Terrance Coyne
Name: Terrance Coyne
Chief Financial Officer

 EX-101.SCH 7 rprx-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0002002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 1001003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003005 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004006 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1005007 - Statement - Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 1006008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1007009 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Purpose link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Organization and Purpose (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2106103 - Disclosure - Available for Sale Debt Securities link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Available for Sale Debt Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Available for Sale Debt Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2110104 - Disclosure - Derivative Instruments link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Derivative Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Derivative Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Derivative Instruments - Summary of Derivatives and Reclassifications (Details) link:presentationLink link:calculationLink link:definitionLink 2114105 - Disclosure - Fair Value Measurements and Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - Fair Value Measurements and Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 2417408 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2418409 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2419410 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2120106 - Disclosure - Financial Royalty Assets, Net link:presentationLink link:calculationLink link:definitionLink 2321304 - Disclosure - Financial Royalty Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2422411 - Disclosure - Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2123107 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets link:presentationLink link:calculationLink link:definitionLink 2324305 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2425412 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2426413 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 2127108 - Disclosure - Intangible Royalty Assets, Net link:presentationLink link:calculationLink link:definitionLink 2328306 - Disclosure - Intangible Royalty Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2429414 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) link:presentationLink link:calculationLink link:definitionLink 2430415 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2131109 - Disclosure - Non-Consolidated Affiliates link:presentationLink link:calculationLink link:definitionLink 2432416 - Disclosure - Non-Consolidated Affiliates (Details) link:presentationLink link:calculationLink link:definitionLink 2133110 - Disclosure - Research & Development ("R&D") Funding Expense link:presentationLink link:calculationLink link:definitionLink 2434417 - Disclosure - Research & Development ("R&D") Funding Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2135111 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 2336307 - Disclosure - Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 2437418 - Disclosure - Borrowings - Schedule of Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 2437418 - Disclosure - Borrowings - Schedule of Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 2438419 - Disclosure - Borrowings - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2439420 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details) link:presentationLink link:calculationLink link:definitionLink 2140112 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2341308 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2442421 - Disclosure - Shareholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2443422 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 2144113 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2345309 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2446423 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2147114 - Disclosure - Indirect Cash Flow link:presentationLink link:calculationLink link:definitionLink 2348310 - Disclosure - Indirect Cash Flow (Tables) link:presentationLink link:calculationLink link:definitionLink 2449424 - Disclosure - Indirect Cash Flow (Details) link:presentationLink link:calculationLink link:definitionLink 2150115 - Disclosure - Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 2351311 - Disclosure - Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2452425 - Disclosure - Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2153116 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2354312 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 2455426 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2156117 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2457427 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2158118 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2459428 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 rprx-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 rprx-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 rprx-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Hedging Designation [Domain] Hedging Designation [Domain] Financial royalty assets, net Financing Receivable, after Allowance for Credit Loss, Noncurrent Customer [Domain] Customer [Domain] Milestone payments Payments For Milestones Payments For Milestones Unrealized Gains on Available for Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Earnings per share Earnings Per Share, Policy [Policy Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net income attributable to controlling interest Net Income (Loss) Attributable to Parent RPSFT Royal Pharmacy Select Finance Trust [Member] Royal Pharmacy Select Finance Trust Available for sale debt securities Available for sale debt securities, current Debt Securities, Available-for-sale, Current Three Point Three Five Percent Senior Notes Due 2051 Three Point Three Five Percent Senior Notes Due 2051 [Member] Three Point Three Five Percent Senior Notes Due 2051 RP Holdings RP Holdings [Member] RP Holdings Contributions Noncontrolling Interest, Increase from Contributions Noncontrolling Interest, Increase from Contributions Income Statement Location [Axis] Income Statement Location [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] RPCT Royalty Pharma Collection Trust [Member] Royalty Pharma Collection Trust Schedule of Repayments of Debt by Year Schedule of Maturities of Long-term Debt [Table Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Segment Information Segment Reporting, Policy [Policy Text Block] Dividends declared and paid Dividends, Common Stock, Cash Security Exchange Name Security Exchange Name Equity securities Equity Securities, FV-NI, Current Contributions from non-controlling interest- other Proceeds From Noncontrolling Interests, Other Proceeds From Noncontrolling Interests, Other Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Exchange Offer Transaction Exchange Offer Transaction [Member] Exchange Offer Transaction Old RPI Royalty Pharma Investments (Old RPI) [Member] Royalty Pharma Investments (Old RPI) Effect of exchange by Continuing Investors of Class B shares for Class A shares and reallocation of historical equity (in shares) Stockholders' Equity, Shares, Effect Of Exchange And Reallocation Stockholders' Equity, Shares, Effect Of Exchange And Reallocation Two Point One Five percent Senior Notes Due 2031 Two Point One Five percent Senior Notes Due 2031 [Member] Two Point One Five percent Senior Notes Due 2031 Increase in quarterly installment payments (as a percent) Related Party Transaction, Annual Increase, Percentage Related Party Transaction, Annual Increase, Percentage Other assets Other Assets, Noncurrent The Notes The Notes [Member] The Notes Financial royalty assets Financing Receivable, after Allowance for Credit Loss, Current Investment, Name [Axis] Investment, Name [Axis] Derivatives Derivatives, Policy [Policy Text Block] Interest income Interest Income, Operating Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Redemption price (as a percent) Debt Instrument, Redemption Price, Percentage Issuance of Class B ordinary shares to Continuing Investors Partnerships Stock Issued During Period, Value, Issued To Partnerships Stock Issued During Period, Value, Issued To Partnerships 2023 Long-Term Debt, Maturity, Year Two Certificates of Deposit Certificates of Deposit [Member] Summary of Available for Sale Debt Securities Debt Securities, Available-for-sale [Table Text Block] Other royalty income receivable Increase (Decrease) In Other Royalty Income Receivable Increase (Decrease) In Other Royalty Income Receivable Audit Information [Abstract] Audit Information Subsequent Event Type [Domain] Subsequent Event Type [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization of intangible assets Amortization of Intangible Assets Legacy Investors Partnerships and RPSFT Legacy Investors Partnerships and RPSFT [Member] Legacy Investors Partnerships and RPSFT Equity Investment In Epizyme Inc. Epizyme Inc. [Member] Epizyme Inc. Transfer of interests Noncontrolling Interest, Transfers Of Interests Noncontrolling Interest, Transfers Of Interests Put Option Put Option [Member] Sale of Stock [Axis] Sale of Stock [Axis] Subsequent Events [Abstract] Cystic fibrosis franchise Cystic Fibrosis Franchise [Member] Cystic Fibrosis Franchise Current period provision for credit losses, net Financing Receivable, Credit Loss, Expense (Reversal) Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent) Related Party Transaction, Rate, Adjusted Cash Receipts Related Party Transaction, Rate, Adjusted Cash Receipts Business Acquisition [Axis] Business Acquisition [Axis] Unrealized gains on available for sale debt securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Interest payable Increase (Decrease) in Interest Payable, Net Derivatives not designated as hedging instruments Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Award Type [Domain] Award Type [Domain] RPI Intermediate FT RPI 2019 Intermediate Finance [Member] RPI 2019 Intermediate Finance Local Phone Number Local Phone Number Credit Facility [Domain] Credit Facility [Domain] Assets Assets [Abstract] Related Party Transactions [Abstract] Maximum consolidated leverage ratio following qualifying material acquisition Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition Upfront payment and premium paid Research and Development Expense, Upfront Payment and Premium Paid Research and Development Expense, Upfront Payment and Premium Paid 2024 Long-Term Debt, Maturity, Year Three Long term funding partnership, number of tranches Long Term Funding Partnership, Number of Tranches Long Term Funding Partnership, Number of Tranches Redemption default, interest rate Debt Securities, Available-For-Sale, Redemption Default, Interest Rate Debt Securities, Available-For-Sale, Redemption Default, Interest Rate Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense Derivative Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Redemption, Period One Debt Securities, Available-For-Sale, Redemption, Period One [Member] Debt Securities, Available-For-Sale, Redemption, Period One New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Concentration risk (as a percent) Individual licensees exceeding 10% or more of revenue (as a percent) Concentration Risk, Percentage Accounting Standards Update and Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Dividends Dividends, Cash Distributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Retained Earnings Retained Earnings [Member] IPO IPO [Member] Debt Instrument [Axis] Debt Instrument [Axis] Cumulative funding amount Related Party Transaction, Cumulative Funding Amount Related Party Transaction, Cumulative Funding Amount Avillion II Avillion II [Member] Avillion II Ownership percentage (as a percent) Noncontrolling Interest, Ownership Percentage by Parent Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Remaining commitment Long Term Purchase Commitment, Amount Outstanding Long Term Purchase Commitment, Amount Outstanding Related Party [Axis] Related Party [Axis] Royalty Distribution Payable to Legacy Investors Partnerships Royalty Distribution Payable to Legacy Investors Partnerships [Member] Royalty Distribution Payable to Legacy Investors Partnerships Preferred shares, weighted average cost of capital Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital Distributions from non-consolidated affiliates Proceeds from Equity Method Investment, Distribution Upfront payment for equity investment Payments to Acquire Equity Investments, Upfront Payment Payments to Acquire Equity Investments, Upfront Payment Senior Secured Debt Secured Debt [Member] 2020 Equity Incentive Plan 2020 Equity Incentive Plan [Member] 2020 Equity Incentive Plan Debt Securities, Available-For-Sale, Redemption, Period [Domain] Debt Securities, Available-For-Sale, Redemption, Period [Domain] Debt Securities, Available-For-Sale, Redemption, Period Expected return (as a percent) Collaborative Arrangement, Rights and Obligations, Expected Return Collaborative Arrangement, Rights and Obligations, Expected Return Derivative Instruments and Hedging Activities Disclosure [Abstract] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Commitments and Contingencies Disclosure [Abstract] Treasury Rate Lock Contracts Treasury Rate Lock Contracts [Member] Treasury Rate Lock Contracts Weighted average coupon rate (as a percent) Debt, Weighted Average Interest Rate Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Revision of Prior Period, Reclassification, Adjustment Revision of Prior Period, Reclassification, Adjustment [Member] Other current assets and other assets Increase (Decrease) in Other Current Assets Research & Development ("R&D") Funding Expense Research, Development, and Computer Software Disclosure [Text Block] Provision for changes in expected cash flows from financial royalty assets Provision for Loan and Lease Losses Number of operating segments Number of Operating Segments Other commitments, percentage of costs (as a percent) Other Commitments, Percentage Other Commitments, Percentage Basic (in dollars per share) Earnings per Class A ordinary share - basic (in dollars per share) Earnings Per Share, Basic Financial Royalty Assets, Net Financing Receivables [Text Block] Long-term Purchase Commitment, Category of Item Purchased [Domain] Long-term Purchase Commitment, Category of Item Purchased [Domain] Document Information [Line Items] Document Information [Line Items] Allowance for current expected credit losses Credit Loss, Financial Instrument [Policy Text Block] 2022 Long-Term Debt, Maturity, Year One Aggregate royalty amount when patents cease Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents 2026 Long-Term Debt, Maturity, Year Five Amounts due from related parties Due from Related Parties Fair Value Measurement [Domain] Fair Value Measurement [Domain] Unrealized gain (loss) on derivatives Losses on derivative financial instruments Unrealized Gain (Loss) on Derivatives Senior Notes Due 2031 Senior Notes Due 2031 [Member] Senior Notes Due 2031 Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Acquisitions of financial royalty assets Payments to Acquire Finance Receivables Commercial Paper Commercial Paper [Member] Other Other Noncash Income (Expense) Research and development funding expense Research and Development Expense, Policy [Policy Text Block] Long-term debt, gross Long-term Debt, Gross Development Funding Bond Forward Development Funding Bond Forward [Member] Development Funding Bond Forward Entity Voluntary Filers Entity Voluntary Filers Class R Redeemable Stock Class R Redeemable Stock [Member] Class R Redeemable Stock Plan Name [Axis] Plan Name [Axis] Assets: Assets, Fair Value Disclosure [Abstract] Total debt carrying value Long-term Debt Distributions from non-consolidated affiliates Proceeds from Equity Method Investment, Distribution, Return of Capital Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Accrued purchase obligation - Tazverik Accrued Purchase Obligation, Equity Investment Accrued Purchase Obligation, Equity Investment Price per share (in USD per share) Debt Securities, Available-For-Sale, Price Per Share Debt Securities, Available-For-Sale, Price Per Share Entity Small Business Entity Small Business Related party, rate (as a percent) Related Party Transaction, Rate Schedule of Cumulative Allowance for Changes in Expected Cash Flows Financing Receivable, Allowance for Credit Loss [Table Text Block] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and shareholders’ equity Liabilities and Equity Overnight Bank Funding Rate Overnight Bank Funding Rate [Member] Overnight Bank Funding Rate Investments, Debt and Equity Securities [Abstract] Total distribution payable to non-controlling interest Due to Related Parties, Noncurrent Other expense/(income) Other Income and Expenses [Abstract] Current portion of Financial royalty assets Financing Receivable [Member] Additional paid-in capital Additional Paid in Capital Supplemental Cash Flow Elements [Abstract] Liabilities and equity Liabilities and Equity [Abstract] Accrued royalty receivable Accrued Royalty Receivable Accrued Royalty Receivable Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs Proceeds from Issuance Initial Public Offering Interest Rate Swap Interest Rate Swap [Member] Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Earnings Per Share Earnings Per Share [Text Block] Purchase of treasury interests Treasury interests Treasury Stock, Value, Acquired, Cost Method Operating expenses Operating Expenses [Abstract] Entity Interactive Data Current Entity Interactive Data Current Thereafter Long-Term Debt, Maturity, after Year Five Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Organization and Purpose Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Continuing Investors Partnerships Continuing Investors Partnership [Member] Continuing Investors Partnership Merck Asset - Phase II Clinical Trial Merck Asset - Phase II Clinical Trial [Member] Merck Asset - Phase II Clinical Trial Number of shares converted (in shares) Sale Of Stock, Number Of Shares Not Converted Sale Of Stock, Number Of Shares Not Converted Affiliated Entity Affiliated Entity [Member] Writeoff related to financial royalty asset Financing Receivable, Allowance for Credit Loss, Financial Royalty Asset, Writeoff Financing Receivable, Financial Royalty Asset, Writeoff Interest income accretion Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss) Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss) Reclassification Reclassification, Comparability Adjustment [Policy Text Block] Epizyme Common Stock Warrant Epizyme Common Stock Warrant [Member] Epizyme Common Stock Warrant Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Assignment Agreement - Benefit of Payment Stream Assignment Agreement - Benefit of Payment Stream [Member] Assignment Agreement - Benefit of Payment Stream Entity Address, State or Province Entity Address, State or Province Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Income from financial royalty assets Financial Royalty Assets [Member] Financial Royalty Assets Fair Value Disclosure of Asset and Liability Not Measured at Fair Value Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block] Evrysdi Evrysdi [Member] Evrysdi Deferred Shares Deferred Shares Deferred Shares [Member] Deferred Shares Interest received Proceeds from Interest Received Initial share issuance upon registration of Royalty Pharma plc Stock Issued During Period, Value, Issued For Registration Stock Issued During Period, Value, Issued For Registration Current liabilities Liabilities, Current [Abstract] 2025 Long-Term Debt, Maturity, Year Four Issuance of Class A ordinary shares sold in IPO, net of offering costs Stock Issued During Period, Value, New Issues Former Operating and Personnel Payments Former Operating and Personnel Payments [Member] Former Operating and Personnel Payments Revenue from intangible royalty assets and Accrued royalty receivable Revenue [Policy Text Block] General and administrative expenses General and Administrative Expense Indirect Cash Flow Cash Flow, Supplemental Disclosures [Text Block] Revision of Prior Period [Axis] Revision of Prior Period [Axis] Borrowings Debt Disclosure [Text Block] Period of return Collaborative Arrangement, Rights and Obligations, Period of Return Collaborative Arrangement, Rights and Obligations, Period of Return Beginning balance (in shares) Ending balance (in shares) Shares, outstanding (in shares) Shares, Outstanding Number of noncontrolling interests created Number Of Noncontrolling Interests Created Number Of Noncontrolling Interests Created Senior Notes Senior Notes [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Credit Loss, Financial Instrument [Text Block] Operating and personnel payments incurred Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party Equity Securities Equity Securities [Member] Accounting Policies [Abstract] Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity Stockholders' Equity, Value, Effect Of Exchange And Reallocation Stockholders' Equity, Value, Effect Of Exchange And Reallocation Receipt of contribution of investments in Legacy Investors Partnerships Noncash or Part Noncash Divestiture, Amount of Consideration Received Derivative Instrument [Axis] Derivative Instrument [Axis] Issuance of Class A ordinary shares sold in initial public offering, net of offering costs (in shares) Stock Issued During Period, Shares, New Issues Amount calculated for operating and personal payment Related Party Transaction, Operating and Personal Payment Calculation, Amount Related Party Transaction, Operating and Personal Payment Calculation, Amount Reclassification from non-controlling interest Other Comprehensive Income (Loss) Reclassification Adjustment, Attributable From Noncontrolling Interest Other Comprehensive Income (Loss) Reclassification Adjustment, Attributable From Noncontrolling Interest Individual Licensees Concentration List Individual Licensees Concentration Risk [Member] Individual Licensees Concentration Risk Document Transition Report Document Transition Report Common stock Common Stock, Value, Issued Total other expense/(income), net Nonoperating Income (Expense) Payment for purchase of royalties Long-term Purchase Commitment, Amount Unrecognized share based compensation expense, period of recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Customer Concentration Risk Customer Concentration Risk [Member] Basis of preparation Basis of Accounting, Policy [Policy Text Block] Commitments and contingencies Commitments and Contingencies Subsequent Event [Table] Subsequent Event [Table] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Derivative collateral received Proceeds From Collateral Received On Derivative Instruments Proceeds From Collateral Received On Derivative Instruments Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Debt issuance costs and other Payments of Debt Issuance Costs ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Receivables [Abstract] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Purchases of equity securities Payments To Acquire Equity Securities, FN-NI Payments To Acquire Equity Securities, FN-NI Ownership [Axis] Ownership [Axis] Available for Sale Debt Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Legal Entity [Axis] Legal Entity [Axis] Auditor Name Auditor Name Cover [Abstract] Unvested RSUs (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Total operating expenses/(income), net Costs and Expenses Activity for the year Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Class of Stock [Axis] Class of Stock [Axis] Maximum commitment to fund collaborative arrangement Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund Cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restrictions on selling common stock, period Debt Securities, Available-For-Sale, Restriction Period Debt Securities, Available-For-Sale, Restriction Period Point Seven Five Percent Senior Notes Due 2023 Point Seven Five Percent Senior Notes Due 2023 [Member] Point Seven Five Percent Senior Notes Due 2023 Number of shares purchased (in shares) Debt Securities, Available-For-Sale, Number Of Shares Purchased Debt Securities, Available-For-Sale, Number Of Shares Purchased Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] DPP-IV patents DPP-IV Patents [Member] DPP-IV Patents Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Payment of capital Collaborative Arrangement, Rights and Obligations, Payment of Capital Collaborative Arrangement, Rights and Obligations, Payment of Capital Entity [Domain] Entity [Domain] Numerator Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Decrease/(increase) in operating assets: Increase (Decrease) in Operating Assets [Abstract] Exchange ratio Common Stock, Exchange Ratio Common Stock, Exchange Ratio Document Information [Table] Document Information [Table] Equity [Abstract] Avillion Entities Avillion Entities [Member] Avillion Entities Carrying Value, net Reported Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Reclassification of loss on interest rate swaps Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax Senior Unsecured Revolving Credit Facility Senior Unsecured Revolving Credit Facility [Member] Senior Unsecured Revolving Credit Facility Debt issued as a percent of par value (as a percent) Debt Instrument, Issuance As A Percent Of Par Debt Instrument, Issuance As A Percent Of Par Three Point Five Five Percent Senior Notes Due 2050 Three Point Five Five Percent Senior Notes Due 2050 [Member] Three Point Five Five Percent Senior Notes Due 2050 Upfront development-stage funding payments Payments For Upfront Development Stage Funding Payments For Upfront Development Stage Funding Common Stock Common Stock [Member] Variable Rate [Axis] Variable Rate [Axis] Operating income Operating Income (Loss) Reclassification to non-controlling interest Other Comprehensive Income (Loss), Reclassification Adjustment, Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Reclassification Adjustment, Attributable to Noncontrolling Interest Financial royalty assets, net Financing Receivable [Policy Text Block] Pablo Legorreta Pablo Legorreta [Member] Pablo Legorreta Comprehensive income attributable to non-controlling interest Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Minimum consolidated coverage ratio Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio Hedging Designation [Axis] Hedging Designation [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Percent for calculating operating and personal payment Related Party Transaction, Operating and Personal Payment Calculation, Percent Related Party Transaction, Operating and Personal Payment Calculation, Percent Share-based compensation Share-based Payment Arrangement, Noncash Expense Variable Rate [Domain] Variable Rate [Domain] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Transfer to Level 2 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Additional Paid-In Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 [Member] RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 Unitholders’/ Shareholders’ Contributions Unit Holders' and Shareholders' Contributions [Member] Unit Holders' and Shareholders' Contributions Amount paid to CEO Related Party Transaction, Amounts of Transaction Dividends paid (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Treasury Interests Treasury Stock Treasury Stock [Member] Senior Notes Due 2051 Senior Notes Due 2051 [Member] Senior Notes Due 2051 AZ Asset - Phase II and Phase III Clinical Trial AZ Asset - Phase II and Phase III Clinical Trial [Member] AZ Asset - Phase II and Phase III Clinical Trial Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Axis] Losses on derivative financial instruments Gain (Loss) on Derivative Instruments, Net, Pretax Purchases of available for sale debt securities Purchase of available for sale debt securities Payments to Acquire Debt Securities, Available-for-sale Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Purchase of warrants Payments To Acquire Warrants Payments To Acquire Warrants Unrealized gain/(loss) on available for sale debt securities, noncontrolling interest AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Noncontrolling Interest [Member] Long term funding partnership, additional payments, aggregate amount Long Term Funding Partnership, Additional Payments, Aggregate Amount Long Term Funding Partnership, Additional Payments, Aggregate Amount Impairment charge Asset Impairment Charges Warrants to purchase additional shares (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Maximum consolidated leverage ratio Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio Derivative, notional amount Derivative, Notional Amount Net carrying value Financial royalty asset, net Financing Receivable, after Allowance for Credit Loss Other non-operating expense/(income), net Other Nonoperating Income (Expense) Fair value of outstanding Notes Long-term Debt, Fair Value Equity securities Equity Securities, FV-NI, Noncurrent Royalty Distribution Payable to RP Select Finance Trust Royalty Distribution Payable to RP Select Finance Trust [Member] Royalty Distribution Payable to RP Select Finance Trust Credit Loss [Abstract] Other current liabilities Other Liabilities, Current Maximum Maximum [Member] Total liabilities Liabilities Distributions to shareholders/unitholders Payments For Distributions To Shareholders and Unitholders Payments For Distributions To Shareholders and Unitholders Deferred stock, par value (in dollars per share) Deferred Shares, Par or Stated Value Per Share Deferred Shares, Par or Stated Value Per Share Award Type [Axis] Award Type [Axis] Projected amortization expense, 2022 Finite-Lived Intangible Asset, Expected Amortization, Year One Old Credit Facility Old Credit Facility [Member] Old Credit Facility Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Redeemable stock, redemption price (in euros per share) Redeemable Stock, Redemption Price Per Share Redeemable Stock, Redemption Price Per Share Common stock, issued (in shares) Common Stock, Shares, Issued City Area Code City Area Code Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Financing Receivable, Allowance for Credit Loss [Table] Financing Receivable, Allowance for Credit Loss [Table] Equity method investment, unfunded commitments Equity Method Investments, Unfunded Commitments Equity Method Investments, Unfunded Commitments Dividends to shareholders Payment Of Dividends To Shareholders Payment Of Dividends To Shareholders Non-Consolidated Affiliates Equity Method Investments and Joint Ventures Disclosure [Text Block] Schedule of Cash Flow, Supplemental Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] The Manager Management [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Goodwill and Intangible Assets Disclosure [Abstract] Entity Address, City or Town Entity Address, City or Town Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Unrealized gains included in earnings Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) Intangible Royalty Assets, Net Intangible Assets Disclosure [Text Block] Investments in non-consolidated affiliates Consolidation, Variable Interest Entity, Policy [Policy Text Block] Purchase of treasury interests Payments for Repurchase of Common Stock Shareholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Maximum milestone payment Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Financial royalty assets, net Financing Receivables, Fair Value Disclosure Financing Receivables, Fair Value Disclosure Concentrations of credit risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Accumulated Other Comprehensive Income Comprehensive Income (Loss) Note [Text Block] Interest income Investment income Investment Income, Net Other exchanges (in shares) Stockholders' Equity, Other Shares Derivative financial instruments Derivative Asset, Noncurrent Contributions from non-controlling interest- R&D Proceeds From Noncontrolling Interests, Research And Development Proceeds From Noncontrolling Interests, Research And Development Measurement Frequency [Domain] Measurement Frequency [Domain] Debt issued, amount Debt Instrument, Face Amount Interest expense Interest Expense Weighted average effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Retained earnings Retained Earnings (Accumulated Deficit) Bristol-Myers Squibb Bristol-Myers Squibb [Member] Bristol-Myers Squibb Revenue from intangible royalty assets Intangible Royalty Assets [Member] Intangible Royalty Assets Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Entity Filer Category Entity Filer Category Termination payments on derivative instruments Swap termination payments Payments To Terminate Derivative Instruments Payments To Terminate Derivative Instruments Summary of Derivatives and Reclassifications Derivative Instruments, Gain (Loss) [Table Text Block] Income Statement [Abstract] Investments in non-consolidated affiliates Equity Method Investments Fair Value Estimate of Fair Value Measurement [Member] Change in fair value of derivative contracts Unrealized Gain (Loss) on Derivatives and Commodity Contracts Entity Registrant Name Entity Registrant Name Asset Class [Domain] Asset Class [Domain] Put option, term (in months) Option Indexed to Issuer's Equity, Term Option Indexed to Issuer's Equity, Term Public Stock Offering - Continuing Investors Partnerships Interests IPO - Continuing Investors Partnerships [Member] IPO - Continuing Investors Partnerships MorphoSys MorphoSys [Member] MorphoSys Related Party Transaction [Axis] Related Party Transaction [Axis] Class B Holders Class B Holders [Member] Class B Holders Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax expense Income Tax Expense (Benefit) Total shareholders’ equity Beginning balance Ending balance Cumulative adjustment Cumulative adjustment to retained earnings Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Other Commitments [Domain] Other Commitments [Domain] Amendment Flag Amendment Flag Unsecured Debt Unsecured Debt [Member] Proceeds from issuance of long-term debt, net of discount Proceeds from Issuance of Long-term Debt Purchase commitment, additional payments Purchase Commitment, Additional Payment Purchase Commitment, Additional Payment Equity Components [Axis] Equity Components [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Tax Identification Number Entity Tax Identification Number Fair Value Disclosures [Abstract] Accrued purchase obligation Accrued Purchase Obligation, Current Accrued Purchase Obligation, Current Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Concentration Risk Type [Domain] Concentration Risk Type [Domain] Sale of Stock [Domain] Sale of Stock [Domain] Weighted average Class A ordinary shares outstanding Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Schedule of Balance Of Non-controlling Interests Schedule of Stockholders Equity [Table Text Block] Debt Securities, Available-For-Sale, Redemption, Period [Axis] Debt Securities, Available-For-Sale, Redemption, Period [Axis] Debt Securities, Available-For-Sale, Redemption, Period Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investments and Joint Ventures [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Put option to sell additional common stock Option Indexed To Issuers Equity, Value Option Indexed To Issuers Equity, Value Settlement of forwards Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Fair value measurements Fair Value Measurement, Policy [Policy Text Block] Less: Current portion of long-term debt Long-term Debt, Current Maturities Product and Service [Axis] Product and Service [Axis] Number of noncontrolling interests Number of Noncontrolling Interests Number of Noncontrolling Interests Entity Public Float Entity Public Float Preferred shares, fixed payment amount Debt Securities, Available-for-Sale, Fixed Payment Debt Securities, Available-for-Sale, Fixed Payment Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Cash collected on financial royalty assets Increase (Decrease) In Cash Collections On Financing Receivables Increase (Decrease) In Cash Collections On Financing Receivables Avillion I Avillion I [Member] Avillion I Revenue Benchmark Revenue Benchmark [Member] Federal Funds Rate Federal Funds Purchased [Member] Other Other Financial Royalty Asset [Member] Other Financial Royalty Asset Equity Component [Domain] Equity Component [Domain] Financing Receivable, Allowance for Credit Loss [Line Items] Financing Receivable, Allowance for Credit Loss [Line Items] EPA Holdings EPA Holdings [Member] EPA Holdings Period of return start date Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date Cash collections from intangible royalty assets Proceeds From Cash Collections From Royalties Received On Intangible Assets Proceeds From Cash Collections From Royalties Received On Intangible Assets Share based compensation and related issuance of Class A ordinary shares (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Upon occurrence of a change of control triggering event Debt Instrument, Redemption, Period Three [Member] Other exchanges Stockholders' Equity, Other Unrealized gains on available for sale debt securities Debt Securities, Available-for-sale, Unrealized Gain (Loss) Scheduled repayments of long-term debt Repayments Of Long-term Debt, Scheduled Payments Repayments Of Long-term Debt, Scheduled Payments Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Payments to acquire royalty interests, additional milestone payments Payments To Acquire Royalty Interest, Additional Milestone Payments Payments To Acquire Royalty Interest, Additional Milestone Payments Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Debt issuance costs Debt Issuance Costs, Gross Other royalty income Royalty Income, Other [Member] Royalty Income, Other Statement [Line Items] Statement [Line Items] Category of Item Purchased [Axis] Category of Item Purchased [Axis] Available for sale debt securities Increase (Decrease) In Debt Securities, Available For Sale Increase (Decrease) In Debt Securities, Available For Sale Available for sale debt securities Available for sale debt securities, noncurrent Debt Securities, Available-for-sale, Noncurrent Share-based compensation and related issuances of Class A ordinary shares Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Funding Agreement With Biohaven Pharmaceuticals Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals [Member] Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals Other commitment Other Commitment Series B Preferred Shares Series B Preferred Stock [Member] Fair Value Debt Securities, Available-for-sale Counterparty Name [Domain] Counterparty Name [Domain] Royalty assets Royalty Assets, Policy [Policy Text Block] Royalty Assets, Policy Debt Disclosure [Abstract] Payment of capital term Collaborative Arrangement, Rights and Obligations, Payment of Capital, Term Collaborative Arrangement, Rights and Obligations, Payment of Capital, Term Purchases of marketable securities Purchases of available for sale debt securities Payments to Acquire Marketable Securities Consolidated net income before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Unrealized gains on available for sale debt securities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss), After Transfer To Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss), After Transfer To Level 3 Promacta Promacta [Member] Promacta Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Auditor Location Auditor Location Interest rate swaps Derivative, Gain (Loss) on Derivative, Net Cost Debt Securities, Available-for-sale, Amortized Cost Funding Agreement With BioCryst Funding Agreement With BioCryst [Member] Funding Agreement With BioCryst Finite lived intangible assets, useful life Finite-Lived Intangible Asset, Useful Life Customer [Axis] Customer [Axis] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Settlement of Epizyme forward purchase contract Settlements With Equity Method Investments Settlements With Equity Method Investments Put option, selling price, maximum (in dollars per share) Option Indexed to Issuer's Equity, Strike Price Use of estimates Use of Estimates, Policy [Policy Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Asset Class [Axis] Asset Class [Axis] Document Annual Report Document Annual Report Unrealized gain/(loss) on available for sale debt securities, including noncontrolling interest AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member] Title of 12(b) Security Title of 12(b) Security Total assets Assets Investment, Name [Domain] Investment, Name [Domain] Plan Name [Domain] Plan Name [Domain] IPO - Shares From Company IPO - Shares From Company [Member] IPO - Shares From Company Distributions to non-controlling interest Payments to Noncontrolling Interests Purchasing And Donating Ventilators Purchasing And Donating Ventilators [Member] Purchasing And Donating Ventilators Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Net income attributable to Royalty Pharma plc - basic and diluted Net Income (Loss) Available to Common Stockholders, Diluted Xtandi Xtandi [Member] Xtandi Net income attributable to Royalty Pharma plc - basic and diluted Net Income (Loss) Available to Common Stockholders, Basic Document Type Document Type Non-Controlling Interest Noncontrolling Interest [Member] Research and development funding expense Research and Development Expense Product and Service [Domain] Product and Service [Domain] Net carrying value, before cumulative allowance for credit losses Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows Debt instrument, stated rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Summary of Financial Royalty Assets, Net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Derivative Contract [Domain] Derivative Contract [Domain] Write off of credit loss allowance Financing Receivable, Allowance for Credit Loss, Writeoff Preferred shares, quarterly payments Debt Securities, Available-for-Sale, Quarterly Payments Debt Securities, Available-for-Sale, Quarterly Payments Net income attributable to non-controlling interest Less: net income attributable to non-controlling interest Net Income (Loss) Attributable to Noncontrolling Interest Less: net income attributable to Continuing Investors Partnerships prior to the IPO Net Income (Loss) Attributable to Parent, Prior To Offering Net Income (Loss) Attributable to Parent, Prior To Offering Repayments of long-term debt by contributions from non-controlling interest Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash Revolving Credit Facility Revolving Credit Facility [Member] Cash collections from financial royalty assets Proceeds From Cash Collections From Royalties Received On Financing Receivables Proceeds From Cash Collections From Royalties Received On Financing Receivables Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Equity Method Investment, Nonconsolidated Investee or Group of Investees Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Long term funding partnership, amount Long Term Funding Partnership, Amount Long Term Funding Partnership, Amount Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Reclassification of unrealized gains on available for sale debt securities Reclassification of unrealized losses on available for sale debt securities Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Deferred shares, $0.000001 par value, 361,170 and 316,407 issued and outstanding, respectively Deferred Shares, Value, Issued Deferred Shares, Value, Issued Subsequent Event [Line Items] Subsequent Event [Line Items] Earnings Per Share, Basic [Abstract] Earnings Per Share, Basic [Abstract] Basic (in shares) Weighted average Class A ordinary shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in dollars per share) Earnings per Class A ordinary share - diluted (in dollars per share) Earnings Per Share, Diluted Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Vertex Vertex [Member] Vertex Distribution payable to non-controlling interest Due to Related Parties, Current Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share Initial share issuance upon registration of Royalty Pharma plc (in shares) Stock Issued During Period, Shares, Issued For Registration Stock Issued During Period, Shares, Issued For Registration Interest expense Interest Expense [Member] Intangible royalty assets, net Intangible Assets, Finite-Lived, Policy [Policy Text Block] Accounting standards update [Extensible List] Accounting Standards Update [Extensible Enumeration] Redemption, Period Two Debt Securities, Available-For-Sale, Redemption, Period Two [Member] Debt Securities, Available-For-Sale, Redemption, Period Two Subsequent Events Subsequent Events [Text Block] Comprehensive income attributable to controlling interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent RPIFT Senior Secured Credit Facilities RPIFT Senior Secured Credit Facilities [Member] RPIFT Senior Secured Credit Facilities Net cash provided by/(used in) financing activities Net Cash Provided by (Used in) Financing Activities Changes in other comprehensive income/(loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Treasury interests Treasury Stock, Value Related Party Transaction [Line Items] Related Party Transaction [Line Items] Equity in losses/(earnings) of non-consolidated affiliates Equity in income (loss) of non-consolidated affiliates Income (Loss) from Equity Method Investments Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Other operating expenses Other Cost and Expense, Operating Deferred stock, outstanding (in shares) Deferred Shares, Shares, Outstanding Deferred Shares, Shares, Outstanding Issuance of Class B shares to Continuing Investor Partnerships (in shares) Stock Issued During Period, Shares, Issued To Partnerships Stock Issued During Period, Shares, Issued To Partnerships Corporate Debt Securities Corporate Debt Securities [Member] Fair Value Measurements and Financial Instruments Fair Value Disclosures [Text Block] RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1 RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1 [Member] RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1 Purchase Of Eisai Royalties Long Term Purchase Commitment, Purchase Of Eisai Royalties [Member] Long Term Purchase Commitment, Purchase Of Eisai Royalties Concentration Risk Type [Axis] Concentration Risk Type [Axis] Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Schedule of Fair Value Hierarchy Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Total Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Available-for-sale Securities Available-for-sale Securities [Member] RPSFT Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member] Legacy Investors Partnerships and Royalty Pharma Select Finance Trust Common stock, outstanding (in shares) Common shares outstanding Common Stock, Shares, Outstanding Initial term Related Party Transaction, Initial Term Related Party Transaction, Initial Term Transfer from level 2 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Financial Instruments [Domain] Financial Instruments [Domain] Ownership percentage following IPO Sale of Stock, Percentage of Ownership after Transaction Document Period End Date Document Period End Date Common Class B Common Class B [Member] Entity Central Index Key Entity Central Index Key Number of shares authorized under plan (in shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased Tysabri Tysabri [Member] Tysabri Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Research and Development [Abstract] Ongoing development-stage funding payments Payments For Ongoing Development Stage Funding Payments For Ongoing Development Stage Funding Long term funding partnership, initial payment Long Term Funding Partnership, Initial Payment Long Term Funding Partnership, Initial Payment Number of shares available to convert (in shares) Sale of Stock, Number of Shares Available To Convert Sale of Stock, Number of Shares Available To Convert Debt instrument, term Debt Instrument, Term Income Statement Location [Domain] Income Statement Location [Domain] Supplemental Schedule of Non-cash Investing/Financing Activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment [Line Items] Marketable securities Debt Securities, Trading Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Cumulative allowance for changes in expected cash flows Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows Shareholders' Equity Shareholders' Equity and Share-based Payments [Text Block] Accumulated Other Comprehensive Income/(Loss) AOCI Including Portion Attributable to Noncontrolling Interest [Member] Schedule of Borrowings Schedule of Long-term Debt Instruments [Table Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Gains on equity securities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) Repayments of long-term debt Repayments of outstanding debt Repayments of Long-term Debt Trading Symbol Trading Symbol Earnings Per Share [Abstract] Derivatives Derivative Asset Redemption price, percentage Debt Securities, Available-For-Sale, Redemption Price, Percentage Debt Securities, Available-For-Sale, Redemption Price, Percentage Related Party Transaction [Domain] Related Party Transaction [Domain] Losses/(gains) on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Total income and other revenues Revenues Unrealized Losses on Interest Rate Swaps Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Exercise price of warrant (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Reclassification to net income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Losses on derivative financial instruments Gain (Loss) on Derivative Instruments [Member] One Point Seven Five Percent Senior Notes Due 2027 One Point Seven Five Percent Senior Notes Due 2027 [Member] One Point Seven Five Percent Senior Notes Due 2027 Proceeds from available for sale debt securities Proceeds from Sale of Debt Securities, Available-for-sale Funding Agreements With Pfizer Funding Agreements With Pfizer [Member] Funding Agreements With Pfizer Warrant Warrant [Member] Deferred stock, issued (in shares) Deferred Shares, Shares, Issued Deferred Shares, Shares, Issued Term of warrant (in years) Warrants and Rights Outstanding, Term Long-term debt Total long-term debt Long-term Debt, Excluding Current Maturities Number of limited partnership interest acquired (in shares) Related Party Transaction, Number of Partnership Interests Acquired Related Party Transaction, Number of Partnership Interests Acquired Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Share based compensation Share-based Payment Arrangement, Expense Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Other royalty cash collections Proceeds From Cash Collections From Other Royalties Received On Financing Receivables Proceeds From Cash Collections From Other Royalties Received On Financing Receivables Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Termination of derivative financial instruments Gain (Loss) On Derivative Financial Instruments Gain (Loss) On Derivative Financial Instruments Entity Current Reporting Status Entity Current Reporting Status Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings per Class A ordinary share Earnings Per Share, Basic and Diluted [Abstract] Milestone payable - Erleada Milestone Payment Accrued But Not Paid Milestone Payment Accrued But Not Paid Noncontrolling interest (percentage) Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Long term funding partnership, number of additional payments Long Term Funding Partnership, Number of Additional Payments Long Term Funding Partnership, Number of Additional Payments Exchange offering, ownership percentage Sale of Stock, Percentage of Ownership before Transaction Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Debt Securities Series A Preferred Stock Series A Preferred Stock [Member] One Point Two Zero Percent Senior Notes Due 2025 One Point Two Zero Percent Senior Notes Due 2025 [Member] One Point Two Zero Percent Senior Notes Due 2025 Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Consolidated net income Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Counterparty Name [Axis] Counterparty Name [Axis] Proceeds from sales and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Common Class A Common Class A [Member] Income from financial royalty assets Increase (Decrease) In Financial Royalty Assets Increase (Decrease) In Financial Royalty Assets Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Total non-current assets Assets, Fair Value Disclosure, Noncurrent Assets, Fair Value Disclosure, Noncurrent Write-off of cumulative allowance Financing Receivable, Change in Present Value, Expense (Reversal) Number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in dollars/pounds per share) Common Stock, Par or Stated Value Per Share Remaining commitment for R&D funding agreement Research And Development, Remaining Funding Commitment Research And Development, Remaining Funding Commitment Statement of Comprehensive Income [Abstract] Current assets Assets, Current [Abstract] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Prior to the applicable par call date Debt Instrument, Redemption, Period One [Member] Cost Finite-Lived Intangible Assets, Gross Shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Schedule of Intangible Royalty Interests Schedule of Finite-Lived Intangible Assets [Table Text Block] Income taxes Income Tax, Policy [Policy Text Block] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Agreement with MSCI Agreement with MSCI [Member] Agreement with MSCI Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] (Decrease)/increase in operating liabilities: Increase (Decrease) in Operating Liabilities [Abstract] Unrealized gains on available for sale debt securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Entity Address, Postal Zip Code Entity Address, Postal Zip Code Change in control event, period Debt Securities, Available-For-Sale, Change In Control Event, Period Debt Securities, Available-For-Sale, Change In Control Event, Period Diluted (in shares) Weighted average Class A ordinary shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Balance at the beginning of the year Balance at the end of the year Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Two Point Two Zero Percent Senior Notes Due 2030 Two Point Two Zero Percent Senior Notes Due 2030 [Member] Two Point Two Zero Percent Senior Notes Due 2030 Total other comprehensive (loss)/income Other Comprehensive Income (Loss), Net of Tax Fair Value, Recurring Fair Value, Recurring [Member] Distributions to non-controlling interest- other Payments To Noncontrolling Interests, Other Payments To Noncontrolling Interests, Other Requisite service period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Interest payable Interest Payable, Current Denominator Weighted Average Number of Shares Outstanding, Basic [Abstract] Related Party [Domain] Related Party [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Imbruvica Imbruvica [Member] Imbruvica Basis spread on variable rate (percentage) Debt Instrument, Basis Spread on Variable Rate Measurement Basis [Axis] Measurement Basis [Axis] Payments to acquire royalty interests Payments To Acquire Royalty Interests, Aggregate Amount Payments To Acquire Royalty Interests, Aggregate Amount Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Statement of Cash Flows [Abstract] Auditor Firm ID Auditor Firm ID Investments in non-consolidated affiliates Payments to Acquire Equity Method Investments Class of Stock [Line Items] Class of Stock [Line Items] Number of classes of voting shares Number Of Classes Of Voting Stock Number Of Classes Of Voting Stock Credit Facility [Axis] Credit Facility [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Entity Address, Address Line One Entity Address, Address Line One Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Axis] Net cash used in investing activities Net cash flow from investing Net Cash Provided by (Used in) Investing Activities Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Proceeds from equity securities Proceeds From Issuance Of Equity Securities, FN-NI Proceeds From Issuance Of Equity Securities, FN-NI Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Redemption Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions Basis of consolidation Consolidation, Policy [Policy Text Block] Entity Shell Company Entity Shell Company Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Total current liabilities Liabilities, Current Derivative collateral posted Payments For Collateral Posted On Derivative Instruments Payments For Collateral Posted On Derivative Instruments Class of Stock [Domain] Class of Stock [Domain] Line of credit, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] IPO - Shares From Selling Shareholders IPO - Shares From Selling Shareholders [Member] IPO - Shares From Selling Shareholders Money Market Funds Money Market Funds [Member] Quarterly payments to affiliates, percent of security investment (as a percent) Related Party Transaction, Rate, Value Of Security Investments Related Party Transaction, Rate, Value Of Security Investments Acquisition Of Limited Partnership Interests In Affiliate Acquisition Of Limited Partnership Interests In Affiliate [Member] Acquisition Of Limited Partnership Interests In Affiliate Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Ownership [Domain] Ownership [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Unamortized debt discount and issuance costs Unamortized discount and loan issuance costs on long-term debt Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Operating and Personnel Payments Operating and Personnel Payments [Member] Operating and Personnel Payments Gross Carrying Value Financing Receivable, before Allowance for Credit Loss Payments to acquire royalty interests, number of additional payments Payments To Acquire Royalty Interests, Number Of Additional Payments Payments To Acquire Royalty Interests, Number Of Additional Payments BioCryst Pharmaceuticals, Inc. BioCryst Pharmaceuticals, Inc. [Member] BioCryst Pharmaceuticals, Inc. Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Other royalty income receivable Other Royalty Income Receivable, Current Other Royalty Income Receivable, Current Other current assets Other Assets, Current Statement [Table] Statement [Table] Purchase commitment, upfront payment Purchase Commitment, Upfront Payment Purchase Commitment, Upfront Payment Default period Debt Securities, Available-For-Sale, Redemption, Default Period Debt Securities, Available-For-Sale, Redemption, Default Period Recently adopted and issued accounting standards New Accounting Pronouncements, Policy [Policy Text Block] Payments to acquire royalty interests, upfront payment Payments To Acquire Royalty Interests, Upfront Payment Payments To Acquire Royalty Interests, Upfront Payment Purchase commitment, purchase of committed, non-contingent Commercial Launch Preferred Equity payable Purchase Commitment, Committed Non-Contingent Commercial Launch Preferred Equity, Amount Purchase Commitment, Committed Non-Contingent Commercial Launch Preferred Equity, Amount Other Commitments [Axis] Other Commitments [Axis] Assignment Agreement - Funding Obligations Assignment Agreement - Funding Obligations [Member] Assignment Agreement - Funding Obligations Unrealized gain (loss) on equity securities still held Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) Unrecognized share based compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Tremfya Tremfya [Member] Tremfya Equity securities and Available for sale debt securities Debt Securities, Available For Sale, Policy [Policy Text Block] Debt Securities, Available For Sale, Policy Statistical Measurement [Axis] Statistical Measurement [Axis] Other receivables Increase (Decrease) in Other Receivables Subsequent Event Subsequent Event [Member] Beginning balance Ending balance Financing Receivable, Allowance for Credit Loss Cumulative allowance for credit losses Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal) Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal) Total current assets Assets, Fair Value Disclosure, Current Assets, Fair Value Disclosure, Current Preferred Shares Preferred Stock [Member] Intangible royalty assets, net Net Carrying Value Finite-Lived Intangible Assets, Net Amount of loss reclassified from AOCI into income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Non-controlling interest Stockholders' Equity Attributable to Noncontrolling Interest Legacy Investors Partnerships Legacy Investors Partnerships [Member] Legacy Investors Partnerships Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Accrued royalty receivable Increase (Decrease) In Accrued Royalty Receivable Increase (Decrease) In Accrued Royalty Receivable Redemption default, threshold period Debt Securities, Available-For-Sale, Redemption Default, Threshold Period Debt Securities, Available-For-Sale, Redemption Default, Threshold Period Payments for operating and professional costs Payments For Operating Costs and Professional Services Payments For Operating Costs and Professional Services Adjustments to reconcile consolidated net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Forwards Forward Contracts [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Three Point Three Zero Percent Senior Notes Due 2040 Three Point Three Zero Percent Senior Notes Due 2040 [Member] Three Point Three Zero Percent Senior Notes Due 2040 Funding Agreements With Sanofi Funding Agreements With Sanofi [Member] Funding Agreements With Sanofi Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Related Party Transactions Related Party Transactions Disclosure [Text Block] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Accounting Standards Update 2016-13 [Member] EX-101.PRE 11 rprx-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 rprx-20211231_g1.jpg begin 644 rprx-20211231_g1.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#R17AI9@ 34T *@ @ ! $[ ( M - (2H=I 0 ! (6)R= $ : 0T.H< < @, /@ M &UL;G,Z9&,](FAT=' Z M+R]P=7)L+F]R9R]D8R]E;&5M96YT#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@ M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8 M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4 M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ_\ $0@"R AD P$B (1 0,1 ?_$ !\ $% 0$! 0$! M ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $ M$042(3%!!A-180'EZ@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! M @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$' M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F MY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1CA3C MTI:1ONGZ4 0^8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* M '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E' MF-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* M'>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F M-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* ' M>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F- MZ_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '> M8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z M_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8 MWK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_ MI3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* '>8W MK^E'F-Z_I3:* '>8WK^E'F-Z_I3:* )HV+9R:?4I* "BBB@ HHHH 1CA3 MCTJ'S&]?TJ9ONGZ57H =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4 M>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH M =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4> M8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH M=YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8 MWK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH = MYC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8W MK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =Y MC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK M^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC M>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^ ME-HH =YC>OZ4>8WK^E-HH =YC>OZ5)&Q;.34-2P]Z )**** "BBB@ I&.%./ M2EI&^Z?I0!#YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH M =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4> M8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH M=YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8 MWK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH = MYC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8W MK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =Y MC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK M^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC M>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^ ME-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC>OZ4>8WK^E-HH =YC> MOZ4>8WK^E-HH =YC>OZ4>8WK^E-HH FC8MG)I]1P]ZDH **** "BBB@ HHHH M **** "BBB@ HHHH *1ONGZ4M(WW3]* *]%%% !1110 4444 %%%% !1110 M4444 %%%% !117C>L?M!(NO7NG^#O".I>)HM/8BZNK9F5%P<%AM1SMR#R< X MXXYH ]DHKC_ OQ+T/QWX7GUJR9[1;/(O(;@@-;X&[)(X*XR0?8]""*\^N/VE M;=;B:[L?!VJ7?AZ";R9-65MH![?*4V@G@@%P>>U 'N-%#G/3!]*\_L_P!HY8KJSD\3>"]4T72;UA]GU%V+ MJZGHP!101CGY2W'3- 'MM%5KC4+.TTU]0NKJ&&SCC\UIWF*X;X#SO[2V>9M.,[?*./IDT >[T5X/X>_:ETG4M6@M=3C+ HN%]2,_2O> ?> _BG_PF_C+Q M!H/]C_8?[&D9//\ M7F>=B0IG;L&WIGJ: /0:*Y+P'\1=+^(::E/H4,ZVEC. ML(FG4*9B1G(7J!]>?85UM !117,?$3QE_P (%X*NO$'V#[?]G>-?L_G>5NW. M%^]M;&,YZ4 =/17SE_PUG_U)?_E5_P#M->I?#/XKZ1\2[6Z^PV\UC>V>#-:S M,&^4]&5AU'&.@P?PR =W1110 4444 %%%<=XM\9ZSX=\2Z/INE^$+[6K;4'5 M9[VW+[+0%PN6VQL. <\D=* .QHHHH **Y'5OB+I>E?$32O!AAGFU/4E\S*@" M.),,/>>%#':I7)XS@^_'( /;*** M* "BBOGO4OVI_P"SM6N[+_A#O,^S3O%O_M3&[:Q&<>3QTH ^A**\D^'/Q_TC MQWK\>B7>ERZ1?SAC &G$T?S5^>) MEX*%1GYLX SG(QUKSFV_:5M_M%O=:GX/U2QT"ZE,4.JL^Y6(//R[ IQSD*Y M(QWH ]PHKC/'_P 3]$^'_A^VU*]WWKWW_'E;VY&9^ =V3P% (Y]QP:Y+0?CZ MESXEL]&\8>$]1\,27[!;66Y8LKD\ G@ Y-5(R;O[4QG!QG_4T ?1%%>,>!OV MC](\6>(K71M3T>72)[R016\OVD31LYZ*QVJ1DX X/)%>ST %%%% !1110 45 M'<2^1:RS8W>6A;&<9P,UYY\/?B_;>-O"6M^(+[2SI%KH^YI@+@W!*+&79N$7 MH >,&@#T>BN<\#>-+/Q[X<_MO3;>:WM6G>*-9\;V"G&2!D#/IDUT= !117#? M%3XD?\*ST"SU/^RO[3^TW7V?R_M/D[?E9LYVMG[O3% 'H ^^.M '8 MT444 %%%Y=F<;MH)QGMTH L45\Y?\ #6?_ %)?_E5_^TUV7PY^/^D> M.]?CT2[TN72+^<,8 TXFCD(&=N["D-@$CC'&,YQD ];HHHH **S?$6K?V!X7 MU76/)^T?V?9S77D[]OF>6A;;G!QG&,X->"?\-9_]27_Y5?\ [30!]&T5XOX% M_:%_X377I]-_X1C[%Y-G-=>9_:'F9\M<[<>6.OKFNO\ A7\2/^%F:!>:G_97 M]F?9KK[/Y?VGSMWRJV<[5Q][IB@#N:*** "BBB@ HHHH **** "BBB@ HHKD MO'WQ%TOX?65G+J<,]Q/?RF&VAA ^9AC)+'A0,CU/L: .MHKD?B!XPU?P?I]I M<:'X3O?$TD\I1X;,OF( 9W';&_';H*ZN%VD@C=T,;,H)0]5)'2@!]%%% !17 M&?$_XB6_PU\+QZK-9_;YIKA8(;43>5O)!).[:V #V]!WI?AC\1+;XE>%Y-5 MAL_L$T-PT$UJ9O,V$ $'=M7((([>H[4 =E1110 4444 %%%% !1110 4444 M%2P]ZBJ6'O0!)1110 4444 %(WW3]*6D;[I^E %>BBB@ HHHH **** "BBB@ M HHHH **** "BBL/QAXNTOP/X9N-;UMW%O"0JI&,O*YZ(H]3^74GI0!N45XA M;_M("&6TN?$'@C5=*T6\8"#4F8NK@_Q %%##'/RL3@'&:[_QY\2]%\!^&(-8 MO"UY]L(%E!;D;KC(SD'H%P02?<=20* .PHKRKP;\<8M?\60^&_$GAN]\,ZE= M+NMDNF+++QD#YD0@G!QQ@XZU:\>?&>T\)>)(_#FC:)>>(M<90S6=H2-F1D D M*Q+8YP%/% 'I=%>=_#OXOV/CK5KG1;S2KK0];M4+O8W1SD#K@D Y&1D%1U[\ MXT?B5\2M,^&_A_[;=JMW?2L%MK 3;'FYY.<'"@9.<>@[T =G163X6US_ (27 MPGI>M_9_LW]H6R7'D[]_E[AG&[ S]<"H_&'B'_A%/!^I:[]E^U_8(#+Y'F;- M^.V[!Q^1H VJ*^60.LB9 )5AC."1D$#K]< 'I%%%% !1110 445S'Q$\9?\(%X*NO$'V#[?\ M9WC7[/YWE;MSA?O;6QC.>E '3T5P%[\6]+TCX5Z9XUUJSGACU$*L5G ?-;S& M#$+N(48PA.3CI^%=O877V[3;:[";/M$*2[+$T3_A'?[2W6R7'G?;O)QN+#&WRV_N]<]ZY6S_:PM7N56_\(S009^9X M+\2L/HIC4'\Q0!]#452T?5K/7M%M-5TR7SK2\B66)\8RI'<=C[5=H **** " MBBB@ HKCO"7C/6?$7B76--U3PA?:+;:>[+!>W!?9=@.5RNZ-1R!G@GK78T % M%-DD6*)I)#A$!9CCH!7*^ OB#IOQ#L;^]T6">.TL[K[.KS@*TIVAMP4=!SWY M^E '64444 %%7,D7D>?Y6=QQG=M;I]*\=_X: MS_ZDO_RJ_P#VF@#Z-HKB/AK\4](^)=A?_ M H^*L/Q/L=1E73?[,GL)$5X/M'G;E8$JV=J]U88QVKD/&_[2$/A'QGJ.@V_ MAK^T5L7$;7/V_P K'O"O M]C_:_P"VI(4^U?:O+\GS)?+SLV'=CKU'I0!Z%1110 445R/@[XBZ7XWUW7M/ MT>&<)HKQQ23R@*)78R [1UP/+ZG&<]/4 ZZBBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH EA[U)4I* "BBB@ HHHH **** "BBB@ HHHH **** M "D;[I^E+2-]T_2@"O1110 4444 %%%% !1110 4444 %%%% !1110 C*'4J MW1A@X.*\WUR_\$_ KPQ>W6EV45I/?'=#8QS,S74JC P&)VJ,C)' SW) /HTT MOD6\DI1W$:EML:[F; S@#N?:ODI;CQ?J?Q)G\6^-/AEK_B Y_P!%L'M9HH8 M#\JD>4VX*.W&3DG.: -KP?X>U3P[^SKXX\17\3P2:]"HBA*E2(@Q7?CL#YK? M@ >]=/X3MH?^&-;LF-3YFGWTC9[L)I,'\-H_*NLT76M7^*_A'Q+HGB'P??\ MA-7M1! ]YO/FF17&Y0T:?<*J3C/WATKRNV_X6=H/PZO?A>G@B[NC,TD,.IQ; MC"L3L68;L;.*;!;^VL[NX\E&E=-A+DYRK M Y^8U@?&SQ%!X_U;2/AMX(B74+BWO%>>>(YCA959 F[T4,2QZ# '7.-GQ/I? MBKX=? ;2?"GA*PO[_5;K='>7&GV[S& -EY,%0<9+!0>.,DN;^4?Z5J#K,KS'T ^SG:OHN?S/- 'J?C?X32^-+'POH\NM36NC:1 M$R7D<9.ZZPL:IQ]W("/\QSC=P.37$?L[V<&G?$'Q]96:>7;VUPL429)VJLLH M R>>@KW?3+J6^TFTN[BV>TEG@25[=\[HF902AR!R"<=!TKQ[X)Z#J^E?$;Q[ M;K>6YMWC68>=*
3MS*C;L[6_N8QCO7UQ7A?PZ\/:Q9_M*>,M2O]'OH-.NH+E8;J M:U=89MT\1 5R-K9 )X/0&@#@/$_B?7/VAM5TO3-"\)K9?8Y#YUV)3-Y2M@9> M3:H51@G'4GI7IWQA\;Z]I&L>'_ 7@JX6UU75@@>[; ,:,WEI@\XR58DXR .. MM8GQ"\"ZW\/_ (@6/CGX8:9(/$E[X9^(O@NPE.J:='&TFFW<1CF"JWF*"C8Y!+@KU.>,T 8'BB'XB_!1= M/\13>,[GQ/ITUPL-W:WI<@$@G:-S-@'!PP(P<<'9O!MQX8TZ&X6: M[NKT. 2 1D;E7( 8X49R<<\9KN_C3X,M]0^"5Q:6PPV@P)0L2[6!/O' MN_'% &+X[UK6?$?Q_P##W@W0-5O[&TLD%SJ?V*Y>+\E:/C MJWU&;QI)+XL^(<7A3PPD'^B6NEZE]GO)GXRSY3D9W<#=P ,=36'^SAI=YJS: MYX[UQC-?:A(+2*5AR40 N1[$[!_P UER:#JWACX]:[KWBCP5J/BNQOS(VGS6 MEH+D1993'D'Y5VJ-F3@C&1Q0!J? ;QOJVL>,O$7AZZURXUW2K,/+87EV2TK( MLNQ6+'G#*0<'I7.?##1[S7_'GQ-TS3=6GT>ZN)76.^M\[X2+ICD893T&.HZU MM?!K1O$>F?&KQ-?^(O#=]I2:K#+<*QA9H$9Y5E\L2@;20&(X/\)'7BKOP6\/ MZSI7Q6\<7>J:3?65M=3R&":XMGC28&=CE68 -P<\4 >?_ [P/K?BC1=7O-'\ M7:CHL=NS1?8[222-9Y6B.QRRN,;6(/W3TKT/X4?$NZ@^#_B";Q-=3W.J^&6E M\[[7(7E<')C#,QR3OW)SZ"L?X'V_C'P#XDNO"NJ^#[XVE]=;Y=4VL(80J$9# M;2K G;CYAC-N_ CZ7;:)HMEI=BNVWLX$@B'^RH 'X\5PWQWTR_UCX1:E9Z397-]= M/+ 5@MHFD=@)5)PJ@DX'- 'CGA+]I'_A%O!FG: /"@N_L-N(?/;4-HD]]OE' M'7IFNJ^!?A_5M*U+Q1X^\0:;_9%E>Q220VQ3R_E+F5BJGD( !GK^%=EX>\ M6?BCX$Z-X=\5:?);SK9!1YT12:TDYPP!Y4CT[]#P:YCX11>*]#N-6^'/C32= M2ETK;+%9:E]ED: +@AD$F-NQE.5R>#D=2 #B]+\3>)/B9)J>N7WQ3L_!HAF M*6.F-?B /@!@"-ZG;R!O(;)W<<8KJ_!_QNU,_!;Q#JVL&*]UG0G2!),#$YE. MV-F"\'!W9QC(7U-C6O@6_\ &/P=<@ ,=R=L L<=C7.:)XN^*_A3P9#X M,L_ %\VHVJF"VU18B\2+DD9PIC8@<9W8Z9%;OQ)^'OC/QU\+M#N]3BM+CQ5I MCO-+:PJ%5T?&4&25+ *A/8X(';(!Q&J>)O$GPS?3-=L?BG9^,A-,$OM,6_$X M3(+$ ;V.W@C> N#MXYQ77?%WQ5JD/Q(^'_\ 8FKWUI8ZBT,DD-OZ:L,+=BRLT0"CJ>K^V:UOC%X:U6 M]^)W@*71=$NY[*QDB$K65J[Q6RB9#@E5PH '?' H H?$+5_&4_[15MX;\):_ M=6'VZT1%1IG,,0*,SR>7G:6"J3G'7TZTT:GXV^$/Q6T/2M>\3W/B;1]=E6/= M=%BREG"$@,S%"I93@'!!]>F?\2;G6;/]J;3KGPQ;)=:I%;1O#;R-M$V(WW)G MME=P^IK173?&OQ=^*VA:MK_A>Y\,Z/H,BR,MT&!23SM?%72_%&B M_'+1/&VA^&KS7K2UM5C,5HK,2X\P%3M5BO#@YQBM#QMXF\87"Z>^J_"6WU_2 M9[6.9X-K3SQ2LH+)C82A5LC.PY !SUP ;'PIT;Q+8W]U/<_$6U\7:$05BVR> M?)NXPQ+O&?A3QKXJ?P-X?\ [:DN+IA>*-0\6_%CPY/\8+!_#<%K(#$(].D@WG<"-YD;<%R!EN<#L,DA MWAV^^)?P\\6^(KKPYX(OKQ=2NFW-=:3W[PDL<*, 'K^= '?:AKFK^"_P!IJSM=1U6^ ME\/^(H=EO!/<,%.&R[JI!ZA#5O\ :*\/&?X=VNO6+>5>^'KF.:*7/S!&94(!/?=Y M9_X#1^SMH$]1\6:H-VH>([QYV9*-.\7P:"-)T^R=)9Y8P2F$R0"^ M'=B0.G3V%:.L7GC3Q%^T9KOA+0?%>H:7:7"[683NR6L8CC1DU])UX;H/A_68?VL=9U>;2;Z/3)(&"7K6SB%CY48P'QM/((Z]J *?C77?% MOAF[\-?"WPSXBN;S6KY0]WK5V?WK!W8* 26*@!6)Y)P%P>M4?$K?$'X'7&F: MY>>,+GQ1I%U<""ZM[S><-M+;1O9B,@,0P(Y7D8XKIOC#X&\1R>--%\?>";9; M[4-+54FLS]YU5BP('\60S*0#GIBN9\2K\0?CC<:9HEYX0N?"VD6MP)[J>]#C M+8*[AO52< M@ 'D\F@#:^+?CCQ#J7C+P[X'\#Z@VFOK$,=Q+>*2C[9"0HW=5 M "ECCDY ]CYQ\;_"OBWPKI>B6WB+Q/+XDT]GE,$\\9$D,F%W*268D$8QECT/ M [^D_%KP+X@T[Q=X>\<>![!M1FT:*."6R4%W9(R2I"]6!#%3CGH1W(XCXK7' MQ'^)FDZ==R^ ]2TRPLY2B6B123322,.7*[ P4!< E1][J<\ ':_&GQ!K.E?% M;P/::7JU]96UU/&)X;>Y>-)@9U&&52 W!QS1\>O$&LZ/XV\%0:1JU]80W,[" M>.UN7B64>9$,,%(#<$]?4T_X^^$_$=]K7AOQ1X8TV35&TB3,MO"A=P0ZNAV# ME@2"#CIQ7&^.O^%@>/\ Q9X5UJ_\#ZAIEE;SA([>.)YI(\.C/))A04!R,;@/ MNGKB@#M?BQXP\2ZA\2M'^'7@W4?[)EO462YOE.'&=QV@CD *I;C!)(&1SFYX M6\'?%'PAX^MHW\4/XF\-R*#=RZC,0RYR"$5F=@PX(P<'.#CM3^+'@[Q-8?$G M1_B+X,T_^UIK)%CN;%1ESC<,@=2"K%>.00#@]K'ASQG\5/%_CFR9/"K>&M C MP+Q-2A8E@#EBI8(Q8C@ # ZG- 'F,/@37;O]HS5?#D'C;4+;4HX?-;6D#^ZI%*EOIT(/$VL MSR>9%-/;S1) WJ$\EAD< '^$#@4 :NM>&]1\%?LG"UU%'BN=7U2.ZFA88,*L M 54CL<1(2.Q..U=7\0;:%/V0]("QJ-NGZ=(OLS"/)_':WW_"SO%'P_TWX9R^";NT M-JT4,VIS;A"T49^0;B-HQA%/#_ (L^&/@W5O$UBEU9T\G9C!X8#^ 9SQQZ5YSXYU9/C5\8-!T'PFAN-.T61FN=20?(060R,#_ M '0(P%/\1/'U\9;7Q3H_@/0O ?@O2M5OK-;-8[ZZLK227>B *J%E!QN(+ M$>F!T)JEX#\::WX)TBWT?1O@MKL",RBXNG,V^9N[N?L_/4\= .!0!W/Q$^%( M\=>,+?5]:U.4:)I]@ NFQLW[V8-(Q8\X4$% 2.3C'& :YO\ 96_Y$'6/^PF? M_125[7?*SZ?(O\ B2_VI_:4Z?\ +WY/E^6TG^PV<^9[ M8Q7V57A'[/7AC4]-O/&L?B/0[NTM[R6W$:W]HR).H,^M_'3XL:%KUCX;&E:=I"-2_LAA&'O;U>'!*>80".0 F#Q@DG&0*RK[PMX@^#OQ;AU;P3I.HZIX8U M0_Z586,#S>2N?F4A0<%<[D)]USUSI_$/PEXIT+XJ6?Q-\#Z:=7WQ*MW8[2)? M]7Y9^7[W*8' R".10!EWNI^-_@EXTT2+7_%%QXH\/ZM*8I&NPQDCP5#$;F8J M0&! #8/(QW&VNN:QX/\ VG3I.JZK?7&A^(8"UG#<7#O%#(W("ACA3O1E '0. MM8E[I?C;XV^--%EU_P ,7'A?P_I,IED2[+"23)4L!N52Q(4 ': .3FNB_:/T M9_\ A$M-\66#"*_\/WJ2))WVNRC\<.(S^= $%EK6L^,OVG+NST_5;^#0/#D. MVXMX+ETAFD48PZ@X)\QB.*3Q1!=CQ)J]S\0?BG_PC5J/^07IVA:F8Y(T MYP94V!G.-IP (;EKJ21AAB@)"Y^I+M_P* MN#\#Z1KW@'Q7XB/B/X?ZCXEUFZE\RPU**U66(OEB6,K<1AB021SV(H ZKX"> M-M<\6^"->@\0WCWTFGD+%<2\R%71N&/?!7J>>:\W^'&CWFL?L_\ C=;'5I], M-I*UW*8<_P"D1I;N6A;##Y6'!SD>QKNOV?/#NN>&M/\ %^F:]HU_8S,4\IIK M=ECF*B13L?&'YQT)R""*J_!GPAK\/PA\;Z/?Z3>:?>ZC#+#;1WMN\!D+0,HQ MN XR>M ',_#SP1XGO?@SJ?B+0?&.K6ACBG-MI5I-+$HDC96+ K)@EE5AC;U; MK7R-K,$1TLS%\R?:,[5?=U+;"),]#M>\ M(7^GVMN9ISJ5PCJC,2,1@%<'^+D,?I7F,_@B[/QNF^&D#G^PY=834&A7HD7E ME_P(B8K]<4 ?0WP@L-7L_ACIDOB+4+V_U&^4W/4FN$ M_:I_Y$'1_P#L)C_T4]>XJJHBHBA548"@8 'I7CG[2FAZMKO@G2H-#TN\U*:/ M40[QV=N\S*OEN,D*"0,D)?!FC-X;U/X+67B#48786^JR:>)T(9B1O<(P<# M)Q\ZX&!VKO\ Q=\-=1\8_!2&RM?#FE^'-;BN1?KIEAL2)WVE"I( 4,5(]>54 M$XY !BP^ ?B_;Z3IOB+1_'EUJ&IW126;3IYB((E89_C8HV. 0$'4XK1^,?Q" M\1Z//X<\)Z?J%GHFJZK#')J-]YP$=L&;9P[ ;4W!R6P#A1CO6;#\0/B_+H=A MX=TGP%>66J6HCBDU*:$^3(J #^)0@SCD[CWQBKOQ=^'OBC5Y/#/BVUTZRUS6 M-+@CCU.P6$-%/M;?PC'YEW%P1UP00/0 YNT\9:S\-/'FB6X^(UOXYT75)!%= M#[6)VM_F523\[E,;@0=V&PPQQ73Z]X@UF']K'1M(AU:^CTR2!2]DMRXA8^5( MG:JOA:74O$7BFSA'P*T;1M.4C[3<7]@L31\\NC-$N>.BA2<]Q5K7 MO#^LS?M8Z-J\.DWTFF1P*'O5MG,*GRI!@OC:.2!U[T 8>I7WCC7OVB_$'A;P MWXHO--MI(P&9Y7DCM(@D3,T<>*->G\ M1:=JL8>"YN69I%R&VN-Q)'S(5*[B.](-(_:IU^_P#"FG#5+N!-TMB7 MVF>+R8]RJ?[W0CZ=#T/2>%=$\7_$7XUVGCGQ1H$_AW3M*B$<%M=*RR-@-M4; M@I/S.6+8 [4 <-HG@#7KSX]:SX;@\76T$GG3C;&=IQ*&Q\P'+' M[H_#=\0^)M=\2_%K7]$UWXAS^!+/3[AH[)$WHLJ D*2RLG5<-EF_BXZ5I:[; M>,? _P"T+J_BG2?!]]K]IJ, BA-L&V8*1@DLJMM(9,8(&?UK5\?:YXF;Q%/; M^(/@];^)]+7*VD]LC32E>S;PC%..J[1@]SQ0!V7PITOQ+IVEW#:]XSM/%5C( MW^B30-YI7!ZF7.6R,<'..Q]>P\0?\BUJ?_7I+_Z :\8^!/@OQ'I7C+6?$-YH M\OAK1;V(I!I,LC$[BX*G:WS?* 1E@#\W'&:]IUR-Y?#^HQQ(SN]K*JJHR6)0 MX % 'R/\*_'7Q \+:!>6O@CPM_;-G+=>9+-_9]Q<;)-JC;F-@!P <'GFNA\$ M:X_B7]H:RU/XE0OH>LHBI962V30))+@A0^\[@>3C.Z9@VT+@;2HQA1VK>T7P]\0_BI\6-&\0^,]%DT6TTEX MW9GM7MAMC?>$57.XEFXSV'Z@'7^!]7 M:!F153<3@;&<''>.CX>:UK/CGXZ>)M775;\>'-()M[>T6X<6\C_ZM3L!VG(5 MWZ=64^E4?VD=/N=%N/#WCO1I?L]_93&S>0=2&#,GX#$@_P"!5VGP+\*_\(M\ M*=.$L>V[U(?;I^,'YP-@_! O'KF@#T6O!?VK/^13T'_K]?\ ] KWJO%/VEM! MU?7O#.BQ:'I5[J4D=X[.EG;O,4&SJ0H.!0!ZWX@_Y%K4_P#KTE_] -?+WP:\ M)>,O%G@O58?#?BR3P[8P71;%LK"2XGV+P75E*J %Z$]3P:^H]7P_J,<2, M[O:RJJJ,EB4. !7E/[->AZMH7@G58-K)\$_$FM>(+C^T;O0F"P23M\\GF ",.>I^+-4\' MS^-9OB_:V>KJ'GBT'[US M3+S2)=2$'V8W]J\0+IN93\P&0&"YQ6=HEOXE\*:(OAO4/@E8ZWJ<#%8M4FTY M9D8%B?G<(0_<9WCC% '3^*/B/J_B+]F6'Q):7DVFZJ+N.WN);&9HFWJ^"05( M(##!Q[UM?"[PYXVU"PT_QKK/C*[O7N;!FMM%ED=;8DKB(R,&.>,,2$W9. M;;1+)9;'5Y-"%NB3 Q/')Y>-ISRI[>U 'EWBRXOM#\-:GJ7B'XNW!\7QN7@T MW1=2/V4?,,1F(*"#C/)QCC.<<[U]XWU[6/V2KCQ'+J$UOK"^7$;RT&\MVA8YO(V! 8 D88<^Q]* (;+0 M_BCKGPKB\;)X[O;=[2T,UOIR.X\V&(U'X&ZN_P"S_8Z'!Y;^(+6[;46@WC:S M,"K1!CQG;MYZ97K@YH Y74M>\4^!])L/$]C\6K/Q'>NZ&\T;[>)PF[D@+O;< M!T)"J1VKJ?CWXVU3_A"?!NL^&M5O]+35(VG;['=/$65HXV"L5(SC<>OO6=IM MYK]S]@TN/X!:3]MC*I=7=WIBQPR@#!(8QA4.><[F[\5T_P >O &K^(/ >ACP MWI,;2:2Q$FGV"C"(R $1J ,A2H &<'I0 O[2VO:OH/AG19=#U6]TV22\=7> MSN'A+C9T)4C(KC_VB]%O_P"U/#6J2:W7V;0RH N.1U;J>W=?'WPM MK^M^%O#5WH&ESZA)IDI::"%"\@RJX.PYK<^*7C7Q+-XK\-> ?"&H?V;>:I!'+#-5L[Y=0E\S3X[>2:2- F S (" M ?<"MSXI^"?$L7BKPUX^\'V!U&\TN&*.YL'/ M!?Q3\'^.K()XJD\3:!* ;U]2F8%1G#!59G8,!R"" >AQ7LE>,:)XW^*WB_QI MIXM?"3^&=%C8"^_M.%CN7(+,"RHQ.. %[GGV]AN[C[)8SW/E22^3&TGEQ(6= M\#.% Y)/8"@#P7XAO_PL+]H[P[X1C_>6&BXGO!C*YP)7!]BJQK]6-,\!M_PK M;]I#7/"CCRM-UT>;9CHH/,D>/8 R)]0*Q_ GP7N?B1?Z_P"(?B/#K6CSW%X7 MAA">0[%LLY(E0DJ,J!C'0CM1\0O@=+X 31]?^&ZZUJM[;WJM)$R"X="/F1PL M:*< J0?J.E '0?'OQ%XFT?Q_X5M/"NK75E+=H46&.=DBDD,@52Z@X;KW!J3Q M?>^)?@I\.;N>X\77GB+6=8NTAMI[P$K9@*Q']3T+Q+I_A71+^.*YU&^N+KRIUC=58)$VW ( M!;J0<@#@9SYQIMYK]S]@TN/X!:3]MC*I=7=WIBQPR@#!(8QA4.><[F[\5K_& M#P;K+^*/!^K6WAIM6\/Z5%''.-2\4Z%?M%%<_VE=&YVN[,I"N0.@"L"O'..>:^E*^:=:L-=U?X MU>$?$MCX"U;2-"M98+>*,6.'CC24LTDD<>1$,RG@]0I]\?2U !1110 4444 M%2P]ZBJ6'O0!)1110 4444 %(WW3]*6D;[I^E %>BBB@ HHHH **** "BBB@ M HHHH **** "L;Q-X2T/QEIJ6'B6P6^M8Y/,2-I'3:V",Y4@YPQ_.MFO/?C3 MK/B72_ ;6_@S3K^\U&_E\@R6-N\KV\6"6?Y0<$X"@_[1(Y% 'F_QN\2VOBJ3 M2OACX'@&H7<=T@E:$ED@* HL>?;)+'HH'/?$/Q-T[^S/B=\)_#4Q,]MIZV=O MN;I)^^CC;\Q&/SK.^&VN:[\.-+9+3X-Z]>ZG-G[3J,B3*\@S]T#R#M7IQGD\ MG-=Q\5_"OB/Q=HOA+QOX=TQX=/-2AAL+WRV6XOWE?+ M@X^4+G!)V@ 9["O*H-.\8_%WXI>'M8\1>%;KPUH^@L)66ZW!I'5@^!N52=Q M51P, \YK&^,4GB[Q5\2UMI_!_B#5/#&DR[8K6TMIHUNCCYG\P(PY/ (!^4< M8R30!K_">*]^(/QRUKXCK9R66E(IB@WC_6-Y:Q*/0D(NYL="0*S_ (O?"D:3 MX=\5>-=;U.74=1NK\&RCW-LM87N!M7).20A"XX"\@9X->@_#SQ_K>HZO9>'9 M/A=J/A?2TB8)<2"1880JDA<&%1R>.O4]ZO\ QWTR_P!8^$6I6>DV5S?73RP% M8+:)I'8"52<*H).!S0!L_"W_ ))/X8_[!D'_ * *K_%__DC_ (E_Z\F_F*O? M#>TN+'X8^';6]@EMKB'3H4EAF0HZ,%&05/(/L:@^*=G=:C\*_$%II]M-=7,U MFRQPP1EW.^.N^%/ M@J+4O@/:^'?&6CRQ"1YQ);7D+1R1YE8A@& *GH0:Y_X66OB[X:?$"]\&:IIV MIZAX;GE)L]1CM9)(86/*MN (4,.&&F20"A:ZOXT^-?CW7+/P[XHG\,Z! MH[B-7M-PD?+,%)VLI8ML8_> P.>^CX(\1^*M$^)=]\+?&^KS:F+NV?[#J:. M5F7]T7R'^]]T-R3D,O!K-M-'\;?!3QWKEYX?\+S>)M!UB0.J6>XR)AF* [58 MJ5WL#\I!X.16S\//"?BKQ/\ %F;XD^-M..C".(QV-@^0XRGEC(/( 4MG=@EC MT H =\%O&6HZ?#XN\/>.-3N;N^\/327#SW=J[F5FZ/K=O\&+_P MA9?#/5$\0OYGVO4Y+,(DD8D\S*R'YG;: @1>#P1G.*W7T'7)OV0H]#70M4&J MP7&UK)K.03'_ $LR9"8W$;6!SCUH Y+XD:/>'X!>!M:&K3BR6**T.F<^69"L MSB;[V-P *_=S@]>U;OBO1?&7PS\$^'O%%MXUUG5XH[R*2X@>XE2-8F5&2-D, MC J"C*>QW@8K6\8^"_$.L_LQ>&-,L-*NGU'3Y(9Y[(Q%9E4)*I&P\Y!<<=:[ M#18]5^)OP=U/0_$WANXT"?[.+2".[# R.B*4EPRJ0/, ./;K0!A_&GQGJ.HV MGA#0O NIW5M>>(IDN([BSE:-_)8 )DJ(O^$2_:*T?7OLOVO[#90R^1YGE[_FD&-V#CKZ&J7C#XR:E\7M M!;PEHO@D_:KF1'5TN#1VSM#&09,AG VCJ.I[BK?QK^&5S>+#XT\"P2P>(]/=7D6R4^9 M(?$_P[M].\0V'Q6LO%<\DJK?:2+\7"ID$D!=[97@C< I&1^':^./#WB#XQ?! MS3;S^Q[G3O$NF3%IK&\MVMS,=N'V;P.&^5AVX*YS6)IM[KNHW%CI\/P T>*Z M5@MWF+%#)V)4M& G//5_84 =!\4_B/KE[J7A3POX%NQI]UXD@AN3>$_,D MQHG@?XJ^$/&NG-:^+I/$VBRD&_\ [3F8!%SAE4,SMG'( M*]QS[Q?%SX?Z\-:\,^,?!&FPS7F@QQ0MIL"C:L<;;D"+QE1EEP #@C ]%TSQ MU\6?%_BS38]-\(2>&=+C;%\VIPLRNI(RP+JC9 !PJ]SR?0 Y[Q=XWUCQI\6M M2\+VGCB#P5HFDEHWO&N1"TLB$*PW;E+-N)&W< I)YZZ_P '_'FL1_$;4? F MN^(8/$UO%$9;'58IA+YF K8W@G=E6YR25*D9-8_BWP1K/@KXLZGXGM/ UOXU MT35BTC6K6PF:*1R&;"[6*MNR=VT@AO7IVOPJBU#4-9N=2U+X7:-X2MXU/V2X MCM5ANAGC9C8&/&*>Z=UAQ,X M&P$X7@ <5ROPML/B/\3/#5_'%X^U'3+.SN"5G>626::5E7Y-^\,J *#C/5CP M$O M#FK7'AWPM+XDTZ6X57BMV;S()MO#;55B5(QGC^'J.X!VG@37O%GC;PGXP\!: M[KD]EK6CL%35X26E 27]XA(*EO\ 5EC\/:MXMT;6[OR] M)^T[=!0.8;Z;[,=A;#@9W,O\)^Z.?3T'X*^!/$&GCQ)XF\60_8]2\0NS+;., M,@9F9F8=LLW Z@#WKFO@N?'?@6:^\*S>![IC,GB@#F_#6HZ_XYL)-2N_C0VB:TTC!-+N)WMXR0>.0ZJ ?15;TKZ4\(6FL MV/A>T@\2:M#J]^J_->0Q;%D4_=Z=>._&:\!\37^OZXM[:^(_@7]HU:?H6 M44BA"<@$NB'>0><[P#7J7P,\*:_X0^'8L?$[%+B6Y>:*U9PYMHR% 7(X&2"V M!TW>N: ,_P#:1_Y(Y<_]?<'_ *%7F/AKXI?%G2_!VG6&C^!_M6FV]HD=O='2 M+J3S(PN VX-M/'.0,5ZS\?M*U#6?A3<6FCV%U?W)NH6$-K"TKD!N3M4$UY;H M/Q'^,GA[P[8Z-8_#^5K>QMU@B>71;LN548!)# 9_"@"W\#;*RU[1O&D5KJMS M8^+M1C?>D2FV^R\DJT94YP)",],<#'<])\*/B7=0?!_Q!-XFNI[G5?#+2^=] MKD+RN#DQAF8Y)W[DY]!4'P.\#>*(O&NL^.O&=J]A01Q)E1M#'"Y;<>,9&WVJI^TW_P DEC_["4/_ M *"]>J:/I=MHFBV6EV*[;>S@2"(?[*@ ?CQ7F_[0^D:EK?PP2UT;3[K4+C^T M(G\FT@:5]H5\G:H)QR.: /-OA??0?#OQ]ITMV_EZ?K_A5+UB>%#QQESSZXB? M_OKW%>9>*[%YO!^C^*;Q55H0!_WV9.?>O4OBIX!UN[^%GP_ MGTC2-1N=0LM.2UN[>"U=Y8]\2L0RJ-RX(=3D=\&E^+7@#6(_A9X!TK1]$O[^ MZT^WD%RMI:O*T3NL;/N"@XR^>OI0!Z3\1[?5[CQ+9_VIXYM?"7A-(B9#:W_V M>^N),=F*X !P, GOQR,<7\)/&^H/\9-2\*VGB:\\2>'C%)):W5_(99>#@$GMSWKK_ (<>']9L?VE?&.J7NDWU MOI]Q#(C:Y&#D G@] :K_ !H\(:AXF^,W@_;HE]J&D'R(;Z6& MWD:)(S<'>'=1A?E))Y&!S0!/\*]2\0_%7QG?^,=3UV\L=&L)Q#:Z)9WCHA(& M5\U5(##!R2?O'CH,5SVK>--9^(GQ)UK3$^(,'@?0]*D:*"0W0A:=E8KD'>A? M)4G[V%&./7HK/PWJWPM^._VGP]H]Y=>%/$0"W"6-J\B6;$]6V@[0K'(Z#:[ M=*YS5/!>M?#KXD:UJ2_#V#QQH>JR-- GV43- 68M@?(Y0C<0?EPPQSV !L_# M#Q;X@\3W/BCX=ZIXH6[NX;60Z?K]I)YC!(+^/Q5>6-OH%Y%)?Q1[MNI*&ESYF' _@;KN^^?Q]:^$UOJ%U-=ZGJWPXT; MPB,%+:6VMEAN'4G.QEVAL 9)QDX^7TX/X>V/BWP1\2O$.C7W@V^O-.\17RI M+J"JWDPP^9)^\W!2I!60G!((_2@#%T[Q7XA^*&H:IJUY\3[7P3;6\I6PL&O1 M!O'4!@'4D8QESNR<\<8KIO!WQ,UOQ'\&?&UOJ>H%]9T&T?R]0MI-K2*5?:X9 M<9(*'YAVVGKR>9TOPMK_ ,+=1U+2M2^%MOXXLYIM]G?"R$S 8P/F$;D#&,J0 M,'//.:]"L=(U>[^"OBA[OP%IGAS5+VPDBBM=(M@LMR-AQNC49!R>%))Z\#N M<[\'-%\;^.=+TSQ%JWCS58-.TZ[,:6:RN[7JJV]O,TUBPNK"Y%U,QANH6B< MP=K &O3* "BBB@ HHHH **** "BB MB@ HHHH **** )8>]25'#WJ2@ HHHH **** "BBB@ HHHH **** "BBB@ I& M^Z?I2TC?=/TH KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %>=_$OX77WQ#O+?9XMO=)T]8A%HSSCD'H*]$HH RO#'AVP\)>&;+0])5EM;./8A;[SG.68^Y))/N:U:** " MBBB@"&[@:YL9X$E:%I8V02+U0D8R/<5YEX*^":^&_&0\4>(O$M[XEU2)2MO+ M=(1Y>1MR2SN6(!('( STZ5ZG10 4444 %%%% !1110 4444 %%%% 'GVH_"S M^T/C+8^/?[8\O[)&$^P_9<[\(RY\S?Q][/W>U>@T44 %%%% !1110 4444 > M8?$'X/77Q!\0KB:7IMKHVDVFFZ=$ M(;6TA6&%!_"JC ^O3K5NB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH EA[U)4I* "BBB@ HHHH 1ONGZ M57JPWW3]*KT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%>6^/?@S<>/O%!O=0\7ZA;Z.QC+:1&A9 RK@LI+[5)]=AZFO4J* *]A8VVF: M=;6%C$L-M:Q+##&O1$48 _(58HHH **** ,SQ'I=QK?AR^TVRU&;2[BYB*1W ML&=\#=F&"#G\17&?#CX06W@36+W6[_6;G7M9O$,;WEPFTJI.3@%F))P,DD]. MW->C44 %%%% !1110 4444 %%%% !1110!Y]IWPL_L_XRWWCW^V/,^UQE/L/ MV7&S**N?,W\_=S]WO7H-%% !1110 4444 %%%% 'D_B3X''Q?XV;5O$/BS4+ MO2/M'G1Z,5;9%TRJL7(4'!SA0>>M>KJJHBHBA548"@8 'I2T4 %%%% !1110 M 4444 %%%% !7.>/_"7_ G/@;4/#OVW[#]M\O\ TCRO,V;)5?[N1G.W'7O7 M1T4 8/@CPS_PAO@O3O#_ -K^V_849//\KR]^6+9VY..OJ:WJ** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J6'O452P]Z )*** M* "BBB@ I&^Z?I2TC?=/TH KT444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 >3:)\"Q;>.[?Q-XG\57_B*2SD\R MS@ND.(B"2@+,[$A2<@#:,C\*]9HHH **** "N/\ B-X)U'QQI%O9:7XFN_#Y MC=C+);*S>>A7!1@KKD?4GZ5V%% '+?#WP%IOP[\,#2-+DDG+R&:>XE #2N<# M.!T ]O7)KJ:** "BBB@ HHHH **** "BBB@".XB\^UEASM\Q"N<9QD8KA MOA3\,O\ A6.DW]E_:_\ :GVR=9=_V;R=F%QC&]LUWM% !1110 4444 %%%% M$-W US8SP)*T+2QL@D7JA(QD>XKS+P5\$U\-^,AXH\1>);WQ+JD2E;>6Z0CR M\C;DEG]25'#WJ2@ HHHH **** M"BBB@ HHHH **** "BBB@ I&^Z?I2T4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 M5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*L MT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5 MJ*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT M4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J*LT4 5J M*LT4 5J*LT4 1P]ZDHHH **** "BBB@!&^Z?I5>K-% %:BK-% %:BK-% %:B MK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% M%:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK M-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% % M:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK-% %:BK- M% %:BK-% %:BK-% %:I8>]244 %%%% !1110 4C?=/TI:* *U%6:* *U%6:* M *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U% M6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* M*U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6 M:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* *U%6:* * MU%6:* *U%6:* *U%6:* *U%6:* (X>]2444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 5E:KXI\/Z%,L6MZ[IFG2,,JEW>1Q$CZ,16=\1O$M:I EW?7>IQ"X^MDN+*>*X@D&4EB<.K#V(X-2UXUH>G1_#;]H*'PY MH9:#0/$U@]REB7)2&YCW%B@/3Y4_\>]AC,\/^-?B')\:/%=L/#;7CQP6V[1Y M-=40V(\M?F1BFUBV=QPHZ\YQ0![(WB324\5IX::[QJ\EI]M6V\MN8=Q7=NQM M^\",9S[5J5XIXS\1CPS^TQ872:?=:E : MZ_PK\2+S5O&$OA;Q3X9N/#>LBV^UP0OW/0\\4 =Y17"ZM M\1+X^*;OP]X+\-3>([[3E4W\ANTM8+8L,JAD8'+$#H!_(XN^$O'L/B>UU6*X MTZ?2]7T9]E_IMPZLT1*EE(8<,K '#>U '6T5Y5X,^,6K>.TT^;0? UY)9O,L M.I7;7J+'9$OCY=R@S87#D*!C.*]5H **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBFR2)%&7E=41>K,< 4 .HKG MK_Q[X9T[(GU>!V'\,&93_P".YKG+SXRZ+%D65C>7)'=@L:G\=(TG\MM9,_Q:\3S$^7):P?]-]*UEK2SUME@2&%@KV\3G+1(Q^8J3U)[U3C^.7CI/O:E#)_O M6R?T I?5*G=&OM$?5U%?,=K^T-XQ@&)X-,N1W+P,#_XZP'Z5M6?[2E[&H%_X M<@F/]Z*Z,?Z%34O"U4/GB?05%>0:;^T9XUUF#\/G K*5&I'=#YDSL:*AMKNWO8%FLYXIXG&5>)PRD> MQ%35D4%%%% !1110 4444 %%%% !1110 4444 %%%% !6?>ZI%I-O-=:M+'! M;*P"O]:ON2$)4;B!P/6J5[;V^H:<(=4LA/'(PW1%=P!SUIKS,JG-RODW_#YE MF*XCGMTFMV$B2)O0@_>!&15+0[Z_O[-Y-4T\V$JRLJQEL[E'0U9,$,,49MX% M8P+MB5>-HZ8%4;O^W3XALS9^0-+V'[0'^_GVID3E*+4G?T7GU^1KT445)T!1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '+?$SP[/XK M^&FN:-9J&N;FV)@4X^:12'5>?5E S[US7P\^+'A>X\%6%KK^M6FCZOIUNMK? M6FHS""198QM; <@G.,\9/.#S7IU9&I>$O#FLW0N=8\/Z7?W"]);JRCEC'3+!M574VLK8Z@L7D+=F)?-$> M<[-^,[<\XSC-$FF6$VI0ZC-96\E[ C)#X% '@6BZ19V?Q4 M\;Z9XE\;ZSX5NKG4FOK1;:_2UBNX9"S!@74ABHP.#^'!QWG@C0?"UA>>*-1\ M.>*[SQ-J%S!''J%Q6R3!?IN!Q4UCI>GZ79_9-,L;:SMO^>-O"L:?]\@ 4 >?_L]J!\"O#Y )-R M3@=?])EKTJJVGZ;8Z181V.E6=O8VD6?+M[:)8XTR23A5 R23]35F@ HHIDL ML<$9>:18T49+,< 4 /HKGK_Q[X9T[B?5X'/I 3+^'RYKG;OXR:)$&%I9WEPP MZ$JJ*?Q)S^E:QHU);(AU(+=GH=%>17/QJN6!%IHT49[&2!2?%'Q6YRM_''[+ G]0:O>'?B#XGO_$-I M;7>I[X9&(9?(C&>">H7--X2HE>Z$L1%NQ[?17R4/C9\0!UU[/ULX/_B*LV_Q MV\=0G+W]O/\ ]=+5/Z 4_J=3R-/:(^K**^:+?]HOQ9&0+BPTJ9>^(I%8_COQ M^E;MG^TLWRB_\,C_ &GAO/Y*4_K4/"U5T'SQ/>J*\LT[]H/P?=L%O$U"P]6E M@#J/^^"3^E=?I/Q"\):V%_L[7[*1V.%C>3RW/_ 6P?TK*5*<=T5S)G244@(8 M94@CVI:S&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !136=44EV50.I)QBLZ?Q)HELQ%QK%C$P[/ MPKI;FG17/3>/?#$'W]9MF_W"6_E5<_$KPFO75E_"&0_^RU?LYOH MQ<\>YU-%<=J'Q8\%Z7>FTOM9$4X1)"AMI3\KH'4Y"XY5@?QID/Q>\"S, OB" M!?=T=?YBE[.?9CNCM**YZ#X@>$+@#RO$^DY/0->(I/X$YK8M-1LK^/S+*[@N M$_O12!A^E2XM;H=RS1112 **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **SM8U_3-! MMO/U:\CMU(^52,ZGK.HZS<>=JEY-=/V\QLA?H.@_"J5=T,'%?$[G-+$-_"=UJOQ;\07S%;' MR=/C_P"F:;V_[Z;^@%LLA;'TSTJK177&G"'PHYY3E+ M=A1115DA1110 4444 Q=V@D#8/H<=#[5\.U8L=0O-,NTNM-NIK2X3 M[LL$A1A^(KEGA(OX="U4?4^Z:*^:_"O[06N:9L@\20)JUN.#,N(Y@/P^5OR! M]37MGA3XC>&O&*A=(U!1"_*TG0M:O=3ET=1D1_P )/'&17?/HUC)I\]D\ M -O<.7E0GAR3DYJZJA%"H JJ, =!6DZ\6W)+5O\#+#5)8?X4GZJ_P"9Y\-3 M^(FB\W^EVVKP+]YK=@&Q].OZ&M72/B-I&H7"VE^LVE7C<>3>+M!/H&Z?GBNM MJGJ.DZ?J]N8-3LX;F,]I$!Q]#U%9<\)?%'[CK>(HU/XE.WG'3\-OR+8(905( M(/(([TM8-AX>FT*>-=%NW^PYP]E<,651ZHW5?IR*WJR:2V.6<8Q?NNZ"BBBD M9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M5C:[XLT?P[&3J=XJR8RL*?-(W_ 1_,\5YEKOQ@U&[W1:';K8Q=I9,/(?PZ#] M?K6U.A.ILC.52,=SUV^U&STVW,^H74-M$/XY7"C]:XC5_B_HMD633(9M0D'1 M@/+C_,\_I7C5Y?W>HW!GO[F6YE/\0T444SK"BBB@ HHHH U]&\6:_X>=6T;5[NT"G.R.4[#]4/RG\17HFA?M#^) M+ JFMVEKJL0^\X'DR'\5^7_QVO)**SE3A/XD-2:/JOP]\KA,_[XRH'N2*]"@N(;J!)K:5)HG&Y7C8,K#U!%?"5;&@>+=>\+W ET+5+ MBSYR45LQL?=#E3^(KEG@T_A9:J=S[9HKPCPG^T4K;+;QC8;#T-Y9C(^K1G]2 M"?I7LVB>(-)\1V(O-#OX;V ]6B;E3Z,.JGV(%<4Z4Z?Q(U4D]C1HHHK(8444 M4 %%%>1IXU^(_B+X@>*=#\&V_A>.UT":*(MJJW D<.K$8,9P>4;L.HZT >N4 M5POP[\>W_BC4=;T+Q)I<>FZ[H4J)=)!)OAE5P2KH3R <=#G@CGD@=U0 4444 M %%%% !17G7Q,\:^)/#OB/PKH7AI+S7Y9X_,U19#&GEA"/]601G>?7I6; MJ?COXA^ XTU'X@:#HU]H?F*MS>Z!++NM 2 &9)>6&3VQ]>F0#U>BN>US6=9& MEZ7>^#-,@UM+RXB,K-%?O22N%4?B: )J*\]USXO:38[HM(ADU"4<;S^[C'XD9/Y8]Z\_UCXD>)-7 MW*;W['"W_+.U&S_Q[[WZUTPPM26^AA*O"/F>XZGX@TG1DW:GJ$%OQD*[CQZ#?\ QBUNXW+8VMK:*>A(,C#\3@?I7.7GCCQ-?G,^LW2^T+>5_P"@XK!H MKIC2IQV1BZDWNR2>YGNI-]S-),Y_BD8L?S-1T45H0%%%% &%\1?^1TE_Z\K+ M_P!)(JY>NH^(O_(Z2_\ 7E9?^DD5 M)M*VC3]?U&%%Y$8N6*#_ ("3C]*ZW2_CSXVT]O\ 2KFUU%>FVYMP,?BFW]*5@/W5UF%L^@W8!/T)KX]HKGEA:;VT*4V?>"L&4%2"#T(I:^+- \;^)/# M#+_8FL7-O&I_U.[?'_WPV5_2O5O#7[1LJ;(?%FEB0=#=6/!_%&./Q!'TKEGA M)QVU+4TSWVBL'PWXW\.^+(=^A:G#<.!EH2=DB_5#@_CTK>KE::=F:!1112 * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***X[ MQ=\1M-\-A[:UVWNHCCRD;Y8S_MG^@Y^G6JC"4W:),I**NSJ;[4+33+5KG4+F M*VA7J\C #Z>Y]J\L\3?%^23?;>&8O+3D&[F7YC[JO;ZG\A7 ZYXBU/Q%>?:- M5N6E(/R1CA(QZ*.W\ZS*]*EA8QUGJSCG7;TB37E[,/\ MD9I?^N%O_P"B$K#J5L=BV"BBBF,**** "BBB@ HHHH *='(\4BR1,R.I#*RG M!!'0@TVB@#U;P9\>-O??"WC30_&-C M]IT.]24J/WD#?++&?]I3S^/0]C7Q95K3=3OM'OX[W2[J6TN8SE98F*D>WN/; MH:Y:F&A/5:,N,VC[GHKQ/P%\?;>\\K3_ !J%M9R=JZA&,1MZ;U'W3[CCZ"O: MHI4FA26%U>-U#*ZG(8'H0:\V=.5-VD;)I[#J***S&%4M7U2#1],EN[F1(PH^ M7>QG>'?%=EK6E1S27$"W0B M\V>%&_U8JY-K%A<0F"TU*%+B: R1$')"X^]CTK%\-PQ+\-8)%C02-9-E@H!/ M7O5?PII=K;_#Y;P1JUU-:NSS,,MC! &?0 =*T<8W9YM.O7<:<79WC=O7R_'4 MCUFYN8_#N@L-4-Z[WJ![F/Y1*,GT[5V$NHVD%]%9RW"+N*\YNG MDC^'?AIX8_,D6[0HF<;CEL"MWPA+$^H:K?Q+HL=Y]D?4[99PVTH9!P?2LKQWKXTC1?)MKM M;>[N6548'YE0GYF'T%8VK74NM^&;ZXTO0;2/361W%U.P5WQU=5 SU]32:^1< M?#?1IY@'D+VXWL,G&11&"305\94G2J1C_+=.S6FW7\&B9?$VC>'5M(=*U1;X M7-PJW,D\[2>6N.6'I75MXBTA+!+U]1@6VD)"2E\!B/2L'QA9VR7^@!+>)0VH MH&P@&1@U?UN^MK6]M=.L])BO[]PSPPD*JQKW8DCBDTG8UISJT74BVK*R6CZ_ M._\ P37L-2LM3A,NGW45Q&#@M&V<5-/,MO"TDF[:O7:,FN*\.+=VWQ#U"*[M MK>T>:S21X;9BR9S@'H.:[GKUJ)))G=AJTJU-MJS3:^XAMKN*[C+P$D*=IRI' M/XU-1C'2BI.E7MJ%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **1F"J68@ E:0IRJ.T M29345=G;:SK^F^'[,W&JW20+SM4\LY] .IKR7Q+\6=1U+?;Z&IT^V/'FG!E8 M?R7\,GWKA]0U&\U6\>ZU&XDN)WZNYS^ ]!["JU>E2PL8:RU9Q3KREHM!TDLD MTK23.TCL+=SSZBMS1?%VI^'K"2WT@ M6\#R2;VN3 KR] -N6R,<=,=S73>-91K'P_T37[^VCAU2XE:-W1=ID0;N2/\ M@(/X\=:'-J236C!135TSSVBO9;;[5#XCTC2;.#?X6ETP--^Y!A<%&)=GQU)Q MW[^]<7HD4?A/01XDO45M0N@4TN!Q]WL9B/0=O7\QXJE11ON![YX)_:$5VCLO&T 0G"C4+=./JZ#I]5_(5[98:C9ZK9 M1WFFW,5U;2C*2Q.&5OQ%?"]=#X2\<:[X+OOM&B792-F!EMI,M%+_ +R_U&#[ MUQ5<+&6L-#2,VMS[0HK@/ 'Q;T7QLJVLA&G:J!\UK*XQ)[QM_%].OMWKOZ\Z M490=I&J:>P5\^Z&_CJ/XO?$Q_A_'H2V2)F+H(PX.\%0 ?G&,$U(SGO@6EOJ- MGKWB.^N9Y_$]_?&'68YHA']FDBR!$J@GY0#UZGOTQ7(Z_;?#6^AUAK'2_%7B MK4XC-OURTCN+C[/,,GB4$( I]!C [BO2]*\#:AHWQ8U[7;*>V&A:]:)]KMB[ M"5;E> ZC&,$%L\YRQKGM ^'?C[PSXAIX>9I5CU"2WD:^CCD)+#9_ MJRW)Y)_#I@ Y_P 2:K>ZQ^Q;]NU*X>XNI+:W5YG.6?;>(H)/]=%_P ( MG8?#3P+J?CB*6ZU/Q3'I3M-J-U.[^<[ $90G:%5MN !D 8S4UU\+]9G_ & M]>[?#N]UG4/AWHUSXG@F@U9K<+=)<1&.3)$HGG2 M/RUD?')"\X&>U 'E_P 4O^2S?"O_ *_+S_T&&NW^(?V8_#/Q+]OV_9_[+N=^ M[_KDV/QST]\5SOQ,\%>)/$7B/PKKOA&?2H[S0)9Y/+U1I!&_F! /]6"3C8?3 MK6?J/@7X@^.X4T[X@:]H]CHID5KBRT"*7==*.=K2278076\GSI M8T(++MP,]L'Z'J?'W@6X\1Z/X:T_03:6D.BZQ:WICE+*H@A5EV)M!YPPP#@< M=:M^([?Q_'K'VGP?>Z%-9/$%:SU>.1?*<9^=9(\DYXX([<&@#DKWQ/HGA+]G M_6-=^'&I2WME",69EF:4VCR.D80!_F4*7#;6R>?0UP$NEZ))X+^U:9X2^(#^ M,#:B:+7OL%R9)+G;D,6W$;"W'0\'UYKU/0?A0D'@/Q%H?B.]2[N?$EU->7TM MM'Y<<4DF"/+4]E(!&:CTS1OBSHVEP:-;:IX6NK6U00PZC^N>X!#XCOM)O?A?X;N_BC<:E8S3I"T^FVIDBDO+@QX,31H-Y&23M&,'& M:XSPO\-Z=JMO=)?6>I6\L,5SLB+HZ*Y.2"HR1[>IKT7Q MQX&UO7V\,ZOH^IV8\0>'7:2-[V$BWN6=5#[E7)7)4$8SCGZUGV_@CQKJ?Q,\ M.>+O%.I:.1I(N$:QT]) D:20L@*LPR[%B,YV@ <9H Y;QM8:9:?$[6+_ .+. MD:IJ/AR>.$:3?P&5[;3P%Q(&$9!1BW.[D^E:OQ.\3?\ "._"/0+3PGJU_=V^ MKW<%A'J-O)Y]RT# EBC=6D(4*._/8UT^O:=\2Y+S4+;0]1\.7&EWFX1MJ,$J MSVJL,%0$RLF.<$X]\U1D^#]N?A!I?@R+5)([O29!=6>I"/F.Y#L^_;GIEV&, M]#UR* /-=:M['1+6UU/X7^!O'&F^(K6XC?SIM.N=EXF?G2;)(8$9/3K79?%G M3G?QUI6H>*M'U/7/!$=BT<]KIY=A!=;R?.EC0@LNW SVP?H>CL[;XL2RP6^I M7_A2WMT=?.N[6&>2:10><(V$4D>Y'-:/B.W\?QZQ]I\'WNA363Q!6L]7CD7R MG&?G62/).>.".W!H =\-V\--X01O!.I2WVCM*QA$L[2&VSC,0W_,H'7:W(W> M]=77'_#GP5<>#-+U+^TKV*\U'5M0EU&[>"/RXED?&513SM&.]=A0 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%4M9U%=(T*_U M*1=R6=M)<,,XR$4M_2@"/5?$.C:"J-KFKV&FJ_W3>7*0AOIN(S4^GZG8:O:+ M=:5?6U];M]V:VF61#_P)217DWPF\":7XI\,KXV\H^)-)TG6]+TC4+OR;[5VD6RA\MF\TQ@,_(!"X!'4BO)?%/B[QQ M9_M!:7I^G:-)- +*?R--&L".&_0;_P!\WRX1ACH03QUYIWQ2\0OHWCWX7:WK MFG30SQ_;FFL+4_:)!*T42B)" -Y+,%!X!SVH ]LHKSK2?BAJ7_"8Z?X?\8># M[OPX^K!_[.G>[CN$F*C)5MH^1L8XY.2,]:T_$_C^72O$D/AKPYH<_B#79(/M M+VL@P?U&0#LJ*X[PGX]?7/$%[X=UW1IM!UZSA%PUG).L MRRPDX\R.1Q^-&JZ[J6J:;X7\"7FK7NE7TUO*_BE MI^C%[72 M_>+P6!_=1GW/<^P_,5Y#K.OZGK]V;C5;IYVS\JDX5/8+T%==+"R MGK+1&$Z\8Z+4])\1_&&.,O;^&K?S3T^U3@A?^ KU/U./H:\SU76M2UNY\_5; MR6Y?MO/"_0=!^%4:*]&G2A3^%''*I*>X4445J9A1110 4444 %%%% !1110! MA?$7_D=)?^O*R_\ 22*N7KJ/B+_R.DO_ %Y67_I)%7+U$?A1VA1115 %%%% M!1110 4444 203RVTZ36TKPRQG$_B!X=\9P[M%OE,X&7M)ODF3ZKW M^HR/>NEKX2M[B:TN$GM9I()HSN22-BK*?4$XP?J:X*F$:UAJ:QGW/HFBJ6DZQI^O:='?Z/=Q7EK)]V2)LC/H M?0^QY%7:X=C0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "JFJZI9:)I-SJ>J7"VUG:QF6:5NBJ/Y_2K= M>4?M%.6^&MI:,Y2VO=7MH+EAVC)9CQU/*KTH FMOBKXIUNT&I^%/AGJ.HZ,W MS1W=QJ$5K)*O]Y(F!+ ]L'FNI\#>/=+\>:;<3Z='/:7=E+Y%[872;)K:3GAA MZ'!P?8CJ"!TL4200I%"@2.-0J*HP% X KR'2[!7_ &E/&FG6LLUM;ZEH,;W4 MMM*8Y(I3L165ARK;2Q!'0\T >F:-XFTCQ#"YETNZ:TO%$;+Y4J]5^ M8#/U&1[UA:!XPO\ 5?BMXM\,W$-LMEHD=HUO(BL)',L0=MQ)P<$\8 _&O-/@ MWX-2?QCXQG.O:_'_ &3XDD14CU%E2[V2'FV. MF:]/HE@8K!KZ:RPMU(/LZ[$C<@A.L MZY>:U86=G%J%E=W[>9/&AX96?JW)_3MG%<%I/Q#T+QG#=ZSXQ^)>K^';F6X< M66EZ7,\"6D0.$W[4(D8XR&?$-[I/A_P 7>)_&&KWES-91R+IR3XM& MA:'">8F,O)@ARY.=U 'J-%%% !4<\\5K;O/<2+%%&I9WY[ #N3Z5X3XR\=WOBJX,*;K;3D;]W #R_P#M/ZGVZ#]:WHT9 M57Y&52HH(W_&GQ3FO3)I_AMVAM_NO=]'D_W?[H]^OTKS4DDDDY)ZDT45Z].G M&FK1."4W-W844459 4444 %%%% !1110 4444 %%%% !1110!RWC#_D9I?\ MKA;_ /HA*PZW/&'_ ",TO_7"W_\ 1"5AU*V.Q;!1113&%%%% !1110 4444 M%%=EIGPL\2ZGX4O/$1@BLK"UMGN0;MBCSHJEB44 D\#@G .1@US&E:7>ZWJM MOINEV[7%WP694HKOY?@_K>V[CL-5T/4K^S0O-I MUE>[[A .OR[1R/3/MUK \->#K[Q-;WMW%=66GV-B%^T7M_,8HD+'"KD DD^P M_F*7M(M7N.S.?KOOA[\6-7\#S+;3;M0TECAK61^8O>,]OIT/MG-@DR Q] 3[TI)O[K+U!_R M.*UZ^*?"GBW5?!NM)J6BS[''$D3JV-HRN==3)8EFA>*091U*L/4>5S%[F!I7A; M^R;6XM(]3NI;.2-HXX),$1 ^G&:NV&C1V'AU-(25WC2(Q"0@;B#GG]:TJ*IR M;,(8>E3LHK96^1SQ\(VYT73=.^U2[-/E$J/@9<@G@_G5C4?#<%_K-OJ:3/;W M$2E)/+ Q,AZJWM6S11S,GZK1M;E[?AM]QRR>!XTLI-/&K7W]G-G;:97:N>V< M9(]JN77A:"[\.VFD/ +N=3V(QC%='10I-%S MPU*F>%XM-UI]3^V7%Q<2Q>7*TQ!W\YS[?2MRBBDVWN:4Z4* M2Y8*R"BBBD:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53U75K+ M1=/DO-2G6"%!U8\L?0#N?:J'B?Q7I_A73_/OGWS-D0VZ'YY#_0>I[?D*\%\1 M>)=0\3:B;K493M&?*A4_)$/0#^O>NFCAW4U>QC4JJ&G4V_&/Q$O_ !*SVMGO ML]-Z>4#\TONY'\NGUKC:**]:,(P5HG!*3D[L****HD*[KQ[_ ,BEX._Z\#_Z M#'7*:/K>H:!>F[TFX^SSLAC+[%;Y202,,".PK9D^)/BR:)XY-5RCJ58?9HN0 M?^ UE.,W)-=/Z[&D7%1:?4C\)^&8M5\[4]8D^S:+9?-GK9:7J'D6ZL6">3 M&V">O+*32ZKXX\0ZWI[V.IZAY]NY!9/(C7)!R.0H/6ERSY^9_P!?@%X\MD7? M"<-U>VT[ZKJ5W!X%[SQ3-I=G=W+:@M MC!#;%:P"/< %Z=3C/')KB'U>^?1X]*:?%E'(95B5%&7/)- M6T%)4TJ[,*3$%T**ZDCH<,",^]*5-MW&II:&EX_TVTTSQ1ML(1;QW%O'.8%Z M1,PY4>@XSCWKF:GOKZYU*^EO+Z9I[B9MSR/U)J"M8)J*3(DTW=!1115$A6SX M1_Y&RQ_WS_Z":QJV?"/_ "-EC_OG_P!!-3/X65'XD>0T444SK"BBB@ HHHH M**** "BBB@ HHHH **** '([Q2*\;,CJ0593@@CN#7MWPW^.LMLT>E>-Y6FB M)"Q:D>63VD]1_M=?7/4>'T5G4IQJ*TAIM;'W=#-%<0)-;R)+%(H9'1@58'H0 M1U%/KY1^&7Q5OO!-XEG?M)=Z)(WSPYRT&>K)G]5Z'ZU]1Z7JMCK6G17^E7,= MU:S*&22,Y!']/IV->35HRI/78WC),MT445B4%%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !5'6]-76?#^H:8[;5O;62W)(S@.I7^M7J* /&_A#X^T M?P[X1C\'>-=0M]"US0G>WEAU&40JZ;BR,K,<$8('7MD<$4FK:O:_%/XO^&+/ MPNXO]'\,SMJ&H:A&,P^;@>5&K=&.5SQZ\'Y37J6K>&M"UYD.N:+IVI&/[AO+ M1)MOTW XJW8Z?9Z9:K:Z;:06=NOW8;>(1H/H ,4 >3^-[^RT']I#P?JNM7D% MA8/I=S +BX?9&' ?@L>!]]>I[^XJQXXO+74OC!\)[RPGCN;:=]0DBFC8,KJ8 M8R"#W%>E:KHFE:[;K;ZWIEGJ4*MN6.\MTE4'U 8$9I6T72WFLI7TVS:33P19 MN8%)M@0 1&T_:+UEO$ M7BK5?"]KK-C ^GWEG=K;I,454:)G=6&<@D#CK[C/N5WIEA?S6TU]96]S+:2> M;;O-$KM"_P#>0D?*?<4W4M(TW6K7[-K&GVNH6^<^5=0+*F?7# B@#S[P9X=\ M)0_$234]-\<:AXGUV'3V@9;K4(KKRH"X/)1!CYCP"?XCQ47P*4?V;XS; R?% MEZ"<>T=>B:7H>DZ'"T.BZ79Z=$QR4M+=(E/X*!4ECIEAI:SKIMC;68N)FGF% MO"L?FR-C<[8 RQP,D\G% %JBBN<\7>,['PI9;I2)KN0?N;96Y;W/H/?^=5&+ MD[(3:2NS5U;6;'0[![S4[A((E_O'ECZ =2?85XOXO^)-_P"(#)::<7L]/)Q@ M'$DH_P!HCH/8?B37-Z[X@U#Q'J+7FIS%VZ(@X2,>BCM_G-9M>I1PT8:RU9PU M*SEHM@HHHKK.<**** "BBB@ HHHH **** "BBB@ HHHH POB+_R.DO\ UY67 M_I)%7+UU'Q%_Y'27_KRLO_22*N7J(_"CM"BBBJ **** "BBB@ HHHH **** M"BBB@#<\+>,-:\':D+S0[MHB3^\A;YHI1Z,O?Z]1V(KZ8^'WQ8T?QQ$EJY%C MJZKE[21AB3U,9_B'MU'IWKY+I\4LD$R2PNT,Y%28X2#42<*Y["3L#_M=/7'4^XUY52G*F[2-TT]@H MHHK,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !7.>/O!UMX\\%7V@7GZY M\7]'T^+2KWP3I^MW,*",:M%K$<,($L/#MMJ.A M>(-6%\VH_;UB-HKG,F8SEG(R< 8&1UP>-KPSX:U;3OC/XVUV\M?+TW58K);. M?S%/F&.$*_R@[A@^H&>U=[10!P5CX8U-/CIK.OW%H/[(N]&BM(YC(IWR!P67 M;G<..Y&*P?"NE^.?A=8S^'-(\+P^)]&2XDEL+J'4H[:2)';.R19.I!)Y7->M MT4 <5KUEXF\2_"37++4M,M;;6;ZSGBALK:Y#J-RD(ID;:-WJ>!6UX*T^ZTCP M#X?TW4(O)N[/3+:">/<&V.D2JPR"0<$'D'%;=% !5'6-8LM"TR2^U&41PQC\ M6/90.Y-/U35+31M-EOM0E$4$0R3W/H .Y/I7SYXM\67GBO5#/<$QVT9(@MP> M$'K[D]S710HNJ_(QJU%!>8>+/%M[XKU(S7!,=M&2(+<'A!ZGU/O6#117L1BH MJR//;;=V%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 'O#?B:VO_&7A4R:WIAMK<)JB_NW9''S MY P/F'3/>O.CX/MK?QA;:)>^)]%\F>,N=2M;CSK>([6(5FXP25 ]MPKE7+)S M73_@%ZJQZ#\/_AKXN\-?%"PU+5HHX;2*9P]V;M"+@,I7Y1NW,6W9Y%9LVL:$ M&\=^#M:OSI$5UK4EQ;7OV=IE!28@HRIST48(]_Q=X:TCP[\-M0/B;6?%&DZS M>6BO]AT_2+CSO,D*D NV/E&">WX]CQ&@V<'BSQDSZ_J=OIUO/*]U>W,TBIQG M^TL8#]V"(QLBN?0DD%CV_#-1:NUCX8^%>J:#/K^G MZS?:GJ:3P_8+@3A$4#,CD?=)QC&<\_6B/-&2_K^O,'9H\RJ[I&L7^@ZK#J.D MW+VUU VY)$/Z'U![@\&J5%=6Y!]<_#7XEV/CS2]K[+;5H%'VFVSP?]M/53^A MX/8GN*^&M)U:^T/58-1TJX>VNK=MTCL;1E?1G:T445R&@4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6!XI\7Z?X5M4>\+2S M2'"01D;B.Y^@H\7>*[7PKI)N)<27,F5@@SR[>OT'<_XUX#JFJ7>LZC+?:A*9 M9I#R3T [ #L!6D(\6_;KC6#J%[=_;H;P;[:Z481TS]T#^$KT*]C] MWF7?;W M"#Y9D]1Z'L0>0>#7K4:B:Y3@J0:=RE1116YD%%%% !1110 4444 %%%% !11 M10 4444 %;/A'_D;+'_?/_H)K&K9\(_\C98_[Y_]!-3/X65'XD>0T444SK"B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KL?A]\1M3\!ZH&A9KC396_TB MT+<'_:7T;^??L1QU%3**DK,$['V]X?\ $&G>)]%AU31[A9[:8=NJ'NK#L1Z5 MIU\??#OX@WW@/7!-&6FTZ<@75MG[P_O+_M#]>GN/K72=5L]"/\?;M7D5J+I/R.B,KERBBBL"@HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH ***XGQ]X]B\-VYLM/99=3E7@=1 #_$WO MZ#\3QUN$)3ERQ)E)15V+XZ^($'AJ%K*PVSZFXX7JL(/\3>_H/Q^OAUY>W.H7 MDEU>S///(HC\*.T****H HHHH **** "BBB@ HHHH * M*** "BBB@ KV#X5?&2;0Y(=$\4S-+IIPD-TQRUOZ!O5??M].GC]%1.$9JTAI MM'W=%+'/"DL+K)'(H9'4Y# ]"#3Z^9/A)\69O"]U%HOB"9I-%D.V.1N3:,>X M_P!CU';J.X/TS%+'/"DL+K)&X#*ZG(8'N#7CU:4J+_$UKX0\+7FL MWOS+ G[N,'F1SPJ_B?TS7QT_B75'\5?\)$UT_P#:7VG[3YN?XLYQ].V.F.*Z MJ&']JFV:TZ?/=GW!16%X-\4VOC'PK9ZQ:;5,RXFB#9,,@X93^/YC![UNUS-- M.S,VK.P4444A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M1SSQ6MO)/<2+'%&I=W8X"@^*7C3[;<-H.F2G[/"W^E.I_UCC^#Z#O M[_2M:5-U)61$YJ"NSG_'?C.7Q5JFR M'IUNQ$,>?OG^^1ZG]!^-JGER@ M8Z;1D#D=>>>AKU[QI*UM#S[2J.YP=%:VB?\ ".[9O^$C_M3.5\G[!Y?OG=O_ M QCWKJ-.\.>#=7T;5-0LI->ACT^$R.]R80K-@X48!R>.G'6G*HH[H48.6QP M-%=CIOAG1(M+T:;7YK\3ZS*RP+:[ L2A@H+;@<\D'CM5"W\(3S^,;K13,JPV MKGTX[>IH]I'4.1G.T5:U,6*ZI<+I+3-9*^(6G(+L/4X Z]<8J MK6BU1 4444 %%%% !1110 4444 %%%% !1110!RWC#_D9I?^N%O_ .B$K#K< M\8?\C-+_ -<+?_T0E8=2MCL6P4444QA1110 4444 %%%% !1110 4444 %%% M% !1110 5I^'O$%_X8URWU7293'<0-G'\+KW5AW!_P \UF44FDU9@?:'@OQE MIWC;P]%J6FMM?[L\#'YH7QRI_H>XKH:^.?AYXXNO OB=+Z+=)9S8CO(!_P M M$SU'^T.H_$=S7U]I^H6NJZ?!?:?,D]M.@>.1#PP->17H^SEIL;QE=%BBBBN< ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MKS']H+5]1T3X37%YHU_H4S$.?^^2U 'I\GQC\ 1:F;%_ M$MMYBR>49 DAA#>GG!?+_P#'JZ#7?%&C>&;6SN=3@#')KRC1?#_C_ %?X166AZ?I_@@:+?:6B1[IKG?M>,8)+.:^4D;/F5'P,G;(0$;CT)IVD?%3P3KOB(Z%I/B*UN=1R0L2A@L MA'.$E6/ MC/I=CINF^ SIUI#:FS\3V4%N84">5&0Y*KCH,JI_ 4 =[XF\<>&_!_DCQ'JL M5G)."8HMK222 =2$0%B/PIFA^/O#'B73+V_T/5H[N&P4M=*L;B2$ $_-&0'[ M'MS@XKG_ !5XLO(?B-:>&_!^@V&H>)'L&N9;V_?RX[6WW8 +*I=LM_"/4>O' M.>!!KB?M%>(O^$FBTR&_DT2%Y5TMG,+?.H4DN 2V/44 6?!OQWTG7O%6L:9J MD\<$*WZ6VD-!8W&ZX1B0#)\IVG./O;>O3BNX\5?$+PIX)\M?$^M06,DHW)%A MI)",XSL0%L>^,5Q?PC5D^(_Q.#J5/]LH<$8X/F$4WX;PV]_\9OB)?ZHBRZM: MWD,$!D&6AMMIV[/0$ 9QZ#UH [_PQXR\/>,K%[OPSJL&H11D"01DAX\]-R, MRY]P.E<3\&#G5/B'G_H;;S^8JK#;P6/[5ACT11$MUX>,NIQPJ I<2X5F _BQ ML_,>M8_ABZO++P5\9KG3"RW<.M:H\3)]Y6"GD>XZCZ4 =WJ?QG^'VD:N^F7_ M (FMEND?8ZQQR2*C=""Z*5!'?)XKJCK>EC0SK/\ :%M_9GE>?]L$H\KR\9W; MNF/>N.^$FCZ(OP5T."VM;:2TO+%9+L/&I$TC#]YOSUPV1SV&.,8KR"W"M^R_ MXEL%N9!8GQ$UMI!)^62+SHB@))P$+;R3GCDT >N/\=_APDJQGQ"Q9_N;=/N6 M#_[I$>#^%=3IWB[1-6UZXT6QO?,U&VMX[F6W:)T(BD *L"R@$889QG!.#@UY MYJ>C>,_'FI^&+75?"MKX9LM#U*&_DO4U".GGBMK>2>X=8XHU+N[' 4#DD MUX!XX\6R>*=9+1%EL8"5MXSW]6/N?T%7"/,R9.R,S7]>O/$>KR7]^V6;A$'W M8U[**S***ZMC$*UM*U*!;=],U96DTZ9MV5&7MWZ>8G]1W'X$9-%,"WJVE3Z1 M=B*8K)&ZAX9XSE)D/1E/I_(\&J-;>F:G ]F=)UG M_7J*S]3TV?2KTV]SM/ >.1#E)4/1U/<&NVE4YU9[G+4ARZK8J4445L9!1110 M 4444 %%%% !1110 4444 %;/A'_ )&RQ_WS_P"@FL:MGPC_ ,C98_[Y_P#0 M34S^%E1^)'D-%%%,ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"O0OA9\3KGP-J8M+YGFT6Y?]]%U,+=/,4?S'<>XKSVBIE%35F"=C[MM[B*[M M8KBVD66&9 \;H M_'?CZ&KQJM-TY69TQ=T%%%%9#"BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH ***Q?%7B2U\,:+)>7+ RGY8(L\R/V'T]33BG)V0FTE=F5X^\ M:IX6T\0VI5]2N%/E*>1&.F\C^7J?H:\&N+B:[N)+BYD:6:1BSNYR6)[DU/JF MJ76LZE-?7\ADGF;+'L/0#T JI7LT:*I1\SSJE1S9T.DZAX6LM,C&IZ+=:G>L MQ\TM=&&-1GC;MY/&.O?-7/'&@:9ID&DZGH8EBL]5@,BP2G)B("GKG_:'KT/- M9OA?PW-XCU$H7%O96Z^9=W3\+$@Z\],]*?$&GZ5HRB+3[7; M9V6[C.2%W'N <#\!0]*FC]0^QK\B;P'X:L-19M1\0H6T_P Z.TACW%3-,[ M @@X&3Q]*ZB]\*Z['XA\ M/V.F:>1H>CSPN93-&#*VX-)*5W9]>V>OK7-^-QJ_ACXC-KL2"'SI2]K(2K"0 M!%5@0#D#G'..O%8QFYR=GNM#1Q48ZK9E#4K'1M2\%2:WI.FMIDMM>BW>(7#2 MK(I7(.6Z'/I5?6-(L?#WAV"VOH3)KMYB9@6(%I%V!&<%F]P<#TX)Z'3]:8^' MSKFKV%E9Z;:SE[.QM(?+6\NL8#-DG(7'^<8I;_PIIVH^()--U#4+Y_$=U;&Z M:4E?LYDVEM@&-V !Z]!^%4IM.SV$XW5T><4445UG.%%%% !1110 4444 %%% M% !1110!A?$7_D=)?^O*R_\ 22*N7KJ/B+_R.DO_ %Y67_I)%7+U$?A1VA11 M15 %%%% !1110 4444 %%%% !1110 45K?\ "*>(A9&\_L#5/LH7>9_L(;C_B7RD+:W$C?\>['^$G^Z>Q[?3IY!<6\]I14EWI]Y8>3]NM)[;SXQ+#YT93S$/1ER.0<=1Q43A&I'E8TVF M?=-%>)? _P")OVZ%/"VOW&;F-<6$\A_UBC_EF3Z@=/4<=N?;:\>I3=.7*SH3 MNKA1139)4AC:29UC11EF8X 'N:S&.HJ"VO;6\W?9+F&?;][RI V/KBE:[MDN MEMGN(EG896(N Q'L.O8T 3452.M:4"0=2LP1U!G7_&J^JRKJ?AV\72M8M[-G M0QK?#;*L)/?&0,X/<]Q36X'SE\=/'0\2>)QHVGRJ^G:6Q4LC9$LW1F^@^Z/Q M]:\KKV]O@%I!;+_$"T+,>IMTY/\ W]J:?]G*RM8UDNO&L4*/]UI+,*&^A,M> MO"O0A%13_,[(U*<59,YSX&^.O^$9\5?V1?R[=-U1@A+9Q'-T1O;/W3^'I7U) M7SO_ ,*!T@<_\)_9_P#@.G_QVO<-)N(])T*QMM7URVO)TA"_:W98_/ X#8W' MMU.>M<6)E3G+F@S&JXMWB;%%5(=5T^XF6*WO[661ONHDRL3^ -.AU*QN)O)@ MO;>67GY$E4MQUX!KD,2S14,MW;031Q3W$405Z#X8B7P/X? MG\3:G\M[>PF'3K8_><'!WD>G3\/J*Y'PY=:79:];W.NV\MS9Q$LT40!+$#Y< M@D C.,C-=3KNN^"_$6J/?:B_B0R, JH@@"QJ.BJ.PHJW;Y;:!"RUOJ<'7=^) MA_PC'@'3/#J_)>7Q^VWP'4#^%3^('_?%Z'_:MSI\Q-@ZW#1LI9@0I !W?-CT["NFOK1KBWU736U"*UE ^V M>(-0CC+@,2=MN@!R0/3/;W(KBO#>MV?A^*[O1%)+JVSR[)BJ^7!GAG))R6QT M&,?G4GAOQ%;6$>JVFM)<3VNJQ!9I(2#*K DAAN.#U.'AHBV5Q;7BWUE?Q&2"<1F,G!P05).".*Q:WO$NMV6HVNFZ?I$$T5CIL M3)&T^/,D9CEF(7@-TJ.T;J\;%64Y5E."#ZU%2"G'E8T[.Y]X45POPG M\-_!>G>/O# M,FAZS+>Y]:Z:B@#!\5^$ M-/\ &-OID.IRW,2Z;J,6HPFW95)DCW;0V0MZB@#DO%7PZTKQ5K%KK+7NI:1J]K&88 M]0TJY\F8QDD["2""N2>W7/G&<[]_F MN2-Q<\#KC '%=?10!Q%U\*M&G\<2^*+34M9TVZN)(Y;NVL;TQ07;)]WS$ RP MXZ9 Z^IIWBCX6:)XFUX:XEYJNBZN8Q$]_H]X;>61!T5C@@]N<9X'H*[6B@#F M?!_@#1?!7VJ73/M-S?7I!NM0OIS-<3XZ;G/\@!4_AOP;IOAB36WL7N)AK6H2 MZA50%'R^QR?>M^B@#S.3X$^'%:>'3M8\1Z9IEPQ:;2;+4V2TDS MU!0@G!],U4^+F@P:)\';70M T0R:+'>6\5Y#;0^;);VH8L\B Y)?('SO5Z* /FG7X_AI/HJQ?!J*^/BYY(Q8_V4;I'C8.,F7?\H7&[.[_$UZ5\<+B& M#X)WMMJ\?VJ]O!!;0)$,%[HLI4K]"I;'< CO7IE% '/^ _#*>#_ >D:$@7=: M6ZK,5'#2GYG;\6+&N@HKG_&GB1/#/AV6Z4J;F3]W;H>[GOCT'7_]=-*[L!P_ MQ6\7;W_X1_3Y/E7#7;J>IZA/ZG\/>O+JL1Q76IZ@$B22YNKAR< %F=CR:VKK MP%XFL[22YGTI_+C&Y]DB.RC_ '58G]*ZE:*L8.[U.=HK3TCP[JNNB4Z7:&98 ML;W+JBJ3T&YB!GVJK?Z?=:7?26>H0M!<1'#QMU'>JNA%:BKFI:3>Z1+%%J,! M@DEB$JHS MM/3(!X/'0X-4Z "M;3[^"XLQI.L,1:;B8+C&6M'/<>J'^)?Q'/ M7)HIIM.Z#?0FU#3[C2[QK:[4!U (93E74\AE/<$<@U6K>TZ]MM1LETC69!'& MI/V2\(R;9C_"WK&3U';J.^0T444SK"BBB@ HHHH **** "BBB@ HHHH **** -[ MPMX?L=>N+C^U=?LM$MK= S2W.6=\]D0.:W]<^&MO;^#9/$_A;Q%#X@TZW MD"7)2V:"2') R48D]QUQP0>E<$ 20 ,D] *];NXS\._@C<:1J9VZWXFD646I M'S6\ V\L.QP#^+8_A-8S%F\2>)-;BT+2&F\B"5H&GDG M?G(5%() P>?8^E1>+? O_"/:/8:WI6JPZSHFH$I%>1QF(K(,_(R$D@\'OV.< M5TME_97C/X/:1X?37]/TC5-&NI7:/4Y_)CF21V;*MZC=C\#Z@UIZAHUMHO[. M>HV?]L6.KO'JZ.);*0R10N0@V*QQD[\73M,T^ SWM\Z; MQ"N#@!(-!OO#.NW.D:JBI=6S -L;4_4?D0#VJZU-58:?(47RL^U:*IZ1JMIKFC MVNIZ=)YEM=1B2-O8CH?0^H[5)I_%.O27;EEMT M^2WB/\">N/4]3_\ 6KL?BOXO\^8^']/D_=QD&[93PQZA/PZGWQZ&O,*]3"T> M5<[W9PUZEWRH****[3F.RTSQOIMEX330;OP[]IA+%YF2^:'SFSG+;5SZ#&3T M%8^M:IH=]:)'H_A[^RYE? MW7'X5F45?*KW)N[6-?Q%K[:[

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end GRAPHIC 15 rprx-20211231_g4.jpg begin 644 rprx-20211231_g4.jpg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�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�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

<>(]542GE&+@WFG? M9B_HW.7Q:T^(U=E\$O+X6C'!#(Z%"P,8RR9#/(A$@ 7.HZ7?QF/G*(_1OXQHX+'U0&+J75Q#.'B85(B80<%(G12(>K>$S9G?6- MG'J<=;MA+Q^!;O9FK6[@0,_,>\X7K[Q$ M@O88B2W)S+!__1LI6=C(LETE599DF;G0QG:KGHQX*C,BX_9SB7^(SF9)?J02 MTH/B2H-W+H&)B4?/%*/5-M'^*;=,/T3I^XNW1<1S=P=OM(JSA Z,J1W)9!+@ MN-8@M&=%!Q6R;90L^!1:IA^B_0$$/N#E3:=!'EJ18Q]Y!J:=JI/!+7C-:] _ M&)&T(3=NJV;\+ :C[*/EP>79X)ID'5+Y4?3SQVP=.EE9-DHE)C378-&3BV1\ M!L\Y0O'9L%@*)J#*;,; M20[01!-OXB&0L61Z#Q*'3$8M&3_!0?3T!U?"(B]UQ%B;66?IE)2U6842/$>)HK1IY-4)WO@&RX J MG;761\.6(;__^RN]6W@-2D05> PUMD!6E-)')*+011=N!1M2+(3SCF1 MXG!Y-]@YKNVO36!\LU,ZR54VW %+==Q@$1Z\L0ZL8KR$E(WW;5S6W7B>E]4Z M@$X:>#IW46VF_'3 U=16O0_9<B8L-JX8&UN?;V33_0+D9H? Y&5O:](W9 >9,F'"HF._=(X:M[]E9EQ2F>5?;%9*57(*_$BDLWJI1:%F[*[=NP , -5%[Y8 M+'!EE/\Q"7%RN3+'KQ'F=],?M6WT"_0NS#=_?1D6DUNY=2A]BIQ>,68BO1** M#F2':*!(J8MTW K3)BX[Z#(.W9/7&'Y NG%J7L3%*NARH:,DN2@R5S@M1S'C M()12FR0X;;2D'V&;]/='H1VQ5G-T!FYO\L/JK<74HK#X7+.>X<9Z!Y(J"BT*F7D$,1-DMA6'&-6EQTAC@^T096[W9KP2:Z:=.Z M/=-[\[&^0.M+%XS+"S1>.28E&#JKR#BR"J+0%F(V084DE-=MYM'OA'-NY#A< MY@U"IR^^D?U0;]E>S^8?B:X_H[OYVRO::(G+%]:8@DYJ*#5/0&$J) N(&.R MO,04=6I3%],3Z+F1IZ6>!KS@7*69W"N)#3BO-!G!20,OM74G#Q*\,.2.98M& M"):,>=3%Z/2D8)$M' MI69"8C$^M[GW[H_UW+C46%L-&NK?!!G7DKE(P7JE J&H\65E$2%(93.-ILT.M82QNDF< M#B^/H_U3Z3:Q^P)]7=N,2CCG-93,:XMI29LZO:=@-*)SDI9DVB0TW(_I6*F4 M1^)(IV!';UTU.(4_(-F\D[3$O!OC[N]NAD]VP-XT!?,0],=)TQR*";,CJ_'4 MJ"@U%N$E!Y^%H+?3THOI)(-@DLM,1=3;7LG94O"1M-!39& ?[35@WI^S*7[_ M,\S_B$2;705%%BQ:"YZ\(<9 MD>1P=;0838KSY;J3<1WJ_!M^G2TFF]1G9P2&)%P%9$!)9FF=G /';%3.(3+7 MID/A Z">$U\&4DW+>XQ'AI(\2F)#11)_I_VVN M 9[P9,M>ZNPQV;*/+EI.MKP%36S,/:>]*SG5, .9>X+>%8^>0W1U.*.7+/(V MGOT#H)X;3?;1Q4B[B;R&QKD2B7$+6-OUJ%S(/R"LX'@VI& K4VP\7O NJ.=& MDWUTT=9#NW>P(E/>AD+:)":7]6QI\AX*U//76>DDQC8)_R<\)_?D?+-!M->@ MSTF7$8Q=(/Z:FSN(@O>8>[J/=HXT-]<6&U#H# (#0?5DI 5>^T!YA1XU2M-Z MHO<3G)O;FC]]E'*LN;E%F!1"#,!\;7OKR)R/GHYBIZ5"Q7.=VCF>F_XDYN;V M4NL^IHN"\RJ6CSC_-DFTY'=E5V^/VM5[L?M'F^DL'=;2U#P:8T^?K M8V;;J=.UCVI;9"/,YE]KD0C^7(2X&5NB),<<)1B9'*A "*/& CGKY*6V(31J M4/ @K/&MN.-I_$Y&RU#J&BW[J2B=5#$.N.8)5#06?"(3A8=Z)S+X,H* &-^H_ MSVBS,;ODZ>D^Y B*%=H),VV'+M)Z+:>CU;1IV'7D$7@G0Y+]U='@WN&>H8V< MF>*M<&#]*HA]'D M;"PU#.@C]0.+"IG"9"#Z5&>+EMJG(T1 Z9PA!X],\$XEW4^!*_=<^AV1*GVD M/R!%5JU>_IS-OWZ>??R^L:JYYT;[*"$7.@=5C4"[3*BD],XJ@URP;I-QG PFNP?U9M9?>E5N]>E;<%=H6)URN9UX&E7V : *#'-!K7DOD<:_:/%W/5^D MVD0M"?@X\0Y!U#U M=@/($?34X(:V+^P857*.6Q !:1.M4^Z]]$2"H )B<$A;\_G2ZI%PY/%9U4<] M3>*-N]O2W4+ZC\GR\_MZQ/\UN^^W-W-*3<&DL@ Z_C4H;LC7CT[7)G72HF$Y MR$9=C 9=Y8T]^>GC!6V.> M/!8?/9,R>:.\,Y$E;XUV2>O,I5.]QCS=>?*@701WV)LK _-OTUE3R\O_Q,O\-[+GP^7D?S!OQEA?B"0#B\Z %9($Z02=G(X\-O2. MI2!J%^7&]5=[(C]ZM]!1.?QP7\;&>A_04U_=&OR<>K/=UOT#9OSRM8KJ_7R2 M\#VYN+0AA4](5AZG_SE!QVB-3%C!('+F@1F1,_FDR7;LF;TG@.=)N=%4-O2M MWL.8_\\564PXO_S^/GQ?G7@7@3LLJ0ZC$*565(L(CAL%+DLM,6)6+@U KSL/ M_D6K)BH:,$NF ];7DW]COL99Q[J21+P&+HGKRM:.WYGI6BYBK5::9=_M_KC[ M,W^1:&C%##V'ZF&8KSY75^W-=)7@,[O\_1O!I7UT,LL7 9F64=6("PI04CD@ M=TW11JJ=$B[PI-@ ;+H?P2]NM57:@,DW'4#_ ^L \POON&'\=DLP7V291+(^ (6F2C?00DU @58R,>3K.8[VRNA_KS1<+.1HN2F"U+$D9K-EKB@![YP,=\0X[QN][/O@7 MJ9JH:,#Y7,/*[3H>;E)0F3%(DBE0'!4$@9Q$*%ERJ7A5&C=$.WP11YIL@%TW:%FKWU_&I\Y9>6XL9:V0_D9L?BR6KN C(3GNK M>/))M]DK3Y^O>_85.!FZ]E%M YJ^)[;@G,Z;C\M9^N>F-[^33F1O0)A<2#@J M@'>MQY9-D"CW0Z*%31Y4YC;SOI[Z=' MCUQNM*_P9T-(KF5W^X>'0H0HI38Y0N*K+ [P+VU\R@X?5^T$B7?91V])E!QFBNK#+@4AT^S^JH 2P?KH:N0I'XB\B)PT<)$E*"D%Q+J!DU]4S[ZZ.)HF=^K(/'J_5'22&FB &=B 16HHW(763!HX^) M/$P>ZQ0E82(X2Z\ *SG[;$6*C69DC,6!1RYT1J- 'T$W4/U'.MKHZ-N9PQ"0 MJV)$AN2* *6L@5"T!:-"2D:H*!KU2GL U/@7-8?J;/M &$C@;6-<,(Z/:JKE^Z M+NL:)\XU\,J.'A([A$!-RB@&TG[+N,;0ZU.JT*M/2S.^5JP@;0/., .I6'(T MA3&N=$H,.7-6=P_#/052]U%Z S+__M]7D^7W.W.O5,B>[(\"0IH::Q*:#%PE M@0#)S)SS7K5II[4;SU.MHSQ4W[/!E35PGO'.WN#9F80\D#OD1 1EL@2'@D%F MRG!/D(+L-./NJ0]H.$KV\<$:&;"XME_3\2X@G_V(AEZ:W*OO_CYJ.-J(ADB; M:&'. ^I2@T="@O>93GA?/&.8JC=]+ESI.Z*A/57Z2'_H8-K+R>S5_/MB^7[5 M337AU7*2PN7BS31M6MMF'ZVT&22:.J&".? U9T8E^M((:ZSLUO/AL2>=ZA"' M7MJ9M1+M"78-_GCUY4N8?Y^5=;NFR?15F,^_T^F\^H!966='[:P4&Z?-\.$ MQ^Y+/+!(MQL9FRB4LZB",HHY&='+F(35.=J8M.O5R/APJ*=P??#'3<<+G6Q" M[< (K8%,1@4^H(9";H%V)@C6*-Y[TIV/]X7S*ERFJ\O5EQ]FEY?74S8O @^% M*=H\!0NF-A.I5P>VSO1-L42/SOA3OIK9O:JGZE7OQ_TV-SH#\*5E%.?6?EB' M MQ9S.+GU?R\])5@5A]SP5DQT:M:>15)T$85",&[U5A)%ZRVQNNV_!]H)4^5 M\T/PK$,QP6@D&:F09<_U;+K<+2Y$)C$:YD%&5F?FDKU+7Q3@2;J(PEG#&PV\ M;K":7^0_';*TF-D^W)HV8P'(Y[N\(D/\S?3=\C/.7\V^?)WCYWHC\8T^BEP% M7 T/\-Q[YSF#7#2YFN@YN9I)DFNH&)>:(_WWU-^2?DO^]2H],=J-5*.[Y\(_ MXG*Y[N:WN"#ID[@5 QDDK\T.:A^:S.@LC>0'ZRB$:NQK#+J>7V_**1%FP#*K M!JOZT<_IW=7RW?5-S$60UF1+=,U:,E"2U;<\9_+Y/(8R<3^%-@O[]6*< M)(4:Y-FW6-Z;Z7)VO;HBE5(Z2P@BUP(4]$ +HM5)H<@DE3ZDDW?.=ZSKU_MQ MB@0:NI7[T:S'%V6)\XTT_MJ((LGL:-$:I%>:3$JR*WWAI"H=(H],!B&WFFO= M$S4\K77]>I>>/-N.U_1^,]5FQ]1 RUWAWD0Z6%,&Q94$9V2$*)4(ND@14F/' M?U_HO]Z((]'@+H_=J1P@-]6^BPO&;8E)2+ 6Z4S4=1Z%#KZ.-Y':\4A68[?! M1VWP_:+OR6C_+J']"3D,Z]",$BI9%1Q($2,HFQ-XIAG0:VN#0<9Y:9PDT"1^ MUU^R]YW1-YO:?\XN,SUWL[>]F][J#C"?+.A'OUU58.N& "^QS.;X5_CW12B< M95?9ZSC]$9BFLUS7020^*9FB=[G--46S)3W5/6:8_(#38,K)UB^ML]15="[7 M]%+T@I9"_X& G$3M>2S%!OI?IU[$1\J+>=JCCHZ>_-*? R(K%"UINW M14(IM;0_YEI_33: YVB98#IKW[C!Y3F6.??B2.-6)=U_2IS M'J#,N1>!QJH(W4?[3XG=3A81LPB@,'!0DC:$*'T '2,+V9.W9XYZ9W0BK-Z[ MS/DD2=U'Z>.5.1>9HQ>YFMY8S7%9ZK6#!.9U*EJ(:-BO,N?V^NY6YMQ'62TZ M[CW0M"<'Q:5Q%F3@ I1A&4)P"(:,'*FUM#P^@RY))TFFH=36XH1=7WZ^(A=G M'M)RPW-AA6-8[QZ%KY?IQ8!'0L6L165*H+>@T?FX$\\O'@VEK 8IOS_ZE9;9 M?!$N\MAE=@RQS7 MAX=:D%%IXPKEJ@>NCPR\K[,3H^.2!6:3:CSR_.QG'@UTA3*4%D>J7[A_'$87 ML+]F'@VO]X-&TNRCM*///++H:$]7&5CB=6(/\^!TG>@J@O&Q.*;EKYE')T*P M/KH:>>:1*3P(8SQ9"'5ZH; 9HJ$S/?+DBPY,H&K<0/7IS3SJI,X_ZZ*)E M??8M:&(SCDF[PK1RP)6HC;^R .=4 &&D23YGQF)C4^HNJ.=&DWUTT:(Q][T- MR*,PA5F,P$P@$O,DP >M(&J9,I=6N<3:7#B=\Y"'0TSL8735P(/;T;N\"Z)G M/N2AE](>[_"_C\3'&?*0.0:>50$CZ^6%=QZ"";7/9(PY"\=#:),9>/)#'@:F M0!]!CSSDP3!;HE<>,-3&'38C.%8(:;8*@[%*>6QSFIQ2^.)0G?4(//01>+-0 MULN=T%1RH227R>3QK'8-3!"%SI"2#BYD1C9/RU#63E!GPH7#!7[OOG#$9HKI M,^:K2YR5WQ?+R1?:3/./?WU!IA=F K-RO=;V]5@M%/>$-7KCQ"'$M]4ND67B MJA&TE;BDM..U6:WL^7&VG^Q_/$O_/$C/S8S>E^-99"*K#9\"1#((82L!,K$# M\19A)!K]7)K40 TM[Z)N(+TK':6T=IL9XUP7E4"'&@1-FH-7QD-BTH1D@M"B M31;5P=!'3_T?F8?'T?$))OD_%)P0(N;$!0/O,-2['@_.I@0HR/127#(EVW@_ M3R1V/0YG]HM8]]'=T>.(7<#^BE@/K_># HK[*.WH3(LV1%NT@,"C "4*A\B" M!Y93MLX')(BB3'$15Q]SRB$%@#"DV M/AF?7L2ZESI[1*S[Z*+M7-A;8E@7YZ\F(AO/MI[PMJ<#)S<(4E'WTI M1C0WHG8!>_;6T\'::I#H]WXV7^G@9LD[Q+6Y*N\ M:G1U /LT4VFPY4]&U=3 M+0^T&X#5@7[QI4Y)VJ1L[&[R#[MAV MT> L&EPE#6C3A^E)1UURUF!\Y*!A4Q^4X_.I MF;JWRTU;Z:I% L_UK+(/^)6D0U;CZN6Z'ZXS.J"W&FRH&6VAQA:\RI#HKUH9 M*;-KTQJX)]#S95=+C=UKF@^<#K )"W]8_WR=:?D6ES]&Z=W[&X=$^P]_ZB#! M_($7OQ6KMX6T6D2N31F4=SQR9VT)/AA4:$NZ&.#Y!Y:8IK0ZP,E7Q45U7F=A MNK@):=X$J!@=Z\5K!=H&VAIMBA"=02@L1"6C\[:TJ6_HBO#0S7?U^3>?^Q_S MVOHT"ZX-KUGGUCA0L9HV,C&0I$0?&686VG@2N]",OXTV8T\.X+ M[;^XO)S]B[Z)KV?S5W/,DV7M";CNF;MX,_W]WU\QT?;_*BP^OZ;?7%P@LPYM M]B20O!I>8R%888$IKE,V*6+RC^V10X$Y,]X<14=##[C>E3ZRZB+>>Q7.%?0^ M,#"*2_*YB@"?29C:Y^RUY8(IO2_3]H/T3/@V@KX&O)WM^=91^]7L&](WEW_-)Y\^82W_NW:X9W,B\&2^JO9[5]Z'Y6IT M&CG9#&.PH)FO039)1J2V @01V_"LA=KN1=A]4^H'Y!>EL#C)RVH>]E :4C@6"J_-1T>NH MN$VE=&K'3A]_BW/TMVV^[7[^L9(M1M'X;##)#^@I5C1OPQ=:^4^8-FT1.H#J MDSO1B1;WPADW.V((/V0U\.O?J^6$[2ZTFLY[6^?)XM-#"D8(900%H*H-GE2 M!J))":Q"*:)T&;7I9-4^^)CQ+-8!]3!K(L2A[Y?_^KX(<3[9($G62^81K-49 ME$J!C"&6(*G '(M>%?YH-.WNQSYY]>TOI*'?QC=?XOSJVR2%3:ZN=X)K="#0 MT)*$E[3K$* 0A'92Q9QDZ*2PK0]^\BH[1%!#WW3^?\LPS1OV,!GK>#0!J)0% M51R][-;25U9EE73VD7>;]G?[4Y^\NO86T8#W?>M7?8Y?RO<-:[+31G'B2@Q, MT*MN!!%FQ1KC@A",R^U^C/?MA[<_]LEK:W\A#7TO]_NW^??%#7&\)NR,T:.9 M!.50@]?U38\)8\E&"=,MT/G3QSYY=>TOI $ONE9(WM-20UINF!.1B:T.*LI[9W0/FY!W*U:WB>7104T+(8I^ MFU3ON)" U@'FR=T X!>7OC@1LBO>](HMS* HS:F!249QP= M^9S<<5V\7=+NL%@/.GHS39=7=9#LCY3DY7P2KY:K>^K9 MV]FTQ@Z(K/2)G]Y,ESC'Q?)".K+%:R5.*K4Y8;$&@DT29(I6.Q?KG.HV$:9! M\!^A.J4U,^\VA!U=T2U:!?X(K?00X#JZ4HRG3N1 MU0)]!,7(<'1U=C*34HK(M96R4\E5I[A(%T3'#YVV)<:LH8(&CJ8]AN_:X^B" MS+U]FT9D^N7B$NZ@S*I,'$==B&SFL5 M(L@@38A22+U]FSOTI)!=L)Z)N3.\BAITX]G"M&G4T %4T[X[.V$=>4S(X>K; M.>IZ"-DW&YJ^#S[S@D0?EDP>IC0:5R#\+*"S8F#3CVCC%&S7[ZP[RB03$ M^G#L3A? 1BH;H;G'^GU_,WT_QP6=]-<]>M,<0W4/9SLVB>MJZ0NMD 4O&119 MIS9DK2 P(\ FA3$$VN+\_@6F^Z(Z8[(=5X,C] #9M9#?\*&%;"KVWY7-DKB+ MDA6A@:1(@L68P66-X(R/1CMF=3@5\= *\XG]\-[QMP<49$-^H'T$-,_YI/:[;,L+F*L_3JC M)FYXVMN1@'LMZQN$LO@0I,$V653[H'V>U!M6B0-6.OQH)+KQ-0E@K3A?P[M^ M._*%309%L<0 @QZ48^NVH<"U2(;3&X.ZS6"$AW$] S(-J)@&K47Z>$,^,Y,5 M2Z!5+#7SJY WY 5D8GR02='IWBGV.YX#>[B=N_LY.Z]K5EO!K)0+JR6S)H-W[%A:N[? XB@9KCD'K:U%VC@R R5K MA@&79'%[[HU%I7UIE(1]GAFNA^SV(ZGQR62X\D0G1+(!-'=T9G@Z.#PO")+^ MKJ(,3K'Q:,I'+V+TS7#MHZ#CI"EV0?@KPW5OG?;/5]Q'(<>ACDTYL! $ M<)G))XO9T$N#].8H'/$1:1P,1;$\G<=0:QQ^WBN>2\"71[DK_J.-3 T1A-629!9++0>ML5F/\*+H![I+N>\9Z M5D8H,N6"M>5=K:- '^DK(T%PK92W.;)&HUD>0W:4*Y)AV;+C#GLX9;28Y'L_ MOA"Y4YO2K2T7F-!C%SGZVR8^]4 MVR!/XEYU0)ITW\(.4M>XQ]X-T-K"[-I][P*W:8E=3\!'&F_?B@#=B3:8]DZ M=$P+'7/,P",=]TI87MNX"K(4:0G2&1[I+#O5+G61VE#YR#_]O[] MF[]?S^.YO@[D/E;;T(/SM=>VX1RS3\H(/UP7 ML^$$>?1[U2&:0_;X]+8WI+W:,TK!A2C,!,VT4BHZDTN4SC'!C$@1'[@&';Z_ MXN/&OXHY"(Z&_#A%YE;AJ];/"-9G3DX BR6=XUWGWQ98KB[_F!2\*")AH%<3 MA)8.:GX<;J, --UZ[-M7NA^%^5F0; M7)$-[/57LVDB"V ]Z/##9/'/]^1RTS?")^07QA;+9(B0DJJ%_HQ!="6"B5X: MAK[PTBD$WIMD#Z$Z0PH-IH3CWHIREQ23U@-/A$\)1R+(VM)?D25O"'^WC(GG M4IWHHZH[6M[=2<(5DJ$^@@3XE(8@TK(?)L6+-& V=T*]J+)@?< MBO91UPE<4'6!^^M6M!D!#KRIVD=[)T Z#,$*%2684B,4F 1$5*XSY96A]*"#HFXK@($+.-X*56 MAC&78R.S^S%D9V[T#*J8!I[;77P;=-QY895J^/DF8 I8QQ M+[2-,PM>;R!H7S6.$\[B"*=@@$:CESSRTFA*TG%(\XA-X MJ(U7IE?X]L>@NEB"CY;3$2R$!*5E7-=1*Q%0%(P!4Z-Y.[O@C&^R#*NU[>N? M@T4^CJ7R%_VK:T.<^&UK^R=6ZEU7]G30UI> 1Z,,,HY&MHE7/ #J^=DG>ZFC M07>D.] JL(W+W@':N%;)#;B3,4CV4^1C!#E0"V.8(;<@%LF\LL)"]"K5W2Y! MC,;6#E],:ZY]3B/Y/:T)TM_X:,Z//L(?^K+CS31/ODWR5;C\8Y)J4!47=Z!> MGXA6TDD8M0!M8FWAD9&67SAP88+/1Q>" M,S4L!A'X@"WO;N%9O)CF:T2+S15@!U"#MPNY%\[X'4(.U]1=M0\DYH%;.]P/ MSEJIM$=%: B7DBF#DP5KABQ&CO0.\$X=L4Y1]P^T^AA)]7VD.[P-L#/%]?I$ MTD%IAF3F"!\)6:@5/B98H!W.*8%1)GPT-_CQQXS;A&,@/D5WQ#===66ZE-'DR];PW#H)*#I0-G#B3/%'( M\:QCX2':: !K>?;Z;TMN.JORA)YCZ0)@2K&2G16TN;JL\*G)"67"=9 MQX@8*UR;2XM.\,Z6,\,KI\%E%YWP=*3F!R#^5EUR.AH6[^:_31;+^21>5?4L M/N#R:CY]5UZ%KY-EN+RH/>^E1@'&(;T*3GIZ%5P!'2T=>^2E&]%FBL%@2SA; M)AY'R0W2"]XM/^/\U>S+E\D*]45.0;OD @0>2"C19O#<60CTUF0?K<;4YOS; M G*VS#E$X /&<%:>PQ:6Q4W!PD7F3&:1(H2B GDCBMP&QS)L(M=.!@51U8D-1A?PQGM(7#M3+($5;>:1 M=,,W5LW92+M+ Z6<2M79[@6]G9'S>'.[MOX!KB_5O6%29)$A*8ZU$W&"H+T! MXXU2UB@RQ=H4:O2&>OR8Y'!TZ73>#:6V!HY^+\";O. .D)NF1>T!^CCI4HWI M< CY#M#EB=#0ZER$5A*X]9E.CD+N9Q82I DE*AF#MVW.VI.AWR/)6*?/OCXJ M/#;KWLW_8SZ[^OJN;+ZQ"4X&8U+@5H&ATP%4X@;(AS$DPV($QYB,;M-29Q#X MXSL6S8ER"#$'T?+ F66/V2UWOXM8"Q!7KW26*NL@R;[.A8'RS$%,BNSKX&DA MW&8G.[&S4][)(4C/T"H<57D#WJM7W/?AVE2,=$ V>$K;PYC&SVL;3[>SIHH9 M. GN$82N\) 48X!1)% JU7D/-2/*\M4IW*]DZ7, ^EPI\B8/OH8.G?N M#_P4TO( :6:?MBR1EE&(8VHWO&I,(C5^-C,:&/K(46_-DGA\J_Y)%QNCC&7)1$QT+G%:2G!16Y">IR0C5Z%C>5*7IXU_USR$ M6F8M93JX@_7_;J-[,\G'VM,OGPV^NK:9Y,/UWWAC^@B*W' MIP]1SK;O8K8*VWCF0=0L0Y^RXEQY2YL]1I>5(WJ8?-'C.8>=VIL'$:]N/>O% M?!ZFGU8Y1J]FM?%!6OXU>X_S,IM_>3V;KRA^NY\WYS);DR$%7Q.R,P+M0 5X M<%PR[203;3+@AT!_J-VS&\.UDBYB=?A4[2]@7:FUI!(\O>] )[RRF$IBN8V3 M]""L\7?%T7FV;3(-IZ:A#]$'D?WM*\ERNGP?OJ_D1;O_'+],KKZ\#Y-\P;U1 MZ'SM>%83F(,E_[+>#Q26@O!)>/(S.YVH>T-X1D0:45=#V^:[47_ *G Z4*[/ ME5L5-M$J95*6P*61%6P"9R2'X#":*)6(6AY K/N?_(M/ VJFZ5"4 ^2VOA+3 MHD0G:!%"% \J*0,.D1;&M$DV,U2Q=?+ZH6L8*\']Z(?GD=1^[/3X>L7_:G9% MGSG_&N;+[S]BXX@UZ.4<.=G(:BR%@4O602HE9]32F#Q<>YU="(Y_W3TN$68# M*F3@_),/^/6*Y$ ^^8M/<[Q>^L\0-QVC.H :BE >&,H*J8QNC986PFSJS-A9K.C4T> I<>2"3Z4A4Z2/]P2_49_.OGV06I+EI^OJ_7&@%3<1H]8=/*=;/*M#QXW8MY(]K.!!#>T;W]M MP/]8Z^(?D^7GCV$Z*Y-K=,FXK&52$"RKQR *\,ER,($I)X6UR74+B3SZJ+-3 M]+#"'?K]W497P;VNU<,8FS!!$M,1,IPEH=W'Q?)O^#\TUBI.9%,<&@N#J?2><,+B1-[EFFI6?A:7?: M_\6__:BSU_UAPFV0'O/R:D%^]V+Q(OWWU62Q%G:U6*QFTDF9P-;[/Y65!._K M7;,J049T+/,V5=/W 'JF;N20:FIPR;8+5OUR?JM [7& 3?.L'H5XG)2K013: M@22':Z-! M;C0#DKEO2)X 32AIM(M2'&#&0@TT$I'=I&<=HCT>61M*SCL*6/ M$H:V23<&TOM56D/"JV5-(%F\F:9-_HB-!B4I4$0I@$YD"4ZY0&]>#G1 .^=S M-XOTL2>-'^@96#.S5F(=J:/TR]E\/OL765&+S6$\*S??.R CI]L'#Y&,L\<2 MMO)P-!,F1S(5,3&EA0I,>&N,%_2*HV'AHMLC#MNW?\.X?#-=+.=7U=ZY"=AH MVGZ,-0RX0@>*VUJ*)S1Q*)40%))1V\98O ?0H>?3SQ_[FMZ3%U^J8W#!O==< MY 3H7 ;%5()HF ;KZ.V0-DBCR@@+O4$T_N8T! >VCZ)!Y-V@7_3/N-Y4SQ 7 MRP]AB1^7M3G"[?:/B=88L3IO@O9-:3DXG0HX+\FG,Y$EUJ:A8G>,Y\B5P70R MM/VR!7.QN I3HO7BQ36^=^5]F%\PSHVWC(%AUI(@R'2+*7H(01?);!+)=LM> MZ?2XITV 1F)MX!7_#/)OT_!E-E]._@?S;Y-%JOO:=;;5ZB8A_EC%J]EBN7B+ MRPOC&4=/5KVPF>"S.BG\7VD/& CYEV0:J.N M:U2%%6F-MI"-(E1*25JE09 2#7*=6);M7_,;/.>G_CUEW:#?\L\K70<6LJU7 M CR3=DR=4JX4[48^@#3&%9D8#]NM8)K8"Z,FFK8_^?O+]MA)H+>9N[QF[H\I MPX9E[5#4"72RAIB-!L>$)-5J:1+S+HK<;(_81G.L:-[!&MZQ1QPDZ0;!E6U, MUU?&75 U#<3MQG6GN$" <(?3Q*^&P,'5T:E#""T,4Z.L#Q.H(Z^Z"] M#XW& 8U)A4Y (!XJ]P3%P+SZ=73#) M13 F8"W6I&TJ:P52&R4<:NG-&!'<(]5MC,V&/M(>.C#U?D;R^8C?BG1IHPU)]6#HB,08DZKZ5*1&RN3ZUA>W>NQ MQ[Y VE=5LU'D/'3EQ[LIKL#^]:_9_\/Y[#ZH>M/%R6;MZ_ Y'I,AJ%:##]Q" M##H;2R^'8=T:8O9[[CEPHJ&DA]XF-E ?9;"]!HM<.&?RJC]<($-7UKXD44+6 MF"*FA%QUVRGZ/OF MOYB2JQL>R2[B+)C@#$_=6B_V?_99D*.MQ <,:6_!K51^@,YZ@S;046<$KTVI M>2)_S-'!Q[D'M")R*Y4/4?7D1\='GQ<]6LA[P'#W+C(_!'>SVZ'(4NI<.Y95 M/\HI AX9!^T\8LAT0KIND^W[/_N\^-%$XG<)8ML6C+P-\WE8TBH&J1*Y\VG# MEH8\#':[+ZN44VIF9!D@@A"89&91!+$&/&V)YS-/1RK MVFJO2<"FX'R.^?5D^@/6?\QGBP69[2;I1(Y+OZZ<)EG='X!,4X2T8?DA]GI"-K M+ ;I8A9LV_0=<)]Y -BYT&(XZ3>H^KB_*N[W4C M;PSY6ACG<@X^)T%&NBV@ MHC'@ \DERR*$4(R1 3_"D?0(S/,A3AO--"@L^1GL!\SXY6L5^?OY)-V&*8C5 MV60+*=O:S[!60-08A.*125YTH7^.0*![ 9XC=8;11N.BE-=A,O][N+S""^6, MM2H&L%CK)(BY$)E1-?'-U2K,%!KU!-@)YSP(<;BDVU>D$+P+GUAQP6C@DJ\F MZ9+1C#5I1DC++0],^33"]E"QG(?B#Y3QO?=N![STM*YWY149RI/JJT\NZT3) M\._)EZLO/VZ>7H6O])/E]PLCE2%774.0FC8H;1.=:M* 5HF'S*HIW<8T[8/R M/)C23"]W.>2&W3E>AL5D\?'K'$-^-_U[F$]J6FZUD_B%T<%&KPLDKE(]X! < M"P@R9A]"X4'P,?:3^Q&>!W>:Z.,N;_R C35>S;XA^>FK+7%QS?-7L^EB=CG) MM1O('[CVU0CW9':1E&?"!0<$F]>$*MHS$Y-@A--)HB"Y=4M=.P#$TZ;*J"K8 M<9]V6*;C HSYN'#=2Y@ZU#MA#Z>7FDK*WEU9_?O&8,@RK>:U"6 MKQH$.J#].H"/CGF!+$3;K07_ 2#.G&%#JF '=PZ^+_X/DMCBC]EB@8MWT]__ MO22*$Z\_?UEU25IU,1',"5)E"5;3S/+?,A:1=5FVMD)=I,8T&?O+=N3 M[B8AZ/@++&1@.68@V Z"2PZ20&ZD+"[R-D'M4^\FT4O#7;I)])'T>*T#NJ!Z MWMTD>NFM6P^!?80^8H,151*SWH"I_:)5R H\5P&X) M:VD@HVW0M//5N$@V8 MT$?6#1AP*QETDT3N>?*E>!#&Y&KQ*HC"D;>46#2E*!5CFYRX.U!.II-$+QUM M3S$]2, -DN!VM;9(A@5OR2XJ$B6H@@)B,IIX;8V,O!B)SZ]_R"%:/U3(3=[T M;4"Q*$WKDY!S[8V3DR?GI3@0.D2G64'>*)9S!\I9Z/PP 3?O'+(ZP#*RQ$MP MM;JT>D&%.)BU!>Y8"85IBZ'3#.$#/<)S,O4/E/*8'6.ZX'K>'6-Z::YKCY!] MQ#YFQQCT@K.:"6UDH4VOI%!CQPR8$ +I=!)ANW7]DZ1#_XXQ3=C01]I#MX*X MM[182">#D+3C<<7)L9$.G*P)\M%Q])[1(=BM%O,)E&OW4L!L:.D-W?+EWFH^ MP1CSD9.OZI"OW8R@. -#9YD.R7BINM7E/X$JR<%4NI?TAGY+__J,M_W%)'/1 MY![4$1@UM4<1NTJV9)@*P06ZB*9; /#GSST']1T@J:%;J:R9],/O^X#?9I?? M:H;6S_E;UY6VL@X KTT]#'D8BDL/CAE.:!EW/#M' NGQ;G9[ZCDHO)F4AVZB M\N']FU6!P!?"%9;X^J\U\FL?\2>X$US\-0_3]!E?;'8?K0F[L!ZX):=$I=JZ M-)8(.I+-8331>;LN]1Y^' 3C' @SGAZ&[KBR%_*7/WK%I*0M*QZT][79H180 MF-:@&)I0DM36V78,>OG<&;27'AH4=-Q.]ERY-$1AQF1-#/9U/#TR#T&;0GLB MG=1G(NUS\'2;A!^>!M/-?4[X*HZ;7/74S'N? Y3%X MZ-F!+!8KG6 %<\6?4.+<,V*3MY-EU9I)'PO2-.54>8\/WQYN6[#YO^H5H[EH4 M+IBNO4X2D,OBR!,V*GCF4;IF);N/PWNR_&BGA.9AP%LUYSB?S/+J%(R.@"2- M((2MDS)BAI"]A&*\$R)S)1J=#8]C.Q?_8& MC-DI8H5P\[9TP#ABZ'@WRE,( M(Q^NX5X$.D ]S4/,]V"E_=;2-NAKU[="QR99W3$[!5H+'XT(6?DQ;2JVM+E2&8\"CYBI8S"@CY0;:/[AA)*B->UY4D#14=1130JBSG$U MEMZC4,JZ-H;#B>7U'*ZY62NQ-S L?[3G>_G]QY?_.<$Y/>3S]]J*Y'+U*J#R MO"0>0!1.IR&3'B(Z7=-!+2_1B=2HFJ8;OG,Q'!IHHT$GQ1_0_L2PN)JORO@7 M=_%NQSSHX7>[Z-6,Z6U"/WV JUU<"@9@8Y&UAGF$:+D$M"I MS#$:XY@Z5X8]8MV<','ZZ*HEL=Y,OUXM%RL)B,TH*<]R870B,U//^LA8'52H M()48!)I:*FG;TN@NJ/'-H(;JO(\X!^IB0.LHX^3B#_P4+G^?+G]X SG;$$T" MC)J6*)V%().KC=:B5BG$X,(#M%A@^E^?9M_^-WWTBA'_K>J7L/YR18,=#WWJ M=LVA"?7C_1C#N?\I 7X^SV228 MH\HZEP R(8%3M05T2!9TX?0#41O1=1N3^-B3QCM?#U/ K)7T[CT\6XT\_)@^ M8[ZZQ%GY@%_#]Y5Y,5MU&XS?_R^&^2"3$+L^9-@!B7LM;6MNHN)2. S,IFB5 M-:4693OF@+*B@+-* B]"9>D#UZZ-- Z"?>R(['YL>FCJ2%O--;B'[06^OM5_ M_6MVP9@L67(+,>4:H)!U>GK($$717!D=LVH_NZ8KVF=(LGWTU*@18C_,-6'A M LFX,,(4DHLB,?E2(&1'="@A"JXDO1EM&NSNA_>Y\JNWKAID8_=&_7IV-;]( M5BO.A"'_19"PG';@O16 R2']-Y:<3N"PW,!]IOSJK:D&99_]04^^X842UBAM M HDIDWMLJWN@!^D4A9_L';E-0 M"X_D4>=F]3(]]D7\;,CV?[Z:I"$MS6E(\SG=9[+]?1X M*RP7R!5HE(2->P^1T69;1\>CR;XH/T;N]\^HSH,O@\F]^53*_G/?>31"TQ8) M' NY%CPYB-(&D)X560QMK+9-S/M X.?(K+;::S <8CZ- 9,*!$;G6XB0$ M9] !%.8U5Z2'K$L2H=4#WSL2I]]-9QK,H>0A^/$M&KF*)+M$TZLJ.2 MDQ"<-Y!8BKHPDSRV\X5.>JS*\$SH(^L&#-@U_\'X'(VN$RAY;07'=*V>TQ&2 MX(5<*ZZT:M-LX92';/324XL09,X3571IR TY$"XYC M\5HE3'DK8OS4FKGW$O8#S=S[2&JDU+R/]'?\/+ND)RQ^_^^KR?+[VS"?A^7D M&QZ0B]?A4X=(ONL+?BO;CGD>%/=,>ZE(&'S#ZS*O@R+ MQ;OR<3E+_[RY@"I1J&(U0DBU_,&@@EB* QNL3:B3"*;-[>Y.. =M%6^O*O'? ME=4G(WWVWV=UT/3J"1=>61F3*N"<(FM9V40;(^V3*O',3<" OMO&\=!3CE!* M?+!2?]I#!A-A ]_@8[C$ZY5N8*[>F46]\\;\9EI[AR]"J@*_R"D[9$Z#=Y*P M2D9^C#;DUA@C%5>.EM)H"F:J>^NEHME M6/6IO4C"%*%X@>!K00/&")[[".BXR"[67J=M1C<_A.H+IUUOPV^3;)6*<,7!/P55A\?A\F^8+.EXP.$80TM 4%6KSS&"$PBYH9 MP3RVZ<'0!=U39D@S+;1(3]H NP6V8J-M*B8ZHR*0QRM Y>(A6N(RN;HYI1"- MY8UR)>]!= Z,&$3:=UG@#K;_U@?6U^M!)._GLT_S\.5G=_;%U?+S;%X3[_Z: MO<2;7\X7,O+@(E=@O"<*>V/ Y>P@^^!2]@99H\9E!\$^!SZ-I[>[I/,#'E*O MPM?),ERN 7_ !9%,B2YJ#3(Y>DM*$.!5"L!E"5PD MK9QN4RW7&^HYD*NM?G;<;AU^05KQO:S<)NQ?<;H(:YG/P_33*F/SY?>;7WF_ MKF1X\:\PSZL_/N!_7TT6DR5^I.6M+?;)+'-RU5R6F2PXRV.@U\0;H/U8@.&! M,>D,+Z5-_D63Y9P#,X^OYQWL/?AR]L7EZG[_^N7^*%)AS(HX4'RP1X\^].Q&[YSX%<#3>P@S,'WN+]_^7HY^XX;'N\&2Q[J M-W))<4?'C9?@Z0""R**P/EOF5)OL_P= C54]UL"&'$C2IU)#]G%) M!LNJ]O:6J%89D4JKQ)AAX$3-D%]5_GL44!(J33X9ZE:\N0_2L=+(!]/YG6N8 M(63?8@[)+3S7V95=$+4=2','TW$RR0=2VO:ER3 2'XD+V6?.B@<3N:8C3R&X M'"Q883';*&).C<92C<2!1]+'QZ- #T&W4/WJ)F^%Z\5F"+4H2! 2:"YK1U3D M$(PG6-&D$KGS233*>KV#Y;AFZCX:VGE1NK=X&V2*WD+T57H-$S?>785H+8U9'DA:HG'(%T L/ M*L?:X+*HVN!2*-IFDFY4\74;Q;E9[GM+N*&V-^,^.J!I:JC_C.2M-]9#KT MP?R"Q,W6I6QOIHG\C,DWK/"N3Y>49 I1.D#I.)TIM'OYP!348B(EO!)LN_+L MGK/YX>>,?SP?HH)9&_FU*,?:>(]KA/7">3:MO1'7'B1CFM4*L20STJED-#CO M+21FDPZ1P,DVV94/PCJW\WLX'32HJMC"M#%4.X!J>J[OA'7D.[C#U;<=-QI, M]@V._=W@D!F=M680+>E-%"6S LK5JC>F,G!)GIZ+)2;6L&CX2;#W$0/HQ,G;1\$-2/L!%\OY)-7$W'J^ M_(T4LOCP\6^;ZP I'(^%U0&= I2F$R9(+% (+#.F*-L:Y-$N$!110%MG-2\:;7[HSN9)C9\>VE8[5)X#EKK? M&?_:!<>9CJ'NI8+[YA?O([\!M_\[>*PH0L3BP!M+FU$2Y$H6KR 9';FOC;C, M0_,33D6//<90#Z+&/F(;^K;CS?MWKV8$9GJUZI-0T[5G\\7[,%].<;[X//FZ M<>>S-"FCB5"$Q]K/V8)3NB92^.)SEM'H;D&1KD\\XECJ7@J9M9;F@(?K.K'B M0837 #U+&*4TM=-1G!4B5LS)T"!4A.ZF[R].>HJH'E^*];W;K5JDH7H81$9Z\ GYBO_4 1?!6!RT&'K(UGVYO7 M0&ON!.]4RK_Z,&/;=1Q>#TT2 6B]/[V(;Z;I\JKV>7M?9Y61R)?D ,>K9?6N M_IKM?CLO2F*:"2NAR)A!^5AKSXH&&]![3!)58(TR!H; /S[=&I!C5W^5<34[ MM.&]&Q(M8XYA@:])J-7"6*V!EK.X$,%IKPQ"X8$,%5;(4%&:06%&\Y2MI+>V MDT'6\\'G1)_F@A\P^_0!K*O&Q86H_Z[<=+:3(K-2![H&;QC)0PIPR16@;TKO M).WLL5M7R.[/?";4.%C<#5*8MI?_&][0][?)XH:^]^U]_[G>/"\8-SX51\Y) M$ Y4M!X\TS65(S)3BD*7&YE* ZW@G$AX5.TV",F_G\_*9/G';+&X2+*VW@P( MT28Z:@T/$$Q0H$5&I9C./+;I17>#X1R9LJ>$A^Y?>]<>^WNXO,+?2\&T?%=^ M_W?Z7(-<+Z;Y X9U$Y_:=5]8% 9=G3'K:1.M5V&NR$+GJT@^)8YQ.Q?WGC-K MO^>?$R'&4D.#IK@KU.NA#+]=S:L)OVH!LH+^%O^U^LGBPMHD1>$U[*6(WJH& M.KE5@$'&5*+19;OK]9!>V&/PSHE*[?32H$_N7#BQ7RRH!_=)OQ;I+WSK_#O"VZ*XB5P M<%YQJ(6M])5S@#Z8**+04K5)(FVUHG,DY4EHOT%7WOO659?P 5.]X9V4R?I$ M?Y'_ZVJQK'*N'L.+=Z_>D&2OI][\6.N/A:&P#F,DK\#4XY]H ('< _(43- L MJB*V2]$;T_K@)3TG7H^K_R;=@8>YS'4^!EEJ%8I0A?R?G,B =0%B2$QJD7)Q M;>KP6US3'WXC].Y?UZ%HVL9JB6;XA"^___SH]:]<>"S..<- IZ!K3QT-0?$$ M(FD=N(M6V3;9P7M#/HL(VBCZ:I&A_D""8DGD0BJ903.N0/D4:"N1IMXW>:Y" M-,7J-N_@J;9"/(0B0TGZY%HA[JPB9-SEY)P@%>M AV/QM?HL -$Y&6Z]YLW" MK$^L,+N7[GL59O?1P6CUMUU _2K,[JV^3H6X^\A^O,+L4AS'', )'T$EGVHS MM]J-Q$;CO-6BT0"(IU*8/3P?^HB\ 0]VF\[7R98..:/CMH E\XCL(OK*%Q.@ M$&950O8IMZ'#0ZA.IK:[C^)FC:3>N$RH&.9%#@8B3V1K25-S>6TUN$P6&=DC MCLS9E GM8Q\<*L\!,U_NY&AWP7&F94*]5'!??'OZ8EJ\GTSI< M[*_YU8^S (7U4K-Z)YXSJ!A%'5QG0?H<$OG!-5#8*9[?Z7%'K!KII8I94SD. M71U4J9N^/U2[Q ,=[2XP*#6RI]#4DN/(@4>1:>DIL>V4L7NT_.BCGJ*&AY7? MX"V)NU0M$>N$]T6"C%E6DTZ"][K0R14C2<4GFU@G!9]X[=?>.AY+/UMVWN]\^AS M<64.DVDKY6[Z=72 TN8AF75;+]YNEWS8!G/6PEH MKZO2-L/]5UQ<5H0?\F*9BGU _OJ^5[7(3A\$ M^:"9-2S.]KWTP.N7K;>^Q:OS^/OM';8+R>:6&CR)Y\]&#)B^.,08C1@'-9T(A-*KE/HZ9' M81WANJ$=-QY<03530(?D\C_S]?< O#=_TRQ;17>M>A#=C0F[#[N6V)56!]!2 MUE2MI.T^SU2W5\P"_$$8]3^W;%UD3Z*Q'-Y+O25X.HV9) M6Q QT'02-*>"3XJV6VT#JA"+[Q,D<\PTNDG4MC^Q;HS,FU<)N#?T>V&D'VAJ M7%Y_6)S/%Y_F[TO)-69]9I1&7F\:T.4$BI$I[L@( YF,M*8VX&!AD,$Z]LNG M38O^RNC0N.H1O'MBJ,F*]-ZR#);3EJUJHTWR"S1PQ;DRJ+RR<8+-Z456-3G& M*M17@QWJ$HP4TLP)QAV/$9Q9WG1EA&!3@&@P&NNB*+E/P/!(H*^1;FVUUZ&\ MP'"XOYQ?W%SG-&-2I)"P0-"UE@NOV?+1."A%YL*+9=@I/GTTU)^$.UR##:L< M; #_*Y^??28<;_[."SS+?]Y4F;XOJ\8G[V^NKZ[QLAZ/W1<1"]9$F@L@A-2@ MBO,0LO#DPBA63)&6J3ZT>Q;<4_+X^NNK@]TV"O0,55(\NTB2J??,6DC A R< MYS&3;+C /@<*HV!.3ZH)5'\(V4;IK<.APK+@68T=_(?-B.X$ZW M@AF26\.3HHDI#-F:2&/Q&!RY-[4DA%2"J3Z)@X=C?PUTG%C#TRV$:UO@@>AF M+GK&HZU1&UA+(&4R$Q MY)0=$U99V\F;& GT-;"OI^YZ] 3=98+, @_""V%! M$]%!2AS-:3P^09ZCBPZ.X?<@MIT,?OMMM07?"6USUNC M6 #OJA!"\8#<$72GM]Y0 M[HTC$O_*7V\6\3-9]&_.%GG)KVV(F^CI 2";AZ(.AC=]D.KAFIQ/I8:C<2;: M+(2) 4*HY4RJ?KVCK=9RZ\AZ%T7CH O"'X$KCT2^'HDJ8Z3?/'.H+I5OUX6E MU\&?(1CA?28GC7E/>'CM@\8-. *:C67%;_O;^Q*%'KY\V@#93CJ8-Q3@A(E^ MM4#PAX^_?=J@E%D[YPA;+2^MC&2 K!10B7SU+ T+ ]4\^),GI_P^PNY1W6M3 M4.1N.:OE\A9U85X) ^1.$1Q!F! E!RUMO?0C_\N;/O[*/DBG;5RVU4B'T]F[ M>#;S8P"BKJ6:'F(Z[/9PW(QOG:AB$G5U.=DP9OH:/4CB\9[ M4[3L;+S04Q/NTK5'Q &M:(M[?(S'KN M8+:3M:2TQNADM9>*,^6"(U6)R&VPW'B"@\X-1T_@L4@/7;QJ;>Q=D=R;XMCWJG=[S*IH4ZMU ML-HJ&"$(:6H);_+[,5N1^H0[C Y_7+7E5O;BV$O=;W1*B"9S7"OR)9G;T(&6][:V5/'0?B[_E*$Z7L4?3=8>SA\>VFK>Y MS!=Y>[3?^UT8CDX53^:W-8$V(",A,&] "R.9CDYJU6=)/0#TZ;)R*DTVC!E; MGN@^KQ_+L#V!:6NX+>"U)G&R$"&@=Z -S^1&%*]Q6!G%?AA/CX\O2:D-0]@: M#:ON%?L&AHC,! DDU^4DU#5&&,%&VAJ$38[AL":>/5'^Y&M?Q?:(J&MC8'-K M>;)&T0"2)D/%TRBT1-HCA*(AR)1X^F$D>=0KQU5KLLH,HM],IFB=U1JB MK+9;S=@+@D5@QJC:,#I&U\=.WP'FQ \L#A5_E\2?%;-6@-Y_S0M:'B[/9B&A MX 4]!%UJJ46IP&FRZ$-)5M-04>E>V3P[ 9T\,PY70P?':J ,5M?:M&NE5&P" MJ;FD\0=R CDCP"&R9&P.)70Z$1V!(_OIB)$-ZI(0DN6EIK9:\KXP@LK1<:8-N5Y]KCA_E.9A'?@P0N0=>'!G MF5S6'=E8YIM&X,]QSS9-L% '4QLGNQS(:#-<04#:RD/PL2@I,)8^3F:_,;V4 MQF6C2+/?2CJFQCO<+M\?V??>]@_'N,:+/.G,4 &:.IM%K: CK +I-0\U>CE( M-P%#GT9Z5+?OJ"QYE+R-57R$Y76$V&+.7IEE<+T7H!*O8\H,!!K''&/.ISX' M5.W&\)/&QZ5%WZ.1#?AW>/7YMXOY__QG3F?Y5L"/#H)KY3#HZNM[\K\D2X"U M*5PV)96B96*\3]IW$_@G9A5,I,>^J^T^GW_3ARH:F8I.8'/-6:IG3:AH;T@L M"Y]DJ<7[CG5(=Y*D:JB/#JO8]K7@^YOK]V4 ^E6*:T;B/=;.+HG5@I^T%AO, M8'*VQF<79.G3Z>$0U"=_+#>92E\0'3?)\P/0=SW>.PS_<H.P) M8F9'CH)K9#29ZST/DIO&:#P^J@0I%,S>\!!YGQKK+Y&J3YQ0_JA,':/C%\30 M34^O[)QA-H/T(M3N8 702R-\^[3 RRN,RVC? _(&GWIEBV3!4;"W,P1I":(U2EONO&*2"! QR\)C M+"9Q++.G7G[H,K'S[;_?1B@$Y41E"B03R URM5.UE(PLC%C(BQ$\9]]I(7@< MV6%-'G>__"]ZN(J1S*F>!] ,R^=?KTD*,KCB:>/06B H&VO]<1^!QR!M1)1Q MN_#%OAZ0XSY\C/6L(2'N]XWL*//6A7$>P?I/O+BI?8ISO%DL SHWIYE7LQK' MYP@TB%BC^H27X%1M_6.2*,YPQK=K@8YGR?[/OQ*N-))_\[:QNQ'?!O6]N4P? M\N)J?HD7ZRK;[_ BUHVZJNA+K34T2R&(DK0![6HI*)X,N*($9":T#2HPQ@_B MSQ@PKX!-W733\(SD7-WBQ["" 5WD-%,_R+-F0K2X6O&2&'(>8@; +X)9D MQ&R2R1^T3.W[\"L@31.9=ZA^O@?NQ[R\%ON/?$E^_CQ/=YT.;K0L&B7PVA5896X@)*:! M+,)BT=H08Y_>6WL G1@G6HC](1MLIPVQ.J@S5VM^)2' 26&!7 ,:KB=?U.88 M,0=BL>YUN[,7U(FQHI7X'S+#]3"EWZV.Y&DW_.UFV0ME[53RE'WV08.VRW+A MU@-:C& )OXY%,%K4#K&D]WSW1,C06^(/R>$/;E<[O\Y7RQ/.OVO(1TT%CMGR M%'R"HI<1C?0G1*' ^)"U\ 63Z6/[/L1R(KQH).P=)X1=#I7_486,%Y_RXLO, M66EIR X8)EJ[DJ8-+6$&H32/4KFH#EL0[GSK1)3=0[([-'_P?3S9MM4#NF_= MSF)*3*A:"];1AJ648( B\@0H-HM]TG/\O] MZ>I]N?.LNCR,J&DAZ^#JUWNBT]Z^^W>;Y81[B4F#)$CR*@" M,5PD<,8:P"2,=,4I,L"[T.A9<*>J&M.53?T5]5+*Q0P;WZK[ABBTO-+&[7RJ M63XI@,]9@@XF6.3"2MZGC]%PC,=O;-2-+\,LKD/UUB6F^CN>3>^= 8@Z)Y]L M8SI60DD?+3Y"E@-4, TYLDW9EE+ "IH:MGX,)4I'@R M=>-8G!@C^<:-5/_ 2SQ;[FSK.'N9O(XV1_JXJ]5'C07,V@,W0MMB#!?<#F'! MH'ZIVU\_KFW\'&W,&XFR84APQ?*FE/.+\SJR7R^OES>2J[((2:0H$4'4@K** MD?>/F<>:N%F=.IZB'73[.TBYNS'\T"IN(-;6D;P?R**9_Y[/YHM%OL8U()9B M8%PEX%;70L@N@-/90R#F>1F-B6++<]ES8K+K[3^L!MO(JTM*\>Y3O+K5T-!" MCO7.ST>")@D:44J!$GX, 3>9I?\ WHLR^LIDAR51#/[D MR9"@CY";)P2NEZ81S7IM:7*S4?"$B.Q!,!9[P.IYXU-8=S)_]WW\5Q&DD_M;I?&^N MKL[/+I=-GLX6>7E\]C9?D@JN:R3"+W(^&6-51?'7$$#2;(:@$ [IW-< M0'%:$1ERT'Y88NC(#Y\,1WH*O'4;N!U8UP'2[\/%^=FJN>(:I\)BO+,1HA45 MIPD08HR0$MGEQ2?CV3 39<1'3YD4303=,/-MA7.#KN;C_?'QW3\V5G0Q.N8H M0! K02FLD=)<@V$F"T%^FMHN\[A/^;L_<#J*;B# ANEJJR/9FT7\C%723OXG83R_J/]LPSM.(\R<+.-LF07E5 9??(3@0[;1*^'2L+:-P[YW,BKO M(-Z&*6HK5M:0L:NE>-^7W\^_G*_%L!V&^(_+VQN835DPZYW1/H 3B*!BJIGF MT=$6A;6^MB33!H=-_.=".!F>3*.$ACELM]<"CW:%48Q\(1D5<*%B=8 NIG"Z[1ZAO4>* MVXRT$.H<:X-F#L%F!]PF9S(RR[!/+\<=8%Y,)X(Q:GHLA> 9,N[0K>K11AJZ M)"VRJ>$^-2L[5L,'2P";=?:&16EB'XOBA^AS<@ 1FDF]<9#DNYI-EQ=?JT'T M)ZZ+=7/O/"/3%B0:2?X2_8G^*\"$LD%+])8-R@X9%$NW"\'IFY!-9-_P3++B M^2M_7?G3^?8H91OBIECV )!CK,A!1!D,;UIKLHTFYU.IH?'Z,1RL8YX,)Q= MNIKW'WD!GPH'[;G/W&1/J^NI<&6/H7E$JHR1?NL+^+>+\ZOK^<4?W_+BZB/M MK"%LH@)D,,E&0]MH[?%DG""36@9:.)-TH:"UV]VP]IQP[?O"=)9#1VW,6XNR M<4#^]TUS=XFPAT]SOF6^T<1QVD A8R%)2!W!.VM!2I]9$+[P.*@AVJ!5X1"D MK\,DF4R7#6_/*NY]N-;S;0BRYO;*XYBF-U*FT^V\JV(:6S!/(!0J:Z:8!1:X MH*TYT=8LM085@N4YFE)"NP7J&)1YQ%9YB8P9HX_6ALRO7\__[]N7VKQGT^79 MR,"MBB!$5+2/2PZH3(:(F5!:J=-VTMD> V;[S=,:+BU%/F\EKXDZ';V;?_ER MOBIEBI?IW?RR7B'GRWB>#VEV-."M+?H=C06_U?+(1H5HH[.N,"6Y"X8S3S^Q M"!-<]+,![S_L,/+W^>59K0JWOLC/WS_X^VW1#2W0(-<>I*CML9QRX(57$")3 MP6N,C/6IXCH W$'+R;OY!3V:KZISOUF02;?*L?WK_.SS]=6;RW0W0 G_]_S+ MS9!UK-BF?:V2&!%UZ:E:=EQODXU<@"P] M:U%36-.?W;:FU+T5[7@J:YT@,68D:\#ORSO\>GZ-%S.4*'S0"E*JW1RY21!4 MU&1_.A$#ZA+8,,?]$!2OF%H'*:2U570(\&5%4)9+D)%KR)H$I:Q$6%:@4-$K MJ5+M):6ZL^DXE5A?+*-&*Z9UNL48\+6S1;S.Z:]\?;,@>]5QA3XC)-0G,]3/<1=S@J36"E9.H@Z MTGY-/C7!#K1IBR*R348;VV'+NX?A%9/I &6TSOIX/NR/U[BX_J7VV3#)9"*& MJD'M=8E%3DLL"8X5^HTQ$AT.JU7? ,Q/5AVDGD[Y)W>$LOH3[<]_SB]O#W26 M3_,BGN/%[WAS&3]_()KDQ2*GU='@NF>'I[F@HW'@0DV_33I"X#&#T)J5S+@/ MV!36B5'N>"IKG?JR7TPK<.]OKJ^N<9F*-_,F&"^8 <><(U>#O%BG:1^W M-@?F#.%.PVSV$1\],>+T$G>'M):GH,XPRFA%%B!+)L\SN BHK(=05")PWDK? M)P[Y*62GPYDNNFC8J6G/8OA?7TE$E]?K\XI9*CR'; HD6\NO1\4AF*"!FUC; M6'IZ^MPMZ?Z73D?Q[07;O$'3#BZFM!3W;>OF&0I+SITQ$%FL#<14 )<*K6B< MFQ2U#"D/2XH?\+&35_YAXNW1IFF_ %813@PY5])&T*FV?/&HR5_C#*R, D,0 MF:<^Q2.? #95KX+C;0OCY?]2&A/L']/;;^_(53N;+[Z]+U5VF[^1EJ$LR;C MD9PW:5V-IN,)O)<9,LM"9J5L*'VR8IX)^%BQBDTY,YB/[737(Y M1@-@=\W3?2;PXV3R3D*.P81LK]D71,SH+/F-)I-)$#6H;&@.6T%V@8]&6&5S M,GWRA%\4(9_()/Z1^#A&H:U#!_9CWC0+OEO3Y^WY_#/^G2\_+*/@8KZY/H]X M<5MMU"4C(GFHV64:A_(.'+-R6=$KV]J&*PZKH=,0U$OR&QJR8-BI4U\5MHZ' MVC^.S9/WY=?S*SQ?%2(\SQO0Q0@I0\G 693U!C*"C[Z 5RB]TCJY@7%WST7P MJDG64#F39%8[Q;A-'M )"TJ378TF!B@Q&)>DB6R[F-N)9%;W< V:2+EAW-+( MY-T!('_F4(_1Y/-RJ)^AAJ/E4$O+4[;*@S9*UYP:2\L9BY#J,8_.OD3_>G.H MNU-EC/1;6\I_S!=?/\\_?MML;,ZY(%6P-9C.TVA]6E4CBK;N:9:QS(?%?&R] M^*5F3(^2_;R1X#I4W_E$?^]]N1-)LO+[: Q%<0M"!@05!-;^3 D$V2K"AR"U MZ^-4[X1S2C9".[EW*-%W!TZ-)?IS?HG?G]Q-\=[X1P/@=CT4' GX.(>!#50] MGUY/'8[XQL)6-2PM6@LATM120B<()=$/Z:3B60G<;G5Q2K1ZXDCO^*P:HYX. M;-H7"GD':3WA616AF._[VQN_7"FA#%=@,RW@Y(@C^%J]Q-)&3JL[F6LA=Z%: MRU%,?_#2E3+S%Z+OB1*_/]Z$J_S?-X3QU[^K/ _(]M[WJA8IWH-@;N5UHS2< M.<6U=%DISWSFM!X9':R5SFL]V_?2 XM5WW_K[[=Q"%[JQ 3I/+-2(\C(Y@Y! M.W VH/;*2%1]VF_O0W1@6]I5^NZG^;*L^"*O6]/<5A&_S?A=!] %2?2O;8J* M0PDJ)P8>:]BE*MH++P5S ZO[C_SR] M4$PIL-;7M*.W6EPA/@MT*LN.R&/)E M$"S6["7I!?CL&&@>;2*'5WMKVC#CV,&,1R#& ;)NW\GZ":Q_WE3QD7VY'8=W M-5/*BE@P FF< W=:Z:!U O3F1&U]%7^GY*J9OA'Y."BI]\K/W;&?/0"Z[67K0OAH M*0.M!4G), U>) 4RN-KKF]N@_:&&PU,@3ILT;770HS?=?6&L[F@S\]P+B: 0 M&0FB-GJ/.9"KGXAKW0CM28L(4"GR;% =*?E!Y)VR!EG09%^SHA-+A,$P*%MO0_623=IP#P MQ+1XJCWAI*P8(_3^;%A?(V>+28G (=OB0$7RL+%H!3%Y3"P9^[^_O6FJG?Z7.F^]2IKNKJ?W&ZN?QRN0IT?Y7]@BVO9O^[W&UO\IM_TFW[3 M;_I-_W>3D("0D)3 KR^+H(24J("4B,2?7KM"(8 3X U8 2R SE7)_:KD"M@" MOP#))8R(V=''QT.*G]_=F\_*%FQMQV<#=N.'6'GP"_()\ ,R\A /*QL7.Q\6 M:SL')W=9SH.V+DX6)UM93@-1+0$M#R4[1R>U0"\[W<"'3VP"76PD;3GEY4@( M92!2$#5D_&RM9?2N:_RUQI79[*L M?WT6?W]_/G]A/K"7 [^@I*0DOX 0OY 0[U4-7N\ =Q\K"*^[-]M?;W#?SMO& MR\G#QPGLSO+KW,H:[.LCR^KKZV0K96]E+VIM:RO*:VTE;,LK*&AKQ6ME*RS( M:RLL;"LN*B@A9"]HS?I7\;8V?Y?NX>OE^H=L6QM^.U<[-SMW'^^KWA#D9^7_ MWROSJHO^+O1/N_]*QZLZ4DI>=E8^=O>O6.Z7@7D%?GV?_,W ?(*"PC+\_ZZ> M#/^_>]#_@MZ2D[&UD;+Y]4Q@K[^(U[7S_%^SMJN3W+^%U'_1\NKB7PI7M[_R M/0(" AG^?ROY/W8%_U]=[ZKT=T>]:LGR_P']%O);R&\AOX7\%O);R&\A_V<) M^0?8M7._0KC^5U#V/AXN"!\//QK(- UPAM$5QB#D)+L.O$-&DHZ M6AI*&FIZ)LY;](P.[RT+'P"_-S"W%R\W#_N@D6Z-HU0@)" M"B(B"FX&&@;N_S1==@,WKF$/7[/%P6(%L&]@X=S NNP'F $ "P_K#_I;7H"% MC8.+AP^Z1D!(=%6A\3J C86#@XV+@X>'BWOU:\C5[P#N#3SR6X**^#OH&AD;&-K9V]@Z.3L[>/KY^_I" P,AG4=$QL7'Q:>DO,C*S7K[* M?EM85/RNI+2L_'U]0V-3<\N'UMZ^_H'!H>&1CU/3,[-S\U\6H# X8FU]8_/; MUC;J\/O1\O&E5[8N+@XN*!?>F%A^_^J< ,7[Y8@ M/KGB8Y"5YTU6H:?7*.ZEOJGK(6 3UD%26GM-$E*QB\ X4+]4^T.S_SG%(OX? M:?9WQ?ZA%Q0@QL&Z,A[.#4 >^*D2S_4:^S?_YO\1IR93(*8R4SNW?C["E;,) MO'@1D+3S4]?Q->C7\?&&>,V6UMMPQE]'U9?+7<5B\8#_KR/3KZI0+JSEWTW^ M?]($V_%+DY?3,8/LM@; ]3;^#U:1T$W1B/D$MIAZ!VX-S3#_KW[&WTW^2YH\ M2:US79L1O2O[#5N#ZVTXX2_^PS6,5%_-_E_MPE!H?7"2,F, MQVD9%_ V_L^YZ"IZO&A(.M6>"N>95*8 'O]+ABS7G2FR[LRWAD6VLY5!LGEE M8UM;F^R?F#)0T3\>6XH2,P/(( MV%-@0BA[&1_T=Y%^DP-B!KXOB4!]/]YI,LS:S'MIRP)ZL[HI*Q#",[Y["3BN MQV^/:=^$\#^9],F98W:8,4NH*/O63?%(1?*'IN>T"-9>@YY+TKVQ::V0>]O; M-*Z(E,].7[N5'SCX!5JW@&.8J=Q"V7:RU_,+WC5V5+\<7?LJLICT45B I-YQ MH7>35M819Z+T;3O;@$5#,X9-CG?F2!M]_V+VA"@KMNCP$FS3FHH/;&6J\5"1_BH!@)B8TM5P*-X M_%)%7Z+8%\07/%C/Y MGGMG'U@T:2^?>*Y> /SBR,YJQC,Y$H0E%R,S5;O=L%(O\M]EA[H.M.E M;ZJC'4H?TOB"=-CC+8*D]XNU/JQY.UHDN_26QH&:%7*:3R$(+?:"C)%U,823 MN?[%D7\*Q\Q>9!*)LKR_ 0 M:0F%[8;M:3>/L+J=&:37.^H6M"R,'3@#1]Q_"[<\:1:QK:9=%&1/J][D:ZG0 M$,^39Q Q*%EZ8&WW1S/6"L_+&)C\&YO_,Y/W+1>5P@YT_MK-%(^PQ;_*:]3H MT^\7%!O\.TB8#(?S:!JY\]D:OHDB3E,;PGI"G!827D/QX;P(][V9&22LAZZZ MXJW1!Z-C@0%*8%]!A6A(7A@GN>4U&?CM!S,>N'Q,(SBF!L&U;\S(Q[6P^=U@ M,RXK(DHEU'45$,Y-]*V1;+H:E!>38-\RM/R3N@F^8D&E\OI]?9;OA[N$GF/W M/K Q?L-9XJH6'KH$;AYIQUPP-\W4^"]WG&("3!937Z%!?MI8"FP%GCW5FHKH MGUER'/63[58P6=4^!8HO7)7G_F;3P:)O MEYQ;9Z>,%Q;+'%+'+11 7H& I.@HYB[ZN=QM1X/6M"T'+1.30G #WS/]\^Q]1WD8R==UM9&V,UW:GL&PF0G0)(5!(H3^ M)&5*Q@C.8T:O.[D^Q=G^7!G,#[T_69\?/^24ZX(AN%I"%\B]"%GN-5V+Y&^J+C+^=95ORD?1PU679PZA?@Q+I@*- MGERD>-)=3!!L?*]#;-DE2#\/GN0P>$+HF8:O,/Y.R\?G:FQZK%#*L8?UUD_< M/9;?K=F3;_@:4C!ZIIW>O&X_YM<4>O#@$W>S(V)2^ JDC":_2.4, 8A9.WG MX78ET5;(J./!5U+X(9Z:/P09*SW"_ Q*<0Z2&["^_!'@39-J^LWXSN"^0Q&N ML'S-'4UOV4^?L =?0N\E[X9Z[NV[5%_Y&G?G&]\31K'M X=7)Q!SLU>#>Z]S M'9HU@#KEX/5+@,3A$M"QN- +.]/RLR -E=]BDIY'3/(=??!)^-%'@_/P=O(] M?+_]WN=?<),%!X5S;7'FOOV"K94K-YQ7OC!1S_JF<.XQ+YQXFP5(G_S(-Z9: MS&5PH!DC@7#^F_ D@G7D1@F_P#M_$P83G2^9#H/1G%&G.XC.OSI_L^$P:KHW ME"GU'V3M29Q><&)PX+%1WCJ^?EXQ]/:QPD#9@#GK'A?/AS^>^ MM?80%+4F.L3.@:^$^/3FRD>KINCKM>DS;%KX6R0/H,D*$% M3IYOT ]/^Z>T[ZA&?^JT!AP\%^E1BZ^KJZF=6)*^$KM^)%":56?DPCKZ%3T, M:%'R<(ZN/@NBH?+/#B<_WK48WFJ\&6 R@IO>YF()D($5E[-@*?V:X#ASZG2] MZ/'=FTH>$UK.]M_%KF.!_&:'69*7"QL!OR=_1*)_9LJ[LMO<@&F?BF,&2PG"2PB3\5\GEY:F)[=2!KBNX/7\YBP/VQ M^2WPF=HUNX8/*%"$J!F/"18H6SEZ%&?T0;!P MF1G?CFVK]2@_+<[&?99*KF M&(0JW*"_2AC6%7.QZ%?A'\*#UU1[TS7@P]HFB!#_H>9$ONKV M4D-YF_)W:\V7J!?\<#(^[B>ILCA$!,[;7#GE KOA6R=VB?MX+Q&O*3^BB>"D M.2C2P8M3Y0C(WMW]SK$:"<*IO#?->(P@V1\_'X&,_ICYO K(9<"7 .%9S]3. MRL)53S.9CE"G;OXP6O+,6S0IF6KWOZ ;ORCJPI1? B?9P$^Q>+@<'49W2H[C MB^E(21]OWM=7CSU=!'%+76$O4MK;;WR)D/(9!_\*C,PH\:$N9'4P>^O*"?@D MTUV'C'/\L!-I+S=\*)7>.LBU':@X;*= M?QEKX\%V*.V+&\RQRTS(FA-YZ"705!0E-WM2PS_RG>/P>[W5U^0.U6(@D/(O M@9MM]2"VU2+I^&N0]B0L]W8\:H#],/RM@0V+M*HI&7_9H/?T#$[UOX+O?V5L MPZ"9C'_Z^\"_YSN_$ 7OKV#QFO#H3P++WYB-RY?[*XWE*KQ]Q;0+J=U=0VS^ MU40ZND]"% M])8_%#Z-T3AL Z.-H&1]%2M16ZL);87"ZL12N2:)/#?K[.GKZG.;".P&]Y4! M/PM\#.];].:J>985/ >OJZF^K>7P<;'/%\WTW J<@I=SH,'Q&XJ(HK-S_1T? M_RRZD+9/EB19Z7B*@YIXH&0A5=&/& D451L2H7(F5X!T,/_0]2*LV)FTGN=3 M"' F">U,*/CT78&I!!'V; H]-=3[4Z9U9JY5+/4FQYIG>NL.$5T)LS\+&V9( MXFOWVOR-,^F%GI)@1=1Q1G: W\D\$85ZFE_Y*!<.9WY$Q\J#ULPS]8:VEJ8@ M=8>G'$'^8]]>O2"/8?$B&%*<:@]:S8^LV+*XT1[D7>YDT*1_ZI]3M?ZA&3)G MM:GA%15.+*"(F'D$:IP?WD.175"6[.'!SVW.^,^TQ[/A\R-GJNG-0H7N8W,7 M&X+)Q\<#$(N^&C(7JK"&DL1&GG.FGR12VT09T=LN!H;V7V7NXWF)-2EP1D[0 M :LRVO 0[Y/H69\.X7O([(609*5-L[@'RSI-^.9:Y90J!$,Z@08EP5:HSHXB M%R9FY%4V0S6O-QL!:G/%H1,.<(H<$]*+DQC&26Z,0Q%UMZ[T70*Q5'*2:*MW MIDNJ,FW@AE&:5SVR)FN/0E5IQYEY+),+Z<(H,!QP,G)SM .J+2\L MEKQ";S&LGCYL <\AB:H4.G2%#K)KX "$?LMKC(&86$2+9D]IQARRW7VC2<'I M##-CGN<>FJO#/!;OMTARL8(MM--[PI*DZ*.R][>/)'##55363<-I8"I>GN.T MU0<([4C>8[(( ZK,/I+7W5EBGS:?U_'-X9X-M:$& &OT@?%48BH"%$!TZGS)\C=&H!I$[,S?\ML M-2\^"1HI2*Q?EZ3]VOVU&X=1R^IBC,YLHQ*ZF7P\*&SA3$ZD5FPU2;#1,CS" M+^D&TV]#AQ+;E6$[55X(LZG*OE&K #]-C>'WN_IW _KN@$#%W@7$(D&?PX8* M;OI\%M);P3I+&3A9?*KFQ$>FB@F)ZA:KHG[]@17X]>9%= M*;3$0V/T6B5 W^*N!OZ4@K6$?*^J.?=!#YAL1\I@ ,Q@MIVM=9S1.'-(<[NE M"3)EZ6"380^(@V0>@0HPI$BY9G@2M4'[),:L]%O=8KWRB;0Z>Y)#QEMIAO)A7 M0[H2@W'@FC6$VYUDG6)9\R;KLV*UT==+593AS+,-59H#3'(H_)SS M5+L@BC0E5]W1'YJO#,OS[P$ [0[:P YV !BA"UHI6IXX^DDTQ@XTDB>1IF/*YU1LX6=JFOB2)H<5\NUKU8 M]X)(,JH!. E3&"VX=ER:<^#ZZ8"T/'ZL_1V;=Z+H<#G \MIR"9@%?.N]O^<@ M3P4R;'#O 88*15I525/CFT:80M=T^HDV/AUC&#. MXTE?<)18IVB\>F)F8&S=39MP?)-1+^IP/\8BQJ7OYDDNJR:7 V&X0J=*/4: MBT<>:]UG4V5\IDF36NB&>H6=\L*!#;<.*^[D-:FF*C)E((4"S;6FR9;+';57_C8%+U5(A?QVV99;Y>.9KV-,5L'1=!R-.U 3=,43^VB76!HA ME;+3/"^ V)_3%7N(,MV_,<+33>3?VY%%H6L?C$,*$_(4W%XYT8 MBV?>EZU4DR[R4";T^) %48-TQT,>S11*I^3OFBZ$40:J@X]L,^YBOY%-OL;X M'JO?.?\VBK-/?%ITD3G>+U3HY@/RLP?5)$#MQG#,KKSBB M3'+(XF'#9!EZ$48VX$:F,=^N[0UW8S;+L/GJ8_@^T^-9^*:[IGKZ"OJ:DX18(),VH0"1Y]S>MW'#%D%1 ?N[T29E%Y[@G M5+IYS$]=R_*IU(NT*_!81XKEJ\OL!>M-81Z_Q7A-RKB]03M_-V]H;#3\I!__ M23-%@%):+QZYNDE3148/R1FD)BKIK$!FKEA,.30F.T2Z:,OHO(\827KV1G]X MK.\YUK@IX!I\9[)=TR;,5W:\W\2"VO$^98)K?G!.2Q_U70VF0O<-YNF9BDWM MJ'P2%/$E0#T_H)]/6=!C3.$I-&HCDO+**\IOSX-F/1;<2N&&R/[)%RXGA71( M:'> :=.ARS DL*N\N(R/[Z5IS9=W+8?AJ2<%7U,3UXZ/*N;SN69D3% V?>D8 MR]HPDAX7%L%K1ULLR_[8XJ_H/4R?9F[BU([<6F;L1&;??JFQ7APU-NE:QNTV+)F9.]E<*Z$:/MI:!2I7T+P'' M&C+:"T;HSASONCDZ<$/R;9:\@(K=/2S9TP"'"QS5W;TW8_DW9X*-RDF@,;$' M3'Y> AH\XM^];YW2O":SK$ENIT7I7E"&)07KB9^(GY0L[K_R/*GA'%U@*]@7 M\VY;+ Y),*='4O?]'$M!@.G&*[;$YZXOC;TCX*O*YW@1D)9;9HGCH:K]6($! M'+EHC&Y$(1ZB@NFN3?F<<:H[9 IH6 DI\()X(&IX?9:IR!$H29_T G;1MROG>%&!V_\=VX\]%IX.S" M^0[(CQ"+(SZ<,FXM%Z]GYTFPQLKU4)"I4_;Z9B)?\.,B,]-K?%4'XKEB4XLJ M)]9".->[DPU2DWG>H?M6P3=&$%K40\L$329[2IIZZI7CR[[Z=Z\Q#SS_5(23 M_[+:H;\"!4(D#;YZ:PZYM]D+5:[JSM\.FD#P1K1%'^MX$%D" 3+9 !3=C$BY MOFTNA#QXBB$K%FL" M2>@_1*=K.[SHD4&EL@M9^=_A>/E<13!3E@RGJPACC.2/%3F@A@0-,8%JW53< MZ+A6,T<4_6T3TXKX]7$%=9,#;RPEL\$;A_K#XK(?YOGSAQ_S"O6.Z<0YIJJ+ M3*GU9?'4"CRB!C*8@\K& <::P8+K+K\0 0[4*;#Q%R) Q<&:/_Q"!(^C]5C$ M00R3J)U^NE_FQE,LY>R)Z[^96Y4XD%=' \M"UTM=%G,/D;*R[F]"C5 M:)$%494I]D]-R#?^N%*MC)&9N!&D4IZFX.0NF"7D$AC(IYRKN>H'ITS][\^2 MER7RG=CZ"F72K!05O 1;R%H#X>'2%@E, BB^-R@>5;3OZE?5L]LF,T9\X!>P M07_&U\D*A,4M/>Q/4\?<(28]*Q3!MQ [CBL#9' PR?#KKZ.EGY3XO*XIV_L1 M2["!0!(2>]KPHIG:RZ!&#PA8=$RJ,L;,(@N5<1WW;>T>$>57*NQ8 MR$.:I@5J8UMZ+FUV(ZSI5HH*.SQMGNI M18O9$@\'EK$5 ^I_?UWPSXQ;>UK&+1$T\^+O;Y-^O6^JF(T^*]G2^_9/>6Q3 M80ETN]5MK*#T_NW&UKBWV4)JI(D"*JHR\8=AL1BQC_3BKD<:534+DR MM\G6Y/"8P6<\8_T1=GY3TC5+SS19^?[ C+$46)[JH]KWF1?;T*]K$7,THPUC MH(^O21\^E#(8-2=O0=DG(>B[*"$EL)A8&:W*<,91JW[DX++>3H*U!K(I"V-G;_7K#XX+G[FR.@]3L MP@Y@['!9U1XF"N0ED"!'@Q;71XG&FYEN9=Z@#UAVT.:T%X!8RH<[R'ANF7LC M\HSD1(,M)WR8"=ZT3#<8T5;[LC/?PGL^W'T)^%SKUL7<1PV2N 7;-:(>IJS* M$G6'$DTUFNR(UAL>5%=6L6<%LA"6&BD.PHEN;#V=R"Y>E:=S"268XCT*H5]M M:L,6YFII]1;[D=/VX4Q>5IL16'T$\D;=A*FAYA-YCT-<=%\X9H>$$[T;_'RV M$*DVD"+Q2%%!;0W!8$FW<0G8@7]<]TTY(R@XI\C8\_\X7K)4COUI4@ @3O-P M&>ZR[R#3GVB_6=Y3[>2?[3KES#$E/>H?]2JX@18KG-V6R1%G@0=A$2-/U04S M<%YFO03B^$]*3EYL70+\H=I9ZPT%NV+>&T$VE"=Z$-7=8UB2ME8[JC*4;6)_ MC_> H_E&U7DAZ\/7X[D@&JOOQ.>J58"7F'_@RI!V AU5APVLKM@):CI)GU,[ MJ-PKX46G54[;AH?#)I@;,1T=Y@SD^59 L@)! MY" !)RWV^YIV7CA99!<5;+;]9M&V5$FTJ-)%AI4-SN>UZE"[6XH]IOOW0N9E MO4M09+WF=R8ZN8TP6DBY;-\0%/?7+WNL%L>A1C]"3^\\[1YF2U6@]6\M2+H@ M@$S?3[! *0_%R\A7:%BG5O?1LO4\ZG>WYU:P5"")'![R;&K=J%N]!* ^6U+5 M%2&>;]#1V',>2Z;2 \1)PX0TL(='=H /:6-<4#%Z$0%.$C'RO02(3:_2\Y\/ MWAF1[]:F/WYX5'#I? ,TTME%WDM1J,?& :>]Y)&Q?& M R[\8P*7RGBN'L$/]=H?UYX%KT[(2)(N)D#XS&YE*]/TE4IP?K*6'+L/*4+= MI[;IS^X8[V>.#T,F&:?\P-N"4KVS21/9Q'_RA79,+!?P4N_!P6[H<@@CT[1: ME<0HE6)?S>/NQMOJ-%;QV/O4S6']:&'Y=4:)ZK,YRPADO5A.>+SQ8NNS#77P))AGVXPWOUD(112 M**UWZLM;&R<\+UD2C/4!]3#.<9ETOOU66 ET\56)5$:O5*$@VXUP Q#Z W%H MQH8PFG47XYX#*R(-JUV?N_G(T>"M\GH6YEI<_+FG K-2,$OM[.X%S58:.N%1 M1]<,^,77CZ?U[=5/?RB/IBD0-:?HN#P[+P];4YR\!'9ORQ_ISK>4E[.^Y=)[ M'/[:$FO+7/),PS&PJ6TUCYN$3+-]YEW*8U+4PF+[IXKUEA%" AQV;P6&^Q8- M:VF.@HX3:&[I.)+61:[,LT]&I!/M0^O!"Q?[+J_1FL7.7007UR%9_1>WWKL$ MK#_VQ'NQPF-%\6Q)JGK#U:9:KG$),@HK3DGII(<:FG4W_6SLR+6?6D\G(WX* M^OCU)$U %3%#N":#118?;((<-T6'(/+X=>O:XA?>U,^ W=AO#!=&X0WW45@* M1GX\^J8%>/@%KL1CE& N-;2F&+/&:5%E(4WPFY .Z^52[8\VR]CID8T:8J&F M^2[OV]'K936[9V XS7TEBWSD5O2C\'(UBKHL\(/=GJ$'S0\\3:MC[. 6^(Z? M81W:JXU9L:(T9E&=%;?S.>_1QM$OL8%P.)FE5BW]JJ_PP J)+S,-AB+ZXWQ? MMD6,:$NU\L^M3'IRSI!BPC3@T8#:\?J3F\D*^'?EL-!=X**M3M9)3(!OJ;._ M,D?.PWQKECA#!_270IMP!<49>$.H(.8>BBE%/D:&LV2;*O!V17D?0W;2:2ZN M7T^. VFWFU;/B"M.%,V!42U& =W%%V,%^\K9;9!I7%R:?$?TSANY!_'A9/!' MD1)K^[*H^#:4/^P@7C1 1AB^:"8U:CHGTL*6HEMKJ*0L-[?2*_@CR]-#U?2Z MPA&PL2=C5XD106W$NF/$C#X[=MYKMELZ[FI2NMS<*45UX353S3K@S/D5#MKJ)7 MF7Z1TK!D\>6N%K-,J_#]#XBW49RR \;S[?*5G\\,OT';I;2.LFT]N()FF[P) M"[@5(]!021;? P6:P(S39-$#*'\_$Q5R)9Y?9-&)#>O5>@!;0RS[@\\, =W6 M'D("H3;#8RY*O:TKB7*,P2X-2/%XT2V,EZR=-N<94K>.2_T$NC-]ICE6]6:^I(%=4@82?$JNSB])Y='IC0%,;B/"NNW M2/++ET2I/)6/\=GCOL5 -:\QRF8I-DL?D?Y=TOH+3B/@ >4,%]T93S$>CUY% MC16[E1DO9F69*'+F22S20CVY7(.[O8;V4_K\^^5NSP=KHEPL)D578KW1Y./: M+8Z[J>)O/X8_+WK_WM=4S*@K(3FCN'H1,G0U)3?PU<#S.'M.H>?O"H'XFZ[T M]H0J!'?+%]5L!Z_1GKL8#$$WXW+Z=1?1D:O'77%'C1^AVJY)(L5!8LA$W>2* M!LM3F4<@.V2))HHOKWA)K ,AK4UI.+SR+5UAVPXRW^BW"703E<-']_H$%B8\'U9<=#M(MR1VP1W8/W@M()$24NP2MK6 K,;!@>U'P_&9$C=6;G-63SR>?< M9G/;^C"')5/7=.>D#TGA#(!'P$8K,ZY+"MP"2C>JB\X@^A;XD;4X(VU!A("] MY9;2@?33-83D2/?P*L,XX+)"VAI0^D@ MA5_5'G7?RO4+[F##R78EA"R5%M6T.N3KJSWS+VY)I\_TO%LRW86_A+YF#'MZ M_-FB+ZR!+#:8'DZB__-DZIQD,.MD-"O+D3953_SFT[IO+ M"*\P9N!*K/R:\7K8@VQ;L3]P_>5]>GIC)00I0KLO7F\=4.)H3S%K. MB[1]%G,2)=]B7&_K_=1I3!S>32Y$)H*5A!R%+U<6X&+4JR 1B#.5@WN6M>K2 MP8GF$T2U0>,(HTY^Z,+V-A.D@;F9F^H)Y_IAY!ZQ M@K2NU?CHN(P;AA7M7;D=1BSC!MOS?M ^Q3'SC-E>_*3F.E_.*^U/^ J6'P8< M'#,O.)#O8COI9^0(#'<"77<).U5\.)^+-TB6W* ("BPIM&%<+D:./]" M)C.YL;G6N^VW^])!<:[VCCF!G01X:BP"/4,=;L%\R,VD1B(2^<'6\<3J _.- MGNQ%Y4Q5$VL-.!L;OB2"6$UK07)D4R!8';E1X7\F5Y64\LQRVO=.]=ML-\[[ MD9^>2'^0MC%_"(R;!F9O^W20&7TXSW=KT.3('#)(OT?U+1WGYA!G5E*)3-G> MG@*3&7PT88^LSSB_&,Z5[(]I9VVFJU?43>J[=FMS MBQX$S NEDFQ/>GH%@JUBY(:FPF^]G[C@VBD@A*/>0_9/ON[Q$L_]])).$:.) MN7O0MN%':$),+\F0N.IB@?&:G3X)JY^WOO&NR]?/!R'7TR"4])G+_-5BLA0^ M^"$/3M\R#SH!U)-C0;QE3MHRLW?,8\3R?K:J62*9TUZ?](T:L5 W%<^@U''5 MGNJJ^]5T5W^>' /*O&!I;'-3?KTL5B_ /8DOX^"^'&@7N+H1+FFF:8[2?GJ4 M0W;S"\:X'L6XTTK_F7X/[I'S@87O9 ET[UX98T49^A3AIGMQO0!_1XYN%GS4 M,,OFM+CKKWW#SA%A6?DD$>&YM.'.,O /M!XB?DU, M3C-(21HPMG$PX',),+5C5: CNP-ID,OI].I%=>1.)X0"L<-8-TIQ;FF$ [0] M6PI$9YHNT,Y(6!Z5&9E>Q[1M&FIV>0P&XQ/SX5 ;KI8_29@$7P*-,J+EZE5+ M(WAH0^MZMP&W/#UQM2XQH<5H#RQ$67D8A?L%>[ &\B2+=SR\D5$.^E'G'0TL MS>A=1E;60H/0:Z)D5?WM('\+YF#>FIU0*N3L\M/B\5+U=QK&CK?N'1*7K^XR MY!N &+XKT,C3L%VE> 71V20O0D5F#VI,'KT8+>7MKQUAS1B^YU_'$I2]A"Y& M6)!_AG>10$"]=#$G;AMEN%Y+*PZ;6(< R8PECR!;>C>N=RY_(@F\*[: 1(1G M/;C)K8!Z$OY8)>^R#A6,X8'#%4R11:F\&C-J^;82W')C##)A@MQSA . M(3E[@@KBJ']> K&A;'U5CM^7S*FCK^U)3!C,1)MP>UY? MY^L;Y6C)!=8T)18]OM>PUE/\(E3(05PH8;!D6SYB8#Z?= M:?JV7BQ$5M)<8H,YOM6^&1X6RTPFFB>M,,N$M?;9"R_W&73CB?5[S\/KPKF( M8K\N!AF<(,0!=E5G(N4Q#^W IQO">-^CIRK#\[%8UAP2PV6_X0R)\@8-R(&F M7&6T;5#.X_W^U=_ (N#FN%[WM?"V10]& L(BOQH+5.:;*G1.+Q/SS!$_^=8% MY20_(G[S<6=+ZV&)X5>]B/N+'M?P6I][ :L.;>;NNV/TNP;)\'?XX2F@[;EE.C>3OI]/'@]Y%SJE!B3< M(/LP:P/8::R2"AYZ)T[@RV4AC#"RJ%&5"G=US M[;[PG=5CPA#44>/_XN*ENG8M&"_9H+&S(22S!UQED_Y)#:JJ514AG,&R21PF MM5 CBYZN1&=I(NE-T,(/N]IGP.N'Q)EB!SR+ Q%&%X\\'F)'7DQ>9=A,8%1; M?U,G=[H&VF85@O_&GW&*P)C3#>67 ..G1_L_@/A^YK5N2]=,EW.F6K@]IL"1&GVMFS-? M> "P#9T0HM>.ZR([8,%RT,R-.3C\?(.Y3#XO,+.D$"WJZ"GC5X/U:_=0X2W/\TG"23K&V?>"4RN ML8,MR%$[RU%/3=TF\&1)M7K&G4:-3\F0+W4LNWT)#(4(70*&:.4RHRTQ _%Y M[;MXEDUQ17[8>IR$K].??@9<,;R70)HV+.4,7_$2>$U8@PJ[4+L$XL)V1KI> M5JR0[/'=#:5!^\V=$+A5WYI^HV[UBE!*X/'S)X=D=:5R=Q:^.LL38A2=2A:U M?+U%<^YZ]-#Z>Z=V/QX1P?K>U=<%!5U<9\8S1H==W"AH/L]; S>$='W\^F$T M9(6W+A%1Y7L)X#5H@?O#*$7Y8[.@ I-'HRVF/33W*GCD)@\=Z*.Q.%K)(0?) M;3#MB+(@L$5G\L2VAS. M2-\EZ]N=3P;'G*WXB+.O"2%=Q*954-$Z K^B\!*GMT.L)-XENO1**?&-ESQ)WUQ,AA+$T' M/P*;"4+ OP=,ZRP5+,=WA8A%I7/:#LBT./K&_7G4-BAQY8@8,O"$Y%<P6U*@9.J=R(-^ MWQF?VUS!>M9NG,F"W]6ZW[Y'G+]9#Y6LL6E#RNZ_0K*"KT$\>RVJ7UKJZU!_ M?I$X,NZV5CM^]@1K;9FOK0-Y^NS E]$"?CQS(91L-E+B)/7*1?'[T_J/>C32 M7@'=3#&=0XDRJF'PE0527@<#NZ#%F"0[7U/P'=_U_6X$.PLGXV?O0/>4JD4, M31F MGG-M)%2R!G!PSU=M)91X]+X(P<48+TORKH"0%.N++.)RA>^ Q,F. DT87;!# MZ;98_O6)=J*RKR;FD'C;EF3XF'X2)A.XK9$;Q7$8MB2Z.R?693V]5Q6\Y7#( M:HA9R&WKG,#?L!GAI&4_KGD5YN!V^ZS_0HINK';044;0^NZ>/UGK)POGGXSE MMC_M7+;I@!\Q"(/8+ACY^=N&D*#=+I*L^D;_WU<3[:.1+!B\-P;BLQ9=?T$,;+O*=80(TV:Y*K-\F#<:EA\YW54=>Y<)U]Z/_1N$?TEL"?Y$M<4EJ$DW.0Y MS+/D?4 ],![S$SG7+HQ@QG6J_1SP>HB"]UUWH?,0O;M"PN 3NRP )T) EOH! M:GZ@@!I=KY6BA7R63SN%<+40*R$2:DT3ZFXMM 4\*I8.0P#) VK(BB&J9*!* ML_\\Z[3';A*/\+ _/K]+4\6!V%%5C6; *^JE;Z0[UJ8>QR(I#?%");\Q-"7HL M"7. P8 'V=0'E^\?)[$8HDYI9!0:&UO-R%O_!<\S0K7.^KB!UPA90Z2WF7;O M'VN'^K5C#0+?I8?8N?G8"VAYNJ**NC]N*K[*MJH7WX]F*?FY[UDT2'%-BV=+A?/NY\NQ$"3(#NZS;>_R";V5A8 M^V06QE&,Q7$.)R?,O 3T#21'2+USO3]A\"=%OV%D*R#-*G/[F [./6D?"E*K MSIS=(2M7"=JE40SG?G*(+&BUYJF,8DD*.21GX/EYB@Z*J)ZW/E$(W][>GO'] MY^YMX+3:9?4#:N6I?2>R9SX>0@ MYPIKT!N]6AH'""7'[&FU'I&VN.5E(47$\^W7S,KZ1S7%,K><*K^@S:?(R)TG MMD^WNT37!%V-*,Z7\R '@R[=P5IA-3L)02YP^:=ACK,E2W7;5(_5WA ,X[;> M6E;-O ]U3$EU/O M-)WQLU>H/-G$OB<\S4#L+\O9FQ+G_RB8&86[?+LU?U,/.:JY&5)][[!%4C#: M7I(S=&USX@DS3CL)/+;=I1*],^A78^5=RAZ;>7A[R"^UK^W%Q76Q59R1\689 MYO\]J[Y*]L0O ?9,^3,"I2MLTQ'X+J5XT3&;-S/+NLUM=U6-E7FW% B5,&3;V -NSV%GW$2%9Q73C#$E@U\!T>=3@1+HT[R>!=_ M!(9VP9YT6$,>H09-O^_$%ES\/*7<,.>I"VAG+D2_0WD'P1FU=5I2#P/T'!68 M3Q?2"P*/^>/SL>;V+ZB"Y0O4ID3I\^Z-/M0T:8/PFJVG!&OT"Y4NM=R:6?/O M*48WKI)8RT?E8TTUA)!?7.QH-S\WK2JN^#@I7>EZ%A&9V!GX\Q&H"*/:/+LO MH^EP7H;(L2" :+'>5G().PG:B1-FWR5#I.LBJDK@: M&748@B+-^*O%L%T6-\6:Y.8'"Z7$IZJ)&,D*IX(&9@R'U.:S XP1[(?UDPAI M:7##2[5$@#@$G^'F&.AS[D8A4B4++G)>9(O"KX#)JJK5SKQ^KGR1;,Q%/=H+ M\J5_DLK\ &E("'R* -.C1Q$I\>VBAQU.50PF"\)'^2#PZ/ M#S,0BY$F\"^7P#,>N$/?EFB2RH[>Q7#$LDO.2*>3 X&744Y:P.HJ>9#W\E50 MC&%BGG,-<[*@V=W%0*[X-B86N6:YA0V2QRB\!.IE;I9 < MA'CDR;D8X#YBDB VNHLFT$3H.Q6D\?1-.S 2:."JC MXV(7OT>5EQ&_QOC-@D/][,OC9-E 'GF2[16B4.GSDCZH[/I\E,Q]["6.I(KA M3%=M?2CI1*67%$EUMT^U]Q.D>2-R!Z[26,;?]T7&\\WV>Y$)SH7[G['L>9\> M2MX3OQYJ*C D&XX_WD=&A8[L/Y7C0ON70]ZX[\,:GV_]/"_*M\$;OO=Q6S&L MLY+4>[[@H?8J.%KT#L8)3H3&Z 78@%^;*W-@'N\OEG$Y>6]8=5_@[[0=% S- M==XTV:;6-=L.;.Y+HN]EP^,M;FHR=&=4'QLT>U,+T'+22OP(D9"/:9+C1:KV MUUS_-K],TMD^W:X<7,;WNGSY@<"/M-#O'CI%E,]SR:^=<^%0/T19Q(9R.=.] MJPI RN91LC\T@\:>!B0Q]\+O01ZOZKJ3#7R1S5=2-1GNYWX M]PX_Z+;!V;CQ 8?FXW,![W')FGMU4Z)!71&=7$%=6$[Y#+/\KNSQ/&:L7^XV MLUD-?INQ9N'RZ +:,HY.0[Y:G#6M;:S]0ZPI&;U/%=?/V0+OICC[^ MRX7]F4S''*ID@6E_V8SX9_QK)[BFVHK/.1=VQ[_8AOC?Y8"5_JZH^97K![PG MD*93]>FY6Y2?GW&-,P[2>UB+EXY+K#%%=)#' Q^10S&N,ARP'%XR=7T3$XF3 M6^#V34E[N;4T[0]5QG])YJ^YK[KDT*ZJ&U-EBBFR'M]3$9(=",B*Z"2HB<;8 MRCR&\Y,OH[.>Q&DLCOH\"PB@]]*4SF0A![$0'VV9E_SY?H6 DT)D_9D2@C;LQ#!M?\&=,R.[Y\NPWD7]6A\D*!5H]GN]GOE[U>27AF$B6 MI9Q I/1Y@^MH0:[=2;1<&TG@[:QWT&]0K72F8/AB!6]E*$ M]SQ?G)$M>-9S510(A\G[R_MW!)+\\Y(@4#HZ?=43%9:4HX\B2Q EZF#;8_() M%-1?H'Y07N=%P< 4]RL"FPM?\O-&J5'0X@/,+UH^(]KBTPW4S )S]5_DMET#L,L%,L&>1R8)3 MZ.TVY(^D+Z,<[^L#OAG@T?!4J\X4%/M==2\O\K3;&-S714S"IIFF/CILGP]_ MA*.QB2/!" " ;(>72]F?^&DRG%]NSM"[^=.]#X.>J?&P3@J,T"4095.TLA#F M<@DXA[SWS0I;:,][:6KSW]A[R["XNBU=M A)2 +!71,\:(*[!@\>7"H)$"RX M:T%PMP"!X%:XNP:W0"&%%6[! E2A%2B*R[?OTZ>[3^_==^\^N^^YY[G?C_?/ M>E8]M>::8XSWG7.,,1?5(O_*Y+\S ?SE[W,"O-\3ZSDY/GV6VP^.-O>)/.5^ MX$L$?(H<\LSO,V7J0'"5$"8WI>P].CD1V$KQX)!BQ)6BV)OJ4/NON=4_$/WD M +IYY9-2),5E?!H/;-C&B#$,(^O^#[_XQ[#_M7(.XR\=X_]?>KY_RL52?1_H MEW]U^#]8[(55SA.H3CKKO0:2CY& "CF#N[BGJ?M_^,5'Z\=:?P4H\O*A?Q^43&*P2M"L( M!G=2'Q@N5Z[6&RX2/7X?S_B!1(D&_@.7/07I!<_O=4)*0#007$EV%0>&!8\] M_#Q*^KBHA^E#GSE@V?/&OO3\&2#.-GNT)PT-.D9$K@91L]7N0[(]@"C-G4VO"G MS$/U)R\?*7!$O#S(?F:?#4N1_%!7"O";=\DK#P2R@U3S76TT,I&CN2;5,<9'^9YR'? M[WHZ3%.ECZ<<(LF+IGF#YBJ;VTLY8R&]\3EF0E4Z__M/Y_W_%5[4*B;(F^J] ME=O_X?@ (!*Y4X7R6<\4I?OE1^Q80^[-E%!+=RF% JBN8RNCQKJ8$ MY:R^9S@0H_0IW.U9DV6>IJFD&Z+H9OB:-,D._W!'<0K$V9 DV5]%]$,]E:F< M[GP<9Q-]Q=R@KUP^-A=X!-6#./LJ(N?"EZ]O/HC'Y;-6I;K= J*R!*<:4NKK9A?>*;Y_5^5 E%&O./B335W+9T8( M+>RY)W%1B)-];,1R=B]UALU#OG.23D\3^ J&GEAY%?#!DV\T8:D=!P\M\MT_ MN<'R6MET( >(='X<=YG7^@H=HJK2,R.[$W%&0K)%Z7!(L3X:4%9BW71AK\YT M;R@(,219Z :S[(^[;U. #<(W[!MLF'V'DG!D?Z%90C/Q.TF4DHW*MLUGGM16 M>".+A4(OHO<%;=_;F03IO]$I^1<87+86&*JVSQG6UW1_*K_7-5O5\ORQ9G/@ M]_-2O<:+J]",YS,EGB>9V O]34!5T]UO7OBZ+7VZP-+""YG;DMVTDY$A:I?W!/\^_:]QSU?0/_ MA69'6E=:S=I0_OPY_Y5X\V>"HINIGX$4I,,%B"?!X6FZV:U+VHINL,[?OW)K MA:T:VO ^8C0PHS+"&&(1@E"(K9V:9AI0I@:W"Y:]5Z9W/2R/"!O[ M4!@,1LC'QG"'M0M_N(@'\N W"7+'7_-"'WS@/=SMR9D^[V#I MZ:H'QU@B:,'617)^8)B2_:5S>(I435X\]CNB9#&\7=OYP\/U^B9%SO>QC\S( M%3 #PFW@*E4L&<\'M):_2&URTV:)^\M (-_=_!-M9V.FT!MH\CG_BW.A0C? M25J7.G_>)K%-H3%"ZQ0B&XU]7@.C89][/++.DR\2^<5E&GDPCAX /$FC"@P6 M4&\1G6D;0*H#"9+6%FCZU:1=U=0L>[,Y1W>@V_/(:%R\]>Y!K[48K)Y9LBQ6 MJ*_P1AN$R(;LI0)MKI.+%\WX M..\A\FL.N_+!K)Z:=G1*T^@Q#BA9T+5Y,=Z]=0@J0 MY*R&!3Q+LYTJ;AKDQ@\:#HNV\PVY'#>:W)#@Q7C ME[O*I2]02I!_$T5R)TWE7!"EVX&DZ7R:60-*H^B )V/?-O'"MX9BJ1YUS#*S MG)L9EG/J3=S%D,,SO4 EA$*_O7,38O!7-(6."P<7)1\$U!/:#39- )KR8;'PL$Q])(R%)9&2= V)Q4".CXZ;] M%G ^-2.90XP&:P]-PQCV1]A_1H%@W/T)\5PF<* T3BKM>2KO2 M!2@9>$HCV;4HL#9A?MW,2ZQ)$D[:? M1PF0N>>GML.'4+CDI5&)2<5F-OG^NC(BYPGD,[0UQT2TXX\@TO< MTLB=/ M.5N&<.@C^Z$[.#R]>0LHLN[H.BY"!^C1^94"]YU_I\=L77)FU0X9T;TY*ZW7 M,[;NH7LBO"VLXGZGGPV>_TN*CW,3[S=%X2V@DO06L>Y)/O,AV=M9^EG^T9DA P/,G[:ZDJ[=[5>,*SA:8WM;-(>3U:E MI!_9SX?'* ]$E=J4VQBW20,9I42N@P^9^V>I>8DP&KP&7U%=#C?L,9Y#KOK% MD@HNHJ/1^R'D_O0MEL%12%?.MW[JK595Z2CV:VG;](]#8DKW;&8W@W@VA -0 M$KJHP'/^PRQB9,QZ%7FQ"8.&IDOT-Z5;@ ?K+2 @N^/<.,Y[HT3&<9GR!;/; MW9 ^:/RKBVC./.MJ#7DW?:0[\>IFZ]I#).Y"XHZ3):9=J>(5\(FG/9"]86QG"+QDB7G./V7=23!Y-IK2 MJJ+IY#G(Z>;L.TQ^M76&8K>OUPIVUSL7V=3&4UF/XSVZN$[=AXBC!Y!QOAY+ MMBDIIA&$EG2%UIZ2AK/V7/9GJI[/H/67VHS!3F*WE;S8_5E(UKK8E28:RI;5].A7W[:E&2QE ML IOPLNOR?V?(6/GKC^L:D6IA*X=-]6[41#< AZ+.268G.[.\EB?+H@!%I>$ MO32RJ).2TEM+"61RGI2^!- \L!9!V US&J%PJF>8PI!:_J6W@+2=7FUD1-XI MJ'#1!LZ]8NN.47-V<$4Y,R7!8$T9T@,#EL-T-IVV5K@FU'/LL[/8*TJ]8Y/ M^Q<_GZJ-4WV%6.-3^^%I&KCT (G]-RLV6*%H)E&O0?5>AZ'&1Q8/%)^=/#I6 MT1>@I?TFD\4_:;_Z2[AWP?B5A>9^S(Q_1N1*>;J*68I3-+#UZ',D:\''_[9U MIJY V\8876]-4LD*VW!T^8M3Q54X 0I"\M/P>."I_+&K(4WK?#_,X.4)76_. MC7]#@PA12>V=DP^ZS#DT4(D++$&*363M\-'"QJPWMN$S:.[=1KFD-Z%V,M*3 M 2>;*(ADH>?,]LU*OJ-E5TO*3VV492 !9Y968(PZO/8 MJBB/GU>8QB_2CW/_A/Y:J7:IU0DM..7''C[*KDF7F4?M-Y#,4#J%]40SO?@W MWFTD<3>[";6#-Z>W@)ST@8KL1[> H04S].];P(3J&S3I6W]&KZ?$FF\._B4+ MRW_F0&J+IG6SH])KJW_B4BNLUGLN>Y+=IY=G!:R7C.!X4M1D;5O:)W$:N#4$ M(OD-0L!.E-F%M8/1C/S,<:5_M*1T7RTH'E463%E^>II:%@RYWF3#:J'O>((= M;I^C5%&HE.?48BJ 4RXN30)/_F1%RSG7SNW(--&@$B7AK>JN92-EDRO-)@ M;1II8 -V.4QG[Q%CN99C_]2(B GMG5@QB(XKDP=I/;[2J[/*>C;EJ_"!FT\4 MZ?!.W)!Y6ST?M]0OG*1?1!N,8-!AO."SRHL<>O]_'XJ^9;T)#$?3(P,W,O&Z M&]%DL7-2Z:Q1-F6.C([[?>\&'+WD?XG$UF,('LO1E)&?BY3VR39._E2"/-^@"-E45-AX&Y0.M_#]4C!T%<[X7CZ>7UW+H8C KGUJX@N1]$V2D,AH>73['3EA8AY/V-L-^ MDQK7:]B9I+=4=/G+L0E5UT EB3CNN)I[\[*!J3.4L.K1 M[ZS-$F20TF22.[A8VF% IBUF<+=#U>DJ>X"&<,YY;_:2[(>(@-B==>V<59%8 M6CJ/]Z?%*K$P3ND9.SH"28L(^Y1^>3^]!0QPVF\ZS\-@L!>[BCPO46I8>\;; M.[%BJOXN$G6NG1--R7+5 MG)2S^F.%A!&"($,K*($.1D9O 4KTE::M<>%=)R(JMP!37>"5$HGS.0%2$T9< MVD_.DUC@^NRL(*_XZ9CD0!;S5&.,)!#Z7FY+GDL_YXY*DN*F6I>Y-R$Q]1>W M .66!JA>T>(WQU?(HM4Y_I_0M\H93*TT,(F R3M]R:[ EGX1PL= ;FW'1&A^ M=?C)[)1_UY"E7_WAP:(NQ+@I4A?S4L\@I&Y7\!W1&7.G>%[+=DC1Q42A@-]: M.86TUB/Q1X5547QX5,BD7IRN^?3^L78;$/1HE>X&O@"XBQK._69GQ_RHJ1?M7">I7GX8U-BSZ%,>*%3BD\*(7T$'9 M8,/B'FWW")[$R#:1;X6]&8UDF MM&/20:_JY>-2;"(^=G9B_&:'XT1 J=@JKTWM7=Y_/,(7,P41AHJ>N@7,88-N M\)/#C+)>WL78=.#5NL,M((^P>E]W\,,\:UZDV;\;EZNSF!9' B]#"4XY^#[! M1)!J7H"X47JC=O[K+#\I*9 M0YA"9C;=<"K!SP-WI:L$7+=58?+#X.I]UKPZ^'5][G<.P5VTA?&L]/#'):&? (\]6SJ+#6'&/JPW:E/[4, MH;K1+TNR)27#_\K)SZJU8863@.\LLWEL-E7C*XBC I]]3,I'R)]D\3E W?0< MV)-N4M'5N]U.4&:B:O/K].6HV7V,;"DLYE$[N'C&+7/YPL?[X_B#S]!DZ4 M#/.G]#0[932J9TT;V$SY7K'Z2(5HG[)BO/J)K5/+M91+ C6HA^@F0_N+:TLH M%>%-[>=K9=&51>#Q+2!,,+NOE<,CV]Q/;<'R:7UNO*,?._N@-W**#\@,.[0[ M.C+0(:=+T\A."YO0%:APXVI:_W80PRU='Z=J[D&F7:WGZ^:FP3L'G;+=,O85 MG 1_Q8KO:%[I9:$@EG_,1X)(9E$N,$,UJ8U9-P&[\RP0 C'K,_5ARC.D2.,E MMJ5AL4.6E.;ML$(WNPW.YQR$Y^?DI# 9&64@1OA9.1VYP2(3.H!PA>EI< M KKY?_&S5AQ M2&O+E[#>^&$X8XTV*/W(^[PX42ESWF:J0K6Q?-KVZ'EC6^01#YQ0)A/,IB 9 MHRK_:BHRJ= 4%D*L*=7S3V4C^7>E!N$ 9Z5#4Y>-X\A9F)RC6X G^HY="UZ,Y-:]1)+!YYIB(':==#%1##&@G*P]X8(V-48 M2Z.UH1NS3&:=\/!(\8YP@I"(V3"!@B3#EYJJ)KP0JRJ+QNNW$@Q3?-^$!)&& M)B_Y5EL>DCT@3[4IP\F;41*I+TS)VR-G)[!)/K3E=^E"$G]%T@*BA M;'.[VF"SV+Q,QCB^*HY*"$/-QX_"'.IWPVN)_T/6Z$*"05N?:FX!OK> 7>:: M,LL>R1,!_5M )^B,2%LR))DN@E96CEA;Y#],=N6>R'AA+K#P*,Z'/[/G+)&L M6V(0ZD/+EDSLT$S[>RT;1F"27XNHQWC<$R.S+'35BINM@PKQL0C-MRQ=4/ J M6NIWLV,=42$*U47)^7*;X 6W.U4BN:X/*9D6%!<"4V!OZK5N >U=T'?7C'/SZTCHNO/\C,2) M%@>NF[N^2H><-N[(@JG8^?MX<28R?]AEP,6%OP7X.T43:?%F(4E3KF*R.C9$ M#])V$.(WB#"#6*M@T,=$CD#"8I9MP/F^SUF_L\A-4Z_1KEMHS11*9Z-"C4'@ MQGE*-"JN[@>/YQ?\@!=GY-^/V*?.JC!M* 7[8WQ,:K/FK0S/\_PJY]L>ZVY[ MXN:3=S^H&W<>:#G$7%^-:^=='_:E*CCPIO3T2M>)TTA^,%7[,(0 JXQS> MRNXM @C? @AMFEH'?QE='"JO'W$5-#;II8T;7*S0?U9W">#QF9.[!3S*#.M5 MO[?O+Q1I5*'>_VI/;=I&4+OM]_AW@B\L5CIVS0!SC&CH'!#[/.T68,D$O[>L M'_/V=<0.!=W0R%*$_\78JJO9T7F5=-^R6*;N^$N.RX4,[E#[3GO!53QF];T5@@,1[TX@B62^'0B.Y4A.FY8W7>5Y3DISF MOLXRIX%94(SM6P!QUU:=+_LMH&H4-_?+4U MCW*97B491[V!ZT6(R6U(/CGH),A6CCV52O$2Z] L(.CZBH]W_BXI)FRZPG)? MX@$R:+-96PT96&5U(?(BP7!C5"K29$Y9&#:E-!*]662%&=U%A@VG6Q=J9?%" M/ CEO8&L$M\"!MWGU!&6:AZ(V>1BSS(%Z#GDOL*'28@M./7]@]D3WSTS&6RN M)9R+[BM:\.#*@V8$;=QZA:2T0$K\;FM_Q5ZLUDC>(YW4#W98&2^_"U&[E?DS M-"%0WH,P7SJ?7%5SQ -;<5-ALA&G[$SS.,:=V$>'W3FXRI=]5RS!798W9B9( MIQ(5'XM'_6DI'[_ Q&(3@C'0%D^,!6:'=R;F,+A2\Y36NAJLLPB1 >B7 GE6 M#%ASZ>?B6.LRTFN2!%;^#!TJ;=F$)JI>?ISU_L9. M2LR/3J 76A@4Q6=C5!OC,87=^48V6:2M#0W2."(Q/_3HK$Z@[TBC?0L#Z%:N M=IKO2S!T3CGXDR'MCS=B!@K-^/:PU8M@:?2))VN#043R05X4C(?DW0.VT?". M\>1\7U?X6.KG,W&?7F_W,@?7U%GOY/;J?I=:^MW=2C5%-AZ%II(J.<1@8$.' M7SMOV>Y5YE<$5IA)0_J5[^6]7/WAX^X!6!0YN$8#LY06X+[##[> C?&$4AL) MZBPA^2001O)A/9R,\"%!O&:42UO2GF$74;OJG2\=]XC?F^[Q;KA9[JSR>!#L M'=.>Y3?B3NS M8HZYE?G0$,[.:2.!:P[4UIWT#/.SJ*,5QNK3Q5[5]?L.]_>U5JT.VS:?P")B@%43W&BZOP%F;/!HI)CK]"0'.<-ZSUQO3X1@<_%L)]5[XO*;J:] MG.-#K^P9^"6R2^9M+J+<"H%&0*.FY72810(>ZK$2R=;JX_;'A4AP+_NF _6\ M=*6M]V;[KSG$X_Q0\7Y- G+\AP]!^+R!.N?+A)!UCP'))S:FQ.'6,,OP(]QO MQ?.OG;"%O\=\=L7B7"Q:$/\-O8J M #)TGPN#1K&*":$>U>YD>2UM[>V?F:_$=V\$Q*!*^3V6ZHSJCEU7N0A"1?#5 M:;S OEH([-T5<:1)Q4&ZZP2$;C'=%EO[(N)^!;$RO0Q@1>6EAB>6>#'F(FN5 MR)0_JPT0_G4/38<("SI""5U5@W[MK1R)!G\M'M:%2<@/"&UM19]72!(AT2;L M??%(V]YT:O2S.?.@0VY;ZH/[[O =JJV$6C*6G.X;>2E1-O98>'8US#8&8@-:@B^>AI^A0(G2='6_Z+9T-<>N$-/Q M#G7+.9FR(PO!N_V'K@%-EU'=[T!N%)?BD&I4OQ=N7=6^]\U"\XQ]ECMDI&!= M>YY;VL2UNC:K=I)]MQ@22-U*-DGP# FU.AJ[S_:,\U=IXN3>#XQ8G30>_WQAU.K;*,K M+00%A'.I%U>QY^4Y1L\4A'XSHOOHJ;Z!%>9KB7M(^OO-FL4A\V]F]=++J^@X M[SW;=7:?B HN0A^#@L]6XUN) FPC?M+4D1?JF+Z@CFE4&QV%_-SL$FM'A%0R MUK7*9%AS]U7Z6DFPK;Z-+<6E1$1>B;7(0':5]>3J[J63J>'PI7E$+>^N'U[- ME@YL?7[BO]JV\8^ K:BLU, J774<7&K,V9!9_M&@T#XR__<-V[*7PB'Q=BSAP_!Z^JAWK'Y^8)C-,L#N23E MB567BN/RE4^XP9.I3.DS-\_VNHZ-?^/XC M&@Y-1OP"C1S%38WBTI?$N("JYU._2&X!UNJ4UK.U8W8.)5:O.J"-4U^W(K5K M2)+#V!95\!5DQP#>'V,V[!CZ!$62.^,\N2RFCM*G$*\_=;XMF_%_QWM.07L> MDN/9IY^N3E ME%>V')S0H%\'-0S.C]2<5M1CAS<,*U:7TRSIS:P]C:&W#-\ MC4OD#Z67%QH>'I0,^.,[Y@@[S$'OIO N2Q#)/H^-.BLYE"KLWJ4?$ANCU=$=/O7 MYZ-)F5",?;X_RJ^H3_MM[4^7%&OD*%,\7 )R/)AS9OA5Q*G4$B\UT]Y_?C5* MNU.-V2*1O"[!@U@^CJS$>=&ZJ"9_LP0XN04<2I9<[$H:KL10Z/C+Z["Q,H & MLHE_=O!8HZG<0U>/.E85DFY6C^+\NY1/M908DQ*]D^1(#J;!E#:30DR"@G_9 MX/Y;1/&/I;/^!_0LBGPY$%S@=14( 3E];75#HT^\_7S^>&1AA!P@Z?M:!F9" MD/% 9? M_"9X6EUU,J?6LWIM1_BX75R30V>0)L/O\+F@JG95!Q\/DIF4;+,/9(=D3:?D M>3*#3UH B>K5Z ^I]5%ZS;_&_=N.P[I(^4&8/QJG[:%\*4*V!G1?.S;%.S/Q M&EV,YR+:N4'K)B9\-Z][V56>J./,3CG$6BT>U6:MK<4&%7)'B''ZK!MPK,]8 M-)'I:3R&S0J8,;5F?7X3@$DGI=[QPEG5X/R!JU_@>A7Q'BWG5.(M0+9-)3P6 MLTHAHJMU%$IW(E3AC03W9''.^%)5,!?F06H&"5\O%8S>S-(,[HOJS= "D!&% MR,LW/(9T]%?X$I,?#U/BEKRKND[V3"T^B8)+YV$\+7/:3!$?0S;B+6B4J\\? M9LNYD+4$%GH:73//;DR)J^T;"3-8;7Y^0X OD?&Q84OO(_Q MF?VSG>S9^N)2YT\]Y-YO?^4UZOZF1L!C6B9=ET4/M7Y-;Q/FKUD,L03]GHE1 MZ'4$'@AL% WN_JJE$PZ=*KE9%1T J6H7_I$U;]ZQ?MCZ7;#0V-E8A2V5_([TZ[G)X M5C'"6K#HDZY=^$0EYB4#_R[1=#?@;?G)H:C-I*ER5[@U5R^/L)'$C@F:J!$,BS;Z!0F\QF(Y%D ME)W .UAIM5I?5C4=X&TEA9JZ;J$;!<\VPUBK M#%]&D^0Y*JNI_;H;2IY,6Q7M+6"H<.WX"BYYA>,V8G6UDIMC^JV#>?/7:2WY MZ"_=WTKWHU\R5%>D23 B:ZVRA/F-\TMTZ3Y&Q8/6^+]L"C+.J1_4%!B_-?13 M1+&L?VT BFK/,EX+1%F<&O]0P\X:ZBQ 3,]!(\/Z.YD="&T4)^4N;+'?GE1P MAJ'JU'M;OJ,"#N63-AWP=[V]%ZR]PQ+LR_59DJC>9;77)JF4(C?[1%:R+D2R M];CYVHONMR4NTU-4FEYH1 M\PK,WO)D0DQQO[=TVV$;RYZFI_V\UNX>'IS%G-'X2_T_^VT!<8X8WFY"$.KT M#3J]3C]:\1?@_B_.%+I,?NI/CTG12P9#0H'>K_^(:RY*S0N?I!60LM3)LV!6M&VHN77GEG.ZI.M"K$$=2 MT)"3O//&5]!4K_KB3^&KTPE7W3!8K4_U9HPY[/%;C23-F7D.\RP3:^I_^:>6"2L83>L9P-&Y M1:)V1HL&G,,,0KB%H K3O QAW6\N'H0+E)>$LMS3J-IHF'L\.FJ"SUBF"]0$2F4V%UW$:&[D!TC/$?<9"&<<%II;+,^+]RUP6[YB,E9/ MS!ONKVU:6.9I*S.7AMN2MP=+B#NB&GW]S6':4:C,7<0O*\VFL=6N@-3]X/)] M4[A\T"Z@'^ E&7/\JYX.)MM]5=G@]2 D:,_C)794V *Y(]WGP<#+N9+C([;! M6&Y.-^YHNL?''"RQ/V$>4,9(JWF>UJ]FSX*6] IM6IF3*Q4'1?.+!E$1Z5XA[>QTWQC,7!H!H]0X2# M*1(!;BSS>E'(KHV[-7TX3DJZDX^X6,8[:B766X!5;-"\/^.<8"4R2 -!FS>7 MGM&_F/=LG8$V4A24,6OG_<5Q,K1V)H.?7=BJ\0EK7NNXXU_)&OTE14=**<<8<;'0%HRS45W5[>=9;(MKW/ ,^OOW/(G+^6&1,4X]Q\:ML- MBV^?.(+1JQ\_=TA_H9#/#:K2G(^\,EN_[(^A&R1@*DLP*RO=/F1\'R'^QA(9 MUJ2YM]*I N[GB'^3V'-(G5!M[BK$IB"#9Z:ODTL9]:-X./]HG[VWD]S7DYD3;3-H2]%)_7>.5[W62:!Z<:NRD\:33@-_,5FW@$2_W>FVHNNLD'AYV M$\A$ODQ@]OI.;3F/ZY2TK"E%J[G>@3=@BHU,V+A?#3]LS,_U#-(E&RN^Z?@@ M$+G#\Y$WQ9G'\>%#!6-:@7;>]0HC-21DT\[]9&YTVDV_/&4<]$K]JUDP.RKG MB%PBQ[+!HUX#ZX'9>HRJA(BMR$U_#GJH;3*O/M:,/O,$ZT&JO0>N:$)D-[PR M=3,[9)87Z:((;Y=@F4S<4/K$E0O-;TQD=!\?)E4K(/0RGJN8E*+6[;#8<"!$ M, M-'[VO'PXOT=8AO-9NALKWLG(]4X+N,5\&)699NR$6A#TDJ/T+S1$D]3O5+HJ ME6K*M<87N?NRC)<2 ;A;5WJ0+$Z$Q4[DN:QX]ZM%><7/2[3XWM=)2W-R3[C* M3EZ5:4I[A46)&?EL="B..;YQGTQ\UH053 N&7L\^)=:K(2\N8X#8-?VARU_] M9T>44#=%2VY]3$4W&]T"=H/+19;^?2I5JU&4M%N.6/O?UDYB_*+#/1]3-X5# M^J@R/US9MNA)NVHSF-.';ZTK2(F'N-P"'O ;/679>(-7 J&I57=@)%!EOE<0 M_5!8G/>S).6!&&:.OJ=/KS]S8Q1-^LI7NXH>FZCK)G.GTRT&A*9%LOD)B#G].0=;T^TA+/W7XB*F!$;YNJZ97=PI;N)]A ,-6@/^YLU7@" MR6P#4W_#\0+,X@'SLWPVETGY1Y ^N,CLS'<2JW'Q<^"(S+%T>#&]'" ', M3P]EC,>&JQ=EH?1A*JVM4[[J=O=A%95Q9@_CE18!W&[ MV!D7LU[/)K.^U+(UY:IW\]F;YQ_,2 QB,2G(IP%CA@BM.4VUQE!MD(1 !E1Q MT6M/)7M;3:]5R/&6/S-0T;><,<;K7Z!X-6T.S=;C0KR+@B2ZP >"L*RBI-X+ M[$"AUQJ\# F72@.O,D[/\\0F$]%=52_=K4[9V@ILR:YPRW#S"Y8Z&J!/6QAE MK^@T?(*Z2]_JZ6[1&:/XD:EFFV/*%=!)]0/GD.HISG*HX/9JHED5=7 M)37GY# M-#LGOW^%O0%>F6C/U)?*8_$N2*S-^P;+!;=/U@2R#X4[-+9J!KM"EC&1RF?L\S?.CF5Z;Z!3 M*Q0<;N2P3=6,GXISQZ^7[R?LY.,-AV%!]6;X6OB&)QP,#G^:7%P^DC!(@GK3 M]M%*K\U5R.?9?EDK>9@Y\E93SM[\;XJCNG6ZWU0G_MT[Q\J@DF_!Z(9^H@GKIO#, M86>UAMJ-A"[^+[^.]5L OO4*R^3[&3Z?D"S8^\52VOW>&MID,)#.5Q09 MY+SV*GKCQ]HFK<,W4A1A/V9US"EADS:X+#NQ[,J#\ MVO02#*,*4+'A(]LCK'G5K/]]FUK-V72>%]Q/%[]QBJ>8J.FLN>%CHE2/=R6) M!HV"F82=^]*4Y$RB-JO"\3UM2&NK%R6*-D/VJX/^<@M=59BIZ=(^6:*)Z8]3 MR//1MHPDM-^+) CG6"_$B4&%(]I@>5R%")KTINI#,OF4H;W7#)OPW8MF-WOY MG[SM_R4%\1=(]Z,<:4[QB^_&C6Z>G@.]%]5RY*4>[U.4:9H M7>^W3%P#>:*"79XPE)L W7HI_HCOZG?2.DM_6CNW&VG4QN-T55+91F&J)*O! MYEN &=1]7S3H[(?6H-@+#JY:^36>UHQ0K&;^S9E"-N@DV>*\R*& M"9 G71$WO$ :R0@W!80>BE'5]18 UI?JW_+WAAW.CN,_;K16OS^IM0N?1H, MK*LHK4/[KSOZ? M_\-G;/T_04$,8;@X+-X71:U9XN$N] 2+,3VQW6B[V3-H:V=J V,1Q_*R!U"3JLN3*T4QCIM1E5=0^9R9VW MS)0Q'WMRMXCB)!)7N)8M1BFX ('65R&59>!N/_"/I$6UP,T$/)RG7B2[U\+6 M->T6KOIWGIWQG\;1_QE5KVYR&OP47B-5G;SR@4M[ES+[)$2P'Y/-#UJHO@1% MGNV? &%Z:,4QR(V_]"T@5P.K0B_#]^&,PWE)F1@$9> L(@J![FB4?&Z\8H <,@V%.%AG2KFVIQ=JO<$'' MB5",O1-?,_A]P[0:$.&B5Q3+%_/'SX,%P1EDH[> P;*<.5_-?,^/L^,[QITJ MBMSVB5./*0R2MQV5HXN%[K_86L-QMAWA ^(A;P%Z2#F+W+TKT.>'47Z%>0JM MMIG7IJ_"A&0$3YNS_.UMFOJZGJJ#4?1(G_4J B6:K03;65(]5:(:/2"7SK-7 M@$T'BK4)K'SK+E)?['+;L7SK%<:Z]-]*5!(6"M^'%Y]C4,7)6,,4^M7O'W32 MBY F;; ;92HP_[ZYOD Q@P$6^=N.@KD]AO14B+ER69# MTW( -EOJIR9XG.;!H/":="7+(59$0QN;[C>)R M .XPZ ?BRE"MZ;()FGP/KM_"DQ6VLRI=9T\'B?[!E,4GW2P\Y4QL(??'!F'$!))EEQD=907DGA/O!H* M7UQ%?41&@$KI1\L,5V3O/Y1."5VT7JR;P'_HM"MNA=D%'XQN%]]D)VN#CY<] MS"4V?WS?/"Q.7) !,)KM**)'!'^W\Q89EGU%Y2#YM;1ZL=OL6I?\3(Z E39*/<#WX\MT]B<2R*SQ0@>O^UWX(0CD;A" M@(=W]@ H#"9?>65Q"XBH2-FC,RMW&J;/=WW6^D)#P3>+O51D)86/M_QN06X$ M^NAE"EJ\GS]R@LA<;#5;:3X.3I<([WK@*L1985=0WUYCP-4[4*#*@+?B #$6 M4! /%1I@'^+L:?K5M6'TH"5>/YN OS%>Z;=YU'AX#F/&?<[VI"QA/HR#.,3J M>H]R339^C>7U-]?K%#ST'L$:F@2ZM\(UR6_GO2E7TW'*3V7K>6319)7Y*%+J M235'#D$HQ8"C&NY3KY_@?$_(8'IV**<;\ D,^7%4%IK;E7C._VB'BP&+H*>8 MIW3)[Y<9YG0:FIX;10\D\678#$>K&*7A1I144WLYF_<-S@LH28RP8DY\1# G M847:H8295OAMH]Q;8^?E^[X&/JMY)Q 8K\#XL8%]M)/R!4*P#X_<!!Z4\IP2P"P+G.'U%\\>*@8)#04^"RJ.]62_YO;TV&IL2 M?<+T-V)4VFJ^:P@SS@5X;O;7>H(-. DL:@*2FZ(OS\V.0-)ZCTYYS']%CX%, MVQ&T54PWUQ;?@J4OS4Q'V'DBVT_V($_Z2L/WA@EH$9H#SSQ>K-;XZ&RI M'*M:4^-JGNR41W4_XN;]Q%6%P"SFS%-Z'_7BVFVR2*?[! J!6LW:VR^VY$4< M&'Y[9^=6/6QN3C_:4(E*HS0H^#!^Y*R?M06]*BIQ*]_7!@*'S+,^CM+V3N!) ML17Z\%F5:IZ*[2=3+TSLB82%E-,9ILAH;+1A5I7FX MHC@414ZGQ9UN ;,5W"2V!)[@/DK_Y'S6*/6&14N+MNBMD"6? $=)#-FIHCBH MQ$ 7O0,&TJ97\R/45R:D_A8@(JIHMO1VC+<:<.^1$,7P+>" ,MF7!;SLJ]\\ MR2 ?I18R6F^SU3CQK?&SLY>8'WMQ![RRC2[<5]*LR'K+REL,WO)EC)RG<6U* M6<_=S\>RJL+%7Y"R*U2"0:"-\)'OG@IL2+DZ_K[..REAS R7V';=5]\R,K,. M9!5(R/<;+9XJ#\I#VTF8FPKV*HI4[+PY5YX[3I5'ZCW;;J6^TO$S4ZR!7X:] M:^P,'JY<^?#Q03AI@OM]RP??EJCQU![ONMY8QX6-MY3-&QCL-=:EUM74AXT: MC9:_XS7/"!G\/?#" ?4";"/Q+$D5RH^]@Z"9J6FU5@+6I0FDS#\4?(=Q,.%/ MHFPG*AZ\Z>;JU4^L:6(I]-?ZM_]+10[_ R05=XH1'!Z2T([^/B,Q0N:5_J^0I./NI]Q1 M7;NZLUUP$^Y; -%;CC,:H&9[^K3Z5)5]Y3M&%1S2HV,*+"SGP 0(]>2/MI T MF8ZX-4B__&3E!_A.N+WD!O %MJT3 VBPC6Z=Y1I<@HS%N]8XI'F ML[0=9$NVD BFE5/R *_H>TG:UVITS8-E,M M\IN6\TS]?D09G\+MLW?51<*&G,8-- MVED-_1')PJ/I. -E41X1-7)OPW2FCYCU*XX/+1(Z]QE'^M" Z5QHN3WSR;N. MIA13_]?)*DYS ;;Q?75RLIS+]40*Q)<$"HQACV+7R"2^GY?HS,RQ=HU&Q=&YI_#2'(V"+?GRF])50E=:XZS2:/ 8)+%"4P: %%Z1/(/(LC"C\Z9<4K8/S":7>([ MYI]L72?I,&XS+=@P3D4=V>YVLD7#K+W=CL)NRES /U2#*GKE1PP"GTAA>8S% MJ?6TVA[(-S?-N,Y"Z1N^X#5Z!FG$\JR]8K%K!3A+G4$68+\Q?#H#O\&7MM320W(&"$4TJ*!8C T],JRL+)SK-I5@]!\2Q#WHP%ZSX)XUHL M.VE3NTK%@HU JWUV@32?KLBG-PGUR%/&C\(?GWM2SSZUPSZY'M!J.+LCZO+X M?UI;SE_=(E$/E,1?5($F];26=^T*VJM^:T+5?KD%8$UVG7%7>"ZSB2LMQ_ M=&@RXYD8%;5M*>-Q]R<%?W<>Q?@R!D4&]KSNY;'R_M'T$C;,IFPX,P-D6[N^,X1 RO *G0';$>Q2URK*;)5MW.=D@_I&3Q"?#H=_C>5"L;*^;X M&I*_<$%^%J87X:M3M!>H^K;@"9X.W8MWXD&Z%RUKG PFDZ[B;%Y<.0T3 M1X='A_=Y/O?G:A67CY-7=^^TG%>F1P*Z$)>_+[S4E^K?3YI_N,F M"RWS./>)!2SV4^K H&.%2-1S,')@]4V8=LI/IFDW\@9RU3:V)$:?QM A8>#7 M+1PZ[Y6\ &%N$E^1J7:=YS=3R@U3 MFU:N2C,"<72ZP\/ M-#HSQIPD1.Q=4 $DDJ$HJB+D!U6[7Z8;[RML"/?)V!U'OBNQK.A@*(S^7],<^POFOK4(*"BQ LE?I9!]V9&/2H=AY*E>]$$ M6VH2)YW#(P5A*FN']XVIH_@#A!XS$?C,=RG[:[;WN39X]&6#O(IJ,=WT@J 8>L ME:-0^>9)RJ#CHV/3-#F "QH3/N(I^=U;/CC0P]"H],=;QZGLM$7$AX'6)^S9 M"' $4:\$3\K^>^O<[>Y]RU[MZGW1_C5\W6YJ@YNGR]]Z_W<;97 M1J&ME_8=CRYF:V^UM^51XLR9K_:%"!,2X*J3/E87 MEU%D-U6.<,$[RW$1RGQ243Z"J/S86T MU7O,Q5HI C4+O94;JR?L$F2GS'"[LNYB3L*3+8!M2V6QO].8VXPJ/VO'.;,J M&\.[>2VC4P)$GGD'"*$WNJOGY11/;*0(^3X]5Y6R^8>&\W\ID8[BW;9$739= MP@&L!8L M6:=7O=)T5Y2.K>C9[U_AO4*A.W_8:'_$N=$P8C_AA-/.B05#LVU^[@LS?)>7\J2P>%&."0__&(.#WFR:HJU@?A>W M#@R MV,Z0::YZ ,30D8.+2O3OH3(5[D@Q+6SN3.R96'N>%85Y!AY([6 ,_$-,Z MX[U$\]QJQ% \'8I:PR&9L=7SB\Y?\.A2 )5)VCWUC1UD4NE1=@<0Q$@+DMZ, M\T&P*A&$2,!'T_:DZL2W&=8)[]AE-)IKSM15FFGIT1[0JY@"3L=+>.0TDL:, MIR]&V.JH)#IDA/B/;C7+(Z6G]EM;&-'O0]GT8??;0)5KY_AV-1-3.I8GQ$8LXI/9N3ODA7GU&;.[7FYI)E7 M3;R3G9^)#!FYB9QT:@!'?O@KR<0_L1ZR%N;9%9O5UD6_"Z9G.UHDP,YIKQC;L%,_)J]7:J'T#L MW&6JX(:V1D5V*LVA*TLLKP2?O'N/>R@4V:]XVI1LOLH[8@\7N?RF0)P8<_WC M5[)0/]C@!M/LG#"JV":)\B)#)A/F?8ECFA3\$5P]$4'URJM+K>&3W!GNV@^!VNOE[AD4Y"LZA9 M[,3Z^!@4U$'/C8$$''@@ =5!I;--R]LIIB2+F^NDW8V.+AK"CC93K&ER"_?_ M9N2???C_\[I,_-R6ODB-/7C>;*2NE]R$XJ40.GI@S[&JQE1\[/)2J[4U:?S: MFE08TW1A!<4#6.PKJMR3]BX$]S2"V?K48)\XX>> _J%*O<5S$C6Y&7'-PQZ4 M%.R+;EBNIB_YFG0],(C3NR*>O(&3(_@4)Z!?\AFFY?'J.TE5RWG^+]6IF6== W^CA M V@2@]P#T:BOX;^BHXJ=QS>_IL1WBF2;3C61>$095H^Y'I/ /AM,'//>,2QT MHQ(+E(LZ&P@L&A#1AOOW(%YZ:W(^10+L82&K1L4.J[;YY!W<^QE'IR8I4KP_ M26ZV::-XTH5N_(#3IZ?.P-^[YH^ M6$;&!:ZS%EMJP8#F>1Y#Q&1]MF"L!NBSQSFV$+IXDI9K]_6S;*6S7@8<#<^O M^/VVCA279[SJ;U;770196C:>^;XN+?8C\K@!4GJ8&ZW&N>J_PCM[R14[VW)N MYX=.6^4388CC#S=T72DEU+>9RD[B$^%XJQXE_,+/')&Y\'2LD=.:FDM:RW*. M8)96+L-J4\KEO69<\&OTLH(;^TS;PEVWF^!TED&P,TF,@/H$;E*5$7_WZTT_ M /5)F,^;*1\N$5P*6,R\X[Y_C>DTTP(24&]H%&U)E;L>H6YDIJ5@4N=;85JR M9.9PNW,X7%942@73UVT\14LH]=#CM;TU*$K.TERA*#4P7/$#;=;<1>$]/EG9& G=GSV5-U2XB6TK-E MQ4M;OW!.1^D$JA8_- A^6U]NVXX7#G9*OG7OH8Y[YV$K>\H9#%8=AC MEW>F,S'L")*^?)N2+EU\*(_SS*8)9W(M%J3@79_U4E^W:*^55M2>O67!:1%; MT-@+U7,KVC?'",X,POG4V57F*H*AX]- >0LSV4;)D3&"'1N%?O<0%G01HZ)^ M)D-Y<$ET3!+V>DLZ>UZH=>4+0/5&F\_AY!*QOQIF[?[%-UV[/'&KRH$/1+<- M".SRE9!1V. >+J?.-\^4,@*6WM[=_2D]0()$"090F_54TYU/!7I M)+HB(BIOQ:B)9 S25;]*]2PWH9:T#)MQH'0O0[\^S-6%GXG_C.T.!YJ3?1>KCK3/,IX:U+5Q"C@**S8UWR M/L2H?."&S/*ZXH[,R;W-M^UVBZ-O7/QH8QWKY*:T6'Y4IT@$:W+G@NU(HR+5XUT^Z[1KXHL23D\CQ7WWY1]-"=(OS5 M!DO0A2C%)4-&6?G$!0378!$6UO':W+Z>#:P[)B748TWRT,_NO0@ -.7_%VMG[-QW":(&N^08FG_!9LNXN M=PIA*=J# N[JQD9*KBZ;6XD#D=VUC SU[[]>9P_=4,R$SCIEL#!E-$I^_+-9 MB,V&/W8;3&W_L7(95S;SFR7X[<]TR6.7KC:'TYT81["[HKD1.5$S'*(+A5\( M7AAE[D9>7-*IT8VR17/7"6(6Y=)$%?L\-U;R03M-N-P.TG_3F.!Z]/5ASGI_ MB]_QW:\KCYV'-]-H'*G3PKPY-U2E4@3:*7;_2 ?1K9X;GF?O^**SQ%HA&Q8K MM7F65KN#8[J4I!39%4>HK3P!KA(Q%AZSRG[:)20*Q<;M7E*3>6\SB:4O39,1 MQOR7*33X_H,^=^M( %XZGD>,=-"5KEXL80UZ@$CSFLS&(R_WCF5NF-TS,!?1?JGT4.-FU)\!+>X_=RW;[\4C_OS!E'$7TP7XF_X]E=Y4(6 M,&.P'])1'MQ<-;X6-C9( .F1V)4YN6+!45^F/#6P3\V46@,2&K+_(*I[UTMW M-N"G&0#HV$Y+,7E@" IID+',]T#,D4C,[5[&G^GO.D(?D)-@0N;L/<6_N_X( M$$QUY7.?V&B8+BYY6UOW;F/A36_]#L[;ELNU"MO:4PJ]N)#V>5M.//EN-;!B M/X&S/-T7R"[;!A9_KZ(,(5#5HBOM%^GV-NL08M>_-;3!;J3%"!PD8 M%P#^&DB[5VO/W:3VC(]S[A(V>P.^FZF=01O5T&A>]8YY0_(\X':CI/Y4 JZM M6_1NTM="R@&%\K[3(0!EQCUL^]7:#(WB4Y4"",3VEJ\Z-=\^R(.TN'2?U- MP'NND4CP3ATTY"(]F'45#-$5IIM*BFX(7ID3W6[KKC\>>-9N2PW'X.UXDY[+VN3@)5@W]? MAXK!542#?!/)R<*TO/:AFM_1(LA=['1'&$%U,3(]C 3@^LC=2Q%Z&)V.L6MJ MVML0] !(:#,>D(8U$P-6&8VQ@W]V MQ-#+IA=(0,\NYYVG+F273K-_6O4_%4@R@$]%),*8"OXA2LIM%:V>QAT&L[;S M*E()T;XK"L=^C>KT6&SWJPK:%9S1CP,)^)&KAP2TAC?#-2T,]NJ"MK+XR.MO M\X\#63$2+2QB62-R'85Z6KIS6+()OJK-/A [O%C*]J1?RG3E6QSXMLQ[1NS6 MTM)/!0(\U3>4N.QD5&"M/8S?XB'8QRP*T!#3_.E)U1U6*D7T2NY1QQ3TB5A1 MN20ON)8N(JP\746&9C)507?B(A%/R5BUOMF%1+HN-9M%[,$[1XV\C/[WOST. MU>:M.&R[MR:V32^\N?YK8A$&==VB$=?%;?O.4M7QQ4EQQ&%7*N31X==BK,Z& MSW1JG)HF3EB^R2O-^*UK2,#CF?UG8*U$+EX3)*#PR_O^ZVVJ3/1&SV\%/N7; MADH_6 O)JRC;Y>//^!K>Z6K*RR(DU)TQ[I%);>\IRUK>K:?)2W.OW MK6:G[HA@220@4 [2%@73 A)#=LR ,-X$..N.'M/-Q"UGC5CAGWY0%*U[=;GS MEE("(_OTH?S;: .ZNO#PXL"49S(O&O=F<[QUDO;XPMQ>F;T!]Q5'OA(D)3T. MBPGKR]96=U',VOS=1!S][V&[$V)M+F@1\2PN5,]\C\ARW@'T?L=AA'667D]7 MSU'@G+T2W6U!7%,SP=% \,?:WR8;]543M">/JC"B+A+P$A\/.<:VP-&I@S1* MW;X*T61X.B?P)M^?<"7-_PV0\K N*D2<21SW="D]GR>NFG-CT8LD.0 T'HP$ M? C;W.V)8@N++A0I:RL(C_'EDI>3TPWN7NQI'=7UQ.1FM@V$2:X]<86@S,_L M 1ER'U[3?2W:4('F5^B=6GCS ]YD>F8W:FV]=_"(//E*\,B:]M;)^.I-!35Y%# M$K?585%&I]BYCMDP^46[P[BA=<#3#OR @\6*PT$OHPASCM2,N3D#1;#H+_"+Z1D*G'N3IH=:7CN[DA^F*:Z(?&Z=6&QNX84 M&,1;!4,"C!!+I^".:/Y]6\B"9& KQ@2"D7$W;,LJHQZOO&SX7H@)6OZS M/+!^KX[GQ-/KSEV6+;-Q9%(0R17$?S#&"+S!\$,/-TW/2 *+_.!-JGBR$C^W M)LM!:Y4=$58GV*HF', <-TH7NO;9I:K67,F"_HF#2 I&%26M\QVBK[M4!6>B!8J[1UIF77= MR1!1"AEB2^W>)UY2LW@UWI]/E*G M.)?H00QGQN#%Y:/GK1N6QP(K/,,EK-M[!P@FV^8Y!$?,$N.B0VX4/6"W&38\ M+0IIL0TO-<4"Q:3G;VNE\P:$,97$/ON3'^5?YPW_D4,\>]79K7A*AZ"LBR6J M^\+].K9M(!,)L%"]+@@[O2E[ZRV>G#>_K%L;N3:G&<](W=;GA+.KJO;4T9', MS5U\-Z.\@:M$*Y^.F;8]]>S#1 ]RO]^):T/\*U)Y5_K M42P]H<16]0NE: M_\5U]PK.FHN%;?.YIZNRUL215U7*&SWEKS0>.BW]L0*Y[]Q%?<:C@ 08L",! MYQ):E/(S!_KW2JWXWQ<#%<"VCM["K9:H4#SH8B0=6_<)H?LM"X;Y8OYRYY.N M-_RP-,EKRLP='=Q=^1W,N7K;K"7#-D;9CV[7M(?X+R-%(S.=3? /A"[S(96' MQ1[C;+32U&=S^_C-&](MP!4AJBKEO;.M&P?^LS7]4*Z(LUK3*&6K"8Q@=I9A M<;LQ&^[( ,S.9V*16^3)"V!C4SD&J/-FI98"Y4>VQUQS)6/MHRF;,]YX4I:J M4O7^.T@ BN@;%U H_V6Y^#Q8%:LP8.8!XHS"721X%'%=6E"X*J*?6%3ZO*[* MF>)$MEQZO: \)? Z[-9; MYE4+PK=1DRS5U5FTP=OUW M/'"K#35+X+VI*(*O'[0F=)HTMC17@@1$5)4E^((+=7?4EZSU#NH"7O6+VK3J ME.?WEYQ.X,(+]6X[GKU>%9CZ(1+]'>?9A>F(KY.CKA])F?ETZ=%!Y77E(8M5 MG-;26ZA/XF8;Y'$W8:)UKK*/BBCO*S!W'P0:Z1PDFF7FS<50O?G9S9=/=%.M M6##_-=![40]:?&YS,UMXUQ/3CUJ+AR[-G+]X.-%'>VM8H*O!%8VNES[)2S<<4A7%H<2@J_)'.M'$25LY-HR/:J M$,CQUEPFGETPFIDI+F+GH3]7;I610H\]+R!R\%XEG^_W=-E/'N1?LTA[4JSN M_=R^H/_B6,(]8KI#J'.\9)7UEC/M\KBQ&>/K<4;3&-PXHSMO,;E?9Z"4L./# M$\!\7[7P^E3V^%%ZQ\OJ3-\UHO$8::!E%305OU_E/89E#$A/O^9"R;UCSG#@ MQFYJSLDSCPC4'%##U@YS'GD:UC:&@R/AVQ@>)IQ6*C84)Y[H[4RY,24"76]?>R)=ZN2\32"*VJZ1XA/ZE?9DU*ZN7E>R8P$,/#8M@1C",^RL M>J&)]ZUU\QOVM\)I! 48G997K5\/M8 I[U_ MUDFCN(-+=9W=.4_N-QQHLPQ?PE&@/PDY(4=(@'%HD6M8 MA=_4WNVAKT\M&'J='!_O_M*@?M#C5]=K#'*<^D'#C+ M^VTH25[A[UP-P9]J MG-XR)F2K,K38FYI7"#Q\.9?O21O:&NN)!)@*"5*V(%C.NTP*=",!I P-Y8B= MI3V>A13$:3_.V_GSXIWNQ(6AK*(H]GAFFKB,-/Y(*4$S5YK (RSN1F7;6/=G MGU7#6'=:6O2_+FGO+'OXH6J)+0?Q*@PDZW+PSN*8WNXT&[R$S]51Z''763Z1 MSIY.-%K2V:#^R#F$MS@?Y3NX:?YH:^GTU#^IR!-.*X:U[WK,OF'[3=\ M]\C!)?_"5S.-6RMX:Q.URHCP>C""!!!+#AN0:;XK(I5#I0C D;=1YMA18BCJ MXB[GTGZDJ_R8%I5,?E>7N+-Z<^31]#N#\DCQA>^NU.TZ7?;E5E8GOF1:L9E-F=R;C%2\=(LQW(63#&@+SDF4K?G_VID.+_6YB< M_XFJ..$C=>]2QXQOSLJ1@#'9PH2\J+;(D8PPE@]_-O*YP;AT/F5.5YX0%1+9 M+$X^U%I)7WF'XG] CHY -UHVIH2_/$6'TQKC5A9.@W_*<.>39 M: O$G%WA519?F*;O&R$!IS@JPNX?+AC50^)0,8X;@H _^'X->ND([FPXOC/* MOP<5AMM,?P6/]GNT(Z2M(?M!S8A/\NW%PR20GD'.N_=0)&#TB8XKJVG9[W0Q MUS]&*IJ?%3 *+\TKH#&&@1P:[P,GHUZ)#1,\, H;XR?BAYP]:](U@/1CL,DZ M[YC=9N[5([XVSU-;K,M5A@U3,@ ;DF>.@2ZWW_6T#U =K::5G@X[EP\M!FOI MQ\^0>!7<;5,?!:K9C[$AUA3RY45ZO_V ^R^U+S/Y%HKKFJ5IQ5A:TYG&NPO1 MW2:9$_F^JG68VJWWJD!#%63ROY#K3> E9$I; M!>9PE_:>;IS#B,VK,/TE]> W/\*S.V^!@^6"2BJFR[#R2IN"-?]+VN6Q'V.\"F!* M^C,RW9Q4J)+H<9,<3BTB+E-*FZ(#+_#%*79T6,5=HXOQ5==*FEH6U A^5;1].]"]_+V$=$V_HXB/ MK[AD?I9S,I9_GF%'#MA[->K3W+AR+5ABR1R-B<&T M6O%$=;43)WM.1VD'5I7MKI+7UJD@SD)DF\,OK7;4%!5Z!BH[R-5(.T[/%.55X$4RG37> MC-&K1HM*!SZ9"6R9M4=NO/FT':MK%M*4I,J/\]X?: LX#\BVMF8T2NS,V]"2 M57TE;CX?G;9+OYI;C5I/ZJ@[L4AVCA]WV*B$7&^ZU8\#C_-ZX-JG^=89)8F= MJOID(4&N$?P\;-41;"@(_?EH%C]ZYZANPBBUE_>.\\-_*,U&]%JT66@BI:RY MN2!-Y$>RQ53BSF=5@W4%MESYUJNJ_A[?G5_@'/OW<_IEUA0]=5%KX,[Z62_S MXN5_#&!0YG9TE["6TXU6-7S46><1.:6P3Z.4WAP(!@L03_3^''-<_TI2@9@W0MJ06J]\ MXCL2H&LMK)@Y48@2-=:T4E4;=C9$GNR&0]!#)TW92HK6A%]:ZH=KLSQ/C>%B MK>OO\>*6!WN]GUX: L!9-Q#LV7_V?+-7?%U0. !4:R%,\6O&:N- M^1K-J%F1@/66Z+YSRIT M<,GX>LT2]R-RN M1/MX77W'\).*7TXNT8WF]\'!B81RR##KZS+T*1G2GO.GKR^RW_-\8&MAZA4% MB$Q]&F4,V9K8_*QL?+2 OT6%!.RUL/?LR*(L!4]M1[A9CTKE,BK./Z2XV9)0 M6+FQI)I,GBXF\\^^3.4>?S$V>DQWR#<[ESGR:>*"ZJ#E1H/8*WOSC,V=IRP4 M6XW@ :WDP><@Z@\%7U7-[E&1^M])Z_DQBG62;TC;HG-G]QOH-)^(P@\'"F+' MZ[+75,\2,7T1IQOG\S,6&4Z;VF3:HEUA%V)>6)P=QFB@,/MS5BP,C6"X_CSY M8Y]/Q\_6!95AY+7;7T4O",?F=\DHTR,K.1]28^^ZZ[DB8NC3K@]_.0V9NG$_ M\?*/.QR'V@Q.R8'OGI^EX1CFMK&#;CG72D*??\E0XH+:08B_9;\"GKRH,FV] MD4[_ 7.#D,'2ID0*S=C1$MYR!^OWWA"9>&5<75%EHL>.N_)7G-+G%/05C"QF M]^I\I4$5M ,(HD0&9NM?C7^JGK@-#GLER<3R&M4,=RF^@2>+*:>?[;W$V,!> M]/>%@6X CEZ/,:&UG>;G@2_U8/T0_WANR!(M=81:>'8Y=ZJ-RV(N7402*_^] M I6-VYM":STQRW]$$S$E]JHXICW(&.\@<]WOB5;LIY,UL]J(B*Z.A-%&@V*T M&H,.=YV=G%DO:Z/S2[+S!Y^-ORD%8QXE/!%\W'')NO?(M!VK)"%_T6!AECS4 MXE449FG0R@8%;OBI89L-46DN!A(@I#63@P1PU3SP]8Q8TZF M%2*H+[,9]E'U_"H%Q^6"&G7NQ3.'.O4Y]V4V%_]M0V(3AKR2.WXW3/ M*\66XEET&<$& /O5H-0E#JXZ%-I3=G'*H:C%,'[%7XIFRP MFF>5FP]C/U(JJ1D3[[*3?&ELZY#VZ:K^PD15VRT_JIX\2Z: +\TQEF3,XQ26 MXZK/Y4CQPD1/1W'7_XN**2,P0LG6'>M '%QOK[@NV,TG6DS&\L6^-_9>IS__ MV2*8("'JIQIPRZ(/37(SOO\O4Z';9^B@0LBT+DATOEGX[*KL?6 M_PYQ8OX>H(HS9P-E]%?P)FVC=#71VPI MWL SK>$:4^S+_JL)[%DVMFDC2Z7QRX'A^7"W"=ZI34.>J(Q*/DH,C;'WKAC, M;R7'%.VE;P1[@/Y%-Y*_#0W>O,&@I3-E9U$$P>A+,]=[?^PUVU05:%R1H#'^ M0J?TK>'5E-7+Q\>\IK?-2\:K^^,Y6$K6[F)!&^Y:3I4\'?/1TWG [2K!WL[% MIZIJ6N8VK$Z(,2RC,25MN=!W\5QUE[WH-\TWMB1(0)K9!74;Z ?:S_V1CU\G M1[N9:NI?_K?^.Q3.1ON_J7G_TZ4]"JGPR]SV,-8:CV('NS']EW_EVH M4!XV_E/1\MJV+!O=;S< X4FX-;],?*S:5X@[EV1Z_O6,WV/KF'T!!XQ6^WYK M>S@)..'=SW/3JW0$JERV^P@Z$F#&_G.Q8+'3>O\IXM+A=H6"^=*I,E.EO!() M^.(:4!]U[> =JNPK86J"/AIH.E7!E+'8DG9TLW?SZBJVEX>I[=@NB.J#&U7; M]W^2^/E;.F8/@5Y'C=U$V;\>8%%?-U&"%5&J2#*D%'N]ER#LI(BYU53]1OT@C; P19:+;,&5M$5[^+/H:=S1K>K/\ M9"O=3NEB.#ZY^#!$0_?I$2D*P/*DI=/YYJI#3-U@! DHRZ@8=XEXV;LE9YT] M[\G,BFD"I4L+;,[]7H0$P.1+8UN;3R+T.QTJ=<1L/K$)S9.E6J7*"6&KT/+VR 7>^H\PS:"97 MY)OK_I#P.E^WC\+)8E2PJ.$EF'9 G[S0JF0U3$+A38GX+F-L ([1I'Y[FF#3 MR5&L:_9G2A'U\2-SW:1IU0]]GVE(%@"T*:9G1G6_-@QDK-!HE\+_O Z[(XEP4DVTU40R, MPWE.?OT$1(@3K%QJ/@7&N51MR.DID1>'4Q.;[,:7]3DZT!\P.^ZH0&EN+0E+ MW0GP=)0(^TJ_F#YOI0!W\T+C?QK-]CNXD\23$F-_M'Q1#EPE^_5=WSM""V'+ M!NFNKR$/N=(MJXFRF\Q)4;.?$F(D[=<(J5ZC8^(6&_=[[7:5ES-E^1^+D8"27X>,Q M\+1F\)T ;;L]>)3X@40,#JCM\R +^7R/O9DGX6JD;-?82\EPBJG((OW&2)V5 M/6F*ANE)Z^S4XE*(V!!+ET+US]'MZ16,#)8"-IO9=B0 ,P9[#V2_N%]P*IWA M['%;/JWIF?DW[_$*(!4+8 V"%N?)%"NG)+CW1,G,A86G/>4)2X.QAU+4N"6;1^MHVEBAY]"#NLV5@E)?? M%+OMM!,57B5=BMVU_;22826<>LG))L*Q*$+/1'*/R#WR^X5.VX? L^W3XL_4 M,-F-D]0Z/,*!9>2BU^U"3^2/?E\ M'^L57M,JQ#WL#3_9>PS\Q#?33?:F_IV4U+EJV%#UR$$Q)]B\6COJH/H0TTK\ M:(HF)6V;=JIRGRQ&S8L2IL>=393;#$=M?G5ONFE__JG@18PI1Q%A@ >\TD@? M^R!:L 7BW]/%H5],!JJKCDIYA3S^9Y7T_UCQ&+6'%1OR/>3'3*("$R[ ",VZ M<5Y?&2!X7(T9!UY=(:[@*[^2#P]2D%((,U7*3*\_X8=71^=U K,$)'LA.4X: MB'>UAY*R$[R)#VWXG?5CKQ1^/%V6'$$0[O#Q:CNWDLM0A/0[-))C]2QKBI*% MH(\TV6_'JQI]=LVT2HI4Z@R9I0.>37560]9#6*_!10JE#X?\P"]N,%KGF'%B M&<EAO.WP;"^"_B(\_7;CQ!L_W3?7:+?"4R^H:&K,35>EQ+?+*\Q01+5F[#AF M;["MIQ;U95]=6D%[#6T RP\!8A?%C*RB/LV_2X_GVM2Y5DTF3O&^F0=_X0 [ MQUWJ#'N7SOT0!CCAA."QN8M65;C[[ MA3I*[?BS&=%KY&R8WB8250[7&'3F CZLFK&SCG 1T5Q:G3A,FSS M)":6-=T0O?7YEKDM1PJW MIWB,!!B<( $W3_BTC+%MOV .9BY_O[#51KG66CCU5;PV-N4/B]&W7D$"C#&C M[V'#1XAP9-X_ZY/]GZ<'_%Z-&49(@ 4L$-0T)#[H2C%[/G>_,_E,*7+_JX 8 M#;R7CF/Q^;O$0/"H7Y] E/=5%C['>3@_?= ]Q5JRH/85X\(G;"HU6L- MYJVGU:(T_+_Y!92VKQQZ.<:-ST+VLSZE9^*J;1+64[/Z8LJSYH>L'I72W&U4 M?[D5_7@/MF@F87[D0M2[PAD_D("<]T34A4\3M##RC89 /]I'C6)M3^9!;G-7 MQ+%0X\4XT!:6^/RK$SL>V0!2/DZZ@I[1H4[";Q_R&YZ1SIP\O-T(UQ!]@VL3 MGKA&Q5!1VWAJ4*;;2G=\Z>VDQ MQJ.;4$O3>6G7[XWND$TV;A#=B!7]M(:B+5E1+F\!#N5>:Z$&1M0RTF+L&PPL M89^D=AL2*3C<7#0Z(@&9 E.GV9K%GUV?4Y)N;FL&S[-FZW0Z[/+.)!D/1'R_ M(53QW?MXA6^H.&ZH1#<&7?(DJ:#.Y]OC\1$\&6@^/78OU+L72=/T:]0"?!_6 M2@?8K]-[: LM)(I" EY9YAYL-/535P;N>0X2+BB=%&JI)ANJR]6=8XAT0 M,!7P^/">&DBRYK"W'%[:YEDPGD@S9._6RN66]8WJ7?GAGQ(&'#6.N H2WX[I MR6;^HB6,^7\K@WN/6PEB06]#_YBK^>?ROX\$?(PA]NF>]4_/CH#D3\H M#(.)U_OA64D*W8VGB6UZ'=JVY9\VJV?;$6@("%17JQXWU 8O0AI9@ZB++:"A MYVLXLU*3VW=>(O&AT1GU=3]8PE$(JF2 #5%^JQ M#%_G#ATTSL<#OFD(0L2;\N7"(EW;+FJ0N/(["# MBW?$HTL+UG1QYE:A@P>B=U(416IUV@M+&14HAI+6B7JK_%A!]" ML*NPBJ;[1A>O66U-=L8,BM>AJ:2D.V@:V.G^P:A$; Z5LO07&1:GYB;@ MOC>C SRA1*>-O6.U;XA9[[HY]Z.&:8H*6#!.YU9'J2Z2E:7JT>@?HX2G.;WT MW#>4"7]W*K+'[#GLE&Z]H1W\MVIA ;?3N&JTWN"S)*44&W-.C^ #=' M IXT1?GZL/FU7RI)V+*GN2)]N!'@K9Q;H6!-9'&LU59=58Q(,.G-W?8C](,"%0C=9<'V[[I?KN;;\X<8X MC-UA:1A4IT.7KG"F&MC37?I->K5RP[&UY+@C"5%U4K&ZE5EH.W<,IYL^9)$R MW9[KM/FQ_"&WOX7&J>.B130,<&[#VE[53.J1V4;V^)2N&=>%&E<4,\KS1SOF MXZ+P%N[V%]5GVF+*SN'K52[IN**.>3-[?H3C+JEZR^U3]T+S[6S?_?V31S4: MF'DH/O[)@M=Y*.,V3=_==J%T;J'-<68PY>D.(C<>J34EFVD#\G:]94G[YYZT MM+!)/X/ D5)4K9)L)("FOO1F;;DO:0%D.@ &6S:F2-KB*SS_W=@[:$@G9<%5%0;"7AY?'-)N,,_$2.$ MI\5=>#X^HN@^:E&_6R*WNUZQ^200/E,ELB=7U M)A+Z=@&+-E+C:671:X,NUG/7F,\EG MZ.SC*(180^E.4\#9I#=&=JK--XJM;:'TB)U>4I2Q;*4+UC@7H3KFL:Z3OM&^ M;$IL4I"*==7?+C;Z+Y%H(B>##B9FFPZ.CKG*#F2%/5IWV@L["!)S&:,C#XD< M+*^]DD9\U*S3D(ENDRXZ6'BD&F-CH,XLEXF-@[%7I[0]5XE1#WYCDBGA)QWW M>).,_[8ELB7)$"C!W\1"P2Y-!*01GL52P6L:8B"$3WBD3R],;3ELJYS+8JPWNP[9M\_!N>3BQ.B M8_1%'NI)!%D2,[&S877.?[NN#KO\O/S4 Z3>6S.JURLZS7%^,D5->S%A8O6)^CCG!#3![MJ''[D3IX9CX5E%.+X,%SK52@L& M'83:KZ)&\;?&;SKN^93+1Y6P)IJ;.45FZRH_C0[ DAKGQ0MCROE3J-*0LSUG M]I3V-?#\E@0^Q)I4$K6Z=P2+^'YK_ ;",*B((.*KO;PWFD9/QO[5G)KGR@'H@!X.JK+E[L&NB8I00*6J7NTS+U48*K=[#/JZVE6D$GY7<0^KF)&7LS8 M7L+^E4,)^EV5P^F/"]9$:0:K+22@I.P>47-I6F6;B91US O='27G]*5=O23V@R?P\!C_4U$4\/$L[7\;5\7&'>E_Z M42TARUY=P'ECS0VI',%=43W&;&:O5:E.#,*Z>;J(^Q[L*K@X;+'@L5-0"\B/ MTPT7?[6!\#U,K_(-.H /LV%4M\06=^:SX@E']W#EN7TIS#78:X]+DB]4SB0EOHBS^S$(FQYKPH#A@0L M^5/?8^'['4@=S+:K&B:>T,=R'E6-X615FT/.B6QBJ(/J4I>PXNZRPKQX0UE0 M8%^[]V6J0MY?.HF6_B=8[K7<01W41)/>$>'NP)!V>PB.?F=;%3'4@\?MYYM) M_N6J1!@2[/]<&#/X&1_A=6.@2A"OV^(BID(25AG'WF3E'>UJWV.&0; MB 472K]!TX^"!U>-3 =RAJ:RFF2$L4C_N_DQ/IOKE6=P]\+ +GL,/Q/J?1W" M2;A22"\L*._4GR:B>YUL^V+0*>Y8?0ICY&S[]&5&F(9T=$!&O.G(@UBM5U^U M/NJAE8ECZAFNH\"-)$U_=;&<&SV9S@;AVO)G<:2)G1//5;)QD1P+R'795]EI=66?[R]I4C>)P MVA>?"\7;]N+]4>L59@*1 MHU>P&^.Y&E"O&:?=SO\R0MOZB!8ZO*<#83FRRG/-T:X([9,\^25G?'%%'$-] M::A!#7=! H0;<0+.2>IF$D%%,)S%%T 9%*'#M ;-;*F8QGC%1@<%YCFFHRKT7XJ M,INE-EQ(Q2<[]OT$)R[,O+WMK"_!K<%H(BF0ZCO]W9;+(@P1N>/C%U65X?V\ MQ54$[L#M1K+P7<9IUW02PV3")!%R &9,EEF1:I=P0TBAZ7+SZT$>T.0[,,CW MP]EY*C8IQZKV2C\3N9K,A<677,I@P)&R186O@Z7UW>I$JUN!U?>[=J5$D.8Y;;=U]&'GR,N7H("R) MJ.2&HRCAM4_/-Y+MS\!]4X>&Y@3)F0^VY0U0609UU#1P0P]]P&NX8UK(_DQD M!ZZ1IR'D8REBV6H.\_!V1+$:$W3JZO%[.I09I!(X5^K5 +[M_(5H:*9-+#%_ MMTF@JOOM;[<-2CGRHK]4HK.\"Z:]U@R9+-V,,N^<2'ARUSO\K3G63%.8Q8"6 M?51>R8ZN^L:U!V@SZI)8,7$70''I:P%K9L!H M)Z#\2$:%"W-3$$NLH2+I/5Y6LSM0TIN-4H*J]F2>< 7>3)+Z$5MSQH+7,/*& MS=-:[R6_*1ZT:VA.B(.%'<0R+BCG1[!X!N8[9#&6BAV*B-HFI2Y635B%A$[? MO2%RIYUBA3DC 3[QZ.>EAWB>6?6\"=K]>\58.YJYI1&K!;1$#Y4 M+;[.U,'DPWIH/-IYW-/TJ<9!W>CRC_D7Z(1@/E]IOKF$J^>0^JUJ(-N$*&\= M=]//NLSM.M9E>@][X/I1NW+M55H;* M*!\BD<&NY;_&JUTZN )YHNPY?GR(!.S/P0# XTJ';0T+F.7JM=PM?W&^7F2; M@M5V]QHI"Z7P9X^O!:\O1.O"SH6:" +3RSPB!R*7;:#QP#M4,97D58N&Q%OV MKD3WWVKT<#:3DD2),2(/3 GQ!%XYQ67C@1(Q>H2)V&7 MYEK>2LHW574;B\^.4W_+WY(B^,U4]?U\4OV=.WY1PSC/:8-*)P]70K<]L^*;6W MOS]6DE(J&6_I&G\] P<6-.F#]R#!P:<"#-7,DDFLWL!&VK*(CNC"4FE ^'CA MP\L]7_Y?L@V_] _4_&T=28$L\2CW@KILX,>G]DNW/H#26R>T7W^V=+8X@W&# MH]FS!PGP6$<\M-JT<^IL(U;3]]-JO!/V2J[KG*R*C^/K/+>0I6TU5XWQ1+F9 M[%0)(Y0FP 2(:#.N@?EU?)Z+%N<9*KS4X$[P*4KGW@#OB)6%U>V3,V3-HJ M9=5UZA-*3VONI-XVMQ_C9 4K\2^!&>ZWSX85&2N.;[TA0TE3'Y@OJL7_T36_K',O^;']FC M%Z%V2,"HC[0]N,0L=L,[VYAI&Z8E=0WZ*>A@8Q^+-56U>C&Q-<'QO*Y6*P;( M(I'_N'>NWHO",65;="H^Q,.U%&O.8.E-N/V+NS7"OK(=CW/!']>1\?0:UGK3 MVD9)D"3>G3QV,-Z@3PW&8T@PMQ/^C!>.0U]NT="'OW?]W0CZZNQ,N/6)0^@A M7*QHGXC,MWA,F3>9O\:5(_R#B0FV 97L"H4EP3#!7A,;K#2;&G.'BF"R02Q[ MJ:[D1_Y^-(:[;.!#3=I>NA33W6[2GDMA)I0!'^_5WM5)/W(]*R_?CBD]Y6*\ MVN 7:TL$K[[7HFP"L',?EC789O6C=ZD7>U2T"4=]%A6=\VK/[;:TONRL3*!I MVO$]O?IT!,2QS/@@&K(J_=G;])2GB^QK&D%LN[#]CT>9LWJ>3S\5%/3)]/"C M"2[T"3VJ+8H"[#Y8+"*%X MYCU=-_J*BO,[7&0*+K,"H3+T")BPUBL-9^!NM]K MP^-?>PDLO'K<)XN+/=[ M!+["")BW&=<'OSY=ORK()/&P 8AZLB <[AD J?]E2A>[W QQN=]@_1HTR*%! MYH2^NLO@KKQ&W),W8^0OD[ MKS>OLJCY4Z0ON94._&, #*#\3C]C54T#^WNJ_F%\<0PG#=[PJDIZ . M./-9#VX1=Q\,:X]OM*W74^67VDAX%[5;KII>C&Q%85UB2-6=&;PG:)W ='D[ M/E+J2[]QHWE+S+TJD&GMD], Z48,4*X M( 9U8;_T:],6MOC?5MZL/$@?RU.5TM/2PI\,(E!5_,=)TN),9FFO*;@J([U8 M,&-5EHVLDZ3_'];>.JRM=]L63DM;*!0H[J04B@5W3UN*%W9[\D?5DK?6^@3 M*+KYZ X0%SU2>;ET6MO04>[UO,4!0G\-8\VU=H,7=2?GZ0^Z, A8Z56/;HFB MEZXT86J[:.^*@KDHQX3[%XDM=5PUB./4?[H&72CC7E)@=Q\:=M45B7>3#^[P M:!P7)]NU/P'15( U>DTNDS1%)3RC2]6L=FU:N/GYVNH-T7X)%>UUH[2V3_AO M3Q]"]LX&-=67>EI&JNIN65=_H*YC=.\ ID4.P'8(>V=D*#EC>MV0PVC/D8![ M.[+[!)[F_R7IR0C+!T^9('+EWCJN;G1M.#O>ED,5/$Q;DLE M&#ND#(KUX\#4A*ZU\LUYNCD(/='P/)+!=5,"MH<0&([SHM 5\T%?4!S\ZEJI M@=_^9C\MO^15W=IUZA<1Q4Q)LZ91N\9P?K(E99[77O7X&2?%ODW'6-_W,T]8 MLR-)4*#%IPB(R!4<]R6\T MV#ID!L'LO=&6A6\'[>*NWP<8>7^7Z)#U<16CN , "RD6 R[:G2SKFU-S&6_* M^C;@JI?@WCL -*%/.=J7SCJ'I$( $V2B>1CWC8?(8K+R1X-E-'2Q\EV';QA7 MSB$O5"G!B_B>9OS7PI1=,9)WYI=IOWYMWM(!>V50,;TPGT,%7.&5A<@.,V/\ MNGM4\!Y]1T)"RA+\IFBX<"L]^##LOWP)D[M)P/-.5X@N.>$="_H2!LKE%2&V MY9"<5N/1H!]/@D]85&Z7$(O7V'L?+).S8GTQ'CDSYRGX15!V=8((^E-Z4NH[ M .@!=*A)HTQ$9ED4U,DGCY-EUVRI)_7)'U_2!^JPYYYK=6I1\+73B+TW.#,! M49RZ:6ZZG4HD LI[7N0Y9:? -R]5TY+;J%7*8]OLTOQTXZ0'0%GP,&B M3@8+76UVHG!:#@,S7S3<[C?&<^CEMO6(BGY#@%).UH.>D!EPI^2N09B_\GMQ MSQ6%+ULKGU]:APW;M:SYR"TG#E=O*0M3]F3%'#LZ)=T!=*9*$I!,*R4DU6G4 M<6G6^#PU"@!-M0^X>2PXCWWP,F<7=+:5Q//F;\OW-2\J]C#)&I8 OLZ.4Z; MG%ID1BJ.D;:GFBW%G7V,Z?&M_YL!RD=J+8V3GDZBL0$44,3[ M(;#8:#L\E4PX.I2X'&&JM^K()P$0^\_*&OXCQMD5X3+4"/ARJ[!^^DAE_XCJ M-^I0]0X0]N66V>N+[2\=W>YS 3M[\Q 96CVV]=>> /"P["DM2((RU'H $V2A MP&$C]K)2IL@HD O#^:MKP0>"\6,B%I1!QB\]O41&VPV_9661G^=KP&6Q[(*$ MH;;UD=_I50?+0;+CL;T9H0?9[4-K#XVHWD+%=[4)QYO3K7]+$*IC_)=5N[RB M/83=+/&(#'OQ9 ]0%5[2_:M'L*$N$%===8-_3>#66B]RSHK/3"6=)X28EZ7[ MEW*DC:.^GA?+JT7OT77(YF>9$9ZV!74J#(E5C.-Z]G! \!\7508F_ M>BZ1Q;!&7R17I]YLEFQKK(ZQW(-.?9X:[&W2Z9;XWMO'BK B.BA14V&0BWQ\^C9 *R^HI=@/!( MZX1T*YV K,V&BJJZR@@HO8G=EZBMRWM>\OF,5_JOCJQ?4[C?XR-796+YF!=G M8M>XDIZ_705G.?]PK]^(36C\\+0&HT19DJ\_#$@=]L0WK6 KKSLR26>FI!N% MN[GCH*;I1H63X76/^J@OXO @=2#V8UXZ>-/Z@!D[G5REJ,8.X4_@S1YYEH1N MSE.[B.#HV(&/U0FB'69LWH(9TK@7+%,$5]V5DV0B#$M7XS;N[JV0)EL?1O#E ME8,.H88]KOPIJWK"S@=P>^I3Z9_!JSK5]AJ13)^1?#DG^>R'.0HN8/,C\2=[ M;,XK_B>:]NOZMG]H5N@=P""+^42 _U(NWY9^5GO4XE19)"+J#N"3#IW*;6D[ M(&&D%^42_@S>7#A^*H,DZBV1O>=:7G+72$RMH$EJ<:>E10(XB!<6Y*(5XUDQ M(XV^&:+!G2&YKB];GO1<$J/$.W!G96YCP>,E>$_0<%VCI8:73[]\H9_KGGZ8 M;.#V5B@=CNORWOJLYQ_M0%,82SR=QS=9["I9R1V[-\S'TU4@1$H0G32&0"2# M,&=B.]^.;I[?CC/RBR/ZNM+6A#ZXI#5+Y]F1+ AF>@E9NHK_)F\,$WVHW_T2 MVMJ%NZMF>JF=(;UGVRCE@GD'P!S.>=*-?&J*BL$AT.V\O^JOS.$^BASI30\- M VK,AJ>1XIFR38WC/.\A:-1@G33VMA;"PJ^V^WN("0@A>0 Z^,NGQ2RY<1\L M>='X;F5][.'/WKJ6'7++34I?D [PQGLVZ,-(>U8HERB7R-18T.]ANP;\S4P$ MCLC,3&FG^4_]' _.X[Z0V+>WX$#EV6;!%]LVON6-K':V(C29NC5/*!BCCE^# M-!K)O-]O_VG85OGO1G3]?SG0_(]2_4\'577EWYX,<\D\?YOW0OT*\NSBK/!; M(\VOSA"KOC4W#TI48IG^XK>,P4HNB$L/LOL^M-;M[.4(.F8YI2CKS1(NCY[V M (XK=R6Z(31.5ZN\#KBQB;17FB.?&-.39^?^N>:0F>KM>;]T#8$U3,:ZD.N; M1Z3BA9*C;R.NYVMY6);Z)*^^\%NH:Y'C2T>NZJ/0<3 2O?3B(^8J;^HW-]5 M_[??IM^ZD2\E,X"6;M!$#3["K_QJ+ MN^&;/GQO&Z_GU6*?OGI4K!#,!&\CPLMT>::][? MV@VK^MI,\)@$Y%"#EZ8H230) N\LK-#5%*$W;V]-WQ#B#9R^U8 MNM1-@R%BD4GVV3-4_'#YBQP)VG8N.0+""%*N\B0BVC1".&B<[I36-6$JD;KL MN7JDY#%BE?)C(AD=KB20XV).6(UHZ-)"6YY!Q;1A[B-;7%^].AF-4_N7VW41 M:(=;<3IB<@^1@LX\^TE]8EU?NN>##\8+%&_KZMYZ[X4GI)7>9O_YJ 3A@-^_ M4HX6BN<:W(.\[J:Y(T@=C>&Z^E;FF%?8/K%Y2\HN"NQ=T')]_97^#C#R._]P MZUHLS^=QTW#0:O#YP?),M)( M%OC=U__.ZJE\+RBEZ9G,([Q._'WI">8OTP^^**8'7Z'-8/888L^$$EIEK3.7 M5XX.8.!+KO^P4YWVLS$(MJJT$/J4VE$R?L"U* &VOW%I.AW1:Y0C',K/E"5) M>Q&"UKNMW+G<8%EIU$#Z8:TY 6M M8, WY818"_'E13N,B/K"PZ$'%.G,-A^.FRD4N^@9SUKT?BI=2X9!_J/IJTK"8T M^61)>;A@SSG)V;IAQLBD=\FFY+]YA+>ON941[]<^)K,]>SB+V%(EAR2:\!9G M\PUK) RW"\Q8??*C_-KF+J&P!Z6"0UDW[<7H;S M=0G_+3.P.T<\R9_>",);O@]7.<6U/&=[HBI>'MSI)<]&GWA":XDD M$3L;E\/2*6FK/"&PLG/9F$FO(>&W)\JJV^;M_S9QRPW;XM9R6^ <9?'59=R8 M-$,=#7"$B:)J_6SZ;2/MFQ(\SKXFNYWJ_/GO ^]HPNGV:U%D8]$DH. MG5?L$AK*H6BS>YQ5\,EVGZ3_+6<(I>/BX4L;S�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

  • VDW&*4,3 HVS+V?O-#B+W,OI^\;WK#)6I:,^1A[7P,6H' MTOQ BV@95".,L!/IP:OQF) M#G9=80K!#GO>BXYKMS:_%G!I1G\.DW[2?+:X(C4RNULNX<.VT+W[-6S1VK*; MZP!E./04 'HM\/+7L1UI>R2^,D35O,,[B.VD80U]84T/',,5P)PNLLQ">?B; MCA, H#!4OQ3I>O46JLUC9)UI<=^/\I'Y M&5Y">Z#^WLI-0>\J-J!^Y,$/#I8Z#O4)WW<;L!'A@_T=;PZ&,9->?B2SNN6_ M>ZHC(A\5>?W%'A@^1+8%2\O_^KHO!L52]T,ZM9?^Q-B9Y-L,CI>O(KI_[N_O M/WV*IN]J>=1I:^N4_%:6G@8<_/XL*^P#X^H+BWMK"BU$^L.8 ,8X52=-@_E[ M#2^?5GM-H,ZPI2[%2C]O@ETA8_O[Q7^+0Y-13:< J:*!\@W%@]I2)4<.D7R( M_%4;T!@=[84GQI^[YW-+7=861\K.5Z9AC%)[(?2C^W2)?=SKF?/-M4K4IC5<:*VIN0:'370<#0088#K?@>G M,K 5WY#Z)UY-(P.IJ^YG@YETNR__F8A"/>PY!:*<98@YKP@.HR$4EJG>NSOR M:_$U/V#6T5^L5]OVF#J?CZ;NQ:(NAY]A C@^'=J2,Y'0$QG0W[)U\GS7W)]Q M9PN=F@9OFLBID/=9-;&"-RP_7TO;-9'\I0V$]F4M<^Z! M'UUHJT0[8E'8_"FD)OFUZBF00&$#J^H1#B8+?9/Y.8FN[E",9%R8C5UI&J'] MX;7M3O?TSW?*?*)(1.)MD;37*5E MK(&DI>8SH8'ZZY))BU\# VF(H0-DTWO4_8X>D\34AC1YS\#5,YVON^T38"9O M;M:^_4QSOVLC00C#,37I2X7,![I?M_JHB+DH 2$K9/65YU*8*^D;]JP]B#7& M8&7=UM%_8^\]HYKLHG71%T&17@3I!"F"M$COA")-I%CH)2HB'00I 0*A2)6N M@(!T$)$FO8B$7A6D=T@"B%(31(@0PLFW]SW[G'O/'N.<.\[^SKU[C(\QYA]F M>%F9:S[S>>9:*RNURQ*[?94+<#8%F;&-0)^/I(+F7Z1A([;.^"G6J$#$DL1$ M8+RP%XG)QUZ:J\MVX&M*>0=&*\Z:V](<-_I;HP*?4 [5^+8H\A'<# MVM J>Z[&ZE[DSAFTV M_^@'NXY=CF"LY'J2VIDZF/7;0O?^GMC4NY;X>?*O_+>BTLE5 !HIZN*\]11@ M3[_F32@]<5!=\BR[:J\!$86\FLU :21CJX?>YW 6L$A:T!U=8TE9LFZ+'!A) MDY;6%'RU)9]_R:MQ_XJ+]3F0W'Y?X:5D0U;?2FZIU4(BQ*"QA6-1L9E^7S"> M8?AIAD99.O72-\I!9%-T)NHP=7&'^FFX3GL MKH2,*%>5,'/P"(I76QFB_ 0VH5$G&;4.I&BF&31:[CZ>?C?CQ=\>/;2,TGUU M)]WJ[IL+7<][&&4:>(H+3@W7C@E7VE;7%':%BN$.$QT"KJ'4,Y76"P;\#1^3 M-KXTX9D,KGR*2D#KFJ7I*/X<&GV"Q!HI2B!<*R")UGI]:EXFGY-^>GE*/)U$ MM;;F(<1&TE_LGS8R7YB'\D4M:7F0:87!DG?[L*MK>EW["VXV9\6A]%O)U=8] M7EZ/JJTL6]HR#0]VT6 O;X^I3ESL4\6-.SFCJZECGTDYJ'@.N#!0AXX'F?3R M.)E@3_ 6_;.(]/A7UU.#,4.[CBW??GOPN7+>>4RC*)'ZPE#VWI_5UL=/K!XP#I?2 M=QH[=2+FKTX>/<=F)E&^\,.? VA5G%^/_2HL[?2.1;/!D$^$BFSJA=YH*^J! M[WZ>E@G4 .&8!"-1O-?MF0XQN&[+E.RVVSSJVUKT#>%8I5L9]^H^;!8X J"[ M?6ZD-\&P?]TD%LI293;8_,JP/GUMQ\HQY0:!O'D3JA\Z L4:(]A"AX(V22T, M%>'AI-?UF8:CVM>NZ@Q.!V\N2=U^@^2N2.EEU ;T. :GSQ(0J+P@Y$[ VIF> M72T^QPWC(6/6>"I96&:$;FI.G0Z0?:H4M4AQ;5!8I/.] )#22;[+2= EC?0= M8NAD#C&;D7X.%'*>-;19Y54[?TQ O=RIN9:](3A58!KCE0U7H%UV?T*?">0UDOQ&[ M9AA#+ZK0+^< RV^;IKLLO!Q3%RKDOQW(?2IQR>O+34=P$JI)([!Q)@IC,R,0 MSE[Q0;+TE^)0IQ4V5/).HQV6V1NL0>LU:5GLD&VV&:2VNB1QB"AU5GSHYD4/ M-\5_>(57$DH*3N3JZ@ 1!T_="B_"?SYM;7M1BX.YNG*1,]8IF@]=4"]NK9GP6M>6D9Q!5Y@WT-4%8^UC!+U7L-'(9@\S6A M_Z%^%<=],E,LKEQZ'*>JX^WDHWIJ%];@XN#]O?#Z_0P_P4SVO1#1R2,_?/BI M)&D6Y8AR,(&!H([$2M&NY\'OY!.?RPY12%]N[H?/.8B=]@5T4F9Q?H(RD%XI M4Q/*"'\PI6J#-5F3K,=VC)@.+_TX!^9O;GG_<6P.='5\5OI@T^M-TDA>V=L3 MRETWE&4[^2D]P:;!P_C4?JI:-LY3CL[I@:-;SL_1/FGU/C-35C,S)C,S,PV M&O@S0+P\BP+3XXN/0O!OY>RN]I\U&MDU5,P+AUN5-_^S+C> M@L3S5U=]<$$RD\#PF"NC';OCG[+4$(X,.'J15:QG-M3E"TY3X=L.MX%B#9!4 M^)'>U7IHKPB<8\U2%13B73/D?LR6;7*4X!WI0B\41_$M_;53M/A(YS"WQ=QJ M/6CG>5'H$(+F=RYYYTG15\QGR\!,>Z'I'0):<+CDEE&;?GZ;T9=;CS5"GXZL M?P]3IR)E@-4Y,*RA#B81"HA$#9-5I5ZD6 GYG=W'L.WJX>K[>85_">%T-C*V MLR39,V-' MKT6W^0);+0A_&1 Q9(XA MKO14%7UD\^9IUO77NMM!\+)5SI1%2UJ?$F_[5%+A=^ZXB,?5P"WQ=S%O5)EJ M8/&4,583OR4$3DWN?')ZMBL2YQ2^EM(6+?2D_WD_>P09;J 3P;C5P48:[@#L ME]ZX@D[Q=F;0:^L&*42%B(119VJ,T4J0\-=9R1Y\XG,HUM2$? M:B]S-0C,D M== VR)_8-_K*<13'>B2L%"X&DG6B3*YX*JUG"0W<_NOFB)"SY'8%+*@_3Q(? M4^YZ@&_&@.+>9:_=Q['N4+FG5B9_-^!F+.<7%"=3>@H1X>CL"]S/]5,MV(UT*09_M(3R?9FV%B$?+:# M?'L&Q/$[$8HY2Y/Y<5+:;JT7(YC-G^2+CPM\*MHCZM@:J,E#;=,=/+L90[A" MB0'W@ME(+<@LAL:(2PL'2FB,BM\[@QM6C[T;H^GH;94[%3 N_FK@]E/O'@!ZJ-,8F?GW\C"P-4TWI0 M#/T,]_#O,Y]@HK1X;" L M]ZNF&X(7YBW%*O1R[N9'ABK JZCURM%WDL$<&OH$^^D>FPF/YOVYUTVE1EL88[ MG>'\:V)[TI?'IN[_*&!(\2"I2W7Z>OS0.4!C#8J#,K$-D*29V_YN=J M(ULR97R[UQJ$2VW)]*6-H0I-#KO'[C5:FY$$+JU>SZ=*_D\W:^Z$W$#S7-KN M4>>IFP3[[1KV'LNCTQOM;#4DRT:8%?XPZ?!J7--\P$%-->*8U,<"W-4A&?0: MX3$)=:5P1KS,VD@-E;WMMCW_5&69_.RD\U7OKUXN(N[**D.BGJ+//SUT9]0S MU0GAP99A!J)"Y6%LQCA$I)]S8R[U'Y-,U8<58N31>EKD N6H<@["Y0+ZMG@< MF#%TQIZ]#F<13X"@/S/T@AC]&"[W"^) !'ZLS1#OJ]P!]T35<2K!;L@>^A>W M^Z-FOOB]#B;"0VSF@ FY)?Y3EW5[T&A<0+I5"BMLG7V9.U9#9#LU7:!%[;(L MV?RX/3ENX&@'+W$*^7-$%,0E-N[57]4<][UCO^+)\@V@[;2!3F:9R%&J II#BT$$.Q)5#J50I\4?;'=; M9"K/QC:*W?C:>+AP\>USFX7;7/1)![=SXM_NS7%1,$TQ0?7@-_"U:&ABWL7) M=BAJV5K"2:OC_L88N^AP)SKU6]C@%DQ4%W%!A+SZWRXZZ]#&DWJ5B[?QU[!. M YGVS.VM,^TZY5;&'C7OOHFO9:],F,[Y!J0]6'JPZ=\YQY=4$'^B@C;I2Z8F MN&,E/Q8,?9\9Y7M4HZ8 M&E8\HB<(%*O.M\7+E&" @>!U4,UI:L(J2?.<@47,!B\0RSW?%>=Z/#59E^$" M^"XT."GO4BTN(*(1]CN7>5^TGD\4-RC5IL08=G=60%3O61"C,WG]WSMV%(0; MX3D6L5I_#N1[84S8%^VWI9[PL-WJV_V.SD]/IY\; QV,IU@T_U#^HL[_K6'7 M>OZ)8?"V\UZ1E08]Z]1-6C(!1554-H#48>TF&./'T8@7J_.F;A8R)I5N5\XR M;W\[G#/Z2BP$VWWL;D^A%-^\7)SAR/V-TD]'6ECZ5M(X";-7N!S$=I[ICWV; MS76#-E!&-H"2\D!XO8! ?EB/[>3U:8]'U._ DM*Z_2IU/!'#P_(IM\!IZJ:= MO*DZK-:G]QHFUI(,1]Y["*19HO3R-,)+_"_'4JG62U%3WM._$"8^_A?$[+UQ MS6OG0.0YX+0LTS-+O-F>-K%J.^-Q:'B?.IK?RN!L+4*77Z,TM[63AXH/I%=P M(5[DO[-?^\D@[G:I4V6XS!3A.>:GI&[R8P=MUM=:5M]3YT3U.-/('IOX $": MKB@T',G9KG"J!9<:)P2@%=J4)=^!1@SGVLLQOOYZ>J;ZM)4ES_35-/F^AZD, MB]1A!DS]Z&"L LNNS!^?24GSS.:H M;I/EEYQ)SX"(]@0G)?9M#1Y6UC5D/7CW/BI_H:>;,SD6?K4MO9TS!%W7UC!= M-<.Q%E*8_K%ZR^SU.N/ $GE?,"O HU< MQ<*;7+A@B#Q/OUH%G=D/H8-;)C](UFW)IK/1S]]9J'[Y7LMC__!G:[<)C4\K MD/XHW7NXGMZ9O AG_/(Y!LRP\K,I>Z80O?CR]5S;NXQK"O*$A#>$'^O)BH-_ M4GZO45+ 1TY5_SJ4 FI_5*[.UZ2;I?;VZ/#&J-USEE M?UCR?H/#TO^1W3DP,)9DG?R"X(TRB2+2R2?B*/LGAR7VP XN#R=V'FD=LZ7Q M"02:F3,5BG*>+ M:?T@_\)'OFM<]3Y+HO' J6[\ 7@!.L KAC=$41&OX9_UE5O"['A/K;&'XV#" M'?%+DS)ZX)5XYU2[J8/$7V(WANM.V"+@CB4$;6SH2TP(]4\O7X_'HV+;!K.) M./W"3(':KG5>S4$U$7)/4F8QY-1 'D*B,O-!<@POQ>4&&T-NZ^2;CJ.GY%TR MZ^*832=OL3U/EA=9%X&.2,;??FLQ(?MW[/G^C\9A?V/<$ZZ#/EV6G[2>4E7Q M]LEA>S#1>_W[:NHK4"YWZB8'2)JW_2$J.0OA1.)Z"+_8N7V?V5E+Q(K M<_W%RC;_PLH/_PP7LK;7DEB9%*._6!EZ5X/)NOOHZ&.?X(%MN_.'R6$6U1>T M5ST*)$WNAU&JDMT;U_G7=/VO9C%Z#C0,[**Q%4=F4QZ^-5?MMS@S8R7YKU2_ M+%RL/+[!)$@9LA<;AD+)7/!.N5R=>>1Q5MG!0YRV![5/M=.5WSF^2EL14NK* M=-E+0N'"@[8+FO1HB0S_VH >-33[5A3NC5Q 83"J&.0@R"U^VN M6E]RM*Q@W-YZ%)F$3$.='HO(A29.*T:I>VR"3(98KZ-X;'+_R#G Y**LO>(2 M*HS=&&J8@:M4WOJX:CE(!5*ND*Y+H^>5=U1O(/MY:)%%>'Q6&LI.(*]U2^;! MC]SY5C+_6=P>*K]WE]A[F3;Q-TU\(Q:T%A.#<*Z)/K)7Q%8&#!6NF'A34)I& M/4YO+[>6]RC,H;Z=)OT\0IH,$Z9&'?]G]>C-6;LZ:^AP6V)U.F9D6?L>[F*O MEM^XKXI?W@:_8-C^YW%&;NY+#XVER5@GB%^1C9D]R(6*GN/LS/#&&WF8KG2O MABJM:W0;[U"W,S7T19\]&_Y2$B&3H@,$\_S7M&']A=R5.H7!1<_2_;CLQ/HR MVZ)+,32Q+[:+?OAOJPW?,B!;#2[B4U2D[7S[Y()8Z5D.P@T<@VBTB-F7 Y.[ MWE?KBQ1==;%^H<4U8M29+AF6\@"%3L\RH'#BBP>.E,5&B(*AWU8X\ %K'E>Z MJ+S>P_('LJ=,O!W0B53\P:W7- SO[(JG]E$#5=$9MV@?1 U1W"-PG16U"^#J MSH%>:^.4XVQH'$')QT,NGWZ;25QA1OJ"WNB'+Y4ED3&)62950%#(WSO\+T2I MT DD;2C97.- $L'QG?,]]Y4,,#@G0.0<>$QQ2?MARJ)B-%U$R9A^WBMU.&#R M-]W5F3WY+(G?L>I?GZ5&7[-;$WR]5*!(%TT6C:I*YY5BVT6BP,RP[^= -XBA M89^18#$K>W!Q"Z\\JE3E4:=_<6\S0P085.37HK],D1H/G##'_]G&..TVH_8C M. TZ\)GH?'88XV"2Q^,IV9(VF]8+>XP#:B7U&H***-4/BD-\SZ%:_X[@_U^A M<5NVE^IRL.>=HZQD?J!/+V;:B>)%#ODU01HDY#KF M,@]#DJI3"4$9Z]F,20SZ8>7?95:FZJ;FD.>;DB-]F0(-E0 =VP6!>1 M ;^-B>DSB7Q.N-60?*MIJOTNK44'!_9[>8>8D?+0FS&L0IT"C^SC!4])5/FE8E2JI$>-),?Y#45TG4E-239%")\YBG:-[T2"A0SUUQ5S.V[HL7E)M=MC72M@G./1 MR_=*>6MZ,Z5UV;#L.%)5CUY)F4-)2/^EGI#=6-_G$5ZI^L9<% M3K1A)PQ(H@VX/AJ')A:%48O\C5;Q85Z]M'3%6L]/+B&3L=W0SUTC@WE8PU>0 MJ<5)@"\AOE$'@&N?/B3V(RC@7*<@/,9#H7-!-_7]#T[M%7-%[5&MR5HH)4:8:;VV.^*HU MTES-4_#XII)IB1-_\D+Q40/^&LX-4PP7PXWULC= HT.YVI(VH4FCHP=;)HSV M_?.&0L&PMT+M=Q3TYY=&62VX#"V^01F(2G#ELUH""'>E$T$OZ+9Z>=&97#_' M_.H]:QLQNSY5K141QT3VV+4[>0#9:\"9_#L4SY_=5(4EH7RT/$1@A41BTRVM M:<^17]7OUTKDE61Q*6W;_[49I8WKVU&_B<]$?4_3FZP6E_CMO":\GF2Y+B5% M7NN8+K.]D7S[$(D7:,P=ZUFEAWMBRV(+E,UKTJLT-IU'9DQYKGO6*M9O->JD<2G@7*S)>79%)3='5"GY!$GS=RW>FORX;L M@S*),5[0]R :Q'H63(_8>80X$1(A7\]?I#R2P0N@5N=(FN^*2\>E"=E$/8T) MWH,!VWA6SDA;73)MB:&S]4^+U%U#E('[$6*D9X)">;;SJ,XRJALEGM[P>(B[ MWBA95M8EPI?C)2J28_KM:3.-L I)"+3=]JZL9_;FT2WEO%[*31/^>RQ[W$Y*K&@H]B\9LW_&,T9T ML .? TFFE--F%F9U(8:&[0U)6VX)"K\-^Z L\&]75Y&!%Y=-U M4!."L&.)AU4F?U1?)/&IJ?*[+<& M,AS#;N0I!X$)Z[6#6(MK6"5WX=0M+G!A"'2HUJ%.U*P6 HSUHD'=KM1#]*9K8>$E!-. 2_@=T^&L B>DW("(JI-7 !CP(Z?@]+*P,7]ZH %AP- MK#!#]K% HC0,N&1*5L"0A4#%NRXT]YP#+Y5+#Y,#@]^[F6.^&Y#B)_O'N+/EF2D@3D3XD&O<\BGVY WK)!PJ8EIJ M\/QZW/\/B(/'"E\V:_2-LL?)RV[RY&*(D^!W;IRMVRG7J83V*B5>5<7+BV7CI)Y+:D06\*-=PUX)1G MNC:D"'B:RFB 6=<]91'4X@X6I^T&E22\IKN(VV8 M'>YGR\GLUFSWZI_K]DQ_K0KF$^-N$Y"D@*XA!L>PR<3VW^ S^A6DJ?K5-J74? ^U^>FOH-#L4WFU"=AS;\YZ9Y5DEJD ;O?^&BIIT(U!C\:NH9O+ER& MY:!-$@Z#69TZIF1M%O59@[($P\!/VB\3/.).F[FX'[GA?O]!6#./C('\%T@=0BO820MXJZ/4MEE]HI MB=0\6"=,3/_J?#<6"B/O:K/"1OM5N#28L-K9+Y5(Z78[%X0K5 MP: /2'.F0/S&!!M TU=AD??:[U?"S/U;)]&I'8'BUQ\/. M+;'RQ!6F*/VZ_ M?Y22ZH% U:[0ICUE[%_HB(Q)V:64ZBU^M3\P$P:YKWX%G].7)XG5R2M;\[I( M$I9DF!OV.OF:Q.F7]PY8;5]XJ?,Q-8O0A2F.,MS>$:W.^3#O9AZQ;=+>C&R4 MQ,55E5I=\5'2LQO6'ZZK2YTKITRU]1I@B,,2KN&=*F$O1VP^&YEY^.9"%(// MM.X)-#9I3F6FI\)^2 >1:X"RH5CS*IG>U:N5>P2W=P;?\93HO>H\=MAK4-Z) M"#_5)'Y19YGU] R=K'$9/P<4F=PS:/"\AQRYN7(LBWTYLFU,W\-D9&= M@+*? [6#O^A&."+V%!4Y%+_"216%H@C?&(P5/DK!670AKP[*]LT*!DM1[(;3 M5[E^*213I=O^7G-ZIS8\3X3\,/,H[NP#7.54?15FHYG6O=V[HHBS6_=7!D4? M'M_*^*[W+'P]=72N>&GXTVB@*GFTP!A!YM3W+/DH#QH.95(EP>YR"\3\ M\8GQ!S]#FB+LGP\*#8S*3SQM=P1\4IXIU21!4,79>V58)R(U![8>8U_K(4OD MJ']YIRU"YYZVMI?O]^^LYX#[)8GD$]>RSZ&9I7E8D.*/_^1#I*AENG;GDC$@2[:9SPQQ-P+WK/(TU$00:;[E#("8 MO01D;*U#/EK-_4R-)2S/6G )/E&YN6BNH"BV_!JDB*,DL%A#R>!!WSKH8$AT MXDSF6N)]N\G#0HFDCYG63O-[&XE7MY061-;A5#(?N]O++[X^_ ,]TIMZAS4A ML!9CS)(3A>5/9LH#JFRLU4@39B/XJA+K(>A:"J M$+0VQL@FI(U'<(_\I%Q#!5^267M"G10%.EI7<_UIF/K7LV:(%YW-D=1LN]S% ML9X<*.M/7KYX_[K/R;T2+C=AJC5R3UXL*)JJ_L!JOUW'2IE!W$P63RW.,GP1 M9-MI!-DFG&0,9A'4H.D-BOW:,/.+(G%%.&%!D8_*PBUZDR[=EI:P?PY<_%*? MM4.D619_LMA_TFLB_/"+>'QRKT"HV3"BRTK5JM@UGX00IQ#ED0<-GSJ((VYK M7A0?]OB"W1ZFI2B+,79>F75S*"Q@J$&ZCR7Z^R/JKJ:O09@(HI,=?# V:%U= MZXRO#9+1P$&N,'\H&'%C8CGA34#7,P?'A1+REMTR+/BH"O\<.WM$-=EQ8Q$F M3&0$7_I9I5::'W6X6!\L<%LR3T@G?9JF/3GSZ:/4#,&W5VRANY_/ 9&*"<@. M'7KLC'JA96R^N ?!0/ FY?,G;%F4NI#=V#M8<"_GSL(3Z])/_(V)2]DO\IW> MU+\5C0&8?6[V\E+QD?\\$SZJQ(&/3'IRH99X;ZIQU<#W2!NO+_<+L?L3M]VU2G\.N( H?JXRJP,NZHI3'B\4 M['EQU/AWEI9:D^D7W+P]&G93+?]X/C'V8;C>3CW0C>!"H+(1/*H@=%Q-$2Z_ M!\'B9O[3S>&CD\J%:E?8J(D M9AIH\"Z29LCIK$R=#RZ$-66.$E^TU;^E-_FO-!H/LPO89'<@1,Q8:'#O &8>^L M)H#HVUVP,?V9]C1X%R=LLL9X(UCZ +R;)4UT\K,/QR9X M ?H*IW?$$74%EPW+E;&^ LV5INI#+;O5\N,?-.P*4\@*.Q"D3JK$J"#\[^ M,]H.A#*O\,.\I%&2E&A8!MO';X["EL3B'-/8BR.D\G]'Y0B[?JA]9*]-2DP( MMJ.>YQSH S/)2O>A_SRN^VAER<0]*SJA1!W\6I?C\)?%S$<(*AE!FOFKD!TF M"#%33P/D%MH':8Y./GV4S_1SK?O8GA['&\ULDZCL5NO'U;LSS.$XSS'HV'-# M,R'ARJBJ"8FHUPQ7YTG$AU?#C?6<8NPTC IA&3-\6M#Y_O&V8OJH(P/)B>DS"-8R.5:=HQD;TY-(UKBKUK@-8M$LMW.YNR2VK.E^[77@&*/0M($ 15+P MTXZF#CRYV]K8"PC]8>[3@U^W<5XO=MT]?<<8K1_:S4&U+PCHDWM:F/>(]?^Q MN*>YHU?C@EOJ>>3!LXY;MA>_76_"HBN8VLF5=?^Y!\7ZFC!'OXDU< !.@C*J M2F"2Y\$8DWC?*J@)CBUJ3_7&AX: -CAN:7'I?7,6!VNXZ !,1#<4RX?ZWIJ/ M%XZ.K(!Y'8'Q5DY55%=_-_R4-'MJ5\F7C;$J8#\\*$GFG:O1QP]@0QD2LT-S M"[:#JGK5Z:\$+G2\= \WKF9*+8JVJF]]1%O2)G*1>+?UP4TOC6CVW<(D=@?+ MHD0M06? S/0F0%YP(0ST'[&G_+]IE/&NJ[4UW2!6**SL+LXDXG#UZK:Z8&O& M]U/S&935/HL"%;=T:AM%X@7^R\,IC,R&S ,H+[S :O>G,X6UV3ZOJRXULAU4 MDQY.V-^-DV]+EZK\N%-3>LBR'D<*DR9J\YL:-+D[&C1M7O,!1WEG^3.;7="+ MQ(NV(]4V17>>SCOXN4I<2V)+,RS/@]W_&O":_ZV?]&:8E 9(ACAL+Y.#R22P M(C%-S8%B(T[LW@E5EP 4%"]A7)UQQZ%IQNL< MJ*OA3PX7]_DYWL0P899(++<+V/F-Q6RC\@FLDP,G=H=T=#5QXG)J-H:I'RMD M%:1+QX:VF#(L\9M2^;=[L=">8&3<*M;*ZZKKT=V&$X6H&DA#(\W[KAM<0@G/ M^J/:+LGJ0,P])LEY7'V?CTAFIUVA(5#D3MP9%+U3._T>>BL/0/>=09)+8S[PDLWTVY 96=C M9^.RMS[N>T2A4OE,H+8EW:_%CN(NY1\4%6^;9]L5GJ>4F M'H+F;3$I]6<9YEK,4(F6D$IM#U7NA[-?D/_.:L,#B^'_X=<6TP_(,-G-.V[8 MF#Z+E1M3\/NHSPI];6-QDHZM'=.-+5>#^^BZ]6A+/,,%-&(CI$LH*-)Z:_%< MI *(K3X'C/"_<39]V6Y?P1&^BU8$-0_?S1L!8G9Z@D]N=CZU+!CJ7!NUS]K< M@BSF'+5A$3WFC?B[D*2'6,]&C/[MK86M19. ZR_+/EY;=@CG2>RM2$]@O+ 9 MS'AA+^?([JP,Z?2[%6O1A0BWD-[.^/&*H\ERV?JEOD/4>MJ64Q[++[N-RV4\ M=UI1M*:47T@)FIGP'5]*HGHO?%75RNV#LW@ZZ^')5^%T#=\6!KI^4$MZ#URO ME4WFM,.S$6GN5Y2^8M]MS"&)A(K!8I0A=YNO1^1AN@/B@X7=J1I&Y(:=D4*!1@I?< MB03T-6G6>9.]T5"\6$Q_,(^>E*UM4^MS9N3%M."6:H&!L_IGH:_)?JYB+9$+ MY!9X+VQF3P?9M^J-VA;.*I*C7U$=$F' MDOM D[G\.1!!8%X_<9D.E MX"+?5%W0P1QR:O>[ZFS5-M);),0SI#]P")IQUR86:8<3Q#<; R!80W""LDEO M\KQ*CS4W6TK39[3F]<8_R=O#Z-)PW^Q7=_(QT5 $7H51@;)7L;8C2GECJ,\3_4;M7I6W M#OQINP??$[04-C1 MT)G\IN/:D[%?Q#)9X7P+AX8.X:^)HAS! ;"E.-2]9V* MJ]V$H^&9!G/U+-THEV@+Q^%8PFI#?PT6>?2X%C_T#B\_"VU4]LLK1Y2,5386 M+_8\>X\(X&M.N3T\\;[KP>#0J.XDEI+ ^JHO6[X<"ST*F*QL-#3\M+_3U"&/ MO5V-H6QJHKI!7E1+2Z;FWZ3,>5)QE'<.O+98/@?FLHH1NU6 CS6I@73\O3^_ M;X'/>D?@G9;CD'7[W33MOMOH)Y\--Q[\."0QJ572D+!.D22\P";Y0'KSPQDI MY5!%F4@*=1:"##[9!3L#881!!SCA"J:!*WSR ?[U[:$N<9BK=6(B6BTI$.%G M"S=I?%:Q^E#J'PO'.V[53) 8%F0 M$&6(/$G!FU49HFMB+ZTP[/9WW(I8^=E>Z$TKZK *23O86<(P;G"_0\G8?\+4 M+$S,F"3389W0>V%Y\KC?517V6_FN4Y#ZPV5)1L;O;N$LH[9_4A-K>_&29 )O MG8E?U*FP1\VG8@1:.T/MR<9K97@GW:E*XJ+KJY#L[1WOYGQ>K+]!YF..9[IK MD= <$)GGGCJII>DR41=U7A''C59@5^_-UC2ZJ80\[A-O-OZUHO?\@E1[<[9< MT@,=4?^*JU)A/4*6Y(<(%,.NE0-NRX0;YK^J[45/,,!Z?&FRKHGV$VOOK1=3 M%ACP2SZIS"771:)BPD->W6'#^I M.[O6+K.LR:>;T)ZBS7WWV<[3 . B.<5'RMD.*N)P'AE>X50/7]R?#4UJ-\&8 MQ-KS3;[+L6R:OEX/L[Y1EDC8- RVS+CNE."^$4!V??J:#8C4>W:IG@,;UU>O M(O<>G@.3";YD1TX[X:>A+JN-PDF$NZ@0O:[,/ I<4B3WJZ&RL2 PL_Y:^J/, MXPC%HS:5 E$+?!U5U\ 0]/_]VIMM,EXXGU"RB)D]^P(Z\4Y*7M#2:?R7<[G2 M!F^TN5Q/Z'FU&[@'F)-,D"!KX'064Q8%USS5)PX0I2="^? <<"J,S:[TGGZ# M3+G.!RZ5-P%JE46P!V+,0UQHW6>W9P-)XYH%B]7[AW; M6@\*W>FOKJ,M5ZT0N,&C>4\YGK!!&B(?WG.;R)C\,KMTN&%!MS#XD0/W/'L/Y,^AZG/X 5P7-WV3&>OU#GPQ98S#:MT^*=@ZI]6[5.> M DT1W(NW*C@>:T4O'T11UI#+'3@1F"P&U'FAX1TWL)%N_C38Q*2?<;?S?Z,6QY@:S?.S6_D4A'X&G&"[W;4@=]^VVP@?5^.U;BW'R9 M_:?*_(JE0Z:2L^%-D03I_)M+PP^$ ][W/5?/]^-)[[:V5[WST=: +;MV4'.A M3UH!>.:_[L0^6,"0H Z:7]J&8,W.@;B%C#>5;9[)J& 5.NLG=S\N#<\<:',Q M$7184O.\.7C$=N-1ZHP$KHD.QI\+M;P>I-" T-'O(7:/[$S^H]P MB15VH=/#>319@^*!/V9(5":DGDM*&)UGL/ZJ9BN?\,I^ *MWY(\//%5RSHY. MQ>[W5*"WZ;10=K8#1Y]>OA(,UXJP=N$) ^C)!NR5Y'X@RWN1O.Y6M/2L%UMP_12OVBS5CRUX<0B_@ M@P8TL7OI+D4_9J1BJRK='UD6Q85<"$_V"4XSJ'(5(=^LX0WM7*4(O>'J\AX_ MT!,T$.]5?-$AWQ+G6>L[7JXDFK,W.CV&3: ^3+Y$8,+6A,&O!*,E6-R>.;.9 MAKQ97(*]O-L*XY^O?\(\HF+@>>'P(.MF(/U5=# MPM!IR)_KGY-1R3N[V%]'/N-R= +HU1B+GAG.J,ZVUN3= +;K!A>B*!HF5 " MFSRIW<=M_,?__X-Z$;^X]^9'!PJG&2,_( Z,@D%=H/E%].;.1I$K MIUX/DKXFIE*.)MSO.6AA3_).VD5J*I<2?P!0I.2!K<\6CVN U&"_CBZ1T&YX MWTBO7YUK1O5^"+L8]\G 2[^7[Q(-AAZL^OM7(UX\M/A HM/[Z/T7R@Q'X&B+ M!S&&=D4J'GK6GZ?,+YHME+,M/$WI#4-0/PJI^%@41HVOT<;?]SME"9W,$\?- M9#KX!6*],-=G9T*[/".5J,OW)EV?5A+C>U> 5^! Z M@*!6-5K[T\%G4K9=@QFIVI,;@;!M8>^\7Z_5SQ9K9.K[Y.-T5A),[L7P4( M%W%BZ+/\B'8;] ^""7I13B>"QQ[C5KXF6FK6U].:\V5!_Y?"GI*2Z@Q;5_Z\ M,)IMYS1$[C@,SN!0Z'KE6F)-MH%GM3_O!Z&LY6F39Y0(>-&ER0JF>-KTM4+I\H/5CM%B8NC?\U38TD]2XSD83A+&S M1.HH;(X.]FM&%OH<8'#A;(XV79A[$4_C;M>_^XF;/+(E8_-M7FO- O7!/-(1 M&I%Y1;6.P(NEK1OLR]/#]J4^?>QC<%W2"/"$V^+!J/RD%18O.ORO'I($&?\2 MX1B!:I/U 31@ZUK5B1&Z9N%= H4U0ATDX/@21[-CHG;@$'"/BNRD^*9;[ S- MZ>!3%PZM5X)#-]-LR3K]'[8J]AN'1DWXYO!0WJZ?E!T1"U$QJHN2J'+?Y;?D#V,UTR#3Z 3(S'^0][7?/^4FB.":>W(I.X/VXCZXAC)].PZ)N9W3 MVU:82,87MFZ[EW+]&Z.^I:[T%6?!JS"3HYMX!13RTC),SQC[+*<[4\$;:E"X ME9W[O=!QL@Z K]W%A5*17#%10W$P[W08DC& M[7K@W=9:+V?:B[OC CHM5)P7#*C# /%]=G/XQJ\7FO)\[/HS=ZQZ"-[M2N/=GUMHSI]QN06[18P'^IRC=\0U3V*VD3K0/_26U:%*.K$8@ZQ2Z M:^9GS=NG0GEA_ML]KU8&-FS[LY<)V#LR*=8<3K 1^B\6SX:Z.)2,$$=:>"., MA(/-U'=L>W;(:)M4Q;N7%?8_4UP?INFW12\XK[UEME%_W!3 _5MNQ]>44JR4 M((%MCB%<6*$>]XTE0-"O/(]&'(H&CWBMU0-8TJ[JZ2H)!WUT?[NI.IL*XR*2 M (<%HS/*GK_'&W9G9\: JSV>U&6O&>%TJ\B':%\VCLR^Q\S$=JK&0 MH:"TR,>(\'.@?C6.(0'.@XXCB)5;:PKG!(-BY:XPQ7C:WDY^YN#;N1QSC\PT M*$SOM1N":@_IX;7PO%M=?=KW]*5))(+!K&17< M:V]3-U16$;'Z[D?Q9O([P'MYE(IRT;F 7@;#UK5Z&7ZW96*O7:N#LWE"=9F)^K4I M3_>ZWJM>]4;/<)2#(/6ORX'KLQ](K*D &R%239^J$[1PYF48$V;8U37+63FE M!R6:O/VP8\_XC]V"IVRII@=3-X , %%09#'?SM/I^Z)RR1&Y/8G^F' MD1!<F4_'>=>AU=)!14^(D=E 6##-@\!]]B:4AP \A9*Y M9+^+\OV%X=']/B*N^?14=I:!$1[^:V=Y-L\HJ(H%L!A$-*SNG%;C ];V M(R$N##'63Q;&8MO5+^;'$I2>%HQ5_/Q2Q=5.'G9,Q9WX0OC[(N]E$?*00!W@ M,0S<;VW2"Z*9@T5JM[CE2O\VU)VX-:Z<_C@I*8EQTA+3;JES_/ MAKY>BQE2O0MZ<5\3Q_VB(;LF&KS78)-%I?3XP&KDBI1PFH&2FML<"22@;L1% M. _J\R.YEW2BAE4^B@LL,W(OMQ.-SP0>DO,O+1L(?B@CYY.G5RK[7Z7!Z@62 MR.TX)5)-GBJ[\K+58@E(VIW)._6YU0*6X/UK626.U'=>"78;/*,DFX]87^-0 MVFUBF^,ZF$D-/6VCD=B#=JS:RQLQMU_U*F?(EPL)!%X< M[N3257.-!PYJ(J!UYT /8OX+M*SG*S-I0,=+2U;G@ ?4=E$%CFP_>)JUQA!U MMUW$G=:)VPR1N%J'Z-Y?D#']^ D?ASZM85)[86]6*6S=T=0<^R2MF]U)_SAW M#MSL3:8I*$(^2XH+! WM1M 26+$))$V72))]4>29$:/[]]LZ&"]\^"3@%B?H MO-:=H%LB(A3+\=CD!J[XR 1O<*IMMVA'T, :)2$1GA$B^R_2%FUCNP:U9263 M'C#KW]/G4/5QF_E10,^ 'NM$7H!?PSJ.1<%9T8L(6N=FT>XGDX)I'"7BGPRS M>@)+<>/'>^SL A?:)[N0'QDZQV(ZKJL+8,>BY"08[,3XFXH=,(G62F\@J[3= MVX(*\-\UA3\*&,CP :>4!":\R5JP%SO,L#N@#1PGL338]D*=?VH^7UA]7/LIH,_J<^UK=+"GRW3 M MV,^;C^N13H)RT=F1NX=Y5XW6658H\&.U'M)51=,9I)KO>LK)X>4U[.XV4O;= M*G83R .&NC\DO'WZV?CO^3[8?^P?^\?^8\T]>:-_/V&7 E-_#C1!?F8225P[ M4]$,P>V#3V/^F-,!SN> .V(23 @^!ZKTC@;.2%P]@#R9SM7YQ_./YQ_//Y[_ M%!Y7O0^!:?R!EDL:H_O$1F@EC1<>__(,1]@._9]^4$G4;C4D0R-'X8F34I_F M6>TY< >)(SU#KP(QT'T.M)X9W2N@ ^TFGSB2&CG$[_?$N7/@'11/:NNLZ]__ MX_G'\X_G'\]_#L^(87ZC+M1SB=M!J7PKX]4YP+M+/ <.6?W_K1;RMY+^,!"Q M!!G^Z!:T253;. >>G0.B7?]GMS__@XU* KF& 1\/_*HZZ6PBO;]8Y"IHM/D' M\&_WS?S[1BYL3GIQU#GP_"2[U,*/1"C08TCYAP?_>A70?TXCJRHA4>8G!/+L MHMT':Q-"99SV$BDM_[R>%_V83_&^3OGUA MD:C.?P[ $G_A MTF3WRF6<[)T%_T*U[T,8C(U5QH0V]WC>EZK('[J:@X*,#'JSZN(P!TTLA;U\ MQA'FM(>Y,], 46)IZZI2Z+=4]Z(Y?CQW#(&*(8)@]F EO[[9= MQ?ETD6YZ+\OOT6;BAZXUF]@UIX1H]E3->SYD@HP0N7/@Z5BBO>!9;"@_+.;( M#]\J!:6SH\K1F'F;SW_IM?S O2";+R'G0,#UG?!,@9_(N-5&66C=ZDXN-M^T M<5)@AF!8[6+]-*=DSN1&TI5KC0D-=1\YYB(YR-.L]#@$@1!OLT731B,ME:NM M45XE<66&#GR_..5$*]'/TPK:+@1=Z)FR^!K*=5;6KH/.7TB;14%[F0I7W#B; M4MKR7M4XF]=;:QQXI&:O& 8ZOHZ,?7*MMWV7'&BB#"-^"97$YZS5X$5B^EKD MO-A^!C3S@AH]))^VC)?<_/S"HC;R8J6A#]+)(4W[DU&$@:./,_FA:^MG&XQ" M]"&$VUF=H6.ZL DG^9FNKS^G[.;C8Z9.UE*^\/"&FXJ"S.0.*C8\0J$/B,O6 MLR_A;+A@-')7Z=V8ZHG$N^;KJ8]TM](3,)WF6HGEH;WD#40 M E%CB_EK%G&()Y_=UG)^K% &0QBV,,/'.M&C.,=/S:O4#:G#GI>C7G]1K@P+ M,V$G"X-H.==$0]Q B\A^$'4'/1R,S\<>C?7,9K,E%%QLV WMQMB\#*0-?72V M8\%432EBX60F[$U)WC$-<67@@HN>EG"J0I9 7/2&V4J1ZI_PIB0=(.2^#ASR7\A[K["FHFA=- B*4J1W(2I-J5($ MD1(4:2(B(+U$I(,0$($ (4$0$)"J@B!2! 2D2:\2(/3>2Z@)B'02:4M(PL&' ML_<^]SLO]W[[?N?A/*R']9"ULL8<\Q__/^>88Q0BIZ'<=N0JD@U!3HNP&ZYR MO\9O5R'EY?#<#/NB.W^_U@;TKF$UITVQD4KCC1;]4Y!49_F)-<* \"V'D()+ MB5*1P\VS+4-C\Q,6NG[NR ^(#1MN)O]7&Q&JL M;QJW4P9.037.[?&Q4%JDQ$9:*R$NC$C?EN)M8>%BN,ZESYWZV4VH%Z:H;'## MA?FF@>24]QX5%J2&^]IL",R?6+N=@FAN[T:@+_M^,6A3R&11>12Z_'3J@"-I MZMZH9-@=UWTSAS"Y%^) MC-\8GU6,E46N2_%JK<10N:/OB])U!:HO ^H"OXB?#S,![Q/5(4=P.Z/;'H:X M<,,]*.?KHK65CBXLP8"!"9SZ1T9F9^[")>ZKF0;5]7%_)OG>6B%DLQ+Y:!QU MNN^H3?R5.7LI#?":R(9/V4HD9':J245B$M>1U\>GC*MK1^PR;K[PM^I]'JTA M%";P?>0I29Z?*_V_ LPLU_X58%+I"B#N+ MNZ>@>V8N_S.NGA/_C[!26XI:7H >,?TIYOT_NU!64)H=%./Z7#>WQO]^D?P] MO4Z=%KLZCN[-;L%Q7M(>0;2C[%WS=7*3BAE![12T+'#&DBY.IL#D)X\.CQ7> MI40R:XK1BO0D+/>WMKU;?O>$=BV6@Z@8"7&'\"'8R27/ 'ZBW^%0NZ5G_0HZ M$F$!YO9@V":/[W%[JK6%W'TH'DWT[]R-A#+M;F\A#)=WZ0'/0_SYAHA9LTF/ M$H V6V;"-OKM[45VEP:I,"]#NXG;_/?Y@BSH0Y](E+8^ M7KK$K?+Z7YDTC"N$G\+K/G5L$Y=*9&I+B]TI?)\_:^GN-]H3$.&@9E3T7K2_ M&"T58'0WNKJ4])S %$[2A^%^.G<)\(VJ:'K9F[^*V;9(N9Q'O] 5UYC-V&0_9\(.S!)V#-B'A+5NCH8.@*516B02Z^3TR%.:";@,S[HOIHP MU-6M#]=Q[J9GV6'L!G-P]\>A?O*YXR2J@U,0%4/L.R3T-]" ,L_3SR!D* MZ'')VQ?3!K'!T:-:HS"Q<#V0R6=!07FJ!4/KW3 U0;@!_G;Z$9*-J!:+CS'G M%JI<:WACYLHG\#I-X1D3/Z,#O&BY%@,]MS&4!W^/!X>KJ!9F,4Q:EM9Z>,B& M#7_P9X"(@79<2F&ZP$<<(ZJM$IZI1S2-*H2[\5,\*UT+,))I'BQDWX=[8[!#J%**S]%U1)^D^N M^?]F/4KV/Z2&B?]_42#_I>Z;61N$8"P="^& ./,KMU%$"4SMRO,BL^:-03?W M ZI^JJU>K'G K0(3KD]@U7"0N]6S[,*=Q=184!:-AE>V"$< R[.("O M(_GC4E4D&4)Y?*LG)0>2E)YE\P:?4'->?9:^@O\^0PH&[ L U),I#S5!X.'O M!V,9=W9];_CVF=54NUX6M!!B];C?%<+][C#K\I_H59C:#;BB/B$6';U#LLJV M!"R7Q#5*]0OO)QM=&!RM3)[V"7LG,+&"JM[M\## H"HRHRC7$ K$-WXI:8A; M"],;6//JYE#XU6AM]T:[S^V]L9Y)ZBKA7YM4C[4! J_ Z>@0S,"- [A M4Z*AEN_O>+LSY[NUA&DYJ;*W\=/5I^HU9TE .M,.?5V:06OY%BP 3]"%HS:5,L9:/^?S.AOBC\?.'!Q&LO#!!<'87(X$1&H,%((Y^8"T0Z'E51<-F&'W2MP^ MU;"A]>]W9_1)&S?G5P$OZ[@K'2'8\#QYM]B-&7OID^]3V5MS 5>8+$N6F6(R M+@!!%[XH1B.<<;N,&H7BJA_2.HO.?YT7"Y=X+GMG ?1J<&[YY7$T:/-&J;L> M\'F)#(/&WQ]K,LM>W'R)+=D/]"C-84B1]FR1[1C@OXH6X>&_5*9)0X,\#O(9KKI!?I8JW?'\KS9!L9Z.NLM;3V/XZ MT+%E] NC7&)N8D,/7TCOQDMN@3<"^.8'$Q!7]TQ^Y+2 **" O*K8MLEX873. M4M?=PV4*.['R-DDVM]9;GU5,O%2091=13DL-HM[$BG>0^/ 0?@2$:-:N !3B M)<5@YURPGID!N?#X+?=G[]X=H5Q/]#S%?TMU4\U4*WSJ-I'2?$;I1]>8O4&Y M!@=U<@9JY>1;EF865I?&VZOV?LLNL!22J9S_RS![R.5,3=]"?4<)1+WF)IY0 M W0LB0]QHMJD82/JHRE[:TST$<*K!<5 /GM ME@8158 _] MYZZQR?'%LS;]@C3G3@1?^H5J/9;I+CI$L:OP%< K4/260.W]>J)J\R.LQ-T/ MTD$"=W?>*!#CO=7Y;__ORDC"ISJDF>'XH;/@\CB<@#$G:D?NSSBEG8+,J\;W MU\X%_*ARNQ[M_L9?S#RYV_#UG^0RQZ\A:H'D:HA#B>AA"0 5R:!14),9G?@] M?&!Q@>8ELZ+&-6JUIY] Q\S%5+-AO\%5IZ"M,#PJ%EKIW%8BK6UEKN*_!)=P MM*+O:>OP,EJ0SV"2>9E=JY6K*/['_HX2V,E0'0QV054NQB#%D+.\!EW2'/"7 MRZV\HI%5ON4_1G9W2TJEI4IK'G[3.I%/TBHO^$+ MB3])AUAUES,U> G*+9^DT"B2%7/HLN"0GE5+VQ^ U !?O3H']N[$')+9J7YE M5MG6+Y,5<>2)2$PF[2(\QW:"95MMQ+G TA+EE&-GB9A[^#E=7$8]*[97\9DO M 1T/J1")7Y:>B5N^3]@-(Z%$Z@X-._+@?KN=E392J?+N)^^%%'E3*_^,N1C_ M:)Y )7AW3>\_H<5 *YMCB"A<[9;W..E3-*'(*0G1Y-WJ1\#B3C:1$@+YY7.2-EV91H;9X M_Z0V8K*#8]O6](N#[_N=;UR]%G)U[]\]HV21= @/$;H$J5J<:[6'QH/:B9*T MT:#Y&VU2IB)X30V)EU?G&A.2WH1T<;^XM81RRIR)T2 GDV2"<4,,\/AVWIIP M7R_/R3ZK( O.2V^IYGG%X8NK=%D13M0N+33I(8AK9RI#%G!18Z3T0,Z16*6: MYX[Y6RN3UA@N.5C!OH1LT7->]>,NRR'Y$$2[,@4@+Z 1E+N3)'D$>&D7-/OW M6]#GDZ H7_%6P3N*$.2Q 0'ST%N>Y.GX(PX.HW@;=K8YJT M\3:0QZ-ZNC"[KP/N[%JF2[V=>@%7:N:D%#U:UM/?;_->^.R=XS*9K&A9LEKK M36,'?C+.R9'Q$A+5+M,E@)K7%!BG(C)%4A@0AJ.HI3Q;(>"G-.:G;M.EPJ_K MAM!O>=]2.32+.1?=7&(G3T'BMZH^4?=/:_'6:0/R.T\098<9Q9Y^)% M5TR[(H7-\6PF"-?'+005J>^L#;^=**=Y<5W\AB>H]V L_4MB/Y MR#EJ8B1/(C+S3!\<9N-KW/7E[KD7[(A65TGS-5K+/QJ!V3/<>>I$S3AT6P\# M*:>4X.)G^]HS6;=RW6&1#8/I:1\GONL+],5:]8,;XC.E3349Y5HM>I MSGQP3\_"!&0I'TS7=!OG MDD0YPM0<.Z15#1?"*B3,7MKTK=Y:$FLG)J8C1JDFPB&8M+*WS==1K0^:E0!% M,^+E\.R-P-*/WMFN71V\C]+>*H ;.ZJ+W7U!6O#/@QNM/[I@0E-KTAAHJ-IY MX-[A)"$^HG@_YO/J8@!"4=_?;T94SEK'4O>R+D190/?V ,*%>S@,ABD[N(;L*4:<@&G(8)AEY M'08&PG S]4VC!ZW/AW4E6/2O9DR8!27%"/QZPO/ZUK<[U )])WPD]<^'Z034 M&S51=U/![;L"B>08^B%8U1?U'UQ'+.\G^)_7T)E]<[3^?;WYP]@K567-$8]7 M0?1\0:HBD^>K0SNY/]K%<=@4\69QT[%3Q7TJ+HO,O$Q2)N2T'ON'(T3SNG)< M> ,K9BT>[.!5!P<7Y9+:DYV4A#)/E8.HVBN!D MM?D!/U+?73/IZ.DYT3F!F_HK#Q-;B!Q8P[8+&U3G&LNPV,D@)FS\H51-_:0P MD:-?=FVDKUB?6OVH7[KDWI>"O^E]DRWVT4M/%0JY$ZTEFC3XYOV0Y4^B\J$QX$B,[TR#Q2"LOD+= M;*^-T:">-4?:C$OJIVHME-!A[DJ\X+XPEW4EQ"=1'2Q)$JX;1^B?83<4:(3A MN\/[>5%O'&K'GC6ICW2XV';!DOEBBRMZ']]-!:OJPU.V6HO<&_))K+O+U1GY MO_6_FO?<=?6XU5MJQ/61#=)V)>(4%##;[+Z?V06M7 QI%G)7:.BLSWF$G:\N M,O]6DK]A9LI5XMD2$?Z[-EE)Z-W*+_ZW2BHOW?O1;F61Q\ZA$'L#;@#<@F1I M_./YZG!L?X )8_ETZK&CW_R7A)Q;M P#@MX9^4(.U#@#+I= DS(2RQ%NM;1F M>-:=&8BV*@KJ'A=:0!V&KP2%7?8/<(_[R8)J$*\F-UUK(&JW&TP3X+'"'MI& M>B;C1YS1QH(#]JNA3R.,ZS]GT[!UBL^<@NPR9\K:;(7(Z:3SKD2VEL!Q 3'" MSU\3[5B#*$E?/G&3.O>BR A415_% HZ4RASP^G+3F>M7[5<=:,K07YWZ!)N*1"!P*L6E&75+C1 M!!.T )Q11>Y;QU+F%CR5I,31\"U31$)BE6J[DV5J0,UID@9&59YPL9\<'("4C.6<2C M9B#R_V[]EZ.;TJ*J M][29(/+:YZO^=\U?MIW8CH-Q16HOCR'VL;M<-%?4YEOD0%[]%VE;T!4H3%!9 M?&8%.DS$()J7Z0VX54TJ^*6%Y*M+GK[9",>7&6>QPT/ .5U$/=ON?(U6_?-\ M5:9.Z?-KS2JGH-!FN*+&5!7@JWI]5V?1QUEV5>G0=>HQI^;:QL,;8B^Y'76N M)D(= <5#>4"2<(+G(HE0!(#@;ZX9PJ:N@@VQ>2Y+]A-?P],[6(X>T#A'OS&/:O04L(CH^LUK>__@<_G^O1:^7]X'+[@\\ARH)T39?OL%.UK*/ %#%+N'L7 M[V)[60B:$ ; U GSAQ6>*)QDY83:K-!%\%:SM>['A0R[A9<7^IG]Z?[Z+YN1 MV'8UQYJ4O8F80QBQG<()?P&UJJVL:1+W$+JFTGERN^V'R^LG2.VY7.*'*TPC M0VQPG\?$^(@#&VKS:JMY09.JY,X_$ZD?]&D*C!X(ZPB*M3LP!Y3=_GQH %@( M%R?? IST(9JIM?I9ZPUYOS+>RZ@B^BY^L_(?"AY)/\IB"D&_&(K*$/K7UH*F M"U#"GX*XKD*9-]1$8K:-+KZQ]4^YG,>J7P6B_?2VP@OT%^#N"*K==L0/15I" MVZ1?^R.%IJK#RERQ$9F^V2[- DW1@D%![+=^.;MR),D;**@.!AA*@W8Z@NV( M?$M#HS?X5'S<%K\$J(N=*S]G,S\E1_H%MY M :\@2X60*]?JTUH=,S%_]'PO)ZU@^5Y+939Z(D_$Y4/*04G6N)?J9P2!EB1! MC(@_@2"'%R\=P&C=;66 SW@FEC;)@Q(Y??=-Y75.\_2JE%Z&6[+,?V3[U_I^ M7U9D%=^'WB.G(-D!*_Q3 ";R MZ\DL?%!\;Z@-76G0;@79SI3&YW<:A/ESG1D="X?H$A8JBV;;;9VPB["*5S6) MZ>>%"75#JK+J"FC/ H0SP> 02?Y$XL$S:DI5-?+@X]N3>LM\G"4.^SSMHDT8 MOKE\?'0*DM+",:LP7SSN6HIO/1EBI PO" ,I/D1I+:)0AN*P79(-%R:0;\:\ M]\F=#7G!.;BQOQNV2(6@)M!JU(TBJ'%%T,LSUMW"=7\R M=!U3([PMD^>\D^7_M M"?"_N1PV%HD$] [*^.GWG9)3$)B>\OO@]L/_I(.DM3,$&D7UB &^9QA?> K: MOUNT&Y;C$]KLDR)K^+;93&XV,ZB7^;&8M7:0M-%XU/LG<3N\#UT MNJ-'CX;,'3(V6YKZ%;E:L)R??^M'7F)LXV*$5)*3_?FRURQLJ MCD",D>P)TH>*Y(\DT5(MK%^,2+YOX>9A;8)R"W_IY Z6[Y.&^!V6H9LN%;+V M*J%4X#Q>R%89H4M[JFK E:2L4/]]W:TH?Q[^WJ1ITK*;P>./VHS\5XEG]DXR MK]=M_-N'PI%L0!?.HDEQ69]NJOVN1*F00NU#I!DH9*TE0HOJ+4,NR_LA>:HE M-"/*>;JT60X^VREPC4@)6]97QD,BDOA.08QKEO0SZT=/LB)NE![=GN]$^?^\ M8#"P*F/\)Q$J1^D.]"PG[.&9.LIF!$UJDW<-ZB;"Y_QE[]4_3FI%3H[ZG0NR M\XQ&A?\633LY63IJ@8)(5,,[\ID@P&T*4V,F>\E3)3_)PLDNG4/(,/F9!&"*QBR_YO9_(#)0,'_' Q4+/B^E=I'2C:KZF;Z@5$NTF]S].B4\MD^^6>PAG[HCE1-P M/>K1GE=+]DRC6/:EP26#:13W*<@9'8FJNO#9U7[Y7_,*>#2?@E--DG823]9\ M;*MPU,=Q_J($/EIJ5;'PHRTTH?,$QXN0/@6]L?%0N5A:H1"?OS"'E2B^O-5+ MU"F3LF+P+^^A>ZS##2*- #W?W9^@6N^>@7ZL+/5UP-YH8B7>E$XGSM0JRI)[ MY<#X9+)U^0;3$_$U&+>M&Y:6Q-'7ZM=\Y0W&N0#^1+-8X\5K^R#'N+6(]^!Y MEZ56U0EVWW/-WT?03I"(0'!;*H57$_>QB2!?P8,J]]6;_0Q\?7Z//)*A[1)B M5T_#*PUF@IPA MS3?'6T2Q2_#&[1*%&**UJ_K']$!BC*Y,! \['?0 M5;L_&3K&1_R_MX8(DWLX"12#&>9^5\OW>QZ"^LWUE18!/7NV/!R_>G[5EL^I MBPK1@4CO@.RE+_3W_G5^)S$0,S+S9K'PFMUVLQ']D@=UC3=2N&:9=8\^LG>^ MN7'UPOGR)-TS#?@V@VD$^8\'Z$.LB>DV!*3$_$#&@\F=DAZ.:TPC_R-)'B.R=ZV_6N_ M]H)%U][E)%13?_^,TW-UM;OQ[;9"1#,2^QX>%7Z@C](8D=J5ORFORD=A_2*E MKP6N5/';/0R")V\PEHG))WG.S?SM'*O#IVR_)Q0C_O7T\UE#TI\Y8FN3/V<, MOKTFS-1=SI,#->I#1RV4RE*STOW\PFB31\O)9_S15C;A\W)GM7,1L-EJ:KE: MY/(]<2&@TJK74%'@6GW@05H2XXR!SAKV#0@ MXQT+;,PM[Y\+A\Y;]?'63%C??.;WJV;9QX%Z+]^UQQ9]0KOA8CM_\.)Z M.O(W0UB#QCEM,CIZ%J$,B,N8M;VS'RK;8O; MS!=:,KL=%E*O;(FJ%O4CE2G]4#J4IP$W?+*G=(50V[Y(:R.2XETP<[=/*%'^ MD@23"BW5LIK]C:M%3@I\!!FHBUF:.[02A2GQ:3>C7'^/0=L1)4F=05^"='_6 MCQWP<'\5&?.%77_(YG9CF@_&KZ0$^BM]*#ZA)D92 B*),4O0>-\]/%F\S?*^ MC86;A[C!2D !@W<4WRH=L0XFV3-M?PW>HV)&8MTT)U!23ZZ1; Q8W4MP9,G= M,MN-PP68U"J]MQUSLDMY\EST2[K0>[.=WM!L)!4 Q:$B[OK^2HG8_[0EV/RE MM$PD0"@#O_/\ED.&JT7NQVZ0IY](728MI1M-VW0.849^O:2J: !EG^US+?J: MRB\::H"F*Y)AZ435;=D,?7%QUI28A2W?A.N-8&]O3(X1Q$6 ;"LA4TS MEII:>==;KB+>W":AMU]^+U"\(B9CUU)6=@IRS:3;; :3T8!KYFFJ\=\;BP?'_L5_I 32V3K(I4@P1K)#HTX M]AJQ;[(Z!4D/U>VE.3)P9*#D!KRH;V$'S6C>F850IA9!I'MX@_@%%C2A.7\9 M%AYX.19W+^\>'DVS7AOXWET)WA*'5O2E@YTWZ[>1;!>K/[5NMSP^E M(7O.XN5.LQJRE\*0JG;#18T910/4'_0X5 \+UT^&$S_V!HR1JP(RO%+/A;_A MG.']%9U.ICKA1R@"'4OH&-X?4\CK0"5>NFV]RH>2NARLL&E0I[AJ@DVT6E > MY+ WF^MR^[+T+#%Q.X.1'*M&CU #PD]!E]"1S6#7-.H>/ AJAG_CR0T)E4 1V2S 7R7)C+;D!R9G0O2XZ)6DJ(/(DS"'3\5 MR00XPI+O)+*DIKZ](K;">:'9CIQV"O*$OET0)>?D 9+$S!8_-1:B2;]1WW.L M><(-A[=#Y1A=L88JG2UA[4XS;J7N$ZC1>(F\Q]W-)^CZB-[.2=$,_"JN39O= MC5ZN4N!UO2Q2E#Q3]@ 6Y SV(1:_2O-BU'J<_';D:\;):GX]TQ[P%O[F_!GZ>L+82J?':[YJ@N%TNQ3>_B?[='RI*&0AL@[C=0+3Y5R*B#\UG MY7JH)E2G<7L@^1.XIWJN(XF_O]]FY&'1G18G!G70:QM5!/T91R\%WC.U+X8< MJDE,F74$&G1X< ;-;#_./%\^ZFGRZ^:A#ZNXO)4)>Y1>9M-LY+TCIG=-NF?_ M&O;FP,/G1-QX"E*YG5M/&1@IH8P$^%0Y]T6HQ.X$GN_NR6),(Z*QE814 M)(\5D(P?%9\=T#"N'=FZ7O\!XRDE?'EV->& M$]01GWT*:LL',I=*:H9\R'G+3)>#0_NWQ53*13\M*LTGU*V(!YHN;C,2NEH6 M>9OHF4(0_J<@@>:K#2<*:2-)E7D;]R1Z"347+3CO?/.$7[-XK/$L) "%0<5 MN<8ZL2\"-P%HIQKCA(J^_U>]0I?#T9F!?(^0/OH"69U*]0Z_""$%BY>/X<%' MVY+XH;=0;J0P'(S[H 9^K28PG8O]2$'33%VG;(>QN-)U2"!U^'@LG:0C:(\< M&#+?G[&K+_9XV);)R0.73'K8&3/#W0#T\3!6&Q<%X^[L1_XZ)H\*&J.B7B== M[TDJSEU>Y>&OW=+(75S+K.K:#GGLQ,^&@X,@3 M61+BWUX#+*Q!,>Y5G^G8P"0@M<6/^6SU:5 HWFM#+O3R!9,/"7+1Y<1(,DK?O>VHW4[;_^\2CZ^0C[DKW@?&8;/%W _(X3N,]V>I&#!W"H6!-JER_5$ MVC9!K;0CS>3I ><2BSYO_O:7<]H7)F0&6+0NF'AT>5W3Z5("JU!:D/Q$[18T M5FY9NJ5VRA.AL02C[X %VPEW79_9.?N#DR&JT$,/X&,AZ3G ME3&NWG+TLJM83(CQ9]Y.D>(;B7A_@6G M9W=V.@OA8^U0KF*D$@#1(TR%R]MHXSPF*FM^EMK8;/VL^BP='@>YY?!,>P0L M_(GU4P]I!9C)GR5)D<-0SM+12#;HEL';Y-K#Y)'-Y-B:#1U+^D*&QXL!RXSL M]G:](0^7&30#(=OG[6"P,V9K"K ATA *7,??8NT"4+\>"+HZ[TG;SXOZ/4OL M3/6\WYF3Q4ZUC68XLVK96ULQ@9Q:0?9/8@,4MN]SIS0P.:^P5EL9&7NH./?<.N7+GVEUTI *LT5WGUI;C?&$R7$$W)\ M&05L(16O&%-UH@QEL9H.S9Q];N]2>G0--:67NF(G&#I;DYY.I0[.GVA%P(%\ MIE;I,*0TL7\2OW?"9I"T*N[D\=6UO.9&SQ:OEJ;H#Z&EJ=_YTR.=N4$!T*-2S M^0YR(+.*J?7DIY'Y/JJ:G/+0/<+5M->"\W[Q!>12$O=<0>?CG=_R5/N03H,( MRJUQB&,J2;N(Y$1TCO#U4+R?V5Z;DL;X>X9WU]B%OOA1KZ+D=V]VO^$/57 HR"\U^6]'9]*;?N$(]= M5?VJZ61*ZV EX;Y(IR:&> 6@",?T,-XS$W^=0(@0^?4>-1&:+ OJQK?'GC^. MEVCCR>)A;;NO +9/JFCG%,]D46,Y(P$7X@F_<9Z5W]T$)"@#$QX(77PFGXU% MR0>Y+O8_O0GW8S[N.7R\_]<[Z7J4[*Q_^Q7J];3_*W? +IR%/!0N/O*NM65* MC(IN+ASZ.-D.QK]:&\X(N3Y]PT?)2(\SA)^#>]P5-5T>B M52M7BM&7\E887ES17^WU@]3;[H=OJD-/EJ3;X5)V<7@NPFI.@])3VU^=E]0J_X2AFUWG MS=^09R_L,BYF,Z-F$D?*ZIWQY/KKW;FS.3!/UB8N;K80'O>6$&L1WAX[6R, .>JWU#-/HJBJ!8)Q!%';W]S7V18TMPH7(;_MF!TI13P%13]WKY-T M&E?K<'9W*Q+D^9:N>1-4+)M0R,?*O-^[0CW2Q$?,Q^VV>QC9*+8AE0E#T;>Y MLQ59+=:P'3_G>I@=C:_IS+]],ICC)Y-,75?:BY8[!3GPZQF.HY?RH?P[JR.G MH(IJT^&RH_5:MMBB6XT_: +>7C;\Y'#'^N,SO]_1!VX*VO[\P[?FI4]VNFF=+?^U-)+ T W>D1!:6O- I1A M 66B66S5 +4E< ^5C77GO3I9M1TX9N@^?UOQID--8[I55J@G2"P#ML MH93% M!/_:3$U^IZ:,> (,G)B1'#_;5(R42E852E8%;.=,B$1+2EUTKE>79-O:/@P= MY*Y4>I/!]$B,+'UBAW!I(&>>@IPA//"QQYK!EJ/SDEO44K^LHG+-[5_>90X_ M2@CXMBY<=HR&<\"', G<2],"U>"/!DNOX$K_/\&1I_#(C;3O$ MD=([N3]OL.VMJXJ>WEE.&8SEX9A7>%__M(=;R(N^0%43$7,&[QC QS& H" = M&=37+-3$T>T^M#+@/;J D&J:0:OU;@!'^+9 M7%]^G.KLFJ-%X6P>.UC;OG:MU-S 7<7X[?"S'SHBII" 2K U+^BP01S_TYE" M9V*7#3"U05@]5>AV"9AVRZJ&AV[>;K/5RKJ"DG4#CBLT*X*W+BE[*;-2;:'= MXV4,N-78Y^ [;VBK 7DIE^-,2/V+_V=79> MET#'T>5-%LL&3 "M=K!5^_'.9]S 37Y[]VW+/\KFU#)MA0'<4@9V&>XM:O1( M+)10B7:!L2.N$IE"?,%4P'O=:J[)=12*L<_Z@:EB>PQW^TONU=BV(AV91B&6 ML![2?7)Q'H#&H>,%KA"D0X?>-MU>VK[^!V,Q)3+^@%5E@&:C;72Z?0&NP9=D MJ?.'Z]?\QV[:L32##H/S[@MLC42M5#R9UI PD&KG4V+IYJ7G?.D)/6VJ^=NQ+?++)3F;2TC32H-QB1=LC>A1MC M)+ZS06HB#A:5 &I374B!&-LZ&V.-AO&5'WLELUM]'SX*^ORTSJ;^M:;S3)UV M#<9(F4)2 UPG["0UXL_(T%\C\F2+QYE9<#F#G^XI<@$5\=+;E[.65YQ=N9U7 M.[D3$YARA?YE"8.YF.ATEQ<9M/%A=ZIY!=T5VHX&[[0CM<@G@]I][_9L\I#/ MD*.\BV\/RH ;^5M;"!,<7$6FJ'.2+[MB7&T1)O:YY^)-Q8\LSR^;O+X7>D?B MHNC&*>CM8LW58>1U^$G+PF5"E>T-(OAUE0CQ0OF%_,*:3_&>Y;GADNGW%#_A M'.*5FZK_MC $M-".LIOU8J>V$U'+!M-EEL $85.S-O1X]%)3GS3SHUY)7H6; M@M+)Q2)7M\5RLYX%.':.=2.[4%4'[C[06W-ZP!BGHK72L/[1V?L7?7>S16=MPC#!VV?UZFP>;]?J/" MG;83[HA71C%U3Z:UU>1[QOM>D0[V=OR%W)@QS$VXE3C]]N]3F\$0\,/_W_6=(97*5\Y3%XK^*+MU"HHH "1/09JH%A1@;($B8@]X257-1-$( M-?XSQ'S>9%P(Q!B/-BEFY67)S;L9=WF\X-7G9/672VC\,GU2[KDR3+M>%H&P MR@;&]/3U,-C!S-+U0:_:-,=Q?^;RPU="X,'JHCW[0U'"U%L8^D79NXR[@'_. M@!TA^5"YU?GP0W*7_G@I0_0S%D0^?=/#U@F^/FU!ESGV8UI,)G!3.TKM)N#< MZ6_+ [ 4PR.AA(%^F:%"B32X[E5(KQ1,27\PEBL8=/?2/L)4Y!38:A'%3= M4K>\R**'FX!_$;*?*Y,O?M#")^/+=76%RBD9Q7LVJ[H7 G,^9_S\^,]R# M9B$@!>\?"7'>]F\7N!33EK!1JU^XO@W[3D\8?BB9:F3_ZX']AW/%3RY8*U[6 MN1J<2!P[;!]'TE*&%R\W\\[#!19-?A"KM_/R,JHY:T9Z0,FXJWY)<[,L'YR[ MSVG44?6^#Z':G^#8,V@MFZ4[P:.V-9#C0Y^M.'S/2T&BD-N@NC/54U.OR0XE/-/*1;X\U"< B&MRI0=7LG);"- MLF$<^\=B)I>5)T>]5T^N*Z'E];L$J@-'#H+H=BMQ%Z\03]Q;T@ZILN*C9Z2V MG=J/-?0HE7:(6*68[SZ["?-K$^$D1OG]?O:)E-WX N*_-KK!MJZ0Y#99,VGY M^<&WU87!7Z77XAXA>I.JO%.>!,IHB@X_H0D\>ONJC'X]:<-R,M\YUW7X%%3< MB/YR-4IN8TL=_,4G WPVLX\ZDOUK \'Q*G+%6//.T7F#_$W.O:YS5$FCLDIT MH(W'YQ%4!.?VR,/I,]X?!J^!<2=^A_.UR-@T1^)FRYNG$#YY32^;A#PD9C., M'NL\"TMH"LX[T44.4/C)6U\L2ZO\\./?"UM+VV?B8H"#[Z:D[8P[<=M>QK0,_-ZM0L=R$2+I>?*LO^ &L@_,B%$F>\']/2?&GD%0S0 M:_)>%@^/?S2FN515J^,3IC*V]=[-MW/\N5\-[940_P6N,PC?[<1NNF3P$W D1O4L0LNFW<&97U8<>G]J?XC=Y3"M)K8 ZW9L@@VH.9J4*R8\BLP1 M+!3#S/&2=LC%*-=YC<,$ M37L$EKI-IWO-XB='?0OMS/Z_)O)T*'==DNO)/3AZ"1U%$@1'(&"X$Y.?C';? M^>^W;5Q/O"-^,X++N 8^R! \=%_&EN4$0O(#"HD:AR0@*F^CP2]<$AWQ JSE MH:!J"R^I.OOE6WUYQD,G13D9$&Z2>=JP_EP(2.T4]+79G C>'J'1QC\NP1E< MJ(U&5L:$@]WP,J#AQVX_\ MKU4ZTY##X'-5IR"L8(LL +$@@M^J0'*L=&FC)J["1ZX$LVL*DYJ6)6Z-:@W"/\L[DDP%VXWBEV>:XW>:V] MX"6&08FZ[.'Q3C3H=_-5N +DK2WC!$))H;#091+[060AZ*>(2?2*UF*PX8R5 MYZ_>9&HOAHO%K MB(HH#KH%6X*%JTD,D^YY!)1L'F7PE[_7)Y "?XW[:.=8Z0P.)N,$[^ON\?MW MV[1]R0[!_\1&WP"5\N$76\ELRPHQ>=/NBG>_94I]+.@J>?CW(BZ !_AZ-!H%"&Z;-YDAH>P;=I")HMAI655J;[9--[3 MNE[?*W0$0^^,K(IE\7"_.LEV-^L\!55"(A$VRY)6'9;(\A) T69RZT)*B0W< MSUSP;EX!]Z5;R3P7EM0,Q5XD7*8..1^XS4Z%1[.@':"@LR'G^H80^G,@S0A7 MUD^ZZ6$W+$6*8NXTC^UO;7\=4ZE F+%OW 5A$H&/9^SQ% 0$$04[,JX0(8=' M[YKD\*KT!K5CD@<>M)8R-KKLERKDA"H$RX.;N(QX&I+T@V4T_QW0OT1A )R7 M.N,#['%K4K9!?P<6<,^Y;S%)3BU+_8-]]MWCQ%3CN%,1X M8$ -I,^C[-Q@GD?BSC>BM9CGM.\6O+AR;N3&G=\T2V&ARO\*MV\+'@H3I#(5 MWY2451NPP,,P BP-[@/4;0T_YXS6L8CN:2OKD+TPUXZ.7BS+6?< M8M2B0!4JIK99ANCT&5_">\=N3'!LI9RS)K&K[LW3I)&^TG+62JXO7\=QSCJ5C4R_@M"7)78* M>\JREXU5/:$=0M&?@IXS@4AR@#(>%EZ&*H67M6#W,UYA;=&2C0&LW@TZN:$7 MTV7$>7J:%<,0-'V#&O%-ZZ^V$FBJ?D0=K&R#;#\^W[5]WI>8#!& #TYU5@:\3=(4 MR?!8"L^1N6BD4 FYWGF_\+G5+YKR%^_S3N0I711NF 24".:^VW/?C6&F^3JY7NP#W^")"/*C> MZCL%2>S/*L,Q].,) '_$21C@%R8F^ M#68Y+CE3!:U/U%A% E &P?A1;_!UP2_M)K&#L!FWJ@]^'I+8^NWTM"]:-*KLF%86.8? MUT5ZR.9O\U/0:%YIM)(3J\EZ*T9K_@#5NX@2S&B^GGOSH6%@V9[V:")E(H&( M;G/F[]V DK]7G:D4-WU&XN^UNV_4FJW73D']=']KHH]YO"@VDH6SJV?W1%/[ M**@[07O"#UKE'UHFLZJ6]QRU_K/ [A04)U,:KP^4+_TT?PW#6PF+5D]NHLC< MH+)W+J5BZ3)A*:TWI=-.08+PU>K)=;E=*Z7L\>=[+WY'_('LSCZL8!K0+>1Y MF,X2M@L]CYTW<)0=@,DG//PI%!7]@Z3IUR#=N[T&J99#%):ZR*"+CU_E,9$) M,[248X[U!3Z@'@?F\-#3?ZYL%7$*2O%0#V#:IR'EDB^5?6EWY)Z3JORV/>^& M9AK?+[2_83(J.[5S=^/F -]5FKB+W:KQPV/N7, M=NZFY:^=_+SY]1J_NY??>Q?,Z:G4_*$Y?TWK1CVWU,D35JIG.K2K8$"(DE)* M4@"T\>#S\-HV6S%",UKMIW?1_;2NR#(/CY5:=W?S5K:F^Y*S.;"$&OP%=<$[ M)S71H+]@"AT*MPWK1%4*+0@0%B.KT:R;9@UY11W.7UW]N^?214$A-JC>&;)].-YMR7R;R8RV![\YBX1S K1$SL_+L6P=[^?=:A6/'.*&HENUK0 MU*8J.]5?6"ZEOUD)J/Z7U3K:1.^!&W#7)@Z%D^XIE)$CB]?W7/_,(_9(4;^_ M1O:;";\V#NVK5>HN*T8[0-XM,B,"EM#T *H#0P!%#$HZC< MY(*3)&UG'12#_/D"1I)U'#NU[G='ZW1WTSBG[3^\08V'3G<])=9N%1$HJ' ( M.XD%?\\C9V%(*AX/9ESGLIR/G6@J=;@9H[.2)+TH:5)JA#=- _.67.(<\-$F:F"RS*S\RL95A8?D2GA^.[L>["'7T,@ M5RAR"%5@F[AXZ%@^CM DU'9R9 I.\ M)_'.\O'#H#(2N[T>T:R#20 Y5'O,A-GE63@+SP921448URSK^5.0R?E"AM=?^I<-$HAC4KL/% M*9?RB=*XPUK"8H=IALBX+TV*?E788_=ZZ0>C]Z?-LZ0E@LXWILA^O3$7(L>J MGK,\^P M)KMT;3A6% 2D=X*"@E3ITA(;("HBJ*"T*(@TZ2 !0H(HO0D(* A1BH (D:Z4 MA%ZE]PZA-TDHX884WCSS?O/,?F?VS#.SCW?/L;_O^'ZL/Y#CSEHKUSJO\SS7 MNM=E\;ZDQUJUW7-3TT\V623Z4-,(X]/(F+?!&E#> JPRXB8UDR8*W-R=Z?Q! M7R8Q]2:)2+#*"1G/U;SFEXB4E,K/9YZ!2CY>9W)RD0YM-1K8G: '_0A9C2)& MI.Y2.*SQ//4IN".KR>#P"9?!SO:'Y=P87_.0P^?M2T&##/C^6P>.\2JW)L &)JG-N%'N$7>1 MTQF:]?8N0SWJVP$H>+JB&W$F;S1TX+ M9VP3\>;,/X_W)%FMUY6G NW3D$+5IHT0- >2!=!H0C$CSSKR-R@"Z"O)30]Z MK8O>)*7-_"K;$WT!.AV P&PH M+#35Y0]WO([?^8MO5_"[FY?SYQM+#A6UG(F:>]QXG_O,_<+9;A8]$M=>;$8' M1IN>N2$#6#E]PBZ>$\I:<(:LZ5L,E[LOMMXG6C8Q%^$AVW>6CFVU1U_"LI7N M'N79+5PN4U5U_]K%5>4DE5\EIQ1TG_UJ4T!QN:!DH-[T8<(U!:4ECSM4>H M;5HCX-U8(E_-%C,#B0D(4 M]-0_C^)3/-KR\_;U#Z*'+S;\8EJ"E:,"*&X%" =J*DW:;O(0\7QE%ARY/[CQ MH&<[1;NR_WF;>;VK%1S_PF+LP9"K-:\-&1!!=S-*'-GR(YD0IJ(*<-,?ISBK MS/!=(1 9PK,(/%68U-N)W[WY_J..CXR-MM];G2#>QB,?DD8%GQ\M!-62>>@B MDYN.+0<@7OC0C',Q(::!)M^S([51NJS^ZY4SVMKGZMZ3K.^QB1*SG@];Q\D9 MHTB=+G 673O7@,MCZE&A_#'-=)DZA3^?-!UEUOA"6+!?YME ?I7BH:HX/M'* MX!=W(>87&&B MNSYNSRE9XA,<\"U<2+MXZF70^Z8K<;<,1) MC>_(AV<%AI?!:!*T>",*]91U3/PAD#4C=VI%6!FPQL]]CWE0U#W4@>W]N9GY M51OK?3-/,M@H(#4H"?2R%6[K"C" M=4L(.R3H?G/,H]1*M_TQ>T2B-/\ ?F./JI(&@2P MGEVW)AT"8--,T.!)]93&45C8!D;.LV?&XK+21?2EO,2+Z[4D".AK//Q6V+OH=+66:^Z)U*.UK7USR/R) MASX/1=@5_X1;N].XP\ .;CI'6!SX@&.AW-#DR!F]9BVC;OH6G#^;,F M1G=Y6R5_Q/H<4SV<$4U-1G(#20T'("&<0P2S2=VD- $;2U28>E36XQ5E5I\T MF/@KB6-%OLV=.2=M=LAA?H?Q. LXM9,S-HM KK. MD@GPP#,9L#5*+B?7FXTT^OC;LS.W2S,)W!!E=WZR\/U4"LO5>5.<-ITO=AZ M7N).4>RGIP )4C&^%AX#TLX7N[]$5[ZV5$+R1O09Q5\*W1A2^P#I3)0 MBE7&?9X4"#H7LL1%G\0G!)-I2PQ9 ^$+O)J) =,ZDU"\55",Y?MMN=-7/IFN M7. 6OAKT^<.)3X^XAI"+1OF\,\666V03Q!$"NA',\@@.:T"Q[*1RK]:G"9>E M:!-M TK"G//793-]^I=[1NN"1L]=;!J7'6 /-!4,G'(TO"Q\@+5/A7HYB\2-W]F"];RR*PRM.Q(G!FY^87CZ-)_/-N0]4#:]6/\ MTC'0.:Z(WW;=4762J#(O/\<+#)1O$U@7,NF'2V]5"/ MR3L-%W88?XCYW\ 8,"?BB;Z]GTTN ME ,FOHHJ48W<\6]G7E._K4_A/GT,NMMG@S.=+M7W-AHZMZ4L='6%=GO1ZV?' M&:J^OY P-T;&\;[A]A E1N&SDSZ"S84 :>_'GH&;Z%J5IXGV67NMQ':>>[)S M,OZ1"HI?$YPS;EYKC7)#27/W63@%#B3Y-@IH')LJEPFZQ$6 M/DO5KV]UF*0]-Q"&$O>W)0F3_$$G^]WC[57[TK>I=^R>)3C]WQ5[@#D MXG*L$5T(][;\L4V^$@R>VWAH B;<-5.V$B$<+9)[%O^0$77F$"9&3L:R:=// M7D[?3P]M)&\F5G M:$FR48J5]_)\ ?*7^BZ&(83&V",YVP&8,!V ?F"*#D :'@]113A*4A1KLF:#/VXF:C[G MEU/I;_68K[YTS.NA_R,7=TKVG6S&#(;+?H]VR:H\57=H]PM*Q'%S(3PD8<:R MI[R#OKIVH4^VP8"$>$V^ZY=6_&K469WI\QE9XW(++=$91.45+ \P0MAJ&CO^ M:A;'LA)7?D.D?V8+Q]M^'!R*J5.72GZD)4YH31\\:V%(/5DB^^K<#2&/Z L) M@.XT.LH2 CBW'H!.-$=Z5;,K+Q_+VHXXN=^7?FTO>K//MVCALK=AP91#TH#4#5J+]U(?I6"C@0<_^ZH M/CM\ MJE'=,F\Z+[O&/I3LE7X JID];$ )@1G"Y9HG>8'8;&IE7=J9/H2VP_%'):L) M;[.+D"\>K_KRW;<$%<8=E7&I_9F+H397Y\/_3USS*14*%!(QM; CV_*Y M0)?%JYMZAU1(KW:33,1>A'/MI:2INF9HQL+2T$*XZ:PT.6+YJ!(NI*QC.I^O M".=B5>1P3ZY@)B%DZ?T3ZOZO^NE5*^2Q; ^U^Y&JT"L0:8HO@:>&#"Z!MS>\ MJ'BZ5HGORX!XS4VFG#$O@XY>,AP/!U[A-RA64Y8U2IA\;&%NKS?'QEEX]4>&L=W%ZN\JFV+A@ M$YW$XEWTS*Z@>_X%IT\#<#(^.Q)RP4&'W(@5ZR\E1XTEK9>?6@87B4]<6?O( M.&^77NW%Q?4TVC4]7#+@SS,LM2TPO4A)]J[KVM\;A&[G.FXMX*Y@65"MV0CI M Q FU?H =#.QM/X 5&VX@]J_'?WG)TN8T&0:K_,?M92]A#N ]'G:L M*$KN0;*&JT_IV[TW:.#(4]:<6LPS0LRZ:C;L^:N&9#_[S33(B!53XXY=UT^& M[O)>K%MZU0=+D]=-$P/!U8,Q^SL:$OC5N\"Y;.M?Z^+&WXC'0JMZ-Q[W.QE0 M2LM=:_S8!@P*\QX0FD+P,@;UJNU^63#])^ZXS5X>4='NZ-=^PE+C%%;R;6W7 MGE%X0?_5YIAU*:79%6+, BX!(:L1O-I=1=A(TZHX -7N^3?C0GXN]^\ZD#$$ MK=[PX*;]H0>%T9M-"P)C:L>-_+Q90HA"K(4+GS%O[!M'\@ULE :ZZ3$;[ H5 M@BC!_4@HP/HK,-50E/"M;Y8Z4?74I_R>L&C@1=]B5>& IQ] ^AYIIZ@?Y32= M"*QU:#:EJ:,.R9]S\1J>B7WUOO=;%<,$W$:'V'T,TT&9[\6&-4X5,B*YJ=]1 M#@>@(!0OC1UQIPLGF4 M\=BU1:_YTMD *0H[M1P#.8- ]&-9@*F9M"S"8E-9=W7#74B&<,:IT!RQOQM'GNC=JJG@"MX?9BA1E-YQ@6,;$,1#%E9KGR%!T-#*[P;3V25.WG< M+XXAZ[&+D5/ZGT&EOSXZTKOOS9B!G*@,X#5N.5883UR?((5-@X.9D>R+IH &0:'EBMW7%Z@Z M0_P)J'=U1VY^71Z(O,PSW&_-$5WFD(Y0(P7GX&';+ ]"S M)5/S\_C-U38?1$ZS\7#X3]]M4/(6ZA6TC*=.;I2ID<=2B, :@2HOC3!3P26. MD54VQYXS+@M EC]I7[*_^UB0,G&1&>2,@ .KZ92CA++4+P[?]'-@#J-O^2$) MG\T4,I.2XMG95-48PR_>TA $:<0=VMH(QI4D17FY"-O1!(C9]:O^"F/F@SM. M_/7FW3L&I:/U6N^^OZE7;Q5T_FI=%L_R,43J@]P9;Y2CRTA7_50I3[T2X5GA M%Y352OKL>H7,YD4YKEZ=68BE[KL4OE<2:^XG1-B(S6M/B/5XUEIP9 6L!A<^ M:N18X44JSFG\!,]PO(FGJ2:K33QS>_\@Y:=1PTF>CL7YYR#6QT 0&06GZ\$# M$)NFXT'@.I&MS-JI("C,%]29@G*GQ M-*@#N@135SRKKUO;,9TSATOK'&V[M?5B,_.Z:(M>N!:NBOW\N+"UYE9X*?D. MG(AEIG5AI0>4-#Q#3!Q=OMF1!I=X_*E]H8\9,P3WBO+ GR [?11.P-Z6X#$C M][J*ZRE/:X_2DA-?_Z&%-AZ%%K>)\4KP"Z5#BS!^E ,=M5$\54*$["O=N!E) M.II[;>6O?<9RJR1V4PY 56DHV:L_-C///.#[%A)]7R6[%C5Z$7$;")N-"4E> M#!$C8*(1PMVI5]LT"GTG3S@X(H:+7Y+N0A%0?A7Y[BP=G+ MA22+U_L;;=VB?I1YWK'&78'LL\OPC:Y]YL)*[BPE; G/JL.LA8V[<=#*8 MW88HWH")2(;&E#CF(%7SV[HPCCQFWA;7.$YP"X4>UIY7Z7G-^[AF#A\ ^4#] MBK-CUB79 9NL^VP4V;P+TV=> GG=9L!_B;M1T+6.I&AYUB\+[9HN*JU+EM@ M:G&A:$(9C1-^JPD]0I>=L+'1Y_PQPX@-C9:MTRH=9),7BI'K?-L8-&HZ%[UI M0Y.EYXYJ*#UWX#')6'$XF:YPB@W6>]LGE M1V'>SY?F<;"?%I44.JTB&-<8H'1H-RD4*P]'ZU _:FH0:$,S::6Y@.V](K\\ MM,#EYC45!=#<]=DG?'N<[BM(MR"'K9@@:)D*ABA'>@L$$1P,#C]:]FT.\EQ- M&=[A&DIS]&N.?B@:=8(L6>(P96=DQF)B+V!:Y8U'157=FYD"))/JNYB6:3)$ M3F&>@9+MJJIN7)FS:9W>*9['Z.+WIQR@7GRCG*(F3-:83:>)-[!8 MR4SG2NN3WNJ0:;F&?&_\4+T^M $K1H!D$S:,?_BPZS,82]N&2B6<\CZKPGLJ MJB5[C%=\RY%TWC$4^JQKE+;9=;=?*6^5R;Z4R6Q"EF2F$6H;R/0CW2;QO DO M?$A$\&+;-\D;&FF"U'R(".6W*H8V(T"KYK5<1XC2H*:^2HA+@<,NJY]64?G[ M,_Z]B9WL/ \Z+TNS7/K(VE\AM;5J!I3BZ>J'%$I-+=&0XP!"&O@9&F0@O4/F M1<3C>2H9"Q9WEMG'&_J*>1]J?KG9].#B=T:I=\D&PD 2C?');%>0*;31A0]P MJ=-_0GIURK1A]]FPGK6+1H37=^\;*1UOUYVRK>).R[7=/[)=1.<]M)/7B!E- M8![(*2"-E7>U?%*LLJ?4C;GL4^Z=OG$?H^N8PLSGQ3/EIQ_&;UE_/(S]/Z\_ M_^^\(M_D+<6#FEDE11#RC)"YJ;'NT:@^A]6)F8EB9X-\0IUWVSQ_^?[1S;7+ MVZWX:E.<$H4I XB?3:)PILS:C N+5Q$^XV;\SSH*':=I:/AEV):F!YW0F_4: MKIVS IVZWA%LWLTP6DAY.J0I2L U"FL [V=X$[%>LF+CK?-%C M/QHFJBON\.5K]$G-A(U%V F44QXJ%,RFR3,#98/? .Z@!.UL882!!M]W56;O M%,]L9@O?1]YN/&L[RE1P0F#7S=*-+(?0'4*Y_'9\ 2\>B#U;]&B5T'X^PB// MM":W.CSLS/MTWKM+LPL/:C1TY.,C\Z$DWT':D54T"^T\XF9UK]=1P'9FCH + M+H&=TM,<,J5N1TD;S[R._1@U?B='U&+65=9&W_&,P6?T58QIUF@@<0SYBA"TC6U1!1X:\-?#C]UXL6;E";$2/OFKT MIH_X#(#"EP=NX[CA)G=I_03:YZAS68OQ8A"KX*?B3\._TC_X1OTN0S#E+C6_ ME G,"X^I@S%3M)[@G6SK]C^_RE[U-L5^?+[^)-X(&SYY270X>N,,BSLPPJ81 M\\ZDS>4JX$?$CS6D@8C@,$VS= OX81CS"L=R175BEF07R>?LB<;8V998OJ=7 M,UE37&O4^( ^T@(UT6N*!>B%Q: 9E/'*S8,E+:46A]4T!RK[N?K*SX?(+ MD93QSXVC#45K8W&<[(=4UQ;)=+ G?21V16X;,-CO!_1IJ@J>\C*;WT0.]BI% M;%[5F3><7Y0+5IO7D9I:W5JDG?SU"?5<;G3X4(#FK8L@U/#5?=R5G",+(U 7 MUI#]I'7FF:G7P@+16PWJDUD>8CRFKV\\*2X>X8P[S1=LXS(Q.R?@0][CQ63F M;2V2 NY"I_,/0(=;>,7K;QK@.KZ8+"F#$!VJZV$YRW2D32*P&A*T2W2-PLU2 M4*?-')TD-HT''5_+.#LEL5S7N!EVPF+DU/#BLM#-E5M"D!6\E+W#SL3)X M$_M,Z<#7")=LTON5GYYR/=;REMKHR1=TDF7)SJU] M)EXTJNW:*<*56B&>6EB8L!0L E4R59MZK]&45CZSP6J_:QH=EF/I4)QZLX;E MNN,+<*>(3VZP[(W- ]"H&HBD=8U410R.(,L"(?B%YG;S;"$CD9"X.AZWY"ZX6UH4,50Q/8!B+<$-LH?_?["Q26W[Y$;;T-;1$Z> M;.=M.KV5)C6:1T\S)<3R< 0#\1[),*8^38;('6)?T)P]MO*"'UGLP9S5;Z^< M'D"0#E2,E0I\0:D)\'@9HXT#\C$(=_I\OUZ=8BC8J7:Y2I +\E3Y3C[_*K?C M??, \83TC7@XI('3K*[ MY%OZ)94C\]1TSJ1G'N7NKR)W5XW_?+L[7V!&I4*F7=;[X8 OH%:QM%>@7OG&HS51[\S+ZNB!27'P2FW+H#=XM[#[Z!\/ M+RK;O)4BXWVS2"_;[C19ZJB9;..[1"MWO;GDFQ(8S^D_^1NC!'W\,E:AVWE\1F9C?=YZK>@" MM*W0+N?#?3Q^/UHNX;,/K,E)BLR*7XQ##^##EBOJPZP]=!'S?"5?]*<;RG7YZ'W*P>@OS;= M=DW6, >@$?"2TCT;D5OZ8D[2P5KV78VD?MYN4>1QW-Z;KE"?@"W#D#'I("D:=39OD;# M46#KYNW#+B@W7QZM["NMJ^UY8%]RQ'37>BX!,VL2:V]#QYLZK8+6E]08#%=Y M;$JOFN)\:]=E 6_R61R?!$86:W:U+-<=)[>I&F6O^Y/V.I5?9;0F=UMIE.(- M<)$]*#>!\V7[?C!4GX? J'A#YIHS-96 8,= !ZSAJ"+N%T M,[6G4\%AY/DG6TO\&5]N-]/>X2;>^EH$27V ,=A13#\$J.%P.IC0/] MW-P>$Q/CU^SMG8/U"F3%V)K966XI"H.$/V,YJ1D'H.FL1%/.)'6&NH?I_1L\ MGNY \J9TK8 M>(EXD;I(WMCN*T,E?S5]76OB_9XO]N;D MT&;?J9;]7"VF'-J@[^YL:MEG^/+8^+KF/ZGUL MW80F/JQB+\PXMM8P!=7!FRXP#$(5=$S6[==+9"4RVW)]!2+I.\$VENKV8G+U%? M+1)-:J:"L,?[D.<=TOB&(.#YKYK:GTA?8)"0O+UW_8!.BD;Y;8-O4G; #T""O$YZ7_=), MYK-GHI$[7=F(FX0FS*S!T95DX3 \#R&?] D\TIG/C$M58I,_?._T^*>G%[Y+ M?5BS$G"T9LA.#] \ )D#/#-"'M-90W49V?XQ=1SVJ)%;3L]?E!BNUU44,NR^ M#/!O5GL2G^;8BF5!-JH<@.C<$ YMQ)XE6L/+MFI->2BB6/Y +:5'Y[)P&PSO M53>>*NH7&>O76TU3?V[!;O?\:4$*>Q$C9NY\(EY */JD T5;M:.[(5YRZU)2 M9$?X+]$7\GI,C4H&4<2B&S4!;7Z!S#XQ]9@1Z/T8/'?$K$&8L%@?Y=87N,O] M064AEBZ=ON3.03Z7A:ES#9_F8B>O'IY1=8HI=%=%9RY]9%4'\@FO$<9$AGIR M2H?)VB@T:*=TZ',OK0NWOM4HD/]-KNHY6PO-=N)Y@N6[CGO4= @[/'Y6]>6G M;HH<$?P0L,[1]1-J=QB53(Q[.*065E:ATO<&:2+X\DU]^ Z_Q)'%#0%DFX?# M%'>5./%>/40QY2H0\FDY+W,"1FP?@PM8(A_Z M$EQ\+.2WR[_A?SABUT[4@V\T^$?_%%QHFXN&D M%8DC[3A[@Y4LE#^& ^"8V4YWXKD6<8,[KK,%%+)>O-=Y?OCC*3&W MXXNN:LH[6IR'-J<:6(?'+(GH=?N/%+AY;EUT-ZM(ZDC8-.>RV!5.(P$378)%SY. MQ#6P\FK/2FT<66[/MN,N\[W4]RDRX'*:Z[.W[;(7W;,XN8Y*-#Y^1&L2ENY# M.>#8$%[%0%)F066>6:M#\O-)[MCUZ9BUY:-J9P%%!6E#;DWG,]\MZET&.>\R M=$ +;=?\_,DB]A#17MR,\JO&"N="3>\KJ,*HM]_:\LHU:#TB-E)C=FJ+6GG+ M#O^^JG4F 4 ]R<0;(,HU@4'P+$VN6;-UK9)JDW5?6U)4XJ>3#QB[3B>>9Y=+ M8CL%!E?"+D/_8Y9'3X>&YNQ^=ZQ<#(YXT=F]V;.]XV MA_;-PV1NOVMUUT5I@^#>33$C;Q$Z0.[T1AA-@,@.OX5G"%K_)9WOQ12E"1OK M<%%RUVF5ACQ]FL!Q\WX(KZR[0)8GM!BU1OZ(_#G%N*;),;-<("<2;/+C![:B M)G%EAHC5.?*RY@'(\X%AG+M!SO_.[F!5RF5J,L7'*\>Q%U#$*^>7)>4#*;>) M8J/BH=OQWLR9I*'!(1;29J.T\T?J>[.VQ[4M4A4*"]KK=(9\] 4!";LFO=J MBGZ]/"D^6,JWDT)%F7Y3/>GAK_A*+,:%\QOEG< #KGXY!O$/^Q/T]1*RMDOF M [JFQ1M_.XJR @WW?8:=E*]VG/!M0C$JG7UFG_;LHOHD^D+Y+9&C>0$""9>X M5I""@!P^E8<40&1H8,*$^Y+R9E)O=IN- ><]#S=UU!A6WZ$OB]A2+JSUCQ3< M;^=*1.&K)#G@Y2QF5*,>Q_<+(F.7B!0C4)CLLT=JIT>8TVL^6Q<.E!Y>,T#+ MFKE"5051^-=&*@4_+P5?B MR,(4&-GL#B21WI8"L^GPGA(#7OMN;:=L,PM[1V^KT#.)?-=[PJQ]5#,SF3%\ M,(] .8H6-6X6\,N@W,&]:@C+15P' OH@N7C']4OO1.5P)[F^_%1IPEH_08S' M1Q8R@O99PD% 1LT!B& @Y%>#*U:-HC&-(>[V_5)RX5@YB3J?(1?F>HNUBE_D\)JU^.CV7886,"_N"9J38C6(Y5@90G-XID)V M9];DF0Q$ZXJ4O._I2CL+:ZON,5Z79_ZX>*9SX]VQ;59N9+NJ"5A0!*B?WN T MA9LU;]G#1M0SRTW5L-]P,0XY;VK$PWJ:&FJW;M1)B$PO3M%SR#L*E'QZ&,Y! MLB7"ZF(8X2EKWI.2BBK%> N3.V3SKR+/4-(H4(1H5P2V_A 0/."L_=!$E9%#3C=^JL!7[ES,^37JC-EZM$C?E M8WB9#\G=YU*"8EY^P9\PQQ]$S2]Q[?)R=';")PQ.DP5IR:BYI.-[4-R*PFX.IYR@;:Z-M!O_<7\]@GS/%$/:""P].N^B*6?[H]I24>PV5,R4 M>',7-RK9?^PVIVI-6_(V,P+1^R MC-3-H]%ESR9,\P*-VDR+;XMH-$95ICJBZ M5&D=8S3.DF&'S8K9WQ&.]D:5UG#M7YD&AUH* %DS$2ZG@7L/RP>WP_8-G.\8 M5F:&NK;,5GP[CCLJ50EH$"N;P(<1=RLV7BL;%Z8&W(JP/T[VRP372ML&"_DW MN9_0' H+;W]BNIF5B3ORF>N#IQ^XHL3D)>TGK$P\"&K/)/_X"Q9,S)3_];U' M_ W;Q2,+<2-=4Y:9F$G+/;#\;MO>S;>+.N;QQK:>3S,+ L,EO@;_T;O7?Z\Y M_J7PG,._J]*MU/S4& >IK^\ 9$M60RC.9!S/)1[&2Z\_UU0W^H;7TR7>N-+6 MO"W3=,1))W*UXRJ3D>N%*Y]9.\PI!R\8JL!*]D_/Z!L%M^..\G.6BGHV'/:-DC0 MZY?>5Y?3\%=&1.-2O[Q5GKX5TZRU?.6.B?:D.!/Q<^_22M$PQ]>U]4Q"RDG& M/@.2:CB1]'"I;H6_>XR#>AQ0.P"=3R44T[!>,51)4\K>W[Q(DD^?LXW[_C!: MO&@*%^4D!:=D;ZC-16+H"/I[(OL%CADIZ8!F\3I5IS^9((7*M-]4;9DEMU,' M=\'1CN'IA?DZ:6=94A_ BV:,[L]E,3R+^8%0QCLI-O%KFGZ.=2-%F,R\)1!5 M/=WH&@LRD WC CB:*[+KU^U=MI<5HH+21@UV/+)W'Z)$^TT&:4S$LJ39=3XO M(5E+D\/X@98MF;&>$+>E"=8%JUI_'W^?C[0+0B.(2KZG'N[GD") MH39B9/GO]O\?M/^>P\?_)QU!6Y!(_^N[:<-07%RZD/_7RP]Q$9.D]&> M#,;3]4+7LZ4]7,&DC5L M;Y\DV'1)-GCG(GH<7('$O/VMD7B)W,8F,\6-9"D/RXI>A$FF'?828=2),!7V MD?R4S4LE_DC8>@HU9^Z4EGRDL9!_$&-/P[T'HL6T_$V(59;J'6?V)3JD.#_[ M,[;H$TW[+9&=9=Y\$^="PAFMR;DR!2B9'F3I5I:_ZE?3 Y =Y1 0PJ>1W.FD MLL.QK*C3@&1G;<,^Q7P '!_$V"/MH?W;NZ_!22L]_Y3%YU.*FCQ'X]IKV?YV M *K?PW73 9\EX._\^H>;4G,MEG8'=P=Y[CVR'/N>*!#A<\I=9WI.X9O:46$\ M3A]GC1IK&\-?'0;$\5KCQI;2+<'-IO%L];DO[B<5Z2_Y0HO]-W[R2\5P!&6' MATCO_K(_^5TC8Y_-1K*!+5 ]_":%3(U N5QN?S+-&JX>+5_&+-4P9-!75._9 M7'ZY*"U5@%R_S1F)4@>^Z@C#[3<-:(+;ULK*GN4_NBT-2 M\D*65XX#SSW+*8N;?08>KO-S"CW^QR[9%?C!]ZZT[1F,EODB=S3\N8W(; MT30EW2V_-QU?H;JMU?A\J G*@A2!432&>FE#"F-ZKRM*Q)F4D&D-7@R%%&W_ MEQ]7RX0E>M9++110)8_,3^5YVFCUA#QCR,&T*D9^>>1UQ\Y1?XWL UV]M^;Z ML#$L"MV RTO*20_?Z^O]?V&!\/O*ZW[ZA((05+ZC:O=RLOYK?:V!^7JG:#$A M/6@+BYX(B[YEW/5@-;'87HD,HPVQ2"[#RZU6!J!#DSAQG+/+*!X6+7P>Q0BW M(@[5\-__;AR9P)]:,]TYF:,NHH6U;CWD]^W=(ZLO[OD5Q>KQ=TW4<&-,I))^ ME-T49X2,4DHY5#-7"%7OT?9O5'?+.'9" M2LRG*#Z^DCY=I6)_9IW[Y20AX/W1W>3L.GWG^3/?B)R!J]?3GC&6C7XI&+B= M%NAU6'%HX6$-W_EJ[,*DF4;8XS25<+L/&4WUQQX*GO;?@J6J>,#$OG$^'_5&).4_>,!6P *2!$M;5.C,KI8[^Z+!AJ9T'&9VDW_/"%L!:+A0/\WF^2N5 M#>\(F%6*,V2IZ!7.X:+Y1W]L0E4QEU4DKR:##M\&6 M%HQD<@"*VYLQV/T%W4XS!8RQ*]2$ ] <%GZ/2HZABB=BN3#G,>0&7!U.3?@S M&$"I[M.A[4KW/Z*O7/LP@)@AS%>[S_?;V[+ESGO2O]GC[ M/YIJ2W_YVMG.+R'=N\8]+.R\M4OA MEW;5Q,7B+7%D5V2?$0()O!E%QKHVUZJ?BCF>_.6&67FG\'*(^W#=OHC0R>>4 M,9AMTC0-P^)#,2!H[I>JI2;6:G.:?//XPP2'?(40I#.P.\"C Q!,O9F6((-$ M#"VIUG;M*6T$H7>VOJ*6C0:_HW:_0.@40"^V(YQVE 9+5J*#&OG(;Y#_CR>G M6F"ZN9$;0.4K5\_8*TDM,+F_BN?P9,_9$6IVV^9:5#*!B+(:<-V\[Y#WV?Y. M9J[^'8&,C<@\R0KU5H$.+' M)E __HVVYL/+D,'T[*ZF M-HIIJ^MLQPU2;?P*!QF/TY1T;&_=86K]5? Y;F'!V]XFV5AZ4T.P6%XS3D\L M_N[0Y!,"L?[>W;#YSCO.:_3AK(C\'QMC$W2%#HXL0S/1SNIG ($6:8S$^_:? M'>9#F9Y[(_$;<:"+/\8-;&RG/YB\-KPGL25U:/\!WH!U FYB6=WK8N+4\358 MI5E'Z!JKU0G1X4&GIY230"12#<$65#"WA;">#IW]AI/V.+>0#"__KNG>XL'A M=8GQ)])A$)-;BX<4ZMV$L??LTX@ M4"1_JMFS"9UQ>7I'6XX@7P]U3K&5H-? H1#Q/K?R-=^L 2QT/"%IWZ1D=+S5 MUHNY0?=YX:58UD\,9[^[C/KI\\.:,7PZ&4S*HQ.L;M+VLBCB/E'>,8F#9U*. MX$CIW%?O11IL'8""S_\->%;@;%![>*&[ %P6]U3_#+AF_53<;$D85XN6"WHYF]BPE%$5$V/_R M]:-#R8U_!1G_31=\F#2A"89=HVI884!6+D2=>2@)S\IV%6:8?'XO_RN+3M>S M=W.H[_G4:<>5KE!A]5X:+P V)SJ7T2R3,D9+^X#6-;@,?]7AF&D2 M")T!F@R<;$9\4:F:DNN0Q*P8.6]E&<9.5T7A7+I%X:2BGW)EN>OG2E"*:25[ M#Y+N)::'2ZT9:/X13OSW;#3_=3.P]H>D^!R;^)I_["=+D;:D(-=C]Q,4Q[6I MD#255WC6(*=2N[JL;FK'G-0!2'KA2)J6P 9K@89)H]<2[@A-A/4(\,.J,NE9 M; Y^%8DQR%,4&*TU// M\H[GKK!<*-UC(UWY%]CET<3?+S-\_+M'L?V'+Q'%YZ&:ZPY /ZCZ1GD5Y12$ M'!G=/R#YAS/_URT#XSCJ'52B=Z;6+FU+TU3?"P M=2%BO2'U(U;* 2M9Q7[E:?/:OE/$-^C3$B/$=V!6,_&YUS-KF!4=GN[0(-6I M6#0!K5,AL27IP$^,/ "Q,KLX3V5FHH;4*6N8KVT$;*?PJ%EU-73Z@W*V=UM@ MN 0&,?^?D7XMGFG6)B;G)1JFYM6 MR-62VF#EM7LQJI(K6.'4-K5D^IIM:MF[===9QD8@PQ49PC#.3VG#E$&MT:%H M0A%$: 5\2OED^>K^X?8O@-N'J#Y3=/)*MUOKO?=OW>^8NW*7U0_NE]JH$JK! M2S18_*::FY)_J9:JF3 =P$R&T)?^1/U>DA^8_2 NA.3J_4S.#O$DES^9J,)( MH#M%]XRI=ZF9ZY.K=>A37K;S67W.7[W]KK@/@]^^VL*("N>K&VTY;IA06<8A M?3!H,^WD2S(]\EH1A&SR+GC?0 8A!?-"_K7=_.K_,9=CK/^3XT/_H$'H@1'X M@M8+(WRM@B..82S>$LK#; V=-R^=M$%>OH_TE0XX,3;U9(D9F5V48'6B5I"? MYC<0?M'FW$/!0/5P:@(U @D] -71 %5'MQSSO4FI;I+]/G8VZ6T0=:#V %00 MGBU.;MO9W"OC[AIK]$TM$2<]VKAOJ(V8&?R?2$VE&)JQJGU8?KBH!?%9@5NV M'WJM(X<()A2N([-Y%@[)L+HH6<05V^)[@V7@ M:D79QZ\/0!4A/T4_;9W>,048RS6]9F5NX<&1I1@.1_:]T;1\[W/S]2_&U^Z MUC(N'?D&,A9"O@Q._[:=H$Q5;/OP(\N5CHLY?\\2^C?9 O\1.7:::PY J@Z MVVFX59K^?EI"V2 BS4*>G$VY/(9^H+S$M:E:"^9C/0YL]BS&/T,C(,T>\37& MHHX'H!HS^WW;06REEWSAO7Y!DSFU7TPK\#)\]8@#[L$NVC9IB-3_8->4F3[> M18,;_RP"Q?U%TW]E^IUY_F&,*_R^>_[ ^S]LJO]K)I8'F(-VUAY]$B*\2I,? M5/O6LVXZW7#BN+T"]Z6W:;_6OFB-5OA2 /IBRD38+=+3$5/),J!?T51P^@#$ M=LP)#[ULT7( ZST?8UB'5B9]SB0)-IEUA.S]H/5]6 MA@R\W"89;SZ==?^P_OA$V[>VHL4$,6'F)X9ZF0/OP)^3)T@)LS(\UXE3 M(1RV(57ZARJBA3_W3@N5[F^+5<_=Z4W0R@(&8;:4=P>^O_82_Q9S@=QLVG&6%1I[&?"!SU/)$*2A/( ME5:#]/:C[@<@)9>VN!*$!=,*NA@7<4;J;>^.$X3J'Q'V1)R^Y&&=53]KD;\4 MUL\!R_NI#UVB"I8/0.@E5_ ?.Z^(==AN&"H(Z:Y5]?>WWOY3\C$)M9J*GB)\ MHJG:)PT-"9L$ESY6ZC"7WS/B>5)FO3R/'>JR^%2S:LFJ;6OTP:&VSDS^,_Y7 MS))VDB/;&__F:QMZ,$U:'8H/-^.*.-2;48GN&*I2+=?%CKMWAN*^OZ5S%F'. M^($,:]@UD\52^PI%S_D*K8=8F]_D^].[_Z->$09L:8RQ1#\R3RV=,KK8J(SE M6UWYLB*9'>LDP!7$6MS&A_T63DY74KCQ13T^G'*+^I4FR1H) U/,\"?.;7DV M_E!1]V&8)RN)MNL(=Y3@!CK\^"S ]K#WZT*HEL5\V8=C/^:4#+7]WR_^T][R M?Z\$_W/#=@ /\!C@=M61K*G*O217S(ALF!K$"J3@/_*B?!;&9U*.;*>=5ZD@ M97^\24=^;,CZZ=P#4%KAYN7]3R[D.9.?;BP\J[RJRE7*>UX'(&CLRGQI=:H7 M3PE=AHDN?9%(QYV'_,W)RC_%'=&1%$S]A)5"U5]!Z/1MTU7;I'COVG-E,EG# M\1:S%7[TQ*?PF5GM^[J@)Y?7826E@ 9QE7;'!%].C>(OIR7J67::G.C,,-+5 M>M9KS K 8+QT19$';S\ ,4IUT=1T*7*82-3V@RJ; U 0U^(!2+! )WP_)L^( M=B\BS:*SDL8SU 3=EYQ4H&?V<+J6BS:DX]GJ+)C*Y<*'FM'VH0><5&SZ;Y^_ MNYCD44!_R XQAA9>'HDCI%<=@&;?HNKV@>8#D+99$PPPM$01V^;L,E;Z<6_5 MYL=7<3/^"#II3\^?E:-(8*# /)B Q=*U:(\Q,8G&:8*FN/_@E]@OE9MG\?%6 M)Q*W9L^^T6U$\1V&KEC_Z=D'(,#.( JZ;4RAIYF@_M M-'Z.60,J%X[_ #2CYT?OJ01=B[X&^NB]<6G" 4:6!R!BV^SOW5G#S7R"*-&_ MW8R(H7$FX2CN,?__X_^+CZ_%0A$V;^:QTO".&%SHA@&M_S,]@/XO1<+&/Q?% M?^[+W\:PB1]9D]8]Q86;^8@57-X/:7#A6$E4W:<&I79DT0K=/$Y]:W>-K2C2 M>..>2<)P%E1.RU$^8.K09'XE-%4Z^AOFZ@?[LEC#^ HHG XBP+V^?X274@[) MI>B0[91U$\.W5[+M29L6$[5?,:=6UTI"M?\EF R="V$3<;G*CVY?E*[^@\ [:23\^?"BN"%47N9 M7V>\XBZD6Q5$LER[(!AXHN4L3K<*.MN"5$?(]4+.UK!Y1=7?(IZKLCZLL6T8 M%E!3]S,%%GW$V3R.&>EL4H%L0?'E([DH.OZ*EDDN@56&_,N^+=:;-4S(A=7? M#*Z)-.2]\X?$[D7I7DW/%T[9*\C;L;1KRU;$@1#^LU" 8QN&97QFG M?QH&SJ\BWH#>ICWH,K$F8%7ZE:/,=)F^.^S+?GJL2Q[LK-\Q-+^T0^M0'8-5 MPKJG6"D/"_;]]X6O_!,"JN/W%S FZ.R-=>$ =)G.L]7_6>W F@N=3H5RXV;, M:=WM6M#0K\4Z:.AIBC%@,0/CO5+";&T0C7]@&::B\O,5 M=81KB(!)Z%C:[%0VL6 9URQQ4Q^52,?"5_]GU1IB2*3UP]AP,P^079.JQ%/N M>R9YCP=?.*'?F=^Y+A_[*VO7GW,(SXR,/0#5&FO"GU<)3:..7[O C/)1R7:\/S]W](T'NBJ+F_694_3,^.I-\NZ/CG+.I_BTH" M&3>_JKHB'H1XD.5 7%1).BDJ03O7]1,7/H=4CM&^CO^B76>FQ%"JL J*7^T[T6:(+*#_!KWUV*&(S94RK1J>\:Z_#\S@3;J.+.W6QB007N M)$:O.T_2:%(&\YUZ^,/ C0L%G[0YC8^__.LYA[W"">/FYI%2J.&>/-3RTP1R MX]_\Z9<-M-%6V3]:APX2F$O_A1V;O[2*C0#*Y+R#2'B"&)AMI<>\LK?Y_7W??F*=MW*ME-[!) M0<<@-H'MB[F88!K.2@;RAU"_W"+X_"TZ.BU>71/WIN\4>%,3W\7 ]R1 M\X-X-;KJM'F%NDERK!_M384L8ZJ%;=3<.VX5JQF,;-Q2!Z]K92XW/!Z9LAR+ MI7 M.=?.737UVP:"@\,_:]1P[=.7ZM%2(-)K*FCR/,&FX>7G;KG$S9&'6R2_ &\) MTB-1ZYU$G'S>"BL@+A?3%7@ LO>7,XB[FH@4+4'K)?7Y''X8K85H24!-/ZNB M^$,=0^+6,>..-\V+=5?IOQKLA.__HNZ]PYIHUWWA("@"4@3I0A1$D*I(E1(5 M:2*B(" U* ("TCN$!$%ZB8" TJ(BO42D23&A(])[DQ**=$@H(4#*B6M=>^VU M][O7=][W^\[^SCE_S%PSW>?(G=="IZG]R$Q7^N_OH'RDE M)R3^085J_CWYY"\X1#_5@&6?CXV$ Z":5$6FW?!\1IR47^5\,KF[NE^RU/O[ M9_^^M&5=0N2[)@K %P4N0R_0QV9TS'(2;>=EC\<>C6R5]1\)_V@#X!EO$B5> M(P?$-"8&XU2$.Y,;,JBJNN;2GQW)?[^#_-^V8/YCJ75!:!C24?+GU$]MW]B- MM8=HH=C#L:JQ;E"%>CX>%.4YR=&V'U=^I5_W;3=J3_?8/88FY[0[DH3(X9A8OYS1[9"8"Q?WA4M [ YQ9 M#]@V\6.,Q'KO/ZHEMJI(:0TBQXH:V&>$H19V_^6V&87139>MDXN]=29)>8_] M[G3R"GJ_T@L1B%%,I0"N/(Q8(C[Y_?WU[3:)[?@;T)0//R&JN+[0^Z4%4QIY M/RLG?4M/5I;Q!!@Z=#YYN:/5=/-%P45?>#G(;G8RIQ%1I?A*#L[BG\[$H^J6 M]U8D61=E/.6AJO2LKE*T\*2?#63EUMK5CJ6^*0N\-,ZT>=JME0(XUP LG';* M!@Z72;OZZ'RP%9B.^9FZ&^;2\8YFE_>^,N.XC=8O9&:N^7UD!5*4E\P*KN\B M,XR)E5ET/()D8>$88#1*D3#?U9Q][@MW8%:C=)^P2\S,Q?C!'^,J#SV5FRZ] M!EP*@281D+T_&,8R[:_.H MN'L,2!H6FC_,K'TB((="]I0FBG/%?*EWZ!04&=ZHR@K$']P?V-QCXOTTS9+A M+/FEP_7;BG=B8U]?M[%ZMJ:UT\^IO 4?S@X M#"Y;4_3#I/RH!RDK_#@-+2#5<^^/NU4BX;>64T_.[GN,\V\W!>? M-=*Z7XRD?4VSH 2TAS4I$D%8;8.1R\.J*O/?-!X0WGGE!W"8.6%+BRT^M.CA MG[%Z<"TO678F5LD^QP*8E($I,L-0/IQ-;3$02+SHY'8_L\CU MGI#DYUA85T,"C2O-A?2AJYF%QXI^OU5IGO>QYD!53?HSJ>(?Y>/YGNHNN]K,-H ,P!'8*HYFZF -A% M(U1%"XAJ.)-$\4976+4]VF>FY,F[D>]:IF*8-T*(E) G34A)4BR9D:#7#A)L MT,=6S&N'O:CJRKKFIC@K0EID;Y%O*.9H1STJ*'FUI9JW<=#!67KOD0ACXHC2 M=A7)Y.,#Q_R?[81X#"+,FI]45AE/V\07#(\GTA;HV]EYV!^E=$TUR0V*Z^*# MWN::!A<9OY1>KQT_/V<[@9Y[#ZS@;IX-@9TA7IMG/46XK<*T6D4H+>-RN;WC MG0V\['#M:D TX(UEBOC,*U/:8WT($ MO DZI8*I?SI4*'W/KIE1F=-0T!Z0V9V!I=7';36@P :.80$,(->R1V7?>=#X9JO7!MS19TJ)VC/A$P< M]/C+;.AAJ784EQ].- :UD>Q_#%F&^ECHN1B8!*O+U4P@9(7*LFU39QB7/G-" M'V8B*KS1AUI4*SBAED$!Z/(U<.,92%ED=FC_+..^E$8;FK74;J0R V/C)N6C M?UO8&V4(>KLBK1#9=7Z3)AA0**^>H:"F\$_\8O4HZ5B=[S MK_6O^%VW7BF?[DY55&2JUG5I2>3_W-C".:G3N+A7\N,H#,.ZD-)N*/Y))&S[52>\2)-MV6WVK--=O MQ>M885^=]R,JBE!ZK-YT+$<>,@>%^ZR?;K##!'5^2!]5Z4C]:35YKUU5Y?9* MEY#"EO'GNU>$G5V0Q2!GY$0&WH^ZP(&.V5?2FOBH!F'S4DVL_I!/;,J-L+>+ M3\Y]^;$3\!"CQZ4YFP(0U+]B>Z6MZ=*LPBA?WOX.2'8%V0^?$L6K$!PPP(F9 MH7F'EDWIA1;#1BG1]%Z]VC+#>:;0&)I=JYBZRBA/EJL\-HMG#[,>&?X9+KT0%,0)39%KK+C G%:L\@MSSI@#"4&?[ MC?'5A:55 X"=3CK)TT>N6:QS$A7TK(Y1KR#=:RJ:%;LL5+* 5OW\IZA6%A0<7R^\+OWG@:;-^@ 7.:S(:JVA41 M57%0^+P+RU*IO(OXDG3I$MV"9R8F1+60]V0@FXXJ7UH/5SYKM!,:J89XG
  • &8 M5B3R@[E2C$>Q('H(++RT9N2=AY&.=! *H "J.\+W'URM:\]R@X+FS#V,CCX@ MN^Z2+*IN!>/&YGS+ MS]:C9Y*I^*R.^4_3I1HRD/#%C8:PW8*Z5#.]O,H7_^WHY-H]0XD%W%1,X\=D MW>*KH/=[M1$[<>X&V6V? _)">V$L\H9DV^K8 MDR7PZ4\A 2P&J)7XP&"HA]*.;MN>FO=6&16@W?PS?NW_Y@P34WF<2JMV,_!, M@RWRU/BD=6Q08,F-K03Z)W#(2RLI_X[-K!+8D]_.%W;I&I?9_%PDB9RM5$X! MP$M%UE?!.) @Z\"C1U5E0-(:O)@"&'SF]13]$I3V*UY<[".J\?!/"?B_(E1X?YYU+E^-U"%3\^-;1%(;-323Q47 M&UAN\*QWO>LEX"8?<2'F@U-E_K3\ 8@@.F3'?B *E/T]!)Z#/[PZ-#U4#=;Y M@VA" 93G4'>#G1(',?_%Q9\_8#&]3L?GXZG:P=K]'Q16&PSA:"!P'%M#U ;N MF;I\LG2N4]M*"_*F4;S:T%^N\@9PM_R9$FW*ZG=D@ZH [M="*^(4Z+DR5%A2 M\09WA'R\@U;HKV>/N%-G;W2\"%(-\VQG49X)65Q$],%/DR<1Y_;XX2Q-Q>O+ M;3>X$OW2A RA9PFR!91ZR ML(<^$CJKMID0=CI!Q1E\;2)$2.Z6<,%3U7:K#DE8U!C/WA-_@ =9+@<=[HJ-DOQLLADHO AB%8&_(J7>*T?8XK)YI"TDWW^QHC\A<.\7BA'+W6K 3I3!G;]Q M$"Y?_(W))/HN4X;VI)DN70Y+PJ>7*3:W&N?K#;B@P[/G5)T_K*6KY\Z'<645 M?;A@]>X<* Q83K MHDW;XQRMLV=1DO[KC>;+49(-4H7^=\7,?]V)W0SU?>OZJIU6]'MGA.1]4\_0 MVDNL[ 0#7'T'D+8JMM2@D7P!<;N^/DK#XXO2KP1C>F%O3XF+%Y;IXN(RSR9G MW##8/(GCUB D!R\5,Z%*-PX^_D]X_N+5CE.)*!S_!VT:V/P0,;)+N;I5JE:S9]E M>3H5<0*QYP,N9%ZSFRM$BN!,-]MP7>WF]R;MIR;1O.;87RB>6&P]%C/8N/C&\BGGT5%B)0)[KT0H%81]F1S..WN):VU8CSO MGQ*48974%I68^'FE4^M O8\""+V') J3>0FU\U*Z22VWC6SX'WQU3Y1)2C-0 M>)Q]0C*J-?MJQJJ9,QNN35VI/)12A5IKE_74'O1 M\N?ADS+SK+%$0571(*1(?H1JB\3S(W6$>';":7S;F<=T_'(TE7S[)H\@5'S\+&(REK1&C6M#H4)'E'A_AWE8L&KI"K4 M55U3'YPI.!$&>O4#5M^4QWGS>%:FI]BF3-()U) M:X>5ZC0*0&P0=BQ: 5L5-CU) ="E4 !)H 70,0N<))J D@-/=2Q L4&QMKP MQ9^BU+LEZ2/W!@"Q_!"TS,:4[T+\UW;QR#"8"RB6 F"52\[SMVT-A$7N_4K, M4ZASB_3^+BP]_3B\FA?43]-O8D!C-IBEIK8$0:LH_)[-\71ARJCL^D-]S0CPL,NWE#RS7U MK +-(H0H&#BFT33\Z\V"6Z "+.UI\,/L7?UY)N_1L.+WE.U=37"?)\"($@H$E\C&"F \4X@.>FGZ2^#"&) MF;]INPE9HKS!#'*+;M.[)CV\P?13]T1W7$5Q,>IQ]2^ZB)8S;,R!R!BTRVQ< M]HW!]G?S,ASCZ^GN*:+'TA\PF[+^#:W*)I.CK<^ O[0#P8:9(GJ)Q1I'&X(# M\A+[ZA0 B6H2EP1[* ";:0X*0-O"=-$J:+3VV)OX J<0YO/1:4:Z:M@[J* A MNL35FUD>XTU>-7*+')AZ!J#!P60"#/'RQ;L/G6;N)Y=?\":^CO&?[WOSX9$U/-)D62Q M6X*E!42Q,6DN*=$VV9))_=9/)RM&4GQ;/0U.V)T0'DY>6JA%^C549AC49X_. M*T3,<@Q2Q M?=@T(B;VO?6 YLM("V46F6;5FC7.Z4=-DT79^=3*[W&89.%N]^P9:>IA. M?(,<0X==*\O-6TDLZ*X#1X=/ >^D-O\"_0K;07Z_NYM7Z^%C.[7O"2L@6"F C9:\4\OM3?G(I M.:1WP@_<+^%.?D1X+/7"WI=U\Z&$! MZ\QO[.G_'W8@[?SJ1Y&\B_@>O+%K= M^3\[;RU!QR- 4PK@T_=?;; 3,)D>OD^RSD(?KC) MJ'M8 !I%,2+K*KEW555RT Y?%(#&BFSDMGX@]^_UN7'T MX ^TKFD6#J;244[TQO,1]-Z7NZ3Y/UPZD$7,5Z2C.H1_)[]F_GT4G"N@\^HB MS\&_EO<(2 MT?[B15J]?@["O:HR.#V,2$?4/>@5@DS^U J'#G=/O_PW71FIU\FII/WNZ"NT MYUWN+2#ENS9)A[C5:\4Z\V#(J%B M-=PW3'+$X;*RCQ13+@).W/ULIV09WP(H%%V>',W2&8G)]+VLVS81?NZA>938 M1^3*C4P^=:1+D%?NQ/J#VU/IS<0?%S)"K[:+:K<''#[VWOO^Z22CQ.HL0+D%.AFEV7]Y/W)/>.?<(5K^NF7KS9Q7;J\8X'^)K)HR+QST96 M=Y.6?*ER7OT?HP!EQRW 4_M(=L@57%JK5*DS9ILE.)U#+I%=NNQRME*KCC]0 MO-97=6&1YW!'B2]%1"*W__>?%/PW:&M>D*O>P3#::3LJZ;MG5]!YX"M?G!9( MD_-8Z9LF]#)Y; SH1,I'7099.OLQ4 "0ZME5:[P!T1$D,[S4"A';H8X*58GY MT]EG!ZP3P 5Y=#,L6JO#\BTRM$&?9W"_2DWH-LS'4QD@)\LVL;PD"Y!U;EDI M>!.0$D)Z2Q#X0(5-7/XU+6F-_/4>)[M?W+B1D\(N4R'9"+='M@>2]']G/1/- MP^8[PN>'?"1>DZ]ARS(G'\5?Y-^6&_PQNK/'>TWVM('UF6>955 S4U6GNO'T MY+2VY[,CE]'\E@_R-PH+2JL^4]79Z/]C[>Y_IH[;?81+,Q]M1\F7'SM$ETJ* M"I,Z+X-)Q>"/*8>%5&R5D^'6BA9H(VVR*Q++V&#F5*L7W3UV_ @%3EP9(/S6 MGDO\?R9![K^[V!J9#)O+O]MS?'WRM1+X["3'WHXKJ$QB7?S0C\RHZX*'3[B2 M< AATR_)JTGK%$"%J3TK:5XPST?]%%1G0)/S8#GUKP2=. ^ &RGS*\0@+/TC M;,8F>1RKO["F,%"@G&90:R.B)'#/"Z"KQG5K%VV_69K.L% M[:,EJB*0-+QF+^SY+]/Y-:HT[M\R7!)W>92 \Z, Y'=-[_P0_V0)--H(E'!H M%Q1T8R1D/!CL#O6?2SXPND*GQP$8^"H,?\>(:"\OWKRH-$Q=^($(";&O-=QU M5*$L^=-U&V!O0B!(HB50,GBP>1HFEHKB0C:\$-ZI7!>C &K=V,DZ)R% 3I!G MS"[LPQZO=IOBB@'U/2,J\SMD" Z(" Y"RS'',>Q'7<34!LSY6 '2K+5Y#,R[ M\12M_DK$\.[9:83.=,K$FK?I2GG/YX=*W(2$3%43HOOWX*&#X"S$5@\\B@7 M?.@!.Y "_O/QQ%?D(M'T,+(ZTFM/FJHN*(#(*MB(. 70147[M<__TRFYIPTF M.H_N5JM407SP^<_YBF!G"J!E$KV6 EMJHP!^5F%!\0U65&1/ ;09_\N&IX([RVOCH81RH;E7A;8\M[[4=)_!CAS=S!WZ9& ML3IUA"=/$)ZY2$FJ%K^5TS.M^5H>X9]Z13K*[D[BXXM-C78M,D\E, 9G6G(, MRB;RHUR1)95/*8#5ZZNIG5[NQ:%0G1F=X21W98^XY-ZKT%)"[;$6Y"(AYUC; M__J\35K[9'#JJ^H(%\5CP9[%E%+[76$J^'\!.-5Y1F?A>;L?! 45DC86&D0E MD22=N3]LI $%&_0PVP0QN[Z0RO'**2#CFGFSV9JO^_@=\,-=J;3E;!.3URD_ M0CA3;MZ\UN6 26D"Z1%0!6IU&YOG&OL_A!1L\#E0B8PD M0G&@\ 8/G'-KMB@VKJYE-7USX^C3ZW63Q%OR#;MW=W3Y#CV_"]#8:+#G9W(> M^BGXF[MFCM6[^8"'O?PL]M5VR0PP"D#DN!6(%Y^A %;6 P]/H-))\>K*$#E2 MED^/09N@B!NGD_D^/DOZ;?4-ZXP7+J4#BUHRO[[]J(R[X]S>1BMU\%4X#EM( M.(DA/5_C:QN#0ZP<.*(O#K*D..1]>GOI5;I=P[N8;!JQHL#YJECW4D-+I(7W MIH?;N;+@6PM IIIHD(W!Q'(SWT8I5S'2/V]TLM=E5NYJC_QXPCT8>Y1=G"TI M=Z\$S0-YAAW;F#K6L'JN@)+ N:9@9%@L1=Z@3G[&?BM>3>.:.E=7(7\4\$6' M 5:IRQO/?XV0Z6/E6 @=JPEK,89'&MOW>64KD[?O&XK<,;_X\ MO-/9"!0* 7!NJM^@&D T;.J'"?3BHQ 78!%O9XL4?1\SGWE9,KNA>9M+S&; M_+$G=CQ6W>=,@9\+S]4N>&][E^:X=0^]4WM7>RQ)'K(6[( W ]4!YHB*B@D4@%VPPX)?M#PK MF]/#]>H:9LQWZ6?O*(!YQX*?]3K2LR(U;T)TE:22^![O0&T160UV"[%H+O^9 M[=;7+8*QU_7XS2U69^OUQ.:-=82CXMB$[VC2(W\P*/_Z9H O(.5](N7(J$K( M/H;9ER'RM7PX=T;41PJ_"%D:["37WFUAE-Y^*VX[6:=>-CR2FG27 I#9'4]P M41U813(CFI 3LYB^Z&5<9'2#Z#Q,H*_ *1T>U:#RJ0,6Y,[^[&SSF*'55"?[ M LN/W)H*U$(X[QP%X(2,SP80)G(("L=W*DH0.-)]Q^R9L]#:Z M)E[;5I()DY"&2R8S"F"W MF\W[?0?=*O4<77.TQ.T2>,HA+"B?*B87SG^"Q-3F%*1]AG7=N>&;+,T5ZSY C5?$ X/'Y,<&B=%6P0 MQKEA6OQ#.ZP&A$,G]J9=FT]C_'-V:9\^WCJ?M7XQKJRIZ9*"NX1P*X('Q>0, MYGU**#\5/=_EXKRI6V* D8\9=MQ9$_]QR)UMOQ_]R:I;-;2UPB;$_6K^7%\D6"@T0HH#,4V"&4ACP*!*.#J*%<:E&N(*!50W$17/1"@U57 -625$ T>K,D)L#E7I(!JN578,\B_%5 MW-3EE*6W ^QL.>$/IE*BI7FUNX,\8>7 UJ#9:'"E0SLK+R'W)*D]=Z[G_L[. M#$>Y.4A][$#GOOL'P*W,.9K,L3?^P 7%E^HTDX3\1X07,R(C$'")F6[NA#4A MM'=F5.KRS.TS"71&NLL].R$\KQZ.N=FRQ"9G\C5L"D".X>FCP?)J1E2%6.8- M)HBBX^41&SU\6P>Z.,W2J@^(>Z\N-$_QS!AK/E015G:WFTTZM=D2,_.5L%M& MV,6+1LX[1&W(Q?MUS)S#63C>,*DJ<.ROMRANX8^^<^N.77(/C<:5![9:%SZ? M:DAK O*B.*GF[4O"-VR^<3TN=&WR5XY@J<('AYS)SI.5/RZV.I7ZEPI!U[<% M7FWUGKKV>MC[Q M0[S-K!XX.)40OS@%G]P<0G[/=E%BX.4, M#;Z:I-=RK\O?BG^-OSW'D[,">I7]:=EKWA1.!!U+$'TKL&4I"P8\_EZWL9\K M=!L4/_D_'=63>GCFK&J?AS!8&Q_YEJL;SO6@FIO_%E(,Y];N%F[>L9'Q$7*E MHAX7ZVPN1:S[ALI1AS]/W?UY->W@_L?-=QP'7V<4S\9M@GSK0>S0$3 M687@ MIX$B=,RQLDW[']RKLC"3!['HG_>8*=K;Y\#]\$FE+KOJXO N8-I+R[&-4ER8*6$3@XZ9/=.@[Y G$R:,=?F5D^\8&/SJ M@69>)Y-6P9-#/:Y3#Z86'5P&0G4O);="^V!5]"$H0:+-*"1X7O^ZQ=!'%_E* M?=$6J$!%1%"0BEIY25!^.H8W\W0OU.#=V]H+256(8SFB#4$#"VS-OC'LYDIT M*6XI=?1:4=!U^V36VNFH^&9;LK8>](TE_':9*5.]JQVI\0("%Q?EJ4S+",4S_J:.,;2=E*+GL\N3JFP<[OJV>-+1$<"!K.'JP[#O&O0R%^KT!?%9[67/D^RO'O)+B6CYZVR M"^;+8\^ 9>6R2(Q!^W:D(#=!#<>/,8W&X+1R,/&!Y!ERB_&@2^G[;],"^/IXN]P#+$XGGCSYN] MUZW>8)1^0&)ZZJ?+4JV?]U39>1[$-0"+B2"<5CZF!SJTP=>;<:VFKGK7T$#Z MUK#K[4>D6T+E!1_K1S8+7__N#/Y?Q;#+"*)ML]@0R"-L9#2Y$T\!;.@;]AD> MR[Q;.IRYMWZYAZ#B5PO: :JRT73D/T&810 L($9 M-Z4;-'O:.1&LQQY1^_DU3UEI!06@)J3Z,EOQ3.&%N?1=',^-\6#[RNW^27EA M-;C&QQB)5_W&QRWKX"ATU2LMX*3MO&3F0G50':" M]J-@T< \SD,TE6 M+?@3)TXY_[C[[UR;RI*18C__C(=T]!\A]!&I?P^L_X.]:OY3#OWH?A\QJ(N, M(1N'_?FR4W_@YE(N%0Z1.Z'J#VJ3IE]LF4[9+:K 23OFWW8:#O#16 J * ($ M0(577_IURD1N"\KO)RFEWP$>##+.LDJ;]Z?9HV7M2LQ!9YY_C"&Q[?Q+E\Z_ MJFOHAX=!Y4#<((=@)N-4#85O&&XPJU/ I0H+FZK,CGZ7:2Z#2[G/3:G$NUR[ MU=F-GFAMP+*V>[I!<8$'5BYCAJOFM7I9C'\;IO?L&F+UGUVPX25@TE4'&&6 M+/ $FT..8.6%S;GD4P!"5)O'\IGPD +0H(]#8Q6&*(!$YXT8B8KU<<3RLR E M7W5%*E-^#!&C #Z$M8,)_-05_IVJT4K4S\'ZFQ9DB,R5%,"B^;%0C/JW:+*O M8*\ /)X"P(P"&4$K-K@T\JE)V Y54ZVSA@/WKOZNC:)U 1URH;Y_A".?PK(B M*R)M%V $G\AF^!&/JAT%0'T9Q%AMXHT6C#;IC* L!= X94#61'X1R_D]GB<; MF/$_/L'8+X=6-\9)?^X%T02(XI-+0X]7CGKP66XB7:=2V1'^W9ACG3Z=MA?&%,:+JZ+5IK8;OHQO)7;75 MI\233G>=A:>5^I>%8:;U6@^\IAQ]X0&J7&G<@T5L"K?H#.1Z=96:V^."<2^3 M;A;$Z_Q8]3Z$VE9HN9Q[:)[T#_^325H$1 4VOWW6,5 PC:9VN$JB8&/S SW_ M8F)H09^K3MD0/H1PI9#<-WNNRN"44]J)PU(391O4XSA''X[W=HFFHK3*1IU+ M.@7+<-GP?8&LLH">+G&Y\DG'V*EB_ M^K/K6K7+NQH:Z;,GN&YV+/W478IBI$\CA#T*,Q^51KIX%ZNQ,V1XKAX%W;6) M#+D:878)XG>8N;_76'*TKGYN%<4V@KKXO!JJ-N(F!SJM)\&L\6!H0=: \<53 MQA#X2#6\;IPNDZ\C]:KK1_,4WSWE&Q*F;:E'FHB8JK>J(!\U?!CG1F?^M-7E M3OMJ]JO1T^Y7VQ22KBJ+QOPH-2E:#.=< 7%4@B-O@".(9Q5#Y4D&9J-E>VUI MK:ECV!<)/PX8WF+4S;NE%D?ZFQMBZU?BB"=UG\BJ7AEWH7ME; M^$FRWZ-]S>_8[J[3M'+K.N\5B81V8\X5,*\<.))/.O>#: N,;0UUL2)#+\+J MOK[A5.=5ZZ299XX[98^8&VQ>3LRJ!FPJ=;VS_-UHP_CT/U+@33%]X2ZJ/KCD MQAE^=-+S%S[Q]AWWOR9-A/XH[W$O+[]]BR;$-B[T^OBHL<\L#6QQ"7J. A@? M^$0!K#[SZ8MR,7+A%N@;0/Z998*,.<*+'DZL'/_?L7 1+U&"A+1Y^UI!.,:% M?==R&(RXW"LT17^052=$ 52VL@:2]LJ"&F=9(?+8/@VX-K8ZVN'#:F=?L@.; MU?)Q[[05>O*IP3??!]UKAG&UI%_XZRF<$A8:&/!+-%9OEG PHG[%:09."LOI MI 2ND K=VQ7]@],?]_3&9,=^;=[]FD,)5/O>:&^CWK/>EAE*R)PY7D9(Z'H M:^1QQ\Z*,X\6/]7068:'0]5A3;?WAO+)HS-R[O6V=7K\X0<]F1<0QRORT*:Q MI1HBI\1M:KM M+E?%_@6__/^;C7;/@LQP/>_M'BR&[Z6U2(9^C0D%X&U9P4H,<-XN(AR3&?S> M4P .Y+ZZT4]=T?) -OW*HX[S; 440$?LV+@\]MVKVO+KL-&.?#T=JD*0Z)/_ M/Z1\[U[V#X&[,\X2B74SOQ1";ZV5Y1JL..X5M3T^._R ?IA1FMK\%JIX-FVJ"50'AFW>"+C:@R,-1"7$U8A7LH+G[ M+6O,_C[0^/O0P;,([P!VD]]AJ2JVO]*Q:F7Q^;053T[A=SNE"T;4'92Z4H4^O3[IG7X?^32FI(?IM=]) M5WZ>"X47.'VW8[!K^Z"0;"#6+<95U3F7T 7^C&WU$P1*Y#JEO[(;E* JB=Y M0B9+6CRC.=]IF2B\SJ8ID1#[D6%DJJFUNA*L-B\SCKR-RZH$<5 ]C(\4^M7 M\G]J![&$>8@YQ^HN"&D^,E/CR MPR$(;T&/?-N.I=1PD9 [/HDS!?(U&G@U3C@Y#F7L$7]\=47F6(WXK!*'JL=Q M-P?"PO?>O)D1 +;Z'E2LE^P MR9A>5OYD;I@0F^.TFO=SW8_!S9FN1K969_%UY@DZ=$([GKXK'7%I;E;6I&(= MU5=;5S4TOF- YT0!,-KW0WSFW0- 1U=Y#^]#,4!%':_8Z JQXW91CW"D;F*V7!@],FY"# M/;=/-'YE%W()N]['ZUHQ)QTV-WN:*$]XE^%[<'C3 X4L*LSHL/;7),C M+CIQO=6*[/!O"+4S4?4)Y^).E)JHRSK-<.& &Q88*?:%^>KX>2#'<[Z1S9$M M:9'L';S#]<(JYX%=H$-" MY'SDAMO<)@C_$3O6S,K0.7]:!$4!&*!'Y"561*,E(=6)W4Z?/VB?4#[G9D^W ML8\TKB%X%?@C,/!F?BM0*XP!8BP8^WYR=@H159/V #S1)?W+^,ZKLG4;SH?L M=C:0CSJJMMW2^WU :#>ZJB8<)4:T&'X!T;:=EU&3EM=GM*NK3O_9*N0=YV*H MFGA)JI+F-8!N09?M#LE@C$Z8!%HG5R:!UI"X07LK2Z5^O"1W+TF9M" M3:)ZW"XDB4[J_(Q3LE/Z+ER +"5?(O<":1L4R\#^@RT+6F&%_MP]Q]Y0[J%G M9OL!YZHU,Y\C4WI]H\]+-WJVA#HO,:G($'3D"5)2FF4(_'I*S$4/]XLU84$8 MOR[A)V<]9;?& <^R\^JQ.X8-;S*L_8:VB??RZ@0'CI5NHUD;Y!=@<=QZU0;, MDS#[E9.$7?F@JN<+=GUGGL3VO$$J-0/OXL&33G2DCQ3 ,W DFN_]%"B*>*,8 M0P&<_:ZP_>*JIE\'24YL+M#*NTQC0:&^E-Q' 9PA _W!F)K6'LG5S[=$>FN" MY^#G6EVEJ\S&W]$5TH5JQ2@MQ)^=\'C92??2.O*8D_CT&^X@DBSD;[L@VFHA M :=S3OR=,I^- M]JAIA*P?JT* @T2?//_E]FP1#DM_O<8CS]F95?P7GE_H]-M=;JY ^BZM9RZ] MLC?/G\F,G8PHQ!JU T_L=U7DB(:0Q1Y;(_$N"[)RY=;RB*HX%D MK2>%O.R=W&>=0!MB'9K0',1[! T<:VN=6E]X@T^^IC,PIE+@+E.73OKUJ]%= M'SQXU9T5^T+C8K^ZN(PLH\]!&2$*! D,Z3Z,8%8';-UTW5&H&92CLK/RYW,B M:8JFLMK"XIN6F[&B7F[GUVHR_7E38?7H=OQ14UA M8C^^))K-5G-N(3!H>G)7FF]R3\&JKZ!@S./\YW<,#=B#WT9,?-V4/.6[I=1[ M_;&69^;[#$COP6S%82#GL^2-)_Z[F,@05=IC*##R+$%VS!"KC\__M'HE=QH\ M.*;.KV6;G3PVPT4886U#,^IBXO7, M!F0X#$)7U'/H$H.SU2I:W2]&G:YI2/JR8=7B>.%4;_^6JB@5MIQD1W0$PN!$ M"<573X:?#;OZ2)2:J]R)#:Z7;KM^^/2I9>(QXBI :U[<6%?)=;MS&7V8\(," MN-Y+/D>%6]P)ZJH0N_Z2O4=CK.&F1FFWL1FSN@"T?UG4+5^U5 M/%N2K6$XM08.1TS\Y5Y89(T@#6X_H02W'JBJJ%@D4K$SD)C#K455#M)7V_IH M:NEIZX=1YR>=9P50$DZ^0 ZB"L;%5V6U"LGLS.:?/2FA]T%^*BOTEZ(*\,=3 MCQ1Q*!;PJXYUDFG>$LT.4P T_DP8KC"L8AN4 M$_M*5F->@/78F@+0'Y-QE MX)!W!Z6)O/EZ["LF+#Y,_!FQSN,8YLL78@_B76-?ANC7LS$LYUVC %ZL>-=O MAU$ =!<&&TPQ+M"%%KX3CN8E?.K?''TDKQ^ZQYT>O-U;J\7_ANU:K^QU-_Q, M!7:VW>T\ =:>S84["/)7 8F6X\_NAT!,U+3AB,,%L#AR1_J+ND:!DO]QQ"SXC6II' M5W4W\ET71W-[C([EF8N-GU)^MWTFXO>RQ:@T_UB7J#$'/$_T($CB9EAEA;%^=A!@0,!X+"&:B M%C93$("3ZL/G?9!J+V:N(F?4.UM*F-7N9FL]W?@@_"(Y+"%W*#.7IRA^LL_* M#WWX@OWN5L<3+!)_$^L7"7L1;X212=B;H@#8'='/@C7N-NCM.I^O/J8M3!%^ ML(3:8?]RX6?\SFLM90I@@LH)9YM@<%]U:2Q7&D;*L*NUSO6E1^$J60XUO"AK MJ<^K>5E/3OV1D[GF11JO2C8+U;%\(I"P_1%B0JJ31\2DPZ/DJ)A&PJ \3:\\ MS7JDM,0^Z1J/#KY-./+IAO5MCW!Z1V4 $$2*@*@]P>;/'\1O$1\N&-"M^K*M MI)G+F<+G8[EBU@+NL5]\%:WK/2D+YJ$7=U_[(?NFR+.S5U]72RUP'3:X4BQ1 M[%+81.0B7&&-0CL$PSHF'4*T6V?/FJTOZ*?I)*TMF?SH<1G4<+]8G:3\S-[A MRD$4OUKE?9X:!CM,R*V6* >3V;0@=K&8RNM&=?F"0L?(Q9N]>Z/_*9A80!NK2 ML\&BWWV"*.,N.9+SG'L4[/=_"B==^TV/#\=F?7:UB>>,FC;GT1->C^OB%7O> MSTZNQ0"671=HR7K*HJ3)[<:^B7D;XN;!BIVQ]1EB!)4:;K->_:N=6O_:EE=1 MD?&@(71T4B%]/H!+;,&ZI-L=<)2LPSH!&X3 M$+Z! R:ZU-DQ._=_2.+O;W;6,TL0[WM)[EAPH_-O%L.FIR*D,U3$%KI#]=<, M:LUP>P9.!"TTF *8>S_+0EV?:J1W5?4%'W=E&I0]N"I8Z'O*=1.>[.TLVH.V M&(DAR*HN\:![-ZPJ5=<&*IMCQ)"/_\N>;O^R?X-V"_0"&IL6Y=WCII=5ZB.E M\$NEWC&M2)?_E!&!3>)&C,5*(TD1IU!HNZ#'S-H1>)MN$&)F7Y>DU1 E?;WZ MU_GEI*1(8%0)XRYH/+\=C7T+4<.9MN@5*H)7[1JT/YY:^P'0^WZK/< JZ:3 MW?)]Y#WDAR[G&V^",VLB$-+P+:*K/\\/:&_I:-\#JJR-*/W/XP/B0?S*51)3 M07K>NZ+9FC'R A-1 *A]LJ/$9_4R NT'"N I\5IY2MJ+NKA!:X7 !15N;+,# M#JE1=.2;P16;9^;X>:[%@<[WA[9[##"JHC* MTCQG>O'S_[+>$"L0!HR*&Q\A5$UZO;5.,9Q+\P?8N>^&!==W&J:V<^&ZG6J^ZTFI GI M/<@.S0?ME7V^XQ^W>I2=5JSYR]SI2+)/+:?&2!!_YV(UILXFXKLHR M\44Y-#<;>1[V0O3FM>%R"+;Q575!+ JN$(U1X].+=A%J^,K-[<>AOQ3M*OI: MO.S@\1/^A[<+XFBR=9?DIQ5F=4;*7FS*6^B[SERFD6?B?/ MNT)[>[\*'@WE\)CWK%8=,7=^IL[F^[\WI:T/0H:A+E<0-.QPTA::8*89)_BG M-FF+@!0CWPU;?H8S'RH.$B.4RH1R=?7L9=NS4[^ IT3VABPFY(I$TV[% MZYF.:A'9ZQV>[0HG9-TY7_;*WACK>?/H;OJ;',5^)Q/]D__!5?][,ZV$=L,J M8J"#@F*H@;0VO.#YKU652=O?4T8&@M,UR[ &9$[UY;4%/[.-.B0\3 M8M/9\LR5A+F 3S)?ZF]0 (W.+Y,URA.VG#V2(C TFJ&,*(-0(HKY;A3SO_\L? M96'A7QFD_>2UN19[#]R]O%4]R91+-O_+!^4 J/V;,;DDD.:[FFOJ^7)O'H)/ M!/ZAL]7_MNX^,8#BXA4\5&A@GUGX(;QWJ(K?\<761S+1\*(V,*8V&8CF#Z@WTQ7VQN]/]Y.2KCIL=%R1BT*.3-)_$Z=B ]$$3=6B/Y \R1 M11*B_4*J;$*;*>!$>"<%$"@C ]SO*9[^X>QI[#T[21SHL5:,[XLN^!ASM!#R M5ZWX!HJ%>!=% .%46K*O#C4%5!97O9NG%_367DH5WL!5((F,Z%L0E]P)QZ/Q MKX-V%O'T1J%J!GI?P?4B)5TH664UFJE](_ [S@._C:8%6]QU?'#:[2QBCU^C M$7E;=#E-[^M3[1X,0 Z(TH$\C-:C#4%2 M!@;4M8@;VOPOC=?_ET)J8Q+3S1'5A\46CN8*&7[%:WZ2)DP2/'P!N1?8;W\, M[79GF//-K2YA[:< 6(F/L>BX$HCH,0BB_WBH.?L"UB!R::#*\E7:?;2+NM17 MV\8NFT+54R(6GM]O8H&GB/QC*%JB/2$'P\JF&9L!/N$?OKF5HI.P=>IS1M<[ MT(0-:W^$T7?Y=\=V$"F<6ZB/ :VU<[8@>FC#%IL0G2>_F,@!J(_I-'RLVI2R MRYD#2U-N7LZ7WT334P".S/P+;HT@7G]8APP_40];$U95.>#CF" R_&*FV3A) MP?;@TP.:)R.A$I[&/?Z995GJ@8'M%H?J%,#R099*O=K KDRS3*BO^F4";+XO M6EVZOJ$<*Q,Q(^%H=.^TFSQ3[=VB6PR0(MO "A7:$*USBYMKM@1:C$P,^$2# M-HX>D])>Y5SDKQ^V/L,W5O:^+M%EW)6;3?^\QZD'G)UG0A!2N'[73;1]1C%K M+/ +K+4O-#4M%9^M4#=LU,HG_VVXDVW8S(2Y7\LL9#;VJ7+'46/@J5800_(C MTEMU6N)SF*#C+L'/!)>06G'<=Z$ :"'[8/H]B"YO$7GVT;>TUH_SFM'5!J M/56I$&3,\')0Q>>R1L/<-NWB4UK?"5(L40,SR^?ZNUD,35E6 MHQ)#8U5B'UQ*NC4DVJ7I-?6"3I !>9N@B,MIFN57IPP*#@OAV!-VF%NXJ; MW',(.J(*CBOQ@[_);"O79$D@A-M\D6]ICQMD]S6=9XGK^]-0R;-TB= M5R![6<[>;9_>8E>'M-882; ]"FVD^9'I]P/:G+*XO[M-@I[2]=+36)&)K,N/ M(,LYHL^A[>JY0AQOG$KDK(F48>1T1+I8<"NR:-%(>1L3VA^A'^A#?1SK-%/@ ML=SW<(]JCM1RO[7<@HZF%JMUG]0]\U'!FRZ"1_E)@H%2$Q[]$ECIURH 6N . MW_*687ENWIN+;ZIKT<"ZIIW<[+X#5!9.8GJ6J N'/K[:V*EJ_XV;S'C]6&%M MYC0AMY"H,5#I.-5TM-55WY7A7R&0LI#UA>&JNL&US\?PDY^$E>>_KL(J1KT_ M;78C=R=(Q^EZ,W#9%0,<-]Z6A$ Q$&T$F7%]"40S/JL.5Y>I^S&T^*N=J>E; M)G'A6I#P.UIV3+4)/&<1^>16:\$!"L Y%O9*712G4"(I;V%;\+RFSNZ315DI ML?"3NG/]T\O@BV/B"?^#N?<,:[)KTT:CJ(B "$@O08J(("A=6A2D*EUZB0H( MB(A("P*)% &I @("0I3>(UU:0J_22^@0(M(A00C1A+#C[&_/.]_SS+SMF'?V M_%@_;C@.UF*M=5WK/*_*&4/.;I2:/23XXW<[/&8>/%'C&I:4BY6G]$W.[Y:U MN$CDFK73I])>>-5H(U5]H9VK/$.=F/>);$1]7]X'RO/S-\6;CC6IYAA^/ :X M:'Q5D-9T>+FGXDQ,\L[3\%9^(7U6-%WNB9*>9^:BN(<[]Q32;.!Q0Y8%KIO@ M0.3 RW1:P]L#I"+5A.*7[ZG[U#2XN6@ER?8V51O'(AWSY4EQM#(X M#X(E+C6F21SO:\A.3+(<;M+ '?%YY-15ORD3TV[K(0A8\*I$,#,+27QY6H<7,DN8-8"QV>"=/>HELJ:H>:5$_R8_"3AD? M+C"QS5(&D3QX4"7VB)J9TI*DLX;A6S^X:L21M2#6+J M+2E)W_J*FAUO/C_X7LTDO8N$WV,IT!WGQ)A,V MJ4/D@^%W2545_60Q(A!7M2RUM8F%<6E[8.GA/!#Y^(<7Q\6_*Y/"EK87=>2XFKH?Y[BJ MRGZ>6[N1ZA&/>#U8LADCOI?#"9K$)34^RDC*R]J:E4RFCM'>O$U/YLBFC-25 M2-$3)NHQ7O!D2[]B<$WBFCT3O@/$$"CZ_%F3W%+MEUJ;\"M#GOZR2*>O,7TW MG3J,O,:VVFIM-TKR9R>'5B:"C@&A>Z(&-IE=\21!Q&MTVV=(>\LQ@%5%5[[* MG?'@8#=T_P?!3I!+RUQ:O[IKV8G3VVDT->XZ562*MO0+!K_3>>K:52"Y-?(7VH*%GJ0IXM@-\W@?$9FT+ M9X9X[M\=>,EEL:5;))-RO?42S94+8>>GY@5YG_>))UL4+JUR!?0JE[@? QB) MZ2]*9F9X%C]SD\4RL+!(CM;>Y49W<[1F(_L/MU3YL=M!'N_;:WN6M<)OS>J8 MC)ZL_\9-9$?=/@8X@*8+NA8!5.',M 9SSDZYSL (UPZ::PX)82*270YJ3]T: M8:G!B5\_2MY2%#Y'Y+$9V5$!%<^MH]V?'LIO5PSDC5O<<.;ZZ?@FC0>!J]@O M_Z"2O:G?9F$>OW%GMZ^\\9U+=M1^C/I_>V%6XUO ,[!6,S6NH[IVRGEBJ#N[ M8V7R_MU5&M'^H-$6PX\,EX%6M-B?G>"&8P ODK,=GX'AB&KBN5J0633]N=JO M2ZC!,.O,T -ALZ$*012]Q[7+8SOY-?5O/GYY/7-3T#-^$J\1 M@@>$H@VWET\F)5!7M?T!\\]TWOR[R_ QWBRZ3X.R#;6 ]A\#Z#*P%MU2YXAV6&G74=OHS#MQ(:-2"WITV_46 M+FKEXH2#VM6SQ9&*9L:O:!^(?_\1-:,5=7 ,$*IBXOLF0@60UWW_-W7&10@> ME:HQ*71+!?,+X5:JU7PK3C+>U;-US"B\?;5D9\T>1.1[N7VU0HM!4>";^;OO MZP,&RI_DOI8.K3:_RV%[\)N+%N8B\HX!'KLA8%PA1=E^0YZ=8A@1:-QH5CES M/:'/YDB0F;(5\9SF5:4 (EU\_ZH9F\O5A.FL^TG15?]7H]&_RQXV>0QP@D4- MDP6((SE/&MX< Z)>$M622KL,^R9-7R6R4M9G12=OV.MJWLG.XV"7V6_LS.+/ M:(,*C\NF#1[6O,ONN?&&M5BQ=:W/#,7=6XRB#Z0*+WT 88;BA3VDJ_'-"-Y M)^F$JZY*;NK& SN!/9995E:$+'1CU78;.G@T 8R\8OE;N%!&5LR6Y[>8_NR.5]L.++Z*SWXY[<9F] M3BJ"K.FV''1Y9\.F4*I,X$O8:7^N$*6ABT]Y&9P!")4;Y6I1XMGBR<(Z_V7D M^";RY#& R@'%?G- 72H'[-E,^&/9__H*8%O"B4FW#QY]OX7VNO7P$7Z-;MXTZB/I=G3*]]?=*= M+HJ]1M4KWOZ?_B6ZD6VZ$OR! M)%:49*S?'.JUST.A@^$?(BA&*T+V MQ)3&GX48ZN. 8?L>C&MX?R7[)%>^Y,JL1F;U';52S\2 1'TW]"HQ?8C9W QH M.A'F_^CW]?YJ^;^JYPUUJ( )C<2+<"#RW$:Z7/4ELG:!L\D(G!BS5N -UF5] M@(FB'Q":U435%JM;9 M,!#X1P,2UU!3?LLBJ'"DN#Z&S]SS?##6#;;E/TW9LK":=Y57-;>5&M5"Y$F5 M.H])E4OLY-RPG>T9[N?:*,\- 9UDA'JVRZ:,:$?[=99YY.!2< M)]0Y0K8F!F! D<-+)"5KF#2- DJ/#.5[WMTQ:87J8X < MQ6U/&QY7,*"O_PPE181][:?^)^M#9_]+9>/6BF1OP!>\>>H=<)O4GP9PO9' M?=YJZ#.77#38F#*$8CH&8#APTY.[@K-%&Y$,#R,&V) O:"=Z&/?I=^VU7..L MH%SC)$/-S6, 8*OMX8)@<;Q!0<'4.F%&_W79ZW=0L\S2NPQB:\77979>PKU, MC36A4F(WY1>V2&&EI2%15W+_T]H-_UG!DUY8W.)G6#=C !86=[#+!#%1M="= M."@94)_<4348O#8RH-SSL;2RY"0-X(6R!2)E_+52[,#4:AF'R*>]9K8=(*X% M5.U\=!;^TW(,1CSZPV>0 MH%)DT:Z=Y:F<+]$I\#85[!7(9^,8/V*O*/ ?A? M?_Q6:]3XF;H0.MU?@=FW^ )K!U!&X/N"L!4'_6, =O^/WT&^$3^DFFFK4AW: MUQ!4<0@_<90#6KMS#.CKRJ"*T-J??_)KF^D[^"63LV1WQ(C],@IG> R8D9NZ M@N/7503B%7^OF*KL(R"44?B^ &S%F3K+MZB_K&EIW*+I&-#>!',U_'4!M%=% M7?*>)A"W"YPQI80QD4O74>0$[7_[AX<#;OJJ<$<=PHE^\=M4%:Q.2S'W7J3H MY%#XL"0]V'#P,2 Y4^$8D'CE+RL*-;;_<0PXCS_* ZW=HJYXD+KBWHNP/TYG M]XG88(*[D<0P0-O[S?'_9T]9"A/^?-@/TAPG+ARE.AQ\)+[8@MM(*)40!R]!'R&.!,H!+ J""'>W5[9/'EE"2CJJE<8=:DM*5] M3H"#+D%'831;5,HF%?:R[O7CO>4) ,D^R7L)NKQ]8GK(Z;F> M0E72^#GRON7\DPHR(1:4V6TT3S*6R]Q-TQ)[Q M'([%' ."W@FH/H^?+EE&3#-'*UGQ/@=C@S4 M$272Z.W\^)PIB)].Q:AWB>66=_]9ELG)F4NOHX2-"G/6 @:N8X]C:EN/]2G M"76.P*]U5%C4F]GZ#ZSV?\)U\V^/2RHQ$[>H26Q>XG-NXR;;/\XH:G.0OAJ" MT[D9YSBDI=7.E,]T"FVL>=]Q>3QE36&8S$^LP:&LB7)X>BM<>#-[_Y'2HQ#- M4\+X+)/[0V8^[4SE3 +H2V $L(YCJQ8.;#HG5W8.[16*B:=IM\WZE3ZWG[SY:)N MF__;?\CU-@G^'!&KE>>S'/_:KS(P?1\T8WW]Q?7TY(:D"J_A_O,'HD>O^3:_ MS4SBXJ-\@#3$'%W\^02%Z0-5R0WE?E=E.N90R2 M;:$O/86I<@B^R9*)I^PF MY@$R^^>BUIH>^A<0T[SA7"XE=1IXL_0GDWW2=PS(^G2J"L*?QH/'HE;=MES, M+:.,2_A1$TCM_ONA!0JTOVO)S7W]\\;7!$IAJ&+-L9G28)[)G+*!^0QJB)Y_ M3P"\T+^7QZG99]#+*"KJ5#\=R$)TH[+LU4CD6 7I6.LK_>%SO)C"F?PX>[: MB0.V@R1Y[/"5-0 GX.6Y7ASB]583!X:DSV/(%3+GE"?T/5WC\ ,IZ2> ]LD$ MHEOF:>=WSC@GW#6.G^2AFE9,"G=FUNYOGVZ'L8GZ4IV( MVZ7!::OUP)K<]L]]0E;43$@\*_4HPS95-+Q9^E*7]B*Q:\,L(>+Y;8$CMQ+& MR!3N["(643:YQS"U:HMFZ!2P2FYW:Q7/K5,FF X[LU$ZMH8>O/OP9?7YQ1^C M*M@Y]V??F$XCF@M,Y!X4,*:M5"]O4?>L[-0_4J'IKU9O$FENJDMEOGW*4&7O MLPXV]JY,A2+@Q'C23 X"!5KZ@*IL7+1OQ7MTFM^K32F'8?AJWCL,OG.4FP;. M:[2]K+4AWE:9BL*WC_D(VS[ZOA6?#W( 3R.!TZN8I[HP%CBGFQO? D+\"B-3 M_[L:6M'(O>F#QPYCG(=]5Q A129F^:NJTQN:5TI^Y]=<^KL;2_X/F63^SSAQ MF\H3N,E45!/RFM(3[4$X!D3;,U8)BGHH=%@_%6^[H;(@ &PS_-4ZE3E/S_R+ M0U?85?:%IH2KK(F8=IPF0WGN@R+:D+-8MHGP#D-&8P-A@ZM/OE("KR ^PYYY M3(V3^<9%\*C0:_:&-/;]E*3'KRI&'SNT'0/0[*(K'AA15PH+5 W1D&/-ME1 M^^F[GJ3D;X&>>_N/L(YMT%1W5V@7ZAS9$$?8N34#C[!JTLAY)N1E(\^^QYS5 MLI5*D^CWTB(;W0$\I7;%+I"'6((9XI@)3_#>S'-[ST&QF:TU<4$M&5>=#WCK MMKO+Z^+; (QTLE,R]LJQZTJ=<>_[5CI960AYSXI>$7 >YSZ0[FNJ2J9%F_TZ M!L 'L@S4LB8L3"]O[OR5:S,Q:Z]S'JALM1M*Z'VEG9_O]/2]>T!H= M$#^E,^R4]J8%\#();!M3IUK)8KC MO"%JG#4#3P1FMJ+?7YMSWGJB;7H,T#][#$!"ZQ&6B &9+ZH&/ M$M1Y?(4H];BY3!-A^/O6+<<__T>?K?\_6QS_G\%KT648IL34#8IH2 U3T>1B M3[VE>WK<07K&5C*P/FF.M6>'GJ85T3D4@Z(E:^ 4NNLH;'@15*K?,[]V3_[ MC$)=Y.UIFY7,/HEWBB[!>3 T%XX4@A+FO[R^?S.;, MS";?%-\1B0LV;9],KHR?OF^D! LP-0P(YLLDW<5EI&,3Y*>W\M1EO=?$ MR$]LT6-5JZEO*2J)NF4-Q,#'DI9%B]G3_,E*3WZ3ZJ6_*VGP?SB!\ _C=-!= M_:K)ZMEF9>/J\&. 8>.;CU]JOMS"#_ P2%=FG15$45^XI[M3Y3^6GGU2B"*+ M7IR)>"69^S,U-57/5T7[TH:#Z.NWQX"&N:6ZS=.:?FX>A59#KGX>C/-Y'>X7 M)P_/\M\T#N>R,CS%W'JF\?F7(HPS9'N":_"58K0UQ&TO'+_5I(=H7]:S2XF\!-G6KDZ>8!67C M"J.LWB]=C4D,$E\'AQP#3AN&6_/!.BZ$%B_)E27%'&4/;"!=7> =^-7 M;?;_IF4PJ03637WAZH_T34H:ZLB!4B3X^,35?SHZ&H>8J2/<'T&Y>M!KOG$8 M#7Q8<(G[66EOLM.W]Y>[+TO[GWJ1FRB3R/1-H8,I BE M%GN/P8P0N#ZJ74B6C%%T?-CS\*TF]- B 3H*K *%@UREZ&#.&Y^\MU^.\)"D;*.N M.]8Z#'8#NYE53=6PM.F$YS=#VRD[^17DN)?OZFMLX&_>6;CC Y9VHZ"TQ+[5 M=JCXV,P@ 90EEG3M]+A_2XIH]]<"H-&+LZ>8;?6#PAQSWV7OQ#'6_7OIUW_. M(KQ/NU5"N@2)(+R=?#V7K\_1:IZXW3QI=?-MW+WK-.V]<4<< EE]+XI,9+-7 M%1S#L[]MQ3!-UQ$<\:#M2\LY3GEB8_OB6J9%;EZ7;MB(4=@HY##O6T&] %;P M9S@]E(,8L+08O+][#O)X;*O!*?U;XU*_IUC7S]P':LZ/;JJU, =4M P!J0 MGBSZ$(-@<*UPM59-W(X[^U.B>U>YSL)7)44E?4U\&?]^^E&>4ZZ%QDB!_FU_ M*L:S=_U3X/#_)GOR?QQL=CD/^IYK!FJ0K(X!K:I/FYZC*5+$AZ>4G"-Y9.R( MWFQQ,_AZD8^B)\68#@V8&]U5H?/9#5^4]\7W ^NR:9GUZF!]:L)=VTT??MX*B&9YU0 M/)K%$GEHRZ5O(CZW8=>7S6I3/?84177;AW_7\&V6N?#WXL1]4\QN+ CS/) . M5Q=M;ZA@,WH+][UNS$N7A<;C!E8T4/%T//X2FTC@(8F>?"M:FY@4M*1OL'0[ MF[@\Y]J:*^IHT7?7JL__&)"5=L_OA]M:2?_-:E+O]C,AEV<"OE$ZL\65'RY MPRQJDB<.16X?93;S+_J6C':_B2OHES/V(?>X9$<1AF2I"[;!(%KT#3O[V3^5 M5+:LEX= R 4 %I2E$V;SG#&/#GUH*+LJFF9I*5X51@N-=3' M@V>CI&"=OOA0K4 M1D9FW&R[=W./*IB.'X 8T0_003-WTWN5:-G^,@63JKIQ[\TO7RW8_3SI!-.8 MS)Q4F \0VG1Q1:]]%U1CGIB:'H#@4>+[K(0T*K%R^YIH1TS"7/B!>30Z@+%Y MHP;IDH8." $_P,;D;^Y?:T$$^ZA*_M A!U^? MM!_&@9 M#L3[S$GM;[I,VA#^FU.C%U=4XS^ '(\!1-'!(CSG#+%@6;]Y,A1C M6GO77?P]0HY-42 +?T<;#TR+F&^Y5++?K3&\OTB_5FNM%OO0(V_=W#C2O73; M2-A38 M [MW0%9X@//JJ>U.T*!<1U[%<_"C/?WMJ_]+ITQ^--=FZ7/Y9&\"_ M(*<'27N$0#V]!EL:VG;%%2_0[6PA>5P/32PW?PAMUS5EW8\>U.;ZB1Q@(.S% M' ,NAOG*$2(ZAB)GI-I@-!L+8N@=;/58-=%:X[NBJ0SVVQN9B?G/Q;3""6!Z MRN1BU3&@DPE(Z;7P31\*;1(]*OBD#XJ6E'.7Z3A4L'@Q^%VWG&"3JH:!6[?(AXVR'ETH3C%V[]&)!+EHVR;OF\ Y^E]CGESS1) M-08 81P=@G,,Y&$8_+([W!'/!H]URK@=M?W4>1Q5(<=\NGJ@SB5M "G(V/00 M_J2BY]3V4W_TE@^>,HM-W;KKSS= ]N._@OL>X97[Y"W7B8S#Y]+M,N=S51Z> MWWD=&I/(&!A+DMN8446060JP$\A//D^J^)[9:@B5'^TRAK3X'GS75 X:_\4- M.!(CUI%, J6)' 5K,_&Q*MJ74_/=Z)#M1J'ZC4TU7TX]XWD<(GHO^>>K:XDW MN7C'D:Q'^4ANXFSW!2)(#W\Y4-OSB529A,?39T\'MNM/O7'/B'R^CY%!NL5(6(Z@EJMA5#>37\PYOT ?Q^/MQ+53(-?>KGU6]P1P?UWZR M.960_9980D >O17$?< O/O%\+U7.W7:KFZ2B3].86'!D%:4,?T1C1#OQJWO[ M-2ZB'7ZA!D:SR2]EQ],Q<\]DSG[FB;7/?*4FK^?/&(IWPMEIO1=YEA$]LXU" M\EO'@"?'@-?<$>VQRMV^"]?K,MJMDS%CI(L/.5G]L98QMLIEN#1&94_1< V97^FN^,A4(8N: M$<=0:C PYLU)I3FT?!:O>T-GMFL=;(;;?S^]OX^DSE_P_I)5L'/4SS8'!#/H8X 66H0S6 M*G654"&Y&I%4LEX^!C'G4U)657=T'Y9KO6M\$?JZ-<[CHP4?#H(*^QV1?ANG M01@DYN X="J_\-/@CZI??I56;S7IZ_[*>,->J\7!+[AO#,.W<(;A: MN_T(A)F,QD8WO[@+.K]I(JQD,[>.-K8#ZVR9RX:/9+/V#-Y/-HM)X73J$Q(3H@;A:N;D( W;#/DWX2Q'"!8IRWG-M,K&BJ_5,&N/A1>!TX+Q)[* MGLZ3#(98W%M*!W10)XJ!CJ7S-U+O#/(J\2Z>HY/[<:U/YUCG]]B@8M>4U%HW MMMZT;&!CR*ICR057AP6+JWFO!"S60.V-10@DD/AX>=E*4O+RZ+9CHJME52/G MNQ3A/5V5;^@5T6W5,I=?$626_J6+\JF^2?:2B'.16!]I)DGZ;Q\<$/V7;BVL M>,V@3* ,;NE^D106B++1*&*[1IG..^,AW\2'$HFGYG+F)]Z]U7&Z&G16J ;@ MZ_T?;:1@D[&G-67RJP;CI=L'?$KK#%[3"WTA*C5/(H"$"T(U!,- M>;R>CO\RB;PXWYT#KI"D\(T+@QZ_34KZ=N^%@UK43S#AG<7J:KP:+Q&.@39? MCEUN/O]#?3QGM;5C[6<4+=PQH![%6 M>W:'(V'G!GQ7"\O( ZO.Y2;@IO/T[+?!_E!1V;4B-SZFE@WQ?0VL!9GENUC3 MD3;F6?U*W;6CU^4@H$XY@!P:7X+N +*H,5%Y]OE<"14'3)G&K=]3_JYE.:ê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

    • L&$PAQ& MFXR5$&Q>Z^GK#P$2CY"11T;>O1EY"Z-2"N(RFB%("9])J54E&6=8D@1@*Y,[%^LBGZC$J8;K +S>Y(J8A2X\L MO7NW]!9&MA3.:Q%PC,95U]]+JQ MS#FO6?3:56<]*Q[B6D]VG=%=;X XFCB:.'KY'%VD\: 2CT)JD%5B/0:O!1=9 M2@'!DP&]HO2\^>E2#^]0MUE9%FW1#*H>9DX+8! R9*^YX;&0"4WT3/3<(GJV M,6CI8HX^:%#&.)>T*5KX5B+CC/O$0+ 84&@TWV4%TQ M7_+FKJ$Z&1J&MTZK[M.4-SA]HTG?YP^\/7OU/_8^W?] MX^26SUTKYN;Y/^:*WK_#Z,>SP7\W_=C"=D/PD^V87O%I?U*_+7Y[@P#J!KW* MN8,Q#@_JW7RIV'4&PTG]OLFP,WF7Q[GAG2G .,FI4_H#',0^[M?[KC]HNKN. MGUR[Z./OT5!O[<-PW&^>Q:>CO(^3_L?\TZ=^FKP[H;YSGSK>='[V$0SU#@XG MUW_D'M&]#DO9W)-7%[$X_^>[T[;]9_VWO3>?[K^LOM]<[SWYZU_I8[ MSW9W7NW^MK6QOK>YT7FU5__:WMS9>]79_;GSJBYC\]?=WS8V7[Z:UF+8GSJ; M+UYO[;UIP[+FY)4?M@:508:']:II_*]+"ZAJ8#H ]%3HIY1>;W02P> ?/$>'D']^KT75SU+G:K7A5NMEO'7;%G3$%9MD<'?&]MGOV M2J_U/X]HK2^/UOHRIYP/IB;-PUSM1BYY-*H^X#\LK\KS:/AIMI/ 2BUUO=YK MXWA6-_\]XHX_BP:N63Q3[H9WUO6&F[FE_YQ^_=O6,PC;7RBQ\ M_-HQ!*O9I^_J.@,:L'9_I3#--;]NO_^SO_W^A7@CM_AVO?;N+UMZ>^__]7?D M:]AYG_;?[&VK-_W94ICF_K>_[!QL?=G9^/W]F_=6 MQ?0Y7'8U?)Y\WJ_^=:^FJ1$ M4\@>&E/U3YGJN^>/M92DR**@05X/1TZ_G,KI[49XM518R:(@BX*F73UD!MMY M=LI@MYMSU5(&(W.#!D:ME#R>Q2B^>U142T61C DR)FBJTH,@J;/PQ'?/4VHI M29&]0(.)'HZ2J*7"2A8%610TO>)ELZY3);C5(A&ALV1)--$8S-QXOC6V?TMAM MAVT0DRU;J!\ED]%<"N*T&4Y[<C3(:&_&0">SU*8'==EY$ M&XVRN?M\'(^2:&6?CZLE^6;=%K]5YWK%FE>CFO4X\_1]TT+NLY*8$":$"6%" MF! FA EA0I@0)H0)84*8$":$">$'A_ &Y%+P^C_6O+@^RCKZ,/K\].J0Z=8@-MW[\\^CX<&%:!'%4A<72]V^D."N M>UB4"9DU1Q09.*V90Y59,KK9W^@=EK4>N*Z^?4L_DDSBOO8@/ ?W"7!1H=2B MA 1:2E=X9;_L1'%>9FV)^U:(^UZ?*^Y!U-HC*RYS!O799BB292"=C3R8S#6V MD/L>5$OXJV5SHS^^9:KHBC6O!BU]'_%?O<7WT72&$":$"6%"F! FA EA0I@0 M)H0)84*8$":$">&'@_ \1XH6EBLZJ28,Z$4IK_G#=K/2.@Z^WEYLMS M'RLBD252; '"\Y#BPI)(1(KM)L5S"295BLQ&L +),$C),\]=8'_OB7$S_-HVA1^L<(L9V7YV?#@8#B8'CP\ MO;.3KWZ&XW?/L9].19&3*-Y %*L8GC1K?N;YG_]]Q^/![P/\PQ_NOM]__^?]6;6^\Y7^^?PL[?^SL__?KEMK9>*MV MOO[]:>?]WV)[[\U?(8>DH%HX1@1@4)QBSH-CJ1BOH#X"1N6U'G]BW"69[GS( MH\ZS?1R/.^N=X:B*#(Z^=*8S#<[$?2H3CZ,(@\I<"&%"F! FA EA0I@0)H0) M84*8$":$5Q?A>8*B/*0 ID@=C*M_Z^"5X$$JF92WPN'<0='3Z$D3-:'(YD+# M*><:E6>E93":,\N;\7VJ '.&>Y:]D%ALD=SKM9YTNBO)L?V;&V^>9Y\P)>E125CAPR^J"*P.!\D!#0ACPW\5QNZ3K= MC5?'7TY$M"@B>G-,0M/9DEP#>(N*^:I'&%B+S"F?F409A>!@G6^:"T#7FLOE M#U2VU(:C[PN0Q!NWB9^*),G;O/+6/Y4WK75T.A@FC8O-+-? @BO5*]>\F)1E MJ)9;E3<2M3:8VU;.$VQ^P7+VZD >] (K^<35<& MC3XI8-7B#@SJ[K(@K665.XWTB2NTZ5H-2%71[0DQ$,*$,"'\>!">TU^-7H0H M*YD7!!6%2QY$4,+E8*) 0?YJ>[7USIFVEDK;NI&2>6^JO\I5?9528@5,TB6E MDA.2OTIT]_ 0GF?*$@_:R2036 [68,@HBS<6=2DZ0;J#B #1W>+H;O$\"- > Z-DCD/ MT6&1#B4X5 $#+P5D4;QJ&763-#-IE"6&N\Z-?2\>DHD.F!72,\#B&*IHF$?7 MV C9"ZVJ!=V5($FAM"$*?0_-.T@([T4(SWIQ""MT*%&P:$)D30:6N9@*2R(H MS!Y+!EOM.I!=;V]3_D$2>#<2F').)7&EI7 0)4<=.$;A3!K/>4OGP$G 7LH[?SGTG"E_[D^ M'E_S:$AR-[?Q?NFP7-,)XY$-AVY#:>16 MW96<-@Y'%;KG=17#=)1JFO[YGV9'GYW;4"*PN0@LGJ^)# 'KME=K7(2F49Z; MUH84SJ0V]9DV@KOHJW%^ZZGU=":"3IT0PH0P(4P($\*$,"%,"#\,A.^W5N5& MSM+ON'^8K_.5*,VQ.$?J7/4*9*&C 6!9&69!S)#EU>0/]<1A*Y-EEC8,H49*":?@<^*,85 MU[H8@9AC^PS11]!P92=/.OU!'![DQ]5KA8J;"6%"F! FA EA0I@0)H0)84*8 M$":$5Q?A9?;4?SX:EO[DM^&8.H\L,(BT^>FWO@F&@A&)>6<=,%-99$X(1E=M$MRJKKN2B1>SV"$XD'HU<:,XBCO*[ M/!CW/^;CC."//^Q7N?C7TVLS@W, P1L8KF(TN@9=@ZZQ&M=84#W$E(EMNUGQ M]6"4ZUU\S:GS%ON#<:I=O)DM^SA9\J=+#!W\N6WO>E_ M1[F3J$OP0B26E$Q-7K@P9W1@W%A0W!>((:[U3%>I6[=#(RE>C7H,DN(5D>*S MZ@[A3?):.:9=TXC#8:Y2+"Q3/$F7Z[9#*FL]W96W;VI(4DS63GL07F9M!_'D MBO#D6:4(*E 0G*SLB$W'^ PLZ,P98-"Z/AY9);G6$Z)K.&\142ZH3&05$J,O MI[2Y:N;"<,ZC5""!/"A# A3 @3PH0P(4P($\*$,"%, M"!/"BQ@)>6_9TB94.!L&64_O#\>3@SR8_#P:'JSO/MOZ>3AZA?MYMYS%%"F M> N32W:MIWG7>=,. MEOR'+&GJCS_LXY?F/O.W3ZW2;])OWN5O/JB^[_9*=?,?W&\F3'=PTMG(,1^$ M/.HHT>TT^N(VIYC#<)3RB!TM[:FJ3)&&ATT50+.BDWB= M-BOLJQ&<;R1UCCIP2-6E00LRBE"=FABL@I"U,C'\M77#H1;3B^\>3L83'#2( MD89=H(8]T:[3F17<91D*%*80%(.@# M@-:L&5Y <.$;!UWJ@9->;RQVY3H1H M*<;Z]]1!+4)R;V'=+XU8VL;,_[>,C9MCP]I$M5<$@1?%L\WPH'?#_8K=>/-_ MA_W)E^H1[1\V@#T?CJ9^T&0RZH?#25/CMC?<&0Z:^Q@-]^OMO]VJ=U1I>D+\ M.S?_;IWRK]969.,LX[8TM: )&'*NF'EN7GYQ9O>E M;)2UHMI]&!D8K'ZWLY8IG2SWP>8LU&E&BGB9C+^E&W]."0\Z6E0F0/#HHZ_N MB8100LK6P2V,/^*1.7GD;.:L#0F*$"4V@YK( MJR;K;?G6FX]%F!P=9@F ,7C@PI6LC3!84N84NFL)O\13?C%1874%137M(F<@ M4F&AQ,!X,-KY8K7F64DF\3+S<)EX.14MK4N3:2$@B^J*BS\%;4-:Y ME);)RV0TWY:<_SXE9U^B$"@E\]S(I@]9@@BR.(\BH:<55=SV]6*?'.B M9Z+G%M"SBL7+%)0.&D!R&T0&E7P6!H0UG#+>J\K,TR&I1V>Y>.+1\^Q80!D9 M:%FIN8F<%B6+U847+)SL9B)F(N86$7/(E8X3@(X>SGD]!!I,A&V:41P;**A:F MC1'J/YU A\;YM9XP7?"7>SX1.1,Y$SG?.SES%71P3@( UO^OI%QY."/:P)N& M-O=^3I/(>:'D?-;,RZID@S><57RN;,(>]5==%8LE640*QY*URSX),GKE2GP"E M<]U_N]83O"O!=35<)D@R8^=M%/GC]%FO?Z?^Q]Z_ZQ\GMWSN6C$WC_ZB:4+P M$URG5WS:G]1OB]]&&J B_2KG#L8X/*AW\Z6"T!D,)_7[)L/.Y%T>YX8[IDCA M)*=.Z0]P$/NX7^^[_J!IJ#I^IX]WC9Q_!4._@<'+]1^X1W>NPE,T]>;B(Q?D_F]N=\[R(]?X=1C_VKEK%4N&^I/2FC^[+W3?KO^V]Z3S_=?WE M]GKG^6_/KGT4VW++G6>[.Z]V?]O:6-_;W.B\VJM_;6_N[+WJ[/[<>;;^ZM?. MS[_M_O&J#UJNF\;\N+:#2]W2NYJF,3ZFXWNX^?ACGIR]^ZK%!/M/#?==EOOZ?5]5_:NIM5[FZ0O>&& M_4.3W!,[@#=6P%4G%H6^]+M7^$M'HGD_[H&[D7OP)N-HW-DUCPHR3I#-"9GP\\AANUMYWVS-SW#\KE/VAY_& MG3(:'G2&'_*HN@75_6A\SX_3>0Q/;_(<_8,K>/G9F/<9^R>P;W.-!WJ3"YTL M_\3JMCS*5XM<$E!UILM;1G3;D8?1I^?/A\-JRRF<3.\IGG-&S5>E5#KF^-0ZX=WV[]LP1OY9W];_GRP??"" M__G+R_>[?_S>__.7%U^W][;T]M>W/S<\[STY"K1_^WMW;_WMWX^^O;[[^ M_F[GZR9OPK*[>]M?=_?^%KM[;]3N1KWB'UN?+X5:#U[4^WL!NWL[[^LUZ_V\ M@.V-S?H=];[W7NN=]Q%VWO]9[_OG_G^_GG1DW9QLK_]EBY7:2<-BDM T?1;, M!568EX:#-B4*P"8)I83N.@V7XJSMF% U!T'/JA,BL0=)8EBLSX;+8BR <=XY MF;DQ$@LXXPV?DA@_(3%.)+9Z)/;EE,22#"D&$UA1V'26SHF%*#S33FL3311& MVH;$A!1=+R^?M"42(Q)K(XDI!%MD?8(Q PA=?%;&RI2-5U5;R^ET5N&/24QX M(K&5([&=,TLL&FMMX([I;!(#&2+S(D4FJP*+6:/VV:WU*H$IZ'(O6T1B"XKY MK+3/W!],HY:YLLYO&*Q^[P"_;)2.! MOU.!/W/'(ABIG0O,!A\8I,@9YEB8MM&%NF?><5$%'E37ZEL[8R3PK17X9;LO M)/!W*?#G7!>TQMFD@&&TEH%/F7GN,RM& B\A1 GE2."E;Y.&?US)OMW)NSPZ M]4[BC!OS77[*3<-+J\QB]^JG3/>((C'W3F>OSSLL&H.'#):5[) !JL!"GIZH M%2$4DZ--U6$!Z(J'&$LFP5^&OT*"OS3!/W-.H=&)H50J M&EDLGYXZ('J@4AA6"B(3*6FMP+/1433I%"Z7%]N>$T9E/N1TY/&/YW1L9M.29/[ MK@>?)K/=NU_ $> M\B-9OBOW@63YOF3YG+-0)#0-+S/SU;ABX+5AJ+Q@R6)0OKY,"9K>'%4QFQ8) M\R-+5]1/?9RV"YR666&5C::CPFT\A\<0X+C#GOA8W'Z9#DZD2?K[I50[%%B.92$V#F&PT\]4V8UH7Y 4E*!ZGX0*C6J*W'U<28R^/#OH# MG,KGAV.QZ=37Z-*:BS?\=@;GNQ/)MJZ8]K:_'0\G*Y2U_I?1CFL MQJ1GVO/$P&;%0E:10=U"Q;D*0C;EFJ;+_>4CXG,/[Z0(9PM%^FX<#A+I^Q7I M[5.1%J5D! =&=033@R6Q9-4-1ZB\ M]&C>DN3RTC4U7Q2Y08)-D6J M"S_^O>?\1(\*>$7\ M31-S#"6-'U[2<)OSJMN;][@U;^S.#'[(%E775S^TB N=13C"()8%\H#'(0%? M1),0G,U *\;C)'_V(AWGV2JVRRP6O3;+6Y="&*-$D*2O(L483FW%#'"*)BB:-=12$*B"Z2<1[> M!4(QB/03JUO<4J*'PL4=A+D+*R(99YS)E&0R!@NM6$$XC7,B RIE)B.I)1L* M%P\MG(V,H 2,9N>ZXG.,*/A4C"J#1$9<\E@@CSX= M)V&X&\F1(>'Y6,*,0;8?0+:[:".B&F28QB27D294,D48:&U86R%5F@8\XS@C M(V/C+!B*&3^G;-]?,6.0[1\OVUWPP4*>ZCQBA,9A1FB29F"R50:;2+46-,]9 MH9^]R/-Q$JV2Q.UB34.5]?F$7^)SZJNUP6/^Y-,J[+0DO.>\?&(T6@\26S5, M?\VZOX5E/]3S00MO40N'?O2$5/ZQ9!DI&,L)A0WGN5WBX^DH)%:9;$)-,\)32+.,D55Z006:Q9HF0D M^W%4(+G("YT16G!):,)SDM,H(5D:ISS5 M0E(!^B,:!V$V3M: =!LY>@!GX_NHBVXFO(\HB_Y$M='6@[]!&SV4-O)0>CJ@ MLFVXQG:N\01R!JAG1\5D=E&/BFIV-BK-@-]^NN#7C?F";=C5X1I/ MK3[?FQ=MCQU8#GBUJ5&Z?*[5B!=%.2GAKT^L^7)7)NC>;NCW.SU?5-.CXB4_ M+^>#XW5+QVO?(X[\\]OAM_W@. GC.*14$24+36@>8!MFEI$@B\ MXT$._WOV M(HE6J2.'"3D_BWS?ZU3=.\KW$'5M4_@/^L)?4!5F0DN2L] ,P0N)2#-%$C@- M*LJR(@L*"+V2<9#?>1+O(/\[*__W.HEWB_(_]'7>0?0_]D5?Q2PJ$B4(BP). M*(]#PHH0-E@%221$E,9"#6C;=/0G*K=+K M5=R0,KZGR&7O&%S5C#%:D)SFF#+F,>%,!P1BE8@50:JHL,-[\R39C>:0H>]K MUU')@U0_;$BR=YP4.F$B%D2*" =9Y(SD08YEZ83I,!9%GHAG+V@P#@>I_DFE M>ON1R"#5#QIM[!TK'N:R" 51 85 HX@IX;#+A"LN*1-!DL3)LQ=1-@[HZA3N M76SD_,EJ)&\7E3SE-5QO5HRTD8Y1K>6B^GX [Z/-F3P\8$T"0CE64!8DC(2YU)&7+! I!!+),$8CM\@SS^E M/-_7"*U!GG^8/'_T)M'00N@T)DQE#.294Y)K'I.0%KEF*M4JYL]>9/F8L;LP M/0V%BN^-(ES%SX*LMA-&/-J,Q\-%$5[==;^N%WPJ]5$Q:*I[UE3?^JBJ/Z-C MEH&YX2(A*LL20B,FB(@5[&$HLTB$@D<688A#O M!Q+O@[YXYV&4B()SDF29)#0+"Y(7<4BXB'E6J"0&1?[L19S3<4Y7PXM!O'\6 M\=YRB/&=XCW HNX@V1_[DAVEB0YU00FC*G"CM"(*UCNG/(U K%6@MP:+&FH6 MVZA9\"^\G' QT88!OX;S#R(FYD,18R>P47O-[KR95>]A;SI%]@HV:?!3[B<, MV0\//_U]>1SR($PD#4@>XCB>E%*2IX(2D;(@#BD7 @FRLV ,UFLWLB9#%G1' M Y"M"/C@J6PA!G&RG>149 G.UA(B!D\E9>"S:$F24,04O9>,1KL(X!XD?%?K M'(,-WPDY_]B7,^%,N M?=Q3-/(4LBGWVF:.>NNHƆ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end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Cover - USD ($)
    $ in Billions
    		 12 Months Ended
    Dec. 31, 2021
    Feb. 11, 2022
    Jun. 30, 2021
    Document Information [Line Items]      
    Document Type 10-K    
    Document Annual Report true    
    Document Period End Date Dec. 31, 2021    
    Current Fiscal Year End Date --12-31    
    Document Transition Report false    
    Entity File Number 001-39329    
    Entity Registrant Name Royalty Pharma plc    
    Entity Incorporation, State or Country Code X0    
    Entity Tax Identification Number 98-1535773    
    Entity Address, Address Line One 110 East 59th Street    
    Entity Address, City or Town New York    
    Entity Address, State or Province NY    
    Entity Address, Postal Zip Code 10022    
    City Area Code 212    
    Local Phone Number 883-0200    
    Title of 12(b) Security Class A ordinary shares, par value $0.0001    
    Trading Symbol RPRX    
    Security Exchange Name NASDAQ    
    Entity Well-known Seasoned Issuer Yes    
    Entity Voluntary Filers No    
    Entity Current Reporting Status Yes    
    Entity Interactive Data Current Yes    
    Entity Filer Category Large Accelerated Filer    
    Entity Small Business false    
    Entity Emerging Growth Company false    
    ICFR Auditor Attestation Flag true    
    Entity Shell Company false    
    Entity Public Float     $ 16.6
    Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement for the 2022 Annual General Meeting of Shareholders, or Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2021. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof.    
    Entity Central Index Key 0001802768    
    Document Fiscal Year Focus 2021    
    Document Fiscal Period Focus FY    
    Amendment Flag false    
    Common Class A      
    Document Information [Line Items]      
    Entity Common Stock, Shares Outstanding   432,963,472  
    Common Class B      
    Document Information [Line Items]      
    Entity Common Stock, Shares Outstanding   174,212,681  
    XML 17 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Audit Information
    		 12 Months Ended
    Dec. 31, 2021
    Audit Information [Abstract]  
    Auditor Firm ID 1411
    Auditor Name Ernst & Young
    Auditor Location Dublin, Ireland
    XML 18 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Balance Sheets - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Current assets    
    Cash and cash equivalents $ 1,541,048 $ 1,008,680
    Marketable securities 581,872 983,279
    Financial royalty assets 614,351 587,193
    Accrued royalty receivable 53,286 33,155
    Available for sale debt securities 66,000 69,984
    Other royalty income receivable 15,023 6,011
    Other current assets 6,631 8,596
    Total current assets 2,878,211 2,696,898
    Financial royalty assets, net 13,718,245 12,368,084
    Intangible royalty assets, net 5,670 28,666
    Equity securities 269,800 298,689
    Available for sale debt securities 204,400 163,016
    Investments in non-consolidated affiliates 435,394 454,936
    Other assets 4,145 9,997
    Total assets 17,515,865 16,020,286
    Current liabilities    
    Distribution payable to non-controlling interest 107,934 126,366
    Accounts payable and accrued expenses 5,620 10,775
    Interest payable 57,696 42,146
    Accrued purchase obligation 0 110,000
    Other current liabilities 0 18,600
    Total current liabilities 171,250 307,887
    Long-term debt 7,096,070 5,816,584
    Total liabilities 7,267,320 6,124,471
    Commitments and contingencies
    Shareholders’ equity    
    Deferred shares, $0.000001 par value, 361,170 and 316,407 issued and outstanding, respectively 0 0
    Additional paid-in capital 3,507,533 2,865,964
    Retained earnings 2,255,179 1,920,635
    Non-controlling interest 4,471,951 5,077,036
    Accumulated other comprehensive income 16,491 34,395
    Treasury interests (2,715) (2,317)
    Total shareholders’ equity 10,248,545 9,895,815
    Total liabilities and shareholders’ equity 17,515,865 16,020,286
    Common Class A    
    Shareholders’ equity    
    Common stock 43 39
    Common Class B    
    Shareholders’ equity    
    Common stock 0 0
    Class R Redeemable Stock    
    Shareholders’ equity    
    Common stock $ 63 $ 63
    XML 19 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Balance Sheets (Parenthetical)
    shares in Thousands
    Dec. 31, 2021
    $ / shares
    shares
    Dec. 31, 2021
    £ / shares
    shares
    Dec. 31, 2020
    $ / shares
    shares
    Dec. 31, 2020
    £ / shares
    shares
    Deferred stock, par value (in dollars per share) | $ / shares $ 0.000001   $ 0.000001  
    Deferred stock, issued (in shares) 361,170 361,170 316,407 316,407
    Deferred stock, outstanding (in shares) 361,170 361,170 316,407 316,407
    Common Class A        
    Common stock, par value (in dollars/pounds per share) | $ / shares $ 0.0001   $ 0.0001  
    Common stock, issued (in shares) 432,963 432,963 388,135 388,135
    Common stock, outstanding (in shares) 432,963 432,963 388,135 388,135
    Common Class B        
    Common stock, par value (in dollars/pounds per share) | $ / shares $ 0.000001   $ 0.000001  
    Common stock, issued (in shares) 174,213 174,213 218,976 218,976
    Common stock, outstanding (in shares) 174,213 174,213 218,976 218,976
    Class R Redeemable Stock        
    Common stock, par value (in dollars/pounds per share) | £ / shares   £ 1   £ 1
    Common stock, issued (in shares) 50 50 50 50
    Common stock, outstanding (in shares) 50 50 50 50
    XML 20 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Statements of Operations - USD ($)
    shares in Thousands, $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Total income and other revenues $ 2,289,463 $ 2,122,353 $ 1,814,254
    Operating expenses      
    Provision for changes in expected cash flows from financial royalty assets 452,842 230,839 (1,019,321)
    Research and development funding expense 200,084 26,289 83,036
    Amortization of intangible assets 22,996 23,058 23,924
    General and administrative expenses 182,826 181,715 103,439
    Other operating expenses 0 65,053 0
    Total operating expenses/(income), net 858,748 526,954 (808,922)
    Operating income 1,430,715 1,595,399 2,623,176
    Other expense/(income)      
    Equity in losses/(earnings) of non-consolidated affiliates 19,490 (44,459) 32,517
    Interest expense 166,142 157,059 268,573
    Losses on derivative financial instruments 21,532 42,076 39,138
    Losses/(gains) on equity securities 48,066 (247,073) (155,749)
    Unrealized gains on available for sale debt securities (17,859) (18,600) 0
    Interest income (53,535) (28,379) (22,329)
    Other non-operating expense/(income), net 5,678 32,821 (393)
    Total other expense/(income), net 189,514 (106,555) 161,757
    Consolidated net income before tax 1,241,201 1,701,954 2,461,419
    Income tax expense 0 0 0
    Consolidated net income 1,241,201 1,701,954 2,461,419
    Net income attributable to non-controlling interest 621,473 726,914 112,884
    Net income attributable to controlling interest $ 619,728 $ 975,040 2,348,535
    Earnings per Class A ordinary share      
    Basic (in dollars per share) [1] $ 1.49 $ 1.32  
    Diluted (in dollars per share) [1] $ 1.49 $ 1.32  
    Weighted average Class A ordinary shares outstanding      
    Basic (in shares) [1] 414,794 375,444  
    Diluted (in shares) [1] 414,802 375,455  
    Income from financial royalty assets      
    Total income and other revenues $ 2,065,083 $ 1,959,975 1,648,837
    Revenue from intangible royalty assets      
    Total income and other revenues 171,248 143,382 145,775
    Other royalty income      
    Total income and other revenues $ 53,132 $ 18,996 $ 19,642
    [1] Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (“IPO”) in the year ended December 31, 2020. See Note 13–Earnings per Share.
    XML 21 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Statements of Comprehensive Income - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Statement of Comprehensive Income [Abstract]      
    Net income (loss) $ 1,241,201 $ 1,701,954 $ 2,461,419
    Changes in other comprehensive income/(loss):      
    Reclassification of loss on interest rate swaps 0 4,066 6,189
    Unrealized gains on available for sale debt securities 11,600 83,120 6,159
    Reclassification of unrealized gains on available for sale debt securities (50,896) (20,551) 0
    Total other comprehensive (loss)/income (39,296) 66,635 12,348
    Comprehensive income 1,201,905 1,768,589 2,473,767
    Comprehensive income attributable to non-controlling interest 604,323 739,787 112,884
    Comprehensive income attributable to controlling interest $ 597,582 $ 1,028,802 $ 2,360,883
    XML 22 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Statements of Shareholders' Equity - USD ($)
    shares in Thousands, $ in Thousands
    Total
    Cumulative Effect, Period of Adoption, Adjustment
    Class R Redeemable Stock
    Common Stock
    Common Class A
    Common Stock
    Common Class B
    Common Stock
    Class R Redeemable Stock
    Deferred Shares
    Additional Paid-In Capital
    Unitholders’/ Shareholders’ Contributions
    Retained Earnings
    Retained Earnings
    Cumulative Effect, Period of Adoption, Adjustment
    Accumulated Other Comprehensive Income/(Loss)
    Non-Controlling Interest
    Treasury Interests
    Beginning balance (in shares) at Dec. 31, 2018       0 0 0 0              
    Beginning balance at Dec. 31, 2018 $ 4,552,079     $ 0 $ 0 $ 0 $ 0 $ 0 $ 3,282,516 $ 1,215,953   $ (10,255) $ 63,865 $ 0
    Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
    Distributions (880,142)                 (739,276)     (140,866)  
    Net income (loss) 2,461,419                 2,348,535     112,884  
    Unrealized gains on available for sale debt securities 6,159                     6,159    
    Reclassification of loss on interest rate swaps 6,189                     6,189    
    Purchase of treasury interests $ (4,266)                         (4,266)
    Accounting standards update [Extensible List] Accounting Standards Update 2016-13 [Member]                          
    Reclassification of unrealized gains on available for sale debt securities $ 0                          
    Ending balance (in shares) at Dec. 31, 2019       0 0 0 0              
    Ending balance at Dec. 31, 2019 6,141,438 $ (192,705)   $ 0 $ 0 $ 0 $ 0 0 3,282,516 2,825,212 $ (192,705) 2,093 35,883 (4,266)
    Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
    Distributions (1,105,765)                 (313,408)     (792,357)  
    Net income (loss) 1,701,954                          
    Unrealized gains on available for sale debt securities 83,120                     60,617 22,503  
    Reclassification of loss on interest rate swaps 4,066                     4,066    
    Contributions 1,482,322               307,646       1,174,676  
    Transfer of interests 0               (1,037,161)       1,037,161  
    Initial share issuance upon registration of Royalty Pharma plc (in shares)           50                
    Initial share issuance upon registration of Royalty Pharma plc 63         $ 63                
    Issuance of Class B shares to Continuing Investor Partnerships (in shares)         535,383                  
    Issuance of Class B ordinary shares to Continuing Investors Partnerships 1       $ 1                  
    Effect of exchange by Continuing Investors of Class B shares for Class A shares and reallocation of historical equity (in shares)       294,176 (294,176)   294,176              
    Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity (1)     $ 30 $ (1)     1,402,762 (2,553,001) (1,261,014)   (24,022) 2,433,098 2,147
    Issuance of Class A ordinary shares sold in initial public offering, net of offering costs (in shares)       71,652                    
    Issuance of Class A ordinary shares sold in IPO, net of offering costs 1,908,744     $ 7       1,150,383         758,354  
    Share based compensation and related issuance of Class A ordinary shares (in shares)       76                    
    Share-based compensation and related issuances of Class A ordinary shares 5,428             5,428            
    Other exchanges (in shares)       22,231 (22,231)   22,231              
    Other exchanges 191     $ 2       307,391       2,562 (309,566) (198)
    Dividends (112,490)                 (112,490)        
    Reclassification of unrealized gains on available for sale debt securities (20,551)                     (10,921) (9,630)  
    Ending balance (in shares) at Dec. 31, 2020       388,135 218,976 50 316,407              
    Ending balance at Dec. 31, 2020 9,895,815     $ 39 $ 0 $ 63 $ 0 2,865,964 0 1,920,635   34,395 5,077,036 (2,317)
    Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
    Distributions (614,973)                       (614,973)  
    Net income (loss) 1,241,201                 619,728     621,473  
    Unrealized gains on available for sale debt securities 11,600                     6,335 5,265  
    Reclassification of loss on interest rate swaps 0                          
    Contributions 48,539                       48,539  
    Share based compensation and related issuance of Class A ordinary shares (in shares)       65                    
    Share-based compensation and related issuances of Class A ordinary shares 2,443             2,443            
    Other exchanges (in shares)       44,763 (44,763)   44,763              
    Other exchanges 0     $ 4       639,126       4,242 (642,974) (398)
    Dividends (285,184)                 (285,184)        
    Reclassification of unrealized gains on available for sale debt securities (50,896)                     (28,481) (22,415)  
    Ending balance (in shares) at Dec. 31, 2021     50 432,963 174,213 50 361,170              
    Ending balance at Dec. 31, 2021 $ 10,248,545     $ 43 $ 0 $ 63 $ 0 $ 3,507,533 $ 0 $ 2,255,179   $ 16,491 $ 4,471,951 $ (2,715)
    XML 23 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares
    		 3 Months Ended 12 Months Ended
    Dec. 31, 2021
    Sep. 30, 2021
    Jun. 30, 2021
    Mar. 31, 2021
    Dec. 31, 2021
    Dec. 31, 2020
    Statement of Stockholders' Equity [Abstract]            
    Dividends paid (in dollars per share) $ 0.17 $ 0.17 $ 0.17 $ 0.17 $ 0.68 $ 0.30
    XML 24 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Consolidated Statements of Cash Flows - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Cash flows from operating activities:      
    Cash collections from financial royalty assets $ 2,315,854 $ 2,121,923 $ 1,934,092
    Cash collections from intangible royalty assets 151,158 143,753 143,298
    Other royalty cash collections 44,123 18,305 27,448
    Distributions from non-consolidated affiliates 34,384 42,334 14,059
    Interest received 3,135 7,704 20,136
    Derivative collateral received 34,660 45,252 360
    Derivative collateral posted (34,660) 0 (45,630)
    Termination payments on derivative instruments (16,093) (35,448) 0
    Ongoing development-stage funding payments (6,876) (20,479) (83,036)
    Upfront development-stage funding payments (193,208) (5,810) 0
    Payments for operating and professional costs (184,511) (179,709) (88,524)
    Interest paid (130,430) (103,196) (254,964)
    Net cash provided by operating activities 2,017,536 2,034,629 1,667,239
    Cash flows from investing activities:      
    Distributions from non-consolidated affiliates 523 15,084 0
    Investments in non-consolidated affiliates (34,855) (40,155) (27,042)
    Purchases of equity securities (135,134) (50,000) (78,999)
    Proceeds from equity securities 115,957 384,840 0
    Purchases of available for sale debt securities (70,441) 0 (125,121)
    Proceeds from available for sale debt securities 62,500 3,000 150,000
    Purchases of marketable securities (1,196,579) (1,705,283) (817,402)
    Proceeds from sales and maturities of marketable securities 1,597,851 815,440 725,070
    Purchase of warrants 0 0 (8,840)
    Acquisitions of financial royalty assets (2,191,502) (2,182,246) (1,721,291)
    Milestone payments (18,600) 0 (250,000)
    Net cash used in investing activities (1,870,280) (2,759,320) (2,153,625)
    Cash flows from financing activities:      
    Distributions to shareholders/unitholders 0 (285,353) (739,276)
    Distributions to non-controlling interest (479,604) (543,952) (154,084)
    Distributions to non-controlling interest- other (153,800) (181,135) 0
    Dividends to shareholders (285,184) (112,490) 0
    Contributions from non-controlling interest- R&D 7,339 8,482 0
    Contributions from non-controlling interest- other 36,874 58,957 0
    Scheduled repayments of long-term debt 0 (94,200) (294,000)
    Repayments of long-term debt 0 (11,116,196) 0
    Proceeds from issuance of long-term debt, net of discount 1,272,533 11,891,030 0
    Debt issuance costs and other (13,046) (46,715) 0
    Purchase of treasury interests 0 0 (4,266)
    Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs 0 1,908,744 0
    Net cash provided by/(used in) financing activities 385,112 1,487,172 (1,191,626)
    Net change in cash and cash equivalents 532,368 762,481 (1,678,012)
    Cash and cash equivalents, beginning of year 1,008,680 246,199 1,924,211
    Cash and cash equivalents, end of year $ 1,541,048 $ 1,008,680 $ 246,199
    XML 25 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Organization and Purpose
    		 12 Months Ended
    Dec. 31, 2021
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Organization and Purpose Organization and Purpose
    Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the IPO of our Class A ordinary shares that was completed in June 2020.

    Following our IPO, we control Royalty Pharma Holdings Ltd. (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K. tax resident through our ownership of RP Holdings’ Class A ordinary shares (the “RP Holdings Class A Interests”) and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our consolidated financial statements.

    RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (“RPI 2019 ICAV”), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (“Old RPI”), for accounting and financial reporting purposes. RP Holdings is owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”), and Royalty Pharma plc. Old RPI is a unit trust established in August 2011 under the laws of Ireland and authorized by the Central Bank of Ireland pursuant to the Unit Trusts Act, 1990. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”).

    RP Management, LLC (the “Manager”), a Delaware limited liability company, is an external adviser which is responsible for our management. RP Management (Ireland) Ltd. (“RP Ireland”), is the manager of Old RPI and equivalent to the board of directors of a company or general partner of a partnership and is responsible for the day to day operations of Old RPI. Its functions can be delegated to third parties. RP Ireland delegated responsibility for investment management of Old RPI to its parent company, the Manager, in accordance with the investment objectives and policies of Old RPI.

    “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Reorganization Transactions (defined below) and before the consummation of the IPO, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to RPI 2019 ICAV. Prior to the Reorganization Transactions, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Old RPI.
    We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

    Reorganization Transactions

    In connection with our IPO, we consummated an exchange offer on February 11, 2020 (the “Exchange Date”). Through the exchange offer, investors representing 82% of the aggregate limited partnership in the Legacy Investors Partnerships, exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under our new credit facility and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”
    As a result of the Exchange Offer Transactions, we own, through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”), an 82% economic interest in Old RPI. Through our 82% indirect ownership of Old RPI, we are legally entitled to 82% of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish unit trust. From the Exchange Date until the expiration of the Legacy Investors Partnerships’ investment period on June 30, 2020 (the “Legacy Date”), the Legacy Investors Partnerships were offered to participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Since the Legacy Date, we have made and plan to make new investments through our subsidiaries, including RPI Intermediate FT.

    As part of the Exchange Offer Transactions, the Legacy Investors Partnerships and RPI Intermediate FT entered into new credit facilities in the amount of $1.3 billion and $6.0 billion, respectively, the proceeds of which were used to repay the $6.3 billion outstanding debt of RPIFT and, in the case of RPI Intermediate FT, were also available to be used to fund investments. As part of the new credit facilities, RPI Intermediate FT repaid $5.2 billion, its pro rata portion of RPIFT’s outstanding debt and accrued interest. RPIFT also terminated all outstanding interest rate swaps in connection with the debt refinancing.
    Prior to, and as a condition precedent to the closing of the IPO, various reorganization transactions became effective, including the following:

    •the Exchange Offer Transactions (as described above); and
    •the execution of a new management agreement with the Manager (the “Management Agreement”).

    We refer to these transactions collectively as the “Reorganization Transactions.”

    As Old RPI is our predecessor for financial reporting purposes, we have recorded Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date. The references in the following notes for the periods prior to the Exchange Date refer to the financial results of Old RPI for the same periods.

    IPO

    On June 18, 2020, we completed our IPO on the Nasdaq Global Select Market under the ticker symbol “RPRX”, in which we issued 89,334 thousand Class A ordinary shares at a price to the public of $28.00 per Class A ordinary share, of which 71,652 thousand Class A ordinary shares and 17,682 thousand Class A ordinary shares were offered by the Company and selling shareholders, respectively. We used the net proceeds from the IPO to acquire RP Holdings Class A Interests and, as a result, we own 100% of RP Holdings Class A Interests.

    Upon consummation of the IPO, certain of the Continuing Investors agreed to exchange, pursuant to the Exchange Offer Transactions, interests in the Continuing Investors Partnerships represented by their ownership of 294,176 thousand RP Holdings Class B Interests into an aggregate of 294,176 thousand Class A ordinary shares of Royalty Pharma plc. Upon completion of the exchange, Royalty Pharma plc indirectly owned 294,176 thousand RP Holdings Class B Interests. The remaining investors in the Continuing Investors Partnerships who did not elect to exchange into Class A ordinary shares held 241,207 thousand newly issued Class B ordinary shares of Royalty Pharma plc. As a result, the Continuing Investors Partnerships held a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests indirectly held by them at such time which are exchangeable on a one-for-one basis for Class A ordinary shares of Royalty Pharma plc.
    XML 26 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Summary of Significant Accounting Policies
    		 12 Months Ended
    Dec. 31, 2021
    Accounting Policies [Abstract]  
    Summary of Significant Accounting Policies Summary of Significant Accounting Policies
    Basis of preparation and use of estimates

    The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.

    The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.

    Basis of consolidation

    The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record Net income attributable to non-controlling interest in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

    Following management’s determination that a high degree of common ownership existed in Royalty Pharma both before and after the Exchange Date, Royalty Pharma recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date.

    Prior to the Exchange Offer Transactions, our only historical non-controlling interest was attributable to a de minimis interest in RPCT held by RPSFT. As a result of the Exchange Offer Transactions in February 2020, a new non-controlling interest was created related to the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI.

    Following the consummation of our IPO in June 2020, two new non-controlling interests were created: (1) a non-controlling interest related to the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, which amounted to approximately 29% as of December 31, 2021, and (2) a non-controlling interest related to RPI EPA Holdings, LP (“EPA Holdings”), an affiliate of the Manager through its ownership of the RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to the latter non-controlling interest until certain conditions are met.

    All intercompany transactions and balances have been eliminated in consolidation.

    Adjustment to prior period presentation

    In connection with the preparation of our condensed consolidated interim financial statements for the three months ended September 30, 2020, we identified an adjustment to the classification of our short-term investments on our consolidated balance sheets, as of December 31, 2019, based on the original maturity dates of the investments. The adjustment resulted in an increase of $37.5 million to Marketable securities and a corresponding decrease to Cash and cash equivalents on the consolidated balance sheet as of December 31, 2019. In addition, the adjustment resulted in an increase of $388.0 million and $350.5 million in cash activity related to Purchases of marketable securities and Proceeds from sales and maturities of marketable securities, respectively, within Net cash used in investing activities for the year ended December 31, 2019, with a net impact on net cash flow from investing of $37.5 million. The adjustment had no effect on our reported total income and revenues, consolidated net income, total assets, or shareholders’ equity for any period. In addition, the adjustment does not impact net cash provided by operating activities in any period. We evaluated the adjustment and determined that, based on quantitative and qualitative analysis, it was not material to the consolidated financial statements as of and for the year ended December 31, 2019.

    Reclassification

    Certain prior period amounts have been reclassified to conform to the current period presentation.
    Concentrations of credit risk

    Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2021 and 2020 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.

    The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, AbbVie, Bristol Myers Squibb, Gilead, Johnson & Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche and Vertex. For the years ended December 31, 2021 and 2020, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32% and 27% of our current portion of Financial royalty assets, net, respectively, representing the largest individual receivable balance in both years.

    We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.

    Segment information

    Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.

    Royalty assets

    An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.

    In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.

    Financial royalty assets, net

    Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (“ASC”), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 Imputation of Interest.
    The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as Provision for changes in expected cash flows from financial royalty assets and the carrying value of Financial royalty assets, net is presented net of the cumulative allowance for changes in expected future cash flows.

    The application of the prospective approach to measure financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below.

    •Analyst coverage. Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts’ consensus sales forecasts for a product to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst consensus sales estimates are not available for the full term of the royalty, particularly for the later years in a product’s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management’s own expertise. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves based on historical trends to project future sales when sell-side equity research analyst consensus sales estimates end or are not available for the full term of the royalty. In other cases, management may develop and apply growth rate estimates from existing sell-side equity research analysts’ consensus sales forecasts to project future sales for products that cannot be modeled through the statistical curves, such as those where the entrance of a biosimilar is expected to impact future sales. Based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset’s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.

    •Commercial performance. The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts’ consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product’s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.
    •Royalty duration. The duration of a royalty can be based on a number of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product’s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.

    As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts’ models. The most sensitive of these assumptions relates to management’s estimate of the royalty duration in the final years of an asset’s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows.

    A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.

    The current portion of Financial royalty assets, net represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears.

    Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets

    We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset’s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period’s effective interest rate. The amount recognized as provision expense increases the financial royalty asset’s cumulative allowance, which reduces the net carrying value of the financial royalty asset.
    In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.

    Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the Financial royalty assets, net line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset’s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either Provision for changes in expected cash flows from financial royalty assets or as Income from financial royalty assets on the consolidated statements of operations.

    Income from financial royalty assets

    We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition of a financial royalty asset, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.

    When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as Other royalty income.

    Allowance for current expected credit losses

    On January 1, 2020, we adopted ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of Financial royalty assets, net on the consolidated balance sheets. Any subsequent movement in the allowance for credit losses is recorded as part of the Provision for changes in expected future cash flows from financial royalty assets on the consolidated statements of operations.

    Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for further information.

    Intangible royalty assets, net

    Currently, our only intangible royalty assets are the Januvia and Janumet (“DPP-IV”) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, the majority of which terminate at various dates through 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.
    Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10, Property, Plant, and Equipment - Overall. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product’s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty’s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.

    Revenue from intangible royalty assets and Accrued royalty receivable

    We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts’ projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.

    Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.

    Milestone payments

    Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts’ consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved.

    Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.

    Financial instruments

    Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than Financial royalty assets, net are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 5–Fair Value Measurements and Financial Instruments.

    Cash and cash equivalents and Marketable securities

    Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value.
    Equity securities and Available for sale debt securities

    Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities are measured at fair value. The unrealized change in fair value of available for sale debt securities for which we elected the fair value option is recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations. The unrealized change in fair value for the Biohaven Series A Preferred Share is included in Accumulated other comprehensive income (“AOCI”) and are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows.

    A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management’s assessment.

    We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.

    Derivatives

    All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements.

    Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of operations as part of Losses on derivative financial instruments.

    Investment in non-consolidated affiliates

    Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee’s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within Equity in losses/(earnings) of non-consolidated affiliates in the consolidated statements of operations. The investment is reflected as Investments in non-consolidated affiliates on the consolidated balance sheet.

    We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the “Avillion entities”). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.
    When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets.

    Research and development funding expense

    We enter into transactions where we agree to fund a portion of the research and development (“R&D”) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, Research and Development, we account for the funded amounts as R&D expense when we have the ability to obtain the results of the R&D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. We may pay funded amounts upfront or over time as the underlying products undergo clinical trials.

    Royalty payments owed to the Company on successfully commercialized products generated from R&D arrangements are recognized as Other royalty income in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria for products arising out of our R&D arrangements are also recognized as Other royalty income in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed.

    Income taxes

    We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (“the Code”) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.

    While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments.

    Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes.

    While we do not currently record a provision for income taxes, we are party to certain arrangements that will give rise to a tax provision in the future. We currently have funding arrangements in place that allow our counterparties to draw on capital over a prescribed period of time. When such funding arrangements are drawn and we begin to recognize income from these funding arrangements, such activities will be subject to U.S. taxation and we will record a provision for income taxes in accordance with ASC 740, Income Taxes. We also entered into an arrangement with MSCI during 2021 as discussed in Note 16–Related Party Transactions that will become subject to U.S. taxation when we begin to recognize revenue from this transaction.

    We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI.
    We are also subject to the U.K.’s “controlled foreign companies” rules (the “U.K. CFC Rules”). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the “Controlled Foreign Company”) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings), will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes.

    Earnings per share

    Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to RPI EPA Holdings, LP (“EPA Holdings”) related to Equity Performance Awards and unvested restricted share units (“RSUs”) issued under our 2020 Independent Director Equity Incentive Plan (“Equity Incentive Plan”). We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable. We use the “if-converted” method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.

    There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information has been presented for any period prior to that date.

    Recently adopted accounting standards

    In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to Retained earnings of $192.7 million to recognize an allowance for current expected credit losses on our financial royalty assets.

    In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.
    XML 27 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Available for Sale Debt Securities
    		 12 Months Ended
    Dec. 31, 2021
    Investments, Debt and Equity Securities [Abstract]  
    Available for Sale Debt Securities Available for Sale Debt Securities
    Series A Biohaven Preferred Shares

    On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”) at a price of $50,100.00 per preferred share, for a total of $125.0 million (the “First Tranche”). The approval of Nurtec ODT by the U.S. Food and Drug Administration (“FDA”) in February 2020 results in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price. In the event that Biohaven defaults on any obligation to redeem Series A Biohaven Preferred Shares when required, the redemption amount shall accrue interest at the rate of 18% annually until the redemption price for such unredeemed Series A Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert all unredeemed Series A Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date.

    The Series A Biohaven Preferred Shares are classified as Available for sale debt securities in our consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within Unrealized gains on available for sale debt securities on the consolidated statements of comprehensive income.

    Series B Biohaven Preferred Shares

    On August 7, 2020 we entered into a Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”), for a total of $200.0 million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the Series B original issue price per share. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares. In the event that Biohaven defaults on any obligation to redeem Series B Biohaven Preferred Shares, the redemption amount shall accrue interest on the applicable original issue price at the rate of 18% annually until the redemption price for such unredeemed Series B Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert any or all unredeemed Series B Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date.

    In the three months ended March 31, 2021, we began purchasing the Series B Biohaven Preferred Shares. As of December 31, 2021, we have acquired 1,406 shares of Series B Biohaven Preferred Shares. We have elected the fair value option to account for the Series B Forwards and the Series B Biohaven Preferred Shares, which are recorded in aggregate on the consolidated balance sheets as Available for sale debt securities. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations.
    MorphoSys Development Funding Bonds

    On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (“MorphoSys”) to support MorphoSys’ acquisition of Constellation Pharmaceuticals, Inc. (“Constellation”), which closed on July 15, 2021. As part of the funding agreement, we agreed to provide MorphoSys up to $350 million of capital (the “Development Funding Bonds”), which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150 million. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds. Our commitment to fund at least $150 million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding.

    We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within Available for sale debt securities in our consolidated balance sheet. The unrealized change in fair value of the Development Funding Bond Forward is recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations.

    The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2021 and 2020 (in thousands):
    Cost (1)Unrealized GainsFair Value Current AssetsNon-Current AssetsTotal
    As of December 31, 2021
    Series A Biohaven Preferred Shares$134,068 $29,432 $163,500 $66,000 $97,500 $163,500 
    Series B Biohaven Preferred Shares70,441 19,759 90,200 — 90,200 90,200 
    Series B Forwards— 12,300 12,300 — 12,300 12,300 
    Development Funding Bond Forward— 4,400 4,400 — 4,400 4,400 
    Total available for sale debt securities$204,509 $65,891 $270,400 $66,000 $204,400 $270,400 
    As of December 31, 2020
    Series A Biohaven Preferred Shares$145,647 $68,753 $214,400 $69,984 $144,416 $214,400 
    Series B Forwards— 18,600 18,600 — 18,600 18,600 
    Total available for sale debt securities$145,647 $87,353 $233,000 $69,984 $163,016 $233,000 
    (1)Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. There were no costs associated with the Series B Forwards and Development Funding Bond Forward.
    XML 28 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Derivative Instruments
    		 12 Months Ended
    Dec. 31, 2021
    Derivative Instruments and Hedging Activities Disclosure [Abstract]  
    Derivative Instruments Derivative Instruments
    We have historically managed the impact of foreign currency exchange rate and interest rate risk through various financial instruments, including derivative instruments such as treasury rate lock contracts, interest rate swap contracts and foreign currency forward contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash flow arising from our exposure to interest rate risk and foreign currency risk. We may also acquire other financial instruments that are classified as derivatives. We do not enter into derivative instruments for trading or speculative purposes.

    Treasury rate lock contracts

    In June 2021, we entered into treasury rate lock contracts with notional amounts totaling $600.0 million to manage the impact of fluctuations in the underlying benchmark interest rate associated with the 2021 Notes (as further discussed and defined in Note 11–Borrowings). The treasury rate lock contracts were not designated as hedge instruments. All of the treasury rate lock contracts had collateral requirements. The treasury rate lock contracts were unwound and settled in connection with the issuance of the 2021 Notes and the resulting net loss was recognized in earnings in the year ended December 31, 2021. We paid $16.1 million in July 2021 to terminate our treasury rate lock contracts.
    Interest rate swaps

    In February 2020, RPIFT terminated all outstanding interest rate swaps in connection with the Exchange Offer Transactions. We paid $35.4 million to terminate these swaps and reclaimed $45.3 million of collateral that was held by the respective counterparties. During the years ended December 31, 2020 and 2019, we recorded unrealized losses of $10.9 million and $72.6 million, respectively, on interest rate swaps in the consolidated statements of operations. We did not enter into any interest rate swaps subsequent to the February 2020 termination discussed above and as of December 31, 2021, we do not hold any interest rate swap contracts.

    Epizyme put option and warrant

    In November 2019, RPIFT made an equity investment in Epizyme, Inc. (“Epizyme”) of $100.0 million. Under the terms of the agreement with Epizyme, we made an upfront payment of $100.0 million for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5 million shares of Epizyme common stock at $20 per share over a three-year term and (3) Epizyme’s royalty on sales of Tazverik in Japan payable by Eisai Co., Ltd (“Eisai”). In addition, Epizyme had an 18 month put option to sell an additional $50.0 million of its common stock to RPIFT at then prevailing prices, not to exceed $20 per share. On December 31, 2019, Epizyme notified RPIFT of its intention to exercise the put option. As a result, we recorded a forward purchase contract equal to the difference between the market value and exercise price of $11.5 million within Other assets on the consolidated balance sheets at December 31, 2019. The exercise of the put option was settled in February 2020.

    The warrant was recognized at fair value of $5.4 million within Other assets on the consolidated balance sheets at December 31, 2020. The fair value of the warrant was not material as of December 31, 2021. We recorded an unrealized loss of $5.4 million, an unrealized loss of $25.4 million and an unrealized gain of $22.0 million on derivative contracts related to the change in fair value of the warrant on the consolidated statements of operations for the years ended December 31, 2021, 2020 and 2019, respectively.

    Summary of derivatives and reclassifications

    The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2021, 2020 and 2019 and the line items within the consolidated statements of operations where the gains or losses on these derivatives are recorded (in thousands).
    Years Ended December 31,Location on Consolidated Statements of Operations
    202120202019
    Derivatives in hedging relationships (1)
    Interest Rate Swaps:
    Amount of loss reclassified from accumulated other comprehensive income into income$— $4,066 $6,189 Losses on derivative financial instruments
    Change in fair value of interest rate swaps— (73)16,954 Losses on derivative financial instruments
    Interest expense/(income)— 114 (9,565)Interest expense
    Derivatives not designated as hedging instruments
    Interest Rate Swaps:
    Change in fair value of interest rate swaps— 6,908 49,472 Losses on derivative financial instruments
    Interest expense/(income)— 408 (2,681)Interest expense
    Warrant:
    Change in fair value of warrant5,439 25,375 (21,977)Losses on derivative financial instruments
    Forward purchase contract:
    Change in fair value of forward purchase contract— 5,800 (11,500)Losses on derivative financial instruments
    Treasury rate lock contracts:
    Change in fair value of treasury rate lock contracts16,093 — — Losses on derivative financial instruments
    (1)     Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in Accumulated other comprehensive income were released into earnings.
    XML 29 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Fair Value Measurements and Financial Instruments
    		 12 Months Ended
    Dec. 31, 2021
    Fair Value Disclosures [Abstract]  
    Fair Value Measurements and Financial Instruments Fair Value Measurements and Financial Instruments
    Fair value hierarchy

    We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:

    •Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
    •Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.
    •Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.
    Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives and available for sale debt securities are reported at their respective fair values in our consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs in our consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported in our consolidated balance sheets at amounts that approximate current fair values.

    Assets and liabilities measured at fair value on a recurring basis

    The following table summarizes financial assets and financial liabilities that we measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):

    As of December 31, 2021As of December 31, 2020
    Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
    Assets:
    Cash equivalents
    Money market funds$598,253 $— $— $598,253 $24,302 $— $— $24,302 
    Commercial paper— 13,997 — 13,997 — 77,176 — 77,176 
    Certificates of deposit— 40,954 — 40,954 — 74,502 — 74,502 
    Marketable securities
    Corporate debt securities— — — — — 32,754 — 32,754 
    Commercial paper— 207,457 — 207,457 — 444,554 — 444,554 
    Certificates of deposit— 374,415 — 374,415 — 505,971 — 505,971 
    Available for sale debt securities— — 66,000 66,000 — — 69,984 69,984 
    Total current assets$598,253 $636,823 $66,000 $1,301,076 $24,302 $1,134,957 $69,984 $1,229,243 
    Equity securities226,787 — 43,013 269,800 298,689 — — 298,689 
    Available for sale debt securities— — 187,700 187,700 — — 144,416 144,416 
    Forwards (1)— — 16,700 16,700 — — 18,600 18,600 
    Warrant (2)— — — — — 5,439 — 5,439 
    Total non-current assets$226,787 $— $247,413 $474,200 $298,689 $5,439 $163,016 $467,144 
    (1)The balance as of December 31, 2021 includes Series B Forwards and the Development Funding Bond Forward, recorded within Available for sale debt securities in the consolidated balance sheet, related to our obligations to fund acquisitions of the Series B Biohaven Preferred Shares and $150 million of the Development Funding Bonds, respectively. The balance as of December 31, 2020 relates to Series B Forwards, recorded within Available for sale debt securities in the consolidated balance sheet. See Note 3–Available for Sale Debt Securities for additional discussion.
    (2)Related to the Epizyme transaction as described in Note 4–Derivative Instruments and recorded in Other assets in the consolidated balance sheets as of December 31, 2021 and 2020. The fair value of the warrant was not material as of December 31, 2021.
    For the years ended December 31, 2021, 2020 and 2019, we recognized a loss of $60.1 million, a loss of $85.4 million and a gain of $104.4 million, on equity securities still held as of December 31, 2021, respectively.

    The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities and available for sale debt securities, including the underlying debt securities and related forwards (in thousands).

    Years Ended December 31,
    20212020
    Equity Securities
    Balance at the beginning of the year$— $— 
    Purchases35,120 — 
    Gains on equity securities7,893 — 
    Balance at the end of the year$43,013 $— 
    Years Ended December 31,
    20212020
    Debt Securities
    Balance at the beginning of the year$214,400 $131,280 
    Purchases70,441 — 
    Unrealized gains on available for sale debt securities (1)12,900 52,725 
    Settlement of forwards (2)18,459 — 
    Transfer to Level 2— (184,005)
    Transfer from Level 2 (3)— 198,526 
    Unrealized gains on available for sale debt securities (1)— 15,874 
    Redemption(62,500)— 
    Balance at the end of the year$253,700 $214,400 
    Years Ended December 31,
    20212020
    Forwards
    Balance at the beginning of the year$18,600 $— 
    Unrealized gains (4)16,559 18,600 
    Settlement of forwards (2)(18,459)— 
    Balance at the end of the year$16,700 $18,600 
    (1)For the year ended December 31, 2021, the unrealized gains on available for sale debt securities is comprised of $11.6 million related to Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income and $1.3 million related to the Series B Biohaven Preferred Shares as recorded on the consolidated statements of operations. For the year ended December 31, 2020, the unrealized gains on available for sale debt securities related to the Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income, including $52.7 million prior to transferring out of Level 3 and then $15.9 million after transferring back to Level 3.     
    (2)Reflects the fair value attributed to the Series B Forwards that were settled in the period as the Series B Biohaven Preferred Shares were acquired, which is included in the fair value of the Series B Biohaven Preferred Shares. See Note 3–Available for Sale Debt Securities.
    (3)Includes $14.5 million of unrealized gains on available for sale debt securities included in other comprehensive income while the Series A Biohaven Preferred Shares was classified as a Level 2 asset.
    (4)Recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations.

    Valuation inputs

    Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.
    Investment in Series A Biohaven Preferred Shares

    The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was based on the cash flows due to us from Biohaven of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6 million following the FDA approval and starting one-year after FDA approval, through December 31, 2024. The FDA approved Nurtec ODT in February 2020, at which point we became entitled to receive a fixed payment amount of $250.0 million payable in equal quarterly payments from March 31, 2021 through December 31, 2024.

    The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate of 9.5% and 8.3% as of December 31, 2021 and 2020, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower.

    Prior to February 2020, we measured our investment in the Series A Biohaven Preferred Shares using a Black-Derman- Toy lattice model, which included the use of Level 3 fair value measurements and inputs. In February 2020, when Nurtec ODT received FDA approval, we began measuring the fair value of the Series A Biohaven Preferred Shares using a discounted cash flow analysis that relied on observable inputs, and therefore, we transferred the Series A Biohaven Preferred Shares from a Level 3 to a Level 2 asset. During the three months ended December 31, 2020, information pertaining to Biohaven’s issuance of debt and its effective interest rate became available and we refined our valuation of the Series A Biohaven Preferred shares as of December 31, 2020 to incorporate this significant unobservable input. As a result, we reclassified the investment from a Level 2 to a Level 3 asset during the three months ended December 31, 2020.
    Investment in Series B Biohaven Preferred Shares

    The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of December 31, 2021 and the fair value of the Series B Forwards as of December 31, 2020 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower.

    MorphoSys Development Funding Bonds

    The fair value of the Development Funding Bond Forward as of December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument.

    BioCryst Equity Securities

    In November 2021, we purchased 3,846 thousand shares of common stock in BioCryst Pharmaceuticals, Inc.(“BioCryst”), which was calculated based on the volume-weighted average price of BioCryst common stock over a period preceding the closing of the transaction. As part of the transaction, we are restricted from selling the common stock for six months following the close of the transaction. The fair value of the BioCryst common stock as of December 31, 2021 was based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the common stock to match the duration of the transfer restriction. This methodology includes the use of Level 3 inputs, including the estimated volatility of the BioCryst common stock, which requires the use of significant judgement. Our estimated volatility could be reasonably different than the actual volatility for the common stock which would mean that the estimated fair value for the common stock could be significantly higher or lower than the fair value determined by management at any particular date.

    Other financial instruments

    We use third party pricing services for Level 2 inputs used to value cash equivalents, marketable securities, derivative instruments and borrowings, which provide documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. Warrants are valued using a Black-Scholes option pricing model which considers observable and unobservable inputs.

    Financial assets not measured at fair value

    Financial royalty assets are measured and carried on the consolidated balance sheets at amortized cost using the effective interest method. The fair value of financial royalty assets is calculated by management using the forecasted royalty payments we expect to receive based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts’ consensus sales forecasts or, where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments are then discounted to a present value using appropriate individual discount rates. The fair value of our financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for our financial royalty assets as of December 31, 2021 and 2020 are presented below (in thousands).
    December 31, 2021December 31, 2020
    Fair ValueCarrying Value, netFair ValueCarrying Value, net
    Financial royalty assets, net$19,047,183 $14,332,596 $18,718,179 $12,955,277 
    XML 30 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Financial Royalty Assets, Net
    		 12 Months Ended
    Dec. 31, 2021
    Receivables [Abstract]  
    Financial Royalty Assets, Net Financial Royalty Assets, Net
    Financial royalty assets, net consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.

    The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2021 and 2020 are as follows (in thousands):
    As of December 31, 2021
    Estimated Royalty Duration (a)Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 7)Net Carrying Value (e)
    Cystic fibrosis franchise2037 (b)$5,335,641 $(48,636)$5,287,005 
    Tysabri(c)1,846,069 (16,617)1,829,452 
    Imbruvica2027-20321,438,730 (236,871)1,201,859 
    Xtandi2027-20281,100,065 (172,101)927,964 
    Tremfya2031-2032881,671 — 881,671 
    Evrysdi2030-2035 (d)727,774 — 727,774 
    Other2020-20394,697,591 (909,916)3,787,675 
    Total$16,027,541 $(1,384,141)$14,643,400 
    Less: Cumulative allowance for credit losses (Note 7)(310,804)
    Total financial royalty assets, net$14,332,596 
    (a)Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
    (b)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
    (c)Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
    (d)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
    (e)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

    As of December 31, 2020
    Estimated Royalty Duration (a)Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 7)Net Carrying Value (e)
    Cystic fibrosis franchise2037 (b)$5,274,896 $— $5,274,896 
    Tysabri(c)2,003,797 (112,720)1,891,077 
    Imbruvica2027-20321,406,291 (46,872)1,359,419 
    Xtandi2027-20281,150,335 (145,565)1,004,770 
    Promacta2025-2028686,129 — 686,129 
    Evrysdi2030-2035 (d)675,440 — 675,440 
    Other2020-20393,022,213 (634,950)2,387,263 
    Total$14,219,101 $(940,107)$13,278,994 
    Less: Cumulative allowance for credit losses (Note 7)(323,717)
    Total financial royalty assets, net$12,955,277 
    (a)Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
    (b)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
    (c)Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
    (d)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
    (e)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.
    XML 31 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets
    		 12 Months Ended
    Dec. 31, 2021
    Credit Loss [Abstract]  
    Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets
    The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of Financial royalty assets, net on the consolidated balance sheets and includes the following activities:

    •the movement in the cumulative allowance related to changes in forecasted royalty payments we expect to receive based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts’ consensus sales forecasts, and
    •the movement in the cumulative allowance for current expected credit losses.

    The periodic movement in the cumulative allowance is presented on the consolidated statements of operations as the Provision for changes in expected cash flows from financial royalty assets.

    Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to Retained earnings of $192.7 million to recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The current period provision for changes in expected cash flows from financial royalty assets reflects the activity for the period primarily new financial royalty assets and changes in the underlying cash flow forecasts used in the effective interest model to measure income from our financial royalty assets. Refer to Note 2–Summary of Significant Accounting Policies for further information.
    The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):
    Activity for the Year
    Balance at December 31, 2018$(1,982,897)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(322,717)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets1,342,038 
    Write-off of cumulative allowance (a)95,158 
    Balance at December 31, 2019$(868,418)
    Cumulative adjustment for adoption of ASU 2016-13(192,705)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(645,612)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets570,959 
    Write-off of cumulative allowance (a)2,964 
    Write-off of credit loss allowance (b)25,174 
    Current period provision expense for credit losses, net (c)(156,186)
    Balance at December 31, 2020$(1,263,824)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(912,710)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets446,955 
    Write-off of cumulative allowance (a)21,721 
    Current period provision income for credit losses, net (c)12,913 
    Balance at December 31, 2021$(1,694,945)
    (a)     Relates to amounts removed from the allowance at the end of a royalty asset’s life to bring the account balance to zero. Write-offs solely impact the asset account and allowance account; there is no impact on the consolidated statements of operations.
    (b)     Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the write-off of the related financial royalty asset balance of $90.2 million.
    (c)     In the year ended December 31, 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights in 2020, mainly the final tranche of Tazverik. In the year ended December 31, 2021,the provision income for credit losses was primarily related to a significant decline in the financial asset value for Tazverik, which was offset by increases in our portfolio of financial royalty assets with limited protective rights in 2021, primarily related to zavegepant.
    XML 32 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Intangible Royalty Assets, Net
    		 12 Months Ended
    Dec. 31, 2021
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Intangible Royalty Assets, Net Intangible Royalty Assets, Net
    The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2021 and 2020 (in thousands).
    As of December 31, 2021CostAccumulated AmortizationNet Carrying Value
    DPP-IV patents$606,216 $600,546 $5,670 
    Total intangible royalty assets$606,216 $600,546 $5,670 
    As of December 31, 2020CostAccumulated AmortizationNet Carrying Value
    DPP-IV patents$606,216 $577,550 $28,666 
    Total intangible royalty assets$606,216 $577,550 $28,666 

    The majority of our DPP-IV patents associated with the intangible royalty assets terminate at various dates through 2022. The weighted average remaining life of the intangible royalty assets is less than one year. We project amortization expense will be $5.7 million in 2022.
    Our revenue is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue from royalty assets is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate our royalty revenue from licensees based on the geography of the underlying sales, as this level of information is not always included in royalty reports provided to us. The marketers paying us royalties on these products do not always provide, and are not necessarily required to provide, the breakdown of product sales by geography. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 86%, 97% and 91% of our revenues from intangible royalty assets in the years ended December 31, 2021, 2020 and 2019, respectively.
    XML 33 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Non-Consolidated Affiliates
    		 12 Months Ended
    Dec. 31, 2021
    Equity Method Investments and Joint Ventures [Abstract]  
    Non-Consolidated Affiliates Non-Consolidated Affiliates
    The Legacy SLP Interest

    In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) from the Continuing Investors Partnerships for $303.7 million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also own a non-controlling interest in Old RPI.

    The income allocation from the Legacy SLP Interest is based on an estimate, as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this annual report. Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the years ended December 31, 2021 and 2020, we recorded an income allocation of $8.9 million and $62.0 million, respectively, within Equity in losses/(earnings) of non-consolidated affiliates. We received cash distributions from the Legacy SLP Interest of $21.0 million and $22.7 million during the years ended December 31, 2021 and 2020, respectively.
    The Avillion Entities

    We account for our partnership interests in Avillion Financing I, LP (“Avillion I”) and BAv Financing II, LP (“Avillion II”, or, together, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the entities. We recorded a loss allocation from the Avillion Entities of $28.4 million, $17.6 million and $32.5 million within Equity in losses/(earnings) of non-consolidated affiliates during the years ended December 31, 2021, 2020 and 2019, respectively.

    On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval. Subsequent to the asset sale, the only operations of Avillion I are the collection of cash and unwinding of discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.4 million during each of the years ended December 31, 2021 and 2020, and $14.1 million in the year ended December 31, 2019 in connection with Avillion I’s receipt of the fixed annual payments due under its co-development agreement with Pfizer.

    In March 2017, RPIFT entered into an agreement with Avillion II, which was amended in 2019, to invest approximately $19.0 million to fund approximately 50% of the costs of a Phase 2 clinical trial for the use of Merck KGaA’s anti-IL 17 nanobody M1095 (the “Merck KGaA Asset”) for the treatment of psoriasis in exchange for certain milestone and royalty payments. Our involvement in the development for the Merck KGaA Asset ceased in the year ended December 31, 2020, for which we received a distribution of $21.3 million from Avillion II.

    In May 2018, RPIFT entered into an additional agreement, which was amended in July 2021, to increase our investment up to $122.5 million from $105.0 million in Avillion II over multiple years to fund approximately 44% of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.

    As of December 31, 2021 and 2020, RPIFT had $11.2 million and $28.6 million respectively, of unfunded commitments related to the Avillion Entities. Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments.
    XML 34 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Research & Development ("R&D") Funding Expense
    		 12 Months Ended
    Dec. 31, 2021
    Research and Development [Abstract]  
    Research & Development ("R&D") Funding Expense Research & Development (“R&D”) Funding Expense
    R&D funding expense consists of upfront and ongoing R&D payments we have made to counterparties to acquire royalties and/or milestones on development-stage product candidates. Ongoing R&D payments are made as the related development-stage product candidates undergo clinical trials with our counterparties. During the year ended December 31, 2021, 2020, and 2019 we did not enter into any new ongoing R&D funding arrangements.

    We recognized R&D funding expense of $200.1 million during the year ended December 31, 2021, comprised of $6.9 million in ongoing R&D expenses, primarily under our co-funding agreement with Sanofi, and $193.2 million in upfront R&D funding. As part of a long-term strategic funding partnership with MorphoSys, which closed on July 15, 2021 (as further discussed in Note 17–Commitments and Contingencies), we allocated $90.0 million of the upfront payment to R&D funding expense, representing two development-stage products acquired in exchange for future royalties. Additionally, we made an upfront payment of $103.2 million to BioCryst to acquire a royalty on a development-stage product in November 2021.

    We recognized R&D funding expense of $26.3 million during the year ended December 31, 2020, of which $20.5 million related to ongoing development-stage funding payments, primarily under our co-funding agreement with Sanofi and $5.8 million related to upfront funding for a royalty on a development-stage product that we acquired from BioCryst.

    We recognized $83.0 million of R&D funding expense during the year ended December 31, 2019, of which $18.2 million and $62.8 million related to our funding agreements with both Sanofi and Pfizer, respectively. We completed our funding commitments in the fourth quarter of 2019 under our agreement with Pfizer. We did not have upfront development-stage R&D funding expense in 2019.

    As of December 31, 2021, we have a remaining commitment of $10.7 million related to our R&D funding agreement with Sanofi.
    XML 35 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Borrowings
    		 12 Months Ended
    Dec. 31, 2021
    Debt Disclosure [Abstract]  
    Borrowings Borrowings
    Our borrowings at December 31, 2021 and 2020 consisted of the following (in thousands):

    Type of BorrowingDate of IssuanceMaturityDecember 31, 2021December 31, 2020
    Senior Unsecured Notes:
    $1,000,000, 0.75% (issued at 99.322% of par)
    		9/20209/2023$1,000,000 $1,000,000 
    $1,000,000, 1.20% (issued at 98.875% of par)
    		9/20209/20251,000,000 1,000,000 
    $1,000,000, 1.75% (issued at 98.284% of par)
    		9/20209/20271,000,000 1,000,000 
    $1,000,000, 2.20% (issued at 97.760% of par)
    		9/20209/20301,000,000 1,000,000 
    $600,000, 2.15% (issued at 98.263% of par)
    		7/20219/2031600,000 — 
    $1,000,000, 3.30% (issued at 95.556% of par)
    		9/20209/20401,000,000 1,000,000 
    $1,000,000, 3.55% (issued at 95.306% of par)
    		9/20209/20501,000,000 1,000,000 
    $700,000, 3.35% (issued at 97.565% of par)
    		7/20219/2051700,000 — 
    Unamortized debt discount and issuance costs(203,930)(183,416)
    Total debt carrying value7,096,070 5,816,584
    Less: Current portion of long-term debt— —
    Total long-term debt$7,096,070 $5,816,584 

    Senior Unsecured Notes

    On July 26, 2021, we issued $1.3 billion of senior unsecured notes (the “2021 Notes”) comprised of $600.0 million principal amount of notes due September 2031 and $700.0 million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, beginning on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5 million and we capitalized approximately $12.3 million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively.

    On September 2, 2020, we issued $6.0 billion of senior unsecured notes (the “2020 Notes” and, together with the 2021 Notes, the “Notes”). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0 million and we capitalized approximately $40.4 million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50%, respectively.    

    On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933.

    The Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.

    Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.
    Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and, as of December 31, 2021, we were in compliance with all applicable covenants.

    As of December 31, 2021 and 2020, the estimated fair value of our outstanding Notes using Level 2 inputs was approximately $7.2 billion and $6.2 billion, respectively.

    Senior Unsecured Revolving Credit Facility

    On September 15, 2021, we entered into an amended and restated revolving credit agreement (the “Credit Agreement”). The Credit Agreement amends and restates the existing credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) with borrowing capacity of up to $1.5 billion for general corporate purposes. The Credit Agreement extends the maturity of the Revolving Credit Facility to September 15, 2026. As of December 31, 2021 and 2020, there were no outstanding borrowings under the Revolving Credit Facility.

    The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.

    The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. As of December 31, 2021, RP Holdings was in compliance with these covenants.

    Senior Secured Credit Facilities

    On February 11, 2020, in connection with the Exchange Offer Transactions (as discussed in Note 1–Organization and Purpose) and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. The senior secured credit facilities consisted of a term loan A and term loan B in the amounts of $3.20 billion and $2.84 billion, respectively. In September 2020, we repaid in full the outstanding principal amounts of term loans under the senior secured credit facilities with net proceeds from the 2020 Notes and available cash on hand. Upon refinancing our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $25.1 million as part of Other non-operating expense/(income), net, which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.

    RPIFT Senior Secured Credit Facilities

    The RPIFT Senior Secured Credit Facilities were repaid in full in February 2020 in connection with the Exchange Offer Transactions. We recorded a loss on debt extinguishment of $5.4 million as part of Other non-operating expense/(income), net during the year ended December 31, 2020.

    Principal Payments on the Notes

    The future principal payments for our borrowings as of December 31, 2021 over the next five years and thereafter are as follows (in thousands):
    YearPrincipal Payments
    2022$— 
    20231,000,000
    2024—
    20251,000,000
    2026—
    Thereafter5,300,000
    Total (1)$7,300,000 
    (1)     Excludes unamortized debt discount and issuance costs of $203.9 million as of December 31, 2021, which are amortized through interest expense over the remaining life of the underlying debt obligations.
    XML 36 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Shareholders' Equity
    		 12 Months Ended
    Dec. 31, 2021
    Equity [Abstract]  
    Shareholders' Equity Shareholders’ Equity
    Capital structure

    Following the completion of our IPO as discussed in Note 1–Organization and Purpose, we have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company.

    An exchange agreement entered into by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the “Exchange Agreement”) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. As of December 31, 2021, we have outstanding 432,963 thousand Class A ordinary shares and 174,213 thousand Class B ordinary shares. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of December 31, 2021, we have outstanding deferred shares of 361,170 thousand.

    In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The purpose of the Class R redeemable shares was to ensure Royalty Pharma Limited had sufficient sterling denominated share capital at the time it was re-registered as a public limited company to Royalty Pharma plc, as required by the U.K. Companies Act. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of £1 each.
    Non-controlling interests

    The only non-controlling interest in the year ended December 31, 2019 related to RPSFT, for which the net change in the related balance is as presented in the statements of shareholders’ equity. The net change in the balance of our four non-controlling interests for the years ended December 31, 2021 and 2020 is as follows (in thousands):

    RPSFTLegacy Investors PartnershipsContinuing Investors Partnerships (1)EPA HoldingsTotal
    December 31, 2019$35,883 $— $— $— $35,883 
    Contributions— 1,165,258 9,418 — 1,174,676 
    Transfer of interests— 1,037,161 — — 1,037,161 
    Distributions(112,339)(594,592)(85,426)— (792,357)
    Net Income prior to IPO42,151 102,892 — — 145,043 
    Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity— (750)2,433,848 — 2,433,098 
    Issuance of Class A ordinary shares sold in IPO, net of offering costs— — 758,354 — 758,354 
    Other exchanges— — (309,566)— (309,566)
    Net income subsequent to IPO46,741 218,137 316,993 — 581,871 
    Other comprehensive income/(loss):
    Unrealized gains on available for sale debt securities— 15,015 7,488 — 22,503 
    Reclassification of unrealized losses on available for sale debt securities— (3,612)(6,018)— (9,630)
    December 31, 2020$12,436 $1,939,509 $3,125,091 $— $5,077,036 
    (1)     Related to the Continuing Investors Partnerships’ ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2020.

    RPSFTLegacy Investors PartnershipsContinuing Investors Partnerships (1)EPA HoldingsTotal
    December 31, 2020$12,436 $1,939,509 $3,125,091 $— $5,077,036 
    Contributions— 35,148 13,391 — 48,539 
    Distributions(56,490)(425,050)(133,433)— (614,973)
    Other exchanges— — (642,974)— (642,974)
    Net Income57,582 266,570 297,321 — 621,473 
    Other comprehensive income/(loss):
    Unrealized gains on available for sale debt securities— 2,038 3,227 — 5,265 
    Reclassification of unrealized losses on available for sale debt securities— (8,946)(13,469)— (22,415)
    December 31, 2021$13,528 $1,809,269 $2,649,154 $— $4,471,951 
    (1)     Related to the Continuing Investors Partnerships’ ownership of approximately 29% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2021. Royalty Pharma plc owns the remaining 71% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2021.
    RP Holdings Class C Special Interest held by EPA Holdings

    EPA Holdings is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period will be grouped together as separate portfolios (each, a “Portfolio”). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests for which we will issue the same number of Class B ordinary shares, which may be subsequently exchanged for our Class A ordinary shares. We do not currently expect any material Equity Performance Awards to be payable until the performance conditions discussed above are met.

    Dividends

    The holders of Class A ordinary shares are entitled to receive dividends subject to approval by the board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings, our consolidated subsidiary. In the year ended December 31, 2021, we declared and paid four quarterly cash dividends of $0.17 per Class A ordinary share for an aggregate amount of $285.2 million to holders of our Class A ordinary shares.

    2020 Independent Directors Equity Incentive Plan

    On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors. As of December 31, 2021, approximately 620 thousand shares remain reserved for future issuance under the Equity Incentive Plan.

    RSU activity and share-based compensation

    We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year as part of General and administrative expenses in the consolidated statement of comprehensive income. The estimated fair value of RSUs is based on the closing price of our Class A ordinary shares on the grant date.
    We recognized share-based compensation of approximately $3.1 million and $5.7 million for the years ended December 31, 2021 and 2020, which is recorded as part of General and administrative expenses in the consolidated statement of operations. There were no share-based awards or related expenses in periods prior to the IPO. As of December 31, 2021, the total unrecognized share-based compensation expense related to total outstanding RSUs was less than $1.0 million, which we expect to recognize in the next six months.
    XML 37 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Earnings Per Share
    		 12 Months Ended
    Dec. 31, 2021
    Earnings Per Share [Abstract]  
    Earnings Per Share Earnings per ShareBasic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards, and unvested RSUs issued under our Equity Incentive Plan. We use the “if-converted” method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.
    Our Class B ordinary shares, Class R redeemable shares, and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares, and deferred shares under the two-class method has not been presented. Our Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because shares of Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. For the years ended December 31, 2021 and 2020, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. Additionally, Class B ordinary shares in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive for the years ended December 31, 2021 and 2020, and therefore were excluded from the computation of diluted earnings per shares of Class A ordinary share. As of December 31, 2021 and 2020, we had 607,176 thousand and 607,111 thousand fully diluted Class A ordinary shares outstanding, respectively.

    The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2021 (in thousands, except per share amounts).
    Year Ended December 31, 2021
    Numerator
    Consolidated net income$1,241,201 
    Less: Net income attributable to Continuing Investors Partnerships297,321 
    Less: Net income attributable to Legacy Investors Partnerships and RPSFT324,152 
    Net income attributable to Royalty Pharma plc - basic and diluted$619,728 
    Denominator
    Weighted average Class A ordinary shares outstanding - basic414,794 
    Add: Dilutive effect of unvested RSUs8 
    Weighted average Class A ordinary shares outstanding - diluted414,802 
    Earnings per Class A ordinary share - basic$1.49 
    Earnings per Class A ordinary share - diluted$1.49 

    Prior to the IPO, our capital structure mainly included unitholder interests. We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements. Therefore, the basic and diluted earnings per share for the year ended December 31, 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares. The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2020 (in thousands, except per share amounts).
    Year Ended
    December 31, 2020
    Numerator
    Consolidated net income $1,701,954 
    Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)479,842 
    Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO316,993 
    Less: Net income attributable to Legacy Investors Partnerships and RPSFT409,921 
    Net income attributable to Royalty Pharma plc - basic and diluted$495,198 
    Denominator
    Weighted average Class A ordinary shares outstanding - basic375,444 
    Add: Dilutive effect of unvested RSUs11 
    Weighted average Class A ordinary shares outstanding - diluted375,455 
    Earnings per Class A ordinary share - basic$1.32 
    Earnings per Class A ordinary share - diluted$1.32 
    (1)     Reflected as Net income attributable to controlling interest on the consolidated statements of operations.
    XML 38 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Indirect Cash Flow
    		 12 Months Ended
    Dec. 31, 2021
    Supplemental Cash Flow Elements [Abstract]  
    Indirect Cash Flow Indirect Cash Flow
    Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).
    Years Ended December 31,
    202120202019
    Cash flow from operating activities:
    Consolidated net income$1,241,201 $1,701,954 $2,461,419 
    Adjustments to reconcile consolidated net income to net cash provided by operating activities:
    Income from financial royalty assets(2,065,083)(1,959,975)(1,648,837)
    Provision for changes in expected cash flows from financial royalty assets452,842 230,839 (1,019,321)
    Amortization of intangible assets22,996 23,058 23,924 
    Amortization of debt discount and issuance costs20,162 11,715 12,790 
    Losses on derivative financial instruments21,532 42,076 39,138 
    Losses/(gains) on equity securities48,066 (247,073)(155,749)
    Equity in losses/(earnings) of non-consolidated affiliates19,490 (44,459)32,517 
    Distributions from non-consolidated affiliates34,384 42,334 14,059 
    Loss on extinguishment of debt358 30,272 — 
    Share-based compensation2,443 5,428 — 
    Interest income accretion(50,896)(20,551)— 
    Unrealized gains on available for sale debt securities(17,859)(18,600)— 
    Impairment charge— 65,053 — 
    Termination of derivative financial instruments(16,093)(34,952)— 
    Other4,461 9,621 (2,122)
    Decrease/(increase) in operating assets:
    Cash collected on financial royalty assets2,315,854 2,121,923 1,934,092 
    Available for sale debt securities— — (150,000)
    Accrued royalty receivable(20,131)370 2,471 
    Other receivables— — 150,000 
    Other royalty income receivable(9,012)(770)7,390 
    Other current assets and other assets1,857 34,986 (41,028)
    (Decrease)/increase in operating liabilities:
    Accounts payable and accrued expenses(4,586)(766)6,496 
    Interest payable15,550 42,146 — 
    Net cash provided by operating activities$2,017,536 $2,034,629 $1,667,239 

    Non-cash investing and financing activities are summarized below (in thousands).
    Years Ended December 31,
    Supplemental Schedule of Non-cash Investing/Financing Activities:202120202019
    Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)$— $303,679 $— 
    Settlement of Epizyme forward purchase contract— 5,700 — 
    Accrued purchase obligation - Tazverik (Note 17)— 110,000 — 
    Repayments of long-term debt by contributions from non-controlling interest (1)— 1,103,774 — 
    Milestone payable - Erleada (2)— 18,600 — 
    (1) Related to the pro rata portion of RPIFT’s outstanding debt repaid by the Legacy Investors Partnerships.
    (2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020 as recorded within Other current liabilities on the consolidated balance sheet.
    XML 39 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Accumulated Other Comprehensive Income
    		 12 Months Ended
    Dec. 31, 2021
    Equity [Abstract]  
    Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income
    As of December 31, 2021 and 2020, the only component of accumulated other comprehensive income related to the Unrealized gains on available for sale debt securities on the Series A Biohaven Preferred Shares. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in Accumulated other comprehensive income were released into earnings.

    The components of accumulated other comprehensive income as of December 31, 2021 and 2020 are as follows (in thousands):
    Unrealized Gains on Available for Sale Debt SecuritiesUnrealized Losses on Interest Rate SwapsTotal Accumulated Other Comprehensive Income
    Balance at December 31, 20196,159 (4,066)2,093 
    Reclassification to net income(10,921)4,066 (6,855)
    Activity for the year60,617 — 60,617 
    Reclassification to non-controlling interest(24,022)— (24,022)
    Reclassification from non-controlling interest2,562 — 2,562 
    Balance at December 31, 202034,395 — 34,395 
    Reclassification to net income(28,481)— (28,481)
    Activity for the year6,335 — 6,335 
    Reclassification from non-controlling interest4,242 — 4,242 
    Balance at December 31, 2021$16,491 $— $16,491 

    The total reclassification of unrealized gains on available for sale debt securities of $50.9 million in the year ended December 31, 2021 is presented within Interest income on the consolidated statements of operations, including $28.5 million attributable to controlling interest noted in the table above and $22.4 million attributable to the non-controlling interest. The total reclassification of unrealized gains on available for sale debt securities of $20.6 million in the year ended December 31, 2020 is presented within Interest income on the consolidated statements of operations, including $10.9 million attributable to controlling interest noted in the table above and $9.6 million attributable to the non-controlling interest.
    XML 40 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Related Party Transactions
    		 12 Months Ended
    Dec. 31, 2021
    Related Party Transactions [Abstract]  
    Related Party Transactions Related Party Transactions
    The Manager

    The Manager is the investment manager of Royalty Pharma and its subsidiaries. The Manager is an affiliate of RP Ireland, the administrator of RPIFT, RPI Intermediate FT and RPSFT. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of the board of directors, and as a director on the board of directors of RP Holdings.

    In connection with the Exchange Offer Transactions (discussed in Note 1–Organization and Purpose), the Manager entered into Management Agreements with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the Management Agreements, we pay quarterly operating and personnel expenses to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5% of the Adjusted Cash Receipts (both, as defined in the Management Agreement) for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in our consolidated net income, is calculated as the greater of $1 million per quarter and 0.3125% of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months.
    Prior to the Exchange Date, the Manager received operating and personnel payments payable in equal quarterly installments that increased by 5% annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships. RP Ireland receives an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the limited partnership agreements of the Legacy Investors Partnerships. After the Exchange Date, operating and personnel payments were calculated in accordance with the methodology discussed in the paragraph above.

    During the years ended December 31, 2021, 2020 and 2019, total operating and personnel payments incurred were $145.2 million, $112.5 million and $60.0 million, respectively, including the amounts attributable to Old RPI, and were recognized within General and administrative expenses on the consolidated statements of operations.

    Distribution Payable to Non-Controlling Interest

    The distribution payable to non-controlling interest represents the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPSFT’s non-controlling interest in RPCT. The distribution payable to non-controlling interest as of December 31, 2021 and 2020 included the following (in thousands).

    December 31, 2021December 31, 2020
    Due to Legacy Investors Partnerships$92,608 $100,047 
    Due to RPSFT15,326 26,319 
    Total distribution payable to non-controlling interest$107,934 $126,366 

    Acquisition from Epizyme

    In November 2019, in connection with a royalty acquisition and an equity investment in Epizyme made by RPIFT, Pablo Legorreta, our Chief Executive Officer, was appointed as a director of Epizyme, for which he received, and continues to receive, compensation in cash and shares of Epizyme, all of which are and will continue to be contributed to the Manager and used to reduce costs and expenses which would otherwise be billed to us or our affiliates. We continue to hold Epizyme common stock as of December 31, 2021.

    Acquisition from Bristol Myers Squibb

    In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”). We agreed to make payments to BMS based on sales of the products over eight quarters beginning with the first quarter of 2018 in exchange for a high single-digit royalty on worldwide sales of the products from 2020 through 2025.

    On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly owned subsidiary of BioPharma Credit PLC (“BPCR”), an affiliate of us. We considered BPCR as a related party due to the sole member of the Manager having significant influence over BPCR’s investment manager. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement.

    We began making installment payments to BMS in 2018 and completed our funding requirement, net of the assigned funding obligations, totaling $162.4 million in the three months ended March 31, 2020. We began to measure this financial royalty asset using the effective interest method once our installment funding obligation was completed and we received our first royalty payment in the three months ended June 30, 2020. As of December 31, 2021 and 2020, the financial royalty asset of $130.9 million and $150.6 million, respectively, included in Financial royalty assets, net on the consolidated balance sheets represents only our right to the future payment streams acquired from BMS.
    Other transactions

    Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI, Inc (“MSCI”). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI’s thematic index suite with the launch of new indexes. In return, we will receive a percentage of MSCI’s revenues from those indexes. No amounts were due from MSCI as of December 31, 2021. The financial statement impact associated with this transaction was not material for the year ended December 31, 2021.

    In the year ended December 31, 2020, we reimbursed Pablo Legorreta approximately $1.0 million for the cost of purchasing and donating ventilators to hospitals on behalf of Royalty Pharma.

    In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 9–Non-Consolidated Affiliates for additional discussion.

    RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnership whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3 million is recorded as treasury interests, of which $1.6 million and $1.9 million are held by non-controlling interest as of December 31, 2021 and 2020, respectively.

    Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.
    XML 41 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Commitments and Contingencies
    		 12 Months Ended
    Dec. 31, 2021
    Commitments and Contingencies Disclosure [Abstract]  
    Commitments and Contingencies Commitments and Contingencies
    In the ordinary course of its business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.

    On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys to support MorphoSys’ acquisition of Constellation, which closed on July 15, 2021. As part of the funding agreement, we agreed to make additional milestone payments of up to $150.0 million and provide up to $350.0 million of Development Funding Bonds, which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150.0 million, for which we have recognized the Development Funding Bond Forward within Available for sale debt securities on the consolidated balance sheet as of December 31, 2021 (See Note 3–Available for Sale Debt Securities for additional discussion). Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds.

    On August 7, 2020, we entered into a funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones. Pursuant to the Series B Biohaven Preferred Share Agreement, we agreed to provide further support for the ongoing launch of Nurtec ODT with the purchase of committed, non-contingent Commercial Launch Preferred Equity for a total of $200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030. During the three months ended March 30, 2021, we began purchasing the Series B Biohaven Preferred Shares. We have a remaining commitment of $129.6 million under the Commercial Launch Preferred Equity, for which we have recognized the Series B Forwards within Available for sale debt securities on the consolidated balance sheet as of December 31, 2021. See Note 3–Available for Sale Debt Securities for additional discussion.
    In November 2019, RPIFT agreed to pay $330.0 million to purchase Eisai’s royalties on future worldwide sales of Tazverik, a novel targeted therapy in late-stage clinical development that was approved by the FDA in January 2020 for epithelioid sarcoma, and with the potential to be approved in several cancer indications. Under the terms of our agreement with Eisai, we acquired Eisai’s future worldwide royalties on net sales by Epizyme of Tazverik outside of Japan, for an upfront payment of $110.0 million plus up to an additional $220.0 million for the remainder of the royalty upon FDA approval of Tazverik for certain indications. The FDA approval of Tazverik in January 2020 triggered our obligation to fund the second $110.0 million tranche in November 2020. On November 4, 2021, we funded the final $110.0 million tranche.

    We have commitments to advance funds to counterparties through our investment in the Avillion Entities and R&D arrangements. Please refer to Note 9–Non-Consolidated Affiliates and Note 10–Research & Development (“R&D”) Funding Expense, respectively, for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the management agreement as described in Note 16–Related Party Transactions, which are variable and primarily based on cash receipts.

    Legal Proceedings

    We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings in our consolidated balance sheets as of December 31, 2021 and 2020. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.
    XML 42 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Subsequent Events
    		 12 Months Ended
    Dec. 31, 2021
    Subsequent Events [Abstract]  
    Subsequent Events Subsequent EventsIn January 2022, we acquired a royalty interest in aficamten from Cytokinetics, Incorporated (“Cytokinetics”) for $150.0 million, comprised of an upfront payment of $50 million and two additional $50 million payments which are conditional upon the initiation of potential pivotal clinical trials for obstructive hypertrophic cardiomyopathy and nonobstructive hypertrophic cardiomyopathy, respectively. Additionally, we will provide Cytokinetics long-term capital of up to $300 million (“Cytokinetics Commercial Launch Funding”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. The Cytokinetics Commercial Launch Funding is available in five tranches, including an initial tranche of $50 million funded upon closing and four additional tranches in the aggregate amount of $250 million upon the occurrence of certain regulatory and clinical development milestones.
    XML 43 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Summary of Significant Accounting Policies (Policies)
    		 12 Months Ended
    Dec. 31, 2021
    Accounting Policies [Abstract]  
    Basis of preparation The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
    Use of estimates
    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.

    The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.
    Basis of consolidation
    The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record Net income attributable to non-controlling interest in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

    Following management’s determination that a high degree of common ownership existed in Royalty Pharma both before and after the Exchange Date, Royalty Pharma recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date.
    All intercompany transactions and balances have been eliminated in consolidation.
    Reclassification Certain prior period amounts have been reclassified to conform to the current period presentation.
    Concentrations of credit risk Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2021 and 2020 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, AbbVie, Bristol Myers Squibb, Gilead, Johnson & Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche and Vertex.
    Segment Information Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.
    Royalty assets
    An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.

    In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.
    Financial royalty assets, net Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (“ASC”), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 Imputation of Interest.
    The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as Provision for changes in expected cash flows from financial royalty assets and the carrying value of Financial royalty assets, net is presented net of the cumulative allowance for changes in expected future cash flows.

    The application of the prospective approach to measure financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below.

    •Analyst coverage. Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts’ consensus sales forecasts for a product to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst consensus sales estimates are not available for the full term of the royalty, particularly for the later years in a product’s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management’s own expertise. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves based on historical trends to project future sales when sell-side equity research analyst consensus sales estimates end or are not available for the full term of the royalty. In other cases, management may develop and apply growth rate estimates from existing sell-side equity research analysts’ consensus sales forecasts to project future sales for products that cannot be modeled through the statistical curves, such as those where the entrance of a biosimilar is expected to impact future sales. Based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset’s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.

    •Commercial performance. The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts’ consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product’s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.
    •Royalty duration. The duration of a royalty can be based on a number of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product’s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.

    As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts’ models. The most sensitive of these assumptions relates to management’s estimate of the royalty duration in the final years of an asset’s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows.

    A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.

    The current portion of Financial royalty assets, net represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears.

    Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets

    We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset’s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period’s effective interest rate. The amount recognized as provision expense increases the financial royalty asset’s cumulative allowance, which reduces the net carrying value of the financial royalty asset.
    In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.

    Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the Financial royalty assets, net line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset’s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either Provision for changes in expected cash flows from financial royalty assets or as Income from financial royalty assets on the consolidated statements of operations.

    Income from financial royalty assets

    We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition of a financial royalty asset, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.

    When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as Other royalty income.
    Allowance for current expected credit losses On January 1, 2020, we adopted ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of Financial royalty assets, net on the consolidated balance sheets. Any subsequent movement in the allowance for credit losses is recorded as part of the Provision for changes in expected future cash flows from financial royalty assets on the consolidated statements of operations.
    Intangible royalty assets, net Currently, our only intangible royalty assets are the Januvia and Janumet (“DPP-IV”) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, the majority of which terminate at various dates through 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10, Property, Plant, and Equipment - Overall. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product’s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty’s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.
    Revenue from intangible royalty assets and Accrued royalty receivable
    We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts’ projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.

    Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.

    Milestone payments

    Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts’ consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved.

    Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.
    Financial Instruments Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than Financial royalty assets, net are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 5–Fair Value Measurements and Financial Instruments.
    Cash and cash equivalents Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value.
    Equity securities and Available for sale debt securities
    Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities are measured at fair value. The unrealized change in fair value of available for sale debt securities for which we elected the fair value option is recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations. The unrealized change in fair value for the Biohaven Series A Preferred Share is included in Accumulated other comprehensive income (“AOCI”) and are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows.

    A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management’s assessment.

    We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.
    Derivatives All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements. Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of operations as part of Losses on derivative financial instruments.
    Investments in non-consolidated affiliates
    Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee’s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within Equity in losses/(earnings) of non-consolidated affiliates in the consolidated statements of operations. The investment is reflected as Investments in non-consolidated affiliates on the consolidated balance sheet.

    We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the “Avillion entities”). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.
    When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets.
    Research and development funding expense
    We enter into transactions where we agree to fund a portion of the research and development (“R&D”) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, Research and Development, we account for the funded amounts as R&D expense when we have the ability to obtain the results of the R&D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. We may pay funded amounts upfront or over time as the underlying products undergo clinical trials.

    Royalty payments owed to the Company on successfully commercialized products generated from R&D arrangements are recognized as Other royalty income in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria for products arising out of our R&D arrangements are also recognized as Other royalty income in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed.
    Income taxes
    We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (“the Code”) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.

    While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments.

    Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes.

    While we do not currently record a provision for income taxes, we are party to certain arrangements that will give rise to a tax provision in the future. We currently have funding arrangements in place that allow our counterparties to draw on capital over a prescribed period of time. When such funding arrangements are drawn and we begin to recognize income from these funding arrangements, such activities will be subject to U.S. taxation and we will record a provision for income taxes in accordance with ASC 740, Income Taxes. We also entered into an arrangement with MSCI during 2021 as discussed in Note 16–Related Party Transactions that will become subject to U.S. taxation when we begin to recognize revenue from this transaction.

    We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI.
    We are also subject to the U.K.’s “controlled foreign companies” rules (the “U.K. CFC Rules”). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the “Controlled Foreign Company”) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings), will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes.
    Earnings per share Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to RPI EPA Holdings, LP (“EPA Holdings”) related to Equity Performance Awards and unvested restricted share units (“RSUs”) issued under our 2020 Independent Director Equity Incentive Plan (“Equity Incentive Plan”). We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable. We use the “if-converted” method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.
    Recently adopted and issued accounting standards
    In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to Retained earnings of $192.7 million to recognize an allowance for current expected credit losses on our financial royalty assets.

    In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.
    Fair value measurements
    We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:

    •Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
    •Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.
    •Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.
    Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives and available for sale debt securities are reported at their respective fair values in our consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs in our consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported in our consolidated balance sheets at amounts that approximate current fair values.
    XML 44 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Available for Sale Debt Securities (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Investments, Debt and Equity Securities [Abstract]  
    Summary of Available for Sale Debt Securities
    The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2021 and 2020 (in thousands):
    Cost (1)Unrealized GainsFair Value Current AssetsNon-Current AssetsTotal
    As of December 31, 2021
    Series A Biohaven Preferred Shares$134,068 $29,432 $163,500 $66,000 $97,500 $163,500 
    Series B Biohaven Preferred Shares70,441 19,759 90,200 — 90,200 90,200 
    Series B Forwards— 12,300 12,300 — 12,300 12,300 
    Development Funding Bond Forward— 4,400 4,400 — 4,400 4,400 
    Total available for sale debt securities$204,509 $65,891 $270,400 $66,000 $204,400 $270,400 
    As of December 31, 2020
    Series A Biohaven Preferred Shares$145,647 $68,753 $214,400 $69,984 $144,416 $214,400 
    Series B Forwards— 18,600 18,600 — 18,600 18,600 
    Total available for sale debt securities$145,647 $87,353 $233,000 $69,984 $163,016 $233,000 
    (1)Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. There were no costs associated with the Series B Forwards and Development Funding Bond Forward.
    XML 45 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Derivative Instruments (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Derivative Instruments and Hedging Activities Disclosure [Abstract]  
    Summary of Derivatives and Reclassifications
    The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2021, 2020 and 2019 and the line items within the consolidated statements of operations where the gains or losses on these derivatives are recorded (in thousands).
    Years Ended December 31,Location on Consolidated Statements of Operations
    202120202019
    Derivatives in hedging relationships (1)
    Interest Rate Swaps:
    Amount of loss reclassified from accumulated other comprehensive income into income$— $4,066 $6,189 Losses on derivative financial instruments
    Change in fair value of interest rate swaps— (73)16,954 Losses on derivative financial instruments
    Interest expense/(income)— 114 (9,565)Interest expense
    Derivatives not designated as hedging instruments
    Interest Rate Swaps:
    Change in fair value of interest rate swaps— 6,908 49,472 Losses on derivative financial instruments
    Interest expense/(income)— 408 (2,681)Interest expense
    Warrant:
    Change in fair value of warrant5,439 25,375 (21,977)Losses on derivative financial instruments
    Forward purchase contract:
    Change in fair value of forward purchase contract— 5,800 (11,500)Losses on derivative financial instruments
    Treasury rate lock contracts:
    Change in fair value of treasury rate lock contracts16,093 — — Losses on derivative financial instruments
    (1)     Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in Accumulated other comprehensive income were released into earnings.
    XML 46 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Fair Value Measurements and Financial Instruments (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Fair Value Disclosures [Abstract]  
    Schedule of Fair Value Hierarchy
    The following table summarizes financial assets and financial liabilities that we measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):

    As of December 31, 2021As of December 31, 2020
    Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
    Assets:
    Cash equivalents
    Money market funds$598,253 $— $— $598,253 $24,302 $— $— $24,302 
    Commercial paper— 13,997 — 13,997 — 77,176 — 77,176 
    Certificates of deposit— 40,954 — 40,954 — 74,502 — 74,502 
    Marketable securities
    Corporate debt securities— — — — — 32,754 — 32,754 
    Commercial paper— 207,457 — 207,457 — 444,554 — 444,554 
    Certificates of deposit— 374,415 — 374,415 — 505,971 — 505,971 
    Available for sale debt securities— — 66,000 66,000 — — 69,984 69,984 
    Total current assets$598,253 $636,823 $66,000 $1,301,076 $24,302 $1,134,957 $69,984 $1,229,243 
    Equity securities226,787 — 43,013 269,800 298,689 — — 298,689 
    Available for sale debt securities— — 187,700 187,700 — — 144,416 144,416 
    Forwards (1)— — 16,700 16,700 — — 18,600 18,600 
    Warrant (2)— — — — — 5,439 — 5,439 
    Total non-current assets$226,787 $— $247,413 $474,200 $298,689 $5,439 $163,016 $467,144 
    (1)The balance as of December 31, 2021 includes Series B Forwards and the Development Funding Bond Forward, recorded within Available for sale debt securities in the consolidated balance sheet, related to our obligations to fund acquisitions of the Series B Biohaven Preferred Shares and $150 million of the Development Funding Bonds, respectively. The balance as of December 31, 2020 relates to Series B Forwards, recorded within Available for sale debt securities in the consolidated balance sheet. See Note 3–Available for Sale Debt Securities for additional discussion.
    (2)Related to the Epizyme transaction as described in Note 4–Derivative Instruments and recorded in Other assets in the consolidated balance sheets as of December 31, 2021 and 2020. The fair value of the warrant was not material as of December 31, 2021.
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation
    The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities and available for sale debt securities, including the underlying debt securities and related forwards (in thousands).

    Years Ended December 31,
    20212020
    Equity Securities
    Balance at the beginning of the year$— $— 
    Purchases35,120 — 
    Gains on equity securities7,893 — 
    Balance at the end of the year$43,013 $— 
    Years Ended December 31,
    20212020
    Debt Securities
    Balance at the beginning of the year$214,400 $131,280 
    Purchases70,441 — 
    Unrealized gains on available for sale debt securities (1)12,900 52,725 
    Settlement of forwards (2)18,459 — 
    Transfer to Level 2— (184,005)
    Transfer from Level 2 (3)— 198,526 
    Unrealized gains on available for sale debt securities (1)— 15,874 
    Redemption(62,500)— 
    Balance at the end of the year$253,700 $214,400 
    Years Ended December 31,
    20212020
    Forwards
    Balance at the beginning of the year$18,600 $— 
    Unrealized gains (4)16,559 18,600 
    Settlement of forwards (2)(18,459)— 
    Balance at the end of the year$16,700 $18,600 
    (1)For the year ended December 31, 2021, the unrealized gains on available for sale debt securities is comprised of $11.6 million related to Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income and $1.3 million related to the Series B Biohaven Preferred Shares as recorded on the consolidated statements of operations. For the year ended December 31, 2020, the unrealized gains on available for sale debt securities related to the Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income, including $52.7 million prior to transferring out of Level 3 and then $15.9 million after transferring back to Level 3.     
    (2)Reflects the fair value attributed to the Series B Forwards that were settled in the period as the Series B Biohaven Preferred Shares were acquired, which is included in the fair value of the Series B Biohaven Preferred Shares. See Note 3–Available for Sale Debt Securities.
    (3)Includes $14.5 million of unrealized gains on available for sale debt securities included in other comprehensive income while the Series A Biohaven Preferred Shares was classified as a Level 2 asset.
    (4)Recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations.
    Fair Value Disclosure of Asset and Liability Not Measured at Fair Value Estimated fair values based on Level 3 inputs and related carrying values for our financial royalty assets as of December 31, 2021 and 2020 are presented below (in thousands).
    December 31, 2021December 31, 2020
    Fair ValueCarrying Value, netFair ValueCarrying Value, net
    Financial royalty assets, net$19,047,183 $14,332,596 $18,718,179 $12,955,277 
    XML 47 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Financial Royalty Assets, Net (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Receivables [Abstract]  
    Summary of Financial Royalty Assets, Net
    The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2021 and 2020 are as follows (in thousands):
    As of December 31, 2021
    Estimated Royalty Duration (a)Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 7)Net Carrying Value (e)
    Cystic fibrosis franchise2037 (b)$5,335,641 $(48,636)$5,287,005 
    Tysabri(c)1,846,069 (16,617)1,829,452 
    Imbruvica2027-20321,438,730 (236,871)1,201,859 
    Xtandi2027-20281,100,065 (172,101)927,964 
    Tremfya2031-2032881,671 — 881,671 
    Evrysdi2030-2035 (d)727,774 — 727,774 
    Other2020-20394,697,591 (909,916)3,787,675 
    Total$16,027,541 $(1,384,141)$14,643,400 
    Less: Cumulative allowance for credit losses (Note 7)(310,804)
    Total financial royalty assets, net$14,332,596 
    (a)Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
    (b)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
    (c)Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
    (d)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
    (e)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

    As of December 31, 2020
    Estimated Royalty Duration (a)Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 7)Net Carrying Value (e)
    Cystic fibrosis franchise2037 (b)$5,274,896 $— $5,274,896 
    Tysabri(c)2,003,797 (112,720)1,891,077 
    Imbruvica2027-20321,406,291 (46,872)1,359,419 
    Xtandi2027-20281,150,335 (145,565)1,004,770 
    Promacta2025-2028686,129 — 686,129 
    Evrysdi2030-2035 (d)675,440 — 675,440 
    Other2020-20393,022,213 (634,950)2,387,263 
    Total$14,219,101 $(940,107)$13,278,994 
    Less: Cumulative allowance for credit losses (Note 7)(323,717)
    Total financial royalty assets, net$12,955,277 
    (a)Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
    (b)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
    (c)Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
    (d)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
    (e)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.
    XML 48 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Credit Loss [Abstract]  
    Schedule of Cumulative Allowance for Changes in Expected Cash Flows
    The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):
    Activity for the Year
    Balance at December 31, 2018$(1,982,897)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(322,717)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets1,342,038 
    Write-off of cumulative allowance (a)95,158 
    Balance at December 31, 2019$(868,418)
    Cumulative adjustment for adoption of ASU 2016-13(192,705)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(645,612)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets570,959 
    Write-off of cumulative allowance (a)2,964 
    Write-off of credit loss allowance (b)25,174 
    Current period provision expense for credit losses, net (c)(156,186)
    Balance at December 31, 2020$(1,263,824)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(912,710)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets446,955 
    Write-off of cumulative allowance (a)21,721 
    Current period provision income for credit losses, net (c)12,913 
    Balance at December 31, 2021$(1,694,945)
    (a)     Relates to amounts removed from the allowance at the end of a royalty asset’s life to bring the account balance to zero. Write-offs solely impact the asset account and allowance account; there is no impact on the consolidated statements of operations.
    (b)     Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the write-off of the related financial royalty asset balance of $90.2 million.
    (c)     In the year ended December 31, 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights in 2020, mainly the final tranche of Tazverik. In the year ended December 31, 2021,the provision income for credit losses was primarily related to a significant decline in the financial asset value for Tazverik, which was offset by increases in our portfolio of financial royalty assets with limited protective rights in 2021, primarily related to zavegepant.
    XML 49 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Intangible Royalty Assets, Net (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Goodwill and Intangible Assets Disclosure [Abstract]  
    Schedule of Intangible Royalty Interests
    The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2021 and 2020 (in thousands).
    As of December 31, 2021CostAccumulated AmortizationNet Carrying Value
    DPP-IV patents$606,216 $600,546 $5,670 
    Total intangible royalty assets$606,216 $600,546 $5,670 
    As of December 31, 2020CostAccumulated AmortizationNet Carrying Value
    DPP-IV patents$606,216 $577,550 $28,666 
    Total intangible royalty assets$606,216 $577,550 $28,666 
    XML 50 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Borrowings (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Debt Disclosure [Abstract]  
    Schedule of Borrowings
    Our borrowings at December 31, 2021 and 2020 consisted of the following (in thousands):

    Type of BorrowingDate of IssuanceMaturityDecember 31, 2021December 31, 2020
    Senior Unsecured Notes:
    $1,000,000, 0.75% (issued at 99.322% of par)
    		9/20209/2023$1,000,000 $1,000,000 
    $1,000,000, 1.20% (issued at 98.875% of par)
    		9/20209/20251,000,000 1,000,000 
    $1,000,000, 1.75% (issued at 98.284% of par)
    		9/20209/20271,000,000 1,000,000 
    $1,000,000, 2.20% (issued at 97.760% of par)
    		9/20209/20301,000,000 1,000,000 
    $600,000, 2.15% (issued at 98.263% of par)
    		7/20219/2031600,000 — 
    $1,000,000, 3.30% (issued at 95.556% of par)
    		9/20209/20401,000,000 1,000,000 
    $1,000,000, 3.55% (issued at 95.306% of par)
    		9/20209/20501,000,000 1,000,000 
    $700,000, 3.35% (issued at 97.565% of par)
    		7/20219/2051700,000 — 
    Unamortized debt discount and issuance costs(203,930)(183,416)
    Total debt carrying value7,096,070 5,816,584
    Less: Current portion of long-term debt— —
    Total long-term debt$7,096,070 $5,816,584 
    Schedule of Repayments of Debt by Year The future principal payments for our borrowings as of December 31, 2021 over the next five years and thereafter are as follows (in thousands):
    YearPrincipal Payments
    2022$— 
    20231,000,000
    2024—
    20251,000,000
    2026—
    Thereafter5,300,000
    Total (1)$7,300,000 
    (1)     Excludes unamortized debt discount and issuance costs of $203.9 million as of December 31, 2021, which are amortized through interest expense over the remaining life of the underlying debt obligations.
    XML 51 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Shareholders' Equity (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Equity [Abstract]  
    Schedule of Balance Of Non-controlling Interests The net change in the balance of our four non-controlling interests for the years ended December 31, 2021 and 2020 is as follows (in thousands):
    RPSFTLegacy Investors PartnershipsContinuing Investors Partnerships (1)EPA HoldingsTotal
    December 31, 2019$35,883 $— $— $— $35,883 
    Contributions— 1,165,258 9,418 — 1,174,676 
    Transfer of interests— 1,037,161 — — 1,037,161 
    Distributions(112,339)(594,592)(85,426)— (792,357)
    Net Income prior to IPO42,151 102,892 — — 145,043 
    Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity— (750)2,433,848 — 2,433,098 
    Issuance of Class A ordinary shares sold in IPO, net of offering costs— — 758,354 — 758,354 
    Other exchanges— — (309,566)— (309,566)
    Net income subsequent to IPO46,741 218,137 316,993 — 581,871 
    Other comprehensive income/(loss):
    Unrealized gains on available for sale debt securities— 15,015 7,488 — 22,503 
    Reclassification of unrealized losses on available for sale debt securities— (3,612)(6,018)— (9,630)
    December 31, 2020$12,436 $1,939,509 $3,125,091 $— $5,077,036 
    (1)     Related to the Continuing Investors Partnerships’ ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2020.

    RPSFTLegacy Investors PartnershipsContinuing Investors Partnerships (1)EPA HoldingsTotal
    December 31, 2020$12,436 $1,939,509 $3,125,091 $— $5,077,036 
    Contributions— 35,148 13,391 — 48,539 
    Distributions(56,490)(425,050)(133,433)— (614,973)
    Other exchanges— — (642,974)— (642,974)
    Net Income57,582 266,570 297,321 — 621,473 
    Other comprehensive income/(loss):
    Unrealized gains on available for sale debt securities— 2,038 3,227 — 5,265 
    Reclassification of unrealized losses on available for sale debt securities— (8,946)(13,469)— (22,415)
    December 31, 2021$13,528 $1,809,269 $2,649,154 $— $4,471,951 
    (1)     Related to the Continuing Investors Partnerships’ ownership of approximately 29% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2021. Royalty Pharma plc owns the remaining 71% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2021.
    XML 52 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Earnings Per Share (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Earnings Per Share [Abstract]  
    Schedule of Earnings Per Share, Basic and Diluted
    The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2021 (in thousands, except per share amounts).
    Year Ended December 31, 2021
    Numerator
    Consolidated net income$1,241,201 
    Less: Net income attributable to Continuing Investors Partnerships297,321 
    Less: Net income attributable to Legacy Investors Partnerships and RPSFT324,152 
    Net income attributable to Royalty Pharma plc - basic and diluted$619,728 
    Denominator
    Weighted average Class A ordinary shares outstanding - basic414,794 
    Add: Dilutive effect of unvested RSUs8 
    Weighted average Class A ordinary shares outstanding - diluted414,802 
    Earnings per Class A ordinary share - basic$1.49 
    Earnings per Class A ordinary share - diluted$1.49 
    The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2020 (in thousands, except per share amounts).
    Year Ended
    December 31, 2020
    Numerator
    Consolidated net income $1,701,954 
    Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)479,842 
    Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO316,993 
    Less: Net income attributable to Legacy Investors Partnerships and RPSFT409,921 
    Net income attributable to Royalty Pharma plc - basic and diluted$495,198 
    Denominator
    Weighted average Class A ordinary shares outstanding - basic375,444 
    Add: Dilutive effect of unvested RSUs11 
    Weighted average Class A ordinary shares outstanding - diluted375,455 
    Earnings per Class A ordinary share - basic$1.32 
    Earnings per Class A ordinary share - diluted$1.32 
    (1)     Reflected as Net income attributable to controlling interest on the consolidated statements of operations
    XML 53 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Indirect Cash Flow (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Supplemental Cash Flow Elements [Abstract]  
    Schedule of Cash Flow, Supplemental Disclosures
    Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).
    Years Ended December 31,
    202120202019
    Cash flow from operating activities:
    Consolidated net income$1,241,201 $1,701,954 $2,461,419 
    Adjustments to reconcile consolidated net income to net cash provided by operating activities:
    Income from financial royalty assets(2,065,083)(1,959,975)(1,648,837)
    Provision for changes in expected cash flows from financial royalty assets452,842 230,839 (1,019,321)
    Amortization of intangible assets22,996 23,058 23,924 
    Amortization of debt discount and issuance costs20,162 11,715 12,790 
    Losses on derivative financial instruments21,532 42,076 39,138 
    Losses/(gains) on equity securities48,066 (247,073)(155,749)
    Equity in losses/(earnings) of non-consolidated affiliates19,490 (44,459)32,517 
    Distributions from non-consolidated affiliates34,384 42,334 14,059 
    Loss on extinguishment of debt358 30,272 — 
    Share-based compensation2,443 5,428 — 
    Interest income accretion(50,896)(20,551)— 
    Unrealized gains on available for sale debt securities(17,859)(18,600)— 
    Impairment charge— 65,053 — 
    Termination of derivative financial instruments(16,093)(34,952)— 
    Other4,461 9,621 (2,122)
    Decrease/(increase) in operating assets:
    Cash collected on financial royalty assets2,315,854 2,121,923 1,934,092 
    Available for sale debt securities— — (150,000)
    Accrued royalty receivable(20,131)370 2,471 
    Other receivables— — 150,000 
    Other royalty income receivable(9,012)(770)7,390 
    Other current assets and other assets1,857 34,986 (41,028)
    (Decrease)/increase in operating liabilities:
    Accounts payable and accrued expenses(4,586)(766)6,496 
    Interest payable15,550 42,146 — 
    Net cash provided by operating activities$2,017,536 $2,034,629 $1,667,239 

    Non-cash investing and financing activities are summarized below (in thousands).
    Years Ended December 31,
    Supplemental Schedule of Non-cash Investing/Financing Activities:202120202019
    Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)$— $303,679 $— 
    Settlement of Epizyme forward purchase contract— 5,700 — 
    Accrued purchase obligation - Tazverik (Note 17)— 110,000 — 
    Repayments of long-term debt by contributions from non-controlling interest (1)— 1,103,774 — 
    Milestone payable - Erleada (2)— 18,600 — 
    (1) Related to the pro rata portion of RPIFT’s outstanding debt repaid by the Legacy Investors Partnerships.
    (2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020 as recorded within Other current liabilities on the consolidated balance sheet.
    XML 54 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Accumulated Other Comprehensive Income (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Equity [Abstract]  
    Schedule of Accumulated Other Comprehensive Income (Loss)
    The components of accumulated other comprehensive income as of December 31, 2021 and 2020 are as follows (in thousands):
    Unrealized Gains on Available for Sale Debt SecuritiesUnrealized Losses on Interest Rate SwapsTotal Accumulated Other Comprehensive Income
    Balance at December 31, 20196,159 (4,066)2,093 
    Reclassification to net income(10,921)4,066 (6,855)
    Activity for the year60,617 — 60,617 
    Reclassification to non-controlling interest(24,022)— (24,022)
    Reclassification from non-controlling interest2,562 — 2,562 
    Balance at December 31, 202034,395 — 34,395 
    Reclassification to net income(28,481)— (28,481)
    Activity for the year6,335 — 6,335 
    Reclassification from non-controlling interest4,242 — 4,242 
    Balance at December 31, 2021$16,491 $— $16,491 
    XML 55 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Related Party Transactions (Tables)
    		 12 Months Ended
    Dec. 31, 2021
    Related Party Transactions [Abstract]  
    Schedule of Related Party Transactions The distribution payable to non-controlling interest as of December 31, 2021 and 2020 included the following (in thousands).
    December 31, 2021December 31, 2020
    Due to Legacy Investors Partnerships$92,608 $100,047 
    Due to RPSFT15,326 26,319 
    Total distribution payable to non-controlling interest$107,934 $126,366 
    XML 56 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Organization and Purpose (Details) - USD ($)
    		 1 Months Ended 12 Months Ended
    Jun. 18, 2020
    Feb. 11, 2020
    Jun. 30, 2020
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Sep. 02, 2020
    Feb. 29, 2020
    Subsidiary, Sale of Stock [Line Items]                
    Repayments of outstanding debt       $ 0 $ 11,116,196,000 $ 0    
    Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1                
    Subsidiary, Sale of Stock [Line Items]                
    Debt issued, amount   $ 3,200,000,000            
    Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1                
    Subsidiary, Sale of Stock [Line Items]                
    Debt issued, amount   2,840,000,000            
    Senior Secured Debt | Old Credit Facility                
    Subsidiary, Sale of Stock [Line Items]                
    Repayments of outstanding debt   $ 6,300,000,000            
    RPCT                
    Subsidiary, Sale of Stock [Line Items]                
    Ownership percentage (as a percent)   66.00%            
    Legacy Investors Partnerships | Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1                
    Subsidiary, Sale of Stock [Line Items]                
    Debt issued, amount   $ 1,300,000,000            
    Legacy Investors Partnerships | Old RPI                
    Subsidiary, Sale of Stock [Line Items]                
    Noncontrolling interest (percentage)               18.00%
    RPSFT | RPCT                
    Subsidiary, Sale of Stock [Line Items]                
    Noncontrolling interest (percentage)   34.00%            
    RPI Intermediate FT | Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1                
    Subsidiary, Sale of Stock [Line Items]                
    Debt issued, amount   $ 6,000,000,000         $ 149,000,000  
    RPI Intermediate FT | Senior Secured Debt | RPIFT Senior Secured Credit Facilities                
    Subsidiary, Sale of Stock [Line Items]                
    Repayments of outstanding debt   $ 5,200,000,000            
    Common Class A                
    Subsidiary, Sale of Stock [Line Items]                
    Ownership percentage following IPO 100.00%              
    Exchange Offer Transaction | Old RPI                
    Subsidiary, Sale of Stock [Line Items]                
    Ownership percentage (as a percent)   82.00%            
    Exchange Offer Transaction | Legacy Investors Partnerships                
    Subsidiary, Sale of Stock [Line Items]                
    Exchange offering, ownership percentage   82.00%            
    IPO | Common Class A                
    Subsidiary, Sale of Stock [Line Items]                
    Number of shares issued (in shares) 89,334,000              
    Sale of stock, price per share (in dollars per share) $ 28.00              
    IPO - Shares From Company | Common Class A                
    Subsidiary, Sale of Stock [Line Items]                
    Number of shares issued (in shares) 71,652,000              
    IPO - Shares From Selling Shareholders | Common Class A                
    Subsidiary, Sale of Stock [Line Items]                
    Number of shares issued (in shares) 17,682,000              
    Public Stock Offering - Continuing Investors Partnerships Interests | Common Class B                
    Subsidiary, Sale of Stock [Line Items]                
    Number of shares available to convert (in shares)     294,176,000          
    Number of shares converted (in shares)     241,207,000          
    XML 57 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Summary of Significant Accounting Policies (Details)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    USD ($)
    segment
    Dec. 31, 2020
    USD ($)
    Dec. 31, 2019
    USD ($)
    Jun. 30, 2020
    partnership
    Feb. 29, 2020
    Dec. 31, 2018
    USD ($)
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Number of noncontrolling interests created | partnership       2    
    Marketable securities $ 581,872 $ 983,279        
    Cash and cash equivalents (1,541,048) (1,008,680)        
    Purchases of available for sale debt securities 1,196,579 1,705,283 $ 817,402      
    Proceeds from sales and maturities of marketable securities 1,597,851 815,440 725,070      
    Net cash flow from investing $ (1,870,280) (2,759,320) (2,153,625)      
    Number of operating segments | segment 1          
    Cumulative adjustment $ 10,248,545 9,895,815 6,141,438     $ 4,552,079
    Revision of Prior Period, Reclassification, Adjustment            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Marketable securities     37,500      
    Cash and cash equivalents     37,500      
    Purchases of available for sale debt securities     388,000      
    Proceeds from sales and maturities of marketable securities     350,500      
    Net cash flow from investing     37,500      
    Cumulative Effect, Period of Adoption, Adjustment            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Cumulative adjustment     (192,705)      
    Retained Earnings            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Cumulative adjustment 2,255,179 1,920,635 2,825,212     1,215,953
    Retained Earnings | Cumulative Effect, Period of Adoption, Adjustment            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Cumulative adjustment     (192,705)      
    Non-Controlling Interest            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Cumulative adjustment $ 4,471,951 $ 5,077,036 35,883     $ 63,865
    Non-Controlling Interest | RP Holdings            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Noncontrolling interest (percentage) 71.00% 64.00%        
    Customer Concentration Risk | Current portion of Financial royalty assets | Vertex            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Concentration risk (as a percent) 32.00% 27.00%        
    Legacy Investors Partnerships | Old RPI            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Noncontrolling interest (percentage)         18.00%  
    Legacy Investors Partnerships | Non-Controlling Interest            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Cumulative adjustment $ 1,809,269 $ 1,939,509 0      
    Continuing Investors Partnerships | Non-Controlling Interest            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Cumulative adjustment $ 2,649,154 $ 3,125,091 $ 0      
    Continuing Investors Partnerships | Non-Controlling Interest | RP Holdings            
    New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
    Noncontrolling interest (percentage) 29.00% 36.00%        
    XML 58 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Available for Sale Debt Securities - Narrative (Details) - USD ($)
    		 12 Months Ended
    Jun. 02, 2021
    Aug. 07, 2020
    Apr. 05, 2019
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Debt and Equity Securities, FV-NI [Line Items]            
    Purchase of available for sale debt securities       $ 70,441,000 $ 0 $ 125,121,000
    MorphoSys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
    Debt and Equity Securities, FV-NI [Line Items]            
    Payment of capital $ 350,000,000          
    Maximum commitment to fund collaborative arrangement $ 150,000,000     $ 150,000,000    
    Period of return 9 years          
    Period of return start date 2 years          
    Debt Securities            
    Debt and Equity Securities, FV-NI [Line Items]            
    Purchase of available for sale debt securities     $ 125,000,000      
    Series B Preferred Shares            
    Debt and Equity Securities, FV-NI [Line Items]            
    Purchase of available for sale debt securities   $ 200,000,000        
    Preferred Shares | Debt Securities            
    Debt and Equity Securities, FV-NI [Line Items]            
    Number of shares purchased (in shares)     2,495      
    Price per share (in USD per share)     $ 50,100      
    Redemption price, percentage     200.00%      
    Redemption default, interest rate     18.00%      
    Default period     1 year      
    Preferred Shares | Series B Preferred Shares            
    Debt and Equity Securities, FV-NI [Line Items]            
    Number of shares purchased (in shares)   3,992   1,406    
    Price per share (in USD per share)   $ 50,100        
    Redemption default, interest rate   18.00%        
    Redemption default, threshold period   1 year        
    Preferred Shares | Redemption, Period One | Maximum            
    Debt and Equity Securities, FV-NI [Line Items]            
    Redemption price, percentage     200.00%      
    Preferred Shares | Redemption, Period One | Debt Securities | Maximum            
    Debt and Equity Securities, FV-NI [Line Items]            
    Redemption price, percentage     200.00%      
    Preferred Shares | Redemption, Period One | Series B Preferred Shares            
    Debt and Equity Securities, FV-NI [Line Items]            
    Redemption price, percentage   180.00%   180.00%    
    Preferred Shares | Redemption, Period Two | Debt Securities            
    Debt and Equity Securities, FV-NI [Line Items]            
    Redemption price, percentage     200.00%      
    Preferred Shares | Redemption, Period Two | Series B Preferred Shares            
    Debt and Equity Securities, FV-NI [Line Items]            
    Redemption price, percentage   180.00%        
    XML 59 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Debt and Equity Securities, FV-NI [Line Items]    
    Cost $ 204,509 $ 145,647
    Unrealized gains 65,891 87,353
    Fair Value 270,400 233,000
    Available for sale debt securities, current 66,000 69,984
    Available for sale debt securities, noncurrent 204,400 163,016
    Debt Securities    
    Debt and Equity Securities, FV-NI [Line Items]    
    Cost 134,068 145,647
    Unrealized gains 29,432 68,753
    Fair Value 163,500 214,400
    Available for sale debt securities, current 66,000 69,984
    Available for sale debt securities, noncurrent 97,500 144,416
    Series B Preferred Shares    
    Debt and Equity Securities, FV-NI [Line Items]    
    Cost 70,441  
    Unrealized gains 19,759  
    Fair Value 90,200  
    Available for sale debt securities, current 0  
    Available for sale debt securities, noncurrent 90,200  
    Forwards    
    Debt and Equity Securities, FV-NI [Line Items]    
    Cost 0 0
    Unrealized gains 12,300 18,600
    Fair Value 12,300 18,600
    Available for sale debt securities, current 0 0
    Available for sale debt securities, noncurrent 12,300 $ 18,600
    Development Funding Bond Forward    
    Debt and Equity Securities, FV-NI [Line Items]    
    Cost 0  
    Unrealized gains 4,400  
    Fair Value 4,400  
    Available for sale debt securities, current 0  
    Available for sale debt securities, noncurrent $ 4,400  
    XML 60 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Derivative Instruments - Narrative (Details) - USD ($)
    		 1 Months Ended 12 Months Ended
    Jul. 31, 2021
    Nov. 30, 2019
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Jun. 30, 2021
    Derivative Instruments and Hedging Activities Disclosures [Line Items]            
    Derivative, notional amount           $ 600,000,000
    Swap termination payments     $ 16,093,000 $ 35,448,000 $ 0  
    Derivative collateral received     34,660,000 45,252,000 360,000  
    Unrealized gain (loss) on derivatives     (21,532,000) (42,076,000) (39,138,000)  
    Other assets     4,145,000 9,997,000    
    Interest Rate Swap | Level 1 | Fair Value, Recurring            
    Derivative Instruments and Hedging Activities Disclosures [Line Items]            
    Derivative financial instruments     0 5,400,000    
    Epizyme Common Stock Warrant            
    Derivative Instruments and Hedging Activities Disclosures [Line Items]            
    Warrants to purchase additional shares (in shares)   2,500,000        
    Equity Investment In Epizyme Inc.            
    Derivative Instruments and Hedging Activities Disclosures [Line Items]            
    Equity securities   $ 100,000,000        
    Upfront payment for equity investment   $ 100,000,000        
    Equity Investment In Epizyme Inc. | Epizyme Common Stock Warrant            
    Derivative Instruments and Hedging Activities Disclosures [Line Items]            
    Exercise price of warrant (in dollars per share)   $ 20        
    Term of warrant (in years)   3 years        
    Equity Investment In Epizyme Inc. | Put Option            
    Derivative Instruments and Hedging Activities Disclosures [Line Items]            
    Put option, term (in months)   18 months        
    Put option to sell additional common stock   $ 50,000,000        
    Put option, selling price, maximum (in dollars per share)   $ 20        
    Treasury Rate Lock Contracts            
    Derivative Instruments and Hedging Activities Disclosures [Line Items]            
    Swap termination payments $ 16,100,000          
    Interest Rate Swap            
    Derivative Instruments and Hedging Activities Disclosures [Line Items]            
    Unrealized gain (loss) on derivatives       (10,900,000) (72,600,000)  
    Warrant            
    Derivative Instruments and Hedging Activities Disclosures [Line Items]            
    Unrealized gain (loss) on derivatives     $ (5,400,000) $ (25,400,000) 22,000,000  
    Forwards | Equity Investment In Epizyme Inc.            
    Derivative Instruments and Hedging Activities Disclosures [Line Items]            
    Other assets         $ 11,500,000  
    XML 61 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Derivative Instruments - Summary of Derivatives and Reclassifications (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Interest Rate Swap | Losses on derivative financial instruments | Designated as Hedging Instrument      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Amount of loss reclassified from AOCI into income $ 0 $ 4,066 $ 6,189
    Interest rate swaps 0 (73) 16,954
    Interest Rate Swap | Losses on derivative financial instruments | Not Designated as Hedging Instrument      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Derivatives not designated as hedging instruments 0 6,908 49,472
    Interest Rate Swap | Interest expense | Designated as Hedging Instrument      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Interest rate swaps 0 114 (9,565)
    Interest Rate Swap | Interest expense | Not Designated as Hedging Instrument      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Derivatives not designated as hedging instruments 0 408 (2,681)
    Warrant | Losses on derivative financial instruments | Not Designated as Hedging Instrument      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Derivatives not designated as hedging instruments 5,439 25,375 (21,977)
    Forwards | Losses on derivative financial instruments | Not Designated as Hedging Instrument      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Change in fair value of derivative contracts 0 5,800 (11,500)
    Treasury Rate Lock Contracts | Losses on derivative financial instruments      
    Derivative Instruments and Hedging Activities Disclosures [Line Items]      
    Derivatives not designated as hedging instruments $ 16,093 $ 0 $ 0
    XML 62 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) - USD ($)
    		 12 Months Ended
    Jun. 02, 2021
    Dec. 31, 2021
    Dec. 31, 2020
    Assets:      
    Marketable securities   $ 581,872,000 $ 983,279,000
    Available for sale debt securities   66,000,000 69,984,000
    Equity securities   269,800,000 298,689,000
    Available for sale debt securities   204,400,000 163,016,000
    MorphoSys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
    Assets:      
    Maximum commitment to fund collaborative arrangement $ 150,000,000 150,000,000  
    Forwards      
    Assets:      
    Available for sale debt securities   0 0
    Available for sale debt securities   12,300,000 18,600,000
    Fair Value, Recurring      
    Assets:      
    Available for sale debt securities   66,000,000 69,984,000
    Total current assets   1,301,076,000 1,229,243,000
    Equity securities   269,800,000 298,689,000
    Available for sale debt securities   187,700,000 144,416,000
    Total non-current assets   474,200,000 467,144,000
    Fair Value, Recurring | Corporate Debt Securities      
    Assets:      
    Marketable securities   0 32,754,000
    Fair Value, Recurring | Commercial Paper      
    Assets:      
    Marketable securities   207,457,000 444,554,000
    Fair Value, Recurring | Certificates of Deposit      
    Assets:      
    Marketable securities   374,415,000 505,971,000
    Fair Value, Recurring | Forwards      
    Assets:      
    Derivatives   16,700,000 18,600,000
    Fair Value, Recurring | Warrant      
    Assets:      
    Derivatives   0 5,439,000
    Level 1 | Fair Value, Recurring      
    Assets:      
    Available for sale debt securities   0 0
    Total current assets   598,253,000 24,302,000
    Equity securities   226,787,000 298,689,000
    Available for sale debt securities   0 0
    Total non-current assets   226,787,000 298,689,000
    Level 1 | Fair Value, Recurring | Corporate Debt Securities      
    Assets:      
    Marketable securities   0 0
    Level 1 | Fair Value, Recurring | Commercial Paper      
    Assets:      
    Marketable securities   0 0
    Level 1 | Fair Value, Recurring | Certificates of Deposit      
    Assets:      
    Marketable securities   0 0
    Level 1 | Fair Value, Recurring | Forwards      
    Assets:      
    Derivatives   0 0
    Level 1 | Fair Value, Recurring | Warrant      
    Assets:      
    Derivatives   0 0
    Level 1 | Fair Value, Recurring | Interest Rate Swap      
    Assets:      
    Derivative financial instruments   0 5,400,000
    Level 2 | Fair Value, Recurring      
    Assets:      
    Available for sale debt securities   0 0
    Total current assets   636,823,000 1,134,957,000
    Equity securities   0 0
    Available for sale debt securities   0 0
    Total non-current assets   0 5,439,000
    Level 2 | Fair Value, Recurring | Corporate Debt Securities      
    Assets:      
    Marketable securities   0 32,754,000
    Level 2 | Fair Value, Recurring | Commercial Paper      
    Assets:      
    Marketable securities   207,457,000 444,554,000
    Level 2 | Fair Value, Recurring | Certificates of Deposit      
    Assets:      
    Marketable securities   374,415,000 505,971,000
    Level 2 | Fair Value, Recurring | Forwards      
    Assets:      
    Derivatives   0 0
    Level 2 | Fair Value, Recurring | Warrant      
    Assets:      
    Derivatives   0 5,439,000
    Level 3 | Fair Value, Recurring      
    Assets:      
    Available for sale debt securities   66,000,000 69,984,000
    Total current assets   66,000,000 69,984,000
    Equity securities   43,013,000 0
    Available for sale debt securities   187,700,000 144,416,000
    Total non-current assets   247,413,000 163,016,000
    Level 3 | Fair Value, Recurring | Corporate Debt Securities      
    Assets:      
    Marketable securities   0 0
    Level 3 | Fair Value, Recurring | Commercial Paper      
    Assets:      
    Marketable securities   0 0
    Level 3 | Fair Value, Recurring | Certificates of Deposit      
    Assets:      
    Marketable securities   0 0
    Level 3 | Fair Value, Recurring | Forwards      
    Assets:      
    Derivatives   16,700,000 18,600,000
    Level 3 | Fair Value, Recurring | Warrant      
    Assets:      
    Derivatives   0 0
    Money Market Funds | Fair Value, Recurring      
    Assets:      
    Cash equivalents   598,253,000 24,302,000
    Money Market Funds | Level 1 | Fair Value, Recurring      
    Assets:      
    Cash equivalents   598,253,000 24,302,000
    Money Market Funds | Level 2 | Fair Value, Recurring      
    Assets:      
    Cash equivalents   0 0
    Money Market Funds | Level 3 | Fair Value, Recurring      
    Assets:      
    Cash equivalents   0 0
    Commercial Paper | Fair Value, Recurring      
    Assets:      
    Cash equivalents   13,997,000 77,176,000
    Commercial Paper | Level 1 | Fair Value, Recurring      
    Assets:      
    Cash equivalents   0 0
    Commercial Paper | Level 2 | Fair Value, Recurring      
    Assets:      
    Cash equivalents   13,997,000 77,176,000
    Commercial Paper | Level 3 | Fair Value, Recurring      
    Assets:      
    Cash equivalents   0 0
    Certificates of Deposit | Fair Value, Recurring      
    Assets:      
    Cash equivalents   40,954,000 74,502,000
    Certificates of Deposit | Level 1 | Fair Value, Recurring      
    Assets:      
    Cash equivalents   0 0
    Certificates of Deposit | Level 2 | Fair Value, Recurring      
    Assets:      
    Cash equivalents   40,954,000 74,502,000
    Certificates of Deposit | Level 3 | Fair Value, Recurring      
    Assets:      
    Cash equivalents   $ 0 $ 0
    XML 63 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Fair Value Measurements and Financial Instruments - Narrative (Details) - USD ($)
    $ in Millions
    		 1 Months Ended 12 Months Ended
    Apr. 05, 2019
    Nov. 30, 2021
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Unrealized gain (loss) on equity securities still held     $ 60.1 $ 85.4 $ (104.4)
    Restrictions on selling common stock, period     6 months    
    Level 3 | BioCryst Pharmaceuticals, Inc.          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Number of shares purchased (in shares)   3,846,000      
    Preferred Shares | Debt Securities          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Redemption price, percentage 200.00%        
    Preferred shares, quarterly payments     $ 15.6    
    Preferred shares, fixed payment amount     $ 250.0    
    Change in control event, period     4 years    
    Preferred shares, weighted average cost of capital     9.50% 8.30%  
    Number of shares purchased (in shares) 2,495        
    Preferred Shares | Maximum | Redemption, Period One          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Redemption price, percentage 200.00%        
    Preferred Shares | Maximum | Redemption, Period One | Debt Securities          
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
    Redemption price, percentage 200.00%        
    XML 64 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Equity Securities | Level 3    
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
    Balance at the beginning of the year $ 0 $ 0
    Purchases 35,120 0
    Gains on equity securities 7,893 0
    Balance at the end of the year 43,013 0
    Series A Preferred Stock | Level 3    
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
    Balance at the beginning of the year 214,400 131,280
    Purchases 70,441 0
    Gains on equity securities 12,900 52,725
    Settlement of forwards 18,459 0
    Transfer to Level 2 0 (184,005)
    Transfer from level 2 0 198,526
    Unrealized gains on available for sale debt securities 0 15,874
    Redemption (62,500) 0
    Balance at the end of the year 253,700 214,400
    Forwards | Level 3    
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
    Balance at the beginning of the year 18,600 0
    Settlement of forwards (18,459) 0
    Unrealized gains included in earnings 16,559 18,600
    Balance at the end of the year 16,700 18,600
    Available-for-sale Securities | Level 3 | Series A Preferred Stock    
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
    Unrealized gains on available for sale debt securities 11,600 52,700
    Available-for-sale Securities | Level 3 | Series B Preferred Shares    
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
    Unrealized gains on available for sale debt securities 1,300 $ 15,900
    Available-for-sale Securities | Level 2    
    Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
    Unrealized gains on available for sale debt securities $ 14,500  
    XML 65 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) - Level 3 - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Fair Value    
    Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
    Financial royalty assets, net $ 19,047,183 $ 18,718,179
    Carrying Value, net    
    Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
    Financial royalty assets, net $ 14,332,596 $ 12,955,277
    XML 66 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Gross Carrying Value $ 16,027,541 $ 14,219,101
    Cumulative allowance for changes in expected cash flows (1,384,141) (940,107)
    Net carrying value, before cumulative allowance for credit losses 14,643,400 13,278,994
    Cumulative allowance for credit losses (310,804) (323,717)
    Net carrying value 14,332,596 12,955,277
    Cystic fibrosis franchise    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Gross Carrying Value 5,335,641 5,274,896
    Cumulative allowance for changes in expected cash flows (48,636) 0
    Net carrying value, before cumulative allowance for credit losses 5,287,005 5,274,896
    Tysabri    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Gross Carrying Value 1,846,069 2,003,797
    Cumulative allowance for changes in expected cash flows (16,617) (112,720)
    Net carrying value, before cumulative allowance for credit losses 1,829,452 1,891,077
    Imbruvica    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Gross Carrying Value 1,438,730 1,406,291
    Cumulative allowance for changes in expected cash flows (236,871) (46,872)
    Net carrying value, before cumulative allowance for credit losses 1,201,859 1,359,419
    Xtandi    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Gross Carrying Value 1,100,065 1,150,335
    Cumulative allowance for changes in expected cash flows (172,101) (145,565)
    Net carrying value, before cumulative allowance for credit losses 927,964 1,004,770
    Tremfya    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Gross Carrying Value 881,671  
    Cumulative allowance for changes in expected cash flows 0  
    Net carrying value, before cumulative allowance for credit losses 881,671  
    Evrysdi    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Gross Carrying Value 727,774 675,440
    Cumulative allowance for changes in expected cash flows 0 0
    Net carrying value, before cumulative allowance for credit losses 727,774 675,440
    Aggregate royalty amount when patents cease 1,300,000 1,300,000
    Promacta    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Gross Carrying Value   686,129
    Cumulative allowance for changes in expected cash flows   0
    Net carrying value, before cumulative allowance for credit losses   686,129
    Other    
    Accounts, Notes, Loans and Financing Receivable [Line Items]    
    Gross Carrying Value 4,697,591 3,022,213
    Cumulative allowance for changes in expected cash flows (909,916) (634,950)
    Net carrying value, before cumulative allowance for credit losses $ 3,787,675 $ 2,387,263
    XML 67 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Financing Receivable, Allowance for Credit Loss [Line Items]        
    Cumulative adjustment to retained earnings $ (10,248,545) $ (9,895,815) $ (6,141,438) $ (4,552,079)
    Retained Earnings        
    Financing Receivable, Allowance for Credit Loss [Line Items]        
    Cumulative adjustment to retained earnings $ (2,255,179) $ (1,920,635) (2,825,212) $ (1,215,953)
    Cumulative Effect, Period of Adoption, Adjustment        
    Financing Receivable, Allowance for Credit Loss [Line Items]        
    Cumulative adjustment to retained earnings     192,705  
    Cumulative Effect, Period of Adoption, Adjustment | Retained Earnings        
    Financing Receivable, Allowance for Credit Loss [Line Items]        
    Cumulative adjustment to retained earnings     $ 192,705  
    XML 68 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Financing Receivable, Allowance for Credit Loss [Line Items]      
    Beginning balance $ (1,263,824) $ (868,418) $ (1,982,897)
    Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets (912,710) (645,612) (322,717)
    Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets 446,955 570,959 1,342,038
    Write-off of cumulative allowance 21,721 2,964 95,158
    Write off of credit loss allowance   25,174  
    Current period provision for credit losses, net 12,913 (156,186)  
    Ending balance $ (1,694,945) (1,263,824) (868,418)
    Writeoff related to financial royalty asset   90,200  
    Cumulative Effect, Period of Adoption, Adjustment      
    Financing Receivable, Allowance for Credit Loss [Line Items]      
    Beginning balance   $ (192,705)  
    Ending balance     $ (192,705)
    XML 69 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Finite-Lived Intangible Assets [Line Items]    
    Cost $ 606,216 $ 606,216
    Accumulated Amortization 600,546 577,550
    Net Carrying Value 5,670 28,666
    DPP-IV patents    
    Finite-Lived Intangible Assets [Line Items]    
    Cost 606,216 606,216
    Accumulated Amortization 600,546 577,550
    Net Carrying Value $ 5,670 $ 28,666
    XML 70 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Intangible Royalty Assets, Net - Narrative (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Revenue Benchmark | Individual Licensees Concentration List | Revenue from intangible royalty assets      
    Finite-Lived Intangible Assets [Line Items]      
    Individual licensees exceeding 10% or more of revenue (as a percent) 86.00% 97.00% 91.00%
    DPP-IV patents      
    Finite-Lived Intangible Assets [Line Items]      
    Finite lived intangible assets, useful life 1 year    
    Projected amortization expense, 2022 $ 5.7    
    XML 71 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Non-Consolidated Affiliates (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Jul. 31, 2021
    Feb. 11, 2020
    May 31, 2018
    Mar. 31, 2017
    Schedule of Equity Method Investments [Line Items]              
    Investments in non-consolidated affiliates $ 435,394 $ 454,936          
    Equity in income (loss) of non-consolidated affiliates (19,490) 44,459 $ (32,517)        
    Distributions from non-consolidated affiliates 523 15,084 0        
    Distributions from non-consolidated affiliates 34,384 42,334 14,059        
    Avillion II | Merck Asset - Phase II Clinical Trial              
    Schedule of Equity Method Investments [Line Items]              
    Other commitment       $ 122,500   $ 105,000 $ 19,000
    Other commitments, percentage of costs (as a percent)             50.00%
    Avillion II | AZ Asset - Phase II and Phase III Clinical Trial              
    Schedule of Equity Method Investments [Line Items]              
    Other commitments, percentage of costs (as a percent)           44.00%  
    Equity Method Investment, Nonconsolidated Investee or Group of Investees | Legacy Investors Partnerships              
    Schedule of Equity Method Investments [Line Items]              
    Investments in non-consolidated affiliates         $ 303,700    
    Equity in income (loss) of non-consolidated affiliates 8,900 62,000          
    Distributions from non-consolidated affiliates 21,000 22,700          
    Equity Method Investment, Nonconsolidated Investee or Group of Investees | Avillion Entities              
    Schedule of Equity Method Investments [Line Items]              
    Equity in income (loss) of non-consolidated affiliates (28,400) (17,600) (32,500)        
    Equity method investment, unfunded commitments (11,200) 28,600          
    Equity Method Investment, Nonconsolidated Investee or Group of Investees | Avillion I              
    Schedule of Equity Method Investments [Line Items]              
    Distributions from non-consolidated affiliates $ 13,400 13,400 $ 14,100        
    Equity Method Investment, Nonconsolidated Investee or Group of Investees | Avillion II              
    Schedule of Equity Method Investments [Line Items]              
    Distributions from non-consolidated affiliates   $ 21,300          
    XML 72 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Research & Development ("R&D") Funding Expense (Details) - USD ($)
    $ in Thousands
    		 1 Months Ended 12 Months Ended
    Nov. 30, 2021
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Research and Development Arrangement, Contract to Perform for Others [Line Items]        
    Research and development funding expense   $ 200,084 $ 26,289 $ 83,036
    Upfront payment and premium paid   193,200    
    MorphoSys        
    Research and Development Arrangement, Contract to Perform for Others [Line Items]        
    Research and development funding expense   90,000    
    MorphoSys | BioCryst Pharmaceuticals, Inc.        
    Research and Development Arrangement, Contract to Perform for Others [Line Items]        
    Research and development funding expense $ 103,200      
    Funding Agreements With Sanofi        
    Research and Development Arrangement, Contract to Perform for Others [Line Items]        
    Research and development funding expense   6,900 20,500 18,200
    Remaining commitment for R&D funding agreement   $ 10,700    
    Funding Agreement With BioCryst        
    Research and Development Arrangement, Contract to Perform for Others [Line Items]        
    Research and development funding expense     $ 5,800  
    Funding Agreements With Pfizer        
    Research and Development Arrangement, Contract to Perform for Others [Line Items]        
    Research and development funding expense       $ 62,800
    XML 73 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Borrowings - Schedule of Borrowings (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Debt Instrument [Line Items]    
    Unamortized debt discount and issuance costs $ (203,930,000) $ (183,416,000)
    Total debt carrying value 7,096,070,000 5,816,584,000
    Less: Current portion of long-term debt 0 0
    Total long-term debt 7,096,070,000 5,816,584,000
    Unsecured Debt | Point Seven Five Percent Senior Notes Due 2023    
    Debt Instrument [Line Items]    
    Debt issued, amount $ 1,000,000,000 1,000,000,000
    Debt instrument, stated rate (as a percent) 0.75%  
    Debt issued as a percent of par value (as a percent) 99.322%  
    Unsecured Debt | One Point Two Zero Percent Senior Notes Due 2025    
    Debt Instrument [Line Items]    
    Debt issued, amount $ 1,000,000,000 1,000,000,000
    Debt instrument, stated rate (as a percent) 1.20%  
    Debt issued as a percent of par value (as a percent) 98.875%  
    Unsecured Debt | One Point Seven Five Percent Senior Notes Due 2027    
    Debt Instrument [Line Items]    
    Debt issued, amount $ 1,000,000,000 1,000,000,000
    Debt instrument, stated rate (as a percent) 1.75%  
    Debt issued as a percent of par value (as a percent) 98.284%  
    Unsecured Debt | Two Point Two Zero Percent Senior Notes Due 2030    
    Debt Instrument [Line Items]    
    Debt issued, amount $ 1,000,000,000 1,000,000,000
    Debt instrument, stated rate (as a percent) 2.20%  
    Debt issued as a percent of par value (as a percent) 97.76%  
    Unsecured Debt | Two Point One Five percent Senior Notes Due 2031    
    Debt Instrument [Line Items]    
    Debt issued, amount $ 600,000,000 0
    Debt instrument, stated rate (as a percent) 2.15%  
    Debt issued as a percent of par value (as a percent) 98.263%  
    Unsecured Debt | Three Point Three Zero Percent Senior Notes Due 2040    
    Debt Instrument [Line Items]    
    Debt issued, amount $ 1,000,000,000 1,000,000,000
    Debt instrument, stated rate (as a percent) 3.30%  
    Debt issued as a percent of par value (as a percent) 95.556%  
    Unsecured Debt | Three Point Five Five Percent Senior Notes Due 2050    
    Debt Instrument [Line Items]    
    Debt issued, amount $ 1,000,000,000 1,000,000,000
    Debt instrument, stated rate (as a percent) 3.55%  
    Debt issued as a percent of par value (as a percent) 95.306%  
    Unsecured Debt | Three Point Three Five Percent Senior Notes Due 2051    
    Debt Instrument [Line Items]    
    Debt issued, amount $ 700,000,000 $ 0
    Debt instrument, stated rate (as a percent) 3.35%  
    Debt issued as a percent of par value (as a percent) 97.565%  
    XML 74 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Borrowings - Narrative (Details)
    		 12 Months Ended
    Sep. 18, 2020
    USD ($)
    Sep. 02, 2020
    USD ($)
    Dec. 31, 2021
    USD ($)
    Dec. 31, 2020
    USD ($)
    Dec. 31, 2019
    USD ($)
    Jul. 26, 2021
    USD ($)
    Feb. 11, 2020
    USD ($)
    Debt Instrument [Line Items]              
    Unamortized discount and loan issuance costs on long-term debt     $ 203,930,000 $ 183,416,000      
    Loss on extinguishment of debt     $ 358,000 30,272,000 $ 0    
    Senior Notes              
    Debt Instrument [Line Items]              
    Debt issued, amount           $ 1,300,000,000  
    Unamortized discount and loan issuance costs on long-term debt           27,500,000  
    Senior Notes | Senior Notes Due 2031              
    Debt Instrument [Line Items]              
    Debt issued, amount           600,000,000  
    Senior Notes | Senior Notes Due 2051              
    Debt Instrument [Line Items]              
    Debt issued, amount           700,000,000  
    Debt issuance costs           $ 12,300,000  
    Weighted average coupon rate (as a percent)     2.80%        
    Weighted average effective interest rate (as a percent)     3.06%        
    Unsecured Debt | The Notes              
    Debt Instrument [Line Items]              
    Debt issued, amount   $ 6,000,000,000          
    Debt issuance costs   $ 40,400,000          
    Weighted average coupon rate (as a percent)     2.125%        
    Weighted average effective interest rate (as a percent)     2.50%        
    Loss on extinguishment of debt       (5,400,000)      
    Unsecured Debt | The Notes | Level 2              
    Debt Instrument [Line Items]              
    Fair value of outstanding Notes     $ 7,200,000,000 6,200,000,000      
    Unsecured Debt | The Notes | Prior to the applicable par call date              
    Debt Instrument [Line Items]              
    Redemption price (as a percent)   100.00%          
    Unsecured Debt | The Notes | Upon occurrence of a change of control triggering event              
    Debt Instrument [Line Items]              
    Redemption price (as a percent)   101.00%          
    Unsecured Debt | Senior Unsecured Revolving Credit Facility | Revolving Credit Facility              
    Debt Instrument [Line Items]              
    Debt instrument, term 5 years            
    Line of credit, maximum borrowing capacity $ 1,500,000,000            
    Maximum consolidated leverage ratio 4.00            
    Maximum consolidated leverage ratio following qualifying material acquisition 4.50            
    Minimum consolidated coverage ratio 2.50            
    Unsecured Debt | Senior Unsecured Revolving Credit Facility | Federal Funds Rate | Revolving Credit Facility              
    Debt Instrument [Line Items]              
    Basis spread on variable rate (percentage) 0.50%            
    Unsecured Debt | Senior Unsecured Revolving Credit Facility | Overnight Bank Funding Rate | Revolving Credit Facility              
    Debt Instrument [Line Items]              
    Basis spread on variable rate (percentage) 0.50%            
    Unsecured Debt | Senior Unsecured Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility              
    Debt Instrument [Line Items]              
    Basis spread on variable rate (percentage) 1.00%            
    Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1              
    Debt Instrument [Line Items]              
    Debt issued, amount             $ 3,200,000,000
    Loss on extinguishment of debt       $ 25,100,000      
    Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1              
    Debt Instrument [Line Items]              
    Debt issued, amount             2,840,000,000
    Senior Secured Debt | RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 | RPI Intermediate FT              
    Debt Instrument [Line Items]              
    Debt issued, amount   $ 149,000,000         $ 6,000,000,000
    XML 75 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Borrowings - Schedule of Repayments of Debt by Year (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Debt Instrument [Line Items]    
    Unamortized discount and loan issuance costs on long-term debt $ 203,930 $ 183,416
    Unsecured Debt | The Notes    
    Debt Instrument [Line Items]    
    2022 0  
    2023 1,000,000  
    2024 0  
    2025 1,000,000  
    2026 0  
    Thereafter 5,300,000  
    Long-term debt, gross $ 7,300,000  
    XML 76 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Shareholders' Equity - Narrative (Details)
    		 3 Months Ended 6 Months Ended 12 Months Ended
    Dec. 31, 2021
    USD ($)
    noncontrolling_interest
    class
    $ / shares
    shares
    Sep. 30, 2021
    $ / shares
    Jun. 30, 2021
    $ / shares
    Mar. 31, 2021
    $ / shares
    Jun. 17, 2020
    USD ($)
    Dec. 31, 2021
    USD ($)
    noncontrolling_interest
    class
    £ / shares
    shares
    Dec. 31, 2021
    USD ($)
    noncontrolling_interest
    class
    $ / shares
    shares
    Dec. 31, 2020
    USD ($)
    $ / shares
    shares
    Jun. 15, 2020
    shares
    Dec. 31, 2019
    shares
    Dec. 31, 2018
    shares
    Class of Stock [Line Items]                      
    Number of classes of voting shares | class 2         2 2        
    Number of noncontrolling interests | noncontrolling_interest 4         4 4        
    Dividends paid (in dollars per share) | $ / shares $ 0.17 $ 0.17 $ 0.17 $ 0.17     $ 0.68 $ 0.30      
    Dividends declared and paid | $             $ (285,200,000)        
    Requisite service period             1 year        
    Share based compensation | $         $ 0   $ 3,100,000 $ 5,700,000      
    Restricted Stock Units (RSUs)                      
    Class of Stock [Line Items]                      
    Unrecognized share based compensation expense | $ $ 1,000,000         $ 1,000,000 $ 1,000,000        
    Unrecognized share based compensation expense, period of recognition             6 months        
    Deferred Shares                      
    Class of Stock [Line Items]                      
    Shares, outstanding (in shares) 361,170,000         361,170,000 361,170,000 316,407,000   0 0
    Common Class A                      
    Class of Stock [Line Items]                      
    Common shares outstanding 432,963,000         432,963,000 432,963,000 388,135,000      
    Common Class A | 2020 Equity Incentive Plan                      
    Class of Stock [Line Items]                      
    Number of shares authorized under plan (in shares)                 800,000    
    Shares reserved for future issuance (in shares) 620,000         620,000 620,000        
    Common Class B                      
    Class of Stock [Line Items]                      
    Common shares outstanding 174,213,000         174,213,000 174,213,000 218,976,000      
    Class R Redeemable Stock                      
    Class of Stock [Line Items]                      
    Common shares outstanding 50,000         50,000 50,000 50,000      
    Shares, outstanding (in shares) 50,000         50,000 50,000        
    Redeemable stock, redemption price (in euros per share) | £ / shares           $ 1          
    XML 77 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Shareholders' Equity - Summary of Noncontrolling Interests (Details) - USD ($)
    $ in Thousands
    		 3 Months Ended 6 Months Ended 12 Months Ended
    Sep. 30, 2020
    Dec. 31, 2020
    Jun. 17, 2020
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]            
    Beginning balance     $ 6,141,438 $ 9,895,815 $ 6,141,438 $ 4,552,079
    Contributions       48,539 1,482,322  
    Transfer of interests         0  
    Distributions       (614,973) (1,105,765) (880,142)
    Net income (loss)   $ 1,077,069 624,885 1,241,201 1,701,954 2,461,419
    Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity         (1)  
    Issuance of Class A ordinary shares sold in IPO, net of offering costs         1,908,744  
    Other exchanges       0 191  
    Unrealized gains on available for sale debt securities       11,600 83,120 6,159
    Reclassification of unrealized losses on available for sale debt securities       (50,896) (20,551) 0
    Ending balance   9,895,815   10,248,545 9,895,815 6,141,438
    Non-Controlling Interest            
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]            
    Beginning balance     35,883 5,077,036 35,883 63,865
    Contributions       48,539 1,174,676  
    Transfer of interests         1,037,161  
    Distributions       (614,973) (792,357) (140,866)
    Net income (loss) $ 581,871 581,871 145,043 621,473   112,884
    Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity         2,433,098  
    Issuance of Class A ordinary shares sold in IPO, net of offering costs         758,354  
    Other exchanges       (642,974) (309,566)  
    Unrealized gains on available for sale debt securities       5,265 22,503  
    Reclassification of unrealized losses on available for sale debt securities       (22,415) (9,630)  
    Ending balance   $ 5,077,036   $ 4,471,951 $ 5,077,036 35,883
    Non-Controlling Interest | RP Holdings            
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]            
    Noncontrolling interest (percentage)   64.00%   71.00% 64.00%  
    Non-Controlling Interest | RPSFT            
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]            
    Beginning balance     35,883 $ 12,436 $ 35,883  
    Contributions       0 0  
    Transfer of interests         0  
    Distributions       (56,490) (112,339)  
    Net income (loss) 46,741   42,151 57,582    
    Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity         0  
    Issuance of Class A ordinary shares sold in IPO, net of offering costs         0  
    Other exchanges       0 0  
    Unrealized gains on available for sale debt securities       0 0  
    Reclassification of unrealized losses on available for sale debt securities       0 0  
    Ending balance   $ 12,436   13,528 12,436 35,883
    Non-Controlling Interest | Legacy Investors Partnerships            
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]            
    Beginning balance     0 1,939,509 0  
    Contributions       35,148 1,165,258  
    Transfer of interests         1,037,161  
    Distributions       (425,050) (594,592)  
    Net income (loss) 218,137   102,892 266,570    
    Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity         (750)  
    Issuance of Class A ordinary shares sold in IPO, net of offering costs         0  
    Other exchanges       0 0  
    Unrealized gains on available for sale debt securities       2,038 15,015  
    Reclassification of unrealized losses on available for sale debt securities       (8,946) (3,612)  
    Ending balance   1,939,509   1,809,269 1,939,509 0
    Non-Controlling Interest | Continuing Investors Partnerships            
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]            
    Beginning balance     0 3,125,091 0  
    Contributions       13,391 9,418  
    Transfer of interests         0  
    Distributions       (133,433) (85,426)  
    Net income (loss) 316,993   0 297,321    
    Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity         2,433,848  
    Issuance of Class A ordinary shares sold in IPO, net of offering costs         758,354  
    Other exchanges       (642,974) (309,566)  
    Unrealized gains on available for sale debt securities       3,227 7,488  
    Reclassification of unrealized losses on available for sale debt securities       (13,469) (6,018)  
    Ending balance   $ 3,125,091   $ 2,649,154 $ 3,125,091 0
    Non-Controlling Interest | Continuing Investors Partnerships | RP Holdings            
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]            
    Noncontrolling interest (percentage)   36.00%   29.00% 36.00%  
    Non-Controlling Interest | EPA Holdings            
    Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]            
    Beginning balance     0 $ 0 $ 0  
    Contributions       0 0  
    Transfer of interests         0  
    Distributions       0 0  
    Net income (loss) $ 0   $ 0 0    
    Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity         0  
    Issuance of Class A ordinary shares sold in IPO, net of offering costs         0  
    Other exchanges       0 0  
    Unrealized gains on available for sale debt securities       0 0  
    Reclassification of unrealized losses on available for sale debt securities       0 0  
    Ending balance   $ 0   $ 0 $ 0 $ 0
    XML 78 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Earnings Per Share (Details)
    $ / shares in Units, shares in Thousands, $ in Thousands
    		 6 Months Ended 12 Months Ended
    Dec. 31, 2020
    USD ($)
    Jun. 17, 2020
    USD ($)
    Dec. 31, 2021
    USD ($)
    $ / shares
    shares
    Dec. 31, 2020
    USD ($)
    $ / shares
    shares
    Dec. 31, 2019
    USD ($)
    Earnings Per Share [Abstract]          
    Exchange ratio     1    
    Numerator          
    Net income (loss) $ 1,077,069 $ 624,885 $ 1,241,201 $ 1,701,954 $ 2,461,419
    Less: net income attributable to Continuing Investors Partnerships prior to the IPO       479,842  
    Less: net income attributable to non-controlling interest     621,473 726,914 $ 112,884
    Net income attributable to Royalty Pharma plc - basic and diluted     619,728 495,198  
    Net income attributable to Royalty Pharma plc - basic and diluted     $ 619,728 $ 495,198  
    Denominator          
    Weighted average Class A ordinary shares outstanding - basic (in shares) | shares [1]     414,794 375,444  
    Unvested RSUs (in shares) | shares     8 11  
    Weighted average Class A ordinary shares outstanding - diluted (in shares) | shares [1]     414,802 375,455  
    Earnings per Class A ordinary share - basic (in dollars per share) | $ / shares [1]     $ 1.49 $ 1.32  
    Earnings per Class A ordinary share - diluted (in dollars per share) | $ / shares [1]     $ 1.49 $ 1.32  
    Common Class A          
    Denominator          
    Weighted average Class A ordinary shares outstanding - diluted (in shares) | shares     607,176 607,111  
    Class B Holders          
    Numerator          
    Less: net income attributable to non-controlling interest     $ 297,321 $ 316,993  
    Legacy Investors Partnerships and RPSFT          
    Numerator          
    Less: net income attributable to non-controlling interest     $ 324,152 $ 409,921  
    [1] Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (“IPO”) in the year ended December 31, 2020. See Note 13–Earnings per Share.
    XML 79 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Indirect Cash Flow (Details) - USD ($)
    $ in Thousands
    		 6 Months Ended 12 Months Ended
    Dec. 31, 2020
    Jun. 17, 2020
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Supplemental Cash Flow Elements [Abstract]          
    Net income (loss) $ 1,077,069 $ 624,885 $ 1,241,201 $ 1,701,954 $ 2,461,419
    Adjustments to reconcile consolidated net income to net cash provided by operating activities:          
    Income from financial royalty assets     (2,065,083) (1,959,975) (1,648,837)
    Provision for changes in expected cash flows from financial royalty assets     452,842 230,839 (1,019,321)
    Amortization of intangible assets     22,996 23,058 23,924
    Amortization of debt discount and issuance costs     20,162 11,715 12,790
    Losses on derivative financial instruments     21,532 42,076 39,138
    Losses/(gains) on equity securities     48,066 (247,073) (155,749)
    Equity in losses/(earnings) of non-consolidated affiliates     19,490 (44,459) 32,517
    Distributions from non-consolidated affiliates     34,384 42,334 14,059
    Loss on extinguishment of debt     358 30,272 0
    Share-based compensation     2,443 5,428 0
    Interest income accretion     (50,896) (20,551) 0
    Unrealized gains on available for sale debt securities     (17,859) (18,600) 0
    Impairment charge     0 65,053 0
    Termination of derivative financial instruments     (16,093) (34,952) 0
    Other     4,461 9,621 (2,122)
    Decrease/(increase) in operating assets:          
    Cash collected on financial royalty assets     2,315,854 2,121,923 1,934,092
    Available for sale debt securities     0 0 (150,000)
    Accrued royalty receivable     (20,131) 370 2,471
    Other receivables     0 0 150,000
    Other royalty income receivable     (9,012) (770) 7,390
    Other current assets and other assets     1,857 34,986 (41,028)
    (Decrease)/increase in operating liabilities:          
    Accounts payable and accrued expenses     (4,586) (766) 6,496
    Interest payable     15,550 42,146 0
    Net cash provided by operating activities     2,017,536 2,034,629 1,667,239
    Supplemental Schedule of Non-cash Investing/Financing Activities:          
    Receipt of contribution of investments in Legacy Investors Partnerships     0 303,679 0
    Settlement of Epizyme forward purchase contract     0 5,700 0
    Accrued purchase obligation - Tazverik     0 110,000 0
    Repayments of long-term debt by contributions from non-controlling interest     0 1,103,774 0
    Milestone payable - Erleada     $ 0 $ 18,600 $ 0
    XML 80 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Accumulated Other Comprehensive Income (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Beginning balance $ 9,895,815 $ 6,141,438 $ 4,552,079
    Reclassification to net income (28,481) (6,855)  
    Activity for the year 6,335 60,617  
    Reclassification from non-controlling interest   2,562  
    Ending balance 10,248,545 9,895,815 6,141,438
    Investment income 53,535 28,379 22,329
    Unrealized gain/(loss) on available for sale debt securities, including noncontrolling interest | Reclassification out of Accumulated Other Comprehensive Income      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Investment income 50,900    
    Interest income   20,600  
    Unrealized Gains on Available for Sale Debt Securities      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Beginning balance 34,395 6,159  
    Reclassification to net income (28,481) (10,921)  
    Activity for the year 6,335 60,617  
    Reclassification to non-controlling interest   (24,022)  
    Reclassification from non-controlling interest 4,242 2,562  
    Ending balance 16,491 34,395 6,159
    Unrealized Gains on Available for Sale Debt Securities | Reclassification out of Accumulated Other Comprehensive Income      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Investment income 28,500    
    Interest income   10,900  
    Unrealized gain/(loss) on available for sale debt securities, noncontrolling interest | Reclassification out of Accumulated Other Comprehensive Income      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Investment income 22,400    
    Interest income   9,600  
    Unrealized Losses on Interest Rate Swaps      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Beginning balance 0 (4,066)  
    Reclassification to net income 0 4,066  
    Activity for the year 0 0  
    Reclassification to non-controlling interest   0  
    Reclassification from non-controlling interest 0 0  
    Ending balance 0 0 (4,066)
    Total Accumulated Other Comprehensive Income      
    AOCI Attributable to Parent, Net of Tax [Roll Forward]      
    Beginning balance 34,395 2,093  
    Reclassification to non-controlling interest   (24,022)  
    Reclassification from non-controlling interest 4,242    
    Ending balance $ 16,491 $ 34,395 $ 2,093
    XML 81 R66.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Related Party Transactions (Details) - USD ($)
    		 12 Months Ended
    Apr. 16, 2021
    Dec. 08, 2017
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Mar. 31, 2020
    Related Party Transaction [Line Items]            
    Total distribution payable to non-controlling interest     $ 107,934,000 $ 126,366,000    
    Investments in non-consolidated affiliates     435,394,000 454,936,000    
    Financial royalty asset, net     14,332,596,000 12,955,277,000    
    Treasury interests         $ 4,266,000  
    Treasury Stock            
    Related Party Transaction [Line Items]            
    Treasury interests         4,266,000  
    Agreement with MSCI            
    Related Party Transaction [Line Items]            
    Initial term 7 years          
    Amounts due from related parties     $ 0      
    The Manager | Operating and Personnel Payments            
    Related Party Transaction [Line Items]            
    Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)     6.50%      
    Quarterly payments to affiliates, percent of security investment (as a percent)     0.25%      
    Amount calculated for operating and personal payment     $ 1,000,000      
    Percent for calculating operating and personal payment     0.3125%      
    The Manager | Former Operating and Personnel Payments            
    Related Party Transaction [Line Items]            
    Increase in quarterly installment payments (as a percent)     5.00%      
    Operating and personnel payments incurred     $ 145,200,000 112,500,000 $ 60,000,000  
    Affiliated Entity | Royalty Distribution Payable to Legacy Investors Partnerships            
    Related Party Transaction [Line Items]            
    Total distribution payable to non-controlling interest     92,608,000 100,047,000    
    Affiliated Entity | Royalty Distribution Payable to RP Select Finance Trust            
    Related Party Transaction [Line Items]            
    Total distribution payable to non-controlling interest     15,326,000 26,319,000    
    Affiliated Entity | Assignment Agreement - Benefit of Payment Stream | Bristol-Myers Squibb            
    Related Party Transaction [Line Items]            
    Related party, rate (as a percent)   50.00%        
    Affiliated Entity | Assignment Agreement - Funding Obligations | Bristol-Myers Squibb            
    Related Party Transaction [Line Items]            
    Related party, rate (as a percent)   50.00%        
    Cumulative funding amount           $ 162,400,000
    Financial royalty asset, net     $ 130,900,000 150,600,000    
    Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate            
    Related Party Transaction [Line Items]            
    Number of limited partnership interest acquired (in shares)     27,210      
    Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate | Treasury Stock            
    Related Party Transaction [Line Items]            
    Treasury interests     $ (4,300,000)      
    Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate | Non-Controlling Interest            
    Related Party Transaction [Line Items]            
    Treasury interests     $ (1,600,000) (1,900,000)    
    Pablo Legorreta | Purchasing And Donating Ventilators            
    Related Party Transaction [Line Items]            
    Amount paid to CEO       $ 1,000,000    
    XML 82 R67.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Commitments and Contingencies (Details) - USD ($)
    		 1 Months Ended 12 Months Ended
    Nov. 04, 2021
    Jun. 02, 2021
    Aug. 07, 2020
    Nov. 30, 2020
    Jan. 31, 2020
    Nov. 30, 2019
    Dec. 31, 2021
    MorphoSys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement              
    Long-term Purchase Commitment [Line Items]              
    Maximum milestone payment   $ 150,000,000          
    Payment of capital   $ 350,000,000          
    Payment of capital term   1 year          
    Expected return (as a percent)   220.00%          
    Maximum commitment to fund collaborative arrangement   $ 150,000,000         $ 150,000,000
    Period of return   9 years          
    Period of return start date   2 years          
    Funding Agreement With Biohaven Pharmaceuticals              
    Long-term Purchase Commitment [Line Items]              
    Purchase commitment, purchase of committed, non-contingent Commercial Launch Preferred Equity payable     $ 200,000,000        
    Remaining commitment             $ 129,600,000
    Purchase Of Eisai Royalties              
    Long-term Purchase Commitment [Line Items]              
    Payment for purchase of royalties           $ 330,000,000  
    Purchase commitment, upfront payment         $ 110,000,000    
    Purchase commitment, additional payments $ 110,000,000     $ 110,000,000 $ 220,000,000    
    XML 83 R68.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Subsequent Events (Details) - Subsequent Event
    $ in Millions
    		 1 Months Ended
    Jan. 31, 2022
    USD ($)
    tranche
    payment
    Subsequent Event [Line Items]  
    Payments to acquire royalty interests $ 150.0
    Payments to acquire royalty interests, upfront payment $ 50.0
    Payments to acquire royalty interests, number of additional payments | payment 2
    Payments to acquire royalty interests, additional milestone payments $ 50.0
    Long term funding partnership, amount $ 300.0
    Long term funding partnership, number of tranches | tranche 5
    Long term funding partnership, initial payment $ 50.0
    Long term funding partnership, number of additional payments | tranche 4
    Long term funding partnership, additional payments, aggregate amount $ 250.0
    XML 84 R9999.htm IDEA: XBRL DOCUMENT v3.22.0.1
    Label Element Value
    Retained Earnings [Member]  
    Net Income (Loss), Including Portion Attributable to Noncontrolling Interest us-gaap_ProfitLoss $ 479,842,000
    Net Income (Loss), Including Portion Attributable to Noncontrolling Interest us-gaap_ProfitLoss $ 495,198,000
    XML 85 rprx-20211231_htm.xml IDEA: XBRL DOCUMENT 0001802768 2021-01-01 2021-12-31 0001802768 2021-06-30 0001802768 us-gaap:CommonClassAMember 2022-02-11 0001802768 us-gaap:CommonClassBMember 2022-02-11 0001802768 rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember 2021-12-31 0001802768 2021-12-31 0001802768 2020-12-31 0001802768 us-gaap:CommonClassAMember 2020-12-31 0001802768 us-gaap:CommonClassAMember 2021-12-31 0001802768 us-gaap:CommonClassBMember 2020-12-31 0001802768 us-gaap:CommonClassBMember 2021-12-31 0001802768 rprx:ClassRRedeemableStockMember 2020-12-31 0001802768 rprx:ClassRRedeemableStockMember 2021-12-31 0001802768 rprx:FinancialRoyaltyAssetsMember 2021-01-01 2021-12-31 0001802768 rprx:FinancialRoyaltyAssetsMember 2020-01-01 2020-12-31 0001802768 rprx:FinancialRoyaltyAssetsMember 2019-01-01 2019-12-31 0001802768 rprx:IntangibleRoyaltyAssetsMember 2021-01-01 2021-12-31 0001802768 rprx:IntangibleRoyaltyAssetsMember 2020-01-01 2020-12-31 0001802768 rprx:IntangibleRoyaltyAssetsMember 2019-01-01 2019-12-31 0001802768 rprx:RoyaltyIncomeOtherMember 2021-01-01 2021-12-31 0001802768 rprx:RoyaltyIncomeOtherMember 2020-01-01 2020-12-31 0001802768 rprx:RoyaltyIncomeOtherMember 2019-01-01 2019-12-31 0001802768 2020-01-01 2020-12-31 0001802768 2019-01-01 2019-12-31 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2018-12-31 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2018-12-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2018-12-31 0001802768 rprx:DeferredSharesMember 2018-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001802768 rprx:UnitHoldersAndShareholdersContributionsMember 2018-12-31 0001802768 us-gaap:RetainedEarningsMember 2018-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2018-12-31 0001802768 us-gaap:TreasuryStockMember 2018-12-31 0001802768 2018-12-31 0001802768 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-12-31 0001802768 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2019-12-31 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2019-12-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2019-12-31 0001802768 rprx:DeferredSharesMember 2019-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001802768 rprx:UnitHoldersAndShareholdersContributionsMember 2019-12-31 0001802768 us-gaap:RetainedEarningsMember 2019-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2019-12-31 0001802768 us-gaap:TreasuryStockMember 2019-12-31 0001802768 2019-12-31 0001802768 rprx:UnitHoldersAndShareholdersContributionsMember 2020-01-01 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001802768 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0001802768 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001802768 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001802768 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-17 0001802768 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-06-17 0001802768 2020-01-01 2020-06-17 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001802768 rprx:DeferredSharesMember 2020-01-01 2020-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-12-31 0001802768 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0001802768 us-gaap:RetainedEarningsMember 2020-06-18 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2020-06-18 2020-12-31 0001802768 2020-06-18 2020-12-31 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-12-31 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2020-12-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2020-12-31 0001802768 rprx:DeferredSharesMember 2020-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001802768 rprx:UnitHoldersAndShareholdersContributionsMember 2020-12-31 0001802768 us-gaap:RetainedEarningsMember 2020-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2020-12-31 0001802768 us-gaap:TreasuryStockMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001802768 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001802768 rprx:DeferredSharesMember 2021-01-01 2021-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-12-31 0001802768 us-gaap:TreasuryStockMember 2021-01-01 2021-12-31 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2021-12-31 0001802768 rprx:DeferredSharesMember 2021-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001802768 rprx:UnitHoldersAndShareholdersContributionsMember 2021-12-31 0001802768 us-gaap:RetainedEarningsMember 2021-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2021-12-31 0001802768 us-gaap:TreasuryStockMember 2021-12-31 0001802768 rprx:ExchangeOfferTransactionMember rprx:LegacyInvestorsPartnershipsMember 2020-02-11 2020-02-11 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember rprx:ExchangeOfferTransactionMember 2020-02-11 0001802768 rprx:RoyaltyPharmaCollectionTrustMember 2020-02-11 0001802768 rprx:RoyaltyPharmaCollectionTrustMember rprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember 2020-02-11 0001802768 rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member us-gaap:SecuredDebtMember rprx:LegacyInvestorsPartnershipsMember 2020-02-11 0001802768 rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member us-gaap:SecuredDebtMember rprx:RPI2019IntermediateFinanceMember 2020-02-11 0001802768 rprx:OldCreditFacilityMember us-gaap:SecuredDebtMember 2020-02-11 2020-02-11 0001802768 rprx:RPIFTSeniorSecuredCreditFacilitiesMember us-gaap:SecuredDebtMember rprx:RPI2019IntermediateFinanceMember 2020-02-11 2020-02-11 0001802768 us-gaap:CommonClassAMember us-gaap:IPOMember 2020-06-18 2020-06-18 0001802768 us-gaap:CommonClassAMember us-gaap:IPOMember 2020-06-18 0001802768 us-gaap:CommonClassAMember rprx:IPOSharesFromCompanyMember 2020-06-18 2020-06-18 0001802768 us-gaap:CommonClassAMember rprx:IPOSharesFromSellingShareholdersMember 2020-06-18 2020-06-18 0001802768 us-gaap:CommonClassAMember 2020-06-18 2020-06-18 0001802768 us-gaap:CommonClassBMember rprx:IPOContinuingInvestorsPartnershipsMember 2020-06-01 2020-06-30 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember rprx:LegacyInvestorsPartnershipsMember 2020-02-29 0001802768 2020-06-30 0001802768 rprx:RPHoldingsMember us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2021-12-31 0001802768 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2019-12-31 0001802768 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2019-01-01 2019-12-31 0001802768 rprx:VertexMember us-gaap:FinanceReceivablesMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001802768 rprx:VertexMember us-gaap:FinanceReceivablesMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2019-04-05 2019-04-05 0001802768 us-gaap:SeriesAPreferredStockMember 2019-04-05 2019-04-05 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-08-07 2020-08-07 0001802768 us-gaap:SeriesBPreferredStockMember 2020-08-07 2020-08-07 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-12-31 0001802768 rprx:MorphoSysMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-06-02 2021-06-02 0001802768 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001802768 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001802768 us-gaap:ForwardContractsMember 2021-12-31 0001802768 rprx:DevelopmentFundingBondForwardMember 2021-12-31 0001802768 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001802768 us-gaap:ForwardContractsMember 2020-12-31 0001802768 srt:MaximumMember us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember 2019-04-05 2019-04-05 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember 2019-04-05 2019-04-05 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember 2020-08-07 2020-08-07 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember 2020-08-07 2020-08-07 0001802768 rprx:TreasuryRateLockContractsMember 2021-07-01 2021-07-31 0001802768 us-gaap:InterestRateSwapMember 2020-01-01 2020-12-31 0001802768 us-gaap:InterestRateSwapMember 2019-01-01 2019-12-31 0001802768 rprx:EpizymeIncMember 2019-11-30 0001802768 rprx:EpizymeIncMember 2019-11-01 2019-11-30 0001802768 rprx:EpizymeCommonStockWarrantMember 2019-11-30 0001802768 rprx:EpizymeIncMember rprx:EpizymeCommonStockWarrantMember 2019-11-30 0001802768 rprx:EpizymeIncMember us-gaap:PutOptionMember 2019-11-01 2019-11-30 0001802768 rprx:EpizymeIncMember us-gaap:PutOptionMember 2019-11-30 0001802768 rprx:EpizymeIncMember us-gaap:ForwardContractsMember 2019-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateSwapMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:InterestRateSwapMember 2021-12-31 0001802768 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001802768 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001802768 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:GainLossOnDerivativeInstrumentsMember 2021-01-01 2021-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:GainLossOnDerivativeInstrumentsMember 2020-01-01 2020-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:GainLossOnDerivativeInstrumentsMember 2019-01-01 2019-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2021-01-01 2021-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2020-01-01 2020-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2019-01-01 2019-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0001802768 us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0001802768 us-gaap:WarrantMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2021-01-01 2021-12-31 0001802768 us-gaap:WarrantMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2020-01-01 2020-12-31 0001802768 us-gaap:WarrantMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2019-01-01 2019-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2021-01-01 2021-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2020-01-01 2020-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember us-gaap:GainLossOnDerivativeInstrumentsMember 2019-01-01 2019-12-31 0001802768 rprx:TreasuryRateLockContractsMember us-gaap:GainLossOnDerivativeInstrumentsMember 2021-01-01 2021-12-31 0001802768 rprx:TreasuryRateLockContractsMember us-gaap:GainLossOnDerivativeInstrumentsMember 2020-01-01 2020-12-31 0001802768 rprx:TreasuryRateLockContractsMember us-gaap:GainLossOnDerivativeInstrumentsMember 2019-01-01 2019-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2021-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2020-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2021-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2020-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2020-12-31 0001802768 rprx:MorphoSysMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-01-01 2021-12-31 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-12-31 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-12-31 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-12-31 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-12-31 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001802768 us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-12-31 0001802768 us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-12-31 0001802768 us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-12-31 0001802768 us-gaap:AvailableforsaleSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-01-01 2021-12-31 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-12-31 0001802768 rprx:BioCrystPharmaceuticalsIncMember us-gaap:FairValueInputsLevel3Member 2021-11-01 2021-11-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001802768 srt:MaximumMember us-gaap:PreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember 2019-04-05 2019-04-05 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember 2021-01-01 2021-12-31 0001802768 rprx:CysticFibrosisFranchiseMember 2021-12-31 0001802768 rprx:TysabriMember 2021-12-31 0001802768 rprx:ImbruvicaMember 2021-12-31 0001802768 rprx:XtandiMember 2021-12-31 0001802768 rprx:TremfyaMember 2021-12-31 0001802768 rprx:EvrysdiMember 2021-12-31 0001802768 rprx:OtherFinancialRoyaltyAssetMember 2021-12-31 0001802768 rprx:CysticFibrosisFranchiseMember 2020-12-31 0001802768 rprx:TysabriMember 2020-12-31 0001802768 rprx:ImbruvicaMember 2020-12-31 0001802768 rprx:XtandiMember 2020-12-31 0001802768 rprx:PromactaMember 2020-12-31 0001802768 rprx:EvrysdiMember 2020-12-31 0001802768 rprx:OtherFinancialRoyaltyAssetMember 2020-12-31 0001802768 rprx:DPPIVPatentsMember 2021-12-31 0001802768 rprx:DPPIVPatentsMember 2020-12-31 0001802768 rprx:DPPIVPatentsMember 2021-01-01 2021-12-31 0001802768 rprx:IntangibleRoyaltyAssetsMember us-gaap:SalesRevenueNetMember rprx:IndividualLicenseesConcentrationRiskMember 2021-01-01 2021-12-31 0001802768 rprx:IntangibleRoyaltyAssetsMember us-gaap:SalesRevenueNetMember rprx:IndividualLicenseesConcentrationRiskMember 2020-01-01 2020-12-31 0001802768 rprx:IntangibleRoyaltyAssetsMember us-gaap:SalesRevenueNetMember rprx:IndividualLicenseesConcentrationRiskMember 2019-01-01 2019-12-31 0001802768 rprx:LegacyInvestorsPartnershipsMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-02-11 0001802768 rprx:LegacyInvestorsPartnershipsMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-01-01 2021-12-31 0001802768 rprx:LegacyInvestorsPartnershipsMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-01-01 2020-12-31 0001802768 rprx:AvillionEntitiesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-01-01 2021-12-31 0001802768 rprx:AvillionEntitiesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-01-01 2020-12-31 0001802768 rprx:AvillionEntitiesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2019-01-01 2019-12-31 0001802768 rprx:AvillionIMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-01-01 2020-12-31 0001802768 rprx:AvillionIMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-01-01 2021-12-31 0001802768 rprx:AvillionIMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2019-01-01 2019-12-31 0001802768 rprx:AvillionIIMember rprx:MerckAssetPhaseIIClinicalTrialMember 2017-03-31 0001802768 rprx:AvillionIIMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-01-01 2020-12-31 0001802768 rprx:AvillionIIMember rprx:MerckAssetPhaseIIClinicalTrialMember 2021-07-31 0001802768 rprx:AvillionIIMember rprx:MerckAssetPhaseIIClinicalTrialMember 2018-05-31 0001802768 rprx:AvillionIIMember rprx:AZAssetPhaseIIAndPhaseIIIClinicalTrialMember 2018-05-31 0001802768 rprx:AvillionEntitiesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-12-31 0001802768 rprx:AvillionEntitiesMember us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-12-31 0001802768 rprx:FundingAgreementsWithSanofiMember 2021-01-01 2021-12-31 0001802768 rprx:MorphoSysMember 2021-01-01 2021-12-31 0001802768 rprx:MorphoSysMember rprx:BioCrystPharmaceuticalsIncMember 2021-11-01 2021-11-30 0001802768 rprx:FundingAgreementsWithSanofiMember 2020-01-01 2020-12-31 0001802768 rprx:FundingAgreementWithBioCrystMember 2020-01-01 2020-12-31 0001802768 rprx:FundingAgreementsWithSanofiMember 2019-01-01 2019-12-31 0001802768 rprx:FundingAgreementsWithPfizerMember 2019-01-01 2019-12-31 0001802768 rprx:FundingAgreementsWithSanofiMember 2021-12-31 0001802768 rprx:PointSevenFivePercentSeniorNotesDue2023Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:PointSevenFivePercentSeniorNotesDue2023Member us-gaap:UnsecuredDebtMember 2021-01-01 2021-12-31 0001802768 rprx:PointSevenFivePercentSeniorNotesDue2023Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2021-01-01 2021-12-31 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2021-01-01 2021-12-31 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2021-01-01 2021-12-31 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:TwoPointOneFivePercentSeniorNotesDue2031Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:TwoPointOneFivePercentSeniorNotesDue2031Member us-gaap:UnsecuredDebtMember 2021-01-01 2021-12-31 0001802768 rprx:TwoPointOneFivePercentSeniorNotesDue2031Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2021-01-01 2021-12-31 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2021-01-01 2021-12-31 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member us-gaap:UnsecuredDebtMember 2021-01-01 2021-12-31 0001802768 rprx:ThreePointThreeFivePercentSeniorNotesDue2051Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 us-gaap:SeniorNotesMember 2021-07-26 0001802768 rprx:SeniorNotesDue2031Member us-gaap:SeniorNotesMember 2021-07-26 0001802768 rprx:SeniorNotesDue2051Member us-gaap:SeniorNotesMember 2021-07-26 0001802768 rprx:SeniorNotesDue2051Member us-gaap:SeniorNotesMember 2021-12-31 0001802768 rprx:TheNotesMember us-gaap:UnsecuredDebtMember 2020-09-02 0001802768 rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member us-gaap:SecuredDebtMember rprx:RPI2019IntermediateFinanceMember 2020-09-02 0001802768 rprx:TheNotesMember us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:TheNotesMember us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:UnsecuredDebtMember 2020-09-02 2020-09-02 0001802768 rprx:TheNotesMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:UnsecuredDebtMember 2020-09-02 2020-09-02 0001802768 rprx:TheNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:TheNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:UnsecuredDebtMember 2020-12-31 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2020-09-18 2020-09-18 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2020-09-18 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember rprx:OvernightBankFundingRateMember 2020-09-18 2020-09-18 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember us-gaap:FederalFundsPurchasedMember 2020-09-18 2020-09-18 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-09-18 2020-09-18 0001802768 rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member us-gaap:SecuredDebtMember 2020-02-11 0001802768 rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member us-gaap:SecuredDebtMember 2020-02-11 0001802768 rprx:RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member us-gaap:SecuredDebtMember 2020-01-01 2020-12-31 0001802768 rprx:TheNotesMember us-gaap:UnsecuredDebtMember 2020-01-01 2020-12-31 0001802768 rprx:ClassRRedeemableStockMember 2021-01-01 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2019-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2019-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2019-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2019-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2020-01-01 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2020-01-01 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2020-01-01 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2020-01-01 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2020-01-01 2020-06-17 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2020-01-01 2020-06-17 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2020-01-01 2020-06-17 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2020-01-01 2020-06-17 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2020-06-18 2020-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2020-06-18 2020-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2020-06-18 2020-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2020-06-18 2020-09-30 0001802768 us-gaap:NoncontrollingInterestMember 2020-06-18 2020-09-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2020-12-31 0001802768 rprx:RPHoldingsMember us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2020-12-31 0001802768 rprx:RPHoldingsMember us-gaap:NoncontrollingInterestMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2021-01-01 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2021-01-01 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2021-01-01 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2021-01-01 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2021-12-31 0001802768 rprx:RPHoldingsMember us-gaap:NoncontrollingInterestMember 2021-12-31 0001802768 2021-01-01 2021-03-31 0001802768 2021-04-01 2021-06-30 0001802768 2021-10-01 2021-12-31 0001802768 2021-07-01 2021-09-30 0001802768 rprx:A2020EquityIncentivePlanMember us-gaap:CommonClassAMember 2020-06-15 0001802768 rprx:A2020EquityIncentivePlanMember us-gaap:CommonClassAMember 2021-12-31 0001802768 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001802768 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001802768 us-gaap:CommonClassAMember 2021-01-01 2021-12-31 0001802768 us-gaap:CommonClassAMember 2020-01-01 2020-12-31 0001802768 rprx:ClassBHoldersMember 2021-01-01 2021-12-31 0001802768 rprx:LegacyInvestorsPartnershipsAndRPSFTMember 2021-01-01 2021-12-31 0001802768 rprx:ClassBHoldersMember 2020-01-01 2020-12-31 0001802768 rprx:LegacyInvestorsPartnershipsAndRPSFTMember 2020-01-01 2020-12-31 0001802768 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0001802768 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-12-31 0001802768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001802768 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-12-31 0001802768 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-12-31 0001802768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001802768 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0001802768 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-12-31 0001802768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001802768 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-12-31 0001802768 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2021-01-01 2021-12-31 0001802768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001802768 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0001802768 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2021-12-31 0001802768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001802768 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-12-31 0001802768 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-12-31 0001802768 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember 2021-01-01 2021-12-31 0001802768 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-12-31 0001802768 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-12-31 0001802768 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember 2020-01-01 2020-12-31 0001802768 rprx:OperatingAndPersonnelPaymentsMember srt:ManagementMember 2021-12-31 0001802768 rprx:OperatingAndPersonnelPaymentsMember srt:ManagementMember 2021-01-01 2021-12-31 0001802768 rprx:FormerOperatingAndPersonnelPaymentsMember srt:ManagementMember 2021-01-01 2021-12-31 0001802768 rprx:FormerOperatingAndPersonnelPaymentsMember srt:ManagementMember 2020-01-01 2020-12-31 0001802768 rprx:FormerOperatingAndPersonnelPaymentsMember srt:ManagementMember 2019-01-01 2019-12-31 0001802768 rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember srt:AffiliatedEntityMember 2021-12-31 0001802768 rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember srt:AffiliatedEntityMember 2020-12-31 0001802768 rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember srt:AffiliatedEntityMember 2021-12-31 0001802768 rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember srt:AffiliatedEntityMember 2020-12-31 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementBenefitOfPaymentStreamMember srt:AffiliatedEntityMember 2017-12-08 2017-12-08 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementFundingObligationsMember srt:AffiliatedEntityMember 2017-12-08 2017-12-08 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementFundingObligationsMember srt:AffiliatedEntityMember 2020-03-31 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementFundingObligationsMember srt:AffiliatedEntityMember 2021-12-31 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementFundingObligationsMember srt:AffiliatedEntityMember 2020-12-31 0001802768 rprx:AgreementWithMSCIMember 2021-04-16 2021-04-16 0001802768 rprx:AgreementWithMSCIMember 2021-12-31 0001802768 rprx:PurchasingAndDonatingVentilatorsMember rprx:PabloLegorretaMember 2020-01-01 2020-12-31 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember srt:AffiliatedEntityMember 2021-01-01 2021-12-31 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember srt:AffiliatedEntityMember us-gaap:TreasuryStockMember 2021-01-01 2021-12-31 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember srt:AffiliatedEntityMember us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember srt:AffiliatedEntityMember us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001802768 rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember 2020-08-07 2020-08-07 0001802768 rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember 2019-11-01 2019-11-30 0001802768 rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember 2020-01-01 2020-01-31 0001802768 rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember 2020-11-01 2020-11-30 0001802768 rprx:LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember 2021-11-04 2021-11-04 0001802768 rprx:MorphoSysMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-06-02 0001802768 us-gaap:SubsequentEventMember 2022-01-01 2022-01-31 iso4217:USD shares iso4217:USD shares iso4217:GBP shares pure rprx:partnership rprx:segment rprx:class rprx:noncontrolling_interest rprx:payment rprx:tranche 0001802768 2021 FY false 129600000 http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member 2 2 2 1.80 1.80 1.80 2 1.80 2.20 10-K true 2021-12-31 --12-31 false 001-39329 Royalty Pharma plc X0 98-1535773 110 East 59th Street New York NY 10022 212 883-0200 Class A ordinary shares, par value $0.0001 RPRX NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 16600000000 432963472 174212681 Portions of the registrant’s definitive proxy statement for the 2022 Annual General Meeting of Shareholders, or Proxy Statement, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2021. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof. 1411 Ernst & Young Dublin, Ireland Ernst & Young Dublin, Ireland 1541048000 1008680000 581872000 983279000 614351000 587193000 53286000 33155000 66000000 69984000 15023000 6011000 6631000 8596000 2878211000 2696898000 13718245000 12368084000 5670000 28666000 269800000 298689000 204400000 163016000 435394000 454936000 4145000 9997000 17515865000 16020286000 107934000 126366000 5620000 10775000 57696000 42146000 0 110000000 0 18600000 171250000 307887000 7096070000 5816584000 7267320000 6124471000 0.0001 0.0001 432963000 432963000 388135000 388135000 43000 39000 0.000001 0.000001 174213000 174213000 218976000 218976000 0 0 1 1 50000 50000 50000 50000 63000 63000 0.000001 0.000001 361170000 361170000 316407000 316407000 0 0 3507533000 2865964000 2255179000 1920635000 4471951000 5077036000 16491000 34395000 2715000 2317000 10248545000 9895815000 17515865000 16020286000 2065083000 1959975000 1648837000 171248000 143382000 145775000 53132000 18996000 19642000 2289463000 2122353000 1814254000 452842000 230839000 -1019321000 200084000 26289000 83036000 22996000 23058000 23924000 182826000 181715000 103439000 0 65053000 0 858748000 526954000 -808922000 1430715000 1595399000 2623176000 -19490000 44459000 -32517000 166142000 157059000 268573000 -21532000 -42076000 -39138000 -48066000 247073000 155749000 17859000 18600000 0 53535000 28379000 22329000 -5678000 -32821000 393000 -189514000 106555000 -161757000 1241201000 1701954000 2461419000 0 0 0 1241201000 1701954000 2461419000 621473000 726914000 112884000 619728000 975040000 2348535000 1.49 1.32 1.49 1.32 414794000 375444000 414802000 375455000 1241201000 1701954000 2461419000 0 4066000 6189000 11600000 83120000 6159000 50896000 20551000 0 -39296000 66635000 12348000 1201905000 1768589000 2473767000 604323000 739787000 112884000 597582000 1028802000 2360883000 0 0 0 0 0 0 0 0 0 3282516000 1215953000 -10255000 63865000 0 4552079000 739276000 140866000 880142000 2348535000 112884000 2461419000 6159000 6159000 6189000 6189000 4266000 4266000 0 0 0 0 0 0 0 0 0 3282516000 2825212000 2093000 35883000 -4266000 6141438000 307646000 1174676000 1482322000 -1037161000 1037161000 0 -192705000 -192705000 313408000 792357000 1105765000 50000 63000 63000 479842000 145043000 624885000 535383000 1000 1000 294176000 30000 -294176000 -1000 294176000 1402762000 -2553001000 -1261014000 -24022000 2433098000 2147000 -1000 71652000 7000 1150383000 758354000 1908744000 76000 5428000 5428000 22231000 -2000 -22231000 22231000 -307391000 -2562000 309566000 198000 -191000 0.30 112490000 112490000 495198000 581871000 1077069000 4066000 4066000 60617000 22503000 83120000 10921000 9630000 20551000 388135000 39000 218976000 0 50000 63000 316407000 0 2865964000 0 1920635000 34395000 5077036000 -2317000 9895815000 388135000 39000 218976000 0 50000 63000 316407000 0 2865964000 0 1920635000 34395000 5077036000 -2317000 9895815000 48539000 48539000 614973000 614973000 0.68 285184000 285184000 44763000 -4000 -44763000 44763000 -639126000 -4242000 642974000 398000 0 65000 2443000 2443000 619728000 621473000 1241201000 6335000 5265000 11600000 28481000 22415000 50896000 432963000 43000 174213000 0 50000 63000 361170000 0 3507533000 0 2255179000 16491000 4471951000 -2715000 10248545000 2315854000 2121923000 1934092000 151158000 143753000 143298000 44123000 18305000 27448000 34384000 42334000 14059000 3135000 7704000 20136000 34660000 45252000 360000 34660000 0 45630000 16093000 35448000 0 6876000 20479000 83036000 193208000 5810000 0 184511000 179709000 88524000 130430000 103196000 254964000 2017536000 2034629000 1667239000 523000 15084000 0 34855000 40155000 27042000 135134000 50000000 78999000 115957000 384840000 0 70441000 0 125121000 62500000 3000000 150000000 1196579000 1705283000 817402000 1597851000 815440000 725070000 0 0 8840000 2191502000 2182246000 1721291000 18600000 0 250000000 -1870280000 -2759320000 -2153625000 0 285353000 739276000 479604000 543952000 154084000 153800000 181135000 0 285184000 112490000 0 7339000 8482000 0 36874000 58957000 0 0 94200000 294000000 0 11116196000 0 1272533000 11891030000 0 13046000 46715000 0 0 0 4266000 0 1908744000 0 385112000 1487172000 -1191626000 532368000 762481000 -1678012000 1008680000 246199000 1924211000 1541048000 1008680000 246199000 Organization and Purpose <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the IPO of our Class A ordinary shares that was completed in June 2020. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following our IPO, we control Royalty Pharma Holdings Ltd. (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K. tax resident through our ownership of RP Holdings’ Class A ordinary shares (the “RP Holdings Class A Interests”) and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our consolidated financial statements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (“RPI 2019 ICAV”), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (“Old RPI”), for accounting and financial reporting purposes. RP Holdings is owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”), and Royalty Pharma plc. Old RPI is a unit trust established in August 2011 under the laws of Ireland and authorized by the Central Bank of Ireland pursuant to the Unit Trusts Act, 1990. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Management, LLC (the “Manager”), a Delaware limited liability company, is an external adviser which is responsible for our management. RP Management (Ireland) Ltd. (“RP Ireland”), is the manager of Old RPI and equivalent to the board of directors of a company or general partner of a partnership and is responsible for the day to day operations of Old RPI. Its functions can be delegated to third parties. RP Ireland delegated responsibility for investment management of Old RPI to its parent company, the Manager, in accordance with the investment objectives and policies of Old RPI. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis. After the consummation of the Reorganization Transactions (defined below) and before the consummation of the IPO, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to RPI 2019 ICAV. Prior to the Reorganization Transactions, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Old RPI.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reorganization Transactions </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our IPO, we consummated an exchange offer on February 11, 2020 (the “Exchange Date”). Through the exchange offer, investors representing 82% of the aggregate limited partnership in the Legacy Investors Partnerships, exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under our new credit facility and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Exchange Offer Transactions, we own, through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”), an 82% economic interest in Old RPI. Through our 82% indirect ownership of Old RPI, we are legally entitled to 82% of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish unit trust. From the Exchange Date until the expiration of the Legacy Investors Partnerships’ investment period on June 30, 2020 (the “Legacy Date”), the Legacy Investors Partnerships were offered to participate proportionately in any investment made by Old RPI. Following the Legacy Date, Old RPI ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities. Since the Legacy Date, we have made and plan to make new investments through our subsidiaries, including RPI Intermediate FT. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Exchange Offer Transactions, the Legacy Investors Partnerships and RPI Intermediate FT entered into new credit facilities in the amount of $1.3 billion and $6.0 billion, respectively, the proceeds of which were used to repay the $6.3 billion outstanding debt of RPIFT and, in the case of RPI Intermediate FT, were also available to be used to fund investments. As part of the new credit facilities, RPI Intermediate FT repaid $5.2 billion, its pro rata portion of RPIFT’s outstanding debt and accrued interest. RPIFT also terminated all outstanding interest rate swaps in connection with the debt refinancing. </span></div><div style="margin-bottom:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to, and as a condition precedent to the closing of the IPO, various reorganization transactions became effective, including the following:</span></div><div style="margin-bottom:1pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Exchange Offer Transactions (as described above); and</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the execution of a new management agreement with the Manager (the “Management Agreement”).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to these transactions collectively as the “Reorganization Transactions.”</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Old RPI is our predecessor for financial reporting purposes, we have recorded Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date. The references in the following notes for the periods prior to the Exchange Date refer to the financial results of Old RPI for the same periods. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IPO</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2020, we completed our IPO on the Nasdaq Global Select Market under the ticker symbol “RPRX”, in which we issued 89,334 thousand Class A ordinary shares at a price to the public of $28.00 per Class A ordinary share, of which 71,652 thousand Class A ordinary shares and 17,682 thousand Class A ordinary shares were offered by the Company and selling shareholders, respectively. We used the net proceeds from the IPO to acquire RP Holdings Class A Interests and, as a result, we own 100% of RP Holdings Class A Interests.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consummation of the IPO, certain of the Continuing Investors agreed to exchange, pursuant to the Exchange Offer Transactions, interests in the Continuing Investors Partnerships represented by their ownership of 294,176 thousand RP Holdings Class B Interests into an aggregate of 294,176 thousand Class A ordinary shares of Royalty Pharma plc. Upon completion of the exchange, Royalty Pharma plc indirectly owned 294,176 thousand RP Holdings Class B Interests. The remaining investors in the Continuing Investors Partnerships who did not elect to exchange into Class A ordinary shares held 241,207 thousand newly issued Class B ordinary shares of Royalty Pharma plc. As a result, the Continuing Investors Partnerships held a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests indirectly held by them at such time which are exchangeable on a one-for-one basis for Class A ordinary shares of Royalty Pharma plc.</span></div> 0.82 0.82 0.82 0.82 0.66 0.34 1300000000 6000000000 6300000000 5200000000 89334000 28.00 71652000 17682000 1 294176000 294176000 294176000 241207000 Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of preparation and use of estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of consolidation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following management’s determination that a high degree of common ownership existed in Royalty Pharma both before and after the Exchange Date, Royalty Pharma recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Exchange Offer Transactions, our only historical non-controlling interest was attributable to a de minimis interest in RPCT held by RPSFT. As a result of the Exchange Offer Transactions in February 2020, a new non-controlling interest was created related to the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the consummation of our IPO in June 2020, two new non-controlling interests were created: (1) a non-controlling interest related to the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, which amounted to approximately 29% as of December 31, 2021, and (2) a non-controlling interest related to RPI EPA Holdings, LP (“EPA Holdings”), an affiliate of the Manager through its ownership of the RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to the latter non-controlling interest until certain conditions are met.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intercompany transactions and balances have been eliminated in consolidation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjustment to prior period presentation </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the preparation of our condensed consolidated interim financial statements for the three months ended September 30, 2020, we identified an adjustment to the classification of our short-term investments on our consolidated balance sheets, as of December 31, 2019, based on the original maturity dates of the investments. The adjustment resulted in an increase of $37.5 million to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and a corresponding decrease to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated balance sheet as of December 31, 2019. In addition, the adjustment resulted in an increase of $388.0 million and $350.5 million in cash activity related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Purchases of marketable securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Proceeds from sales and maturities of marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net cash used in investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the year ended December 31, 2019, with a net impact on net cash flow from investing of $37.5 million. The adjustment had no effect on our reported total income and revenues, consolidated net income, total assets, or shareholders’ equity for any period. In addition, the adjustment does not impact net cash provided by operating activities in any period. We evaluated the adjustment and determined that, based on quantitative and qualitative analysis, it was not material to the consolidated financial statements as of and for the year ended December 31, 2019.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to the current period presentation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2021 and 2020 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, AbbVie, Bristol Myers Squibb, Gilead, Johnson &amp; Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche and Vertex. For the years ended December 31, 2021 and 2020, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32% and 27% of our current portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, representing the largest individual receivable balance in both years.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial royalty assets, net</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (“ASC”), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the carrying value of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is presented net of the cumulative allowance for changes in expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of the prospective approach to measure financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analyst coverage.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts’ consensus sales forecasts for a product to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst consensus sales estimates are not available for the full term of the royalty, particularly for the later years in a product’s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management’s own expertise. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves based on historical trends to project future sales when sell-side equity research analyst consensus sales estimates end or are not available for the full term of the royalty. In other cases, management may develop and apply growth rate estimates from existing sell-side equity research analysts’ consensus sales forecasts to project future sales for products that cannot be modeled through the statistical curves, such as those where the entrance of a biosimilar is expected to impact future sales. Based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset’s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial performance.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts’ consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product’s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty duration. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration of a royalty can be based on a number of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product’s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts’ models. The most sensitive of these assumptions relates to management’s estimate of the royalty duration in the final years of an asset’s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears. </span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset’s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period’s effective interest rate. The amount recognized as provision expense increases the financial royalty asset’s cumulative allowance, which reduces the net carrying value of the financial royalty asset.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset’s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition of a financial royalty asset, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for current expected credit losses</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 1, 2020, we adopted ASU 2016-13, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(“ASU 2016-13”) which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheets. Any subsequent movement in the allowance for credit losses is recorded as part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated statements of operations.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for further information.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible royalty assets, net</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currently, our only intangible royalty assets are the Januvia and Janumet (“DPP-IV”) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, the majority of which terminate at various dates through 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10,</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Property, Plant, and Equipment - Overall</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product’s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty’s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from intangible royalty assets and Accrued royalty receivable</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts’ projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone payments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts’ consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">–</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair Value Measurements and Financial Instruments.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents and Marketable securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value. </span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity securities and Available for sale debt securities</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities are measured at fair value. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unrealized change in fair value of available for sale debt securities for which we elected the fair value option is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated statements of operations. The </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">unrealized change in fair value for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biohaven Series A Preferred Share is</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> included in </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive income </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(“AOCI”) and are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management’s assessment.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of operations as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses on derivative financial instruments</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in non-consolidated affiliates</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee’s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Equity in losses/(earnings) of non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the consolidated statements of operations. The investment is reflected as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investments in non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheet.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the “Avillion entities”). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development funding expense</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We enter into transactions where we agree to fund a portion of the research and development (“R&amp;D”) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we account for the funded amounts as R&amp;D expense when we have the ability to obtain the results of the R&amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. We may pay funded amounts upfront or over time as the underlying products undergo clinical trials.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty payments owed to the Company on successfully commercialized products generated from R&amp;D arrangements are recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria for products arising out of our R&amp;D arrangements are also recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (“the Code”) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we do not currently record a provision for income taxes, we are party to certain arrangements that will give rise to a tax provision in the future. We currently have funding arrangements in place that allow our counterparties to draw on capital over a prescribed period of time. When such funding arrangements are drawn and we begin to recognize income from these funding arrangements, such activities will be subject to U.S. taxation and we will record a provision for income taxes in accordance with ASC 740, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We also entered into an arrangement with MSCI during 2021 as discussed in Note 16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">–</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Related Party Transactions that will become subject to U.S. taxation when we begin to recognize revenue from this transaction.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI. </span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the U.K.’s “controlled foreign companies” rules (the “U.K. CFC Rules”). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the “Controlled Foreign Company”) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings)</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per share</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to RPI EPA Holdings, LP (“EPA Holdings”) related to Equity Performance Awards and unvested restricted share units (“RSUs”) issued under our 2020 Independent Director Equity Incentive Plan (“Equity Incentive Plan”). We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable. We use the “if-converted” method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020; therefore, no earnings per share information has been presented for any period prior to that date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting standards</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $192.7 million to recognize an allowance for current expected credit losses on our financial royalty assets. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.</span></div> The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to non-controlling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following management’s determination that a high degree of common ownership existed in Royalty Pharma both before and after the Exchange Date, Royalty Pharma recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date. </span></div>All intercompany transactions and balances have been eliminated in consolidation. 0.18 2 0.29 37500000 -37500000 388000000 350500000 37500000 Certain prior period amounts have been reclassified to conform to the current period presentation. Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2021 and 2020 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, AbbVie, Bristol Myers Squibb, Gilead, Johnson &amp; Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche and Vertex. 0.32 0.27 Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions. As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties. 1 <div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An acquisition of a royalty asset provides the buyer with contractual rights to cash flows relating to royalties from the sales of patent-protected biopharmaceutical products. These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies. For the majority of our royalties, our rights are protective in nature. In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products. These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.</span></div> <span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we analogize to the accounting guidance within Accounting Standards Codification 310 (“ASC”), Receivables, as it most closely aligns with the underlying economics of our financial royalty assets. Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows. Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate. The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance. If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value. The provision is recorded through the income statement as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the carrying value of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is presented net of the cumulative allowance for changes in expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of the prospective approach to measure financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties. The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analyst coverage.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports. In projecting future cash flows, our policy is to rely on sell-side research analysts’ consensus sales forecasts for a product to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones. These forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles. When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst consensus sales estimates are not available for the full term of the royalty, particularly for the later years in a product’s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management’s own expertise. For the majority of the portfolio of financial royalty assets, management utilizes statistical curves based on historical trends to project future sales when sell-side equity research analyst consensus sales estimates end or are not available for the full term of the royalty. In other cases, management may develop and apply growth rate estimates from existing sell-side equity research analysts’ consensus sales forecasts to project future sales for products that cannot be modeled through the statistical curves, such as those where the entrance of a biosimilar is expected to impact future sales. Based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications. Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset’s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial performance.</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product. For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in expected future cash flows. We generally do not recognize income from, or forecast sales for, unapproved products or indications. If a product is removed from all or a portion of a market, subsequent sell-side equity research analysts’ consensus sales forecasts will reflect the expected drop in sales. Both the new cash flow streams and the cessation of cash flow streams related to a product’s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty duration. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration of a royalty can be based on a number of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product’s life cycle at which we acquire the royalty. Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms. Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term. It is common for the latest expiring patent in effect at the date we acquire a financial royalty asset to be extended, adjusted or replaced with newer dated patents subsequent to our acquisition of a royalty due to new information, resulting in changes to the royalty duration in later periods. Patents may expire earlier than expected at the time of the acquisition due to the loss of patent protection, loss of data exclusivity on intellectual property, contractual licensing terms limiting royalty payments based on time from product launch, due to recent legal developments or litigation. Macroeconomic factors, such as changes in economies or the competitive landscape, including the unexpected loss of exclusivity to the products underlying our portfolio of royalties, changes in government legislation, product life cycles, industry consolidations and other changes beyond our control could result in a positive or negative impact on our forecast of expected future cash flows.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs: (1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts’ models. The most sensitive of these assumptions relates to management’s estimate of the royalty duration in the final years of an asset’s life. In some cases, patent protection may extend to a later period than the expiration date management has estimated. Management may apply a shorter royalty term in this situation if, based on its experience and expertise, management believes that it is more likely that the associated patents are subject to opposition or infringement, that the market for a particular product may shift based on pipeline approvals and products, or that product sales may be harmed by competition from generics. For products providing perpetual royalties, management applies judgment in establishing the duration over which it forecasts expected future cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shortened royalty term can result in a reduction in the effective interest rate, a decline in the carrying value of the financial royalty asset, a decline in income from financial royalty assets, significant reductions in royalty payments compared to expectations, or a permanent impairment. Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears. </span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record a provision for the change in expected cash flows. The provision is measured as the difference between the financial royalty asset’s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period’s effective interest rate. The amount recognized as provision expense increases the financial royalty asset’s cumulative allowance, which reduces the net carrying value of the financial royalty asset.</span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement. We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows. The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. Recoveries of previously written-off amounts are credited to the allowance. In some cases, when a financial royalty asset’s contractual cash flows expire, the final royalty payment may differ from the remaining net carrying value. We account for this non-cash true-up at the end of the royalty term as either </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income from financial royalty assets</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets. After acquisition of a financial royalty asset, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties). Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete. We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status. An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income.</span></div> <span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 1, 2020, we adopted ASU 2016-13, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(“ASU 2016-13”) which requires earlier recognition of credit losses. We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The credit loss allowance is estimated using the probability of default and loss given default method. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default. The allowance for current expected credit losses is presented net within the non-current portion of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheets. Any subsequent movement in the allowance for credit losses is recorded as part of the </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Provision for changes in expected future cash flows from financial royalty assets</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated statements of operations.</span> Currently, our only intangible royalty assets are the Januvia and Janumet (“DPP-IV”) patents. The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, the majority of which terminate at various dates through 2022. The amortization period commenced concurrent with the sale of the product underlying the royalty asset.<span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10,</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Property, Plant, and Equipment - Overall</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products. When evaluating indicators of impairment, we consider factors such as competitive environment and the product’s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty’s term. An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.</span> <div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own. We do not have future performance obligations under these license arrangements. Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold. However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag. Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts’ projected sales, adjusted for any changes in estimates. Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements. Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates. Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone payments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period. For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts’ consensus sales forecasts. Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones. Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved.</span></div> <span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature. The fair values of financial instruments other than </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial royalty assets, net</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are determined through a combination of management estimates and information obtained from third parties using the latest market data. The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">–</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair Value Measurements and Financial Instruments.</span> Cash and cash equivalents include cash held at banks and all highly liquid financial instruments with original maturities of 90 days or less. We invest excess cash in marketable debt securities that are classified as trading securities and reported at fair value. <div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings. Our equity securities represent investments in publicly traded equity securities. Available for sale debt securities are measured at fair value. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unrealized change in fair value of available for sale debt securities for which we elected the fair value option is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated statements of operations. The </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">unrealized change in fair value for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biohaven Series A Preferred Share is</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> included in </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive income </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(“AOCI”) and are reclassified to earnings as interest income is recognized. Interest income is recognized when we can reliably estimate forecasted cash flows. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings. The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment. Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include: the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis. Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management’s assessment.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment. Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.</span></div> All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings. Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements. <span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020. This reclassification adjustment is shown on the consolidated statements of operations as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Losses on derivative financial instruments</span>. <div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method. Investments accounted for under the equity method are initially recorded at fair value. If there is a difference between the fair value and the carrying amount of the equity method investment at inception, we quantify the basis difference and amortize it in a rational manner over the life of the investment. Subsequently, we recognize through earnings our proportionate share of the investee’s net income or loss, net of any adjustment to reflect the amortization of basis differences. We generally record our share of the results of our investees one quarter in arrears within </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Equity in losses/(earnings) of non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the consolidated statements of operations. The investment is reflected as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investments in non-consolidated affiliates</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheet.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the “Avillion entities”). The Avillion entities are variable interest entities for which we are not the primary beneficiary as we do not have the power to direct the activities that most significantly influence the economic performance of the entity. In determining whether we are the primary beneficiary of an entity, management applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant. Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees.</span></div>When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets. <div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We enter into transactions where we agree to fund a portion of the research and development (“R&amp;D”) performed by our partners for products undergoing late-stage clinical trials in exchange for future royalties or milestones if the products are successfully developed and commercialized. In accordance with ASC 730, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we account for the funded amounts as R&amp;D expense when we have the ability to obtain the results of the R&amp;D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval. We may pay funded amounts upfront or over time as the underlying products undergo clinical trials.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty payments owed to the Company on successfully commercialized products generated from R&amp;D arrangements are recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period in which the sale of the product occurs. Fixed or milestone payments receivable based on the achievement of contractual criteria for products arising out of our R&amp;D arrangements are also recognized as </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other royalty income</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the period that the milestone threshold is met. Milestone thresholds are typically not triggered until after all funding obligations have been completed.</span></div> <div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess if our activities, as conducted through our subsidiaries, and as currently contemplated, constitute being engaged in the conduct of a trade or business within the United States. Neither the U.S. Internal Revenue Code (“the Code”) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance. Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U. S. federal income tax for the years presented in the consolidated financial statements.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S. taxation in that regard, we are subject to U. S. federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code. Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax. We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S. withholding taxes on U.S.-source royalty payments. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we do not currently record a provision for income taxes, we are party to certain arrangements that will give rise to a tax provision in the future. We currently have funding arrangements in place that allow our counterparties to draw on capital over a prescribed period of time. When such funding arrangements are drawn and we begin to recognize income from these funding arrangements, such activities will be subject to U.S. taxation and we will record a provision for income taxes in accordance with ASC 740, </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We also entered into an arrangement with MSCI during 2021 as discussed in Note 16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">–</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Related Party Transactions that will become subject to U.S. taxation when we begin to recognize revenue from this transaction.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate so as to be treated solely as resident in the U.K. for tax purposes. As a U.K. tax resident company, we are subject to U.K. corporation tax on our worldwide taxable profits and gains. U.K. tax resident companies are subject to U.K. corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class. We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K. corporation tax. As such, we do not record a provision for U.K. income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI. </span></div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the U.K.’s “controlled foreign companies” rules (the “U.K. CFC Rules”). The U.K. CFC Rules, broadly, can impose a charge to U.K. tax on U.K. tax resident companies that have, alone or together with certain other persons, interests in a non-U.K. tax resident company (the “Controlled Foreign Company”) which is controlled by a U.K. person or persons. The charge under the U.K. CFC Rules applies by reference to certain types of chargeable profit arising to the Controlled Foreign Company, whether or not that profit is distributed, subject to specific exemptions. Certain non-U.K. entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings)</span>, will be Controlled Foreign Companies for U.K. tax purposes. We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis. We do not expect material U.K. corporation tax charges to arise under the U.K. CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K. income taxes. Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to RPI EPA Holdings, LP (“EPA Holdings”) related to Equity Performance Awards and unvested restricted share units (“RSUs”) issued under our 2020 Independent Director Equity Incentive Plan (“Equity Incentive Plan”). We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable. We use the “if-converted” method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs. <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13). Accordingly, these financial assets are presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $192.7 million to recognize an allowance for current expected credit losses on our financial royalty assets. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13). The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss). We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.</span></div> -192700000 Available for Sale Debt Securities <div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”) at a price of $50,100.00 per preferred share, for a total of $125.0 million (the “First Tranche”). The approval of Nurtec ODT by the U.S. Food and Drug Administration (“FDA”) in February 2020 results in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price. In the event that Biohaven defaults on any obligation to redeem Series A Biohaven Preferred Shares when required, the redemption amount shall accrue interest at the rate of 18% annually until the redemption price for such unredeemed Series A Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert all unredeemed Series A Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Series A Biohaven Preferred Shares are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated statements of comprehensive income.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Biohaven Preferred Shares </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 7, 2020 we entered into a Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”), for a total of $200.0 million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the Series B original issue price per share. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares. In the event that Biohaven defaults on any obligation to redeem Series B Biohaven Preferred Shares, the redemption amount shall accrue interest on the applicable original issue price at the rate of 18% annually until the redemption price for such unredeemed Series B Biohaven Preferred Shares is paid in full, subject to applicable law. If any such default continues for at least one year, we will be entitled to convert any or all unredeemed Series B Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2021, we began purchasing the Series B Biohaven Preferred Shares. As of December 31, 2021, we have acquired 1,406 shares of Series B Biohaven Preferred Shares. We have elected the fair value option to account for the Series B Forwards and the Series B Biohaven Preferred Shares, which are recorded in aggregate on the consolidated balance sheets as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statements of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys Development Funding Bonds</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (“MorphoSys”) to support MorphoSys’ acquisition of Constellation Pharmaceuticals, Inc. (“Constellation”), which closed on July 15, 2021. As part of the funding agreement, we agreed to provide MorphoSys up to $350 million of capital (the “Development Funding Bonds”), which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150 million. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds. Our commitment to fund at least $150 million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our consolidated balance sheet. The unrealized change in fair value of the Development Funding Bond Forward is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unrealized gains on available for sale debt securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the consolidated statements of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2021 and 2020 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Biohaven Preferred Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,759 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development Funding Bond Forward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,891</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">145,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">233,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">69,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">233,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. There were no costs associated with the Series B Forwards and Development Funding Bond Forward. 2495 50100 125000000 0.18 P1Y 3992 50100 200000000 0.18 P1Y 1406 350000000 150000000 150000000 P9Y P2Y <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2021 and 2020 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Biohaven Preferred Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,759 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development Funding Bond Forward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,891</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Biohaven Preferred Shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B Forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">145,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">233,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">69,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">233,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. There were no costs associated with the Series B Forwards and Development Funding Bond Forward. 134068000 29432000 163500000 66000000 97500000 163500000 70441000 19759000 90200000 0 90200000 90200000 0 12300000 12300000 0 12300000 12300000 0 4400000 4400000 0 4400000 4400000 204509000 65891000 270400000 66000000 204400000 270400000 145647000 68753000 214400000 69984000 144416000 214400000 0 18600000 18600000 0 18600000 18600000 145647000 87353000 233000000 69984000 163016000 233000000 Derivative Instruments<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically managed the impact of foreign currency exchange rate and interest rate risk through various financial instruments, including derivative instruments such as treasury rate lock contracts, interest rate swap contracts and foreign currency forward contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash flow arising from our exposure to interest rate risk and foreign currency risk. We may also acquire other financial instruments that are classified as derivatives. We do not enter into derivative instruments for trading or speculative purposes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury rate lock contracts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, we entered into treasury rate lock contracts with notional amounts totaling $600.0 million to manage the impact of fluctuations in the underlying benchmark interest rate associated with the 2021 Notes (as further discussed and defined in Note 11–Borrowings). The treasury rate lock contracts were not designated as hedge instruments. All of the treasury rate lock contracts had collateral requirements. The treasury rate lock contracts were unwound and settled in connection with the issuance of the 2021 Notes and the resulting net loss was recognized in earnings in the year ended December 31, 2021. We paid $16.1 million in July 2021 to terminate our treasury rate lock contracts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2020, RPIFT terminated all outstanding interest rate swaps in connection with the Exchange Offer Transactions. We paid $35.4 million to terminate these swaps and reclaimed $45.3 million of collateral that was held by the respective counterparties. During the years ended December 31, 2020 and 2019, we recorded unrealized losses of $10.9 million and $72.6 million, respectively, on interest rate swaps in the consolidated statements of operations. We did not enter into any interest rate swaps subsequent to the February 2020 termination discussed above and as of December 31, 2021, we do not hold any interest rate swap contracts. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Epizyme put option and warrant</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, RPIFT made an equity investment in Epizyme, Inc. (“Epizyme”) of $100.0 million. Under the terms of the agreement with Epizyme, we made an upfront payment of $100.0 million for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5 million shares of Epizyme common stock at $20 per share over a three-year term and (3) Epizyme’s royalty on sales of Tazverik in Japan payable by Eisai Co., Ltd (“Eisai”). In addition, Epizyme had an 18 month put option to sell an additional $50.0 million of its common stock to RPIFT at then prevailing prices, not to exceed $20 per share. On December 31, 2019, Epizyme notified RPIFT of its intention to exercise the put option. As a result, we recorded a forward purchase contract equal to the difference between the market value and exercise price of $11.5 million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets at December 31, 2019. The exercise of the put option was settled in February 2020.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant was recognized at fair value of $5.4 million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets at December 31, 2020. The fair value of the warrant was not material as of December 31, 2021. We recorded an unrealized loss of $5.4 million, an unrealized loss of $25.4 million and an unrealized gain of $22.0 million on derivative contracts related to the change in fair value of the warrant on the consolidated statements of operations for the years ended December 31, 2021, 2020 and 2019, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of derivatives and reclassifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2021, 2020 and 2019 and the line items within the consolidated statements of operations where the gains or losses on these derivatives are recorded (in thousands). </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.190%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives in hedging relationships (1)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income into income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward purchase contract:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of forward purchase contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury rate lock contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of treasury rate lock contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,093 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span> were released into earnings. 600000000 16100000 35400000 45300000 -10900000 -72600000 100000000 100000000 2500000 20 P3Y P18M 50000000 20 11500000 5400000 0 -5400000 -25400000 22000000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2021, 2020 and 2019 and the line items within the consolidated statements of operations where the gains or losses on these derivatives are recorded (in thousands). </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.190%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location on Consolidated Statements of Operations</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives in hedging relationships (1)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount of loss reclassified from accumulated other comprehensive income into income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Rate Swaps:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forward purchase contract:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of forward purchase contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury rate lock contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of treasury rate lock contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,093 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Certain interest rate swaps were previously designated as cash flow hedges. These swaps became ineffective as debt refinancings occurred between 2013 and 2016. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span> were released into earnings. 0 4066000 6189000 0 -73000 16954000 0 114000 -9565000 0 6908000 49472000 0 408000 -2681000 5439000 25375000 -21977000 0 5800000 -11500000 16093000 0 0 Fair Value Measurements and Financial Instruments <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value hierarchy</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives and available for sale debt securities are reported at their respective fair values in our consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs in our consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported in our consolidated balance sheets at amounts that approximate current fair values.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and liabilities measured at fair value on a recurring basis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes financial assets and financial liabilities that we measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">598,253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">636,823</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,301,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,134,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">69,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,229,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">247,413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">474,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">298,689</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,439</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">467,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The balance as of December 31, 2021 includes Series B Forwards and the Development Funding Bond Forward, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet, related to our obligations to fund acquisitions of the Series B Biohaven Preferred Shares and $150 million of the Development Funding Bonds, respectively. The balance as of December 31, 2020 relates to Series B Forwards, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. See Note 3–Available for Sale Debt Securities for additional discussion. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the Epizyme transaction as described in Note 4–Derivative Instruments and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheets as of December 31, 2021 and 2020. The fair value of the warrant was not material as of December 31, 2021. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020 and 2019, we recognized a loss of $60.1 million, a loss of $85.4 million and a gain of $104.4 million, on equity securities still held as of December 31, 2021, respectively. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities and available for sale debt securities, including the underlying debt securities and related forwards (in thousands). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Equity Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Debt Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,459 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer to Level 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer from Level 2 (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,874 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemption</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Forwards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">For the year ended December 31, 2021, the unrealized gains on available for sale debt securities is comprised of $11.6 million related to Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income and $1.3 million related to the Series B Biohaven Preferred Shares as recorded on the consolidated statements of operations. For the year ended December 31, 2020, the unrealized gains on available for sale debt securities related to the Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income, including $52.7 million prior to transferring out of Level 3 and then $15.9 million after transferring back to Level 3.     </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled in the period as the Series B Biohaven Preferred Shares were acquired, which is included in the fair value of the Series B Biohaven Preferred Shares. See Note 3–Available for Sale Debt Securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes $14.5 million of unrealized gains on available for sale debt securities included in other comprehensive income while the Series A Biohaven Preferred Shares was classified as a Level 2 asset.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the consolidated statements of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation inputs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was based on the cash flows due to us from Biohaven of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6 million following the FDA approval and starting one-year after FDA approval, through December 31, 2024. The FDA approved Nurtec ODT in February 2020, at which point we became entitled to receive a fixed payment amount of $250.0 million payable in equal quarterly payments from March 31, 2021 through December 31, 2024. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate of 9.5% and 8.3% as of December 31, 2021 and 2020, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to February 2020, we measured our investment in the Series A Biohaven Preferred Shares using a Black-Derman- Toy lattice model, which included the use of Level 3 fair value measurements and inputs. In February 2020, when Nurtec ODT received FDA approval, we began measuring the fair value of the Series A Biohaven Preferred Shares using a discounted cash flow analysis that relied on observable inputs, and therefore, we transferred the Series A Biohaven Preferred Shares from a Level 3 to a Level 2 asset. During the three months ended December 31, 2020, information pertaining to Biohaven’s issuance of debt and its effective interest rate became available and we refined our valuation of the Series A Biohaven Preferred shares as of December 31, 2020 to incorporate this significant unobservable input. As a result, we reclassified the investment from a Level 2 to a Level 3 asset during the three months ended December 31, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Series B Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of December 31, 2021 and the fair value of the Series B Forwards as of December 31, 2020 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MorphoSys Development Funding Bonds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Development Funding Bond Forward as of December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioCryst Equity Securities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, we purchased 3,846 thousand shares of common stock in BioCryst Pharmaceuticals, Inc.(“BioCryst”), which was calculated based on the volume-weighted average price of BioCryst common stock over a period preceding the closing of the transaction. As part of the transaction, we are restricted from selling the common stock for six months following the close of the transaction. The fair value of the BioCryst common stock as of December 31, 2021 was based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the common stock to match the duration of the transfer restriction. This methodology includes the use of Level 3 inputs, including the estimated volatility of the BioCryst common stock, which requires the use of significant judgement. Our estimated volatility could be reasonably different than the actual volatility for the common stock which would mean that the estimated fair value for the common stock could be significantly higher or lower than the fair value determined by management at any particular date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other financial instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use third party pricing services for Level 2 inputs used to value cash equivalents, marketable securities, derivative instruments and borrowings, which provide documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. Warrants are valued using a Black-Scholes option pricing model which considers observable and unobservable inputs. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial assets not measured at fair value</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial royalty assets are measured and carried on the consolidated balance sheets at amortized cost using the effective interest method. The fair value of financial royalty assets is calculated by management using the forecasted royalty payments we expect to receive based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts’ consensus sales forecasts or, where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments are then discounted to a present value using appropriate individual discount rates. The fair value of our financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for our financial royalty assets as of December 31, 2021 and 2020 are presented below (in thousands).</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,047,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,332,596 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,718,179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,955,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives and available for sale debt securities are reported at their respective fair values in our consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs in our consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported in our consolidated balance sheets at amounts that approximate current fair values.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes financial assets and financial liabilities that we measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">598,253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">636,823</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,301,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,134,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">69,984</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,229,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,013 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,416 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">247,413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">474,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">298,689</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,439</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">163,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">467,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The balance as of December 31, 2021 includes Series B Forwards and the Development Funding Bond Forward, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet, related to our obligations to fund acquisitions of the Series B Biohaven Preferred Shares and $150 million of the Development Funding Bonds, respectively. The balance as of December 31, 2020 relates to Series B Forwards, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. See Note 3–Available for Sale Debt Securities for additional discussion. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the Epizyme transaction as described in Note 4–Derivative Instruments and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span> in the consolidated balance sheets as of December 31, 2021 and 2020. The fair value of the warrant was not material as of December 31, 2021. 598253000 0 0 598253000 24302000 0 0 24302000 0 13997000 0 13997000 0 77176000 0 77176000 0 40954000 0 40954000 0 74502000 0 74502000 0 0 0 0 0 32754000 0 32754000 0 207457000 0 207457000 0 444554000 0 444554000 0 374415000 0 374415000 0 505971000 0 505971000 0 0 66000000 66000000 0 0 69984000 69984000 598253000 636823000 66000000 1301076000 24302000 1134957000 69984000 1229243000 226787000 0 43013000 269800000 298689000 0 0 298689000 0 0 187700000 187700000 0 0 144416000 144416000 0 0 16700000 16700000 0 0 18600000 18600000 0 0 0 0 0 5439000 0 5439000 226787000 0 247413000 474200000 298689000 5439000 163016000 467144000 150000000 0 -60100000 -85400000 104400000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities and available for sale debt securities, including the underlying debt securities and related forwards (in thousands). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Equity Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Debt Securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,459 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer to Level 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer from Level 2 (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,874 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redemption</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Forwards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement of forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">For the year ended December 31, 2021, the unrealized gains on available for sale debt securities is comprised of $11.6 million related to Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income and $1.3 million related to the Series B Biohaven Preferred Shares as recorded on the consolidated statements of operations. For the year ended December 31, 2020, the unrealized gains on available for sale debt securities related to the Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income, including $52.7 million prior to transferring out of Level 3 and then $15.9 million after transferring back to Level 3.     </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled in the period as the Series B Biohaven Preferred Shares were acquired, which is included in the fair value of the Series B Biohaven Preferred Shares. See Note 3–Available for Sale Debt Securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes $14.5 million of unrealized gains on available for sale debt securities included in other comprehensive income while the Series A Biohaven Preferred Shares was classified as a Level 2 asset.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span>on the consolidated statements of operations. 0 0 35120000 0 7893000 0 43013000 0 214400000 131280000 70441000 0 12900000 52725000 18459000 0 0 184005000 0 198526000 0 15874000 -62500000 0 253700000 214400000 18600000 0 16559000 18600000 -18459000 0 16700000 18600000 11600000 1300000 52700000 15900000 14500000 15600000 250000000 P4Y 0.095 0.083 3846000 P6M Estimated fair values based on Level 3 inputs and related carrying values for our financial royalty assets as of December 31, 2021 and 2020 are presented below (in thousands).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,047,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,332,596 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,718,179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,955,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 19047183000 14332596000 18718179000 12955277000 Financial Royalty Assets, Net<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2021 and 2020 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value (e)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,335,641 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 (d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,697,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(909,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,787,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,027,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,384,141)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,643,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,332,596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value (e) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,003,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,891,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,359,419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,150,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(145,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,004,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 (d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,022,213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(634,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,387,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,219,101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(940,107)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,278,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(323,717)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,955,277</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt">Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2021 and 2020 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value (e)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,335,641 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 (d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,697,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(909,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,787,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,027,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,384,141)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,643,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,332,596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 7)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value (e) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,003,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,891,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,359,419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,150,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(145,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,004,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Promacta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 (d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,440 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,022,213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(634,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,387,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,219,101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(940,107)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,278,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less: Cumulative allowance for credit losses (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(323,717)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,955,277</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:9.13pt">Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">Under terms of the agreement, RPIFT acquired a perpetual royalty on net sales of Tysabri. Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.13pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div> 5335641000 48636000 5287005000 1846069000 16617000 1829452000 1438730000 236871000 1201859000 1100065000 172101000 927964000 881671000 0 881671000 727774000 0 727774000 4697591000 909916000 3787675000 16027541000 1384141000 14643400000 310804000 14332596000 1300000000 5274896000 0 5274896000 2003797000 112720000 1891077000 1406291000 46872000 1359419000 1150335000 145565000 1004770000 686129000 0 686129000 675440000 0 675440000 3022213000 634950000 2387263000 14219101000 940107000 13278994000 323717000 12955277000 1300000000 Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets<div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated balance sheets and includes the following activities:</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the movement in the cumulative allowance related to changes in forecasted royalty payments we expect to receive based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts’ </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">consensus sales forecasts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the movement in the cumulative allowance for current expected credit losses.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The periodic movement in the cumulative allowance is presented on the consolidated statements of operations as the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for changes in expected cash flows from financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of $192.7 million to recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights. The current period provision for changes in expected cash flows from financial royalty assets reflects the activity for the period primarily new financial royalty assets and changes in the underlying cash flow forecasts used in the effective interest model to measure income from our financial royalty assets. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">–</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Summary of Significant Accounting Policies for further information.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,982,897)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(322,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,342,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(868,418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative adjustment for adoption of ASU 2016-13</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of credit loss allowance (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision expense for credit losses, net (c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,263,824)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(912,710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446,955 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision income for credit losses, net (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,694,945)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)     Relates to amounts removed from the allowance at the end of a royalty asset’s life to bring the account balance to zero. Write-offs solely impact the asset account and allowance account; there is no impact on the consolidated statements of operations.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)     Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the write-off of the related financial royalty asset balance of $90.2 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">(c)     In the year ended December 31, 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights in 2020, mainly the final tranche of Tazverik. In the year ended December 31, 2021,the provision income for credit losses was primarily related to a significant decline in the financial asset value for Tazverik, which was offset by increases in our portfolio of financial royalty assets with limited protective rights in 2021, primarily related to zavegepant.</span></div> -192700000 <div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,982,897)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(322,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,342,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(868,418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative adjustment for adoption of ASU 2016-13</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(645,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570,959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of credit loss allowance (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision expense for credit losses, net (c)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,263,824)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(912,710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446,955 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of cumulative allowance (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision income for credit losses, net (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,694,945)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)     Relates to amounts removed from the allowance at the end of a royalty asset’s life to bring the account balance to zero. Write-offs solely impact the asset account and allowance account; there is no impact on the consolidated statements of operations.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b)     Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the write-off of the related financial royalty asset balance of $90.2 million.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">(c)     In the year ended December 31, 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights in 2020, mainly the final tranche of Tazverik. In the year ended December 31, 2021,the provision income for credit losses was primarily related to a significant decline in the financial asset value for Tazverik, which was offset by increases in our portfolio of financial royalty assets with limited protective rights in 2021, primarily related to zavegepant.</span></div> 1982897000 322717000 1342038000 -95158000 868418000 192705000 645612000 570959000 -2964000 25174000 156186000 1263824000 912710000 446955000 -21721000 -12913000 1694945000 90200000 Intangible Royalty Assets, Net<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2021 and 2020 (in thousands).</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,666 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,550 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,666 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our DPP-IV patents associated with the intangible royalty assets terminate at various dates through 2022. The weighted average remaining life of the intangible royalty assets is less than one year. We project amortization expense will be $5.7 million in 2022.</span></div>Our revenue is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue from royalty assets is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate our royalty revenue from licensees based on the geography of the underlying sales, as this level of information is not always included in royalty reports provided to us. The marketers paying us royalties on these products do not always provide, and are not necessarily required to provide, the breakdown of product sales by geography. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 86%, 97% and 91% of our revenues from intangible royalty assets in the years ended December 31, 2021, 2020 and 2019, respectively. <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2021 and 2020 (in thousands).</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,550 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,666 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,550 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,666 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 606216000 600546000 5670000 606216000 600546000 5670000 606216000 577550000 28666000 606216000 577550000 28666000 P1Y 5700000 0.86 0.97 0.91 Non-Consolidated Affiliates<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Legacy SLP Interest</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) from the Continuing Investors Partnerships for $303.7 million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also own a non-controlling interest in Old RPI. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income allocation from the Legacy SLP Interest is based on an estimate, as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this annual report. Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the years ended December 31, 2021 and 2020, we recorded an income allocation of $8.9 million and $62.0 million, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in losses/(earnings) of non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received cash distributions from the Legacy SLP Interest of $21.0 million and $22.7 million during the years ended December 31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Avillion Entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our partnership interests in Avillion Financing I, LP (“Avillion I”) and BAv Financing II, LP (“Avillion II”, or, together, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the entities. We recorded a loss allocation from the Avillion Entities of $28.4 million, $17.6 million and $32.5 million within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity in losses/(earnings) of non-consolidated affiliates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the years ended December 31, 2021, 2020 and 2019, respectively. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval. Subsequent to the asset sale, the only operations of Avillion I are the collection of cash and unwinding of discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.4 million during each of the years ended December 31, 2021 and 2020, and $14.1 million in the year ended December 31, 2019 in connection with Avillion I’s receipt of the fixed annual payments due under its co-development agreement with Pfizer. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, RPIFT entered into an agreement with Avillion II, which was amended in 2019, to invest approximately $19.0 million to fund approximately 50% of the costs of a Phase 2 clinical trial for the use of Merck KGaA’s anti-IL 17 nanobody M1095 (the “Merck KGaA Asset”) for the treatment of psoriasis in exchange for certain milestone and royalty payments. Our involvement in the development for the Merck KGaA Asset ceased in the year ended December 31, 2020, for which we received a distribution of $21.3 million from Avillion II. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, RPIFT entered into an additional agreement, which was amended in July 2021, to increase our investment up to $122.5 million from $105.0 million in Avillion II over multiple years to fund approximately 44% of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, RPIFT had $11.2 million and $28.6 million respectively, of unfunded commitments related to the Avillion Entities. Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments.</span></div> 303700000 8900000 62000000 21000000 22700000 -28400000 -17600000 -32500000 13400000 13400000 14100000 19000000 0.50 21300000 122500000 105000000 0.44 -11200000 28600000 Research &amp; Development (“R&amp;D”) Funding Expense <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D funding expense consists of upfront and ongoing R&amp;D payments we have made to counterparties to acquire royalties and/or milestones on development-stage product candidates. Ongoing R&amp;D payments are made as the related development-stage product candidates undergo clinical trials with our counterparties. During the year ended December 31, 2021, 2020, and 2019 we did not enter into any new ongoing R&amp;D funding arrangements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognized R&amp;D funding expense of $200.1 million during the year ended December 31, 2021, comprised of $6.9 million in ongoing R&amp;D expenses, primarily under our co-funding agreement with Sanofi, and $193.2 million in upfront R&amp;D funding. As part of a long-term strategic funding partnership with MorphoSys, which closed on July 15, 2021 (as further discussed in Note 17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">–</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commitments and Contingencies), we allocated $90.0 million of the upfront payment to R&amp;D funding expense, representing two development-stage products acquired in exchange for future royalties. Additionally, we made an upfront payment of $103.2 million to BioCryst to acquire a royalty on a development-stage product in November 2021. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized R&amp;D funding expense of $26.3 million during the year ended December 31, 2020, of which $20.5 million related to ongoing development-stage funding payments, primarily under our co-funding agreement with Sanofi and $5.8 million related to upfront funding for a royalty on a development-stage product that we acquired from BioCryst. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $83.0 million of R&amp;D funding expense during the year ended December 31, 2019, of which $18.2 million and $62.8 million related to our funding agreements with both Sanofi and Pfizer, respectively. We completed our funding commitments in the fourth quarter of 2019 under our agreement with Pfizer. We did not have upfront development-stage R&amp;D funding expense in 2019.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have a remaining commitment of $10.7 million related to our R&amp;D funding agreement with Sanofi.</span></div> 200100000 6900000 193200000 90000000 103200000 26300000 20500000 5800000 83000000 18200000 62800000 10700000 Borrowings<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings at December 31, 2021 and 2020 consisted of the following (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183,416)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,816,584</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,816,584 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Senior Unsecured Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 26, 2021, we issued $1.3 billion of senior unsecured notes (the “2021 Notes”) comprised of $600.0 million principal amount of notes due September 2031 and $700.0 million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, beginning on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5 million and we capitalized approximately $12.3 million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 2, 2020, we issued $6.0 billion of senior unsecured notes (the “2020 Notes” and, together with the 2021 Notes, the “Notes”). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0 million and we capitalized approximately $40.4 million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50%, respectively.    </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and, </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as of December 31, 2021, we were in compliance with all applicable covenants.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021 and 2020, the estimated fair value of our outstanding Notes using Level 2 inputs was approximately $7.2 billion and $6.2 billion, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Senior Unsecured Revolving Credit Facility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2021, we entered into an amended and restated revolving credit agreement (the “Credit Agreement”). The Credit Agreement amends and restates the existing credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) with borrowing capacity of up to $1.5 billion for general corporate purposes. The Credit Agreement extends the maturity of the Revolving Credit Facility to September 15, 2026. As of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2020, there were no outstanding borrowings under the Revolving Credit Facility. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. As of </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, RP Holdings was in compliance with these covenants. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 11, 2020, in connection with the Exchange Offer Transactions (as discussed in Note 1–Organization and Purpose) and using funds contributed by RPI Intermediate FT and the Legacy Investors Partnerships, RPIFT repaid its outstanding debt and accrued interest, and terminated all outstanding interest rate swaps. RPI Intermediate FT, as borrower, entered into a term loan credit agreement with Bank of America, N.A., as administrative agent, the lenders party thereto from time to time and the other parties thereto. The senior secured credit facilities consisted of a term loan A and term loan B in the amounts of $3.20 billion and $2.84 billion, respectively. In September 2020, we repaid in full the outstanding principal amounts of term loans under the senior secured credit facilities with net proceeds from the 2020 Notes and available cash on hand. Upon refinancing our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $25.1 million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other non-operating expense/(income), net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RPIFT Senior Secured Credit Facilities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The RPIFT Senior Secured Credit Facilities were repaid in full in February 2020 in connection with the Exchange Offer Transactions. We recorded a loss on debt extinguishment of $5.4 million as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other non-operating expense/(income), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">during the year ended December 31, 2020. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Principal Payments on the Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The future principal payments for our borrowings as of December 31, 2021 over the next five years and thereafter are as follows (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>(1)     Excludes unamortized debt discount and issuance costs of $203.9 million as of December 31, 2021, which are amortized through interest expense over the remaining life of the underlying debt obligations. <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings at December 31, 2021 and 2020 consisted of the following (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183,416)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,816,584</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,816,584 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1000000000 0.0075 0.99322 1000000000 1000000000 1000000000 0.0120 0.98875 1000000000 1000000000 1000000000 0.0175 0.98284 1000000000 1000000000 1000000000 0.0220 0.97760 1000000000 1000000000 600000000 0.0215 0.98263 600000000 0 1000000000 0.0330 0.95556 1000000000 1000000000 1000000000 0.0355 0.95306 1000000000 1000000000 700000000 0.0335 0.97565 700000000 0 203930000 183416000 7096070000 5816584000 0 0 7096070000 5816584000 1300000000 600000000 700000000 27500000 12300000 0.0280 0.0306 6000000000 149000000 40400000 0.02125 0.0250 1 1.01 7200000000 6200000000 P5Y 1500000000 0.005 0.005 0.01 4.00 4.50 2.50 3200000000 2840000000 -25100000 5400000 The future principal payments for our borrowings as of December 31, 2021 over the next five years and thereafter are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>(1)     Excludes unamortized debt discount and issuance costs of $203.9 million as of December 31, 2021, which are amortized through interest expense over the remaining life of the underlying debt obligations. 0 1000000000 0 1000000000 0 5300000000 7300000000 203900000 Shareholders’ Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital structure</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the completion of our IPO as discussed in Note 1–Organization and Purpose, we have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An exchange agreement entered into by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the “Exchange Agreement”) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. As of December 31, 2021, we have outstanding 432,963 thousand Class A ordinary shares and 174,213 thousand Class B ordinary shares. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of December 31, 2021, we have outstanding deferred shares of 361,170 thousand. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The purpose of the Class R redeemable shares was to ensure Royalty Pharma Limited had sufficient sterling denominated share capital at the time it was re-registered as a public limited company to Royalty Pharma plc, as required by the U.K. Companies Act. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of £1 each.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling interests</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The only non-controlling interest in the year ended December 31, 2019 related to RPSFT, for which the net change in the related balance is as presented in the statements of shareholders’ equity. The net change in the balance of our four non-controlling interests for the years ended December 31, 2021 and 2020 is as follows (in thousands): </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.334%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(594,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(792,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income prior to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Class A ordinary shares sold in IPO, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income subsequent to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized losses on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Related to the Continuing Investors Partnerships’ ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:32.479%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.481%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(425,050)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(614,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(642,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(642,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized losses on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,946)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,809,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,649,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,471,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Related to the Continuing Investors Partnerships’ ownership of approximately 29% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2021. Royalty Pharma plc owns the remaining 71% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">RP Holdings Class C Special Interest held by EPA Holdings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPA Holdings is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period will be grouped together as separate portfolios (each, a “Portfolio”). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests for which we will issue the same number of Class B ordinary shares, which may be subsequently exchanged for our Class A ordinary shares. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently expect any material Equity Performance Awards to be payable until the performance conditions discussed above are met.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class A ordinary shares are entitled to receive dividends subject to approval by the board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings, our consolidated subsidiary. In the year ended December 31, 2021, we declared and paid four quarterly cash dividends of $0.17 per Class A ordinary share for an aggregate amount of $285.2 million to holders</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our Class A ordinary shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Independent Directors Equity Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors. As of December 31, 2021, approximately 620 thousand shares remain reserved for future issuance under the Equity Incentive Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU activity and share-based compensation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statement of comprehensive income. The estimated fair value of RSUs is based on the closing price of our Class A ordinary shares on the grant date.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized share-based compensation of approximately $3.1 million and $5.7 million for the years ended December 31, 2021 and 2020, which is recorded as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span> in the consolidated statement of operations. There were no share-based awards or related expenses in periods prior to the IPO. As of December 31, 2021, the total unrecognized share-based compensation expense related to total outstanding RSUs was less than $1.0 million, which we expect to recognize in the next six months. 2 432963000 174213000 361170000 50000 1 The net change in the balance of our four non-controlling interests for the years ended December 31, 2021 and 2020 is as follows (in thousands): <div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.334%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfer of interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,037,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(594,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(792,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income prior to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,043 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,433,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Class A ordinary shares sold in IPO, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(309,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income subsequent to IPO</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized losses on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Related to the Continuing Investors Partnerships’ ownership of approximately 36% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020. Royalty Pharma plc owns the remaining 64% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:32.479%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.481%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(425,050)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(614,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(642,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(642,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized losses on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,946)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,809,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,649,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,471,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)     Related to the Continuing Investors Partnerships’ ownership of approximately 29% in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2021. Royalty Pharma plc owns the remaining 71% of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2021.</span></div> 4 35883000 0 0 0 35883000 0 1165258000 9418000 0 1174676000 0 1037161000 0 0 1037161000 112339000 594592000 85426000 0 792357000 42151000 102892000 0 0 145043000 0 -750000 2433848000 0 2433098000 0 0 758354000 0 758354000 0 0 309566000 0 309566000 46741000 218137000 316993000 0 581871000 0 15015000 7488000 0 22503000 0 3612000 6018000 0 9630000 12436000 1939509000 3125091000 0 5077036000 0.36 0.64 12436000 1939509000 3125091000 0 5077036000 0 35148000 13391000 0 48539000 56490000 425050000 133433000 0 614973000 0 0 642974000 0 642974000 57582000 266570000 297321000 0 621473000 0 2038000 3227000 0 5265000 0 8946000 13469000 0 22415000 13528000 1809269000 2649154000 0 4471951000 0.29 0.71 0.17 0.17 0.17 0.17 285200000 800000 620000 P1Y 3100000 5700000 0 1000000 P6M Earnings per ShareBasic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards, and unvested RSUs issued under our Equity Incentive Plan. We use the “if-converted” method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Class B ordinary shares, Class R redeemable shares, and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares, and deferred shares under the two-class method has not been presented. Our Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because shares of Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. For the years ended December 31, 2021 and 2020, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. Additionally, Class B ordinary shares in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive for the years ended December 31, 2021 and 2020, and therefore were excluded from the computation of diluted earnings per shares of Class A ordinary share. As of December 31, 2021 and 2020, we had 607,176 thousand and 607,111 thousand fully diluted Class A ordinary shares outstanding, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2021 (in thousands, except per share amounts).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect of unvested RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,802 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the IPO, our capital structure mainly included unitholder interests. We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements. Therefore, the basic and diluted earnings per share for the year ended December 31, 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares. The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2020 (in thousands, except per share amounts).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,701,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,198 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect of unvested RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.32 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)     Reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to controlling interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">on the consolidated statements of operations.</span></div> 1 607176000 607111000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2021 (in thousands, except per share amounts).</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect of unvested RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">414,802 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2020 (in thousands, except per share amounts).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,701,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships prior to the IPO (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships subsequent to the IPO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,198 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effect of unvested RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.32 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)     Reflected as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to controlling interest </span>on the consolidated statements of operations 1241201000 297321000 324152000 619728000 619728000 414794000 8000 414802000 1.49 1.49 1701954000 479842000 316993000 409921000 495198000 495198000 375444000 11000 375455000 1.32 1.32 Indirect Cash Flow<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,701,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,461,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,065,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,959,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,648,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230,839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,019,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(155,749)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in losses/(earnings) of non-consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,517 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions from non-consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,334 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination of derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Decrease/(increase) in operating assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,315,854 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,121,923 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,934,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,986 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Decrease)/increase in operating liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,017,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,034,629</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,667,239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash investing and financing activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental Schedule of Non-cash Investing/Financing Activities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of Epizyme forward purchase contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchase obligation - Tazverik (Note 17)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of long-term debt by contributions from non-controlling interest (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,103,774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milestone payable - Erleada (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Related to the pro rata portion of RPIFT’s outstanding debt repaid by the Legacy Investors Partnerships.</span></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020 as recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> on the consolidated balance sheet.</span></div></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,701,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,461,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,065,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,959,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,648,837)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230,839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,019,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(155,749)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in losses/(earnings) of non-consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,490 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,517 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions from non-consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,334 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination of derivative financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Decrease/(increase) in operating assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,315,854 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,121,923 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,934,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,986 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Decrease)/increase in operating liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,496 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,017,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,034,629</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,667,239</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash investing and financing activities are summarized below (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental Schedule of Non-cash Investing/Financing Activities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of contribution of investment in Legacy Investors Partnerships (Note 9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303,679 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of Epizyme forward purchase contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchase obligation - Tazverik (Note 17)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of long-term debt by contributions from non-controlling interest (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,103,774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milestone payable - Erleada (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Related to the pro rata portion of RPIFT’s outstanding debt repaid by the Legacy Investors Partnerships.</span></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020 as recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> on the consolidated balance sheet.</span></div></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1241201000 1701954000 2461419000 2065083000 1959975000 1648837000 452842000 230839000 -1019321000 22996000 23058000 23924000 20162000 11715000 12790000 -21532000 -42076000 -39138000 -48066000 247073000 155749000 -19490000 44459000 -32517000 34384000 42334000 14059000 -358000 -30272000 0 2443000 5428000 0 50896000 20551000 0 17859000 18600000 0 0 65053000 0 16093000 34952000 0 -4461000 -9621000 2122000 2315854000 2121923000 1934092000 0 0 150000000 20131000 -370000 -2471000 0 0 -150000000 9012000 770000 -7390000 -1857000 -34986000 41028000 -4586000 -766000 6496000 15550000 42146000 0 2017536000 2034629000 1667239000 0 303679000 0 0 5700000 0 0 110000000 0 0 1103774000 0 0 18600000 0 Accumulated Other Comprehensive Income<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the only component of accumulated other comprehensive income related to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Series A Biohaven Preferred Shares. As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were released into earnings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income as of December 31, 2021 and 2020 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains on Available for Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses on Interest Rate Swaps</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4,066)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,093</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,921)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,855)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification from non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,481)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,481)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification from non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reclassification of unrealized gains on available for sale debt securities of $50.9 million in the year ended December 31, 2021 is presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest incom</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e on the consolidated statements of operations, including $28.5 million attributable to controlling interest noted in the table above and $22.4 million attributable to the non-controlling interest. The total reclassification of unrealized gains on available for sale debt securities of $20.6 million in the year ended December 31, 2020 is presented within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest incom</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e on the consolidated statements of operations, including $10.9 million attributable to controlling interest noted in the table above and $9.6 million attributable to the non-controlling interest.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income as of December 31, 2021 and 2020 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains on Available for Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses on Interest Rate Swaps</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,159</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4,066)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,093</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,921)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,855)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification from non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification to net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,481)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,481)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Activity for the year</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification from non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6159000 -4066000 2093000 10921000 -4066000 6855000 60617000 0 60617000 24022000 0 24022000 2562000 0 2562000 34395000 0 34395000 28481000 0 28481000 6335000 0 6335000 4242000 0 4242000 16491000 0 16491000 50900000 28500000 22400000 20600000 10900000 9600000 Related Party Transactions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Manager</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Manager is the investment manager of Royalty Pharma and its subsidiaries. The Manager is an affiliate of RP Ireland, the administrator of RPIFT, RPI Intermediate FT and RPSFT. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of the board of directors, and as a director on the board of directors of RP Holdings.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer Transactions (discussed in Note 1–Organization and Purpose), the Manager entered into Management Agreements with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships. Pursuant to the Management Agreements, we pay quarterly operating and personnel expenses to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5% of the Adjusted Cash Receipts (both, as defined in the Management Agreement) for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in our consolidated net income, is calculated as the greater of $1 million per quarter and 0.3125% of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Exchange Date, the Manager received operating and personnel payments payable in equal quarterly installments that increased by 5% annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships. RP Ireland receives an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the limited partnership agreements of the Legacy Investors Partnerships. After the Exchange Date, operating and personnel payments were calculated in accordance with the methodology discussed in the paragraph above. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021, 2020 and 2019, total operating and personnel payments incurred were $145.2 million, $112.5 million and $60.0 million, respectively, including the amounts attributable to Old RPI, and were recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Payable to Non-Controlling Interest</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution payable to non-controlling interest represents the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPSFT’s non-controlling interest in RPCT. The distribution payable to non-controlling interest as of December 31, 2021 and 2020 included the following (in thousands). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to Legacy Investors Partnerships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distribution payable to non-controlling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,934 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,366 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Epizyme </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, in connection with a royalty acquisition and an equity investment in Epizyme made by RPIFT, Pablo Legorreta, our Chief Executive Officer, was appointed as a director of Epizyme, for which he received, and continues to receive, compensation in cash and shares of Epizyme, all of which are and will continue to be contributed to the Manager and used to reduce costs and expenses which would otherwise be billed to us or our affiliates. We continue to hold Epizyme common stock as of December 31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Bristol Myers Squibb</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”). We agreed to make payments to BMS based on sales of the products over eight quarters beginning with the first quarter of 2018 in exchange for a high single-digit royalty on worldwide sales of the products from 2020 through 2025. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly owned subsidiary of BioPharma Credit PLC (“BPCR”), an affiliate of us. We considered BPCR as a related party due to the sole member of the Manager having significant influence over BPCR’s investment manager. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began making installment payments to BMS in 2018 and completed our funding requirement, net of the assigned funding obligations, totaling $162.4 million in the three months ended March 31, 2020. We began to measure this financial royalty asset using the effective interest method once our installment funding obligation was completed and we received our first royalty payment in the three months ended June 30, 2020. As of December 31, 2021 and 2020, the financial royalty asset of $130.9 million and $150.6 million, respectively, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial royalty assets, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets represents only our right to the future payment streams acquired from BMS. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other transactions</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI, Inc (“MSCI”). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI’s thematic index suite with the launch of new indexes. In return, we will receive a percentage of MSCI’s revenues from those indexes. No amounts were due from MSCI as of December 31, 2021. The financial statement impact associated with this transaction was not material for the year ended December 31, 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the year ended December 31, 2020, we reimbursed Pablo Legorreta approximately $1.0 million for the cost of purchasing and donating ventilators to hospitals on behalf of Royalty Pharma. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 9–Non-Consolidated Affiliates for additional discussion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnership whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3 million is recorded as treasury interests, of which $1.6 million and $1.9 million are held by non-controlling interest as of December 31, 2021 and 2020, respectively.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.</span></div> 0.065 0.0025 1000000 0.003125 0.05 145200000 112500000 60000000 The distribution payable to non-controlling interest as of December 31, 2021 and 2020 included the following (in thousands). <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to Legacy Investors Partnerships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distribution payable to non-controlling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,934 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,366 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 92608000 100047000 15326000 26319000 107934000 126366000 0.50 0.50 162400000 130900000 150600000 P7Y 0 1000000 27210 -4300000 -1600000 -1900000 Commitments and Contingencies<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of its business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys to support MorphoSys’ acquisition of Constellation, which closed on July 15, 2021. As part of the funding agreement, we agreed to make additional milestone payments of up to $150.0 million and provide up to $350.0 million of Development Funding Bonds, which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation. MorphoSys is required to draw a minimum of $150.0 million, for which we have recognized the Development Funding Bond Forward within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> on the consolidated balance sheet as of December 31, 2021 (See Note 3–Available for Sale Debt Securities for additional discussion). Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding. As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 7, 2020, we entered into a funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones. Pursuant to the Series B Biohaven Preferred Share Agreement, we agreed to provide further support for the ongoing launch of Nurtec ODT with the purchase of committed, non-contingent Commercial Launch Preferred Equity for a total of $200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024. In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030. During the three months ended March 30, 2021, we began purchasing the Series B Biohaven Preferred Shares. We have a remaining commitment of $129.6 million under the Commercial Launch Preferred Equity, for which we have recognized the Series B Forwards within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> on the consolidated balance sheet as of December 31, 2021. See Note 3–Available for Sale Debt Securities for additional discussion.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, RPIFT agreed to pay $330.0 million to purchase Eisai’s royalties on future worldwide sales of Tazverik, a novel targeted therapy in late-stage clinical development that was approved by the FDA in January 2020 for epithelioid sarcoma, and with the potential to be approved in several cancer indications. Under the terms of our agreement with Eisai, we acquired Eisai’s future worldwide royalties on net sales by Epizyme of Tazverik outside of Japan, for an upfront payment of $110.0 million plus up to an additional $220.0 million for the remainder of the royalty upon FDA approval of Tazverik for certain indications. The FDA approval of Tazverik in January 2020 triggered our obligation to fund the second $110.0 million tranche in November 2020. On November 4, 2021, we funded the final $110.0 million tranche. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have commitments to advance funds to counterparties through our investment in the Avillion Entities and R&amp;D arrangements. Please refer to Note 9–Non-Consolidated Affiliates and Note 10–Research &amp; Development (“R&amp;D”) Funding Expense, respectively, for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the management agreement as described in Note 16–Related Party Transactions, which are variable and primarily based on cash receipts.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings in our consolidated balance sheets as of December 31, 2021 and 2020. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.</span></div> 150000000 350000000 P1Y 150000000 P9Y P2Y 200000000 129600000 330000000 110000000 220000000 110000000 110000000 Subsequent EventsIn January 2022, we acquired a royalty interest in aficamten from Cytokinetics, Incorporated (“Cytokinetics”) for $150.0 million, comprised of an upfront payment of $50 million and two additional $50 million payments which are conditional upon the initiation of potential pivotal clinical trials for obstructive hypertrophic cardiomyopathy and nonobstructive hypertrophic cardiomyopathy, respectively. Additionally, we will provide Cytokinetics long-term capital of up to $300 million (“Cytokinetics Commercial Launch Funding”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. The Cytokinetics Commercial Launch Funding is available in five tranches, including an initial tranche of $50 million funded upon closing and four additional tranches in the aggregate amount of $250 million upon the occurrence of certain regulatory and clinical development milestones. 150000000 50000000 2 50000000 300000000 5 50000000 4 250000000 Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (“IPO”) in the year ended December 31, 2020. See Note 13–Earnings per Share. EXCEL 86 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�D.1J,CJJC[&NYO;'"BVU(9JS>6!:G;$K%/*PM2-R6">W,U7]%L MR1K@B.41(.V)V**-WW[1 =$&]L'Z#"#M008Z^!VV=8 M]SK2W^L^2T8A>=^*)G$MH@&PO=V]R M:W-H965TRB[ZL5E7[=G)?==M/RT6[?)>;HKV8[V5E?K-;=ULBDZ];>X6[;:1Q6H8 MM%DO:!RGBTU15B?GI\//KIKSTWK7KFVN)/7LOMS>]6H=XOC+*MR(ZNVK*NHD;=G)Y_)ITO"XW[$8/)7 M*1];[7747\M-77_OWWQ=G9W$O4MR+9==/T>A_GF0%W*][J=2COQSF/7D^$?[ M@?KKY]F_#%>OKN:F:.5%O?Z[7'7W9R?92;22M\5NW7VK'W^3ARM*^OF6];H= M_A\]'FSCDVBY:[MZ675?_!7W>-^FVIQG7G7XJRB?XJ MUCL9_2Z+=M=(]:EV;514J^A+6175LBS6T=>J[9K=_C>_1-=J]:UV:QG5MY$V M_K=2-D6SO'^*?KJ475&NVY^5\9_7E]%/__KY=-$I;_N_N5@>//MU[QF=\.P_ MN^IC%-,/$8TIL0R_P(=?RN7'B)')X9?^P^/Q\(62^*@S/>I,A_G8Q'R?VU9V M[2=D)G:&Z5_*Y>[INQ*V=KTV4\CAFGZ^__A/,E()A02 MU 4]Z%*8EGG&J,AURY&O_.@K1WW]_*"6P>"J0E34%NK%2MYT#L?W*OFQYERQZWZH]SL M-M&RWFS*KG>O]_UVI]BZ'%U ,74!>U#FQOU)DMAV1USDYB=F6(XNA<3PH(C1 MBU&/V<>B6;6(+D1[ZI! C0F0E=!WN L.D^I2O5S^J,G868 WP>D]TUEF?JZ4 MV6Y9FV668@L 6$YPF,.C_D/TK7>W*:L[[!,$W)(D=#4 $LE[,)&8J)MXYM@L MT8<. 2@2G(I_U)V*M7IA>U(4@RA69X7Y&2LLQR*UN&NQI32GG$T[#* D6?AS M\C"'SX/29HH_*0F@F. LGKDN+$#-A+ Z;S'EG"-/2PKLI3A[]RNCJJM?W*OC M,)7N!Q>%L/COMGVCST97?;R7T_(/_ZK6I0=&F93 M0#5]HT";FLPUE#9-5("=($(#END,+ ]";S:R&=*WJV(K&TP3(#4-)34%4E.< MU/[ZVB)6P1-A6=&FJ;H'$TQHP#/%\3PIM&RZ\K98(."?T]@A$&6"*A0:B M#.##\$#T4C;EPQ#0V_-Q,YPDJ?518K-$@SBF;1[@4)L2]>\A!<$6+0,B,1ZJ M*0"'X:FX2U,SMS;$-$T2SJ9#"@8 8SC _BL?Y#HB_9)\96C, #I,A&H),&%X MN#8O!&)F4&9(C)F,G05:,9Q6OL$PLQ HSVC"++>5:=K'P71R*7!@%<=9Y14) M4Y9C/%(V$.R.-X9#9S4XXXEP%J,G86F,IQIKXF\N4F-B?UM9@Z M] 7$2B5 M.5"9XU3VE]@-8M1D[!^ F.,@]I#XU0%P F!-XD"E$P!?@H//6^G$S3K49.P? ML"[!6>=6VB/T38!3"0N5%IB3X$FH(TQ+S$J-(2AF,O9**^/@]'(+Z@Y[$V!1 MDH;J"8!)\%S3I:>YJV?HB9F,O0)4)3BJW'I^K3K9R+:+OO5/M^O'8HO) 0Q* M\D!I4R!*BH=J(&UT>RQPEU#@MI;,S'#,J)69)@E'4K84L)7BV-JK3F>D&2F@ M)PW=-TN!*^E[E#A2]R8::C)V%L"5XN#R33-22ZV9I1FUI!D64T(8S\?[56-_ M 6GI&Y2F4W]2CC:W[ QG,9.QLT#8U*?8XI=8I&[<6DS07884 MH)OZ0'?R]I^93J3 WC24O0+8*W#V>D=@P@U68< G(G0BH8 - D\-75$R<+<[S.$Q4S&IX< @[JPC U9EH06,# "4!14P,O>1&8L)^AC, &B9SZX:FQ$%9P"A+'3G+ .D M9'B@-B\8RLRP;.(2 <$RG&"^,7'F?6C&9HD["_C*<'QY!<29&9UQ M%A-+\&ZQG')1.T_X'G67S-S+FSIZ8C/%CYYDP-C,IP[C%R=GM@*+X%:=+:=E M\+.E.0 X]P'P)"IF1LPY(#D/17(.2,YQ)'M'$[D;SJC)V#_ %RCF0 M.@\E=0ZDSM^HQI&[TVK49.P?X#CWJ7&@$K\Z-,Z!KWEHJ2,'$.9O5.K(W:4. MU&3LGW9)!8._T1U*%P^>XA\T6 M/^]!8NWH<^Q@F4WL^2>"2*R=9(Y#=^2(WM;AZ.OPDIU8JAM3LEML';*/^D8< M-=QIV>=42(C>9D)"M^>(W@?B: 3QD]U=%,%M7KBG4<[1[('H/"<')WHS2'@W MB-X.XN@'\=/978/ ;5ZXIT'/T?/Q,CJ>I:U&+1*Z^T;TE@I'3X6?MI9,C^6Y M97_99BH$$=,Y(=%:*(BCA\*B= "NM48(0L-[W?1F-SQX\M*<^C2W^7>W:3T3 MQ-$T,:GR+#IK71"$AF:$1&MS(!0/I?Q4-I.]J95M,76M; UQCD:*2Y.S/$;5ZXI\'.T3XQD63/D5CK@2 L.$/4FAT(PZ,G M+XF9F?OQ.!]7^0Y*6TP%3[!03^NF((YVBFG! [C-]$[=X+11ZXD@# ^H_*3W MR!U1FQ?N:$E_2'.02VSE&;O7L+[7MO^J\I4NG*75FUT5K> MJC'QQ[[JW^R_^&?_IJNWPU?AW-1=5V^&E_>R6,FF-U"_OZWK[OE-_^TZQ^]? M.O\_4$L#!!0 ( &U(3U0N'-&[:00 \1 9 >&PO=V]R:W-H965T M($Y\KH]]C\]U&&ZD>M0K1 //L4CT M>6-E3/JMU=+1"F.F/9EB0D\64L7,4%,M6SI5R.8Y*!:MT/=[K9CQI#$:YO>F M:C24F1$\P:D"G<4Q4]M+%')SW@@:+S?N^')E[(W6:)BR)=ZC>4BGBEJM*LJ< MQYAH+A-0N#AO7 3?)F$.R'O\X+C1>]=@IS*3\M$VKN?G#=\R0H&1L2$8_:SQ M"H6PD8C'4QFT48UI@?O7+]$G^>1I,C.F\4J*/_C[DYC[#_1A.OIS"%^ )W' A2#AZV#)$T@[5BDI"EP6A\ "ABU1YX'>; M$/K!H 9^Y8;?RK4';=_"PZ &/G;#QQ@1/#@(__5XN%\#GQP-?SWW%N6U2FY8 M)3?,X[7?36X3+K1&REZ9Y#G0KK[#*%.*)TNX9)KK)CPDVT[]KM?Q]SZO M$).WB*^!W_$Z5;=_3;M33;OCG/8=TG;BN;5J.UDR6F'3$,DXMDTCH\I]3JV<5P3/G6MQF\0P5R 5H6@(29)JI:$5%;0XG)-WBYFF=8Q5Q M>WLB:O<[/5);O8KZ%:&^D]"4:C JNS[W!:&?,,:9@?MJSSAF/:@&&7S.M 3^ MKH+Y[^RF.<9I'CNE787YSHFH5M')J+;^N,/1F^9Q%M/5;K,W89JK!'Y/T+40.W\/ MSCZIU>TMSAWN"*O;U8E@\']G[4,%*]S5@]#_G'D,=W4A=->%C^;Q MG7"./+;V7@WM7P4W3"TYG3H%+BB4[YW1'E;%VW?1,#+-WQ9GTM"[9WZY0C9' M93O0\X64YJ5A7T"K_T!&_P!02P,$% @ ;4A/5$=3;P-!!0 K!@ !D M !X;"]W;W)K&ULU5E;;^(X%/XK%IJ'&:DML9-P MJ2A2H3.[(VVEJDQG'U;[8!(#5IV8L1V8KO;'KYV$!'#B0C7[T)>2RSDGW[E^ MMCO:[,EJ1!,LKOB:I?K/@(L%*WXIE5ZX%P7&N ME+ N\KQ>-\$T[8Q'^;,',1[Q3#&:D@B[;F4EI@E))>4I$&1QT[F%UU,_, JYQ'=*MG+O&AA7YIP_ MFYNO\4W',X@((Y$R)K#^V9 I8-XO[USOJ7W'GMS!Q+,N7L M3QJKU4UGT $Q6>",J4>^_9V4#H7&7L29S/^";2GK=4"42<634EDC2&A:_.*? M92#V%&"O10&5"NA8(6A1\$L%/W>T0):[=8<5'H\$WP)AI+4U7()9 MD7+ %V"ZPNF2 )J"*1;BA:;+TIA^]P?9$ ;\%C,?[XC"E,E/VN#3[ Y\_/ ) M?#"&OJUX)O7GY:BKM(,&9C";(:?&.1%? AQ< >0@V )J>KNXYX/A5MOS<7M!B[_./C*H7,"-1)JBB1()_ M=V%V6 \JZT%NW7^U%B[ K91$9ZFLB1CHCGLT7Q4FQ1,LJ;P 3RF?2R(V>,Z( MSNTZ4T:&ZUPSBDV37NBJ8%'&\AOPUR-G#.CFVV(1_^W &U9X0V+SSQX(5@T%5%AM9];-6-N,]:YV>QGU25Q +570>TYH3YD M(EKI:=-8U(5J;^]K?@C1,29;J@53O\+4=V+Z30]Y:1)+BJJ2554U@>Q;G^\/ MAOX11ENH!>.@PC@X)\5$3Z57DCNP( 2^!X^!VE(M0(<5T*$3Z(P(TXZWX$'3 M$!&F96:*1\\G-2CTZFGMO8L6A7O\ O^7)BW-[J<(P2#PCMNB00[Z$ U:\@E1 M#1R]O65+W8-V\(( 'H.SQ=IPU10 W1QP7MN6Q@["@X9V%&VQ$/51V *V9A08 MO-(62K%\26'RO2@*JQEH8 ,=!.'P&*@MUA;1FD:@FT>^"9Q*W;1 \;)942/" MT/'I$ITMYPV!ZN MGFN^0IX36*X)@((Z#?+SA7NQOS@>H?%./_ %!+ P04 " !M2$]4\H/ZY: " #Z M!@ &0 'AL+W=O,[VY0J'6 R_TM@L/?+ZP;L$?]I=L MCA.TC\M[33._8CQ-67!4\<7O-*!]P=;]FO2^_D97*F'*7UC7M8$':6&LRFLP*[##B!LOP.(:D#T M64!< ^+2:*6LM#5FE@W[6JU!NVIBWEJO(2O>-EC.D9Q&$+HB *]\!'GX<'K^$^=;5I;=2T-BKYVA^V]@!9 MW)#%)5G\<4YC;E*A7%0MN#2&_NDNK%O.IEQPNVG!-V6W86; [$XR\/.6>.'& M8FY^'5#5;E2U#UMLOA"M-DS8#3 GR+1 HMT78$67E'3N@%D-PU[03L+SN.^O M=J/:4WA.96'2:PI?*>XTBCL'%8^8UALNYU4_]NA\Q=IM6+O_43I)HRKYM^DD M?S>]'<=1I]=]D\Z>PJC7Z41)\B8=?^=D&ULQ5I=;]LV M%/TKA-&'%FAK?DF4BL1 ZJQ;@6X+DK8;,.R!EFE;J#X\DG;J?S]*5DQ%HEBW M<.,^Q))]2-YS>7D.)?;BOI1?U$H(#;[F6:$N1RNMUV_&8Y6L1,[5ZW(M"O/+ MHI0YU^96+L=J+06?UXWR;(PA#,ZM MR,K[RQ$:/7QQFRY7NOIB/+E8\Z6X$_K3^D::N_&AEWF:BT*E90&D6%R.KM"; M*8VJ!C7BL:5%1F9?FENGD_OQS!*B*1B41777#SL153D6553R:._YI. M1XW]7D#9D95V):9G^E<[VZ'$4C,!<+OLGT;7G_FV@(!55_29FI M^B^X;[!P!)*-TF7>-#81Y&FQ_^1?FT2T&B ZT W#?"Q#4C3@-1$]Y'5M*ZY MYI,+6=X#6:%-;]5%G9NZM6&3%M4TWFEI?DU-.SUYEQ:\2%*>@=MRQS.] U=* M":U>@C],#;T"=_OI!>4"^*'/KX7F::9>F$:?[J[!\V*]%KO[U#$\. MPY-Z>#HP_*^R5 I,N92[:J#//-L(5T[WO;"ZEVH5;R T@Q MBA&TP$>!TD.@U!OH=)-O,EXM3\ SHQ,F,P(8Q0')BA=+H:JJ$%_79B&+.4BX M6H&%03GK8S]0V KQ%2(113TN#F!,(8+,324X4 F\5*K*3AXROJTR_A+,A.$B MS.(<8BG%/-4@,[,EG*2"7JR(AI10"#ND'$""613'U,TJ/+ *?W""OA5ZV$\S M03""M!.Y"X<)0P/3P0Z!L^^<#E>0S)%?0G 0AYTH'4 5MZ*F$J!GI4473*"3=DG+@X -:SL(/[T(-6,^SGK$( RZC%Q MW_18/T-^0_NX4WPF4U]56LM!]"S+PAH%\CO%TH1#6$8=_/>!YJ].6'Q M@#@AJ_[H1^7_^Y>%0^A1&+9TOB'CPB',\-#BL(Z OM<23K$X',X0X9@&N,O+ M!30[J"$'0=9"D-]#WN("7]0[L]XZ_M:E=GW5@:QWX+-:!K77@TU@'=E@'@A"&7>?%"C7Q"_75 M=528/[E2C VOQ@RALD@G??'#7Q1X[=%:S^=0E\&_B8@;4' M$GL9W,@RYXGV>0VU4D_A.18TM5)/_5)_Y(*>TKZ.AU&(\,"NEEHQIWXQ/]U" MG=*^A _,-K7J3?WJ_3-6X;09\^ADMDXA_,<0?^J5D+ZZL$)/@[,4IA5PZA?P M8YV&]J67AC$+XMYQ21]((,88D8&L6Z6F?J4^Y>%/7W=?Q3".4?>EJPL8$AH' M0Q5O%9KZ%?JG^$XS9OO@C;"(&4_I\NH#,8D8#KNS-&X= %>G[[]SN4Q-A69B M85K"U\S4M]P?:.]O=+FNSX1GI=9E7E^N!)\+60',[XO2%'IS4QTS'_Y;P>1_ M4$L#!!0 ( &U(3U1H9[.=.@, $(+ 9 >&PO=V]R:W-H965T(JB1Y)VPFP/WY'65'M5$D]8$%>+/ZX[SO>?6?R1GNEOYH"T<)=5=9F[!76 M;C[XOED56 ESJ398TTZN="4L3?7:-QN-(FM 5>GS(!CXE9"U-QDU:PL]&:FM M+66-"PUF6U5"WW_$4NW''O,>%I9R75BWX$]&&['&&[1?-@M-,[]CR62%M9&J M!HWYV+MB'^:,.T!C\9O$O3D:@POE5JFO;O(I&WN!.Q&6N+*.0M!GAU,L2\=$ MY_B[)?4ZGPYX/'Y@OVZ"IV!NA<&I*G^7F2W&7N)!AKG8EG:I]C]A&U#L^%:J M-,TO[%O;P(/5UEA5M6 Z027KPU?HU&I US.\V)#1F,!6F@&O"&P]7QJ U\!Y^$5H?'+V=H16R-.]H]0=O'.VOA=H: MG:B\DY4WO"%3_"U*M1K6.(*Y4[&LQW# (A:%R:GAO,#-/.\"0C49>1 MZ-F,+!\"G_<&?L(9=YSQ:X@\Z-P/7E#DP?>)YCR.V5&B#QKW&+*4!X/PL<8' MP\$)8\)CSO@CC?L8.8O3..S7>-@E9'AN0N9Y3M?C!2Q02Y6!RN$J4QOW,)) M7;*>$2'I?":O40-IYSY]N1J8I=\I1LH.@[A?!A9\>]&"_U<(^ ?^RQ^4';VM M[#7D8=_> <9?4*"6?/@CA?RC]L-UES\+O9:U@1)S @:70[K(]*%A.TRLVC0= MR:VRU-\TPX*:7-3.@/9SI>S#Q#4Y7=L\^1=02P,$% @ ;4A/5*'""9$K M! &0X !D !X;"]W;W)K&ULQ5?+;MLX%/T5 MPNBB!9)(U%N%8R"Q$TR!%@B2Z70QF 4C75F:2J2'I./D[WLIR;(MRW* 671C MB])]G%!$K6N*B;?;J$4F^L)G6Q?/!;+ M7)L7UFRZ8DMX OU]]2!Q9756TJ("K@K!B83L>G)#/R^H;Q1JB;\*V*B]9V*@ M/ OQTRR^I-<3VT0$)23:F&#X]P)S*$MC">/XKS4ZZ7P:Q?WGK?7[&CR">68* MYJ+\4:0ZOYY$$Y)"QM:E?A2;/Z %5 >8B%+5OV33RMH3DJR5%E6KC!%4!6_^ MV6M+Q)X"#4XH.*V"TU?P3BBXK8+[7@6O5?!J9AHH-0\+IMEL*L6&2".-ULQ# M36:MC? +;O;]24O\6J">GLW7U;IDAGMR4V(2,)X 83PE.@?R(,5+4>\P)AB9 MYXPO09&"D[O7%>X;I&3.5$[N44^13(J*W!<<+12L)(_BC97ZC=PH!5J12_*$ M*9NN2R B(X->W^'CXP(T*TKU">U]?UJ0CQ\^D0]&^,]4%^\6YW&(VC<+D/J]U[)]S?PK+@W+A_9J5Q.+3#C8FP-F$ZW MU'K99WY , HBCT:'D=H^A ;G \P/J]!@: MD',=M'>"H* C*!@E"+/W-Q$4' 'RO"#V_1X_QV)^:,=^W*/G6(RZGF.[T3 ] M84=/.$K/#UEHN!199KKH$#5#R,*C6!P:FLYT &Q *@YZ];,X%HI]ZI\ %76@ MHO.@R!94TTI*TTK&4,VCXWA]&GK#H<1=*/%H*/.UE, U68$L1$I6!P-P+S10 M%X2#'F([/MYY)Z9NC^UCJ4N*518%P_%3>S?/[5$$.,3.-,O6P&%S"V(O]OJY MWDH&9_OJ8DBRUU@/\>R=3^CYY#"Y(0%S'6L<^\*)LA[*DM;Z0<;B6+5/A.7L MPG+.)$I7>W=9AMWG@CPT.8,Y?).*E3G5XIA,_\4S')Z3]<@HI+M13'_++*:[ M84S__S2>T\'IZ82V?X+UW?2DX^/S;'(O6@/G?5M[9^8*Y+*^>RB2B#77S5&O M>]O=;V[J4WWO_:VY]]1G\9V9YM+TC4ED2Y$2,C1I7X48FVSN(01@"_9T+H[<(XZ&Z#LU]02P,$% @ ;4A/5/1 &T:] @ MAP@ !D !X;"]W;W)K&ULO59=;]HP%/TK5M2' M5FJ;#TA"*T"BH&I(VX3*VCU,>S#)!:PZ-K-O2MFOGYVD&91 JZG:2^*/<^X] M]^8D3G B!YSKC0/6>)N+IV79TL(:/Z4JY F)VY5!E%,U4+5Z\4T+0@ M9=P-/"]R,\J$T^\6:Q/5[\H<.1,P443G64;5Y@:X7/<]7$V5F;ATE91D(S:0@"N8]9^!?#WW/$@K$ X.UWAH36\I,RD<[&:<] MQ[.*@$."-@0UMR<8 NT[' M(2G,:<[Q3JX_0550:.,EDNOB2M85UG-(DFN4644V"C(FRCM]KAJQ1?#;!PA! M10C>2VA5A%91:*FL*&M$D?:[2JZ)LF@3S0Z*WA1L4PT3]C%.49E=9GC8'PND M8L%F',B=W%".&S+0&E"?DZ_&1!=D:HR3YF9;SDD#V"R! HV:G(X *>/ZS)#N MIR-R>G)&3@@3Y-M2YIJ*5'==-(IM7C>IU-V4ZH(#ZD:07)*6?TX"+_ ;Z,/W MT[U=NFOZ5#V'XM=!\6QG$8>LU"PUIH>%2H=>^0*K5A8D$> M*,^A26*XGSN*O5<"]T%!)XH.-#*J]45']8TFDXOQ UF93@K41^P2UP'C_V#. M3IVM\T_F[#0\\P9SO@G;$755B[KZ,'->O<^<^[!CYO2]OY]=[P/L606)C_NS M =5D4'?KE+!']!>J%DQHPF%N>-YE;'RNRE.OG*!<%0?'3*(YAHKATOPI@+( MLS^7$E\F]BRJ_SWZ?P!02P,$% @ ;4A/5+N4X3DE P P@@ !D !X M;"]W;W)K&ULO59;;]LV%/XK!T(+)$!C77R+"]M M'*^8@:0P$K1]&/; 2$]2"3%[SO?N9!'T[W2 MSV:+:.&E$-+,@JVUY<A*36RS(,*$291- H+ MQF4PG_JUM9Y/564%E[C68*JB8/IU@4+M9T$<'!8>^&9KW4(XGY9L@X]HOY1K M3;.P9/"GU[":K;!9$3A *3*UC M8/3:X2T*X8A(QI\-9]":=,#C\8']D_>=?'EB!F^5^,8SNYT%UP%DF+-*V >U M_Q4;?X:.+U7"^"?LF[U1 &EEK"H:,"DHN*S?[*6)PQ$@'IT!) T@^1$P. /H M-X#^6P&#!C#PD:E=\7%8,LOF4ZWVH-UN8G,#'TR/)O>Y=&E_M)J^;W"&[P%W*"N$!G^JHKIQ MD_$9W/(_HD6J[75ZNO4#)+CG=E>]P2CO^';%^WUJX[Y=?6 M*-/.VE$1L^:6J@SFE:N$'$\EM9L\AE=DND/EI%4YZ21::_4'=3*2R*CP+/^K M/HCX4KKZ]-=)S3KTK*Y#[^;#WG@:[HZEA$>W>X%ZX[ND@515TM878[O: M-N(;WW]^6%]0@Z[[Z;\T=7>_9WK#I0&!.5%&O3$ITG7'K"=6E;Z'/"E+'DHHW0#^^U,62K%L<-/9+(E%S9N9P MACPTQQO&GX5/B 0_PR 2EP-?RO6%I@G7)R$6YVQ-(O5ER7B(I7KE*TVL.<%> M"@H##>FZK8681H/).!U[X),QBV5 (_+ @8C#$//7*Q*PS>4 #K8#7^G*E\F M-AFO\8H\$OE]_<#5FU9X\6A((D%9!#A97@ZF\.(..0D@M?B#DHVH/(.$RA-C MS\G+PKL^%S$@0))Y4'C]RIX,B9@*L/F^]WZ3D%9DG+,B, M!7]23_J7@]$ >&2)XT!^99L[DA.R$G\N"T3Z%VQR6WT W%A(%N9@E4%(H^P_ M_IE/1 4 [0X R@&H#C [ $8.,/8%F#G W!=@Y0!K7X"= ^PZP.@ #'/ <-\( MHQPP2JN;E2.MY1Q+/!ESM@$\L5;>DH>T(5*T*B&-DMY]E%Q]I0HG)[^QZ&S& M(L$"ZF%)/#!=+FE U:, )W,B,0W$*3@#WQ_GX.33*?@$: 2^^2P6./+$6),J MA\23YN;QKK)XJ",>1.">1=(7X#KRB+?K0%/)%PS0EL$5ZO4X)^XY,.!G@'0$ M6Q*:[0_76^#SO>'0:8%?]\-_C8/>Y&_ZX3?DZ1S [N1O^^'W^'6;^Z@%??<6 MFA?4ASV%-(I6-%)_1H>_1[4O>W% %N"ZQ\QE:_@GDB?>6 1O1 AU8XI!?C[ MBX*!A22A^*!B.;3U>N9[F/I.5.)E8AJ6 MX9AC[:7:@2UFEND8=F&VD[I5I&[UII[/DQ* M?F?0,1V]1J-I9IJFY>Q:S:T&V3,#64F'M)&U"[)V+]DY%9+3IS@1/ &6G(7O M)6DWLK>046/8M(&6/JJ5<]ZTTMO)#0MRPP.3&S92,DRCGOBL:64BPZC3:UI! M4Z^4>8?BJ* XZJ4X?:%!D!Q6%@OPKUK7W'T&4R'4X>P,//CJ\)%\F"D4=7$ MOG&*@Y[5[111G>-M*5 O-57O)?N[] D':DV&- W1I@NYB^HZ@0A9>FW1W;;9 MZP5M533^IHF\RKRX2:PQ,L -Y^.6T3DS?B M6/JYKO_2-_VH3!F]H]>F?S4;39U=BI=WM!TLI0P>4*58H8W$O%&K/S&:BCZ'_W5(N&G5M#N:7#_CW]XPX@ M>:"JYHR<^A8W:[&R4?<65XH$= XLOWF :F8(-O;H69L9ZBP$*O4&]>O-!ZZA M8N^\CB25M$YW-\%21! \WKI!I1"@?B'XN ;- ^T6BE:K10@*A)M6F'1G8G@U+#4+^V M'**9%WWM5$H5LH[8Q:7HH$/_],D#[)P-C9;F;?GYTS2;MWDS86?A2Y5#_2IW MD,+W5KY4.C0Z8N5+84('%J99'F"X(TQ&HU9:Y0(Q)'R57B8+M5/$D8KZAB$9"E&PO=V]R:W-H965T\B($3":Q3&8F(%4B:?;5MX 8FPN&<)B=63+>,1ENJ6[VR1 M<()] XI"VW6F8I3*D,5EQ$&D48?XV(R$[3"QD'1?6=!=( MO6!/QPG>D0V1S\F*JSN[\.+3B,2"LA@XV4ZL!_1YZ1J L?B3DH.H7(,.Y86Q M[_KFT9]8CF9$0N))[0*KOSV9DS#4GA2/?W*G5O%.#:Q>'[U_,<&K8%ZP(',6 M?J.^#";6T *?;'$:RC4[?"5Y0#WMSV.A,+]PR&T="[Q42!;E8,4@HG'VCU_S M1%0 RD\]P,T![D= OP'0R0&=CX!N Z"; [KG GHYP(1N9[&;Q"VPQ-,Q9P?@ MVEIYTQ-XLX.;3+7P"&L,? 4L%CGTQMJ6B MIU]B>SF564;%;:""X(G%,A"PC'WBU^#G/\"[+0YLE9XQ.3.WU>-O;'\/ M'><.7,=%=83:X0OB*3AJA"_.ASLU\.79<#1J24:GZ)2.\=?Y4:>HZK[KDP?. M<;PC^OH.YJH"7.U^D Q6A&LE _4#O\N < %__:J\PJ,DD?B[A5.WX-0UG+KG M&,]:3O=3):[.L#NV]]4:U9CUW>'HO=7RU&K8<3K] MPNI==+TBNEYK=,_)EJMT0H+?3% Z2'4:1#2-U!JMW2*9QWZ%"!IU5&#U3/H% MDWXKDR?&DX!MWD1+S0:%K\'5]-&PX#2\6!\-3S(^4GW4D/!106AT7L+A/YA1 M-N=O0L(JP.IH]$@JJ8=#<0>/L7??$CURRD/ N9J:H,K1A"Y5E5GNNKHCD=.\ M$9!;DG);21U/PH<=)R8O KY1&< &QVQ+V^(NA19=C]*B4FK1Y;0V=UW=)/U1 MI1:9U-98N4[OH]FRQ@P-FRM;JBUJE]LUT1_6.A*/11&567 JH_EG4!$H/I:^ M-M1>3>,-&MF5"HS:)?BD[[*V.XI#6XE+94;7(\VHU&9T,7%>Y*ZKU>@-&XM1 MJC-JE^3Y*5[*LGJ2^JD&'9EF(D(WYDI M4J@]F<8R^W0O5HM)]<',9Q_6YVJ"S>;-TDTV_CYAOJ.Q@)!LE4OG?J#V+,\F MRNQ&LL2,3"],J@',7 9J"B=<&ZCG6\;D\4:_H)CKI_\#4$L#!!0 ( &U( M3U1UT4WO*P4 *4> 9 >&PO=V]R:W-H965T,1=M")=$CJ;@M]N-' M4HZHQ#9EH99]8>OC\)R7U,M'LCA9,_Y%+"F5X&N>%>)RL)1R=>%Y8K:D.1%# MMJ*%.C-G/"=2[?*%)U:4_FPNN-JSZNS)&E."Y&R G ZOQR\ M"RZN<:P;F(@_4KH6C6V@N_+(V!>]Z#7-,IU)Z?AW MDW10U]0-F]O/V=^;SJO./!)!KUGV9YK(Y>5@- )G9,RDY_8^E>ZZ5"H\\U8 M)LPW6%>QL3\ LU)(EF\:*P5Y6E2_Y.MF(!H-@FA/ [AI %\WP'L:H$T#9#I: M*3/=NB&23">,JQ9IL1#@'-PK MDR1E1@&;@\:)LQLJ29J)-RKDX?X&G/WT9N))55RG\&:;0E=5(;BG4 #!1U;( MI0"_% E-7B;P5*E:.GR6?@6=&6_H; A0\!9 'P8[!%T?WMQWR$'U2"*3#^W- M]RC!;2$D+Y7-)?C[@PH MY+FXA]'>ERGQR8]WI/^H2 YXS+]3A-E4U4J2<6, ME:H0*1*0"E&28D;!C DI=EV=*GMLLNNY_30]ASX:(U]])MY3<]QVA 8CA(.H M&?JB$V'=B=#9B<],DJR2/R.1'^]0O!T:CH(H M'.&]BJ-:<>14_($*<0&N2\[U-5WI*Z#@H^9'QHK%N:0\-]W9I3_:$O5:MBOB MA=JX5AL?,+[MTN+#AW8[M&UH1[7848NC!9V57/G93)W_P!U+U1C?TR=:@/<* M[N".\ADUAXJ4_->,"__GSZGIL8B-W[$N]C9M!<(#>>D#> B&)5!>(JV]P1@0@8%5= MD]UW '=V?QB'/[O&%5J=\-!Q!4U5>F*N"*^8(@@=$JV=X< =7/[ M[\IJE>,_KQGXBW+F]'OH4F%O(@'NQ?$6\(&;\(XCUP\_U' M'>_.'@RA[[2/!7O@)OO1'.\N,QX-1RV3U.(]Z,AWZ_@#&1^[=%C(![U0'EK* MPZ-0'G:@/.Q.>6@I#WNE?$OVH(7RT%(>GH;R+664Y^$(.R5;RL..E-=L/YSR MR/5'!%K*PUXH#RWEX5$H#SM0'G:G/+24A[U2OB4[;*$\M)2'IZ%\2YEQ/(PC MIV(+>=@1\M;P&O<&\2N'X0.7"HMXV OBD44\.@KBT3;BHSU^1]N$WV-S9,&. M>@5[2W8X#)Q@1Q;LZ#1@;RFCP1XAI^3&RYVN8%]R6C_ F^TVN&/G6R8+=]0+ MW)&%.SH*W%$'N*/N<$<6[JA7N+=D1T/DA#NR<$>G@7M+F7$X#$,GW9&E.^I* M]X;K#=O;GN%#I^DMX%$O@,<6\/@H@,<=GN%Q]V=X;%&/>T5]2W:D+.1R$+:H MQZ=!?4L997KD.TV/+>KQ#Z.^U?6NQQK<>.7?"^JQ13T^"NKQ-NKC?:;?#MWG M=0MXW"O@6[(KP+N];@&/3P/XEC+JZ3V,=DOV&@N!.>4+LSXJ@%DGJM8$ZZ/U M&NP[L_+HV?!J ?,J1MD#3KP[ '6J9MHI+H4I33#/WP.\J*:5?V26VB]:&19-Y?1][Q MIR.EXP>EOV1S(0SYEL1I=M*9&[-XT^MET5PD/.NJA4CAEZG2"3=PJF>];*$% MGQ1&2=RCGM?O)5RFG=/CXMJ-/CU6N8EE*FXTR?(DX?KQ3,3JX:3C=YXNW,K9 MW-@+O=/C!9^).V'N%S<:SGIKE8E,1)I)E1(MIB>=M_Z;2W9D#8H6?TGQD&T< M$]N5L5)?[,G5Y*3C68]$+")C)3C\68IS$<=6"?SX6HIVUO>TAIO'3^JCHO/0 MF3'/Q+F*/\N)F9]TAATR$5.>Q^96/5R*LD/,ZD4JSHK_R4/9UNN0*,^,2DIC M\""1Z>HO_U8.Q(8!]?<8T-* -C4(2H.@J4%8&H1-#5AIP)H:]$N#?E.#06DP M:&HP+ V&1717X2AB><$-/SW6ZH%HVQK4[$&1$(4UA%"F-G?OC(9?)=B9TS.E MP4*FLXP$.I1 M[_[N@KSZ;9?*>0,5C]:I7. J%R+JDL O5/S]*N^:JR"^C!JK^$?[5?[ 5?[, MXRZA_;H>7>(J(S&&&&$]ZD%6K).)KI.)%K+!WBZ.#;E*,Z-SP)LA?U]# W)E M1)+]@\@':_F@D _WR-^G/%':R'_%A$QD%JD<[L'3"8D53XG,LIRGD2"1RDQ& M@(NQ2F>'1N@$8#8VN[)G=;]!<3]+^>4I]8*CP(-_Q[WE9H946_K#(/3[FRVW M.A6N.Q6BG;I66>&L^&9@%N8RFQ=#IZ9[G0XKK@1L6/5XU:R_VD26W>)H5VZ$ZE4FGQ01F1(V/MKN7X;6358RP]0;PMYFSQBM0XL.0[V3J]R 70)/"1B/B> M>RAY;83-!]QTJ?/G,P&3J8CII^T,I@.H+Y.,*:#F:5 M2(.:P73$\7'DK%UP4V6G"ZPZBVF >> @Y?=1#SX753),8;X4&JI^<")?V/J> M&RBG>$8X60@=00!VUS&X.NT.O=^Q8#G:^3CN*GZ*Z504"P@B4Z"*R$QCG_$[ M!5VOC_KL .G7$3(34:[!Z2+.W\FGN:A]O/B.:OY1&Q.$.IQ1[P4FR'FI,MA% MFSWY21WQ:$/BH3/DO%39]"'T0LR#C>(0!]XS9TB-.NWZE&'I1ATP*5YGON 4 MJ;D3[3)T6E/'8/K"9>0[6L7Q(4,C[6A,<1KOGZ]P?"V6(B84Z[6#+FVE-*2. MEA1GV(A+398\AN][K(] MFUP.TB&.U/"8SLGK_9>O()8=DL07!JM MH0VQVOE&H$;1 .6XFEHWR(4_Z9 ML<3%ZVHHYJ#.<*B7H;O;#NCMS=4J0 F,O/5W](G\T'([*%+8EX^?-$\CJ(W? M'F+;GLPQGOEM!(DY)C-\QZ'9KLYEJ;+UOJ9FC<<2#F=X.FR\DVJ%O\SQES6IJ>O3H5]].3,,\71P<&4X7-N*P&X1;-@< M2UDK+&6.I0S'7ZYGL/""DGT* MQEYW %FK5]_7K$Z,6A1?:XR5,2HI#N?P%!#:-H#?ITJ9IQ/[ &ULM5;);MLP%/R5!R&'!$BBS6M@&VAL% W0%D'+E#@S;T9<-%A+]:"7B :>\DSHH;K[&3*Z'7NB]W+CCBZ6Q-_S18,46.$5SO[I5U/-KEI3G*#27 A3.A]Z[ M\&H<1A;@1GSEN-8;;;!69E(^V,Y-.O0"6Q%FF!A+P>CRB&/,,LM$=?RJ2+U: MTP(WVR_L[YUY,C-C&LZ7T9;7L3 MG!F8/<-W9 I.)V@8S_090>ZG$S@].8,3X *^+&6AF4CUP#=4FU7PDZJ.Z[*. M:$<=$TPN(0[/(0JBL $^/AX>O(7[Y*^.):ICB1Q?O)./_-X(;51A,X ?'VD MW!C,]<\]]'%-'SOZU@[Z>\%RJ0S_C2FD7">R( T*#C+)!'"M"R82A$1J&[^@ MVV)Q85#E-$-GIBG=4J_K].S2?1Q%0=R/*8O'S12WAX6]N!5VZF%O[+1J.ZT# M=C0FA2(S+K<_-!$0/DN#>D]6[9J\_3]>1:>F[^RMG29,U!1HB>IL)!4TA]2M MA;J'A.(FH>Z64!BX7[-P4%(W M[ZK1UHKN-I;@;YP1]H#^Q-2""PT9S@D97'9I%:KRS"L[1J[SR4M\*IC3Z+ZRV/T%U!+ P04 " !M2$]4^9-@K 0& !M' M&0 'AL+W=OGGMX M;[H[2I-GRC[S#2$"?$WBE%_T-D)LSQV'!QN28'Y&MR25=U:4)5C(4[9V^)81 M'&JA)':0Z_I.@J.T-YWH:W=L.J&9B*.4W#' LR3![-LEB>GS10_V=A?NH_5& MJ O.=++%:[(DXF%[Q^294[*$44)2'M$4,+*ZZ+V%Y[>>%M"(WR+RS/>.@3+E MD=+/ZF017O1<2< M7-'X]R@4FXO>J ="LL)9+.[I\YP4!@T47T!CKG_!FRPUF9$/CD##^"[C^DD7B M&W@#/F'&L'H^P,F,"!S%_/7$$7(])>4$!?=ESHU:N#WPD:9BP\%U&I*P0?[& M+.]WR;\SRT-D('"DHTIOH9VW+I&1<4:",^#!4X!N_HE001K@(8LSY*^ KCS,\]\&&Z[,*R[)5J[HYBM6= U$,S/1^RRU)+HV M$WW$K/*!D>C&0B,XU$1NX"^N5J)"AK^("_@[O]54/7-N7W.K:>EI MBB;.TW[J=R+F)D3-I$%ITL#2I'HZ@UTZ*Y-:,KW)R,&1@OT#(SL1H-% ;B+D7[,RHU*9D5&9>R*G&1X) CAA3U% 5&PCVC1(S,U,$'PCF!GJ MQ;A4:6PDTM.6WC6$(*")W$IQK#AX- O+,%SBV =8.KE@B]'V?P:?'4J 4 M8NIVTT/4L:P/$CV-FX)6-5YH[KPSLB),U9=EUZ0 J\X'!R^1:%73@>:NDZMZ M"F@FN)!U4755U7KR#M.\P?*/6I_G0SAL2BQKZ-P>NFB"0K_O#H^@'QJ@!Y!; M(Z3NU:KE0'//N:*)S"N0!^^M*5!5XX"CETB$J@M @60=5Q.15&E%&5AE(I,=(.(\P]+A716I6&%?-Q\UE"-+W+P; M5[>UZA#(W"%JJ75IBF[5(-!+- A4-0AD;A#_JBZ@XUH*AWT$&^J"/71N#UTT M0!$_"JHHXZBKKV]#VX)R$A"7Z,2>YSDYNK\HY>HKRCJKRC'UC>T7%U M'30]3E:PN1ULT0FKOVNIRKEG+N?_8<(I&+OLMX/-.V%UPZJ^X<&.74Z9AUPE MS:FLH2%)MGI2WK*HJ)LD8_3@%<+!^\:F%YS%VK5)_T!A9^\-?T+86G^WXG)@ MSU*1OPPKKY;?QM[J+P0'UR_A^35LN/X.GB_R+U\5??XA[B-FZRCE("8KN91[ M-I0UDN7?MO(30;?Z^\(C%8(F^G!#L.QU"B#OKR@5NQ.U0/F%&PO=V]R:W-H965T7@1GY>B[+.GJO[2+)1JDZ^K9=F\.UFT M[>^Z/C^KUNVR*-5UG33KU2JOOUVH9?7T[@2=/+_QL;A?M-T;H_.SA_Q>W:CV M\\-UK5^-=J7,BY4JFZ(JDUK=O3MYC]Y.)>L"-HI_%NJIV?L[Z9IR6U5?NA[__5SZU:;QNC&W>:,N MJ^6_BGF[>'P&Z''\ [@-P; #I X@=0 ,!M ^@=@ /!+ ^@,76P/L 'AL@ M^@"Q&:QM[VZ&9IRW^?E973TE=:?6I75_;,9W$ZU'I"B[J7C3UOK30L>UYS>+ MO%:+:CE7=?/W9/+GNFB_):?)S79F)M5=\GM5SJJRK:NECKU//I2MJE73-LFK ML6KS8MF\UOK/-^/DU4^ODY^2HDP^+:IUDY?SYFS4ZA2[BD:S/IV+;3HXD Y) M?M-U+9ID4L[5W!-_"G/"4YQ MZFL0'#Y6,QV.@N%C./S7=?DF02(8/HFO'7G"K_Y:\M/H<)0!0T%V7U_#] -G27#=UD0P/9 M7*C[HBR[.F[S95[.E&]TMT6(31$=51[/.:*($GDV>MP?1E>7R8Q)Q YU5Y'E M35T=90RG(MOI#MK,=FUF8)LONY[M>EM3R+R4AFM<)5(2HQP=B? M'=]EQ\'L/M5YV=RINEOUBN=ESC?KN5-_ZJ]9[&H68,WCHH'[13@UGNJ!RP2Q M>L:C0RAE@EL38>H12IDB&NA"N6N(!!ORNS9/A;Z 5BIYM:R:YK5OQ9/.Y$*I M$"FWAGDLG1PYIE):39FX,H0ITFN&U3<>G= +"Z-6U[@Z3+NK)##WLUW79 M3.[NM/WJYI;Z.EODY;U*;K\EW151E.OM4O.H)UQ5-YWF;+937+-SY/E[,HNB*+6;Y,U&;!\\WGS#-K_(U% MJ?$5*=C<#TVS[E8UTQ@WX4:OQ9UA^'#]Q\])J3:=4^ENJKONF%6!JZ^O^& @ MLU0*2@,Y[WDA!.;\1[O05__S\'@OQ+X$_[7?Y^=*4!;J3VQRPV!NG\MN:(O_ MJGERKW<8>I)H'_^H_=<&7-VT:'+]QUS=MDFC9NNZ:(M $[";'^*ITPQ7)@G" MEFSJD7'$ M<*,JA&!&SN1S7K)DUQ5YBYO#9=T*TMZJ_T 7&G/$MEQNU.\.AP MRABR>\'5!9" C#] L$'0#A1V!Y=] ?NU>K$_\0A1JM=21FV#$%ODU".TK<1A MNXU'0+!)T [L]-)CP0#/A0SB$3\"#X@,^!%,_B@7B%Q:$R8EL4?9E;$.K,29 MU5'E33TR3N2>E3ALL_$("#8)@RX0N0CVV4"/#"%!N>"!# VJ$(7'2B ME C$ ^L]-OS$,#\'+2%V,>CWA#ZAR#!APAIOGQ#15/) ?V(#5@R#-<867O1E M[/M"O>Y(8:VUE]CEJT\W]N@092FU+QN/CF-$[7Z<^LI#6,J [< &[1A&^Q$[ M0^S2'5-"TBRPRF,#> P#_N7\(799+)@D+#1.!L@8!G*$/<0N%4\YQ9F@]D7I M$>IN9<%KS> 3P_C\<481N_MLANV=Y)5'A3%+2: =AM08WHV_L /$[B;^%.M] MH],\CR[C).#NL $_AL$_[.[Z L00SB<>(:5"[VSM'7!LB5,\9! .&VW(CP=N M#P2L7?*_Y.-U\HN^W/6[#737U2 <9T=@](CA.8%Y;E7U["J25P^JGJFRS>^5 M]V;)0+&)RP"] MM:*VR_;),++1,_'(F'9E@=O-Q!"%P$0Y8N],W.UI:'(9JA%X8_IRKIFX.]E MMM0PC\*HB##,U-USVM\87=,77W M?4ZK(,EAJPP;*2IS*C]D;<)R,52W2/3*:/P#TQPU0&,S7*/3%HC]4C.+ R1,W%.,PQ:(\$_?LI1#/,BO+L4=GSU6/!&>"X(!!Y09Z?.#) MF^.U2]Q#43W$DH9FMR$DAPGYLXC"K?IR%XI[-(\;";HFK$E2&YH.KV!*G/!JVPL!6#!Y(?K>%BCZO%0:N M AV!H1*&MP+F[?>>UPX42WCHO'8@$&>A\]KOJ/&P3PS@Q0#@PU-F(PRV (Z3^R'F3G7O+V/!R6'Z1M4"AB5@]9:#-Y9O0(EAWGM M??$%AF.TIQ8NU4*5&Z0)&&G#7[N!CO#ZO*)/^81AD8!9%&6DA0L/*[?QL&0B MHLDB#5DD3)8CML\R^BQ1&G))>%OX&:A'$0X9GE\.$?*#G,S-!% MPG3Y<3Y9#M\K!26'#3#(DO"V\84=LAQ^F :4'+;*@$_"X!LVQG(0:9-AR=6P M9 I*MLT;[7T5?J7J^\VO'#3Z$EN7[?:;PKMW=[^D\'[S^P'6^Y?H[1AYWI^@ MM]/M[R28XK<_V_!;7M]WTW:I[G15Z9L.X_7VEQ"V+]KJ8?-%_-NJ;:O5YL^% MRK7!Z03Z\[NJ:I]?=!7L?H_B_/]02P,$% @ ;4A/5&D8&ULO5A?;]LX#/\J0FXXM,#6 M6++C/UU;H$W2;L.V*]KU]C#L04F4Q)AMY22Y68'[\$?93IS$LNK;AKTDMD12 MY(\42?-LS<4WN61,H>]IDLGSWE*IU6F_+Z=+EE)YPE*Z2.&.W LD\3:EXNF()7Y_W<&^S.MOIN\2G-R30# 7%WS%;RYUG MI$V9]L(=F;$[S1-WQ]1M6&330\J8\D<4O6E>T3@]-P5$%P92,9 #!H);&-R*P>W*X%4,W@&#&[0P#"J&05<&OV+PNZH4 M5 R%]_LENH5K1E31BS/!UTAH:I"F'PK_%MS@D3C3H7BO!.S&P*H'Z2.HUB>(,/62QDB]W%CXM>2YI-H/%%WOO9WT% MJND#^M-*C6&I!FE1PT*:6$HVS&9L9^,=V?DPL OJ R188L@%F2*P21VQZ M@ES\$A&'. _W(W3TXMB@U\@NY5V>G2 _W\+.TB] MZ2P51T:+]]SA;N/4+<2ZW>/TR^5$*@&Y[*M%OK>5[Q7RO3;YWZ=+FBT8$A12 MI,E%);]?\.L$_WB!S_J/AB,'VR,'5I,^YBF#T[BPJ.]O9?E6]3]"T8JS*4_A M^B9<2E.0#4L1P:X%3A X?K2UHPSI)IU/O# <[).-#>*(A\'M^W37!KH 8F/@ M[=/=-.F(YV,/1V:8@RTT@16:]Q#+IRBK :)*B7B2*SI)&%(<#2%QQ%D.T87> M9H\,4JZ ,*-"94S(9;R2:"5B+C2I6C+T]O8OTUT+&N'A!5'H$;/RX5;Y\.>4 MSWCV:@H&")XDVH(X4PSNK3)%<-A0T2?8"]P#?S7) N)'^-!=8=.MF(2A9S8X MVAH<=0WD0U/O^!--U!.ZA=N?4K1*INB5;D/B*8*B@V9QDBMS[8B:AN,H(.&! MX4TR+QK@*#1;A)VZQ#J_WZ;JS. YHPQT5JMV&@=L35\CEG%H2)Y)8)C4\H@5 MI<]%U\AFB#Y"6H1,/$RHE.@2<3\33IO. AEHJ0$>'^P:L(V@_RNUC]"]J MK5U7S^CP!7\U8DV:D0$7)_(.L6[2N<' \UKN!*Z+'W:M>CT4>0FPN;M_D%V- M'5="=]5I1$>3!+>4-5R74FROI3_HR2K8N_O2KD6;+YMU''P9.N00F2:=]N5@ MT().7?7QP-YI;#J9%70R9F3VPGH&F9V*DKS8U:C4?9H1&;L&;&K MO<+$EFSKM@*'OR)YUU4;V\OV[[GR8VRHY$Z __0$V:ZMM1&ZE).[*6\-.L* MO>')#+I#VW=F74B)O9!V^0X@=1DE]A+V2SO&ZJR]GCP*7'+8XAOH7.Q'D=N" M=UWXB+WPO6<+.GUJZ\MUBW1W>W_]R89<7;:(]_-^J-,\L2?97^N'01-?^-8: M'!8M YWG1!%IBWN=G/=7ZJ1$[$G)G"JOGN&Z8RNPD65*(M8AWVL'KW\DMN]RE?,-DY,(=C?F?)!I"Z* :Y$4YYGJIPZ;%>W0^*K8C1Z ML#[$IR-L6!_CTQO3^B7Q3Z^);]@!=\-..8FL52JGV!^H6,291 F;@WK.20"Q M*,0EK5!+ _YX!2]:(/V([G+_X#4$L#!!0 ( M &U(3U1I^4*K: @ %PB 9 >&PO=V]R:W-H965T;3Y>MN]==M?/U2R>]JR[E&/XJ\5#>#K=:[J]%(+;>\ M8.I#M>,E?+.N9,$T?)2;D=I)SE;UH"(?D2A*1P43Y>#VNK[W*&^OJ[W.1; 1Z\W?@B-EMM;HQNKW=LPY^X_K9[E/!I=)AE)0I>*E&5 M2/+US> .7\UI9@;4B'\*_J*.KI&ALJBJ[^;#P^IF$)D=\9POM9F"P;]G?L_S MW,P$^_BSG71P6-,,/+Y^FWU>DPLT#:,R!N!\3O72%I!R3O'9"V ]+:]HVQ:DM/F6:WU[)Z0=*@839S4;NK M'@T&%J6)K"H=/W[\Z]@R?_7^; MG[][.)X$;$D/043K^6C/?$_[W2[GD&\TRX\":=;<4^C?=PNE)221_P06BP^+ MQ?5B<<]BGR'=BG)9%1Q=Y)52E[YH;*;(ZBE, M)Z>PJ687 M6G!U%?!=>MA@&O3=0[/L6E8%6HN2P>X@8F3URG+]BIA27/N2R[29-3VRUY!$ M:1*-J>4 #Q#,/YEDED?G/F *GJ>9WP79@6$69/AHK%C++J@^6FY9N>'*)$_^ M8P=I%LQ;&WL-YT/]NATR9]=Q0L8QL:S@P@@%6UG!/W=A0PS12@GVVV!\L,$X M:(.[HI):_&1UZ5"M@;T&,X@%!&(_M;&[9S*9I!8S#XI&R=@BYD--2.QG-3FP MFOP2JQ5?:+02:EGM2XU %I%0:@^N-,=-^4E.W(U%.+7=YZ(PSK =P1X4R2:1 MGR2.NGH@"M+\ U(J1"QP7'$IGIDI_(YB5)20R?=UBO&J>.0RQ FU&7I@,8DR MR]MS#XQ.,!WW<#RJ>? [.(XN-E!Y0YD#7/F?>P$G3_'E7M;9SDL.N[L>1ZD= MHQ[8D,19E%&;G@>(DR2+>V0 DXX@"1*<-70@[>0M5;NP81S'B9UV/#A*$MR3>'%7A& :)#T5$)IBL3<' MM,VMOTJ4NCN+Z3BVB;JPF%!JB[P'AN,HZ7-N5__@< %DHK>.V1]&H?=";MHRR8>F001YK KHFE6=9KU< M$C?#Q+%=!WA024QLG?"@^KAT%0X^5^)H+KDZE%ALN92\EXRG#(&JQI$]'XY$ M28)M0BZNCU!7T.!P1?.ME)SEXB?XILZ7)O38,S2(S BZJ7(4@XM:#L_D3U_! MD8WM!#'SXL9I%-EL75P?VZYTP>':Y:'8,2'K P7%F]QP+Q&WP'"2H0N!>C5Q M)" TTRF%KD[!X4+E*Y<%Z'57I_P%&7>+"RB/HXESS#PX&D\2)VFXN!Z:I"M4 M2+A0^8?>5YTX"8WN07>@[BRC6A.!G;3>W, M!\0$3X@=]!X@=!UQ-.DS:U<"D' )7\A)QA=H^SND/22?X)"SX M]=D]XN%W2TB=6PYG(7,/).B53NA)6.A;#JU/6K4_XQJ/C$\B;'='/ECFNL9% M9;2O_R.=W).PW#>TX+A(HX%-6JB[VZK^(I G7#7&XR2SN;DH$(RQW?EY8,,8 M1Z2G]2.=OI-Q,/%>O&7>R]%;YCU-O- =+*!%./?$BW1R3,X\-UC63P@4VK'7 M.C498[+V2)NG0J7JB7^/N,:);:J9#Y;93>G<@TKCHSKS]+EO)\(T+,*':KQS[('%A,=V\9!NLX3:CO(" M:9P2NT'V '&:9H3VM(ZTJP0H>?^#^J?EEJ_V$)!0)'XVC;*QP$/Y#.X$UJ-Y M4R, _[MW/0.F1[\6A%7ZBTF2N[ICA>;\T+,WCPK-\LT3;#B6?_ -6[ZVFZJD M0H],ZI)+M14[OS/.2[D'0B.:9HX70E.=,N^4G(:5_(EKW=C?D)WMQ,_7HJY5 M7IA0L^A>&,5B#HOPU#_W3)T(4GF=$_!B4[Y=;I.P[K^5JD$GMW5T\[L:=AL?_"(<$U80F.RZMR,X3$ M5S35)22+XS@^??:D)13>YA2)-E5ZV8?Z]I:]"P'V-,OLQT[!N4[I=T4!#1<% MGT1N#F#)#R(V1#.9<[9B7CJ9\_N60\>%^%K\X$P-F='1C]\%AX[=O*:@4"VZ MS4^8A[N'5R'NZA< K/L?\=4]]MR?XJMY\Z)#-WWSWL4G)C?FB4C.U[!4]"&# MR)/-JPS-!UWMZI_>%Y7655%?;L%H7!H ?+^N*OWVP2QP>*'D]G]02P,$% M @ ;4A/5!^"TR_-!0 EQT !D !X;"]W;W)K&ULQ5E;;]LV%/XKA-&'%D@J\2+9"AP#2;Q+@'4-DG9[&/; R+0M5!(]B;:3 M83]^I*R(EDG12HUE+[8NYTH>?M^A.-[RXENY9$R IRS-R\O!4HC5A>>5\9)E MM/S(5RR7;^:\R*B0M\7"*U<%H[-**4L]Y/NAE]$D'TS&U;.[8C+F:Y$F.;LK M0+G.,EH\7[.4;R\'3 E6"I7$;PG;EGO70*7RR/DW=7,[NQSX*B*6LE@H$U3^;=@-2U-E M2<;Q5VUTT/A4BOO7+]9_K)*7R3S2DMWP]/=D)I:7@]$ S-B5I6OV!;R_H#$*]+P;-:64:0)?GNGS[5 [&G ,,.!50KH$,%TJ& :P7< M5X'4"J0:F5TJU3A,J:"3<<&WH%#2TIJZJ :STI;I)[F:]P=1R+>)U!.3JSA> M9^N4"C8#G\62%>"&9[*"EFIJ-PS(,_"HA@<_!%_H$_KCG:0KD*MC28O:GPS%I')/*,>EP?,T6 M29XG^4*NJ)3F,;/-[<[$L#*AP&4SB491,(+!V-OL#[DI%T(""1ZUY::F' D" MY ^C1JZ52]#D$CASN6=Q2LLRF2N!?(.1J1$3S( MRR(6CH+ 'FW81!LZH[U2*)B(9R !'@\X)G(.?Y>2P7%WQ2@9/&Z2$3"RC.5>KJNIE16EJVPP#_ J$39UBA,[$=I#IR$ M>^0)WQ:B(=*NT>EU4MMH%8H?^7['Y&IF@OB(\WH6.EW?U!9:=>6'G:XU-T$W M.>W5U4^RKDI545>MBGI0%355%?705)1KR#65P."-9UOS G030R]*AB;@8X*C M0UBPB(4PZ%KPFA?@*XGA*--"DPFL5&N3@WZ$8$?(FC2@FS5ZTRVT@+W)MS:I M;L*%FA&@FQ*L(_L*PH4FQ)\CXJ,.SD4:XY$;XT_N!:YK!_NA$430PTDR W$SP?8CX7Q(HTD2"WGB/ M@S21(#>1]"+0VD:[APJZ6 QI*D'N;4D/ D7F#@-VQ&7_')Z-7M%O8 M!.ZNF#1H8S=HG]YI8;/K-P;3)=(.7$,R=N\*CO=8V.SNC<".BDPM(JZ%I7$= MNW']"Q6GVBQ M4+NAE,VE2?_C4,)RL3L%W-T(OJK.Q1ZY$#RK+I>,SEBA!.3[.>?BY48Y:,YB M)_\"4$L#!!0 ( &U(3U2*VS(8T 8 #,@ 9 >&PO=V]R:W-H965T M'1'9X>3]Y[N%5SYZ%_**FC>+<\* M==Z::CU[V^FH=,IRJMIBQ@KXRUC(G&KX*"<=-9.,CBJA/.O@($@Z.>5%Z^*L M^FX@+\Y$J3->L(%$JLQS*N=7+!//YZVPM?SB@4^FVGS1N3B;T0E[9/K3;"#A M4Z?99<1S5B@N"B39^+QU&;[]C?2,0+7B,V?/:N49&5>&0GPQ'VY'YZW 6,0R MEFJS!85?3^R:99G9">SX6F_::G0:P=7GY>XWE?/@S) J=BVR/_E(3\];IRTT M8F-:9OI!//_.:H=BLU\J,E7]1,_UVJ"%TE)ID=?"8$'.B\5O^JT.Q(I 2+8( MX%H [RL0U0+1O@*D%B#["L2U0+RO0%(+)/L*=&N!;I6L172KU/2IIA=G4CPC M:5;#;N:ARF\E#1GAA2G%1RWAKQSD],4#RZAF(S2@4L_11TD+1:LB4>BHSS3E MF7J#3M"GQSXZ^N7-64>#3B/92>O]KQ;[XRW[7\YD&X7),<(!#AWBUW[Q/DO; M*#@UXF'7(=[?0SP*MVI_M[]XX!"_V5L\[#G$?_.+WU&Y37L'LMRD&C>IQM5^ MT4M3C?YZ#TO1K6:Y^MNC*&H4194BLD711Z%IAD9<: $\4(SR91V97>AIUOI,:#Z=!$&W5Y$@@ "\K2:2,=*G$1)LKIR MS1G2.$.\SMP63V <@*]68.K2>B4R/JJB2<=CGG%X5"X'%GLG*V:1*(YZ#@<< M*V/2B[8[$#<.Q%X';GA!BY1#1J28TPQ23Y5B^A@5S!GS>,.0D$01CGO)IM&. MM;@7Q[C;W6IVTIB=^(L(&JLJY;RI#U=\;Y*-M!/L27JW4=[=3_FC%ND7SY$X M;38\/>S9ZS6*>J\0MMYFL?G"%@:VFP1>]9<3R9@Y+-#&]!3=/5[?>IP*5[I4 M>-CXA18E0[SCP'-M3@N$+W?V.[]X%\T9EZ,2H;&4N3 M_19AF$$8N!MQPDTDW)95"X&A'P,_3AFZHP504XF^H_L9DU0;Z*8%9(1))8J" M99";>063/MA@,IN;+K4 >FA3%M>/$3B+FN'I'@< 8IVEY:(>X/*%Q%H!SJH"A -;N^LT^-1! M)*I_6XZ&A=O0C[>#.I;&KJ69QK(?L-&O*&A'H3^LV*(T]J/T^GDV5SIX^(EC MC2V.XP/C.%YAN[MP/#6]D!G6]K4Y$[Q00$ZSJM";\[&[XG?HBMN!]_1B"_G8 M#_GWCKHQ66ALY06<6,E&3BL=+)C$>+W0%\RM7KI&W:"^'$MO'+LF@>_T8-M8 ML+^Q7"Y1:83>%=K@T'?T4+/4_NK]86#O#^_9A*9SM.#E0JJJE@H(U)3/O$5J M>P\^<._!MO?@'2SWU:Y*M:+5A/9P$IPZ4K^YTH AV<[9L6T^V _]/Y+0AP%Z MK$93:'%581#R\K].KMMC&P@^,._&MA/@'$_5-U4Q8C4W[WPXQ/Z&+.]_(D67R/R(&39$$[\H\Y?C!)_DUW)\DB?>1' M^NLRK[CA$USEZB30BMVZ!H/1YEPC3##Q]-S(0G3DA^B7SH/J[=9LB8*>BU34 M2]>!*TA\9ELDCW9X_AB,5R6:4CPQ5OGYW[WI55V^R>X;367D;:EZGWU$Y@6L_ MRM@8)(-V%PI1+MY0+SYH,:M>D Z%UB*O'J>,CI@T"^#O8R'T\H-YY]K\/X&+ M?P%02P,$% @ ;4A/5&=HM,P^! V0\ !D !X;"]W;W)K&ULO5??;]LV$/Y7#L8&I$ 2B?+OPC:0V/'2(FV-9%T?ACW0 M$FT1E425I.P8V!^_HR1+SB(SZL.6AYBD^-U]Y!V_(R=[(;^KD#$-SW&4J&DG MU#I][SC*#UE,U;5(68)?-D+&5&-7;AV52D:#'!1'CN>Z R>F/.G,)OG82LXF M(M,13]A*@LKBF,K#+8O$?MHAG>/ (]^&V@PXLTE*M^R)Z:_I2F+/J:P$/&:) MXB(!R3;3S@UY?T_&!I#/^(.SO3II@UG*6HCOIO,AF'9/TFBG\FF I^VC]66^>%S,FBHV%]$W'NAPVAEU(& ;FD7Z4>SO6;F@ MOK'GBTCE_V%?SG4[X&=*B[@$(X.8)\4O?2XWX@1 >F< 7@GPV@*Z):#;%M K M ;VV@'X)Z+<%#$K H"U@6 *&;0&C$C#*HUN$(X_E@FHZFTBQ!VEFHS73R!,B M1V,(>6)R]TE+_,H1IV=S$<=<8S)J!30)8"X2S9,M2WS.%%PLF*8\4N_@"KX^ M+>#BEW<31Z-; W;\TL5MX<([X^*SV%V#V[L$S_5( WQNAW_,$H1[9^$+._PF MVR)\F,/=!OA="_)=]RQ\^09YBN2[Y"S\M];>R;@!?F^'+YA?>?_7UCF8)U6R M>%6R>+F]WAE[GX1,0_%T4/ W)DH4T;60U&@/W$A),6M,'EW"[]A6M-"F/=Z69C&&523]$/8,ZN>'/!YP.'S2+U5\6 M9[W*6<^^$_29QUF,)S)B>$;1=$H/KQ=2Y'=A:IB;,K5D-R-]M_B;.+L&%OV* M1=_*8E7X!+$!GZ9N^ZO%F:CBMFH5<+X=4KB M>=AD*+G^BT-!SQV*@N^H12X5TM!FYHNEC*NEC.UA9Y*+P$2]V.4FFG8+XSS> MRK*MQ*WKE_M3;$!I5!L(J&:-M<9NS7N;V4EE)59;2PPNEE*XV4J6QQ.^&3&\ MY2*D.Y; *J1X^?)9IKE/(ZO/6J")]]^+(*DEEW3MFW]T4J?U):3'0:,+^3B> MR$M(1'+E'V\7.J>%YY*C:#S0+/&Q2N"ME4F)I_?N1\:Q8*"DTG74%,9%R>LT MNSW7FMVDEG9BU_9'9N[\)G+UJAIK;X.N>^.!C4,M[.0-93_NX9<-W'%%.3R* M XTT7LIL@:N5FPS^ASRI99G8=?18*?"M]2(]9/.BRJO1\'7AZMIC7*LQL*(C8!K'N]1#S71;OR**C19J_2M9"XQLG;X;X M]F;23,#O&R'TL6,>.M5K?O8/4$L#!!0 ( &U(3U1%4ST4^0( )\) 9 M >&PO=V]R:W-H965TICVXS6EJX=C!=EJ0]N%WG*1IMJ854GE)?#O_\_,YO@V6 M2K^8.:*%MU1(,_3FUF87OF^FNP1\-,I;@$]KG M[$%3S:]58IZB-%Q)T#@;>I?AQ3B,G$$QX@?'I6F4P4UEHM2+J]S&0R]P1"AP M:IT$H]\"KU (IT01#CC.7" M/JKE-ZPFU'-Z4R5,\85E.;9_[L$T-U:EE3$1I%R6?_96!:)AT.EM,8@J@R(0 M?NFHH+QFEHT&6BU!N]&DY@K%5 MK@N/29>7):NKE9&='3_G$X&N.TL+-@KX& M#J_1,B[,$7R!_WOA +B$>RX$1=0,?$L$3L>?5M[&I;=HB[<0[I6TX6_8>2U(!5M$I?09S--F836()=PO0VX;6RG-=OI M9[#)/)V@!C4#%L?<[7TF5J &_NQB+OV?-IBC=N1^C=S_#.0&:,H%M2E:7ROD M-M#^AX-[5I.>[22]4S(! DIAELN84R5CVDK49LXS(DQ5WAZSLPV43K"%Y;QF M.=^'99W@:JN[K%;%-L+SC:SVVOG"8'UJ!OL0QNH8W6M-%>2VZ3D1J31&/"+.Y8D97;9FBCC=CZC3LS19T4 M+P,#4R=:7I]U:_WZN"SOW/7P\NERSW3"I0&!,S(-3OIT].GR-5!6K,J*&WBB M+-WG17%.+RC4;@#USY2RJXIS4+_)1G\!4$L#!!0 ( &U(3U0V-U-F)P( M 'L% 9 >&PO=V]R:W-H965T-A543'1O^M*?PQ$P7IP!@AX(_@;" M,\"D!R;.:%>9L_61(HTC)5NB;+91LP-W-HXV;IBP7_$1E5EEAL/XCB; (Q^- ME)WPTQY;7<9N.9A/B2? =0<&9\ GRAOX$_--R4/=P5!WX'3",SH[0/.+0D9N MJ1),%)I\NX9&8CLI7*_8 W MB(HE#=*$ T%)'J0A!"K)N4W;" 0%^M01K2[OWNCW!:7UCZV2.4.[_ZEC[C1F M3L.VZCX.9XMY:+IW%/G[$^;#P7SX7\U?WOW?S(>OS2^FX\7\M7G_J#7LM71/ M5<&$)AQRPXZN9E./J*[5NP!E[7[[1*+I/3T(RB:8]5Q*/ 2V 8?[-OX- M4$L#!!0 ( &U(3U0B)L9\/ , #04 - >&PO-VT%M5H+=S!DST;(4LAZ2N3'5^SBNIW-6TOI, M54Q:I%"ZI,9V]2RN*\UH7D-2*>)>IY/&)>62C 9R45Z5IHZF:B'-D*1M*/*W M3_F0=--W)/)T8Y6S(;D[??U]HG'3..G=O+G>1TP9Z0^(@\?D! MQ"@M1IH>Y-9=>RR["Y.X.%1BOP!&WP_3__J)K$L+[%^8[##7^SP[ZKBIFM&@ M4')3/ GQ :M-2Q;=4S$D8RKX1'/(*FC)QQ"8*J%T9&S56C-=B-0/'N[Z M'A1TPU-RJ;33]@K^>](,WP'6/3#(A6@-]H@/C 85-89I>64[;K +/H&BIGV[ MJJS#F::K;N^<;!+Z_!)/9\9M,CM-C MW!PRMDXRC\XQ;32"\^*0?(6SJ=B(1I,%%X;+IC?G><[DD^.,I3=T8O\D>L1O MQ^>LH MA;EMP2#;M+RSGBS)K1UW#0C2C-NW/,+UNVAY6K1:7.5NR?-QT]6SB MFI%M6-7F@H1=Y,I=803+\5@8 0S3P1Q@.3X+T_F?YM-'Y^,QS%L_B/31G#Z: MX[-"R-A],)UP3F:O\$RS+$G2%%O1\3CH8(RM6YK"3Y@-\P89F XH_=E:X[N- M5\C^.L#V=%^%8#/%*Q&;*;[6@(37#3*R++S;F YD8+N U0[HAW6@IL(Y20*[ MBGG#GF \/]A3DB19%D8 "SM($@R!IQ%', ?@ 4.2 MQ+T'=]Y'\?H]%6_^3SCZ#5!+ P04 " !M2$]4EXJ[', 3 @ "P M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6= MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6' MTD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( &U(3U3"L4WD>P4 M /HM / >&PO=V]R:V)O;VLN>&ULQ9I;4^,V%(#_BB8/6W:F-(EON\L2 M9E@";69:R"24UXYB*T2SLF0D.2S\^A[;2Y$AG+8/9_.4V/+ELV[?T>7XWMBO M*V.^LF^ETFXRV'A?'0V'+M^(DKM?3"4TI*R-+;F'0WL[=)45O' ;(7RIAM%H ME U++O7@Y/CI67,[# ^,%[F71L/)YL2-%/?N.;TY9%OIY$HJZ1\F@_:_$@-6 M2BU+^2B*R6 T8&YC[G\S5CX:[;E:YM8H-1F,NX0;8;W,7YU>-I#7?.7:,YZO M%AQ )H-L! ]<2^M\>T7[? Z,6P$7=T>U-Q=2>6&GW(M?K:DKJ6^;Q\!7#(// M://AZ;?+Q"/[7[+1K-X-\LR4 M50"9(9#9WB"7&Q[FY <$\L,>(?^* LB/".3'_14W=YL \A,"^8D6\LK>AIBH6ZCE MLN52<7@G@]O9DL.?J5AYMA1Y;:4/,3'7C(EE,Q56;GD3*X (G;?M]:%GQIAH MQL2FN>#2LANN:L'^$-S5]GN#::KEA0Q]/<94,R9V#:" R57;&$>N/(/[-0Y ML.'/[%+T2AI3S9C:-759JZZD3Y4R]ZVUFXST&\'FO9 ,D\V8V#8SB(?U;?/2 M?\M,S#9C8MU<&GW8Z\U/X4XEX6^O[6"N&1/+9B&\K#Y#Y[,5RE3- M3>S@W5UM_.=%FS+M#MZS$!SSSYA80%^,M>8>QB=A5D:8 M3CWT&@;FE(A\_%*6TC\[&;I$#Y51@ Q['6&$&24B-LJR7CEQ5S<=W_GV1703 M81*)B"6"1K*],4N$B20B%@D:R?8Q,6U$Q-K8',2:>Q@ZGP/)PN2S#?),2^P6.A.,3$?),0^P:/ MA7J8F&\2Z@$.BIF$F.@2#;%OW@C9#MDEMY:'DST)YIZ$V#UO8G:5-L3$[),0 MVP>/+'MU$S-00FP@'+-7-S$+)<06PC'3$!.S4$)L(1PS"Y=#AQ M&&)B%DJ)+80/)\(FE&(62OS0KP:8EU)B+P6#7S [/+"HH49 /-HEA)B8EU)B M+_4PNSBIZ0>Z:%Z%:>C-@]?^H< MWGS;;%N&8I]Y43:]NZWLM\-HU*Z"_X.)N2=KW3-L+W8GQX582RV*2WB%@_,Y M5_G8@DCEQN ;OO* R28_6@)\AG9)4M M7_^C3U;9CR]EWPZ[[EBWNU.=?1[VQ[ILML-P^I5276W+H:UWW:DSIR]?IW*_TSLUNO=JOSN5G\.Y3C\8W#Z MZ/KWNBUE:&:O;;\IP[))G_OKZ9HNAWQWGMS,GM^63?_\EILT=9! D$P?I!"D MTP<9!-GT00Y!/GU00%!,'[2 H,7T0?<0=#]]T ,$/4P?E.$.Q/(G9'N3&!W1KPS@=Z">@N! MWH)Z"X'>,GK9)M!;4&\AT%M0;R'06U!O(=!;4&\AT%M0;R'06U!O(=!;4&\A MT%M1;R706U%O)=!;46\ET%M'FR4$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM M!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01ZVVBSFT!O0[V-0&]#O8U ;T.] MC4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0&\??:PDT-M1 M;R?0VU%O)]#;46\GT-M1;R?0.U#O(- [4.\@T#M0[R#0.U#O(- [4.\@T#M0 M[R#0.T8_FQ#H':AW$.@=J'<0Z!VH=_RDWG7XVI=Z[?E>XT]!/TGU<+ZW7!]_ M67Z?1)P7%YS3;45]^@M02P,$% @ ;4A/5-9((R[W 0 *R@ !, !; M0V]N=&5N=%]4>7!E&ULS=K+3L,P$ 707ZFR18WK)P_1;H ML. '3#*E M49/8LETH?X^3 A((*E"1N)M&K>VY$X]T5CV_>_84)]NN[>.\6*7DSQB+U8HZ M&TOGJ<\K2QTM)LV3:ZV^>?8 MN'Y>!&IC,;G8;1RRYH7UOFTJF_(Z>^SK3RG3UX0RGQSWQ%7CXU'>4+ O$X:5 M[P->S]T\4@A-39-;&]*U[?(NMFU93,\MQ7)_B2]Z=,ME4U'MJDV7CY31![)U M7!&EKBUW18_V)Z=\P[3[Y ?GCV7V!>:=M\'YF"<6Z/=Q;R,93D]]+D0A-?M? M\3TQES[X_6B8=DWU#[/S]3ZYL![G$=GX./R./\[XO?XO^Q @?4B0/A1('QJD M#P/2QS%('R<@?9R"],%G*(V@B,I12.4HIG(45#F*JAR%58[B*D>!E:/(*E!D M%2BR"A19!8JL D56@2*K0)%5H,@J4&05*+)*%%DEBJP215:)(JM$D56BR"I1 M9)4HLDH4626*K I%5H4BJT*15:'(JE!D52BR*A19%8JL"D56A2*K1I%5H\BJ M4635*+)J%%DUBJP:15:-(JM&D56CR&I09#4HLAH460V*K 9%5H,BJT&1U:#( M:E!D-?\IZ[USZS^.'Y]E9YO^+9^-_Q%&UL4$L! A0#% M @ ;4A/5,5K:ZDS!P &QT !@ ("!#0@ 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ ;4A/5.:AZX^C P MYA !@ ("!!AD 'AL+W=O# & @($O)0 >&PO=V]R:W-H965T&UL4$L! A0#% @ ;4A/5&U^@*O\"@ 2S@ !@ M ("!,RD 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ ;4A/5&)$QF-=# V24 !D ("!A4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ;4A/5!@DB'>0!@ OA0 !D M ("!O:$ 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ ;4A/5)U99 3 ! R0P !D ("!9K0 M 'AL+W=OB M2]T, *)0 &0 @(%=N0 >&PO=V]R:W-H965T&UL4$L! A0#% @ M;4A/5! W4L'!P OA8 !D ("!\=( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ;4A/5/09&KOU,0 V*T !D M ("!;0 ! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ ;4A/5);FKKQG" 1H !D ("!Z3H! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ;4A/ M5+*P%B'. @ J 8 !D ("!PD\! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ;4A/5#B;&=K< P PPH M !D ("!DEP! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ;4A/5,E(._>8 @ Q 4 !D M ("!%VL! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ ;4A/5,M)MT%(!0 %1P !D ("!7WL! 'AL+W=O M7*9KW@$ ! M%@ &0 @('>@ $ >&PO=V]R:W-H965T&UL4$L! A0#% @ ;4A/5"^_ M9'U6! CA, !D ("!D(L! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ;4A/5$=3;P-!!0 K!@ !D M ("!%I\! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ ;4A/5&AGLYTZ P 0@L !D ("! M;ZT! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ ;4A/5+N4X3DE P P@@ !D ("!-K@! 'AL+W=O\K M!0 I1X !D ("!\<0! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ;4A/5/F38*P$!@ ;1P !D M ("!B-0! 'AL+W=O6\* ";0@ &0 @('#V@$ >&PO=V]R M:W-H965T&UL M4$L! A0#% @ ;4A/5&GY0JMH" 7"( !D ("!<^L! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M;4A/5&=HM,P^! V0\ !D ("!'0$" 'AL+W=O&UL4$L! A0#% @ ;4A/5"(FQGP\ P M-!0 T ( !( L" 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ ;4A/5)=W XML 87 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 88 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 89 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 455 484 1 true 148 0 false 11 false false R1.htm 0001001 - Document - Cover Sheet http://royaltypharma.com/role/Cover Cover Cover 1 false false R2.htm 0002002 - Document - Audit Information Sheet http://royaltypharma.com/role/AuditInformation Audit Information Notes 2 false false R3.htm 1001003 - Statement - Consolidated Balance Sheets Sheet http://royaltypharma.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Uncategorized 3 false false R4.htm 1002004 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Cover 4 false false R5.htm 1003005 - Statement - Consolidated Statements of Operations Sheet http://royaltypharma.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 5 false false R6.htm 1004006 - Statement - Consolidated Statements of Comprehensive Income Sheet http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 6 false false R7.htm 1005007 - Statement - Consolidated Statements of Shareholders' Equity Sheet http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity Consolidated Statements of Shareholders' Equity Statements 7 false false R8.htm 1006008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical) Sheet http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical Consolidated Statements of Shareholders' Equity (Parenthetical) Statements 8 false false R9.htm 1007009 - Statement - Consolidated Statements of Cash Flows Sheet http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 9 false false R10.htm 2101101 - Disclosure - Organization and Purpose Sheet http://royaltypharma.com/role/OrganizationandPurpose Organization and Purpose Notes 10 false false R11.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 2106103 - Disclosure - Available for Sale Debt Securities Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecurities Available for Sale Debt Securities Notes 12 false false R13.htm 2110104 - Disclosure - Derivative Instruments Sheet http://royaltypharma.com/role/DerivativeInstruments Derivative Instruments Notes 13 false false R14.htm 2114105 - Disclosure - Fair Value Measurements and Financial Instruments Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments Fair Value Measurements and Financial Instruments Notes 14 false false R15.htm 2120106 - Disclosure - Financial Royalty Assets, Net Sheet http://royaltypharma.com/role/FinancialRoyaltyAssetsNet Financial Royalty Assets, Net Notes 15 false false R16.htm 2123107 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Notes 16 false false R17.htm 2127108 - Disclosure - Intangible Royalty Assets, Net Sheet http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet Intangible Royalty Assets, Net Notes 17 false false R18.htm 2131109 - Disclosure - Non-Consolidated Affiliates Sheet http://royaltypharma.com/role/NonConsolidatedAffiliates Non-Consolidated Affiliates Notes 18 false false R19.htm 2133110 - Disclosure - Research & Development ("R&D") Funding Expense Sheet http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense Research & Development ("R&D") Funding Expense Notes 19 false false R20.htm 2135111 - Disclosure - Borrowings Sheet http://royaltypharma.com/role/Borrowings Borrowings Notes 20 false false R21.htm 2140112 - Disclosure - Shareholders' Equity Sheet http://royaltypharma.com/role/ShareholdersEquity Shareholders' Equity Notes 21 false false R22.htm 2144113 - Disclosure - Earnings Per Share Sheet http://royaltypharma.com/role/EarningsPerShare Earnings Per Share Notes 22 false false R23.htm 2147114 - Disclosure - Indirect Cash Flow Sheet http://royaltypharma.com/role/IndirectCashFlow Indirect Cash Flow Notes 23 false false R24.htm 2150115 - Disclosure - Accumulated Other Comprehensive Income Sheet http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncome Accumulated Other Comprehensive Income Notes 24 false false R25.htm 2153116 - Disclosure - Related Party Transactions Sheet http://royaltypharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 25 false false R26.htm 2156117 - Disclosure - Commitments and Contingencies Sheet http://royaltypharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 26 false false R27.htm 2158118 - Disclosure - Subsequent Events Sheet http://royaltypharma.com/role/SubsequentEvents Subsequent Events Notes 27 false false R28.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies 28 false false R29.htm 2307301 - Disclosure - Available for Sale Debt Securities (Tables) Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables Available for Sale Debt Securities (Tables) Tables http://royaltypharma.com/role/AvailableforSaleDebtSecurities 29 false false R30.htm 2311302 - Disclosure - Derivative Instruments (Tables) Sheet http://royaltypharma.com/role/DerivativeInstrumentsTables Derivative Instruments (Tables) Tables http://royaltypharma.com/role/DerivativeInstruments 30 false false R31.htm 2315303 - Disclosure - Fair Value Measurements and Financial Instruments (Tables) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables Fair Value Measurements and Financial Instruments (Tables) Tables http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments 31 false false R32.htm 2321304 - Disclosure - Financial Royalty Assets, Net (Tables) Sheet http://royaltypharma.com/role/FinancialRoyaltyAssetsNetTables Financial Royalty Assets, Net (Tables) Tables http://royaltypharma.com/role/FinancialRoyaltyAssetsNet 32 false false R33.htm 2324305 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables) Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables) Tables http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets 33 false false R34.htm 2328306 - Disclosure - Intangible Royalty Assets, Net (Tables) Sheet http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables Intangible Royalty Assets, Net (Tables) Tables http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet 34 false false R35.htm 2336307 - Disclosure - Borrowings (Tables) Sheet http://royaltypharma.com/role/BorrowingsTables Borrowings (Tables) Tables http://royaltypharma.com/role/Borrowings 35 false false R36.htm 2341308 - Disclosure - Shareholders' Equity (Tables) Sheet http://royaltypharma.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://royaltypharma.com/role/ShareholdersEquity 36 false false R37.htm 2345309 - Disclosure - Earnings Per Share (Tables) Sheet http://royaltypharma.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://royaltypharma.com/role/EarningsPerShare 37 false false R38.htm 2348310 - Disclosure - Indirect Cash Flow (Tables) Sheet http://royaltypharma.com/role/IndirectCashFlowTables Indirect Cash Flow (Tables) Tables http://royaltypharma.com/role/IndirectCashFlow 38 false false R39.htm 2351311 - Disclosure - Accumulated Other Comprehensive Income (Tables) Sheet http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeTables Accumulated Other Comprehensive Income (Tables) Tables http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncome 39 false false R40.htm 2354312 - Disclosure - Related Party Transactions (Tables) Sheet http://royaltypharma.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://royaltypharma.com/role/RelatedPartyTransactions 40 false false R41.htm 2402401 - Disclosure - Organization and Purpose (Details) Sheet http://royaltypharma.com/role/OrganizationandPurposeDetails Organization and Purpose (Details) Details http://royaltypharma.com/role/OrganizationandPurpose 41 false false R42.htm 2405402 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies 42 false false R43.htm 2408403 - Disclosure - Available for Sale Debt Securities - Narrative (Details) Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails Available for Sale Debt Securities - Narrative (Details) Details 43 false false R44.htm 2409404 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) Details 44 false false R45.htm 2412405 - Disclosure - Derivative Instruments - Narrative (Details) Sheet http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails Derivative Instruments - Narrative (Details) Details 45 false false R46.htm 2413406 - Disclosure - Derivative Instruments - Summary of Derivatives and Reclassifications (Details) Sheet http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails Derivative Instruments - Summary of Derivatives and Reclassifications (Details) Details 46 false false R47.htm 2416407 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) Details 47 false false R48.htm 2417408 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails Fair Value Measurements and Financial Instruments - Narrative (Details) Details http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables 48 false false R49.htm 2418409 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) Details 49 false false R50.htm 2419410 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) Details 50 false false R51.htm 2422411 - Disclosure - Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details) Sheet http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details) Details 51 false false R52.htm 2425412 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details) Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details) Details http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables 52 false false R53.htm 2426413 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) Details 53 false false R54.htm 2429414 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) Sheet http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) Details 54 false false R55.htm 2430415 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details) Sheet http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails Intangible Royalty Assets, Net - Narrative (Details) Details 55 false false R56.htm 2432416 - Disclosure - Non-Consolidated Affiliates (Details) Sheet http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails Non-Consolidated Affiliates (Details) Details http://royaltypharma.com/role/NonConsolidatedAffiliates 56 false false R57.htm 2434417 - Disclosure - Research & Development ("R&D") Funding Expense (Details) Sheet http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails Research & Development ("R&D") Funding Expense (Details) Details http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense 57 false false R58.htm 2437418 - Disclosure - Borrowings - Schedule of Borrowings (Details) Sheet http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails Borrowings - Schedule of Borrowings (Details) Details 58 false false R59.htm 2438419 - Disclosure - Borrowings - Narrative (Details) Sheet http://royaltypharma.com/role/BorrowingsNarrativeDetails Borrowings - Narrative (Details) Details 59 false false R60.htm 2439420 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details) Sheet http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails Borrowings - Schedule of Repayments of Debt by Year (Details) Details 60 false false R61.htm 2442421 - Disclosure - Shareholders' Equity - Narrative (Details) Sheet http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity - Narrative (Details) Details 61 false false R62.htm 2443422 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details) Sheet http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails Shareholders' Equity - Summary of Noncontrolling Interests (Details) Details 62 false false R63.htm 2446423 - Disclosure - Earnings Per Share (Details) Sheet http://royaltypharma.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://royaltypharma.com/role/EarningsPerShareTables 63 false false R64.htm 2449424 - Disclosure - Indirect Cash Flow (Details) Sheet http://royaltypharma.com/role/IndirectCashFlowDetails Indirect Cash Flow (Details) Details http://royaltypharma.com/role/IndirectCashFlowTables 64 false false R65.htm 2452425 - Disclosure - Accumulated Other Comprehensive Income (Details) Sheet http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails Accumulated Other Comprehensive Income (Details) Details http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeTables 65 false false R66.htm 2455426 - Disclosure - Related Party Transactions (Details) Sheet http://royaltypharma.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://royaltypharma.com/role/RelatedPartyTransactionsTables 66 false false R67.htm 2457427 - Disclosure - Commitments and Contingencies (Details) Sheet http://royaltypharma.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://royaltypharma.com/role/CommitmentsandContingencies 67 false false R68.htm 2459428 - Disclosure - Subsequent Events (Details) Sheet http://royaltypharma.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://royaltypharma.com/role/SubsequentEvents 68 false false R9999.htm Uncategorized Items - rprx-20211231.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - rprx-20211231.htm Cover 69 false false All Reports Book All Reports rprx-20211231.htm rprx-20211231.xsd rprx-20211231_cal.xml rprx-20211231_def.xml rprx-20211231_lab.xml rprx-20211231_pre.xml rprx-20211231ex231.htm rprx-20211231ex311.htm rprx-20211231ex312.htm rprx-20211231ex32.htm rprx-20211231ex42.htm rprx-20211231_g1.jpg rprx-20211231_g2.jpg rprx-20211231_g3.jpg rprx-20211231_g4.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 92 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rprx-20211231.htm": { "axisCustom": 1, "axisStandard": 42, "contextCount": 455, "dts": { "calculationLink": { "local": [ "rprx-20211231_cal.xml" ] }, "definitionLink": { "local": [ "rprx-20211231_def.xml" ] }, "inline": { "local": [ "rprx-20211231.htm" ] }, "labelLink": { "local": [ "rprx-20211231_lab.xml" ] }, "presentationLink": { "local": [ "rprx-20211231_pre.xml" ] }, "schema": { "local": [ "rprx-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 714, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 1, "http://royaltypharma.com/20211231": 10, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 15 }, "keyCustom": 119, "keyStandard": 365, "memberCustom": 79, "memberStandard": 58, "nsprefix": "rprx", "nsuri": "http://royaltypharma.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://royaltypharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Purpose", "role": "http://royaltypharma.com/role/OrganizationandPurpose", "shortName": "Organization and Purpose", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106103 - Disclosure - Available for Sale Debt Securities", "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecurities", "shortName": "Available for Sale Debt Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110104 - Disclosure - Derivative Instruments", "role": "http://royaltypharma.com/role/DerivativeInstruments", "shortName": "Derivative Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114105 - Disclosure - Fair Value Measurements and Financial Instruments", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments", "shortName": "Fair Value Measurements and Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120106 - Disclosure - Financial Royalty Assets, Net", "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsNet", "shortName": "Financial Royalty Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CreditLossFinancialInstrumentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123107 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets", "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CreditLossFinancialInstrumentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127108 - Disclosure - Intangible Royalty Assets, Net", "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet", "shortName": "Intangible Royalty Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131109 - Disclosure - Non-Consolidated Affiliates", "role": "http://royaltypharma.com/role/NonConsolidatedAffiliates", "shortName": "Non-Consolidated Affiliates", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133110 - Disclosure - Research & Development (\"R&D\") Funding Expense", "role": "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense", "shortName": "Research & Development (\"R&D\") Funding Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorFirmId", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0002002 - Document - Audit Information", "role": "http://royaltypharma.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorFirmId", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135111 - Disclosure - Borrowings", "role": "http://royaltypharma.com/role/Borrowings", "shortName": "Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140112 - Disclosure - Shareholders' Equity", "role": "http://royaltypharma.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144113 - Disclosure - Earnings Per Share", "role": "http://royaltypharma.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147114 - Disclosure - Indirect Cash Flow", "role": "http://royaltypharma.com/role/IndirectCashFlow", "shortName": "Indirect Cash Flow", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2150115 - Disclosure - Accumulated Other Comprehensive Income", "role": "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncome", "shortName": "Accumulated Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2153116 - Disclosure - Related Party Transactions", "role": "http://royaltypharma.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2156117 - Disclosure - Commitments and Contingencies", "role": "http://royaltypharma.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2158118 - Disclosure - Subsequent Events", "role": "http://royaltypharma.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Available for Sale Debt Securities (Tables)", "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables", "shortName": "Available for Sale Debt Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001003 - Statement - Consolidated Balance Sheets", "role": "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NotesAndLoansReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Derivative Instruments (Tables)", "role": "http://royaltypharma.com/role/DerivativeInstrumentsTables", "shortName": "Derivative Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables", "shortName": "Fair Value Measurements and Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321304 - Disclosure - Financial Royalty Assets, Net (Tables)", "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetTables", "shortName": "Financial Royalty Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324305 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)", "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328306 - Disclosure - Intangible Royalty Assets, Net (Tables)", "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables", "shortName": "Intangible Royalty Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2336307 - Disclosure - Borrowings (Tables)", "role": "http://royaltypharma.com/role/BorrowingsTables", "shortName": "Borrowings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341308 - Disclosure - Shareholders' Equity (Tables)", "role": "http://royaltypharma.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2345309 - Disclosure - Earnings Per Share (Tables)", "role": "http://royaltypharma.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2348310 - Disclosure - Indirect Cash Flow (Tables)", "role": "http://royaltypharma.com/role/IndirectCashFlowTables", "shortName": "Indirect Cash Flow (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2351311 - Disclosure - Accumulated Other Comprehensive Income (Tables)", "role": "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeTables", "shortName": "Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:DeferredSharesParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:DeferredSharesParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2354312 - Disclosure - Related Party Transactions (Tables)", "role": "http://royaltypharma.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfLongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization and Purpose (Details)", "role": "http://royaltypharma.com/role/OrganizationandPurposeDetails", "shortName": "Organization and Purpose (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "ibabbf759907e4aee8080ea0173539d93_D20200211-20200211", "decimals": "-8", "lang": "en-US", "name": "us-gaap:RepaymentsOfLongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "ifb99eff80794423ca92bd7db72623f54_I20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:NumberOfNoncontrollingInterestsCreated", "reportCount": 1, "unique": true, "unitRef": "partnership", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "ifb99eff80794423ca92bd7db72623f54_I20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:NumberOfNoncontrollingInterestsCreated", "reportCount": 1, "unique": true, "unitRef": "partnership", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Available for Sale Debt Securities - Narrative (Details)", "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "shortName": "Available for Sale Debt Securities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "ia849c0d494314af388e9fb0fc01f197d_D20190405-20190405", "decimals": "-5", "lang": "en-US", "name": "us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)", "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "shortName": "Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i58e8c79f7b7640d089df3eefd8c4584f_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Derivative Instruments - Narrative (Details)", "role": "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "shortName": "Derivative Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i58e8c79f7b7640d089df3eefd8c4584f_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i00b63eb6a93e410fa76fd2e629ddcb94_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - Derivative Instruments - Summary of Derivatives and Reclassifications (Details)", "role": "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails", "shortName": "Derivative Instruments - Summary of Derivatives and Reclassifications (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i00b63eb6a93e410fa76fd2e629ddcb94_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TradingSecuritiesDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i6fb80ebaf7cf4a41b7bb7ee7eecd1a0c_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417408 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "shortName": "Fair Value Measurements and Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i361e783ed15347028eee1b52d6e057f6_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails", "shortName": "Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "if100f3b0b4694f76acfbd85a49861791_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003005 - Statement - Consolidated Statements of Operations", "role": "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i81db589362444c02b90538016ac19ba1_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:FinancingReceivablesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419410 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails", "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i81db589362444c02b90538016ac19ba1_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:FinancingReceivablesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422411 - Disclosure - Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details)", "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails", "shortName": "Financial Royalty Assets, Net - Summary of Financial Royalty Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425412 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details)", "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426413 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)", "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "ifa26755fbc5e413fbf3122ec0db17370_I20181231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429414 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)", "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails", "shortName": "Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i874783a606094b5b9faa8d9db9749829_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430415 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details)", "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "shortName": "Intangible Royalty Assets, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i874783a606094b5b9faa8d9db9749829_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432416 - Disclosure - Non-Consolidated Affiliates (Details)", "role": "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "shortName": "Non-Consolidated Affiliates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "ie3c9990279364489bd57aa8cf39a801b_I20210731", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherCommitment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434417 - Disclosure - Research & Development (\"R&D\") Funding Expense (Details)", "role": "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails", "shortName": "Research & Development (\"R&D\") Funding Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "rprx:ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437418 - Disclosure - Borrowings - Schedule of Borrowings (Details)", "role": "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "shortName": "Borrowings - Schedule of Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438419 - Disclosure - Borrowings - Narrative (Details)", "role": "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "shortName": "Borrowings - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "ie681b3df9681426ba637a173be7ba1dc_I20210726", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004006 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439420 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details)", "role": "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails", "shortName": "Borrowings - Schedule of Repayments of Debt by Year (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i2faebe6b2bb249f9bacffbdee1da7d22_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:NumberOfClassesOfVotingStock", "reportCount": 1, "unitRef": "class", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442421 - Disclosure - Shareholders' Equity - Narrative (Details)", "role": "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "shortName": "Shareholders' Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DividendsCommonStockCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "id30f26bcb6cd4b64982e6cd53528c44e_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443422 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details)", "role": "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "shortName": "Shareholders' Equity - Summary of Noncontrolling Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "ie11ab38cff9248ce8459b4a78a07f67c_D20200618-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:CommonStockExchangeRatio", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446423 - Disclosure - Earnings Per Share (Details)", "role": "http://royaltypharma.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:CommonStockExchangeRatio", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "ie1399e8120f4459da1c98eaec460657b_D20200618-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449424 - Disclosure - Indirect Cash Flow (Details)", "role": "http://royaltypharma.com/role/IndirectCashFlowDetails", "shortName": "Indirect Cash Flow (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "rprx:IncreaseDecreaseInFinancialRoyaltyAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i2e1c8b5adabc4fc993a443e7a95b94fc_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452425 - Disclosure - Accumulated Other Comprehensive Income (Details)", "role": "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails", "shortName": "Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455426 - Disclosure - Related Party Transactions (Details)", "role": "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i355f63584077498c9358681b1f440182_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457427 - Disclosure - Commitments and Contingencies (Details)", "role": "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "ia3775cba07ed49d5ac77571f04f1b439_D20210602-20210602", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "if022a6e3714949948eb2520d7c7ab729_D20220101-20220131", "decimals": "-5", "first": true, "lang": "en-US", "name": "rprx:PaymentsToAcquireRoyaltyInterestsAggregateAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459428 - Disclosure - Subsequent Events (Details)", "role": "http://royaltypharma.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "if022a6e3714949948eb2520d7c7ab729_D20220101-20220131", "decimals": "-5", "first": true, "lang": "en-US", "name": "rprx:PaymentsToAcquireRoyaltyInterestsAggregateAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i7242e01e0d3e49c99430b9b17185b69d_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005007 - Statement - Consolidated Statements of Shareholders' Equity", "role": "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "shortName": "Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i7242e01e0d3e49c99430b9b17185b69d_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockDividendsPerShareCashPaid", "us-gaap:CommonStockDividendsPerShareCashPaid", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i08c8a6f2c3554638b8b9e8e94b41d3ab_D20211001-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006008 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)", "role": "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical", "shortName": "Consolidated Statements of Shareholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007009 - Statement - Consolidated Statements of Cash Flows", "role": "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i148c3a251fbd45228f0b7ce81f892e57_D20210101-20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20211231.htm", "contextRef": "i3422c7350bb14d2d869ff498fa12e855_D20200101-20200617", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - rprx-20211231.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - rprx-20211231.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 148, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r730", "r731", "r732" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r730", "r731", "r732" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r730", "r731", "r732" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r730", "r731", "r732" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r733" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r728" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r748" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r730", "r731", "r732" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "rprx_A2020EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Equity Incentive Plan", "label": "2020 Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan" } } }, "localname": "A2020EquityIncentivePlanMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_AZAssetPhaseIIAndPhaseIIIClinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AZ Asset - Phase II and Phase III Clinical Trial", "label": "AZ Asset - Phase II and Phase III Clinical Trial [Member]", "terseLabel": "AZ Asset - Phase II and Phase III Clinical Trial" } } }, "localname": "AZAssetPhaseIIAndPhaseIIIClinicalTrialMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_AccruedPurchaseObligationCurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Purchase Obligation, Current", "label": "Accrued Purchase Obligation, Current", "terseLabel": "Accrued purchase obligation" } } }, "localname": "AccruedPurchaseObligationCurrent", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rprx_AccruedPurchaseObligationEquityInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Purchase Obligation, Equity Investment", "label": "Accrued Purchase Obligation, Equity Investment", "terseLabel": "Accrued purchase obligation - Tazverik" } } }, "localname": "AccruedPurchaseObligationEquityInvestment", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_AccruedRoyaltyReceivable": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued Royalty Receivable", "label": "Accrued Royalty Receivable", "terseLabel": "Accrued royalty receivable" } } }, "localname": "AccruedRoyaltyReceivable", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition Of Limited Partnership Interests In Affiliate", "label": "Acquisition Of Limited Partnership Interests In Affiliate [Member]", "terseLabel": "Acquisition Of Limited Partnership Interests In Affiliate" } } }, "localname": "AcquisitionOfLimitedPartnershipInterestsInAffiliateMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_AgreementWithMSCIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement with MSCI", "label": "Agreement with MSCI [Member]", "terseLabel": "Agreement with MSCI" } } }, "localname": "AgreementWithMSCIMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_AssetsFairValueDisclosureCurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets, Fair Value Disclosure, Current", "label": "Assets, Fair Value Disclosure, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsFairValueDisclosureCurrent", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "rprx_AssetsFairValueDisclosureNoncurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets, Fair Value Disclosure, Noncurrent", "label": "Assets, Fair Value Disclosure, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsFairValueDisclosureNoncurrent", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "rprx_AssignmentAgreementBenefitOfPaymentStreamMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assignment Agreement - Benefit of Payment Stream", "label": "Assignment Agreement - Benefit of Payment Stream [Member]", "terseLabel": "Assignment Agreement - Benefit of Payment Stream" } } }, "localname": "AssignmentAgreementBenefitOfPaymentStreamMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_AssignmentAgreementFundingObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assignment Agreement - Funding Obligations", "label": "Assignment Agreement - Funding Obligations [Member]", "terseLabel": "Assignment Agreement - Funding Obligations" } } }, "localname": "AssignmentAgreementFundingObligationsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://royaltypharma.com/20211231", "xbrltype": "stringItemType" }, "rprx_AvillionEntitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Avillion Entities", "label": "Avillion Entities [Member]", "terseLabel": "Avillion Entities" } } }, "localname": "AvillionEntitiesMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_AvillionIIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Avillion II", "label": "Avillion II [Member]", "terseLabel": "Avillion II" } } }, "localname": "AvillionIIMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_AvillionIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Avillion I", "label": "Avillion I [Member]", "terseLabel": "Avillion I" } } }, "localname": "AvillionIMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_BioCrystPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioCryst Pharmaceuticals, Inc.", "label": "BioCryst Pharmaceuticals, Inc. [Member]", "terseLabel": "BioCryst Pharmaceuticals, Inc." } } }, "localname": "BioCrystPharmaceuticalsIncMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "domainItemType" }, "rprx_BristolMyersSquibbMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bristol-Myers Squibb", "label": "Bristol-Myers Squibb [Member]", "terseLabel": "Bristol-Myers Squibb" } } }, "localname": "BristolMyersSquibbMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_ClassBHoldersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class B Holders", "label": "Class B Holders [Member]", "terseLabel": "Class B Holders" } } }, "localname": "ClassBHoldersMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "rprx_ClassRRedeemableStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class R Redeemable Stock", "label": "Class R Redeemable Stock [Member]", "terseLabel": "Class R Redeemable Stock" } } }, "localname": "ClassRRedeemableStockMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_CollaborativeArrangementRightsAndObligationsExpectedReturn": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Expected Return", "label": "Collaborative Arrangement, Rights and Obligations, Expected Return", "terseLabel": "Expected return (as a percent)" } } }, "localname": "CollaborativeArrangementRightsAndObligationsExpectedReturn", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "rprx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments", "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments", "terseLabel": "Maximum milestone payment" } } }, "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund", "label": "Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund", "terseLabel": "Maximum commitment to fund collaborative arrangement" } } }, "localname": "CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Payment of Capital", "label": "Collaborative Arrangement, Rights and Obligations, Payment of Capital", "terseLabel": "Payment of capital" } } }, "localname": "CollaborativeArrangementRightsAndObligationsPaymentOfCapital", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Payment of Capital, Term", "label": "Collaborative Arrangement, Rights and Obligations, Payment of Capital, Term", "terseLabel": "Payment of capital term" } } }, "localname": "CollaborativeArrangementRightsAndObligationsPaymentOfCapitalTerm", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Period of Return", "label": "Collaborative Arrangement, Rights and Obligations, Period of Return", "terseLabel": "Period of return" } } }, "localname": "CollaborativeArrangementRightsAndObligationsPeriodOfReturn", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date", "label": "Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date", "terseLabel": "Period of return start date" } } }, "localname": "CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "rprx_CommonStockExchangeRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Exchange Ratio", "label": "Common Stock, Exchange Ratio", "terseLabel": "Exchange ratio" } } }, "localname": "CommonStockExchangeRatio", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "pureItemType" }, "rprx_ContinuingInvestorsPartnershipMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continuing Investors Partnership", "label": "Continuing Investors Partnership [Member]", "terseLabel": "Continuing Investors Partnerships" } } }, "localname": "ContinuingInvestorsPartnershipMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "rprx_CysticFibrosisFranchiseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cystic Fibrosis Franchise", "label": "Cystic Fibrosis Franchise [Member]", "terseLabel": "Cystic fibrosis franchise" } } }, "localname": "CysticFibrosisFranchiseMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_DPPIVPatentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DPP-IV Patents", "label": "DPP-IV Patents [Member]", "terseLabel": "DPP-IV patents" } } }, "localname": "DPPIVPatentsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "domainItemType" }, "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio", "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio", "terseLabel": "Maximum consolidated leverage ratio" } } }, "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition", "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition", "terseLabel": "Maximum consolidated leverage ratio following qualifying material acquisition" } } }, "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio", "label": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio", "terseLabel": "Minimum consolidated coverage ratio" } } }, "localname": "DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "rprx_DebtInstrumentIssuanceAsAPercentOfPar": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Issuance As A Percent Of Par", "label": "Debt Instrument, Issuance As A Percent Of Par", "terseLabel": "Debt issued as a percent of par value (as a percent)" } } }, "localname": "DebtInstrumentIssuanceAsAPercentOfPar", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "percentItemType" }, "rprx_DebtSecuritiesAvailableForSaleChangeInControlEventPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Change In Control Event, Period", "label": "Debt Securities, Available-For-Sale, Change In Control Event, Period", "terseLabel": "Change in control event, period" } } }, "localname": "DebtSecuritiesAvailableForSaleChangeInControlEventPeriod", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "rprx_DebtSecuritiesAvailableForSaleFixedPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-Sale, Fixed Payment", "label": "Debt Securities, Available-for-Sale, Fixed Payment", "terseLabel": "Preferred shares, fixed payment amount" } } }, "localname": "DebtSecuritiesAvailableForSaleFixedPayment", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Number Of Shares Purchased", "label": "Debt Securities, Available-For-Sale, Number Of Shares Purchased", "terseLabel": "Number of shares purchased (in shares)" } } }, "localname": "DebtSecuritiesAvailableForSaleNumberOfSharesPurchased", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "rprx_DebtSecuritiesAvailableForSalePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available For Sale, Policy", "label": "Debt Securities, Available For Sale, Policy [Policy Text Block]", "terseLabel": "Equity securities and Available for sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSalePolicyPolicyTextBlock", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rprx_DebtSecuritiesAvailableForSalePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Price Per Share", "label": "Debt Securities, Available-For-Sale, Price Per Share", "terseLabel": "Price per share (in USD per share)" } } }, "localname": "DebtSecuritiesAvailableForSalePricePerShare", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "perShareItemType" }, "rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-Sale, Quarterly Payments", "label": "Debt Securities, Available-for-Sale, Quarterly Payments", "terseLabel": "Preferred shares, quarterly payments" } } }, "localname": "DebtSecuritiesAvailableForSaleQuarterlyPayments", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption Default, Interest Rate", "label": "Debt Securities, Available-For-Sale, Redemption Default, Interest Rate", "terseLabel": "Redemption default, interest rate" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionDefaultInterestRate", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "percentItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption, Default Period", "label": "Debt Securities, Available-For-Sale, Redemption, Default Period", "terseLabel": "Default period" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionDefaultPeriod", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "durationItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption Default, Threshold Period", "label": "Debt Securities, Available-For-Sale, Redemption Default, Threshold Period", "terseLabel": "Redemption default, threshold period" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionDefaultThresholdPeriod", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "durationItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption, Period", "label": "Debt Securities, Available-For-Sale, Redemption, Period [Axis]", "terseLabel": "Debt Securities, Available-For-Sale, Redemption, Period [Axis]" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodAxis", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption, Period", "label": "Debt Securities, Available-For-Sale, Redemption, Period [Domain]", "terseLabel": "Debt Securities, Available-For-Sale, Redemption, Period [Domain]" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodDomain", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption, Period One", "label": "Debt Securities, Available-For-Sale, Redemption, Period One [Member]", "terseLabel": "Redemption, Period One" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption, Period Two", "label": "Debt Securities, Available-For-Sale, Redemption, Period Two [Member]", "terseLabel": "Redemption, Period Two" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption Price, Percentage", "label": "Debt Securities, Available-For-Sale, Redemption Price, Percentage", "terseLabel": "Redemption price, percentage" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPricePercentage", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Restriction Period", "label": "Debt Securities, Available-For-Sale, Restriction Period", "terseLabel": "Restrictions on selling common stock, period" } } }, "localname": "DebtSecuritiesAvailableForSaleRestrictionPeriod", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital", "label": "Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital", "terseLabel": "Preferred shares, weighted average cost of capital" } } }, "localname": "DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "rprx_DeferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares", "label": "Deferred Shares [Member]", "terseLabel": "Deferred Shares", "verboseLabel": "Deferred Shares" } } }, "localname": "DeferredSharesMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_DeferredSharesParOrStatedValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares, Par or Stated Value Per Share", "label": "Deferred Shares, Par or Stated Value Per Share", "terseLabel": "Deferred stock, par value (in dollars per share)" } } }, "localname": "DeferredSharesParOrStatedValuePerShare", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "rprx_DeferredSharesSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares, Shares, Issued", "label": "Deferred Shares, Shares, Issued", "terseLabel": "Deferred stock, issued (in shares)" } } }, "localname": "DeferredSharesSharesIssued", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "rprx_DeferredSharesSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares, Shares, Outstanding", "label": "Deferred Shares, Shares, Outstanding", "terseLabel": "Deferred stock, outstanding (in shares)" } } }, "localname": "DeferredSharesSharesOutstanding", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "rprx_DeferredSharesValueIssued": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Shares, Value, Issued", "label": "Deferred Shares, Value, Issued", "terseLabel": "Deferred shares, $0.000001 par value, 361,170 and 316,407 issued and outstanding, respectively" } } }, "localname": "DeferredSharesValueIssued", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rprx_DevelopmentFundingBondForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development Funding Bond Forward", "label": "Development Funding Bond Forward [Member]", "terseLabel": "Development Funding Bond Forward" } } }, "localname": "DevelopmentFundingBondForwardMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "rprx_EPAHoldingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EPA Holdings", "label": "EPA Holdings [Member]", "terseLabel": "EPA Holdings" } } }, "localname": "EPAHoldingsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "rprx_EpizymeCommonStockWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Epizyme Common Stock Warrant", "label": "Epizyme Common Stock Warrant [Member]", "terseLabel": "Epizyme Common Stock Warrant" } } }, "localname": "EpizymeCommonStockWarrantMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_EpizymeIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Epizyme Inc.", "label": "Epizyme Inc. [Member]", "terseLabel": "Equity Investment In Epizyme Inc." } } }, "localname": "EpizymeIncMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_EquityMethodInvestmentsUnfundedCommitments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investments, Unfunded Commitments", "label": "Equity Method Investments, Unfunded Commitments", "terseLabel": "Equity method investment, unfunded commitments" } } }, "localname": "EquityMethodInvestmentsUnfundedCommitments", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_EvrysdiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Evrysdi", "label": "Evrysdi [Member]", "terseLabel": "Evrysdi" } } }, "localname": "EvrysdiMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_ExchangeOfferTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange Offer Transaction", "label": "Exchange Offer Transaction [Member]", "terseLabel": "Exchange Offer Transaction" } } }, "localname": "ExchangeOfferTransactionMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss), After Transfer To Level 3", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss), After Transfer To Level 3", "terseLabel": "Unrealized gains on available for sale debt securities" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLossAfterTransferToLevel3", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions", "terseLabel": "Redemption" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancialRoyaltyAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Royalty Assets", "label": "Financial Royalty Assets [Member]", "terseLabel": "Income from financial royalty assets" } } }, "localname": "FinancialRoyaltyAssetsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": { "order": 1.0, "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows", "label": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows", "negatedLabel": "Cumulative allowance for changes in expected cash flows" } } }, "localname": "FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": { "order": 1.0, "parentTag": "us-gaap_NotesReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)", "label": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)", "negatedLabel": "Cumulative allowance for credit losses" } } }, "localname": "FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Financial Royalty Asset, Writeoff", "label": "Financing Receivable, Allowance for Credit Loss, Financial Royalty Asset, Writeoff", "terseLabel": "Writeoff related to financial royalty asset" } } }, "localname": "FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense", "label": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense", "terseLabel": "Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets" } } }, "localname": "FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense", "label": "Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense", "negatedTerseLabel": "Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets" } } }, "localname": "FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents", "label": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents", "terseLabel": "Aggregate royalty amount when patents cease" } } }, "localname": "FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": { "order": 2.0, "parentTag": "us-gaap_NotesReceivableNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows", "label": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows", "totalLabel": "Net carrying value, before cumulative allowance for credit losses" } } }, "localname": "FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivablesFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivables, Fair Value Disclosure", "label": "Financing Receivables, Fair Value Disclosure", "terseLabel": "Financial royalty assets, net" } } }, "localname": "FinancingReceivablesFairValueDisclosure", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FormerOperatingAndPersonnelPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Operating and Personnel Payments", "label": "Former Operating and Personnel Payments [Member]", "terseLabel": "Former Operating and Personnel Payments" } } }, "localname": "FormerOperatingAndPersonnelPaymentsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_FundingAgreementWithBioCrystMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Funding Agreement With BioCryst", "label": "Funding Agreement With BioCryst [Member]", "terseLabel": "Funding Agreement With BioCryst" } } }, "localname": "FundingAgreementWithBioCrystMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "domainItemType" }, "rprx_FundingAgreementsWithPfizerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Funding Agreements With Pfizer", "label": "Funding Agreements With Pfizer [Member]", "terseLabel": "Funding Agreements With Pfizer" } } }, "localname": "FundingAgreementsWithPfizerMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "domainItemType" }, "rprx_FundingAgreementsWithSanofiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Funding Agreements With Sanofi", "label": "Funding Agreements With Sanofi [Member]", "terseLabel": "Funding Agreements With Sanofi" } } }, "localname": "FundingAgreementsWithSanofiMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "domainItemType" }, "rprx_GainLossOnDerivativeFinancialInstruments": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Derivative Financial Instruments", "label": "Gain (Loss) On Derivative Financial Instruments", "negatedTerseLabel": "Termination of derivative financial instruments" } } }, "localname": "GainLossOnDerivativeFinancialInstruments", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IPOContinuingInvestorsPartnershipsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IPO - Continuing Investors Partnerships", "label": "IPO - Continuing Investors Partnerships [Member]", "terseLabel": "Public Stock Offering - Continuing Investors Partnerships Interests" } } }, "localname": "IPOContinuingInvestorsPartnershipsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_IPOSharesFromCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IPO - Shares From Company", "label": "IPO - Shares From Company [Member]", "terseLabel": "IPO - Shares From Company" } } }, "localname": "IPOSharesFromCompanyMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_IPOSharesFromSellingShareholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IPO - Shares From Selling Shareholders", "label": "IPO - Shares From Selling Shareholders [Member]", "terseLabel": "IPO - Shares From Selling Shareholders" } } }, "localname": "IPOSharesFromSellingShareholdersMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_ImbruvicaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Imbruvica", "label": "Imbruvica [Member]", "terseLabel": "Imbruvica" } } }, "localname": "ImbruvicaMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_IncreaseDecreaseInAccruedRoyaltyReceivable": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Accrued Royalty Receivable", "label": "Increase (Decrease) In Accrued Royalty Receivable", "negatedTerseLabel": "Accrued royalty receivable" } } }, "localname": "IncreaseDecreaseInAccruedRoyaltyReceivable", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Cash Collections On Financing Receivables", "label": "Increase (Decrease) In Cash Collections On Financing Receivables", "terseLabel": "Cash collected on financial royalty assets" } } }, "localname": "IncreaseDecreaseInCashCollectionsOnFinancingReceivables", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IncreaseDecreaseInDebtSecuritiesAvailableForSale": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Debt Securities, Available For Sale", "label": "Increase (Decrease) In Debt Securities, Available For Sale", "negatedTerseLabel": "Available for sale debt securities" } } }, "localname": "IncreaseDecreaseInDebtSecuritiesAvailableForSale", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IncreaseDecreaseInFinancialRoyaltyAssets": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Financial Royalty Assets", "label": "Increase (Decrease) In Financial Royalty Assets", "negatedTerseLabel": "Income from financial royalty assets" } } }, "localname": "IncreaseDecreaseInFinancialRoyaltyAssets", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Other Royalty Income Receivable", "label": "Increase (Decrease) In Other Royalty Income Receivable", "negatedTerseLabel": "Other royalty income receivable" } } }, "localname": "IncreaseDecreaseInOtherRoyaltyIncomeReceivable", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IndividualLicenseesConcentrationRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Licensees Concentration Risk", "label": "Individual Licensees Concentration Risk [Member]", "terseLabel": "Individual Licensees Concentration List" } } }, "localname": "IndividualLicenseesConcentrationRiskMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_IntangibleRoyaltyAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Royalty Assets", "label": "Intangible Royalty Assets [Member]", "terseLabel": "Revenue from intangible royalty assets" } } }, "localname": "IntangibleRoyaltyAssetsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)", "label": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)", "negatedTerseLabel": "Interest income accretion" } } }, "localname": "InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LegacyInvestorsPartnershipsAndRPSFTMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legacy Investors Partnerships and RPSFT", "label": "Legacy Investors Partnerships and RPSFT [Member]", "terseLabel": "Legacy Investors Partnerships and RPSFT" } } }, "localname": "LegacyInvestorsPartnershipsAndRPSFTMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust", "label": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member]", "terseLabel": "RPSFT" } } }, "localname": "LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_LegacyInvestorsPartnershipsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legacy Investors Partnerships", "label": "Legacy Investors Partnerships [Member]", "terseLabel": "Legacy Investors Partnerships" } } }, "localname": "LegacyInvestorsPartnershipsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long Term Funding Partnership, Additional Payments, Aggregate Amount", "label": "Long Term Funding Partnership, Additional Payments, Aggregate Amount", "terseLabel": "Long term funding partnership, additional payments, aggregate amount" } } }, "localname": "LongTermFundingPartnershipAdditionalPaymentsAggregateAmount", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LongTermFundingPartnershipAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long Term Funding Partnership, Amount", "label": "Long Term Funding Partnership, Amount", "terseLabel": "Long term funding partnership, amount" } } }, "localname": "LongTermFundingPartnershipAmount", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LongTermFundingPartnershipInitialPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long Term Funding Partnership, Initial Payment", "label": "Long Term Funding Partnership, Initial Payment", "terseLabel": "Long term funding partnership, initial payment" } } }, "localname": "LongTermFundingPartnershipInitialPayment", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LongTermFundingPartnershipNumberOfAdditionalPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Funding Partnership, Number of Additional Payments", "label": "Long Term Funding Partnership, Number of Additional Payments", "terseLabel": "Long term funding partnership, number of additional payments" } } }, "localname": "LongTermFundingPartnershipNumberOfAdditionalPayments", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "rprx_LongTermFundingPartnershipNumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Funding Partnership, Number of Tranches", "label": "Long Term Funding Partnership, Number of Tranches", "terseLabel": "Long term funding partnership, number of tranches" } } }, "localname": "LongTermFundingPartnershipNumberOfTranches", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "rprx_LongTermPurchaseCommitmentAmountOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long Term Purchase Commitment, Amount Outstanding", "label": "Long Term Purchase Commitment, Amount Outstanding", "terseLabel": "Remaining commitment" } } }, "localname": "LongTermPurchaseCommitmentAmountOutstanding", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals", "label": "Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals [Member]", "terseLabel": "Funding Agreement With Biohaven Pharmaceuticals" } } }, "localname": "LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "rprx_LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Purchase Commitment, Purchase Of Eisai Royalties", "label": "Long Term Purchase Commitment, Purchase Of Eisai Royalties [Member]", "terseLabel": "Purchase Of Eisai Royalties" } } }, "localname": "LongTermPurchaseCommitmentPurchaseOfEisaiRoyaltiesMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "rprx_MerckAssetPhaseIIClinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merck Asset - Phase II Clinical Trial", "label": "Merck Asset - Phase II Clinical Trial [Member]", "terseLabel": "Merck Asset - Phase II Clinical Trial" } } }, "localname": "MerckAssetPhaseIIClinicalTrialMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_MilestonePaymentAccruedButNotPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment Accrued But Not Paid", "label": "Milestone Payment Accrued But Not Paid", "terseLabel": "Milestone payable - Erleada" } } }, "localname": "MilestonePaymentAccruedButNotPaid", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_MorphoSysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MorphoSys", "label": "MorphoSys [Member]", "terseLabel": "MorphoSys" } } }, "localname": "MorphoSysMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "domainItemType" }, "rprx_NetIncomeLossAttributableToParentPriorToOffering": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net Income (Loss) Attributable to Parent, Prior To Offering", "label": "Net Income (Loss) Attributable to Parent, Prior To Offering", "terseLabel": "Less: net income attributable to Continuing Investors Partnerships prior to the IPO" } } }, "localname": "NetIncomeLossAttributableToParentPriorToOffering", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "rprx_NoncontrollingInterestIncreaseFromContributions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest, Increase from Contributions", "label": "Noncontrolling Interest, Increase from Contributions", "terseLabel": "Contributions" } } }, "localname": "NoncontrollingInterestIncreaseFromContributions", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_NoncontrollingInterestTransfersOfInterests": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest, Transfers Of Interests", "label": "Noncontrolling Interest, Transfers Of Interests", "terseLabel": "Transfer of interests" } } }, "localname": "NoncontrollingInterestTransfersOfInterests", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_NumberOfClassesOfVotingStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Classes Of Voting Stock", "label": "Number Of Classes Of Voting Stock", "terseLabel": "Number of classes of voting shares" } } }, "localname": "NumberOfClassesOfVotingStock", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "rprx_NumberOfNoncontrollingInterests": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Noncontrolling Interests", "label": "Number of Noncontrolling Interests", "terseLabel": "Number of noncontrolling interests" } } }, "localname": "NumberOfNoncontrollingInterests", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "rprx_NumberOfNoncontrollingInterestsCreated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Noncontrolling Interests Created", "label": "Number Of Noncontrolling Interests Created", "terseLabel": "Number of noncontrolling interests created" } } }, "localname": "NumberOfNoncontrollingInterestsCreated", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "rprx_OldCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Old Credit Facility", "label": "Old Credit Facility [Member]", "terseLabel": "Old Credit Facility" } } }, "localname": "OldCreditFacilityMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_OnePointSevenFivePercentSeniorNotesDue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Point Seven Five Percent Senior Notes Due 2027", "label": "One Point Seven Five Percent Senior Notes Due 2027 [Member]", "terseLabel": "One Point Seven Five Percent Senior Notes Due 2027" } } }, "localname": "OnePointSevenFivePercentSeniorNotesDue2027Member", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Point Two Zero Percent Senior Notes Due 2025", "label": "One Point Two Zero Percent Senior Notes Due 2025 [Member]", "terseLabel": "One Point Two Zero Percent Senior Notes Due 2025" } } }, "localname": "OnePointTwoZeroPercentSeniorNotesDue2025Member", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_OperatingAndPersonnelPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating and Personnel Payments", "label": "Operating and Personnel Payments [Member]", "terseLabel": "Operating and Personnel Payments" } } }, "localname": "OperatingAndPersonnelPaymentsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_OptionIndexedToIssuersEquityTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option Indexed to Issuer's Equity, Term", "label": "Option Indexed to Issuer's Equity, Term", "terseLabel": "Put option, term (in months)" } } }, "localname": "OptionIndexedToIssuersEquityTerm", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "rprx_OptionIndexedToIssuersEquityValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Option Indexed To Issuers Equity, Value", "label": "Option Indexed To Issuers Equity, Value", "terseLabel": "Put option to sell additional common stock" } } }, "localname": "OptionIndexedToIssuersEquityValue", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_OtherCommitmentsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Commitments, Percentage", "label": "Other Commitments, Percentage", "terseLabel": "Other commitments, percentage of costs (as a percent)" } } }, "localname": "OtherCommitmentsPercentage", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "percentItemType" }, "rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss) Reclassification Adjustment, Attributable From Noncontrolling Interest", "label": "Other Comprehensive Income (Loss) Reclassification Adjustment, Attributable From Noncontrolling Interest", "terseLabel": "Reclassification from non-controlling interest" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableFromNoncontrollingInterest", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Reclassification Adjustment, Attributable to Noncontrolling Interest", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment, Attributable to Noncontrolling Interest", "negatedTerseLabel": "Reclassification to non-controlling interest" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_OtherFinancialRoyaltyAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Financial Royalty Asset", "label": "Other Financial Royalty Asset [Member]", "terseLabel": "Other" } } }, "localname": "OtherFinancialRoyaltyAssetMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_OtherRoyaltyIncomeReceivableCurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Royalty Income Receivable, Current", "label": "Other Royalty Income Receivable, Current", "terseLabel": "Other royalty income receivable" } } }, "localname": "OtherRoyaltyIncomeReceivableCurrent", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rprx_OvernightBankFundingRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Overnight Bank Funding Rate", "label": "Overnight Bank Funding Rate [Member]", "terseLabel": "Overnight Bank Funding Rate" } } }, "localname": "OvernightBankFundingRateMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_PabloLegorretaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pablo Legorreta", "label": "Pablo Legorreta [Member]", "terseLabel": "Pablo Legorreta" } } }, "localname": "PabloLegorretaMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_PaymentOfDividendsToShareholders": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment Of Dividends To Shareholders", "label": "Payment Of Dividends To Shareholders", "negatedTerseLabel": "Dividends to shareholders" } } }, "localname": "PaymentOfDividendsToShareholders", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForCollateralPostedOnDerivativeInstruments": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Collateral Posted On Derivative Instruments", "label": "Payments For Collateral Posted On Derivative Instruments", "negatedTerseLabel": "Derivative collateral posted" } } }, "localname": "PaymentsForCollateralPostedOnDerivativeInstruments", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForDistributionsToShareholdersAndUnitholders": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Distributions To Shareholders and Unitholders", "label": "Payments For Distributions To Shareholders and Unitholders", "negatedLabel": "Distributions to shareholders/unitholders" } } }, "localname": "PaymentsForDistributionsToShareholdersAndUnitholders", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForMilestones": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Milestones", "label": "Payments For Milestones", "negatedTerseLabel": "Milestone payments" } } }, "localname": "PaymentsForMilestones", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForOngoingDevelopmentStageFunding": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Ongoing Development Stage Funding", "label": "Payments For Ongoing Development Stage Funding", "negatedTerseLabel": "Ongoing development-stage funding payments" } } }, "localname": "PaymentsForOngoingDevelopmentStageFunding", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForOperatingCostsAndProfessionalServices": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Operating Costs and Professional Services", "label": "Payments For Operating Costs and Professional Services", "negatedTerseLabel": "Payments for operating and professional costs" } } }, "localname": "PaymentsForOperatingCostsAndProfessionalServices", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForUpfrontDevelopmentStageFunding": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Upfront Development Stage Funding", "label": "Payments For Upfront Development Stage Funding", "negatedTerseLabel": "Upfront development-stage funding payments" } } }, "localname": "PaymentsForUpfrontDevelopmentStageFunding", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToAcquireEquityInvestmentsUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to Acquire Equity Investments, Upfront Payment", "label": "Payments to Acquire Equity Investments, Upfront Payment", "terseLabel": "Upfront payment for equity investment" } } }, "localname": "PaymentsToAcquireEquityInvestmentsUpfrontPayment", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToAcquireEquitySecuritiesFNNI": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Equity Securities, FN-NI", "label": "Payments To Acquire Equity Securities, FN-NI", "negatedTerseLabel": "Purchases of equity securities" } } }, "localname": "PaymentsToAcquireEquitySecuritiesFNNI", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Royalty Interest, Additional Milestone Payments", "label": "Payments To Acquire Royalty Interest, Additional Milestone Payments", "terseLabel": "Payments to acquire royalty interests, additional milestone payments" } } }, "localname": "PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToAcquireRoyaltyInterestsAggregateAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Royalty Interests, Aggregate Amount", "label": "Payments To Acquire Royalty Interests, Aggregate Amount", "terseLabel": "Payments to acquire royalty interests" } } }, "localname": "PaymentsToAcquireRoyaltyInterestsAggregateAmount", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Royalty Interests, Number Of Additional Payments", "label": "Payments To Acquire Royalty Interests, Number Of Additional Payments", "terseLabel": "Payments to acquire royalty interests, number of additional payments" } } }, "localname": "PaymentsToAcquireRoyaltyInterestsNumberOfAdditionalPayments", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "rprx_PaymentsToAcquireRoyaltyInterestsUpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Royalty Interests, Upfront Payment", "label": "Payments To Acquire Royalty Interests, Upfront Payment", "terseLabel": "Payments to acquire royalty interests, upfront payment" } } }, "localname": "PaymentsToAcquireRoyaltyInterestsUpfrontPayment", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToAcquireWarrants": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Warrants", "label": "Payments To Acquire Warrants", "negatedTerseLabel": "Purchase of warrants" } } }, "localname": "PaymentsToAcquireWarrants", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToNoncontrollingInterestsOther": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Noncontrolling Interests, Other", "label": "Payments To Noncontrolling Interests, Other", "negatedTerseLabel": "Distributions to non-controlling interest- other" } } }, "localname": "PaymentsToNoncontrollingInterestsOther", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToTerminateDerivativeInstruments": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Terminate Derivative Instruments", "label": "Payments To Terminate Derivative Instruments", "negatedTerseLabel": "Termination payments on derivative instruments", "verboseLabel": "Swap termination payments" } } }, "localname": "PaymentsToTerminateDerivativeInstruments", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PointSevenFivePercentSeniorNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Point Seven Five Percent Senior Notes Due 2023", "label": "Point Seven Five Percent Senior Notes Due 2023 [Member]", "terseLabel": "Point Seven Five Percent Senior Notes Due 2023" } } }, "localname": "PointSevenFivePercentSeniorNotesDue2023Member", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables", "label": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables", "terseLabel": "Other royalty cash collections" } } }, "localname": "ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Cash Collections From Royalties Received On Financing Receivables", "label": "Proceeds From Cash Collections From Royalties Received On Financing Receivables", "terseLabel": "Cash collections from financial royalty assets" } } }, "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Cash Collections From Royalties Received On Intangible Assets", "label": "Proceeds From Cash Collections From Royalties Received On Intangible Assets", "terseLabel": "Cash collections from intangible royalty assets" } } }, "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Collateral Received On Derivative Instruments", "label": "Proceeds From Collateral Received On Derivative Instruments", "terseLabel": "Derivative collateral received" } } }, "localname": "ProceedsFromCollateralReceivedOnDerivativeInstruments", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Issuance Of Equity Securities, FN-NI", "label": "Proceeds From Issuance Of Equity Securities, FN-NI", "terseLabel": "Proceeds from equity securities" } } }, "localname": "ProceedsFromIssuanceOfEquitySecuritiesFNNI", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromNoncontrollingInterestsOther": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Noncontrolling Interests, Other", "label": "Proceeds From Noncontrolling Interests, Other", "terseLabel": "Contributions from non-controlling interest- other" } } }, "localname": "ProceedsFromNoncontrollingInterestsOther", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Noncontrolling Interests, Research And Development", "label": "Proceeds From Noncontrolling Interests, Research And Development", "terseLabel": "Contributions from non-controlling interest- R&D" } } }, "localname": "ProceedsFromNoncontrollingInterestsResearchAndDevelopment", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PromactaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promacta", "label": "Promacta [Member]", "terseLabel": "Promacta" } } }, "localname": "PromactaMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_PurchaseCommitmentAdditionalPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase Commitment, Additional Payment", "label": "Purchase Commitment, Additional Payment", "terseLabel": "Purchase commitment, additional payments" } } }, "localname": "PurchaseCommitmentAdditionalPayment", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase Commitment, Committed Non-Contingent Commercial Launch Preferred Equity, Amount", "label": "Purchase Commitment, Committed Non-Contingent Commercial Launch Preferred Equity, Amount", "terseLabel": "Purchase commitment, purchase of committed, non-contingent Commercial Launch Preferred Equity payable" } } }, "localname": "PurchaseCommitmentCommittedNonContingentCommercialLaunchPreferredEquityAmount", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PurchaseCommitmentUpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase Commitment, Upfront Payment", "label": "Purchase Commitment, Upfront Payment", "terseLabel": "Purchase commitment, upfront payment" } } }, "localname": "PurchaseCommitmentUpfrontPayment", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PurchasingAndDonatingVentilatorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchasing And Donating Ventilators", "label": "Purchasing And Donating Ventilators [Member]", "terseLabel": "Purchasing And Donating Ventilators" } } }, "localname": "PurchasingAndDonatingVentilatorsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_RPHoldingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RP Holdings", "label": "RP Holdings [Member]", "terseLabel": "RP Holdings" } } }, "localname": "RPHoldingsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "rprx_RPI2019IntermediateFinanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI 2019 Intermediate Finance", "label": "RPI 2019 Intermediate Finance [Member]", "terseLabel": "RPI Intermediate FT" } } }, "localname": "RPI2019IntermediateFinanceMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_RPIFTSeniorSecuredCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPIFT Senior Secured Credit Facilities", "label": "RPIFT Senior Secured Credit Facilities [Member]", "terseLabel": "RPIFT Senior Secured Credit Facilities" } } }, "localname": "RPIFTSeniorSecuredCreditFacilitiesMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1", "label": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1 [Member]", "terseLabel": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche A-1" } } }, "localname": "RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheA1Member", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1", "label": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1 [Member]", "terseLabel": "RPI Intermediate FT Senior Secured Credit Facilities - Tranche B-1" } } }, "localname": "RPIIntermediateFTSeniorSecuredCreditFacilitiesTrancheB1Member", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_RedeemableStockRedemptionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable Stock, Redemption Price Per Share", "label": "Redeemable Stock, Redemption Price Per Share", "terseLabel": "Redeemable stock, redemption price (in euros per share)" } } }, "localname": "RedeemableStockRedemptionPricePerShare", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "rprx_RelatedPartyTransactionAnnualIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Annual Increase, Percentage", "label": "Related Party Transaction, Annual Increase, Percentage", "terseLabel": "Increase in quarterly installment payments (as a percent)" } } }, "localname": "RelatedPartyTransactionAnnualIncreasePercentage", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rprx_RelatedPartyTransactionCumulativeFundingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Cumulative Funding Amount", "label": "Related Party Transaction, Cumulative Funding Amount", "terseLabel": "Cumulative funding amount" } } }, "localname": "RelatedPartyTransactionCumulativeFundingAmount", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_RelatedPartyTransactionInitialTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Initial Term", "label": "Related Party Transaction, Initial Term", "terseLabel": "Initial term" } } }, "localname": "RelatedPartyTransactionInitialTerm", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "durationItemType" }, "rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Number of Partnership Interests Acquired", "label": "Related Party Transaction, Number of Partnership Interests Acquired", "terseLabel": "Number of limited partnership interest acquired (in shares)" } } }, "localname": "RelatedPartyTransactionNumberOfPartnershipInterestsAcquired", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Operating and Personal Payment Calculation, Amount", "label": "Related Party Transaction, Operating and Personal Payment Calculation, Amount", "terseLabel": "Amount calculated for operating and personal payment" } } }, "localname": "RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Operating and Personal Payment Calculation, Percent", "label": "Related Party Transaction, Operating and Personal Payment Calculation, Percent", "terseLabel": "Percent for calculating operating and personal payment" } } }, "localname": "RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rprx_RelatedPartyTransactionRateAdjustedCashReceipts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Rate, Adjusted Cash Receipts", "label": "Related Party Transaction, Rate, Adjusted Cash Receipts", "terseLabel": "Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)" } } }, "localname": "RelatedPartyTransactionRateAdjustedCashReceipts", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rprx_RelatedPartyTransactionRateValueOfSecurityInvestments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Rate, Value Of Security Investments", "label": "Related Party Transaction, Rate, Value Of Security Investments", "terseLabel": "Quarterly payments to affiliates, percent of security investment (as a percent)" } } }, "localname": "RelatedPartyTransactionRateValueOfSecurityInvestments", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rprx_RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash", "label": "Repayments Of Long Term Debt, Contributions From Noncontrolling Interest, Noncash", "terseLabel": "Repayments of long-term debt by contributions from non-controlling interest" } } }, "localname": "RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_RepaymentsOfLongTermDebtScheduledPayments": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments Of Long-term Debt, Scheduled Payments", "label": "Repayments Of Long-term Debt, Scheduled Payments", "negatedTerseLabel": "Scheduled repayments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebtScheduledPayments", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and Development Expense, Upfront Payment and Premium Paid", "label": "Research and Development Expense, Upfront Payment and Premium Paid", "terseLabel": "Upfront payment and premium paid" } } }, "localname": "ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "rprx_ResearchAndDevelopmentRemainingFundingCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Research And Development, Remaining Funding Commitment", "label": "Research And Development, Remaining Funding Commitment", "terseLabel": "Remaining commitment for R&D funding agreement" } } }, "localname": "ResearchAndDevelopmentRemainingFundingCommitment", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "rprx_RoyalPharmacySelectFinanceTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royal Pharmacy Select Finance Trust", "label": "Royal Pharmacy Select Finance Trust [Member]", "terseLabel": "RPSFT" } } }, "localname": "RoyalPharmacySelectFinanceTrustMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Assets, Policy", "label": "Royalty Assets, Policy [Policy Text Block]", "terseLabel": "Royalty assets" } } }, "localname": "RoyaltyAssetsPolicyPolicyTextBlock", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Distribution Payable to Legacy Investors Partnerships", "label": "Royalty Distribution Payable to Legacy Investors Partnerships [Member]", "terseLabel": "Royalty Distribution Payable to Legacy Investors Partnerships" } } }, "localname": "RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Distribution Payable to RP Select Finance Trust", "label": "Royalty Distribution Payable to RP Select Finance Trust [Member]", "terseLabel": "Royalty Distribution Payable to RP Select Finance Trust" } } }, "localname": "RoyaltyDistributionPayableToRPSelectFinanceTrustMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyIncomeOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Income, Other", "label": "Royalty Income, Other [Member]", "terseLabel": "Other royalty income" } } }, "localname": "RoyaltyIncomeOtherMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyPharmaCollectionTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Pharma Collection Trust", "label": "Royalty Pharma Collection Trust [Member]", "terseLabel": "RPCT" } } }, "localname": "RoyaltyPharmaCollectionTrustMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyPharmaInvestmentsOldRPIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Pharma Investments (Old RPI)", "label": "Royalty Pharma Investments (Old RPI) [Member]", "terseLabel": "Old RPI" } } }, "localname": "RoyaltyPharmaInvestmentsOldRPIMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "rprx_SaleOfStockNumberOfSharesAvailableToConvert": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Number of Shares Available To Convert", "label": "Sale of Stock, Number of Shares Available To Convert", "verboseLabel": "Number of shares available to convert (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesAvailableToConvert", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "sharesItemType" }, "rprx_SaleOfStockNumberOfSharesNotConverted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Number Of Shares Not Converted", "label": "Sale Of Stock, Number Of Shares Not Converted", "terseLabel": "Number of shares converted (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesNotConverted", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "sharesItemType" }, "rprx_SeniorNotesDue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Due 2031", "label": "Senior Notes Due 2031 [Member]", "terseLabel": "Senior Notes Due 2031" } } }, "localname": "SeniorNotesDue2031Member", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_SeniorNotesDue2051Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Due 2051", "label": "Senior Notes Due 2051 [Member]", "terseLabel": "Senior Notes Due 2051" } } }, "localname": "SeniorNotesDue2051Member", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_SeniorUnsecuredRevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Revolving Credit Facility", "label": "Senior Unsecured Revolving Credit Facility [Member]", "terseLabel": "Senior Unsecured Revolving Credit Facility" } } }, "localname": "SeniorUnsecuredRevolvingCreditFacilityMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_SettlementsWithEquityMethodInvestments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Settlements With Equity Method Investments", "label": "Settlements With Equity Method Investments", "terseLabel": "Settlement of Epizyme forward purchase contract" } } }, "localname": "SettlementsWithEquityMethodInvestments", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_StockIssuedDuringPeriodSharesIssuedForRegistration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Issued For Registration", "label": "Stock Issued During Period, Shares, Issued For Registration", "terseLabel": "Initial share issuance upon registration of Royalty Pharma plc (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForRegistration", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "rprx_StockIssuedDuringPeriodSharesIssuedToPartnerships": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Issued To Partnerships", "label": "Stock Issued During Period, Shares, Issued To Partnerships", "terseLabel": "Issuance of Class B shares to Continuing Investor Partnerships (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedToPartnerships", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "rprx_StockIssuedDuringPeriodValueIssuedForRegistration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Issued For Registration", "label": "Stock Issued During Period, Value, Issued For Registration", "terseLabel": "Initial share issuance upon registration of Royalty Pharma plc" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForRegistration", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "rprx_StockIssuedDuringPeriodValueIssuedToPartnerships": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Issued To Partnerships", "label": "Stock Issued During Period, Value, Issued To Partnerships", "terseLabel": "Issuance of Class B ordinary shares to Continuing Investors Partnerships" } } }, "localname": "StockIssuedDuringPeriodValueIssuedToPartnerships", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "rprx_StockholdersEquitySharesEffectOfExchangeAndReallocation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockholders' Equity, Shares, Effect Of Exchange And Reallocation", "label": "Stockholders' Equity, Shares, Effect Of Exchange And Reallocation", "terseLabel": "Effect of exchange by Continuing Investors of Class B shares for Class A shares and reallocation of historical equity (in shares)" } } }, "localname": "StockholdersEquitySharesEffectOfExchangeAndReallocation", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "rprx_StockholdersEquityValueEffectOfExchangeAndReallocation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stockholders' Equity, Value, Effect Of Exchange And Reallocation", "label": "Stockholders' Equity, Value, Effect Of Exchange And Reallocation", "terseLabel": "Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity" } } }, "localname": "StockholdersEquityValueEffectOfExchangeAndReallocation", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_TheNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Notes", "label": "The Notes [Member]", "terseLabel": "The Notes" } } }, "localname": "TheNotesMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "domainItemType" }, "rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Five Five Percent Senior Notes Due 2050", "label": "Three Point Five Five Percent Senior Notes Due 2050 [Member]", "terseLabel": "Three Point Five Five Percent Senior Notes Due 2050" } } }, "localname": "ThreePointFiveFivePercentSeniorNotesDue2050Member", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_ThreePointThreeFivePercentSeniorNotesDue2051Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Three Five Percent Senior Notes Due 2051", "label": "Three Point Three Five Percent Senior Notes Due 2051 [Member]", "terseLabel": "Three Point Three Five Percent Senior Notes Due 2051" } } }, "localname": "ThreePointThreeFivePercentSeniorNotesDue2051Member", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Three Zero Percent Senior Notes Due 2040", "label": "Three Point Three Zero Percent Senior Notes Due 2040 [Member]", "terseLabel": "Three Point Three Zero Percent Senior Notes Due 2040" } } }, "localname": "ThreePointThreeZeroPercentSeniorNotesDue2040Member", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_TreasuryRateLockContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury Rate Lock Contracts", "label": "Treasury Rate Lock Contracts [Member]", "terseLabel": "Treasury Rate Lock Contracts" } } }, "localname": "TreasuryRateLockContractsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "rprx_TremfyaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tremfya", "label": "Tremfya [Member]", "terseLabel": "Tremfya" } } }, "localname": "TremfyaMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_TwoPointOneFivePercentSeniorNotesDue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point One Five percent Senior Notes Due 2031", "label": "Two Point One Five percent Senior Notes Due 2031 [Member]", "terseLabel": "Two Point One Five percent Senior Notes Due 2031" } } }, "localname": "TwoPointOneFivePercentSeniorNotesDue2031Member", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Two Zero Percent Senior Notes Due 2030", "label": "Two Point Two Zero Percent Senior Notes Due 2030 [Member]", "terseLabel": "Two Point Two Zero Percent Senior Notes Due 2030" } } }, "localname": "TwoPointTwoZeroPercentSeniorNotesDue2030Member", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_TysabriMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tysabri", "label": "Tysabri [Member]", "terseLabel": "Tysabri" } } }, "localname": "TysabriMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_UnitHoldersAndShareholdersContributionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unit Holders' and Shareholders' Contributions", "label": "Unit Holders' and Shareholders' Contributions [Member]", "terseLabel": "Unitholders\u2019/ Shareholders\u2019 Contributions" } } }, "localname": "UnitHoldersAndShareholdersContributionsMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "rprx_VertexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vertex", "label": "Vertex [Member]", "terseLabel": "Vertex" } } }, "localname": "VertexMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "rprx_XtandiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xtandi", "label": "Xtandi [Member]", "terseLabel": "Xtandi" } } }, "localname": "XtandiMember", "nsuri": "http://royaltypharma.com/20211231", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r421", "r575", "r576", "r579", "r721" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r55", "r57", "r138", "r139", "r351", "r394" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "http://royaltypharma.com/role/EarningsPerShareDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r146", "r155", "r162", "r273", "r441", "r442", "r443", "r459", "r460", "r515", "r518", "r520", "r521", "r751" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r146", "r155", "r162", "r273", "r441", "r442", "r443", "r459", "r460", "r515", "r518", "r520", "r521", "r751" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r146", "r155", "r162", "r273", "r441", "r442", "r443", "r459", "r460", "r515", "r518", "r520", "r521", "r751" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r228", "r410", "r412", "r693" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_ManagementMember": { "auth_ref": [ "r229", "r578" ], "lang": { "en-us": { "role": { "label": "Management [Member]", "terseLabel": "The Manager" } } }, "localname": "ManagementMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r350", "r393", "r424", "r426", "r594", "r595", "r596", "r597", "r598", "r599", "r618", "r691", "r694", "r722", "r723" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r228", "r410", "r412", "r693" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r226", "r410", "r411", "r623", "r690", "r692" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r226", "r410", "r411", "r623", "r690", "r692" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r350", "r393", "r413", "r424", "r426", "r594", "r595", "r596", "r597", "r598", "r599", "r618", "r691", "r694", "r722", "r723" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r350", "r393", "r413", "r424", "r426", "r594", "r595", "r596", "r597", "r598", "r599", "r618", "r691", "r694", "r722", "r723" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r56", "r57", "r138", "r139", "r351", "r394" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "http://royaltypharma.com/role/EarningsPerShareDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r3", "r143", "r144", "r145", "r147", "r148", "r152", "r153", "r154", "r155", "r157", "r158", "r159", "r160", "r161", "r162", "r184", "r274", "r275", "r444", "r460", "r516", "r520", "r521", "r522", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r752", "r753" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "terseLabel": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r3", "r143", "r144", "r145", "r147", "r148", "r152", "r153", "r154", "r155", "r157", "r158", "r159", "r160", "r161", "r162", "r184", "r274", "r275", "r444", "r460", "r516", "r520", "r521", "r522", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r752", "r753" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "terseLabel": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Reclassification, Adjustment [Member]", "terseLabel": "Revision of Prior Period, Reclassification, Adjustment" } } }, "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r147", "r148", "r149", "r150", "r246", "r247", "r270", "r271", "r272", "r273", "r274", "r275", "r333", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r459", "r460", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r572", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r749", "r750", "r751", "r752", "r753" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting standards update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r65", "r75", "r76", "r77", "r476" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Unrealized Losses on Interest Rate Swaps" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r59", "r60", "r61", "r65", "r75", "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to noncontrolling interest.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Noncontrolling Interest [Member]", "terseLabel": "Unrealized gain/(loss) on available for sale debt securities, noncontrolling interest" } } }, "localname": "AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r59", "r60", "r61", "r65", "r75", "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]", "terseLabel": "Unrealized gain/(loss) on available for sale debt securities, including noncontrolling interest" } } }, "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r59", "r60", "r61", "r65", "r75", "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Unrealized Gains on Available for Sale Debt Securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r63", "r64", "r65", "r675", "r702", "r706" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r75", "r76", "r558", "r559", "r560", "r561", "r562", "r564" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r62", "r65", "r75", "r76", "r77", "r143", "r144", "r145", "r477", "r697", "r698", "r753" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Total Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r28", "r444", "r584" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r143", "r144", "r145", "r441", "r442", "r443", "r520" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile consolidated net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r428", "r434", "r445" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "auth_ref": [ "r236", "r288" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.", "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of Cumulative Allowance for Changes in Expected Cash Flows" } } }, "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r117", "r370", "r381", "r382", "r569" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r117", "r313", "r318" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r62", "r65", "r75", "r76", "r77", "r477" ], "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Accumulated Other Comprehensive Income/(Loss)" } } }, "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r117", "r322" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment charge" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r135", "r208", "r218", "r224", "r268", "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r470", "r479", "r548", "r582", "r584", "r643", "r673" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r11", "r12", "r52", "r135", "r268", "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r470", "r479", "r548", "r582", "r584" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r255" ], "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r253", "r305" ], "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r249", "r254", "r305", "r648" ], "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r252", "r305" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 3.0, "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Available for sale debt securities", "verboseLabel": "Available for sale debt securities, current" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r252", "r305" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 2.0, "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Available for sale debt securities", "verboseLabel": "Available for sale debt securities, noncurrent" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableforsaleSecuritiesMember": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities [Member]", "terseLabel": "Available-for-sale Securities" } } }, "localname": "AvailableforsaleSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r430", "r436" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of preparation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r423", "r425" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r423", "r425", "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value, net" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r32", "r119" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "negatedTerseLabel": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 1.0, "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r17", "r120" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r113", "r119", "r125" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of year", "periodStartLabel": "Cash and cash equivalents, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r113", "r557" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental Schedule of Non-cash Investing/Financing Activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Indirect Cash Flow" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlow" ], "xbrltype": "textBlockItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r667" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of Deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r133", "r135", "r166", "r170", "r175", "r178", "r180", "r188", "r189", "r190", "r268", "r334", "r339", "r340", "r341", "r345", "r346", "r391", "r392", "r395", "r396", "r548", "r734" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/EarningsPerShareDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r408", "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants to purchase additional shares (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r44", "r328", "r653", "r679" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r325", "r326", "r327", "r329", "r720" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/EarningsPerShareDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends paid (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r143", "r144", "r520" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars/pounds per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r25", "r398" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common shares outstanding", "verboseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r25", "r584" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r70", "r72", "r73", "r86", "r660", "r685" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to controlling interest" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r70", "r72", "r85", "r468", "r485", "r659", "r684" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r84", "r96", "r658", "r683" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r197", "r198", "r228", "r546", "r547", "r719" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r197", "r198", "r228", "r546", "r547", "r708", "r719" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r197", "r198", "r228", "r546", "r547", "r708", "r719" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r193", "r670" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r197", "r198", "r228", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Individual licensees exceeding 10% or more of revenue (as a percent)", "verboseLabel": "Concentration risk (as a percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r197", "r198", "r228", "r546", "r547", "r719" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r128", "r472" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r478", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Investments in non-consolidated affiliates" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r414", "r422", "r707" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r88" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses/(income), net" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Credit Loss [Abstract]" } } }, "localname": "CreditLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": { "auth_ref": [ "r276", "r277", "r278", "r281", "r282", "r289", "r291", "r293", "r294", "r295", "r301", "r302", "r303", "r304", "r306", "r307", "r308", "r310" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.", "label": "Credit Loss, Financial Instrument [Policy Text Block]", "terseLabel": "Allowance for current expected credit losses" } } }, "localname": "CreditLossFinancialInstrumentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditLossFinancialInstrumentTextBlock": { "auth_ref": [ "r282", "r292", "r293", "r297", "r298", "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.", "label": "Credit Loss, Financial Instrument [Text Block]", "terseLabel": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets" } } }, "localname": "CreditLossFinancialInstrumentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r196", "r228" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r132", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r364", "r371", "r372", "r374", "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Borrowings" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/Borrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r19", "r21", "r22", "r134", "r141", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r360", "r361", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r370", "r379", "r380", "r381", "r382", "r570", "r644", "r645", "r671" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (percentage)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r22", "r375", "r645", "r671" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "totalLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r347", "r379", "r380", "r568", "r570", "r571" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt issued, amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r41", "r378", "r568", "r570" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Weighted average effective interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r41", "r348" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, stated rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r42", "r134", "r141", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r360", "r361", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r370", "r379", "r380", "r381", "r382", "r570" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Prior to the applicable par call date" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Three [Member]", "terseLabel": "Upon occurrence of a change of control triggering event" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price (as a percent)" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r42", "r134", "r141", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r360", "r361", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r370", "r373", "r379", "r380", "r381", "r382", "r399", "r402", "r403", "r404", "r567", "r568", "r570", "r571", "r669" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r360", "r376", "r379", "r380", "r569" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized debt discount and issuance costs", "terseLabel": "Unamortized discount and loan issuance costs on long-term debt" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Summary of Available for Sale Debt Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 7.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)", "negatedTerseLabel": "Unrealized gains on available for sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt, Weighted Average Interest Rate", "terseLabel": "Weighted average coupon rate (as a percent)" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r569" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r53", "r54", "r57", "r543" ], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 3.0, "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivatives" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsNoncurrent": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Noncurrent", "terseLabel": "Derivative financial instruments" } } }, "localname": "DerivativeAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r494" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Interest rate swaps" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r57", "r493", "r495", "r499", "r504" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r510", "r523" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r498", "r500" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Derivatives not designated as hedging instruments" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r488", "r490" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r140", "r487", "r489", "r491", "r492", "r506" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r405", "r666" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "negatedTerseLabel": "Dividends" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r405" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Dividends declared and paid" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r137", "r337", "r339", "r340", "r344", "r345", "r346", "r576", "r651", "r680" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "terseLabel": "Amounts due from related parties" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r35", "r137", "r337", "r339", "r340", "r344", "r345", "r346", "r576" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Distribution payable to non-controlling interest" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r43", "r137", "r337", "r339", "r340", "r344", "r345", "r346", "r576" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Due to Related Parties, Noncurrent", "terseLabel": "Total distribution payable to non-controlling interest" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r87", "r152", "r153", "r155", "r156", "r157", "r163", "r166", "r178", "r179", "r180", "r184", "r185", "r521", "r522", "r661", "r686" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Earnings per Class A ordinary share - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Earnings Per Share, Basic [Abstract]" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Earnings per Class A ordinary share" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r87", "r152", "r153", "r155", "r156", "r157", "r166", "r178", "r179", "r180", "r184", "r185", "r521", "r522", "r661", "r686" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Earnings per Class A ordinary share - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r181", "r182", "r183", "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r435" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized share based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized share based compensation expense, period of recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r75", "r76", "r77", "r143", "r144", "r145", "r148", "r158", "r161", "r187", "r273", "r398", "r405", "r441", "r442", "r443", "r459", "r460", "r520", "r558", "r559", "r560", "r561", "r562", "r564", "r697", "r698", "r699", "r753" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r82", "r112", "r117", "r681" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Distributions from non-consolidated affiliates" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/IndirectCashFlowDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "auth_ref": [ "r6", "r135", "r268", "r548" ], "lang": { "en-us": { "role": { "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "auth_ref": [ "r6", "r135", "r268", "r548" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": { "auth_ref": [ "r6", "r135", "r268", "r548" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r33", "r209", "r265" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Investments in non-consolidated affiliates" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Non-Consolidated Affiliates" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliates" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "auth_ref": [ "r540" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 1.0, "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.", "label": "Equity Securities, FV-NI, Noncurrent", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFVNINoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r540" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r264", "r687" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedTerseLabel": "Losses/(gains) on equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r18", "r20", "r260", "r672", "r715", "r716", "r717" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity Securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r362", "r379", "r380", "r543" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss": { "auth_ref": [ "r533" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income from asset (liability) measured at fair value on recurring basis using unobservable input (level 3) and still held.", "label": "Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)", "negatedTerseLabel": "Unrealized gain (loss) on equity securities still held" } } }, "localname": "FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r524", "r525", "r526", "r536" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "auth_ref": [ "r533" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.", "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)", "terseLabel": "Unrealized gains included in earnings" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r529", "r536" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r529", "r536" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r524", "r536" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r362", "r379", "r380", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r525", "r591", "r592", "r593" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r362", "r379", "r380", "r524", "r537" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r524", "r525", "r527", "r528", "r538" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]", "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]" } } }, "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r362", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value.", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]" } } }, "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value.", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]", "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value" } } }, "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements and Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r362", "r414", "r415", "r420", "r422", "r525", "r591" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r362", "r379", "r380", "r414", "r415", "r420", "r422", "r525", "r592" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r362", "r379", "r380", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r525", "r593" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": { "auth_ref": [ "r530" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)", "terseLabel": "Gains on equity securities" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "auth_ref": [ "r531" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "terseLabel": "Purchases" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": { "auth_ref": [ "r531" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements", "terseLabel": "Settlement of forwards" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r532" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "terseLabel": "Transfer from level 2" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r532" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "negatedLabel": "Transfer to Level 2" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r529" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Balance at the end of the year", "periodStartLabel": "Balance at the beginning of the year" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r362", "r379", "r380", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r591", "r592", "r593" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r534", "r538" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r539", "r542" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FederalFundsPurchasedMember": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "Short term borrowing where a bank borrows, at the federal funds rate, from another bank.", "label": "Federal Funds Purchased [Member]", "terseLabel": "Federal Funds Rate" } } }, "localname": "FederalFundsPurchasedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLoansAndLeasesReceivablePolicy": { "auth_ref": [ "r232", "r237", "r238", "r239", "r241", "r243", "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for financing receivable.", "label": "Financing Receivable [Policy Text Block]", "terseLabel": "Financial royalty assets, net" } } }, "localname": "FinanceLoansAndLeasesReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Financing Receivable [Member]", "terseLabel": "Current portion of Financial royalty assets" } } }, "localname": "FinanceReceivablesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r256", "r257", "r261", "r262", "r263", "r282", "r288", "r289", "r290", "r297", "r309", "r310", "r311", "r312", "r373", "r397", "r510", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r734", "r735", "r736", "r737", "r738", "r739", "r740" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "auth_ref": [ "r233", "r279", "r284", "r287", "r649", "r743", "r745", "r746" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, Allowance for Credit Loss", "negatedPeriodEndLabel": "Ending balance", "negatedPeriodStartLabel": "Beginning balance" } } }, "localname": "FinancingReceivableAllowanceForCreditLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financing Receivable, Allowance for Credit Loss [Line Items]", "terseLabel": "Financing Receivable, Allowance for Credit Loss [Line Items]" } } }, "localname": "FinancingReceivableAllowanceForCreditLossesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs": { "auth_ref": [ "r235", "r286", "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of writeoff of financing receivable, charged against allowance for credit loss.", "label": "Financing Receivable, Allowance for Credit Loss, Writeoff", "terseLabel": "Write off of credit loss allowance" } } }, "localname": "FinancingReceivableAllowanceForCreditLossesWriteOffs", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivableChangeInPresentValueExpenseReversal": { "auth_ref": [ "r280", "r283", "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on financing receivable, from change in present value of expected cash flows.", "label": "Financing Receivable, Change in Present Value, Expense (Reversal)", "negatedTerseLabel": "Write-off of cumulative allowance" } } }, "localname": "FinancingReceivableChangeInPresentValueExpenseReversal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivablesTextBlock": { "auth_ref": [ "r242", "r248" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financing receivable.", "label": "Financing Receivables [Text Block]", "terseLabel": "Financial Royalty Assets, Net" } } }, "localname": "FinancingReceivablesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite lived intangible assets, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r317" ], "calculation": { "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r319" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Projected amortization expense, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r314", "r315", "r317", "r320", "r624", "r628" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r317", "r628" ], "calculation": { "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r314", "r316" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r317", "r624" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Carrying Value", "verboseLabel": "Intangible royalty assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forwards" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing gain (loss) on derivative instruments.", "label": "Gain (Loss) on Derivative Instruments [Member]", "terseLabel": "Losses on derivative financial instruments" } } }, "localname": "GainLossOnDerivativeInstrumentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r493" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedLabel": "Losses on derivative financial instruments" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r117", "r383", "r384" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r91" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r491", "r505" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r81", "r208", "r217", "r220", "r223", "r225", "r641", "r656", "r664", "r688" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Consolidated net income before tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r82", "r117", "r206", "r265", "r655", "r681" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Equity in losses/(earnings) of non-consolidated affiliates", "verboseLabel": "Equity in income (loss) of non-consolidated affiliates" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/IndirectCashFlowDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r136", "r160", "r161", "r207", "r452", "r461", "r462", "r689" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r74", "r450", "r451", "r453", "r454", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r116" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r116" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Interest payable" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Assets [Abstract]", "terseLabel": "Decrease/(increase) in operating assets:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Liabilities [Abstract]", "terseLabel": "(Decrease)/increase in operating liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r116" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedTerseLabel": "Other current assets and other assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r116" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "Increase (Decrease) in Other Receivables", "negatedTerseLabel": "Other receivables" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r167", "r168", "r169", "r180" ], "calculation": { "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Unvested RSUs (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Royalty Assets, Net" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r129", "r316", "r620", "r621", "r622", "r624" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Intangible royalty assets, net" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r79", "r205", "r566", "r569", "r663" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest Income, Operating", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r110", "r114", "r121" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "negatedTerseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r15", "r16", "r39" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r92", "r94" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "negatedLabel": "Interest income", "verboseLabel": "Investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails", "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r260", "r642", "r665", "r718", "r741" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Available for Sale Debt Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38", "r135", "r219", "r268", "r334", "r335", "r336", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r471", "r479", "r480", "r548", "r582", "r583" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r135", "r268", "r548", "r584", "r647", "r678" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r40", "r135", "r268", "r334", "r335", "r336", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r471", "r479", "r480", "r548", "r582", "r583", "r584" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r22", "r361", "r377", "r379", "r380", "r645", "r674" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total debt carrying value" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedNetLabel": "Less: Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Fair value of outstanding Notes" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r141", "r331", "r366" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r141", "r331", "r366" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r141", "r331", "r366" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r141", "r331", "r366" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r141", "r331", "r366" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r141", "r331", "r366" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Total long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount", "terseLabel": "Payment for purchase of royalties" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Category of Item Purchased [Axis]", "terseLabel": "Category of Item Purchased [Axis]" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment [Line Items]" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r42", "r332" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r50", "r135", "r268", "r334", "r339", "r340", "r341", "r345", "r346", "r548", "r646", "r677" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r405" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Distributions" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Noncontrolling interest (percentage)" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership percentage (as a percent)" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInMinorityInterestRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]", "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]" } } }, "localname": "MovementInMinorityInterestRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r113" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by/(used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r113" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "verboseLabel": "Net cash flow from investing" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r113", "r115", "r118" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r68", "r71", "r77", "r83", "r118", "r135", "r147", "r152", "r153", "r155", "r156", "r160", "r161", "r176", "r208", "r217", "r220", "r223", "r225", "r268", "r334", "r335", "r336", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r522", "r548", "r657", "r682" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to controlling interest" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r68", "r71", "r77", "r160", "r161", "r474", "r484" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: net income attributable to non-controlling interest", "verboseLabel": "Net income attributable to non-controlling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r152", "r153", "r155", "r156", "r163", "r164", "r177", "r180", "r208", "r217", "r220", "r223", "r225" ], "calculation": { "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income attributable to Royalty Pharma plc - basic and diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r165", "r171", "r172", "r173", "r174", "r177", "r180" ], "calculation": { "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net income attributable to Royalty Pharma plc - basic and diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r146", "r147", "r148", "r149", "r150", "r151", "r155", "r162", "r184", "r246", "r247", "r270", "r271", "r272", "r273", "r274", "r275", "r333", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r457", "r458", "r459", "r460", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r572", "r625", "r626", "r627", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r749", "r750", "r751", "r752", "r753" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently adopted and issued accounting standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": { "auth_ref": [ "r122", "r123", "r124" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received", "terseLabel": "Receipt of contribution of investments in Legacy Investors Partnerships" } } }, "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r143", "r144", "r145", "r405", "r466" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-Controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other expense/(income), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r9", "r10", "r26", "r230", "r231", "r650" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Financial royalty assets" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.", "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Financial royalty assets, net" } } }, "localname": "NotesAndLoansReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableGross": { "auth_ref": [ "r240", "r279", "r289", "r296", "r299", "r300", "r742", "r743", "r744" ], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": { "order": 2.0, "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of financing receivable.", "label": "Financing Receivable, before Allowance for Credit Loss", "terseLabel": "Gross Carrying Value" } } }, "localname": "NotesReceivableGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r27", "r230", "r296" ], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, after Allowance for Credit Loss", "terseLabel": "Financial royalty asset, net", "totalLabel": "Net carrying value" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r208", "r217", "r220", "r223", "r225" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": { "auth_ref": [ "r386", "r509" ], "lang": { "en-us": { "role": { "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.", "label": "Option Indexed to Issuer's Equity, Strike Price", "terseLabel": "Put option, selling price, maximum (in dollars per share)" } } }, "localname": "OptionIndexedToIssuersEquityStrikePrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "auth_ref": [ "r387", "r507", "r508", "r511" ], "lang": { "en-us": { "role": { "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.", "label": "Option Indexed to Issuer's Equity, Type [Axis]", "terseLabel": "Option Indexed to Issuer's Equity, Type [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]", "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r7", "r486" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Purpose" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurpose" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r51", "r584" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Other commitment" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r65", "r75", "r76", "r78", "r558", "r560", "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Activity for the year" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r63", "r66", "r497" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Amount of loss reclassified from AOCI into income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": { "auth_ref": [ "r58", "r496" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax", "terseLabel": "Reclassification of loss on interest rate swaps" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r69", "r72", "r75", "r76", "r78", "r84", "r398", "r558", "r563", "r564", "r658", "r683" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive (loss)/income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Changes in other comprehensive income/(loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r69", "r72", "r468", "r469", "r476" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive income attributable to non-controlling interest" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r63", "r66", "r67", "r259" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "negatedLabel": "Reclassification of unrealized losses on available for sale debt securities", "negatedTerseLabel": "Reclassification of unrealized gains on available for sale debt securities" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r59", "r63", "r259" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "terseLabel": "Unrealized gains on available for sale debt securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r59", "r63" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gains on available for sale debt securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r90" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Cost and Expense, Operating", "terseLabel": "Other operating expenses" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other expense/(income)" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r39", "r584" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r118" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r95" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other non-operating expense/(income), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r105" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchase of treasury interests" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r107" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Debt issuance costs and other" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r97", "r100", "r251" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedTerseLabel": "Purchases of available for sale debt securities", "verboseLabel": "Purchase of available for sale debt securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r101" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "negatedTerseLabel": "Investments in non-consolidated affiliates" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireFinanceReceivables": { "auth_ref": [ "r102" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith.", "label": "Payments to Acquire Finance Receivables", "negatedLabel": "Acquisitions of financial royalty assets" } } }, "localname": "PaymentsToAcquireFinanceReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r251" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchases of marketable securities", "terseLabel": "Purchases of available for sale debt securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r108" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedTerseLabel": "Distributions to non-controlling interest" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r430", "r436" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Shares" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "auth_ref": [ "r99", "r112" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "terseLabel": "Distributions from non-consolidated affiliates" } } }, "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInterestReceived": { "auth_ref": [ "r109" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest received on loans and other debt instruments during the current period.", "label": "Proceeds from Interest Received", "terseLabel": "Interest received" } } }, "localname": "ProceedsFromInterestReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r103" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r104" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from issuance of long-term debt, net of discount" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sales and maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r97", "r98", "r251" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from available for sale debt securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r6", "r68", "r71", "r77", "r111", "r135", "r147", "r160", "r161", "r208", "r217", "r220", "r223", "r225", "r268", "r334", "r335", "r336", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r468", "r473", "r475", "r484", "r485", "r522", "r548", "r664" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "totalLabel": "Consolidated net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/EarningsPerShareDetails", "http://royaltypharma.com/role/IndirectCashFlowDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForLoanAndLeaseLosses": { "auth_ref": [ "r116", "r234", "r662" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to estimated loss from loan and lease transactions.", "label": "Provision for Loan and Lease Losses", "terseLabel": "Provision for changes in expected cash flows from financial royalty assets" } } }, "localname": "ProvisionForLoanAndLeaseLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForLoanLossesExpensed": { "auth_ref": [ "r285", "r654" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable.", "label": "Financing Receivable, Credit Loss, Expense (Reversal)", "negatedTerseLabel": "Current period provision for credit losses, net" } } }, "localname": "ProvisionForLoanLossesExpensed", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PutOptionMember": { "auth_ref": [ "r709", "r710", "r711", "r712", "r713", "r714" ], "lang": { "en-us": { "role": { "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option.", "label": "Put Option [Member]", "terseLabel": "Put Option" } } }, "localname": "PutOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r65", "r75", "r76", "r78", "r558", "r562", "r564" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Reclassification to net income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r421", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r575", "r579" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Amount paid to CEO" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r421", "r575", "r576", "r579" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.", "label": "Related Party Transaction, Rate", "terseLabel": "Related party, rate (as a percent)" } } }, "localname": "RelatedPartyTransactionRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party", "terseLabel": "Operating and personnel payments incurred" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r421", "r575", "r579", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r573", "r574", "r576", "r580", "r581" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r106" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Repayments of long-term debt", "verboseLabel": "Repayments of outstanding debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r447", "r619", "r724" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development funding expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development funding expense" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "terseLabel": "Research & Development (\"R&D\") Funding Expense" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r405", "r444", "r584", "r676", "r701", "r706" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r143", "r144", "r145", "r148", "r158", "r161", "r273", "r441", "r442", "r443", "r459", "r460", "r520", "r697", "r699" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r130", "r131" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue from intangible royalty assets and Accrued royalty receivable" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r80", "r135", "r203", "r204", "r216", "r221", "r222", "r226", "r227", "r228", "r268", "r334", "r335", "r336", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r548", "r664" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total income and other revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "verboseLabel": "Number of shares issued (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.", "label": "Sale of Stock, Percentage of Ownership after Transaction", "terseLabel": "Ownership percentage following IPO" } } }, "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.", "label": "Sale of Stock, Percentage of Ownership before Transaction", "terseLabel": "Exchange offering, ownership percentage" } } }, "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "verboseLabel": "Sale of stock, price per share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r197", "r228" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Summary of Financial Royalty Assets, Net" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r65", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r42", "r141", "r379", "r381", "r399", "r402", "r403", "r404", "r567", "r568", "r571", "r669" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Borrowings" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r493", "r499", "r505" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Summary of Derivatives and Reclassifications" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r166", "r170", "r178", "r180", "r185" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r6", "r135", "r267", "r268", "r548" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r524", "r525" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value Hierarchy" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable": { "auth_ref": [ "r288", "r746" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on financing receivable.", "label": "Financing Receivable, Allowance for Credit Loss [Table]", "terseLabel": "Financing Receivable, Allowance for Credit Loss [Table]" } } }, "localname": "ScheduleOfFinancingReceivableAllowanceForCreditLossesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r314", "r316", "r624" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r314", "r316" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Royalty Interests" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Repayments of Debt by Year" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r577", "r579" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of Related Party Transactions" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r45", "r133", "r188", "r189", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r399", "r400", "r401", "r402", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Balance Of Non-controlling Interests" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt and Equity Securities, FV-NI [Line Items]", "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]", "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Senior Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r210", "r211", "r212", "r213", "r214", "r215", "r227" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Debt Securities", "verboseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Shares" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r116" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Requisite service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r427", "r432" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r409", "r446" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-based Payments [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Shares, outstanding (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r127", "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r23", "r24", "r25", "r133", "r135", "r166", "r170", "r175", "r178", "r180", "r188", "r189", "r190", "r268", "r334", "r339", "r340", "r341", "r345", "r346", "r391", "r392", "r395", "r396", "r398", "r548", "r734" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/EarningsPerShareDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r48", "r75", "r76", "r77", "r143", "r144", "r145", "r148", "r158", "r161", "r187", "r273", "r398", "r405", "r441", "r442", "r443", "r459", "r460", "r520", "r558", "r559", "r560", "r561", "r562", "r564", "r697", "r698", "r699", "r753" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r143", "r144", "r145", "r187", "r623" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r24", "r25", "r398", "r405" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of Class A ordinary shares sold in initial public offering, net of offering costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r24", "r25", "r398", "r405" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share based compensation and related issuance of Class A ordinary shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r24", "r25", "r398", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of Class A ordinary shares sold in IPO, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r24", "r25", "r405", "r429", "r433" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation and related issuances of Class A ordinary shares" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Number of shares authorized under plan (in shares)" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r76", "r135", "r143", "r144", "r145", "r148", "r158", "r268", "r273", "r405", "r441", "r442", "r443", "r459", "r460", "r466", "r467", "r483", "r520", "r548", "r558", "r559", "r564", "r698", "r699", "r753" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "negatedLabel": "Cumulative adjustment to retained earnings", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders\u2019 equity", "verboseLabel": "Cumulative adjustment" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AccumulatedOtherComprehensiveIncomeDetails", "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Other exchanges" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOtherShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase (decrease) in shares of stock classified as other.", "label": "Stockholders' Equity, Other Shares", "terseLabel": "Other exchanges (in shares)" } } }, "localname": "StockholdersEquityOtherShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r565", "r586" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r565", "r586" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r565", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r565", "r586" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r585", "r587" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TradingSecuritiesDebt": { "auth_ref": [ "r249", "r250" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 2.0, "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Trading", "terseLabel": "Marketable securities" } } }, "localname": "TradingSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r256", "r257", "r261", "r262", "r263", "r373", "r397", "r510", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r734", "r735", "r736", "r737", "r738", "r739", "r740" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r47", "r406" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock", "verboseLabel": "Treasury Interests" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r47", "r406", "r407" ], "calculation": { "http://royaltypharma.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury interests" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r398", "r405", "r406" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Purchase of treasury interests", "terseLabel": "Treasury interests" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r117" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "negatedTerseLabel": "Losses on derivative financial instruments", "terseLabel": "Unrealized gain (loss) on derivatives" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnDerivativesAndCommodityContracts": { "auth_ref": [ "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of open derivatives, commodity, or energy contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives and Commodity Contracts", "terseLabel": "Change in fair value of derivative contracts" } } }, "localname": "UnrealizedGainLossOnDerivativesAndCommodityContracts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r191", "r192", "r194", "r195", "r199", "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails", "http://royaltypharma.com/role/DerivativeInstrumentsSummaryofDerivativesandReclassificationsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Term of warrant (in years)" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/DerivativeInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r165", "r180" ], "calculation": { "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average Class A ordinary shares outstanding - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r163", "r180" ], "calculation": { "http://royaltypharma.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average Class A ordinary shares outstanding - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations", "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted average Class A ordinary shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://royaltypharma.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b,d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196816" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6284393-111563" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r269": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "30", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124256539&loc=SL120269210-210444" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "30", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124256539&loc=SL120254536-210444" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124266218&loc=SL120267834-210445" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82919204-210446" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL120267845-210446" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919246-210447" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919260-210447" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919269-210447" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL120267966-210447" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL120267969-210447" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919236-210447" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 6.M.Q4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122651532&loc=SL122037091-237805" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124268681&loc=SL120267897-210452" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "13A", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=125515542&loc=SL120267917-210453" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=125515542&loc=SL120269220-210453" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3C", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267859-210455" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3D", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267862-210455" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r321": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r329": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r385": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r409": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r446": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r486": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90198-114008" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r523": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498357-110258" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r581": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r587": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r642": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13(3)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.11)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r665": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r718": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r725": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "http://asc.fasb.org/subtopic&trid=2197926" }, "r726": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r727": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r728": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r729": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r730": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r731": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r732": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r733": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r734": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r735": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r736": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r737": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r738": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r739": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r740": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r741": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r742": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1404" }, "r743": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(1)" }, "r744": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(2)" }, "r745": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(3)" }, "r746": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1405" }, "r747": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r748": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" } }, "version": "2.1" } ZIP 93 0001802768-22-000011-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001802768-22-000011-xbrl.zip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end GRAPHIC 14 rprx-20211231_g3.jpg begin 644 rprx-20211231_g3.jpg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end GRAPHIC 13 rprx-20211231_g2.jpg begin 644 rprx-20211231_g2.jpg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